{"7d1d78403a919183f5349827f329c6e6bb7e678a": [["IntroductionInfectious bronchitis virus (IBV) is a Gammacoronavirus and is the aetiological agent of the acute highly contagious and economically important respiratory disease, infectious bronchitis, which affects domestic fowl.", [["respiratory", "ANATOMY", 156, 167], ["IntroductionInfectious bronchitis virus", "DISEASE", 0, 39], ["Gammacoronavirus", "CHEMICAL", 51, 67], ["respiratory disease", "DISEASE", 156, 175], ["infectious bronchitis", "DISEASE", 177, 198], ["IntroductionInfectious bronchitis virus", "ORGANISM", 0, 39], ["IBV", "ORGANISM", 41, 44], ["IntroductionInfectious bronchitis virus", "SPECIES", 0, 39], ["IntroductionInfectious bronchitis virus", "SPECIES", 0, 39], ["IBV", "SPECIES", 41, 44], ["fowl", "SPECIES", 223, 227], ["IntroductionInfectious bronchitis virus", "PROBLEM", 0, 39], ["the acute highly contagious", "PROBLEM", 101, 128], ["respiratory disease", "PROBLEM", 156, 175], ["infectious bronchitis", "PROBLEM", 177, 198], ["bronchitis", "OBSERVATION", 23, 33], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["highly", "OBSERVATION_MODIFIER", 111, 117], ["contagious", "OBSERVATION", 118, 128], ["respiratory disease", "OBSERVATION", 156, 175], ["infectious", "OBSERVATION_MODIFIER", 177, 187], ["bronchitis", "OBSERVATION", 188, 198]]], ["Other coronaviruses that cause respiratory disease are the zoonotic betacoronaviruses that can cause severe respiratory disease in humans including severe acute respiratory syndrome coronavirus (SARS-CoV) that emerged in 2003 [1, 2] , Middle East respiratory syndrome coronavirus (MERS-CoV) that emerged in 2012 [3] and SARS-CoV-2 that recently emerged in 2019 [4] .", [["respiratory", "ANATOMY", 31, 42], ["respiratory", "ANATOMY", 108, 119], ["respiratory disease", "DISEASE", 31, 50], ["zoonotic betacoronaviruses", "DISEASE", 59, 85], ["respiratory disease", "DISEASE", 108, 127], ["acute respiratory syndrome coronavirus", "DISEASE", 155, 193], ["SARS-CoV)", "DISEASE", 195, 204], ["Middle East respiratory syndrome coronavirus", "DISEASE", 235, 279], ["SARS", "DISEASE", 320, 324], ["coronaviruses", "ORGANISM", 6, 19], ["humans", "ORGANISM", 131, 137], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 148, 193], ["SARS-CoV", "ORGANISM", 195, 203], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 235, 279], ["MERS-CoV", "ORGANISM", 281, 289], ["SARS-CoV-2", "ORGANISM", 320, 330], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["severe acute respiratory syndrome coronavirus", "SPECIES", 148, 193], ["SARS-CoV", "SPECIES", 195, 203], ["Middle East respiratory syndrome coronavirus", "SPECIES", 235, 279], ["MERS-CoV", "SPECIES", 281, 289], ["SARS-CoV", "SPECIES", 320, 328], ["Other coronaviruses", "PROBLEM", 0, 19], ["respiratory disease", "PROBLEM", 31, 50], ["the zoonotic betacoronaviruses", "PROBLEM", 55, 85], ["severe respiratory disease in humans", "PROBLEM", 101, 137], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 148, 193], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 235, 279], ["SARS-CoV", "TEST", 320, 328], ["respiratory disease", "OBSERVATION", 31, 50], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["respiratory disease", "OBSERVATION", 108, 127], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory syndrome", "OBSERVATION", 161, 181], ["Middle", "ANATOMY_MODIFIER", 235, 241], ["respiratory syndrome", "ANATOMY", 247, 267]]], ["The alphacoronaviruses HCoV-229E, HCoV-NL63 as well as the betacoronaviruses HCoV-OC43 and HCoV-HKU1 also cause respiratory disease in humans but typically with less severe clinical Primary chicken kidney (CK) cells were prepared from kidneys extracted from two three-week-old specific pathogen free (SPF) Rhode Island Red (RIR) chickens [33] .", [["respiratory", "ANATOMY", 112, 123], ["kidney (CK) cells", "ANATOMY", 198, 215], ["kidneys", "ANATOMY", 235, 242], ["HCoV-229E", "CHEMICAL", 23, 32], ["respiratory disease", "DISEASE", 112, 131], ["alphacoronaviruses HCoV-229E", "ORGANISM", 4, 32], ["HCoV-NL63", "ORGANISM", 34, 43], ["betacoronaviruses", "ORGANISM", 59, 76], ["HCoV-OC43", "ORGANISM", 77, 86], ["HCoV-HKU1", "ORGANISM", 91, 100], ["humans", "ORGANISM", 135, 141], ["chicken", "ORGANISM", 190, 197], ["kidney", "ORGAN", 198, 204], ["CK) cells", "CELL", 206, 215], ["kidneys", "ORGAN", 235, 242], ["chickens", "ORGANISM", 329, 337], ["HCoV", "PROTEIN", 34, 38], ["HCoV", "DNA", 91, 95], ["HKU1", "DNA", 96, 100], ["Primary chicken kidney (CK) cells", "CELL_TYPE", 182, 215], ["humans", "SPECIES", 135, 141], ["chicken", "SPECIES", 190, 197], ["chickens", "SPECIES", 329, 337], ["HCoV-229E", "SPECIES", 23, 32], ["humans", "SPECIES", 135, 141], ["chicken", "SPECIES", 190, 197], ["Rhode Island Red (RIR) chickens", "SPECIES", 306, 337], ["The alphacoronaviruses HCoV", "TEST", 0, 27], ["HCoV", "TEST", 34, 38], ["the betacoronaviruses HCoV", "TEST", 55, 81], ["OC43", "TEST", 82, 86], ["HCoV", "TEST", 91, 95], ["respiratory disease in humans", "PROBLEM", 112, 141], ["less severe clinical Primary chicken kidney (CK) cells", "PROBLEM", 161, 215], ["respiratory disease", "OBSERVATION", 112, 131], ["kidney", "ANATOMY", 198, 204], ["kidneys", "ANATOMY", 235, 242]]], ["DF1 cells are a continuous cell line derived from chicken embryo fibroblasts [34] .", [["DF1 cells", "ANATOMY", 0, 9], ["cell line", "ANATOMY", 27, 36], ["embryo fibroblasts", "ANATOMY", 58, 76], ["DF1 cells", "CELL", 0, 9], ["cell line", "CELL", 27, 36], ["chicken", "ORGANISM", 50, 57], ["embryo fibroblasts", "CELL", 58, 76], ["DF1 cells", "CELL_LINE", 0, 9], ["continuous cell line", "CELL_LINE", 16, 36], ["chicken embryo fibroblasts", "CELL_TYPE", 50, 76], ["chicken", "SPECIES", 50, 57], ["chicken", "SPECIES", 50, 57], ["DF1 cells", "PROBLEM", 0, 9], ["a continuous cell line", "TREATMENT", 14, 36], ["chicken embryo fibroblasts", "PROBLEM", 50, 76], ["cell line", "OBSERVATION", 27, 36], ["embryo fibroblasts", "OBSERVATION", 58, 76]]], ["All cell cultures were produced by the Central Services Unit at The Pirbright Institute and maintained, prior to infection, at 37 \u2022 C and 5% CO 2 .IntroductionAll viruses were propagated in embryonated RIR hens' eggs, supplied by the National Avian Facility (NARF), The Roslin Institute.", [["cell cultures", "ANATOMY", 4, 17], ["eggs", "ANATOMY", 212, 216], ["infection", "DISEASE", 113, 122], ["CO", "CHEMICAL", 141, 143], ["cell cultures", "CELL", 4, 17], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 212, 216], ["cell cultures", "CELL_LINE", 4, 17], ["All cell cultures", "TEST", 0, 17], ["infection", "PROBLEM", 113, 122], ["cell cultures", "OBSERVATION", 4, 17], ["infection", "OBSERVATION", 113, 122], ["viruses", "OBSERVATION", 163, 170]]], ["Allantoic fluid was clarified by low speed centrifugation and either titrated in CK cells in triplicate or in ex vivo tracheal organ cultures (TOCs) as described previously [15] .", [["CK cells", "ANATOMY", 81, 89], ["tracheal organ cultures", "ANATOMY", 118, 141], ["TOCs", "ANATOMY", 143, 147], ["Allantoic fluid", "ORGANISM_SUBSTANCE", 0, 15], ["CK cells", "CELL", 81, 89], ["tracheal organ cultures", "CELL", 118, 141], ["CK cells", "CELL_LINE", 81, 89], ["ex vivo tracheal organ cultures", "CELL_LINE", 110, 141], ["Allantoic fluid", "TEST", 0, 15], ["low speed centrifugation", "TREATMENT", 33, 57], ["CK cells", "TEST", 81, 89], ["tracheal organ cultures", "TEST", 118, 141], ["fluid", "OBSERVATION", 10, 15], ["tracheal organ", "ANATOMY", 118, 132]]], ["Titres are displayed as either the number of plaque forming units (PFU) per ml or as the dose required to causes 50% ciliostasis (CD50).", [["plaque", "ANATOMY", 45, 51], ["plaque", "DISEASE", 45, 51], ["50% ciliostasis", "PROBLEM", 113, 128], ["plaque", "OBSERVATION", 45, 51]]], ["The rIBVs Beau-R [19] , BeauR-M41(S) [35] and BeauR-M41-Struct [23] have been described previously, as have the laboratory strains M41-CK [35] , Beau-CK [19] and serially egg passaged viruses M41-CK EP106 A, A1, C and D [14] .", [["BeauR-M41", "GENE_OR_GENE_PRODUCT", 24, 33], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 46, 55], ["rIBVs", "PROTEIN", 4, 9], ["M41", "PROTEIN", 52, 55], ["CK", "PROTEIN", 196, 198], ["A1", "PROTEIN", 208, 210], ["The rIBVs Beau", "TEST", 0, 14], ["BeauR", "TEST", 24, 29], ["BeauR", "TEST", 46, 51], ["the laboratory strains M41", "TEST", 108, 134], ["CK", "TEST", 135, 137], ["Beau-CK", "TEST", 145, 152], ["serially egg", "TEST", 162, 174], ["viruses", "TEST", 184, 191], ["M41", "TEST", 192, 195], ["CK", "TEST", 196, 198], ["A", "TEST", 205, 206], ["A1", "TEST", 208, 210], ["C", "TEST", 212, 213]]], ["The H120 vaccine strain was a gift from Professor R. Jones at the University of Liverpool and nephropathogenic strain D388 [36] , a gift from Professor J.J de Wit at The GD Animal Health, Netherlands.In Vivo CharacterisationAll animal experimental protocols were carried out in strict accordance with the UK Home Office guidelines and under licence granted for experiments involving regulated procedures on animals protected under the UK Animals (Scientific Procedures) Act 1986.", [["The H120 vaccine strain", "TREATMENT", 0, 23], ["All animal experimental protocols", "TREATMENT", 224, 257]]], ["The experiment was performed in The Pirbright Institute Home Office licenced (X24684464) experimental animal house facilities and were approved (AR000772, 4 August 2016) by the animal welfare and ethical review committee under the terms of reference HO-ERP-01-1.In Vivo CharacterisationSPF RIR chickens were housed in raised floor pens in separate positive pressure high-efficiency particulate air (HEPA) filtered rooms in groups of 24 birds.", [["chickens", "ORGANISM", 294, 302], ["HO", "PROTEIN", 250, 252], ["ERP", "PROTEIN", 253, 256], ["chickens", "SPECIES", 294, 302], ["chickens", "SPECIES", 294, 302], ["ERP", "TEST", 253, 256], ["Vivo CharacterisationSPF RIR chickens", "TREATMENT", 265, 302]]], ["Chickens were inoculated with 100 \u00b5L containing 10 4 PFU of rIBV Beau-R or IBV M41-CK or 100 \u00b5L Phosphate Buffered Saline (PBS) for mock infection via the intra-nasal and intra-ocular route at seven days of age.", [["intra-nasal", "ANATOMY", 155, 166], ["intra-ocular", "ANATOMY", 171, 183], ["Phosphate", "CHEMICAL", 96, 105], ["infection", "DISEASE", 137, 146], ["Phosphate", "CHEMICAL", 96, 105], ["Chickens", "ORGANISM", 0, 8], ["rIBV", "ORGANISM", 60, 64], ["Beau-R", "SIMPLE_CHEMICAL", 65, 71], ["IBV", "ORGANISM", 75, 78], ["M41-CK", "GENE_OR_GENE_PRODUCT", 79, 85], ["Phosphate Buffered Saline", "SIMPLE_CHEMICAL", 96, 121], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["rIBV", "SPECIES", 60, 64], ["IBV", "SPECIES", 75, 78], ["Chickens", "TREATMENT", 0, 8], ["Beau", "TEST", 65, 69], ["IBV M41", "TREATMENT", 75, 82], ["CK", "TEST", 83, 85], ["Phosphate Buffered Saline (PBS)", "TREATMENT", 96, 127], ["mock infection", "PROBLEM", 132, 146], ["the intra-nasal and intra-ocular route", "TREATMENT", 151, 189], ["infection", "OBSERVATION", 137, 146]]], ["Clinical signs, including rales and snicking were observed from one to seven days post infection (dpi) as previously described [20] .", [["infection", "DISEASE", 87, 96], ["Clinical signs", "TEST", 0, 14], ["rales", "PROBLEM", 26, 31], ["snicking", "PROBLEM", 36, 44], ["infection", "PROBLEM", 87, 96], ["rales", "OBSERVATION", 26, 31], ["infection", "OBSERVATION", 87, 96]]], ["One, four and six dpi, six randomly selected birds per group were culled by cervical dislocation.", [["cervical", "ANATOMY", 76, 84], ["cervical dislocation", "DISEASE", 76, 96], ["birds", "ORGANISM", 45, 50], ["cervical", "ORGANISM_SUBDIVISION", 76, 84], ["cervical dislocation", "PROBLEM", 76, 96], ["cervical", "ANATOMY", 76, 84], ["dislocation", "OBSERVATION", 85, 96]]], ["A variety of tissues were harvested with sections stored in either PBS or RNALater (Ambion, Thermo Fisher Scientific, Waltham, MA, USA).", [["tissues", "ANATOMY", 13, 20], ["sections", "ANATOMY", 41, 49], ["tissues", "TISSUE", 13, 20], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["tissues", "ANATOMY", 13, 20]]], ["On day seven, post infection, all remaining birds were euthanized by cervical dislocation.", [["cervical", "ANATOMY", 69, 77], ["infection", "DISEASE", 19, 28], ["cervical dislocation", "DISEASE", 69, 89], ["birds", "ORGANISM", 44, 49], ["cervical", "ORGAN", 69, 77], ["post infection", "PROBLEM", 14, 28], ["cervical dislocation", "PROBLEM", 69, 89], ["infection", "OBSERVATION", 19, 28], ["cervical", "ANATOMY", 69, 77], ["dislocation", "OBSERVATION", 78, 89]]], ["Ciliary activity was assessed in trachea extracted 4 and 6 dpi as previously described [37, 38] .Virus Re-Isolation in Embryonated Hens' EggsInfectious virus was re-isolated from harvested tissues in ten-day old SPF Valo embryonated hens' eggs.", [["Ciliary", "ANATOMY", 0, 7], ["trachea", "ANATOMY", 33, 40], ["tissues", "ANATOMY", 189, 196], ["eggs", "ANATOMY", 239, 243], ["Ciliary", "MULTI-TISSUE_STRUCTURE", 0, 7], ["trachea", "ORGAN", 33, 40], ["Virus", "ORGANISM", 97, 102], ["Embryonated Hens' EggsInfectious virus", "ORGANISM", 119, 157], ["tissues", "TISSUE", 189, 196], ["hens", "ORGANISM", 233, 237], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 239, 243], ["hens", "SPECIES", 233, 237], ["Embryonated Hens' EggsInfectious virus", "SPECIES", 119, 157], ["Virus Re-Isolation", "TREATMENT", 97, 115], ["Embryonated Hens' EggsInfectious virus", "TREATMENT", 119, 157], ["activity", "OBSERVATION_MODIFIER", 8, 16], ["trachea", "ANATOMY", 33, 40], ["harvested tissues", "OBSERVATION", 179, 196]]], ["Tissue was homogenised using a tissue lyser II (Qiagen, Hilden, Germany), in 500 \u00b5l PBS containing 10 U/mL penicillin, 10 \u00b5g/mL streptomycin and 50 U/mL nystatin followed by clarification by low speed centrifugation.", [["Tissue", "ANATOMY", 0, 6], ["tissue", "ANATOMY", 31, 37], ["penicillin", "CHEMICAL", 107, 117], ["streptomycin", "CHEMICAL", 128, 140], ["nystatin", "CHEMICAL", 153, 161], ["penicillin", "CHEMICAL", 107, 117], ["streptomycin", "CHEMICAL", 128, 140], ["nystatin", "CHEMICAL", 153, 161], ["Tissue", "TISSUE", 0, 6], ["penicillin", "SIMPLE_CHEMICAL", 107, 117], ["streptomycin", "SIMPLE_CHEMICAL", 128, 140], ["nystatin", "SIMPLE_CHEMICAL", 153, 161], ["a tissue lyser II", "TREATMENT", 29, 46], ["penicillin", "TREATMENT", 107, 117], ["streptomycin", "TREATMENT", 128, 140], ["nystatin", "TREATMENT", 153, 161]]], ["Each egg was inoculated with 100 \u00b5L clarified tissue derived supernatant and incubated for 24 h at 37 \u2022 C. Embryos were culled using a schedule 1 method and the allantoic fluid harvested, which was screened for viral presence by RT-PCR utilising primers that target the 3 UTR as described previously [23] .In Vitro Growth Kinetic ExperimentsDF1 or CK cells, seeded in six or twelve well plates, were infected with 10 4 PFU, 10 5 PFU, or 1.5 log 10 CD50 (MOI0.01) rIBV or IBV, and incubated for 1 h at 37 \u2022 C, 5% CO 2 or 41 \u2022 C, 5% CO 2 .In Vitro Growth Kinetic ExperimentsInoculum was removed, and cells were washed twice with PBSa to remove unbound virus.", [["egg", "ANATOMY", 5, 8], ["tissue", "ANATOMY", 46, 52], ["supernatant", "ANATOMY", 61, 72], ["Embryos", "ANATOMY", 107, 114], ["allantoic fluid", "ANATOMY", 161, 176], ["CK cells", "ANATOMY", 348, 356], ["cells", "ANATOMY", 598, 603], ["CO", "CHEMICAL", 512, 514], ["CO", "CHEMICAL", 531, 533], ["egg", "ORGANISM_SUBSTANCE", 5, 8], ["tissue", "TISSUE", 46, 52], ["Embryos", "ORGANISM", 107, 114], ["allantoic fluid", "ORGANISM_SUBSTANCE", 161, 176], ["CK cells", "CELL", 348, 356], ["IBV", "ORGANISM", 471, 474], ["cells", "CELL", 598, 603], ["PBSa", "SIMPLE_CHEMICAL", 627, 631], ["3 UTR", "DNA", 270, 275], ["CK cells", "CELL_LINE", 348, 356], ["rIBV", "SPECIES", 463, 467], ["IBV", "SPECIES", 471, 474], ["a schedule 1 method", "TREATMENT", 133, 152], ["the allantoic fluid harvested", "TREATMENT", 157, 186], ["viral presence", "PROBLEM", 211, 225], ["RT-PCR utilising primers", "TREATMENT", 229, 253], ["CK cells", "PROBLEM", 348, 356], ["IBV", "TREATMENT", 471, 474], ["CO", "TEST", 512, 514], ["C", "TEST", 525, 526], ["CO", "TEST", 531, 533], ["Inoculum", "TREATMENT", 572, 580], ["PBSa", "TREATMENT", 627, 631], ["unbound virus", "PROBLEM", 642, 655], ["fluid harvested", "OBSERVATION", 171, 186]]], ["Per well, 3 mL BES (N,N-Bis(2-hydroxyethyl)-2aminoethanesulphonic acid) medium [39] was added, and cells were incubated at either 37 \u2022 C, 5% CO 2 or 41 \u2022 C, 5% CO 2 .", [["cells", "ANATOMY", 99, 104], ["BES", "CHEMICAL", 15, 18], ["N,N-Bis(2-hydroxyethyl)-2aminoethanesulphonic acid", "CHEMICAL", 20, 70], ["BES", "CHEMICAL", 15, 18], ["N,N-Bis(2-hydroxyethyl)-2aminoethanesulphonic acid", "CHEMICAL", 20, 70], ["CO", "CHEMICAL", 141, 143], ["CO 2", "CHEMICAL", 160, 164], ["N,N-Bis(2-hydroxyethyl)-2aminoethanesulphonic acid", "SIMPLE_CHEMICAL", 20, 70], ["cells", "CELL", 99, 104], ["Bis(2-hydroxyethyl)", "TREATMENT", 24, 43], ["2aminoethanesulphonic acid)", "TREATMENT", 44, 71], ["CO", "TEST", 141, 143], ["C", "TEST", 154, 155]]], ["Supernatant containing viral progeny, one well per time point, was harvested at defined intervals post infection (pi) and titrated in triplicate in CK cells.", [["Supernatant", "ANATOMY", 0, 11], ["progeny", "ANATOMY", 29, 36], ["CK cells", "ANATOMY", 148, 156], ["infection", "DISEASE", 103, 112], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["CK cells", "CELL", 148, 156], ["CK cells", "CELL_TYPE", 148, 156], ["infection", "PROBLEM", 103, 112], ["triplicate in CK cells", "TEST", 134, 156], ["viral progeny", "OBSERVATION", 23, 36], ["infection", "OBSERVATION", 103, 112]]], ["Each experiment was performed three times.Analysis of sgmRNA Synthesis by Quantitative Real-Time PCR (qRT-PCR)CK cells seeded in 6 well plates were inoculated with 10 6 PFU (multiplicity of infection (MOI) 0.01) of Beau-R or M41-CK and incubated at either 37 \u2022 C or 41 \u2022 C. After 24 hpi, supernatant was harvested and assessed for infectious progeny by titration in CK cells.", [["CK cells", "ANATOMY", 110, 118], ["supernatant", "ANATOMY", 288, 299], ["progeny", "ANATOMY", 342, 349], ["CK cells", "ANATOMY", 366, 374], ["infection", "DISEASE", 190, 199], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 54, 60], ["CK cells", "CELL", 110, 118], ["Beau-R", "GENE_OR_GENE_PRODUCT", 215, 221], ["M41-CK", "GENE_OR_GENE_PRODUCT", 225, 231], ["CK cells", "CELL", 366, 374], ["CK cells", "CELL_LINE", 110, 118], ["CK cells", "CELL_TYPE", 366, 374], ["Analysis", "TEST", 42, 50], ["sgmRNA Synthesis", "TEST", 54, 70], ["Time PCR", "TEST", 92, 100], ["qRT", "TEST", 102, 105], ["PCR", "TEST", 106, 109], ["CK cells", "TEST", 110, 118], ["infection", "PROBLEM", 190, 199], ["Beau", "TEST", 215, 219], ["M41", "TEST", 225, 228], ["CK", "TEST", 229, 231], ["infectious progeny", "PROBLEM", 331, 349], ["titration in CK cells", "TEST", 353, 374], ["infection", "OBSERVATION", 190, 199]]], ["Cell lysate was also harvested, and RNA was extracted using RNeasy columns (QIAgen), following the manufacturer's instructions, including on column DNAse treatment.", [["Cell lysate", "ANATOMY", 0, 11], ["Cell", "CELL", 0, 4], ["DNAse", "GENE_OR_GENE_PRODUCT", 148, 153], ["Cell lysate", "TREATMENT", 0, 11], ["RNeasy columns (QIAgen", "TREATMENT", 60, 82], ["the manufacturer's instructions", "TREATMENT", 95, 126], ["column DNAse treatment", "TREATMENT", 141, 163]]], ["Reverse transcription of 1 \u00b5g total RNA was performed using the Superscript III Reverse Transcriptase kit (Invitrogen, Waltham, MA, USA) according to the manufacturer's protocol using random primers (Promega, Madison, WI, USA).", [["1 \u00b5g total RNA", "RNA", 25, 39], ["1 \u00b5g total RNA", "TREATMENT", 25, 39], ["the manufacturer's protocol", "TREATMENT", 150, 177], ["random primers", "TREATMENT", 184, 198]]], ["The viral RNA load was quantified using quantitative real-time PCR (qRT-PCR) using primers targeting the N sub-genomic mRNA (sgmRNA).", [["N sub-genomic mRNA", "RNA", 105, 123], ["sgmRNA", "PROTEIN", 125, 131], ["The viral RNA load", "TEST", 0, 18], ["quantitative real-time PCR", "TEST", 40, 66], ["qRT", "TEST", 68, 71], ["PCR", "TEST", 72, 75], ["primers", "TREATMENT", 83, 90], ["the N sub-genomic mRNA", "TREATMENT", 101, 123], ["viral RNA load", "OBSERVATION", 4, 18], ["genomic mRNA", "OBSERVATION", 111, 123]]], ["Quantitative RT-PCR was performed using TaqMan Universal Master Mix II, no UNG (Life Technologies, Waltham, MA, USA) including 125 nM final probe and 500 nM final primers.", [["UNG", "PROTEIN", 75, 78], ["Quantitative RT-PCR", "TEST", 0, 19], ["UNG", "PROBLEM", 75, 78]]], ["The primer and probe sequences were taken from Maier et al. (2013) [40] and are as follows: forward primer located in the leader sequence, 5 -CTAGCCTTGCGCTAGATTTTTAACT-3 ; reverse primer located in the N gene 5 -GAGAGGTACACGCGGGACAA-3 ; and N sgmRNA probe sequence, 5 -FAM-ACAAAGCAGGACAAGCA-MGB-NFQ-3 .", [["-CTAGCCTTGCGCTAGATTTTTAACT-3", "GENE_OR_GENE_PRODUCT", 141, 169], ["5 -GAGAGGTACACGCGGGACAA-3", "GENE_OR_GENE_PRODUCT", 209, 234], ["primer and probe sequences", "DNA", 4, 30], ["leader sequence", "DNA", 122, 137], ["reverse primer", "DNA", 172, 186], ["N gene 5 -GAGAGGTACACGCGGGACAA-3", "DNA", 202, 234], ["N sgmRNA probe sequence", "DNA", 241, 264], ["5 -FAM-ACAAAGCAGGACAAGCA-MGB-NFQ-3", "DNA", 266, 300], ["The primer and probe sequences", "TEST", 0, 30], ["forward primer", "PROBLEM", 92, 106], ["the leader sequence", "TEST", 118, 137], ["-CTAGCCTTGCGCTAGATTTTTAACT", "TEST", 141, 167], ["GAGAGGTACACGCGGGACAA", "TEST", 212, 232], ["N sgmRNA probe sequence", "TEST", 241, 264], ["-FAM-ACAAAGCAGGACAAGCA", "TEST", 268, 290], ["MGB", "TEST", 291, 294]]], ["Standard curves were performed to allow quantitation of IBV RNA copy numbers based on cDNA levels using plasmids containing the sequence amplified by the set of primers listed above.", [["IBV", "ORGANISM", 56, 59], ["plasmids", "DNA", 104, 112], ["IBV", "SPECIES", 56, 59], ["Standard curves", "TEST", 0, 15], ["IBV RNA", "TREATMENT", 56, 63], ["cDNA levels", "TEST", 86, 97], ["plasmids", "TREATMENT", 104, 112], ["the sequence", "TEST", 124, 136]]], ["The resulting Ct results were used to calculate the log of relative RNA copies (Log10) using the linear equation from the standard curve.Temperature Swap AssaysCK cells seeded in six well plates were inoculated with 10 5 PFU (MOI~0.01) of rIBV or IBV.", [["Swap AssaysCK cells", "ANATOMY", 149, 168], ["Swap AssaysCK cells", "CELL", 149, 168], ["rIBV", "ORGANISM", 239, 243], ["IBV", "ORGANISM", 247, 250], ["Swap AssaysCK cells", "CELL_LINE", 149, 168], ["rIBV", "SPECIES", 239, 243], ["IBV", "SPECIES", 247, 250], ["The resulting Ct results", "TEST", 0, 24], ["the linear equation", "TEST", 93, 112], ["Temperature Swap AssaysCK cells", "TEST", 137, 168], ["MOI", "TEST", 226, 229], ["rIBV", "TREATMENT", 239, 243], ["IBV", "PROBLEM", 247, 250], ["IBV", "OBSERVATION", 247, 250]]], ["Infected cells were incubated at either 37 \u2022 C or 41 \u2022 C for 1 h (1st incubation), after which the inoculum was removed, and cells washed with PBSa to remove unbound virus.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 125, 130], ["cells", "CELL", 9, 14], ["cells", "CELL", 125, 130], ["PBSa", "SIMPLE_CHEMICAL", 143, 147], ["Infected cells", "PROBLEM", 0, 14], ["the inoculum", "TREATMENT", 95, 107], ["PBSa", "TREATMENT", 143, 147], ["unbound virus", "PROBLEM", 158, 171]]], ["Per well, 3 mL BES media was added, and cells were incubated for a further 23 h at either 37 \u2022 C or 41 \u2022 C (2nd incubation).", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["3 mL BES media", "TREATMENT", 10, 24]]], ["Supernatant was harvested from three wells for each experimental condition, and each was titrated in triplicate in CK cells to determine the quantity of infectious progeny virus.", [["Supernatant", "ANATOMY", 0, 11], ["CK cells", "ANATOMY", 115, 123], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["CK cells", "CELL", 115, 123], ["infectious progeny virus", "ORGANISM", 153, 177], ["CK cells", "CELL_LINE", 115, 123], ["triplicate in CK cells", "TEST", 101, 123], ["infectious progeny virus", "PROBLEM", 153, 177], ["harvested", "OBSERVATION", 16, 25], ["infectious progeny virus", "OBSERVATION", 153, 177]]], ["Each experiment was performed three times.Co-Infection AssayCK cells seeded in six well plates were inoculated in triplicate with 10 5 PFU (MOI~0.01) of M41-CK, Beau-R, co-infected with 10 5 PFU Beau-R and 10 5 PFU M41-CK or mock infected with BES media.", [["AssayCK cells", "ANATOMY", 55, 68], ["AssayCK cells", "CELL", 55, 68], ["CK", "GENE_OR_GENE_PRODUCT", 157, 159], ["Beau-R", "SIMPLE_CHEMICAL", 161, 167], ["Beau-R", "ORGANISM", 195, 201], ["CK", "GENE_OR_GENE_PRODUCT", 219, 221], ["AssayCK cells", "CELL_LINE", 55, 68], ["CK", "PROTEIN", 219, 221], ["Co-Infection", "PROBLEM", 42, 54], ["AssayCK cells", "PROBLEM", 55, 68], ["MOI", "TEST", 140, 143], ["M41", "TEST", 153, 156], ["CK", "TEST", 157, 159], ["Beau", "TEST", 161, 165], ["co-infected", "TEST", 169, 180], ["Beau", "TEST", 195, 199], ["PFU M41", "TEST", 211, 218], ["CK", "TEST", 219, 221], ["BES media", "TREATMENT", 244, 253], ["Infection", "OBSERVATION", 45, 54], ["infected", "OBSERVATION", 230, 238]]], ["Cells were incubated at 37 \u2022 C, 5% CO 2 or 41 \u2022 C, 5% CO 2 for 1 h, after which the inoculum was removed, and cells washed once with PBSa to remove any unbound virions.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 110, 115], ["virions", "ANATOMY", 160, 167], ["CO", "CHEMICAL", 35, 37], ["CO 2", "CHEMICAL", 54, 58], ["Cells", "CELL", 0, 5], ["cells", "CELL", 110, 115], ["PBSa", "SIMPLE_CHEMICAL", 133, 137], ["Cells", "TEST", 0, 5], ["C", "TEST", 29, 30], ["CO", "TEST", 35, 37], ["C", "TEST", 48, 49], ["the inoculum", "TREATMENT", 80, 92], ["cells", "TEST", 110, 115], ["PBSa", "TREATMENT", 133, 137], ["any unbound virions", "PROBLEM", 148, 167], ["inoculum", "OBSERVATION", 84, 92]]], ["Per well, 3 mL BES media was added, and cells were incubated at either 37 \u2022 C or 41 \u2022 C until extensive CPE was observed in the 37 \u2022 C Beau-R and M41-CK control samples, typically 48 to 72 hpi.", [["cells", "ANATOMY", 40, 45], ["samples", "ANATOMY", 161, 168], ["cells", "CELL", 40, 45], ["Beau-R", "GENE_OR_GENE_PRODUCT", 135, 141], ["M41-CK", "GENE_OR_GENE_PRODUCT", 146, 152], ["3 mL BES media", "TREATMENT", 10, 24], ["extensive CPE", "TEST", 94, 107], ["Beau", "TEST", 135, 139], ["M41", "TEST", 146, 149], ["CK control samples", "TEST", 150, 168]]], ["The supernatants were harvested and passaged a further four times in CK cells, using the same incubation conditions as the original passage.", [["supernatants", "ANATOMY", 4, 16], ["CK cells", "ANATOMY", 69, 77], ["CK cells", "CELL", 69, 77], ["CK cells", "CELL_TYPE", 69, 77], ["The supernatants", "TREATMENT", 0, 16], ["CK cells", "TREATMENT", 69, 77], ["the same incubation conditions", "TREATMENT", 85, 115], ["harvested", "OBSERVATION", 22, 31]]], ["Passage 5 supernatant was screened for viral presence using RT-PCR utilising primers targeting the 3 UTR, described previously [23] .Analysis of Protein Expression by Western BlotCK cells were seeded in six well plates and inoculated with 10 6 PFU M41-CK, Beau-R or BES media for mock infection and incubated at either 37 \u2022 C or 41 \u2022 C. At 8, 11 and 24 hpi cell lysates were harvested using radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with Protein Inhibitor Cocktail added (Thermo Fisher Scientific).", [["supernatant", "ANATOMY", 10, 21], ["BlotCK cells", "ANATOMY", 175, 187], ["cell lysates", "ANATOMY", 357, 369], ["infection", "DISEASE", 285, 294], ["BlotCK cells", "CELL", 175, 187], ["CK", "GENE_OR_GENE_PRODUCT", 252, 254], ["Beau-R", "CELL", 256, 262], ["cell lysates", "CELL", 357, 369], ["3 UTR", "DNA", 99, 104], ["Western BlotCK cells", "CELL_LINE", 167, 187], ["Passage 5 supernatant", "PROBLEM", 0, 21], ["viral presence", "PROBLEM", 39, 53], ["RT-PCR utilising primers", "TREATMENT", 60, 84], ["Protein Expression", "TEST", 145, 163], ["BlotCK cells", "TEST", 175, 187], ["PFU M41", "TEST", 244, 251], ["CK", "TEST", 252, 254], ["Beau", "TEST", 256, 260], ["mock infection", "PROBLEM", 280, 294], ["hpi cell lysates", "TEST", 353, 369], ["radioimmunoprecipitation assay (RIPA) lysis buffer", "TREATMENT", 391, 441], ["Protein Inhibitor Cocktail", "TREATMENT", 492, 518], ["infection", "OBSERVATION", 285, 294]]], ["Cell lysates were Viruses 2020, 12, 754 5 of 20 resolved using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and were then transferred to a nitrocellulose membrane.", [["Cell lysates", "ANATOMY", 0, 12], ["membrane", "ANATOMY", 179, 187], ["sodium dodecyl sulphate", "CHEMICAL", 63, 86], ["sodium dodecyl sulphate", "CHEMICAL", 63, 86], ["polyacrylamide", "CHEMICAL", 87, 101], ["nitrocellulose", "CHEMICAL", 164, 178], ["Cell lysates", "CELL", 0, 12], ["sodium dodecyl sulphate", "SIMPLE_CHEMICAL", 63, 86], ["membrane", "CELLULAR_COMPONENT", 179, 187], ["Cell lysates", "TEST", 0, 12], ["Viruses", "TEST", 18, 25], ["sodium dodecyl sulphate", "TREATMENT", 63, 86], ["polyacrylamide gel electrophoresis", "TREATMENT", 87, 121], ["a nitrocellulose membrane", "TREATMENT", 162, 187]]], ["Non-specific binding sites were blocked using a 5% milk solution in PBS-tween (PBS-T) for 1 h at room temperature.", [["milk", "ORGANISM_SUBSTANCE", 51, 55], ["Non-specific binding sites", "PROBLEM", 0, 26], ["a 5% milk solution", "TREATMENT", 46, 64]]], ["The blots were probed with anti-IBV primary antibody (dilution 1:1000, Abcam, ab31671) and \u03b2-actin (dilution 1:2000, Abcam, ab8227).", [["Abcam", "GENE_OR_GENE_PRODUCT", 71, 76], ["ab31671", "GENE_OR_GENE_PRODUCT", 78, 85], ["\u03b2-actin", "SIMPLE_CHEMICAL", 91, 98], ["Abcam", "GENE_OR_GENE_PRODUCT", 117, 122], ["anti-IBV primary antibody", "PROTEIN", 27, 52], ["dilution 1:1000", "PROTEIN", 54, 69], ["Abcam", "PROTEIN", 71, 76], ["ab31671", "PROTEIN", 78, 85], ["\u03b2-actin", "PROTEIN", 91, 98], ["dilution 1:2000", "PROTEIN", 100, 115], ["Abcam", "PROTEIN", 117, 122], ["ab8227", "PROTEIN", 124, 130], ["anti-IBV", "SPECIES", 27, 35], ["The blots", "TEST", 0, 9], ["Abcam", "TEST", 71, 76], ["\u03b2-actin (dilution", "TREATMENT", 91, 108]]], ["Bound antibodies were detected with Donkey anti-Chicken (dilution 1:15,000, Licor, 926-68075) and Goat anti-Rabbit (dilution 1:15,000, Abcam, ab150077).", [["Bound antibodies", "PROTEIN", 0, 16], ["Goat", "SPECIES", 98, 102], ["Goat", "SPECIES", 98, 102], ["Bound antibodies", "TEST", 0, 16], ["Goat anti-Rabbit (dilution", "TREATMENT", 98, 124]]], ["Visualisation of membrane was carried out using the LICOR Odyssey CLx Imaging System.StatisticsEach figure details the statistical tests used to analyse the data set presented.", [["membrane", "ANATOMY", 17, 25], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["the statistical tests", "TEST", 115, 136]]], ["Graphpad Prism, version 7.0 was used for all statistical analysis.", [["all statistical analysis", "TEST", 41, 65]]], ["Prior to each statistical test the normality of each data set was assessed.Replication of rIBV Beau-R is Restricted In VivoIn order to establish the in vivo sites of Beau-R replication, groups of seven-day old SPF RIR chickens were inoculated with either M41-CK, Beau-R or mock infected with PBS.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 95, 101], ["Beau-R", "GENE_OR_GENE_PRODUCT", 166, 172], ["SPF", "ORGANISM", 210, 213], ["RIR", "ORGANISM", 214, 217], ["chickens", "ORGANISM", 218, 226], ["CK", "GENE_OR_GENE_PRODUCT", 259, 261], ["Beau-R", "GENE_OR_GENE_PRODUCT", 263, 269], ["rIBV Beau-R", "DNA", 90, 101], ["chickens", "SPECIES", 218, 226], ["chickens", "SPECIES", 218, 226], ["each statistical test", "TEST", 9, 30], ["Beau-R replication", "TREATMENT", 166, 184], ["SPF RIR chickens", "TREATMENT", 210, 226], ["Beau", "TEST", 263, 267], ["PBS", "TREATMENT", 292, 295], ["infected", "OBSERVATION", 278, 286]]], ["Clinical signs including snicking ( Figure 1a ) and rales ( Figure 1b) were assessed from 1-7 dpi.", [["Clinical signs", "TEST", 0, 14], ["snicking", "PROBLEM", 25, 33], ["rales", "PROBLEM", 52, 57], ["rales", "ANATOMY", 52, 57]]], ["No IBV induced clinical signs were observed in the mock group or the birds infected with Beau-R.", [["IBV", "ORGANISM", 3, 6], ["birds", "ORGANISM", 69, 74], ["IBV", "SPECIES", 3, 6], ["Beau-R.", "SPECIES", 89, 96], ["IBV induced clinical signs", "PROBLEM", 3, 29]]], ["In contrast, chickens infected with M41-CK displayed snicking and rales from 2 dpi, with the rate of snicking peaking at 5 dpi and the percentage of birds with rales peaking at 6 dpi.", [["chickens", "ORGANISM", 13, 21], ["CK", "GENE_OR_GENE_PRODUCT", 40, 42], ["CK", "PROTEIN", 40, 42], ["chickens", "SPECIES", 13, 21], ["chickens", "SPECIES", 13, 21], ["M41", "TEST", 36, 39], ["snicking", "PROBLEM", 53, 61], ["rales", "PROBLEM", 66, 71], ["rales", "PROBLEM", 160, 165], ["rales", "OBSERVATION", 66, 71], ["percentage", "OBSERVATION_MODIFIER", 135, 145], ["rales", "OBSERVATION", 160, 165]]], ["Tracheas were harvested from six randomly selected birds per group, 4 and 6 dpi and the ciliary activities assessed.", [["Tracheas", "ANATOMY", 0, 8], ["ciliary", "ANATOMY", 88, 95], ["Tracheas", "CELL", 0, 8], ["birds", "ORGANISM", 51, 56], ["ciliary", "MULTI-TISSUE_STRUCTURE", 88, 95], ["Tracheas", "TREATMENT", 0, 8], ["the ciliary activities", "TEST", 84, 106], ["harvested", "OBSERVATION", 14, 23], ["ciliary", "ANATOMY", 88, 95]]], ["Ciliary activities of tracheal epithelial cells are used as a marker to determine whether a pathogenic isolate of IBV is present [41] .", [["Ciliary", "ANATOMY", 0, 7], ["tracheal epithelial cells", "ANATOMY", 22, 47], ["tracheal epithelial cells", "CELL", 22, 47], ["IBV", "ORGANISM", 114, 117], ["tracheal epithelial cells", "CELL_TYPE", 22, 47], ["IBV", "SPECIES", 114, 117], ["tracheal epithelial cells", "TREATMENT", 22, 47], ["a pathogenic isolate of IBV", "PROBLEM", 90, 117], ["tracheal", "ANATOMY", 22, 30], ["epithelial cells", "OBSERVATION", 31, 47], ["IBV", "OBSERVATION", 114, 117]]], ["The mean ciliary activities were comparable between the mock and Beau-R infected birds, 99% and 95% respectively, 4 dpi and 95% and 96%, respectively, 6 dpi.", [["ciliary", "ANATOMY", 9, 16], ["ciliary", "MULTI-TISSUE_STRUCTURE", 9, 16], ["Beau-R", "GENE_OR_GENE_PRODUCT", 65, 71], ["birds", "ORGANISM", 81, 86], ["The mean ciliary activities", "TEST", 0, 27], ["the mock", "TEST", 52, 60], ["Beau", "TEST", 65, 69], ["dpi", "TEST", 116, 119], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["ciliary activities", "OBSERVATION", 9, 27], ["infected", "OBSERVATION", 72, 80]]], ["In contrast, M41-CK infected birds exhibited ciliary activities of 1% and 0.4% (p < 0.0001) on days 4 and 6 dpi, respectively ( Figure 1c ).", [["ciliary", "ANATOMY", 45, 52], ["M41-CK", "GENE_OR_GENE_PRODUCT", 13, 19], ["birds", "ORGANISM", 29, 34], ["ciliary", "MULTI-TISSUE_STRUCTURE", 45, 52], ["M41", "PROTEIN", 13, 16], ["M41", "TEST", 13, 16], ["ciliary activities", "TEST", 45, 63], ["ciliary activities", "OBSERVATION", 45, 63]]], ["The absence of clinical signs together with the retention of ciliary activities confirms previous the reports that Beau-R has an attenuated phenotype in vivo [15, 16, 42] .Replication of rIBV Beau-R is Restricted In VivoTo determine the sites of viral replication for Beau-R and M41, eyelids, beak and tracheas were harvested from six randomly selected chickens per group at 1, 4, 6 and 7 dpi.", [["ciliary", "ANATOMY", 61, 68], ["eyelids", "ANATOMY", 284, 291], ["tracheas", "ANATOMY", 302, 310], ["Beau-R", "CHEMICAL", 115, 121], ["ciliary", "MULTI-TISSUE_STRUCTURE", 61, 68], ["Beau-R", "GENE_OR_GENE_PRODUCT", 115, 121], ["Beau-R", "GENE_OR_GENE_PRODUCT", 192, 198], ["Beau-R", "GENE_OR_GENE_PRODUCT", 268, 274], ["M41", "GENE_OR_GENE_PRODUCT", 279, 282], ["eyelids", "ORGAN", 284, 291], ["tracheas", "ORGAN", 302, 310], ["chickens", "ORGANISM", 353, 361], ["rIBV Beau-R", "DNA", 187, 198], ["chickens", "SPECIES", 353, 361], ["chickens", "SPECIES", 353, 361], ["clinical signs", "TEST", 15, 29], ["an attenuated phenotype", "PROBLEM", 126, 149], ["viral replication", "TREATMENT", 246, 263], ["Beau", "TEST", 268, 272], ["viral replication", "OBSERVATION", 246, 263], ["eyelids", "ANATOMY", 284, 291], ["beak", "ANATOMY", 293, 297], ["tracheas", "ANATOMY", 302, 310]]], ["For the purpose of this study, the beak refers to all soft tissue within the beak cavity including the nasal turbinates and nasal-associated lymphoid tissue (NALT), and eyelids includes both the upper and lower lid.", [["soft tissue", "ANATOMY", 54, 65], ["beak cavity", "ANATOMY", 77, 88], ["nasal turbinates", "ANATOMY", 103, 119], ["nasal-associated lymphoid tissue", "ANATOMY", 124, 156], ["NALT", "ANATOMY", 158, 162], ["eyelids", "ANATOMY", 169, 176], ["upper", "ANATOMY", 195, 200], ["lower lid", "ANATOMY", 205, 214], ["soft tissue", "TISSUE", 54, 65], ["beak cavity", "MULTI-TISSUE_STRUCTURE", 77, 88], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 103, 119], ["nasal-associated lymphoid tissue", "TISSUE", 124, 156], ["NALT", "MULTI-TISSUE_STRUCTURE", 158, 162], ["eyelids", "ORGAN", 169, 176], ["upper", "ORGANISM_SUBDIVISION", 195, 200], ["lower lid", "ORGANISM_SUBDIVISION", 205, 214], ["this study", "TEST", 19, 29], ["the beak", "PROBLEM", 31, 39], ["soft tissue", "ANATOMY", 54, 65], ["beak cavity", "OBSERVATION", 77, 88], ["nasal turbinates", "ANATOMY", 103, 119], ["nasal", "ANATOMY", 124, 129], ["lymphoid tissue", "OBSERVATION", 141, 156], ["eyelids", "ANATOMY", 169, 176], ["both", "ANATOMY_MODIFIER", 186, 190], ["upper", "ANATOMY_MODIFIER", 195, 200], ["lower lid", "ANATOMY", 205, 214]]], ["To determine whether infectious progeny virions were being produced in the selected tissues, embryonated hens' eggs were inoculated with tissue-derived supernatants and the resulting allantoic fluid analysed by RT-PCR (Table 1) for the presence of IBV RNA using a primer set specific for the 3 UTR [23] .", [["virions", "ANATOMY", 40, 47], ["tissues", "ANATOMY", 84, 91], ["eggs", "ANATOMY", 111, 115], ["tissue", "ANATOMY", 137, 143], ["supernatants", "ANATOMY", 152, 164], ["allantoic fluid", "ANATOMY", 183, 198], ["tissues", "TISSUE", 84, 91], ["hens", "ORGANISM", 105, 109], ["eggs", "ORGANISM_SUBSTANCE", 111, 115], ["tissue", "TISSUE", 137, 143], ["allantoic fluid", "ORGANISM_SUBSTANCE", 183, 198], ["IBV", "ORGANISM", 248, 251], ["IBV RNA", "RNA", 248, 255], ["hens", "SPECIES", 105, 109], ["hens", "SPECIES", 105, 109], ["IBV", "SPECIES", 248, 251], ["infectious progeny virions", "PROBLEM", 21, 47], ["the resulting allantoic fluid", "TEST", 169, 198], ["PCR", "TEST", 214, 217], ["IBV RNA", "TREATMENT", 248, 255], ["a primer", "TREATMENT", 262, 270], ["infectious", "OBSERVATION_MODIFIER", 21, 31]]], ["Due to a 184 bp deletion within the 3 UTR of the M41-CK genome, the RT-PCR products generated from this primer set can be easily distinguished, on size difference, between M41-CK and Beau-R derived RNA [23] .", [["M41-CK", "GENE_OR_GENE_PRODUCT", 49, 55], ["M41-CK", "GENE_OR_GENE_PRODUCT", 172, 178], ["Beau-R", "GENE_OR_GENE_PRODUCT", 183, 189], ["184 bp deletion", "DNA", 9, 24], ["3 UTR", "DNA", 36, 41], ["M41", "DNA", 49, 52], ["CK genome", "DNA", 53, 62], ["RT-PCR products", "DNA", 68, 83], ["M41", "DNA", 172, 175], ["CK", "PROTEIN", 176, 178], ["a 184 bp deletion", "PROBLEM", 7, 24], ["the RT-PCR products", "TREATMENT", 64, 83], ["M41", "TEST", 172, 175], ["CK", "TEST", 176, 178], ["Beau", "TEST", 183, 187], ["RT", "ANATOMY", 68, 70], ["size", "OBSERVATION_MODIFIER", 147, 151]]], ["As expected, no infectious Beau-R was isolated from tracheal samples on any sampling day, compared to at least 50% of tracheal samples testing positive for the presence of M41-CK on each sampling day post-infection.", [["tracheal samples", "ANATOMY", 52, 68], ["tracheal samples", "ANATOMY", 118, 134], ["Beau-R", "GENE_OR_GENE_PRODUCT", 27, 33], ["tracheal samples", "MULTI-TISSUE_STRUCTURE", 52, 68], ["tracheal samples", "CANCER", 118, 134], ["M41-CK", "GENE_OR_GENE_PRODUCT", 172, 178], ["M41", "PROTEIN", 172, 175], ["CK", "PROTEIN", 176, 178], ["Beau-R", "SPECIES", 27, 33], ["tracheal samples", "TEST", 52, 68], ["tracheal samples testing", "TEST", 118, 142], ["M41", "TEST", 172, 175], ["no", "UNCERTAINTY", 13, 15], ["infectious", "OBSERVATION_MODIFIER", 16, 26], ["tracheal", "ANATOMY", 52, 60], ["tracheal", "ANATOMY", 118, 126]]], ["M41-CK was detected in eyelid tissue harvested from all birds 4 and 6 dpi and in four of six birds and five of six birds, 1 and 7 dpi respectively.", [["eyelid tissue", "ANATOMY", 23, 36], ["M41-CK", "GENE_OR_GENE_PRODUCT", 0, 6], ["eyelid tissue", "TISSUE", 23, 36], ["birds", "ORGANISM", 115, 120], ["M41", "PROTEIN", 0, 3], ["CK", "PROTEIN", 4, 6], ["M41", "TEST", 0, 3], ["CK", "TEST", 4, 6], ["eyelid tissue", "PROBLEM", 23, 36], ["eyelid tissue", "ANATOMY", 23, 36], ["harvested", "OBSERVATION", 37, 46]]], ["Beau-R was not detected in the harvested eyelid tissue except for one bird at day 7 dpi.", [["eyelid tissue", "ANATOMY", 41, 54], ["Beau-R", "GENE_OR_GENE_PRODUCT", 0, 6], ["eyelid tissue", "TISSUE", 41, 54], ["harvested", "OBSERVATION", 31, 40], ["eyelid tissue", "ANATOMY", 41, 54]]], ["All beak tissue, however, tested positive for the presence of Beau-R at 1 dpi, which was comparable to M41-CK at this time point, but the detection of Beau-R dropped to \u226450% at 4 and 7 dpi with none detected at 6 dpi.", [["beak tissue", "ANATOMY", 4, 15], ["beak tissue", "TISSUE", 4, 15], ["Beau-R", "GENE_OR_GENE_PRODUCT", 62, 68], ["M41-CK", "GENE_OR_GENE_PRODUCT", 103, 109], ["Beau-R", "GENE_OR_GENE_PRODUCT", 151, 157], ["M41", "PROTEIN", 103, 106], ["CK", "PROTEIN", 107, 109], ["All beak tissue", "TEST", 0, 15], ["M41", "TEST", 103, 106], ["Beau", "TEST", 151, 155], ["beak tissue", "OBSERVATION", 4, 15]]], ["These results indicate that Beau-R replication is confined to tissue within the beak, and largely restricted to early infection.Replication of rIBV Beau-R is Restricted In Vivotracheal epithelial cells are used as a marker to determine whether a pathogenic isolate of IBV is present [41] .", [["tissue", "ANATOMY", 62, 68], ["Vivotracheal epithelial cells", "ANATOMY", 172, 201], ["infection", "DISEASE", 118, 127], ["Beau-R", "GENE_OR_GENE_PRODUCT", 28, 34], ["tissue", "TISSUE", 62, 68], ["rIBV Beau-R", "GENE_OR_GENE_PRODUCT", 143, 154], ["Vivotracheal epithelial cells", "CELL", 172, 201], ["IBV", "ORGANISM", 268, 271], ["rIBV Beau-R", "DNA", 143, 154], ["Vivotracheal epithelial cells", "CELL_TYPE", 172, 201], ["IBV", "SPECIES", 268, 271], ["Beau-R replication", "TREATMENT", 28, 46], ["early infection", "PROBLEM", 112, 127], ["Vivotracheal epithelial cells", "TREATMENT", 172, 201], ["a pathogenic isolate of IBV", "PROBLEM", 244, 271], ["beak", "OBSERVATION_MODIFIER", 80, 84], ["early", "OBSERVATION_MODIFIER", 112, 117], ["infection", "OBSERVATION", 118, 127], ["epithelial cells", "OBSERVATION", 185, 201], ["IBV", "OBSERVATION", 268, 271]]], ["The mean ciliary activities were comparable between the mock and Beau-R infected birds, 99% and 95% respectively, 4 dpi and 95% and 96%, respectively, 6 dpi.", [["ciliary", "ANATOMY", 9, 16], ["ciliary", "MULTI-TISSUE_STRUCTURE", 9, 16], ["Beau-R", "GENE_OR_GENE_PRODUCT", 65, 71], ["birds", "ORGANISM", 81, 86], ["The mean ciliary activities", "TEST", 0, 27], ["the mock", "TEST", 52, 60], ["Beau", "TEST", 65, 69], ["dpi", "TEST", 116, 119], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["ciliary activities", "OBSERVATION", 9, 27], ["infected", "OBSERVATION", 72, 80]]], ["In contrast, M41-CK infected birds exhibited ciliary activities of 1% and 0.4% (p < 0.0001) on days 4 and 6 dpi, respectively ( Figure 1c ).", [["ciliary", "ANATOMY", 45, 52], ["M41-CK", "GENE_OR_GENE_PRODUCT", 13, 19], ["birds", "ORGANISM", 29, 34], ["ciliary", "MULTI-TISSUE_STRUCTURE", 45, 52], ["M41", "PROTEIN", 13, 16], ["M41", "TEST", 13, 16], ["ciliary activities", "TEST", 45, 63], ["ciliary activities", "OBSERVATION", 45, 63]]], ["The absence of clinical signs together with the retention of ciliary activities confirms previous the reports that Beau-R has an attenuated phenotype in vivo [15, 16, 42] . (c) Ciliary activity was measured in trachea harvested from six randomly selected birds (n = 6) at 4 and 6 dpi.", [["ciliary", "ANATOMY", 61, 68], ["Ciliary", "ANATOMY", 177, 184], ["trachea", "ANATOMY", 210, 217], ["ciliary", "MULTI-TISSUE_STRUCTURE", 61, 68], ["Beau-R", "GENE_OR_GENE_PRODUCT", 115, 121], ["trachea", "ORGAN", 210, 217], ["clinical signs", "TEST", 15, 29], ["an attenuated phenotype", "PROBLEM", 126, 149], ["Ciliary activity", "OBSERVATION", 177, 193], ["trachea", "ANATOMY", 210, 217]]], ["The average percentage for each group is displayed with error bars representing standard error of the mean (SEM).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22]]], ["Statistical differences were assessed using a two-way ANOVA followed by Tukey analysis for multiple comparisons and are represented by **** (p < 0.0001). (c) Ciliary activity was measured in trachea harvested from six randomly selected birds (n = 6) at 4 and 6 dpi.", [["Ciliary", "ANATOMY", 158, 165], ["trachea", "ANATOMY", 191, 198], ["trachea", "ORGAN", 191, 198], ["Tukey analysis", "TEST", 72, 86], ["Ciliary activity", "PROBLEM", 158, 174], ["Ciliary activity", "OBSERVATION", 158, 174], ["trachea", "ANATOMY", 191, 198]]], ["The average percentage for each group is displayed with error bars representing standard error of the mean (SEM).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22]]], ["Statistical differences were assessed using a two-way ANOVA followed by Tukey analysis for multiple comparisons and are represented by **** (p < 0.0001).", [["Tukey analysis", "TEST", 72, 86]]], ["Notes: * Samples from the trachea of one bird and beak tissue from two birds were damaged during processing and therefore were unable to be included in the dataset.", [["trachea", "ANATOMY", 26, 33], ["beak tissue", "ANATOMY", 50, 61], ["trachea", "MULTI-TISSUE_STRUCTURE", 26, 33], ["bird", "ORGANISM", 41, 45], ["beak tissue", "TISSUE", 50, 61], ["birds", "ORGANISM", 71, 76], ["beak tissue", "PROBLEM", 50, 61], ["trachea", "ANATOMY", 26, 33], ["one bird", "ANATOMY", 37, 45], ["beak tissue", "OBSERVATION", 50, 61]]], ["Beak refers to all soft tissue within the beak cavity, including nasal turbinates and nasal associated lymphoid tissue (NALT).Replication of rIBV Beau-R In Vitro Is Sensitive to TemperatureThe observation that in vivo replication of Beau-R is essentially restricted to the tissue within the beak raised an interesting question regarding the potential for temperature to affect replication and therefore viral dissemination through the host.", [["soft tissue", "ANATOMY", 19, 30], ["beak cavity", "ANATOMY", 42, 53], ["nasal turbinates", "ANATOMY", 65, 81], ["nasal associated lymphoid tissue", "ANATOMY", 86, 118], ["NALT", "ANATOMY", 120, 124], ["tissue", "ANATOMY", 273, 279], ["soft tissue", "TISSUE", 19, 30], ["beak cavity", "MULTI-TISSUE_STRUCTURE", 42, 53], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 65, 81], ["nasal associated lymphoid tissue", "TISSUE", 86, 118], ["NALT", "MULTI-TISSUE_STRUCTURE", 120, 124], ["Beau-R", "GENE_OR_GENE_PRODUCT", 233, 239], ["tissue", "TISSUE", 273, 279], ["Beau-R", "PROTEIN", 233, 239], ["nasal turbinates and nasal associated lymphoid tissue", "PROBLEM", 65, 118], ["The observation", "TEST", 189, 204], ["the beak", "PROBLEM", 287, 295], ["temperature to affect replication", "PROBLEM", 355, 388], ["viral dissemination through the host", "PROBLEM", 403, 439], ["all", "ANATOMY_MODIFIER", 15, 18], ["soft tissue", "ANATOMY", 19, 30], ["beak cavity", "ANATOMY", 42, 53], ["nasal turbinates", "ANATOMY", 65, 81], ["nasal", "ANATOMY", 86, 91], ["lymphoid tissue", "OBSERVATION", 103, 118]]], ["The continuous movement of air in the upper respiratory tract will inevitably cool this area of the bird, and it has been demonstrated for several human respiratory viruses including influenza virus [43, 44] , Rhinovirus [30, 31] and respiratory syncytial virus (RSV) [45] [46] [47] that replication can be confined to the upper respiratory tract as a consequence of viral replication being sensitive to the comparatively higher temperatures in the lower respiratory Viruses 2020, 12, 754 7 of 20 tract.", [["upper respiratory tract", "ANATOMY", 38, 61], ["upper respiratory tract", "ANATOMY", 323, 346], ["respiratory viruses", "DISEASE", 153, 172], ["influenza virus", "DISEASE", 183, 198], ["respiratory syncytial virus", "DISEASE", 234, 261], ["upper respiratory", "ORGANISM_SUBDIVISION", 38, 55], ["tract", "ORGANISM_SUBDIVISION", 56, 61], ["human", "ORGANISM", 147, 152], ["respiratory viruses", "ORGANISM", 153, 172], ["influenza virus", "ORGANISM", 183, 198], ["Rhinovirus", "ORGANISM", 210, 220], ["respiratory syncytial virus", "ORGANISM", 234, 261], ["RSV", "ORGANISM", 263, 266], ["upper respiratory", "ORGANISM_SUBDIVISION", 323, 340], ["tract", "ORGANISM_SUBDIVISION", 341, 346], ["human", "SPECIES", 147, 152], ["influenza virus", "SPECIES", 183, 198], ["respiratory syncytial virus", "SPECIES", 234, 261], ["human", "SPECIES", 147, 152], ["respiratory syncytial virus", "SPECIES", 234, 261], ["RSV", "SPECIES", 263, 266], ["air in the upper respiratory tract", "PROBLEM", 27, 61], ["several human respiratory viruses", "PROBLEM", 139, 172], ["influenza virus", "PROBLEM", 183, 198], ["Rhinovirus", "TEST", 210, 220], ["respiratory syncytial virus", "PROBLEM", 234, 261], ["viral replication", "PROBLEM", 367, 384], ["the comparatively higher temperatures in the lower respiratory Viruses", "PROBLEM", 404, 474], ["movement", "OBSERVATION_MODIFIER", 15, 23], ["air", "OBSERVATION", 27, 30], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61], ["respiratory viruses", "OBSERVATION", 153, 172], ["respiratory syncytial", "ANATOMY", 234, 255], ["upper", "ANATOMY_MODIFIER", 323, 328], ["respiratory tract", "ANATOMY", 329, 346], ["viral replication", "OBSERVATION", 367, 384], ["lower", "ANATOMY_MODIFIER", 449, 454], ["respiratory Viruses", "ANATOMY", 455, 474]]], ["A growth kinetics assay in CK cells was used to assess whether the replication of Beau-R was detrimentally affected by an increase in temperature.", [["CK cells", "ANATOMY", 27, 35], ["CK cells", "CELL", 27, 35], ["Beau-R", "GENE_OR_GENE_PRODUCT", 82, 88], ["CK cells", "CELL_LINE", 27, 35], ["A growth kinetics assay", "TEST", 0, 23], ["CK cells", "TEST", 27, 35], ["an increase in temperature", "PROBLEM", 119, 145], ["increase", "OBSERVATION_MODIFIER", 122, 130], ["temperature", "OBSERVATION_MODIFIER", 134, 145]]], ["The core body temperature of a chicken is considered to be 41 \u2022 C [48] , and therefore this temperature was chosen for all experiments comparing productive replication to standard conditions using an incubation temperature of 37 \u2022 C.Replication of rIBV Beau-R In Vitro Is Sensitive to TemperaturePrimary CK cells were inoculated with Beau-R or M41-CK and incubated at either 41 \u2022 C or 37 \u2022 C, with supernatant harvested at regular intervals (Figure 2a-d) .", [["body", "ANATOMY", 9, 13], ["TemperaturePrimary CK cells", "ANATOMY", 285, 312], ["supernatant", "ANATOMY", 398, 409], ["body", "ORGANISM_SUBDIVISION", 9, 13], ["chicken", "ORGANISM", 31, 38], ["CK cells", "CELL", 304, 312], ["Beau-R", "GENE_OR_GENE_PRODUCT", 334, 340], ["M41-CK", "GENE_OR_GENE_PRODUCT", 344, 350], ["TemperaturePrimary CK cells", "CELL_LINE", 285, 312], ["CK", "PROTEIN", 348, 350], ["chicken", "SPECIES", 31, 38], ["chicken", "SPECIES", 31, 38], ["The core body temperature", "TEST", 0, 25], ["this temperature", "TEST", 87, 103], ["an incubation temperature", "TEST", 197, 222], ["TemperaturePrimary CK cells", "TEST", 285, 312], ["Beau", "TEST", 334, 338], ["M41", "TEST", 344, 347], ["CK", "TEST", 348, 350], ["C", "TEST", 380, 381], ["core", "OBSERVATION_MODIFIER", 4, 8], ["body", "OBSERVATION_MODIFIER", 9, 13]]], ["The titres of infectious Beau-R determined from cells incubated at 41 \u2022 C were lower than those from cells incubated at 37 \u2022 C (p < 0.0001), with very little viable infectious progeny produced at the higher temperature ( Figure 2b ).", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 101, 106], ["Beau-R", "GENE_OR_GENE_PRODUCT", 25, 31], ["cells", "CELL", 48, 53], ["cells", "CELL", 101, 106], ["cells", "TEST", 48, 53], ["very little viable infectious progeny", "PROBLEM", 146, 183], ["infectious", "OBSERVATION", 14, 24], ["infectious", "OBSERVATION", 165, 175]]], ["In contrast, the quantity of infectious progeny released from cells infected with M41-CK was unaffected by temperature at 12 and 24 hpi (Figure 2c ).", [["progeny", "ANATOMY", 40, 47], ["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["M41-CK", "GENE_OR_GENE_PRODUCT", 82, 88], ["M41", "PROTEIN", 82, 85], ["CK", "PROTEIN", 86, 88], ["M41", "TEST", 82, 85], ["temperature", "TEST", 107, 118], ["quantity", "OBSERVATION_MODIFIER", 17, 25], ["infectious", "OBSERVATION", 29, 39]]], ["The titres of M41-CK determined from CK cells incubated at 41 \u2022 C were observed to be lower at 48 to 96 h (p < 0.0001) than those determined, at similar timepoints, from cells at 37 \u2022 C. Although it is clear, from these results, that the replication of both M41-CK and Beau-R is negatively affected at 41 \u2022 C, there is a substantial observable difference in the extent to which each virus is affected.", [["CK cells", "ANATOMY", 37, 45], ["cells", "ANATOMY", 170, 175], ["M41-CK", "GENE_OR_GENE_PRODUCT", 14, 20], ["CK cells", "CELL", 37, 45], ["cells", "CELL", 170, 175], ["M41-CK", "GENE_OR_GENE_PRODUCT", 258, 264], ["Beau-R", "GENE_OR_GENE_PRODUCT", 269, 275], ["M41", "PROTEIN", 14, 17], ["CK", "PROTEIN", 18, 20], ["CK cells", "CELL_TYPE", 37, 45], ["M41", "PROTEIN", 258, 261], ["CK", "PROTEIN", 262, 264], ["Beau", "PROTEIN", 269, 273], ["The titres of M41", "TEST", 0, 17], ["CK", "TEST", 18, 20], ["CK cells", "TEST", 37, 45], ["M41", "TEST", 258, 261], ["CK", "TEST", 262, 264], ["Beau", "TEST", 269, 273], ["a substantial observable difference", "PROBLEM", 319, 354], ["clear", "OBSERVATION", 202, 207], ["substantial", "OBSERVATION_MODIFIER", 321, 332], ["observable", "OBSERVATION_MODIFIER", 333, 343], ["difference", "OBSERVATION", 344, 354], ["virus", "OBSERVATION", 383, 388]]], ["M41-CK is able to sustain a level of replication capable of generating consistent titres around 104 PFU/mL, whereas Beau-R was unable to sustain any productive infection at the higher temperature ( Figure 2c ,d).", [["infection", "DISEASE", 160, 169], ["M41-CK", "GENE_OR_GENE_PRODUCT", 0, 6], ["Beau-R", "GENE_OR_GENE_PRODUCT", 116, 122], ["M41", "PROTEIN", 0, 3], ["CK", "PROTEIN", 4, 6], ["M41", "TEST", 0, 3], ["CK", "TEST", 4, 6], ["any productive infection", "PROBLEM", 145, 169], ["productive", "OBSERVATION_MODIFIER", 149, 159], ["infection", "OBSERVATION", 160, 169]]], ["These results demonstrate that a temperature of 41 \u2022 C can be considered as a non-permissive temperature for Beau-R replication.Replication of rIBV Beau-R In Vitro Is Sensitive to TemperatureViruses 2020, 12, x FOR PEER REVIEW 7 of 20 by temperature at 12 and 24 hpi (Figure 2c ).", [["Beau-R", "GENE_OR_GENE_PRODUCT", 109, 115], ["a temperature", "TEST", 31, 44], ["Beau-R replication", "TREATMENT", 109, 127]]], ["The titres of M41-CK determined from CK cells incubated at 41 \u00b0C were observed to be lower at 48 to 96 h (p < 0.0001) than those determined, at similar timepoints, from cells at 37 \u00b0C. Although it is clear, from these results, that the replication of both M41-CK and Beau-R is negatively affected at 41 \u00b0C, there is a substantial observable difference in the extent to which each virus is affected.", [["CK cells", "ANATOMY", 37, 45], ["cells", "ANATOMY", 169, 174], ["M41-CK", "GENE_OR_GENE_PRODUCT", 14, 20], ["CK cells", "CELL", 37, 45], ["cells", "CELL", 169, 174], ["M41-CK", "GENE_OR_GENE_PRODUCT", 256, 262], ["Beau-R", "GENE_OR_GENE_PRODUCT", 267, 273], ["M41", "PROTEIN", 14, 17], ["CK", "PROTEIN", 18, 20], ["CK cells", "CELL_TYPE", 37, 45], ["M41", "PROTEIN", 256, 259], ["CK", "PROTEIN", 260, 262], ["Beau", "PROTEIN", 267, 271], ["The titres of M41", "TEST", 0, 17], ["CK", "TEST", 18, 20], ["CK cells", "TEST", 37, 45], ["M41", "TEST", 256, 259], ["Beau", "TEST", 267, 271], ["a substantial observable difference", "PROBLEM", 316, 351], ["clear", "OBSERVATION", 200, 205], ["substantial", "OBSERVATION_MODIFIER", 318, 329], ["observable", "OBSERVATION_MODIFIER", 330, 340], ["difference", "OBSERVATION_MODIFIER", 341, 351], ["extent", "OBSERVATION_MODIFIER", 359, 365], ["virus", "OBSERVATION", 380, 385]]], ["M41-CK is able to sustain a level of replication capable of generating consistent titres around 104 PFU/mL, whereas Beau-R was unable to sustain any productive infection at the higher temperature ( Figure 2c ,d).", [["infection", "DISEASE", 160, 169], ["M41-CK", "GENE_OR_GENE_PRODUCT", 0, 6], ["Beau-R", "GENE_OR_GENE_PRODUCT", 116, 122], ["M41", "PROTEIN", 0, 3], ["CK", "PROTEIN", 4, 6], ["M41", "TEST", 0, 3], ["CK", "TEST", 4, 6], ["any productive infection", "PROBLEM", 145, 169], ["productive", "OBSERVATION_MODIFIER", 149, 159], ["infection", "OBSERVATION", 160, 169]]], ["These results demonstrate that a temperature of 41 \u00b0C can be considered as a non-permissive temperature for Beau-R replication.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 108, 114], ["a temperature", "TEST", 31, 44], ["Beau-R replication", "TREATMENT", 108, 126]]], ["To ensure that the temperature sensitive replication phenotype observed for Beau-R was not specific to the primary CK cells, the replication of both M41-CK and Beau-R was assessed in DF1 cells (Figure 2e ), a continuous cell line derived from chicken embryo fibroblasts [34] .", [["primary CK cells", "ANATOMY", 107, 123], ["DF1 cells", "ANATOMY", 183, 192], ["cell line", "ANATOMY", 220, 229], ["embryo fibroblasts", "ANATOMY", 251, 269], ["Beau-R", "GENE_OR_GENE_PRODUCT", 76, 82], ["CK cells", "CELL", 115, 123], ["M41-CK", "GENE_OR_GENE_PRODUCT", 149, 155], ["Beau-R", "GENE_OR_GENE_PRODUCT", 160, 166], ["DF1 cells", "CELL", 183, 192], ["Figure 2e", "CELL", 194, 203], ["cell line", "CELL", 220, 229], ["chicken", "ORGANISM", 243, 250], ["embryo fibroblasts", "CELL", 251, 269], ["Beau-R", "PROTEIN", 76, 82], ["primary CK cells", "CELL_TYPE", 107, 123], ["M41", "PROTEIN", 149, 152], ["CK", "PROTEIN", 153, 155], ["Beau", "PROTEIN", 160, 164], ["DF1 cells", "CELL_LINE", 183, 192], ["Figure 2e", "CELL_LINE", 194, 203], ["continuous cell line", "CELL_LINE", 209, 229], ["chicken embryo fibroblasts", "CELL_TYPE", 243, 269], ["chicken", "SPECIES", 243, 250], ["chicken", "SPECIES", 243, 250], ["the temperature", "TEST", 15, 30], ["Beau", "TEST", 76, 80], ["M41", "TEST", 149, 152], ["CK", "TEST", 153, 155], ["Beau", "TEST", 160, 164], ["a continuous cell line", "TREATMENT", 207, 229], ["chicken embryo fibroblasts", "PROBLEM", 243, 269], ["cell line", "OBSERVATION", 220, 229], ["embryo fibroblasts", "OBSERVATION", 251, 269]]], ["Similar to the results observed in CK cells, Beau-R replication was negatively affected by incubation at 41 \u00b0C (p < 0.0001, To ensure that the temperature sensitive replication phenotype observed for Beau-R was not specific to the primary CK cells, the replication of both M41-CK and Beau-R was assessed in DF1 cells (Figure 2e ), a continuous cell line derived from chicken embryo fibroblasts [34] .", [["CK cells", "ANATOMY", 35, 43], ["primary CK cells", "ANATOMY", 231, 247], ["DF1 cells", "ANATOMY", 307, 316], ["cell line", "ANATOMY", 344, 353], ["embryo fibroblasts", "ANATOMY", 375, 393], ["CK cells", "CELL", 35, 43], ["Beau-R", "GENE_OR_GENE_PRODUCT", 45, 51], ["Beau-R", "GENE_OR_GENE_PRODUCT", 200, 206], ["CK cells", "CELL", 239, 247], ["M41-CK", "GENE_OR_GENE_PRODUCT", 273, 279], ["Beau-R", "GENE_OR_GENE_PRODUCT", 284, 290], ["DF1 cells", "CELL", 307, 316], ["Figure 2e", "CELL", 318, 327], ["cell line", "CELL", 344, 353], ["chicken", "ORGANISM", 367, 374], ["embryo fibroblasts", "CELL", 375, 393], ["CK cells", "CELL_LINE", 35, 43], ["Beau-R", "PROTEIN", 200, 206], ["primary CK cells", "CELL_TYPE", 231, 247], ["M41", "PROTEIN", 273, 276], ["CK", "PROTEIN", 277, 279], ["Beau-R", "PROTEIN", 284, 290], ["DF1 cells", "CELL_LINE", 307, 316], ["Figure 2e", "CELL_LINE", 318, 327], ["continuous cell line", "CELL_LINE", 333, 353], ["chicken embryo fibroblasts", "CELL_TYPE", 367, 393], ["chicken", "SPECIES", 367, 374], ["chicken", "SPECIES", 367, 374], ["CK cells", "TEST", 35, 43], ["Beau", "TEST", 45, 49], ["the temperature", "TEST", 139, 154], ["Beau", "TEST", 200, 204], ["M41", "TEST", 273, 276], ["CK", "TEST", 277, 279], ["Beau", "TEST", 284, 288], ["a continuous cell line", "TREATMENT", 331, 353], ["chicken embryo fibroblasts", "PROBLEM", 367, 393], ["cell line", "OBSERVATION", 344, 353], ["embryo fibroblasts", "OBSERVATION", 375, 393]]], ["Similar to the results observed in CK cells, Beau-R replication was negatively affected by incubation at 41 \u2022 C (p < 0.0001, Figure 2d ), indicating the temperature sensitive replication phenotype for Beau-R was not specific to cell type.", [["CK cells", "ANATOMY", 35, 43], ["cell", "ANATOMY", 228, 232], ["CK cells", "CELL", 35, 43], ["Beau-R", "GENE_OR_GENE_PRODUCT", 45, 51], ["Beau-R", "GENE_OR_GENE_PRODUCT", 201, 207], ["cell type", "CELL", 228, 237], ["CK cells", "CELL_LINE", 35, 43], ["Beau-R", "PROTEIN", 201, 207], ["CK cells", "TEST", 35, 43], ["Beau", "TEST", 45, 49], ["Figure 2d )", "TEST", 125, 136], ["the temperature sensitive replication phenotype", "PROBLEM", 149, 196], ["Beau", "TEST", 201, 205]]], ["The titres of M41-CK produced at either temperature were below 10 PFU/mL demonstrating that M41-CK could not initiate productive replication in DF1 cells.", [["DF1 cells", "ANATOMY", 144, 153], ["M41", "CHEMICAL", 92, 95], ["M41-CK", "GENE_OR_GENE_PRODUCT", 14, 20], ["M41-CK", "GENE_OR_GENE_PRODUCT", 92, 98], ["DF1 cells", "CELL", 144, 153], ["M41", "PROTEIN", 14, 17], ["CK", "PROTEIN", 18, 20], ["M41", "PROTEIN", 92, 95], ["CK", "PROTEIN", 96, 98], ["DF1 cells", "CELL_LINE", 144, 153], ["The titres of M41", "TEST", 0, 17], ["CK", "TEST", 18, 20], ["M41", "TEST", 92, 95], ["CK", "TEST", 96, 98], ["productive replication in DF1 cells", "PROBLEM", 118, 153], ["productive", "OBSERVATION_MODIFIER", 118, 128], ["replication", "OBSERVATION", 129, 140], ["DF1 cells", "OBSERVATION", 144, 153]]], ["This was not unexpected as the M41-CK spike (S) glycoprotein restricts cell tropism [35] .", [["cell", "ANATOMY", 71, 75], ["CK spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 35, 60], ["cell", "CELL", 71, 75], ["M41", "PROTEIN", 31, 34], ["CK spike (S) glycoprotein", "PROTEIN", 35, 60], ["the M41", "TEST", 27, 34], ["CK spike", "TEST", 35, 43]]], ["Whilst it may seem counterintuitive to include M41-CK in the assay, it was not known whether temperature affected S mediated entry, allowing viruses to enter cells previously non-permissive to infection.Temperature Sensitivity Is Not a Shared Characteristic of Attenuated StrainsThe observation that replication of the attenuated strain Beau-R was highly restricted at 41 \u2022 C whereas the pathogenic M41-CK strain could both initiate and sustain replication raised the possibility that temperature sensitivity may be an explanation for attenuation of IBV in vivo.", [["cells", "ANATOMY", 158, 163], ["infection", "DISEASE", 193, 202], ["M41-CK", "GENE_OR_GENE_PRODUCT", 47, 53], ["cells", "CELL", 158, 163], ["Beau-R", "ORGANISM", 337, 343], ["M41", "GENE_OR_GENE_PRODUCT", 399, 402], ["CK", "GENE_OR_GENE_PRODUCT", 403, 405], ["IBV", "ORGANISM", 550, 553], ["M41", "PROTEIN", 47, 50], ["CK", "PROTEIN", 51, 53], ["Beau-R", "SPECIES", 337, 343], ["IBV", "SPECIES", 550, 553], ["M41", "TEST", 47, 50], ["CK in the assay", "TEST", 51, 66], ["temperature affected S mediated entry", "PROBLEM", 93, 130], ["infection", "PROBLEM", 193, 202], ["Attenuated Strains", "PROBLEM", 261, 279], ["the pathogenic M41", "TEST", 384, 402], ["CK strain", "PROBLEM", 403, 412], ["temperature sensitivity", "PROBLEM", 485, 508], ["IBV in vivo", "TREATMENT", 550, 561], ["infection", "OBSERVATION", 193, 202], ["Attenuated", "OBSERVATION_MODIFIER", 261, 271], ["Strains", "OBSERVATION", 272, 279]]], ["To investigate this possibility, the replication kinetics at 37 \u2022 C and 41 \u2022 C in CK cells of the IBV vaccine strain H120 were assessed, as were the replication kinetics of the serially passaged M41-CK isolates, M41-CK EP106 A, M41-CK EP106 A1, M41-CK EP106 C and M41-CK EP106 D [14] .", [["CK cells", "ANATOMY", 82, 90], ["M41-CK EP106 A", "ANATOMY", 212, 226], ["CK cells", "CELL", 82, 90], ["IBV", "ORGANISM", 98, 101], ["CK", "GENE_OR_GENE_PRODUCT", 199, 201], ["M41-CK EP106 A", "CELL", 212, 226], ["CK cells", "CELL_TYPE", 82, 90], ["M41", "PROTEIN", 195, 198], ["CK", "PROTEIN", 216, 218], ["M41", "PROTEIN", 228, 231], ["CK", "PROTEIN", 232, 234], ["M41", "PROTEIN", 245, 248], ["CK EP106 C", "CELL_LINE", 249, 259], ["M41", "PROTEIN", 264, 267], ["CK", "PROTEIN", 268, 270], ["IBV vaccine", "SPECIES", 98, 109], ["IBV vaccine strain H120", "SPECIES", 98, 121], ["the replication kinetics", "TEST", 33, 57], ["C", "TEST", 66, 67], ["CK cells", "TEST", 82, 90], ["the IBV vaccine strain H120", "TREATMENT", 94, 121], ["CK isolates", "TEST", 199, 210], ["M41", "TEST", 212, 215], ["CK", "TEST", 216, 218], ["A", "TEST", 225, 226], ["M41", "TEST", 228, 231], ["CK", "TEST", 232, 234], ["A1", "TEST", 241, 243], ["M41", "TEST", 245, 248], ["CK", "TEST", 249, 251], ["C", "TEST", 258, 259], ["M41", "TEST", 264, 267], ["CK", "TEST", 268, 270]]], ["Notably, all these viruses have been attenuated through serial passage in embryonated hens' eggs (120 and 106 passages respectively) [12, 14] , a process that typically occurs at 37 \u2022 C. It was hypothesized, therefore, that this process may have resulted in attenuation of the viruses through selection of a temperature sensitive phenotype causing a restriction in replication at a higher temperature.Temperature Sensitivity Is Not a Shared Characteristic of Attenuated StrainsAll of the attenuated IBVs investigated were able to initiate and sustain productive replication at 41 \u2022 C, similar to the phenotype observed for pathogenic M41-CK (Figure 3a-g) .", [["eggs", "ANATOMY", 92, 96], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 92, 96], ["IBVs", "CANCER", 499, 503], ["M41-CK", "GENE_OR_GENE_PRODUCT", 634, 640], ["IBVs", "PROTEIN", 499, 503], ["M41", "PROTEIN", 634, 637], ["CK", "PROTEIN", 638, 640], ["all these viruses", "PROBLEM", 9, 26], ["serial passage", "TREATMENT", 56, 70], ["the viruses", "PROBLEM", 273, 284], ["a temperature sensitive phenotype", "PROBLEM", 306, 339], ["Attenuated Strains", "PROBLEM", 459, 477], ["the attenuated IBVs", "TREATMENT", 484, 503], ["productive replication", "PROBLEM", 551, 573], ["the phenotype", "TEST", 596, 609], ["pathogenic M41", "TEST", 623, 637], ["viruses", "OBSERVATION", 19, 26], ["attenuated", "OBSERVATION_MODIFIER", 37, 47], ["attenuation", "OBSERVATION_MODIFIER", 258, 269], ["viruses", "OBSERVATION", 277, 284], ["Attenuated", "OBSERVATION_MODIFIER", 459, 469], ["Strains", "OBSERVATION", 470, 477]]], ["The titres produced from H120 infected cells at 24 hpi were comparable between those cells incubated at 37 \u2022 C and those at 41 \u2022 C (Figure 3c ).", [["cells", "ANATOMY", 39, 44], ["cells", "ANATOMY", 85, 90], ["cells", "CELL", 39, 44], ["cells", "CELL", 85, 90], ["H120 infected cells", "CELL_LINE", 25, 44], ["H120 infected cells", "PROBLEM", 25, 44]]], ["This was also the case for isolates M41-CK EP106 A, M41-CK EP106 A1 and M41-CK EP106 D (Figure 3d-g) .", [["CK", "PROTEIN", 56, 58], ["CK", "PROTEIN", 76, 78], ["isolates M41", "TEST", 27, 39], ["CK", "TEST", 40, 42], ["A", "TEST", 49, 50], ["M41", "TEST", 52, 55], ["CK", "TEST", 56, 58], ["A1", "TEST", 65, 67], ["M41", "TEST", 72, 75], ["CK", "TEST", 76, 78], ["Figure", "TEST", 88, 94]]], ["Interestingly, all the viruses investigated exhibited decreased titres of infectious progeny at 41 \u2022 C, in comparison to 37 \u2022 C, at 48 to 96 hpi (p < 0.005), as previously observed for M41-CK.", [["M41-CK", "GENE_OR_GENE_PRODUCT", 185, 191], ["M41", "PROTEIN", 185, 188], ["CK", "PROTEIN", 189, 191], ["decreased titres of infectious progeny", "PROBLEM", 54, 92], ["M41", "TEST", 185, 188], ["viruses", "OBSERVATION", 23, 30], ["decreased", "OBSERVATION_MODIFIER", 54, 63], ["titres", "OBSERVATION_MODIFIER", 64, 70], ["infectious", "OBSERVATION_MODIFIER", 74, 84]]], ["None of the viruses exhibited the temperature sensitive replication phenotype observed for Beau-R ( Figure 3a) .", [["Beau-R", "GENE_OR_GENE_PRODUCT", 91, 97], ["the viruses", "PROBLEM", 8, 19], ["the temperature", "TEST", 30, 45], ["Beau", "TEST", 91, 95], ["viruses", "OBSERVATION", 12, 19]]], ["These results showed that attenuation associated with H120 and the multiple passaged isolates of M41-CK viruses were not due to a restriction in replication linked to temperature sensitivity.Temperature Sensitivity Is Not a Shared Characteristic of Attenuated Strains3.4.", [["M41-CK viruses", "ORGANISM", 97, 111], ["H120", "TREATMENT", 54, 58], ["M41", "TEST", 97, 100], ["CK viruses", "PROBLEM", 101, 111], ["a restriction in replication", "PROBLEM", 128, 156], ["temperature sensitivity", "TEST", 167, 190], ["Temperature Sensitivity", "TEST", 191, 214], ["Attenuated Strains3.4", "PROBLEM", 249, 270], ["attenuation", "OBSERVATION_MODIFIER", 26, 37], ["Attenuated", "OBSERVATION_MODIFIER", 249, 259]]], ["The Nephropathogenic IBV Strain D388(QX) Is Able to Replicate at 41 \u2022 C Although the results described above and in Figure 3 show that temperature sensitivity is not a shared characteristic of attenuated strains, it also possible that the ability to replicate at 41 \u2022 C is not necessarily a trait shared by other pathogenic strains.", [["The Nephropathogenic IBV Strain D388", "TREATMENT", 0, 36], ["temperature sensitivity", "TEST", 135, 158], ["attenuated strains", "PROBLEM", 193, 211], ["other pathogenic strains", "PROBLEM", 307, 331]]], ["The observation from our in vivo results that Beau-R was not detected in tracheal epithelial cells, raised the question of whether attenuation and resultant viral dissemination was linked to restricted replication resulting from temperature sensitivity at the core temperature (41 \u2022 C) of a chicken.", [["tracheal epithelial cells", "ANATOMY", 73, 98], ["Beau-R", "GENE_OR_GENE_PRODUCT", 46, 52], ["tracheal epithelial cells", "CELL", 73, 98], ["chicken", "ORGANISM", 291, 298], ["tracheal epithelial cells", "CELL_TYPE", 73, 98], ["chicken", "SPECIES", 291, 298], ["chicken", "SPECIES", 291, 298], ["Beau", "TEST", 46, 50], ["tracheal epithelial cells", "PROBLEM", 73, 98], ["resultant viral dissemination", "PROBLEM", 147, 176], ["temperature sensitivity", "PROBLEM", 229, 252], ["tracheal", "ANATOMY", 73, 81], ["epithelial cells", "OBSERVATION", 82, 98], ["attenuation", "OBSERVATION_MODIFIER", 131, 142], ["resultant", "OBSERVATION_MODIFIER", 147, 156], ["viral", "OBSERVATION_MODIFIER", 157, 162], ["dissemination", "OBSERVATION", 163, 176]]], ["It is therefore important to determine whether the ability of pathogenic M41-CK to grow at 41 \u2022 C is a trait shared by other pathogenic strains, particularly with regards to nephropathogenic strains of IBV that disseminate through the bird and infect the kidneys.Temperature Sensitivity Is Not a Shared Characteristic of Attenuated StrainsThe replication kinetics of the nephropathogenic strain D388(QX), a strain associated with severe infectious bronchitis, resulting from infection in the respiratory tract and also with dissemination to and resultant pathology in the kidneys and oviducts [36] , were assessed at 37 \u2022 C and 41 \u2022 C and compared to M41-CK ( Figure 4) .", [["kidneys", "ANATOMY", 255, 262], ["respiratory tract", "ANATOMY", 492, 509], ["kidneys", "ANATOMY", 572, 579], ["oviducts", "ANATOMY", 584, 592], ["D388", "CHEMICAL", 395, 399], ["QX", "CHEMICAL", 400, 402], ["infectious bronchitis", "DISEASE", 437, 458], ["infection", "DISEASE", 475, 484], ["M41", "GENE_OR_GENE_PRODUCT", 73, 76], ["CK", "GENE_OR_GENE_PRODUCT", 77, 79], ["IBV", "ORGANISM", 202, 205], ["kidneys", "ORGAN", 255, 262], ["strain D388", "ORGANISM", 388, 399], ["respiratory tract", "ORGANISM_SUBDIVISION", 492, 509], ["kidneys", "ORGAN", 572, 579], ["oviducts", "ORGAN", 584, 592], ["M41", "PROTEIN", 73, 76], ["CK", "PROTEIN", 77, 79], ["CK", "PROTEIN", 655, 657], ["IBV", "SPECIES", 202, 205], ["pathogenic M41", "TEST", 62, 76], ["a trait", "PROBLEM", 101, 108], ["other pathogenic strains", "PROBLEM", 119, 143], ["nephropathogenic strains", "PROBLEM", 174, 198], ["IBV", "PROBLEM", 202, 205], ["Attenuated Strains", "PROBLEM", 321, 339], ["the nephropathogenic strain D388", "TREATMENT", 367, 399], ["severe infectious bronchitis", "PROBLEM", 430, 458], ["infection in the respiratory tract", "PROBLEM", 475, 509], ["resultant pathology in the kidneys", "PROBLEM", 545, 579], ["C", "TEST", 622, 623], ["C", "TEST", 633, 634], ["M41", "TEST", 651, 654], ["CK", "TEST", 655, 657], ["IBV", "OBSERVATION", 202, 205], ["infect", "OBSERVATION", 244, 250], ["kidneys", "ANATOMY", 255, 262], ["Attenuated", "OBSERVATION_MODIFIER", 321, 331], ["Strains", "OBSERVATION", 332, 339], ["replication kinetics", "OBSERVATION", 343, 363], ["severe", "OBSERVATION_MODIFIER", 430, 436], ["infectious", "OBSERVATION_MODIFIER", 437, 447], ["bronchitis", "OBSERVATION", 448, 458], ["infection", "OBSERVATION", 475, 484], ["respiratory tract", "ANATOMY", 492, 509], ["resultant", "OBSERVATION_MODIFIER", 545, 554], ["pathology", "OBSERVATION", 555, 564], ["kidneys", "ANATOMY", 572, 579], ["oviducts", "ANATOMY", 584, 592]]], ["Overall, replication of D388(QX) was found to be largely unaffected by temperature with titres comparable between the two temperatures at 24 and 48 hpi (Figure 4c ).", [["D388", "CHEMICAL", 24, 28], ["D388", "GENE_OR_GENE_PRODUCT", 24, 28], ["titres", "TEST", 88, 94], ["the two temperatures", "TEST", 114, 134], ["unaffected", "OBSERVATION", 57, 67]]], ["Titres of infectious progeny were lower at 72 and 96 hpi from cells incubated at 41 \u2022 C, however statistical significance was only reached for the later time point (p < 0.05).", [["progeny", "ANATOMY", 21, 28], ["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["infectious", "OBSERVATION_MODIFIER", 10, 20]]], ["The ability of D388(QX) to establish and maintain replication at 41 \u2022 C, like M41-CK, suggests that whilst attenuation and temperature Viruses 2020, 12, 754 9 of 20 sensitivity may not be intrinsically linked, the ability to replicate at higher temperatures may be a shared characteristic of pathogenic IBV isolates. from H120 infected cells at 24 hpi were comparable between those cells incubated at 37 \u00b0C and those at 41 \u00b0C (Figure 3c ).", [["cells", "ANATOMY", 336, 341], ["cells", "ANATOMY", 382, 387], ["D388", "CHEMICAL", 15, 19], ["D388", "GENE_OR_GENE_PRODUCT", 15, 19], ["M41-CK", "GENE_OR_GENE_PRODUCT", 78, 84], ["IBV", "ORGANISM", 303, 306], ["cells", "CELL", 336, 341], ["cells", "CELL", 382, 387], ["D388(QX)", "PROTEIN", 15, 23], ["M41", "PROTEIN", 78, 81], ["CK", "PROTEIN", 82, 84], ["H120 infected cells", "CELL_LINE", 322, 341], ["IBV", "SPECIES", 303, 306], ["whilst attenuation and temperature Viruses", "PROBLEM", 100, 142], ["pathogenic IBV isolates", "PROBLEM", 292, 315], ["H120 infected cells", "PROBLEM", 322, 341], ["pathogenic IBV isolates", "OBSERVATION", 292, 315], ["infected cells", "OBSERVATION", 327, 341]]], ["This was also the case for isolates M41-CK EP106 A, M41-CK EP106 A1 and M41-CK EP106 D (Figures 3d-g) .", [["CK", "PROTEIN", 56, 58], ["CK", "PROTEIN", 76, 78], ["isolates M41", "TEST", 27, 39], ["CK", "TEST", 40, 42], ["A", "TEST", 49, 50], ["M41", "TEST", 52, 55], ["CK", "TEST", 56, 58], ["A1", "TEST", 65, 67], ["M41", "TEST", 72, 75], ["CK", "TEST", 76, 78], ["Figures", "TEST", 88, 95]]], ["Interestingly, all the viruses investigated exhibited decreased titres of infectious progeny at 41 \u00b0C, in comparison to 37 \u00b0C, at 48 to 96 hpi (p < 0.005), as previously observed for M41-CK.", [["M41-CK", "GENE_OR_GENE_PRODUCT", 183, 189], ["M41", "PROTEIN", 183, 186], ["CK", "PROTEIN", 187, 189], ["decreased titres of infectious progeny", "PROBLEM", 54, 92], ["M41", "TEST", 183, 186], ["viruses", "OBSERVATION", 23, 30], ["decreased", "OBSERVATION_MODIFIER", 54, 63], ["titres", "OBSERVATION_MODIFIER", 64, 70], ["infectious", "OBSERVATION_MODIFIER", 74, 84]]], ["None of the viruses exhibited the temperature sensitive replication phenotype observed for Beau-R (Figure 3a) .", [["Beau-R", "GENE_OR_GENE_PRODUCT", 91, 97], ["the viruses", "PROBLEM", 8, 19], ["the temperature", "TEST", 30, 45], ["Beau", "TEST", 91, 95], ["viruses", "OBSERVATION", 12, 19]]], ["These results showed that attenuation associated with H120 and the multiple passaged isolates of M41-CK viruses were not due to a restriction in replication linked to temperature sensitivity.Entry at Permissive Temperatures Cannot Recover Replication at Non-Permissive TemperaturesIn order to elucidate which step in the IBV replication cycle accounted for the temperature sensitive replication phenotypes observed, a temperature swap experiment was carried out (Figure 5a ).", [["M41-CK viruses", "ORGANISM", 97, 111], ["IBV", "ORGANISM", 321, 324], ["IBV", "SPECIES", 321, 324], ["H120", "TREATMENT", 54, 58], ["M41", "TEST", 97, 100], ["CK viruses", "PROBLEM", 101, 111], ["a restriction in replication", "PROBLEM", 128, 156], ["temperature sensitivity", "TEST", 167, 190], ["the IBV replication cycle", "TREATMENT", 317, 342], ["the temperature sensitive replication phenotypes", "PROBLEM", 357, 405], ["a temperature swap experiment", "TEST", 416, 445], ["attenuation", "OBSERVATION_MODIFIER", 26, 37]]], ["CK cells were inoculated and incubated at either 37 \u2022 C or 41 \u2022 C for 1 h to allow for viral attachment and entry.", [["CK cells", "ANATOMY", 0, 8], ["CK cells", "CELL", 0, 8], ["CK cells", "CELL_TYPE", 0, 8], ["CK cells", "TEST", 0, 8], ["viral attachment", "PROBLEM", 87, 103]]], ["The inoculum was removed, and the cells washed to remove unbound virus, the cells were then either incubated at the same temperature or incubated at the alternative temperature for a further 23 h (Figure 5a ).", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 76, 81], ["cells", "CELL", 34, 39], ["cells", "CELL", 76, 81], ["The inoculum", "TREATMENT", 0, 12], ["the cells", "TREATMENT", 30, 39], ["unbound virus", "PROBLEM", 57, 70], ["inoculum", "OBSERVATION", 4, 12]]], ["The resulting supernatants were assessed for infectious viral progeny through titration in CK cells at 37 \u2022 C. and resultant pathology in the kidneys and oviducts [36] , were assessed at 37 \u00b0C and 41 \u00b0C and compared to M41-CK ( Figure 4) .", [["supernatants", "ANATOMY", 14, 26], ["CK cells", "ANATOMY", 91, 99], ["kidneys", "ANATOMY", 142, 149], ["oviducts", "ANATOMY", 154, 162], ["CK cells", "CELL", 91, 99], ["kidneys", "ORGAN", 142, 149], ["oviducts", "ORGAN", 154, 162], ["CK cells", "CELL_TYPE", 91, 99], ["CK", "PROTEIN", 223, 225], ["The resulting supernatants", "PROBLEM", 0, 26], ["infectious viral progeny", "PROBLEM", 45, 69], ["CK cells", "TEST", 91, 99], ["resultant pathology in the kidneys", "PROBLEM", 115, 149], ["\u00b0C", "TEST", 200, 202], ["M41", "TEST", 219, 222], ["pathology", "OBSERVATION", 125, 134], ["kidneys", "ANATOMY", 142, 149]]], ["Overall, replication of D388(QX) was found to be largely unaffected by temperature with titres comparable between the two temperatures at 24 and 48 hpi (Figure 4c ).", [["D388", "CHEMICAL", 24, 28], ["D388", "GENE_OR_GENE_PRODUCT", 24, 28], ["titres", "TEST", 88, 94], ["the two temperatures", "TEST", 114, 134], ["unaffected", "OBSERVATION", 57, 67]]], ["Titres of infectious progeny were lower at 72 and 96 hpi from cells incubated at 41 \u00b0C, however statistical significance was only reached for the later time point (p < 0.05).", [["progeny", "ANATOMY", 21, 28], ["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["infectious", "OBSERVATION_MODIFIER", 10, 20]]], ["The ability of D388(QX) to establish and maintain replication at 41 \u00b0C, like M41-CK, suggests that whilst attenuation and temperature sensitivity may not be intrinsically linked, the ability to replicate at higher temperatures may be a shared characteristic of pathogenic IBV isolates.", [["D388", "CHEMICAL", 15, 19], ["QX", "CHEMICAL", 20, 22], ["D388", "CHEMICAL", 15, 19], ["D388(QX)", "GENE_OR_GENE_PRODUCT", 15, 23], ["M41-CK", "GENE_OR_GENE_PRODUCT", 77, 83], ["IBV", "ORGANISM", 272, 275], ["M41", "PROTEIN", 77, 80], ["CK", "PROTEIN", 81, 83], ["IBV", "SPECIES", 272, 275], ["whilst attenuation and temperature sensitivity", "PROBLEM", 99, 145], ["pathogenic IBV isolates", "PROBLEM", 261, 284], ["pathogenic IBV", "OBSERVATION", 261, 275]]], ["In order to elucidate which step in the IBV replication cycle accounted for the temperature sensitive replication phenotypes observed, a temperature swap experiment was carried out ( Figure 5a ).", [["IBV", "ORGANISM", 40, 43], ["IBV", "SPECIES", 40, 43], ["the IBV replication cycle", "TREATMENT", 36, 61], ["the temperature sensitive replication phenotypes", "PROBLEM", 76, 124], ["a temperature swap experiment", "TEST", 135, 164]]], ["CK cells were inoculated and incubated at either 37 \u00b0C or 41 \u00b0C for 1 h to allow for viral attachment and entry.", [["CK cells", "ANATOMY", 0, 8], ["CK cells", "CELL", 0, 8], ["CK cells", "CELL_TYPE", 0, 8], ["CK cells", "TEST", 0, 8], ["viral attachment", "PROBLEM", 85, 101]]], ["The inoculum was removed, and the cells washed to remove unbound virus, the cells were then either incubated at the same temperature or incubated at the alternative temperature for a further 23 h (Figure 5a ).", [["cells", "ANATOMY", 34, 39], ["cells", "ANATOMY", 76, 81], ["cells", "CELL", 34, 39], ["cells", "CELL", 76, 81], ["The inoculum", "TREATMENT", 0, 12], ["the cells", "TREATMENT", 30, 39], ["unbound virus", "PROBLEM", 57, 70], ["inoculum", "OBSERVATION", 4, 12]]], ["The resulting supernatants were assessed for infectious viral progeny through titration in CK cells at 37 \u00b0C. The titres of infectious progeny from CK cells infected with H120 and D388(QX) were unaffected by a swap in temperature (Figure 5b,c) ; this was expected as previous results demonstrated that replication is not affected by temperature at 24 hpi (Figures 3c and 4) .", [["supernatants", "ANATOMY", 14, 26], ["CK cells", "ANATOMY", 91, 99], ["progeny", "ANATOMY", 135, 142], ["CK cells", "ANATOMY", 148, 156], ["CK cells", "CELL", 91, 99], ["CK cells", "CELL", 148, 156], ["CK cells", "CELL_LINE", 91, 99], ["CK cells", "CELL_TYPE", 148, 156], ["The resulting supernatants", "TEST", 0, 26], ["infectious viral progeny", "PROBLEM", 45, 69], ["CK cells", "TEST", 91, 99], ["CK cells", "TEST", 148, 156], ["H120", "TEST", 171, 175], ["a swap in temperature", "TEST", 208, 229], ["infectious", "OBSERVATION_MODIFIER", 124, 134]]], ["The titres of both Beau-R and M41-CK were affected by the swaps in temperature (Figure 5d,e) , with Beau-R affected to a greater extent than M41-CK.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 19, 25], ["M41-CK", "GENE_OR_GENE_PRODUCT", 30, 36], ["Beau-R", "GENE_OR_GENE_PRODUCT", 100, 106], ["M41-CK", "GENE_OR_GENE_PRODUCT", 141, 147], ["M41", "PROTEIN", 30, 33], ["CK", "PROTEIN", 34, 36], ["M41", "PROTEIN", 141, 144], ["CK", "PROTEIN", 145, 147], ["The titres", "TEST", 0, 10], ["Beau", "TEST", 100, 104]]], ["The titres of viral progeny produced were comparable in cells incubated at 37 The titres of infectious progeny from CK cells infected with H120 and D388(QX) were unaffected by a swap in temperature (Figure 5b,c) ; this was expected as previous results demonstrated that replication is not affected by temperature at 24 hpi (Figures 3c and 4) .", [["cells", "ANATOMY", 56, 61], ["progeny", "ANATOMY", 103, 110], ["CK cells", "ANATOMY", 116, 124], ["cells", "CELL", 56, 61], ["CK cells", "CELL", 116, 124], ["CK cells", "CELL_TYPE", 116, 124], ["CK cells", "TEST", 116, 124], ["H120", "TEST", 139, 143], ["a swap in temperature", "TEST", 176, 197]]], ["The titres of both Beau-R and M41-CK were affected by the swaps in temperature (Figure 5d ,e), with Beau-R affected to a greater extent than M41-CK.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 19, 25], ["M41-CK", "GENE_OR_GENE_PRODUCT", 30, 36], ["Beau-R", "GENE_OR_GENE_PRODUCT", 100, 106], ["M41-CK", "GENE_OR_GENE_PRODUCT", 141, 147], ["M41", "PROTEIN", 30, 33], ["CK", "PROTEIN", 34, 36], ["M41", "PROTEIN", 141, 144], ["CK", "PROTEIN", 145, 147], ["The titres", "TEST", 0, 10], ["Beau", "TEST", 100, 104]]], ["The titres of viral progeny produced were comparable in cells incubated at 37 \u2022 C for binding and entry and then 37 \u2022 C for the remainder of the replication cycle and those incubated at 41 \u2022 C and then 37 \u2022 C (41-37), indicating that a difference in the binding and entry step temperature has no effect on the viral replication step.", [["cells", "ANATOMY", 56, 61], ["cells", "CELL", 56, 61], ["a difference in the binding", "PROBLEM", 234, 261], ["entry step temperature", "TEST", 266, 288], ["viral replication", "OBSERVATION", 310, 327]]], ["This indicates that the temperature in which viral attachment and entry occurred was not the determining factor in establishing a productive infection.", [["infection", "DISEASE", 141, 150], ["the temperature", "PROBLEM", 20, 35], ["viral attachment", "PROBLEM", 45, 61], ["a productive infection", "PROBLEM", 128, 150], ["productive", "OBSERVATION_MODIFIER", 130, 140], ["infection", "OBSERVATION", 141, 150]]], ["In contrast, titres were significantly lower when cells were incubated at 41-41 in comparison to 41-37, and also between 37-37 and 37-41 (p < 0.005), demonstrating that a change in the second incubation temperature affected viral replication.", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["titres", "TEST", 13, 19], ["a change", "PROBLEM", 169, 177], ["the second incubation temperature affected viral replication", "TREATMENT", 181, 241], ["viral replication", "OBSERVATION", 224, 241]]], ["This therefore indicates that the temperature at which the virus is undergoing active replication, assembly and egress was the determining factor in establishing a productive infection.The Spike Glycoprotein from M41-CK Cannot Rescue Beau-R Replication at 41 \u2022 CCoronavirus entry is mediated by the S glycoprotein [49] .", [["infection", "DISEASE", 175, 184], ["Spike Glycoprotein", "GENE_OR_GENE_PRODUCT", 189, 207], ["M41-CK", "GENE_OR_GENE_PRODUCT", 213, 219], ["Spike Glycoprotein", "PROTEIN", 189, 207], ["M41", "PROTEIN", 213, 216], ["CK", "PROTEIN", 217, 219], ["S glycoprotein", "PROTEIN", 299, 313], ["the temperature", "PROBLEM", 30, 45], ["active replication", "TREATMENT", 79, 97], ["a productive infection", "PROBLEM", 162, 184], ["The Spike Glycoprotein", "TEST", 185, 207], ["M41", "TEST", 213, 216], ["CK", "TEST", 217, 219], ["active", "OBSERVATION_MODIFIER", 79, 85], ["replication", "OBSERVATION", 86, 97], ["productive", "OBSERVATION_MODIFIER", 164, 174], ["infection", "OBSERVATION", 175, 184]]], ["In order to exclude viral entry as the determining factor for the replication of Beau-R at non-permissive temperatures, a rIBV, BeauR-M41(S), in which the Beaudette S gene was replaced with corresponding gene from M41-CK, was investigated [35] .", [["Beau-R", "GENE_OR_GENE_PRODUCT", 81, 87], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 128, 137], ["Beaudette S", "GENE_OR_GENE_PRODUCT", 155, 166], ["M41-CK", "GENE_OR_GENE_PRODUCT", 214, 220], ["rIBV", "DNA", 122, 126], ["BeauR", "DNA", 128, 133], ["Beaudette S gene", "DNA", 155, 171], ["M41", "DNA", 214, 217], ["CK", "DNA", 218, 220], ["viral entry", "PROBLEM", 20, 31]]], ["Analysis of the growth kinetics at the two temperatures, 37 \u2022 C and 41 \u2022 C, revealed that BeauR-M41(S) displayed comparable growth kinetics to Beau-R at 41 \u2022 C (Figure 6a ).", [["BeauR-M41", "CHEMICAL", 90, 99], ["BeauR-M41", "SIMPLE_CHEMICAL", 90, 99], ["Beau-R", "SIMPLE_CHEMICAL", 143, 149], ["M41(S)", "PROTEIN", 96, 102], ["the growth kinetics", "PROBLEM", 12, 31], ["the two temperatures", "TEST", 35, 55], ["C", "TEST", 62, 63], ["C", "TEST", 73, 74], ["BeauR", "TEST", 90, 95], ["comparable growth kinetics", "PROBLEM", 113, 139], ["Beau", "TEST", 143, 147]]], ["This result demonstrated that the M41 S glycoprotein could not confer the ability of M41-CK to replicate at 41 \u2022 C thus confirming that the IBV receptor binding protein is not responsible for the restricted growth of Beau-R at 41 \u2022 C. infection.", [["infection", "DISEASE", 235, 244], ["M41 S glycoprotein", "GENE_OR_GENE_PRODUCT", 34, 52], ["M41-CK", "GENE_OR_GENE_PRODUCT", 85, 91], ["IBV", "ORGANISM", 140, 143], ["Beau-R", "GENE_OR_GENE_PRODUCT", 217, 223], ["M41 S glycoprotein", "PROTEIN", 34, 52], ["M41", "PROTEIN", 85, 88], ["CK", "PROTEIN", 89, 91], ["IBV receptor binding protein", "PROTEIN", 140, 168], ["IBV", "SPECIES", 140, 143], ["the M41 S glycoprotein", "TREATMENT", 30, 52], ["the IBV receptor binding protein", "TEST", 136, 168], ["C. infection", "PROBLEM", 232, 244], ["infection", "OBSERVATION", 235, 244]]], ["In contrast, titres were significantly lower when cells were incubated at 41-41 in comparison to , and also between 37-37 and 37-41 (p < 0.005), demonstrating that a change in the second incubation temperature affected viral replication.", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["titres", "TEST", 13, 19], ["a change", "PROBLEM", 164, 172], ["the second incubation temperature affected viral replication", "TREATMENT", 176, 236], ["viral replication", "OBSERVATION", 219, 236]]], ["This therefore indicates that the temperature at which the virus is undergoing active replication, assembly and egress was the determining factor in establishing a productive infection.The Spike Glycoprotein from M41-CK Cannot Rescue Beau-R Replication at 41 \u00b0CCoronavirus entry is mediated by the S glycoprotein [49] .", [["infection", "DISEASE", 175, 184], ["Spike Glycoprotein", "GENE_OR_GENE_PRODUCT", 189, 207], ["M41-CK", "GENE_OR_GENE_PRODUCT", 213, 219], ["Beau-R", "GENE_OR_GENE_PRODUCT", 234, 240], ["Spike Glycoprotein", "PROTEIN", 189, 207], ["M41", "PROTEIN", 213, 216], ["CK", "PROTEIN", 217, 219], ["S glycoprotein", "PROTEIN", 298, 312], ["the temperature", "PROBLEM", 30, 45], ["active replication", "TREATMENT", 79, 97], ["a productive infection", "PROBLEM", 162, 184], ["The Spike Glycoprotein", "TEST", 185, 207], ["M41", "TEST", 213, 216], ["CK", "TEST", 217, 219], ["active", "OBSERVATION_MODIFIER", 79, 85], ["replication", "OBSERVATION", 86, 97], ["productive", "OBSERVATION_MODIFIER", 164, 174], ["infection", "OBSERVATION", 175, 184]]], ["In order to exclude viral entry as the determining factor for the replication of Beau-R at non-permissive temperatures, a rIBV, BeauR-M41(S), in which the Beaudette S gene was replaced with corresponding gene from M41-CK, was investigated [35] .", [["Beau-R", "GENE_OR_GENE_PRODUCT", 81, 87], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 128, 137], ["Beaudette S", "GENE_OR_GENE_PRODUCT", 155, 166], ["M41-CK", "GENE_OR_GENE_PRODUCT", 214, 220], ["rIBV", "DNA", 122, 126], ["BeauR", "DNA", 128, 133], ["Beaudette S gene", "DNA", 155, 171], ["M41", "DNA", 214, 217], ["CK", "DNA", 218, 220], ["viral entry", "PROBLEM", 20, 31]]], ["Analysis of the growth kinetics at the two temperatures, 37 \u00b0C and 41 \u00b0C, revealed that BeauR-M41(S) displayed comparable growth kinetics to Beau-R at 41 \u00b0C (Figure 6a ).", [["BeauR-M41", "CHEMICAL", 88, 97], ["Beau-R", "CHEMICAL", 141, 147], ["BeauR-M41", "SIMPLE_CHEMICAL", 88, 97], ["Beau-R", "SIMPLE_CHEMICAL", 141, 147], ["the growth kinetics", "PROBLEM", 12, 31], ["the two temperatures", "TEST", 35, 55], ["\u00b0C", "TEST", 60, 62], ["BeauR", "TEST", 88, 93], ["comparable growth kinetics", "PROBLEM", 111, 137], ["Beau", "TEST", 141, 145]]], ["This result demonstrated that the M41 S glycoprotein could not confer the ability of M41-CK to replicate at 41 \u00b0C thus confirming that the IBV receptor binding protein is not responsible for the restricted growth of Beau-R at 41 \u00b0C.The Replicase Gene is a Determinant of Temperature SensitivityThe results of the temperature swap assays, alongside the inability of BeauR-M41(S) to replicate at 41 \u00b0C, indicated that it was not the temperature at which viral entry occurred, but rather the temperature at which active viral replication took place which determined whether a productiveThe Replicase Gene Is a Determinant of Temperature SensitivityThe results of the temperature swap assays, alongside the inability of BeauR-M41(S) to replicate at 41 \u2022 C, indicated that it was not the temperature at which viral entry occurred, but rather the temperature at which active viral replication took place which determined whether a productive infection was established.", [["infection", "DISEASE", 936, 945], ["M41 S glycoprotein", "GENE_OR_GENE_PRODUCT", 34, 52], ["M41-CK", "GENE_OR_GENE_PRODUCT", 85, 91], ["IBV", "ORGANISM", 139, 142], ["Beau-R", "GENE_OR_GENE_PRODUCT", 216, 222], ["M41 S glycoprotein", "PROTEIN", 34, 52], ["M41", "PROTEIN", 85, 88], ["CK", "PROTEIN", 89, 91], ["IBV receptor binding protein", "PROTEIN", 139, 167], ["Replicase Gene", "DNA", 236, 250], ["BeauR", "PROTEIN", 365, 370], ["BeauR", "PROTEIN", 716, 721], ["IBV", "SPECIES", 139, 142], ["the M41 S glycoprotein", "TREATMENT", 30, 52], ["the IBV receptor binding protein", "TEST", 135, 167], ["Beau", "TEST", 216, 220], ["Temperature Sensitivity", "TEST", 271, 294], ["the temperature swap assays", "TEST", 309, 336], ["BeauR", "TEST", 365, 370], ["the temperature", "PROBLEM", 427, 442], ["the temperature", "PROBLEM", 485, 500], ["active viral replication", "TREATMENT", 510, 534], ["Temperature Sensitivity", "TEST", 622, 645], ["the temperature swap assays", "TEST", 660, 687], ["BeauR", "TEST", 716, 721], ["the temperature", "PROBLEM", 779, 794], ["the temperature", "PROBLEM", 837, 852], ["active viral replication", "TREATMENT", 862, 886], ["a productive infection", "PROBLEM", 923, 945], ["viral replication", "OBSERVATION", 517, 534], ["viral replication", "OBSERVATION", 869, 886], ["productive", "OBSERVATION_MODIFIER", 925, 935], ["infection", "OBSERVATION", 936, 945]]], ["In order to rule out a role for another structural or accessory protein in the restricted temperature phenotype for Beau-R, a second rIBV, BeauR-M41-Struct [23] , was investigated.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 116, 122], ["accessory protein", "PROTEIN", 54, 71], ["rIBV", "PROTEIN", 133, 137], ["BeauR", "PROTEIN", 139, 144], ["M41", "PROTEIN", 145, 148], ["another structural or accessory protein", "PROBLEM", 32, 71], ["Beau", "TEST", 116, 120], ["BeauR", "TEST", 139, 144]]], ["BeauR-M41-Struct contains Beau-R derived sequence encoding the 5 UTR and replicase gene, with the structural and accessory genes plus the 3 UTR sequences from M41-CK.", [["BeauR", "GENE_OR_GENE_PRODUCT", 0, 5], ["Beau-R", "GENE_OR_GENE_PRODUCT", 26, 32], ["M41-CK", "GENE_OR_GENE_PRODUCT", 159, 165], ["BeauR", "PROTEIN", 0, 5], ["M41", "DNA", 6, 9], ["Beau-R derived sequence", "DNA", 26, 49], ["5 UTR", "DNA", 63, 68], ["replicase gene", "DNA", 73, 87], ["structural and accessory genes", "DNA", 98, 128], ["3 UTR sequences", "DNA", 138, 153], ["M41", "DNA", 159, 162], ["CK", "PROTEIN", 163, 165], ["BeauR", "TEST", 0, 5], ["the 3 UTR sequences", "TEST", 134, 153], ["M41", "TEST", 159, 162]]], ["Analysis of the growth kinetics of BeauR-M41-Struct at the two temperatures revealed that this rIBV, like Beau-R and BeauR-M41(S), could not establish productive infection at 41 \u2022 C (Figure 6b ).", [["BeauR-M41-Struct", "CHEMICAL", 35, 51], ["infection", "DISEASE", 162, 171], ["BeauR", "GENE_OR_GENE_PRODUCT", 35, 40], ["rIBV", "GENE_OR_GENE_PRODUCT", 95, 99], ["Beau-R", "GENE_OR_GENE_PRODUCT", 106, 112], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 117, 126], ["BeauR", "PROTEIN", 35, 40], ["M41", "PROTEIN", 41, 44], ["BeauR", "PROTEIN", 117, 122], ["the growth kinetics", "TEST", 12, 31], ["BeauR", "TEST", 35, 40], ["the two temperatures", "TEST", 55, 75], ["this rIBV", "TEST", 90, 99], ["Beau", "TEST", 106, 110], ["productive infection", "PROBLEM", 151, 171], ["not establish", "UNCERTAINTY", 137, 150], ["productive", "OBSERVATION_MODIFIER", 151, 161], ["infection", "OBSERVATION", 162, 171]]], ["This result demonstrated that the M41-CK derived structural and accessory genes could not confer the ability of M41-CK to replicate at 41 \u2022 C. This in turn, indicates that the replicase gene is the determining factor in the temperature sensitivity associated with the replication of Beau-R.Temperature Affects sgRNA Levels during Beau-R InfectionAs the IBV replicase gene had been identified as a factor in temperature sensitivity, it was hypothesised that increasing temperature was negatively affecting the level of RNA synthesis, causing a reduction in the number of infectious progeny.", [["M41-CK", "GENE_OR_GENE_PRODUCT", 34, 40], ["M41-CK", "GENE_OR_GENE_PRODUCT", 112, 118], ["sgRNA", "GENE_OR_GENE_PRODUCT", 310, 315], ["Beau-R", "GENE_OR_GENE_PRODUCT", 330, 336], ["IBV", "ORGANISM", 353, 356], ["M41-CK derived structural and accessory genes", "DNA", 34, 79], ["M41", "PROTEIN", 112, 115], ["CK", "PROTEIN", 116, 118], ["replicase gene", "DNA", 176, 190], ["IBV replicase gene", "DNA", 353, 371], ["IBV", "SPECIES", 353, 356], ["the M41", "TEST", 30, 37], ["M41", "TEST", 112, 115], ["the temperature sensitivity", "PROBLEM", 220, 247], ["sgRNA Levels", "TEST", 310, 322], ["Beau", "TEST", 330, 334], ["the IBV replicase gene", "TREATMENT", 349, 371], ["a factor in temperature sensitivity", "PROBLEM", 395, 430], ["increasing temperature", "PROBLEM", 457, 479], ["RNA synthesis", "PROBLEM", 518, 531], ["RNA synthesis", "OBSERVATION", 518, 531], ["reduction", "OBSERVATION_MODIFIER", 543, 552], ["number", "OBSERVATION_MODIFIER", 560, 566], ["infectious", "OBSERVATION_MODIFIER", 570, 580]]], ["The coronavirus replicase is responsible both for de novo synthesis of the full-length genomic RNA thus generating genomic RNA for progeny viruses as well as generating the replicase proteins, and for the synthesis of a set of subgenomic RNAs (sgRNA), that are used for the generation of the structural and accessory proteins.", [["coronavirus", "ORGANISM", 4, 15], ["sgRNA", "GENE_OR_GENE_PRODUCT", 244, 249], ["coronavirus replicase", "PROTEIN", 4, 25], ["full-length genomic RNA", "RNA", 75, 98], ["genomic RNA", "RNA", 115, 126], ["replicase proteins", "PROTEIN", 173, 191], ["subgenomic RNAs", "RNA", 227, 242], ["sgRNA", "PROTEIN", 244, 249], ["structural and accessory proteins", "PROTEIN", 292, 325], ["coronavirus", "SPECIES", 4, 15], ["The coronavirus replicase", "PROBLEM", 0, 25], ["de novo synthesis", "PROBLEM", 50, 67], ["progeny viruses", "PROBLEM", 131, 146], ["the replicase proteins", "TEST", 169, 191], ["the synthesis", "TEST", 201, 214], ["subgenomic RNAs (sgRNA", "PROBLEM", 227, 249], ["coronavirus replicase", "OBSERVATION", 4, 25], ["genomic RNA", "OBSERVATION", 115, 126], ["subgenomic RNAs", "OBSERVATION", 227, 242]]], ["In order to investigate whether the restriction in growth observed for Beau-R at 41 \u2022 C was linked to RNA expression a series of infections were used to investigate whether the quantities of sgRNA synthesised differed at the two different temperatures.", [["infections", "DISEASE", 129, 139], ["Beau-R", "GENE_OR_GENE_PRODUCT", 71, 77], ["\u2022 C", "SIMPLE_CHEMICAL", 84, 87], ["sgRNA", "GENE_OR_GENE_PRODUCT", 191, 196], ["sgRNA", "PROTEIN", 191, 196], ["the restriction in growth", "PROBLEM", 32, 57], ["Beau", "TEST", 71, 75], ["infections", "PROBLEM", 129, 139], ["sgRNA synthesised", "PROBLEM", 191, 208]]], ["Specifically, the levels of the sgRNA responsible for the expression of nucleocapsid (N) protein was used as an indicator for the level of viral RNA synthesis (Figure 7) .", [["sgRNA", "GENE_OR_GENE_PRODUCT", 32, 37], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 72, 88], ["sgRNA", "PROTEIN", 32, 37], ["nucleocapsid (N) protein", "PROTEIN", 72, 96], ["viral RNA", "RNA", 139, 148], ["the sgRNA", "PROBLEM", 28, 37], ["nucleocapsid (N) protein", "PROBLEM", 72, 96], ["viral RNA synthesis", "PROBLEM", 139, 158], ["sgRNA", "OBSERVATION", 32, 37], ["viral RNA", "OBSERVATION", 139, 148]]], ["The quantities of infectious viral progeny were determined for a comparison between viral RNA synthesis and productive virus replication.Temperature Affects sgRNA Levels during Beau-R InfectionAt all the time points assessed, M41-CK N sgRNA levels were largely comparable in cells incubated at 37 \u2022 C and those incubated at 41 \u2022 C (Figure 7a ), indicating that sgRNA synthesis is not affected by temperature.", [["cells", "ANATOMY", 275, 280], ["CK N sgRNA", "GENE_OR_GENE_PRODUCT", 230, 240], ["cells", "CELL", 275, 280], ["sgRNA", "SIMPLE_CHEMICAL", 361, 366], ["viral RNA", "RNA", 84, 93], ["M41", "PROTEIN", 226, 229], ["infectious viral progeny", "PROBLEM", 18, 42], ["viral RNA synthesis", "TREATMENT", 84, 103], ["productive virus replication", "TREATMENT", 108, 136], ["sgRNA Levels", "TEST", 157, 169], ["Beau", "TEST", 177, 181], ["M41", "TEST", 226, 229], ["CK N sgRNA levels", "TEST", 230, 247], ["C", "TEST", 299, 300], ["sgRNA synthesis", "PROBLEM", 361, 376], ["quantities", "OBSERVATION_MODIFIER", 4, 14], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["sgRNA synthesis", "OBSERVATION", 361, 376]]], ["Analysis of Beau-R N sgRNA levels showed that the quantity of this sgRNA was reduced during Beau-R infection, 6 to 24 hpi (p < 0.0005), at 41 \u2022 C when compared to synthesis at 37 \u2022 C (Figure 7b ).", [["infection", "DISEASE", 99, 108], ["Beau-R N sgRNA", "GENE_OR_GENE_PRODUCT", 12, 26], ["sgRNA", "GENE_OR_GENE_PRODUCT", 67, 72], ["Beau-R", "GENE_OR_GENE_PRODUCT", 92, 98], ["Analysis", "TEST", 0, 8], ["Beau-R N sgRNA levels", "TEST", 12, 33], ["this sgRNA", "PROBLEM", 62, 72], ["Beau-R infection", "PROBLEM", 92, 108], ["synthesis", "TEST", 163, 172], ["infection", "OBSERVATION", 99, 108]]], ["This result implies a reduction in viral RNA synthesis at 41 \u2022 C, further indicating the role of the replicase gene for the restriction in growth of Beau-R at 41 \u2022 C. Interestingly, at the first time point for analysis, 4 hpi, the quantity of N sgmRNA was higher at 41 \u2022 C (p < 0.0001); this was also observed in M41-CK infection but the difference was not statistically significant.", [["infection", "DISEASE", 320, 329], ["Beau-R", "GENE_OR_GENE_PRODUCT", 149, 155], ["N sgmRNA", "GENE_OR_GENE_PRODUCT", 243, 251], ["M41-CK", "GENE_OR_GENE_PRODUCT", 313, 319], ["viral RNA", "RNA", 35, 44], ["replicase gene", "DNA", 101, 115], ["N sgmRNA", "PROTEIN", 243, 251], ["a reduction in viral RNA synthesis", "PROBLEM", 20, 54], ["the replicase gene", "TREATMENT", 97, 115], ["Beau", "TEST", 149, 153], ["analysis", "TEST", 210, 218], ["N sgmRNA", "TEST", 243, 251], ["M41", "TEST", 313, 316], ["CK infection", "PROBLEM", 317, 329], ["reduction", "OBSERVATION_MODIFIER", 22, 31], ["viral RNA", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 320, 329]]], ["The titres of infectious progeny generated from both M41-CK (Figure 7c ) and Beau-R (Figure 7d ) infections were reduced from 10 hpi in cells incubated at 41 \u2022 C in comparison to 37 \u2022 C (p < 0.05).", [["cells", "ANATOMY", 136, 141], ["infections", "DISEASE", 97, 107], ["Beau-R", "GENE_OR_GENE_PRODUCT", 77, 83], ["cells", "CELL", 136, 141], ["CK", "PROTEIN", 57, 59], ["CK", "TEST", 57, 59], ["Beau", "TEST", 77, 81], ["infections", "PROBLEM", 97, 107], ["infectious", "OBSERVATION", 14, 24]]], ["The reduction in Beau-R titres, however, were much more apparent, and alongside the reduction in N sgRNA levels (Figure 7b) , suggests that the reduction in viral titre is likely the result of decreased viral RNA synthesis.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 17, 23], ["N sgRNA", "GENE_OR_GENE_PRODUCT", 97, 104], ["N sgRNA", "PROTEIN", 97, 104], ["viral RNA", "RNA", 203, 212], ["The reduction", "TREATMENT", 0, 13], ["Beau-R titres", "TEST", 17, 30], ["the reduction in N sgRNA levels", "PROBLEM", 80, 111], ["the reduction in viral titre", "PROBLEM", 140, 168], ["decreased viral RNA synthesis", "PROBLEM", 193, 222], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["reduction", "OBSERVATION_MODIFIER", 84, 93], ["reduction", "OBSERVATION_MODIFIER", 144, 153], ["viral titre", "OBSERVATION", 157, 168], ["decreased", "OBSERVATION_MODIFIER", 193, 202], ["viral RNA synthesis", "OBSERVATION", 203, 222]]], ["The indication of comparable RNA synthesis for M41-CK at both temperatures (Figure 7a ) does not offer a clear explanation to the moderate drop in viral titre at 41 \u2022 C, indicating the role of another factor.", [["M41-CK", "GENE_OR_GENE_PRODUCT", 47, 53], ["M41", "PROTEIN", 47, 50], ["CK", "PROTEIN", 51, 53], ["comparable RNA synthesis", "PROBLEM", 18, 42], ["M41", "TEST", 47, 50], ["the moderate drop", "PROBLEM", 126, 143], ["viral titre", "TEST", 147, 158], ["viral titre", "OBSERVATION", 147, 158]]], ["Investigation into N protein production (Figure 8 ) also does not explain the moderate drop in viral titre.", [["N protein", "PROTEIN", 19, 28], ["the moderate drop in viral titre", "PROBLEM", 74, 106], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["drop", "OBSERVATION", 87, 91], ["viral titre", "OBSERVATION", 95, 106]]], ["During Beau-R infection at 41 \u2022 C, at 8, 11 and 24 hpi there was markedly less N protein detected in comparison to 37 \u2022 C, which is likely the consequence of reduced N gene sgmRNA production (Figure 7b ).", [["infection", "DISEASE", 14, 23], ["Beau-R", "GENE_OR_GENE_PRODUCT", 7, 13], ["sgmRNA", "GENE_OR_GENE_PRODUCT", 173, 179], ["N protein", "PROTEIN", 79, 88], ["N gene", "DNA", 166, 172], ["R infection", "PROBLEM", 12, 23], ["markedly less N protein", "PROBLEM", 65, 88], ["reduced N gene sgmRNA production", "PROBLEM", 158, 190], ["infection", "OBSERVATION", 14, 23], ["likely the consequence", "UNCERTAINTY", 132, 154]]], ["During M41-CK infection there was little difference in the levels of N protein detected, again indicating that another factor is contributing to the decrease in viral titre.", [["infection", "DISEASE", 14, 23], ["M41-CK", "GENE_OR_GENE_PRODUCT", 7, 13], ["N protein", "PROTEIN", 69, 78], ["M41-CK infection", "PROBLEM", 7, 23], ["little difference", "PROBLEM", 34, 51], ["N protein", "TEST", 69, 78], ["the decrease in viral titre", "PROBLEM", 145, 172], ["infection", "OBSERVATION", 14, 23], ["little", "OBSERVATION_MODIFIER", 34, 40], ["difference", "OBSERVATION_MODIFIER", 41, 51], ["decrease", "OBSERVATION_MODIFIER", 149, 157], ["viral titre", "OBSERVATION", 161, 172]]], ["In summary, the analysis of RNA levels and protein expression with regards to the N gene, suggests that for Beau-R, RNA synthesis is negatively affected by incubation at 41 \u2022 C, contributing to reduced protein production and a decrease in the quantity of infectious progeny virions.", [["virions", "ANATOMY", 274, 281], ["Beau-R", "GENE_OR_GENE_PRODUCT", 108, 114], ["N gene", "DNA", 82, 88], ["the analysis", "TEST", 12, 24], ["RNA levels", "TEST", 28, 38], ["protein expression", "TEST", 43, 61], ["RNA synthesis", "PROBLEM", 116, 129], ["reduced protein production", "PROBLEM", 194, 220], ["infectious progeny virions", "PROBLEM", 255, 281], ["reduced", "OBSERVATION_MODIFIER", 194, 201], ["protein production", "OBSERVATION", 202, 220], ["decrease", "OBSERVATION_MODIFIER", 227, 235], ["infectious progeny virions", "OBSERVATION", 255, 281]]], ["For M41-CK, RNA levels and protein expression were largely unaffected by temperature, however there was a moderate decrease in viral titre after 10 hpi at 41 \u2022 C.Temperature Affects sgRNA Levels during Beau-R Infectionboth for de novo synthesis of the full-length genomic RNA thus generating genomic RNA for progeny viruses as well as generating the replicase proteins, and for the synthesis of a set of subgenomic RNAs (sgRNA), that are used for the generation of the structural and accessory proteins.", [["M41-CK", "GENE_OR_GENE_PRODUCT", 4, 10], ["sgRNA", "GENE_OR_GENE_PRODUCT", 421, 426], ["M41", "PROTEIN", 4, 7], ["CK", "PROTEIN", 8, 10], ["full-length genomic RNA", "RNA", 252, 275], ["genomic RNA", "RNA", 292, 303], ["replicase proteins", "PROTEIN", 350, 368], ["subgenomic RNAs", "RNA", 404, 419], ["sgRNA", "PROTEIN", 421, 426], ["structural and accessory proteins", "PROTEIN", 469, 502], ["M41", "TEST", 4, 7], ["CK", "TEST", 8, 10], ["RNA levels", "TEST", 12, 22], ["protein expression", "TEST", 27, 45], ["temperature", "TEST", 73, 84], ["a moderate decrease in viral titre", "PROBLEM", 104, 138], ["sgRNA Levels", "TEST", 182, 194], ["Beau", "TEST", 202, 206], ["de novo synthesis", "PROBLEM", 227, 244], ["the full-length genomic RNA", "TREATMENT", 248, 275], ["progeny viruses", "PROBLEM", 308, 323], ["the replicase proteins", "TEST", 346, 368], ["the synthesis", "TEST", 378, 391], ["subgenomic RNAs (sgRNA", "PROBLEM", 404, 426], ["moderate", "OBSERVATION_MODIFIER", 106, 114], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["viral titre", "OBSERVATION", 127, 138], ["genomic RNA", "OBSERVATION", 292, 303], ["subgenomic RNAs", "OBSERVATION", 404, 419]]], ["In order to investigate whether the restriction in growth observed for Beau-R at 41 \u00b0C was linked to RNA expression a series of infections were used to investigate whether the quantities of sgRNA synthesised differed at the two different temperatures.", [["infections", "DISEASE", 128, 138], ["Beau-R", "GENE_OR_GENE_PRODUCT", 71, 77], ["sgRNA", "GENE_OR_GENE_PRODUCT", 190, 195], ["sgRNA", "PROTEIN", 190, 195], ["the restriction in growth", "PROBLEM", 32, 57], ["Beau", "TEST", 71, 75], ["infections", "PROBLEM", 128, 138], ["sgRNA synthesised", "PROBLEM", 190, 207]]], ["Specifically, the levels of the sgRNA responsible for the expression of nucleocapsid (N) protein was used as an indicator for the level of viral RNA synthesis (Figure 7) .", [["sgRNA", "GENE_OR_GENE_PRODUCT", 32, 37], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 72, 88], ["sgRNA", "PROTEIN", 32, 37], ["nucleocapsid (N) protein", "PROTEIN", 72, 96], ["viral RNA", "RNA", 139, 148], ["the sgRNA", "PROBLEM", 28, 37], ["nucleocapsid (N) protein", "PROBLEM", 72, 96], ["viral RNA synthesis", "PROBLEM", 139, 158], ["sgRNA", "OBSERVATION", 32, 37], ["viral RNA", "OBSERVATION", 139, 148]]], ["The quantities of infectious viral progeny were determined for a comparison between viral RNA synthesis and productive virus replication. (c,d) The quantity of infectious progeny in the supernatant was assessed via titration in CK cells.", [["progeny", "ANATOMY", 171, 178], ["supernatant", "ANATOMY", 186, 197], ["CK cells", "ANATOMY", 228, 236], ["CK cells", "CELL", 228, 236], ["viral RNA", "RNA", 84, 93], ["CK cells", "CELL_LINE", 228, 236], ["infectious viral progeny", "PROBLEM", 18, 42], ["viral RNA synthesis", "TREATMENT", 84, 103], ["productive virus replication", "TREATMENT", 108, 136], ["infectious progeny", "PROBLEM", 160, 178], ["titration in CK cells", "TEST", 215, 236], ["quantities", "OBSERVATION_MODIFIER", 4, 14], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["infectious", "OBSERVATION", 160, 170]]], ["In all graphs, the mean of three independent experiments (n = 3) is presented and error bars represent SEM.", [["SEM", "OBSERVATION", 103, 106]]], ["Statistical differences were assessed using a two-way ANOVA with Sidak analysis for multiple comparisons and are highlight by * (p < 0.05), ** (p < 0.005), *** (p < 0.0005) and **** (p < 0.0001).", [["Sidak analysis", "TEST", 65, 79]]], ["At all the time points assessed, M41-CK N sgRNA levels were largely comparable in cells incubated at 37 \u00b0C and those incubated at 41 \u00b0C (Figure 7a ), indicating that sgRNA synthesis is not affected by temperature.", [["cells", "ANATOMY", 82, 87], ["M41-CK N", "GENE_OR_GENE_PRODUCT", 33, 41], ["cells", "CELL", 82, 87], ["sgRNA", "SIMPLE_CHEMICAL", 166, 171], ["M41", "PROTEIN", 33, 36], ["CK N", "PROTEIN", 37, 41], ["M41", "TEST", 33, 36], ["CK N sgRNA levels", "TEST", 37, 54], ["sgRNA synthesis", "PROBLEM", 166, 181], ["sgRNA synthesis", "OBSERVATION", 166, 181]]], ["Analysis of Beau-R N sgRNA levels showed that the quantity of this sgRNA was reduced during Beau-R infection, 6 to 24 hpi (p < 0.0005), at 41 \u00b0C when compared to synthesis at 37 \u00b0C (Figure 7b ).", [["infection", "DISEASE", 99, 108], ["Beau-R N sgRNA", "GENE_OR_GENE_PRODUCT", 12, 26], ["sgRNA", "GENE_OR_GENE_PRODUCT", 67, 72], ["Beau-R", "GENE_OR_GENE_PRODUCT", 92, 98], ["Analysis", "TEST", 0, 8], ["Beau-R N sgRNA levels", "TEST", 12, 33], ["this sgRNA", "PROBLEM", 62, 72], ["Beau-R infection", "PROBLEM", 92, 108], ["synthesis", "TEST", 162, 171], ["infection", "OBSERVATION", 99, 108]]], ["This result implies a reduction in viral RNA synthesis at 41 \u00b0C, further indicatingBeau-R Replication at 41 \u00b0C Can Be Rescued by M41-CKOur results indicate that a component of the IBV replicase protein, playing some role in RNA synthesis, was responsible for the restricted growth of Beau-R at 41 \u00b0C. To determine whether this was a dominant feature, we decided to assess whether Beau-R replication could restrict replication of M41-CK, or alternatively whether Beau-R replication could be rescued by M41-CK at 41 \u00b0C. CK cells were co-infected with Beau-R and M41-CK and incubated at either 37 \u00b0C or 41 \u00b0C. Progeny The amounts of the IBV N protein present in the samples were analysed by western blot using an anti-IBV antibody.", [["CK cells", "ANATOMY", 518, 526], ["samples", "ANATOMY", 663, 670], ["Beau-R", "GENE_OR_GENE_PRODUCT", 83, 89], ["IBV", "ORGANISM", 180, 183], ["Beau-R", "GENE_OR_GENE_PRODUCT", 284, 290], ["Beau-R", "GENE_OR_GENE_PRODUCT", 380, 386], ["M41-CK", "GENE_OR_GENE_PRODUCT", 429, 435], ["Beau-R", "GENE_OR_GENE_PRODUCT", 462, 468], ["M41-CK", "GENE_OR_GENE_PRODUCT", 501, 507], ["CK cells", "CELL", 518, 526], ["Beau-R", "GENE_OR_GENE_PRODUCT", 549, 555], ["M41-CK", "GENE_OR_GENE_PRODUCT", 560, 566], ["Progeny", "ORGANISM", 607, 614], ["IBV", "ORGANISM", 634, 637], ["viral RNA", "RNA", 35, 44], ["M41", "PROTEIN", 129, 132], ["CKOur", "PROTEIN", 133, 138], ["IBV replicase protein", "PROTEIN", 180, 201], ["M41", "PROTEIN", 429, 432], ["CK", "PROTEIN", 433, 435], ["M41", "PROTEIN", 501, 504], ["CK", "PROTEIN", 505, 507], ["CK cells", "CELL_TYPE", 518, 526], ["CK", "PROTEIN", 564, 566], ["IBV N protein", "PROTEIN", 634, 647], ["anti-IBV antibody", "PROTEIN", 710, 727], ["IBV", "SPECIES", 180, 183], ["IBV", "SPECIES", 634, 637], ["anti-IBV", "SPECIES", 710, 718], ["a reduction in viral RNA synthesis", "PROBLEM", 20, 54], ["the IBV replicase protein", "TREATMENT", 176, 201], ["RNA synthesis", "PROBLEM", 224, 237], ["Beau", "TEST", 284, 288], ["CK", "TEST", 505, 507], ["CK cells", "TEST", 518, 526], ["co-infected", "PROBLEM", 532, 543], ["Beau", "TEST", 549, 553], ["M41", "TEST", 560, 563], ["CK", "TEST", 564, 566], ["the IBV N protein", "TREATMENT", 630, 647], ["an anti-IBV antibody", "TEST", 707, 727], ["reduction", "OBSERVATION_MODIFIER", 22, 31], ["viral RNA", "OBSERVATION", 35, 44], ["amounts", "OBSERVATION_MODIFIER", 619, 626]]], ["Levels of actin were analysed using an anti-\u03b2-actin as a loading control.", [["actin", "GENE_OR_GENE_PRODUCT", 10, 15], ["anti-\u03b2-actin", "SIMPLE_CHEMICAL", 39, 51], ["actin", "PROTEIN", 10, 15], ["anti-\u03b2-actin", "PROTEIN", 39, 51], ["actin", "TREATMENT", 10, 15], ["an anti-\u03b2-actin", "TREATMENT", 36, 51], ["a loading control", "TREATMENT", 55, 72]]], ["Identified bands relate to \u03b2 Actin (43kDa) and the IBV N protein (48kDa).Beau-R Replication at 41 \u2022 C Can Be Rescued by M41-CKOur results indicate that a component of the IBV replicase protein, playing some role in RNA synthesis, was responsible for the restricted growth of Beau-R at 41 \u2022 C. To determine whether this was a dominant feature, we decided to assess whether Beau-R replication could restrict replication of M41-CK, or alternatively whether Beau-R replication could be rescued by M41-CK at 41 \u2022 C. CK cells were co-infected with Beau-R and M41-CK and incubated at either 37 \u2022 C or 41 \u2022 C. Progeny viruses in the resultant supernatants were subsequently passaged a further four times in CK cells at the temperature at which the first stage occurred.", [["CK cells", "ANATOMY", 511, 519], ["supernatants", "ANATOMY", 635, 647], ["CK cells", "ANATOMY", 699, 707], ["\u03b2 Actin", "GENE_OR_GENE_PRODUCT", 27, 34], ["IBV N protein", "GENE_OR_GENE_PRODUCT", 51, 64], ["Beau-R", "GENE_OR_GENE_PRODUCT", 73, 79], ["IBV", "ORGANISM", 171, 174], ["Beau-R", "GENE_OR_GENE_PRODUCT", 275, 281], ["Beau-R", "GENE_OR_GENE_PRODUCT", 372, 378], ["M41-CK", "GENE_OR_GENE_PRODUCT", 421, 427], ["Beau-R", "GENE_OR_GENE_PRODUCT", 454, 460], ["M41-CK", "GENE_OR_GENE_PRODUCT", 493, 499], ["CK cells", "CELL", 511, 519], ["Beau-R", "GENE_OR_GENE_PRODUCT", 542, 548], ["M41-CK", "GENE_OR_GENE_PRODUCT", 553, 559], ["Progeny", "ORGANISM", 602, 609], ["CK cells", "CELL", 699, 707], ["\u03b2 Actin", "PROTEIN", 27, 34], ["43kDa", "PROTEIN", 36, 41], ["IBV N protein", "PROTEIN", 51, 64], ["48kDa", "PROTEIN", 66, 71], ["M41", "PROTEIN", 120, 123], ["CKOur", "PROTEIN", 124, 129], ["IBV replicase protein", "PROTEIN", 171, 192], ["M41", "PROTEIN", 421, 424], ["CK", "PROTEIN", 425, 427], ["M41", "PROTEIN", 493, 496], ["CK", "PROTEIN", 497, 499], ["CK cells", "CELL_TYPE", 511, 519], ["M41", "PROTEIN", 553, 556], ["CK", "PROTEIN", 557, 559], ["CK cells", "CELL_TYPE", 699, 707], ["IBV", "SPECIES", 171, 174], ["bands", "PROBLEM", 11, 16], ["the IBV N protein", "TREATMENT", 47, 64], ["the IBV replicase protein", "TREATMENT", 167, 192], ["RNA synthesis", "PROBLEM", 215, 228], ["M41", "TEST", 493, 496], ["CK", "TEST", 497, 499], ["C. CK cells", "TEST", 508, 519], ["co-infected", "PROBLEM", 525, 536], ["Beau", "TEST", 542, 546], ["M41", "TEST", 553, 556], ["CK", "TEST", 557, 559], ["CK cells", "TEST", 699, 707], ["the temperature", "TEST", 711, 726], ["Progeny viruses", "OBSERVATION", 602, 617]]], ["The presence of Beau-R and M41-CK genomic material was detected using an RT-PCR assay targeting the 3 UTRs [23] (Figure 9 ).", [["Beau-R", "GENE_OR_GENE_PRODUCT", 16, 22], ["M41-CK", "GENE_OR_GENE_PRODUCT", 27, 33], ["Beau-R and M41-CK genomic material", "DNA", 16, 50], ["UTRs", "DNA", 102, 106], ["Beau", "TEST", 16, 20], ["M41", "TEST", 27, 30], ["CK genomic material", "PROBLEM", 31, 50], ["an RT-PCR assay", "TEST", 70, 85]]], ["RT-PCR products derived from Beau-R and M41-CK RNAs, 667 and~483 nucleotides, respectively, were detected either in CK cells infected with a single virus, or in cells co-infected with both viruses at 37 \u2022 C ( Figure 9a ).", [["CK cells", "ANATOMY", 116, 124], ["cells", "ANATOMY", 161, 166], ["nucleotides", "CHEMICAL", 65, 76], ["Beau-R", "GENE_OR_GENE_PRODUCT", 29, 35], ["M41-CK", "GENE_OR_GENE_PRODUCT", 40, 46], ["CK cells", "CELL", 116, 124], ["cells", "CELL", 161, 166], ["Beau-R and M41-CK RNAs", "RNA", 29, 51], ["CK cells", "CELL_TYPE", 116, 124], ["RT-PCR products", "TEST", 0, 15], ["Beau", "TEST", 29, 33], ["M41", "TEST", 40, 43], ["CK RNAs", "TEST", 44, 51], ["nucleotides", "TEST", 65, 76], ["CK cells", "PROBLEM", 116, 124], ["a single virus", "PROBLEM", 139, 153]]], ["As expected, M41-CK RNA was detected in CK cells incubated at 41 \u2022 C, whereas Beau-R RNA was not detected.", [["CK cells", "ANATOMY", 40, 48], ["M41-CK", "GENE_OR_GENE_PRODUCT", 13, 19], ["CK cells", "CELL", 40, 48], ["Beau-R", "GENE_OR_GENE_PRODUCT", 78, 84], ["M41-CK RNA", "RNA", 13, 23], ["CK cells", "CELL_LINE", 40, 48], ["Beau-R RNA", "RNA", 78, 88], ["M41-CK RNA", "TEST", 13, 23], ["CK cells", "TEST", 40, 48], ["C", "TEST", 67, 68], ["Beau", "TEST", 78, 82]]], ["Both Beau-R and M41-CK derived RNA was detected in CK cells co-infected with both viruses at 41 \u2022 C (Figure 9b) .", [["CK cells", "ANATOMY", 51, 59], ["Beau-R", "GENE_OR_GENE_PRODUCT", 5, 11], ["M41-CK", "GENE_OR_GENE_PRODUCT", 16, 22], ["CK cells", "CELL", 51, 59], ["Beau-R and M41-CK derived RNA", "RNA", 5, 34], ["CK cells", "CELL_TYPE", 51, 59], ["Beau", "TEST", 5, 9], ["M41", "TEST", 16, 19], ["CK derived RNA", "TEST", 20, 34], ["CK cells co-infected", "PROBLEM", 51, 71], ["both viruses", "PROBLEM", 77, 89], ["Figure", "TEST", 101, 107]]], ["These results show Beau-R RNA cannot be detected in CK cells passaged at 41 \u2022 C but can be detected in CK cells co-infected with M41-CK, demonstrating that the M41-CK replicase can rescue the replication of Beau-R genomic RNA at the non-permissive temperature.", [["CK cells", "ANATOMY", 52, 60], ["CK cells", "ANATOMY", 103, 111], ["Beau-R", "GENE_OR_GENE_PRODUCT", 19, 25], ["CK cells", "CELL", 52, 60], ["CK cells", "CELL", 103, 111], ["M41-CK", "GENE_OR_GENE_PRODUCT", 129, 135], ["M41", "GENE_OR_GENE_PRODUCT", 160, 163], ["CK", "GENE_OR_GENE_PRODUCT", 164, 166], ["Beau-R", "GENE_OR_GENE_PRODUCT", 207, 213], ["Beau-R RNA", "RNA", 19, 29], ["CK cells", "CELL_LINE", 52, 60], ["CK cells", "CELL_TYPE", 103, 111], ["M41", "PROTEIN", 129, 132], ["CK", "PROTEIN", 133, 135], ["M41", "PROTEIN", 160, 163], ["CK replicase", "PROTEIN", 164, 176], ["Beau-R genomic RNA", "RNA", 207, 225], ["Beau-R RNA", "PROBLEM", 19, 29], ["CK cells", "TEST", 52, 60], ["CK cells", "TEST", 103, 111], ["M41", "TEST", 129, 132], ["CK", "TEST", 133, 135], ["the M41", "TEST", 156, 163], ["CK replicase", "TREATMENT", 164, 176], ["Beau-R genomic RNA", "PROBLEM", 207, 225], ["genomic RNA", "OBSERVATION", 214, 225], ["non-permissive temperature", "OBSERVATION_MODIFIER", 233, 259]]], ["This indicates that during coinfection at the non-permissive temperature the M41-CK replicase is the dominant activity and the Beau-R replicase does not have a negative effect on the replication of M41-CK.", [["coinfection", "DISEASE", 27, 38], ["M41", "GENE_OR_GENE_PRODUCT", 77, 80], ["CK", "GENE_OR_GENE_PRODUCT", 81, 83], ["Beau-R", "GENE_OR_GENE_PRODUCT", 127, 133], ["M41-CK", "GENE_OR_GENE_PRODUCT", 198, 204], ["M41", "PROTEIN", 77, 80], ["CK replicase", "PROTEIN", 81, 93], ["Beau-R replicase", "PROTEIN", 127, 143], ["M41", "PROTEIN", 198, 201], ["CK", "PROTEIN", 202, 204], ["M41", "TEST", 198, 201], ["coinfection", "OBSERVATION", 27, 38], ["dominant", "OBSERVATION_MODIFIER", 101, 109], ["activity", "OBSERVATION_MODIFIER", 110, 118], ["negative", "OBSERVATION", 160, 168]]], ["Overall, the results of the co-infection experiments indicates that Beau-R and M41-CK can infect the same cell at the same time, and that incubation at 41 \u2022 C does not result in permanent or non-recoverable damage to the Beau-R RNA, providing further evidence that the Beau-R replicase is responsible for the observed restriction in replication of Beau-R RNA at 41 \u2022 C and that the effect is not due to an impediment with the Beau-R RNA.DiscussionFor birds, as well as mammals, the continuous movement of air through the respiratory tract results in a temperature gradient in which the upper respiratory tract, including the nasal cavities, mouth and throat, is cooler than the trachea and lungs that constitute the lower respiratory tract [43] . .", [["cell", "ANATOMY", 106, 110], ["respiratory tract", "ANATOMY", 521, 538], ["upper respiratory tract", "ANATOMY", 586, 609], ["nasal cavities", "ANATOMY", 625, 639], ["mouth", "ANATOMY", 641, 646], ["throat", "ANATOMY", 651, 657], ["trachea", "ANATOMY", 678, 685], ["lungs", "ANATOMY", 690, 695], ["lower respiratory tract", "ANATOMY", 716, 739], ["Beau-R", "GENE_OR_GENE_PRODUCT", 68, 74], ["M41-CK", "GENE_OR_GENE_PRODUCT", 79, 85], ["cell", "CELL", 106, 110], ["Beau-R", "GENE_OR_GENE_PRODUCT", 221, 227], ["Beau-R", "GENE_OR_GENE_PRODUCT", 269, 275], ["Beau-R", "GENE_OR_GENE_PRODUCT", 348, 354], ["Beau-R", "GENE_OR_GENE_PRODUCT", 426, 432], ["respiratory tract", "ORGANISM_SUBDIVISION", 521, 538], ["upper", "ORGANISM_SUBDIVISION", 586, 591], ["respiratory tract", "ORGANISM_SUBDIVISION", 592, 609], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 625, 639], ["mouth", "ORGANISM_SUBDIVISION", 641, 646], ["throat", "ORGANISM_SUBDIVISION", 651, 657], ["trachea", "ORGAN", 678, 685], ["lungs", "ORGAN", 690, 695], ["lower respiratory", "ORGANISM_SUBDIVISION", 716, 733], ["tract", "ORGANISM_SUBDIVISION", 734, 739], ["M41", "PROTEIN", 79, 82], ["CK", "PROTEIN", 83, 85], ["Beau-R RNA", "RNA", 221, 231], ["Beau-R replicase", "PROTEIN", 269, 285], ["Beau-R RNA", "RNA", 348, 358], ["Beau-R RNA", "RNA", 426, 436], ["the co-infection experiments", "TEST", 24, 52], ["Beau", "TEST", 68, 72], ["M41", "TEST", 79, 82], ["permanent or non-recoverable damage", "PROBLEM", 178, 213], ["the Beau-R replicase", "PROBLEM", 265, 285], ["a temperature gradient", "PROBLEM", 550, 572], ["the upper respiratory tract", "PROBLEM", 582, 609], ["the nasal cavities, mouth and throat", "PROBLEM", 621, 657], ["the lower respiratory tract", "PROBLEM", 712, 739], ["air", "OBSERVATION", 505, 508], ["respiratory tract", "ANATOMY", 521, 538], ["upper", "ANATOMY_MODIFIER", 586, 591], ["respiratory tract", "ANATOMY", 592, 609], ["nasal cavities", "ANATOMY", 625, 639], ["mouth", "ANATOMY", 641, 646], ["throat", "ANATOMY", 651, 657], ["cooler", "OBSERVATION", 662, 668], ["trachea", "ANATOMY", 678, 685], ["lungs", "ANATOMY", 690, 695], ["lower", "ANATOMY_MODIFIER", 716, 721], ["respiratory tract", "ANATOMY", 722, 739]]], ["Beau-R replication at 41 \u2022 C can be rescued by M41-CK.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 0, 6], ["41 \u2022 C", "SIMPLE_CHEMICAL", 22, 28], ["M41-CK", "GENE_OR_GENE_PRODUCT", 47, 53], ["M41", "PROTEIN", 47, 50], ["CK", "PROTEIN", 51, 53]]], ["Primary CK cells seeded in 6 well plates were inoculated with 10 5 PFU (MOI~0.01) of either M41-CK or Beau-R, or co-infected with 10 5 PFU Beau-R and 10 5 PFU M41-CK.", [["Primary CK cells", "ANATOMY", 0, 16], ["CK cells", "CELL", 8, 16], ["M41-CK", "GENE_OR_GENE_PRODUCT", 92, 98], ["Beau-R", "GENE_OR_GENE_PRODUCT", 102, 108], ["Beau-R", "ORGANISM", 139, 145], ["CK", "GENE_OR_GENE_PRODUCT", 163, 165], ["CK cells", "CELL_LINE", 8, 16], ["CK", "PROTEIN", 96, 98], ["CK", "PROTEIN", 163, 165], ["Primary CK cells", "TEST", 0, 16], ["MOI", "TEST", 72, 75], ["M41", "TEST", 92, 95], ["CK", "TEST", 96, 98], ["Beau", "TEST", 102, 106], ["co-infected", "PROBLEM", 113, 124], ["Beau", "TEST", 139, 143], ["PFU M41", "TEST", 155, 162], ["CK", "TEST", 163, 165], ["co-infected", "OBSERVATION", 113, 124]]], ["BES media was used for mock infection.", [["BES", "CHEMICAL", 0, 3], ["infection", "DISEASE", 28, 37], ["BES media", "TREATMENT", 0, 9], ["mock infection", "PROBLEM", 23, 37], ["infection", "OBSERVATION", 28, 37]]], ["Cells were incubated at (a) 37 \u2022 C or (b) 41 \u2022 C, until extensive CPE was observed in the 37 \u2022 C wells.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["extensive CPE", "TEST", 56, 69], ["extensive", "OBSERVATION_MODIFIER", 56, 65], ["CPE", "OBSERVATION", 66, 69]]], ["Progeny virus present in the supernatants were passaged a further four times in CK cells at the same temperature as the first passage.", [["supernatants", "ANATOMY", 29, 41], ["CK cells", "ANATOMY", 80, 88], ["Progeny virus", "ORGANISM", 0, 13], ["CK cells", "CELL", 80, 88], ["CK cells", "CELL_TYPE", 80, 88], ["Progeny virus", "SPECIES", 0, 13], ["Progeny virus", "PROBLEM", 0, 13], ["CK cells", "TEST", 80, 88], ["virus", "OBSERVATION", 8, 13]]], ["RNA was extracted from the final supernatants and assessed for the presence of M41-CK and Beau-R genomic material by (RT-PCR) analysis using primers targeting the 3 UTR.", [["supernatants", "ANATOMY", 33, 45], ["M41-CK", "GENE_OR_GENE_PRODUCT", 79, 85], ["Beau-R", "GENE_OR_GENE_PRODUCT", 90, 96], ["RNA", "RNA", 0, 3], ["M41", "PROTEIN", 79, 82], ["CK", "PROTEIN", 83, 85], ["3 UTR", "DNA", 163, 168], ["M41", "TEST", 79, 82], ["CK", "TEST", 83, 85], ["Beau", "TEST", 90, 94], ["RT-PCR) analysis", "TEST", 118, 134]]], ["RT-PCR products were separated by agarose gel electrophoresis alongside a 1 KB+ DNA ladder (Invitrogen).", [["agarose", "SIMPLE_CHEMICAL", 34, 41], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["RT-PCR products", "TREATMENT", 0, 15], ["agarose gel electrophoresis", "TEST", 34, 61], ["a 1 KB+ DNA ladder", "TREATMENT", 72, 90]]], ["The red arrow highlights the marker bands relating to 1000 and 600 bp.", [["1000 and 600 bp", "DNA", 54, 69], ["the marker bands", "PROBLEM", 25, 41], ["bp", "TEST", 67, 69], ["red", "OBSERVATION", 4, 7]]], ["RT-PCR products relating to Beau-R ar\u1ebd 650bp and M41-CK~450 bp.DiscussionFor birds, as well as mammals, the continuous movement of air through the respiratory tract results in a temperature gradient in which the upper respiratory tract, including the nasal cavities, mouth and throat, is cooler than the trachea and lungs that constitute the lower respiratory tract [43] .", [["respiratory tract", "ANATOMY", 147, 164], ["upper respiratory tract", "ANATOMY", 212, 235], ["nasal cavities", "ANATOMY", 251, 265], ["mouth", "ANATOMY", 267, 272], ["throat", "ANATOMY", 277, 283], ["trachea", "ANATOMY", 304, 311], ["lungs", "ANATOMY", 316, 321], ["lower respiratory tract", "ANATOMY", 342, 365], ["Beau-R", "GENE_OR_GENE_PRODUCT", 28, 34], ["M41-CK", "GENE_OR_GENE_PRODUCT", 49, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 147, 164], ["upper", "ORGANISM_SUBDIVISION", 212, 217], ["respiratory tract", "ORGANISM_SUBDIVISION", 218, 235], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 251, 265], ["mouth", "ORGANISM_SUBDIVISION", 267, 272], ["throat", "ORGANISM_SUBDIVISION", 277, 283], ["trachea", "ORGAN", 304, 311], ["lungs", "ORGAN", 316, 321], ["lower respiratory", "ORGANISM_SUBDIVISION", 342, 359], ["tract", "ORGANISM_SUBDIVISION", 360, 365], ["Beau-R ar\u1ebd 650bp", "DNA", 28, 44], ["M41", "DNA", 49, 52], ["CK~450 bp", "DNA", 53, 62], ["Beau", "TEST", 28, 32], ["M41", "TEST", 49, 52], ["CK", "TEST", 53, 55], ["bp", "TEST", 60, 62], ["a temperature gradient", "PROBLEM", 176, 198], ["the upper respiratory tract", "PROBLEM", 208, 235], ["the nasal cavities, mouth and throat", "PROBLEM", 247, 283], ["the lower respiratory tract", "PROBLEM", 338, 365], ["air", "OBSERVATION", 131, 134], ["respiratory tract", "ANATOMY", 147, 164], ["upper", "ANATOMY_MODIFIER", 212, 217], ["respiratory tract", "ANATOMY", 218, 235], ["nasal cavities", "ANATOMY", 251, 265], ["mouth", "ANATOMY", 267, 272], ["throat", "ANATOMY", 277, 283], ["cooler", "OBSERVATION", 288, 294], ["trachea", "ANATOMY", 304, 311], ["lungs", "ANATOMY", 316, 321], ["lower", "ANATOMY_MODIFIER", 342, 347], ["respiratory tract", "ANATOMY", 348, 365]]], ["Research on human pathogens, including influenza virus, rhinovirus and RSV, has indicated that the temperature of the upper respiratory is between 33-34 \u2022 C and the lower to be 37 \u2022 C, commonly denoted as permissive and non-permissive temperatures, respectively [30] [31] [32] [50] [51] [52] .", [["influenza virus", "DISEASE", 39, 54], ["human", "ORGANISM", 12, 17], ["influenza virus", "ORGANISM", 39, 54], ["rhinovirus", "ORGANISM", 56, 66], ["RSV", "ORGANISM", 71, 74], ["[31] [32] [50] [51] [52]", "SIMPLE_CHEMICAL", 267, 291], ["human", "SPECIES", 12, 17], ["influenza virus", "SPECIES", 39, 54], ["human", "SPECIES", 12, 17], ["influenza virus", "SPECIES", 39, 54], ["RSV", "SPECIES", 71, 74], ["human pathogens", "PROBLEM", 12, 27], ["influenza virus", "PROBLEM", 39, 54], ["rhinovirus", "PROBLEM", 56, 66], ["RSV", "TREATMENT", 71, 74], ["the temperature", "TEST", 95, 110], ["the upper respiratory", "TEST", 114, 135], ["non-permissive temperatures", "TEST", 220, 247], ["upper", "ANATOMY_MODIFIER", 118, 123], ["respiratory", "ANATOMY", 124, 135]]], ["Unlike humans which have a core body temperature of 37 \u2022 C, chickens exhibit a core temperature of 41 \u2022 C [48] , which means it is likely that the temperature of the upper respiratory tract is 37-38 \u2022 C, increasing to 41 \u2022 C in the lower respiratory tract.", [["body", "ANATOMY", 32, 36], ["upper respiratory tract", "ANATOMY", 166, 189], ["lower respiratory tract", "ANATOMY", 232, 255], ["humans", "ORGANISM", 7, 13], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["chickens", "ORGANISM", 60, 68], ["upper respiratory", "ORGANISM_SUBDIVISION", 166, 183], ["tract", "ORGANISM_SUBDIVISION", 184, 189], ["lower", "ORGANISM_SUBDIVISION", 232, 237], ["respiratory tract", "ORGANISM_SUBDIVISION", 238, 255], ["humans", "SPECIES", 7, 13], ["chickens", "SPECIES", 60, 68], ["humans", "SPECIES", 7, 13], ["chickens", "SPECIES", 60, 68], ["a core body temperature", "TEST", 25, 48], ["a core temperature", "TEST", 77, 95], ["the temperature of the upper respiratory tract", "PROBLEM", 143, 189], ["upper", "ANATOMY_MODIFIER", 166, 171], ["respiratory tract", "ANATOMY", 172, 189], ["lower", "ANATOMY_MODIFIER", 232, 237], ["respiratory tract", "ANATOMY", 238, 255]]], ["The effect of this localised temperature change on the replication of several respiratory pathogens is well documented and has been linked to viral dissemination through the host, viral pathogenicity and interspecies transmission [30] [31] [32] [52] [53] [54] [55] .DiscussionThe data presented in this study demonstrates that the attenuated IBV strain, Beau-R, exhibits a temperature sensitive replication phenotype and is unable to replicate productively at 41 \u2022 C. This temperature sensitivity may account for the attenuated phenotype observed during in vivo infection (Figure 1) , as it will inevitably contribute to the inability of Beau-R to disseminate from the point of inoculation to the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 697, 720], ["respiratory pathogens", "DISEASE", 78, 99], ["Beau-R", "CHEMICAL", 354, 360], ["infection", "DISEASE", 562, 571], ["[30] [31] [32] [52] [53] [54] [55]", "SIMPLE_CHEMICAL", 230, 264], ["IBV", "ORGANISM", 342, 345], ["Beau-R", "GENE_OR_GENE_PRODUCT", 354, 360], ["Beau-R", "GENE_OR_GENE_PRODUCT", 638, 644], ["lower", "ORGANISM_SUBDIVISION", 697, 702], ["respiratory tract", "ORGANISM_SUBDIVISION", 703, 720], ["IBV", "SPECIES", 342, 345], ["this localised temperature change", "PROBLEM", 14, 47], ["several respiratory pathogens", "PROBLEM", 70, 99], ["this study", "TEST", 298, 308], ["the attenuated IBV strain", "PROBLEM", 327, 352], ["a temperature sensitive replication phenotype", "PROBLEM", 371, 416], ["This temperature sensitivity", "TEST", 468, 496], ["the attenuated phenotype", "PROBLEM", 513, 537], ["vivo infection", "PROBLEM", 557, 571], ["inoculation to the lower respiratory tract", "PROBLEM", 678, 720], ["viral pathogenicity", "OBSERVATION", 180, 199], ["attenuated", "OBSERVATION_MODIFIER", 331, 341], ["IBV", "OBSERVATION", 342, 345], ["inoculation", "OBSERVATION", 678, 689], ["lower", "ANATOMY_MODIFIER", 697, 702], ["respiratory tract", "ANATOMY", 703, 720]]], ["Infectious Beau-R was only detected in harvested beak tissue (Table 1) and was not detected in the trachea or the eyelid, unlike M41-CK that was shown to replicate in these sites and was shown to replicate successfully at 41 \u2022 C. Unlike Beau-R, the replication of other attenuated IBV isolates, including the vaccine H120, were found not to be temperature sensitive (Figure 3) , indicating that temperature sensitivity may not be a universal cause of attenuation or loss of virulence.", [["beak tissue", "ANATOMY", 49, 60], ["trachea", "ANATOMY", 99, 106], ["eyelid", "ANATOMY", 114, 120], ["sites", "ANATOMY", 173, 178], ["Beau-R", "GENE_OR_GENE_PRODUCT", 11, 17], ["beak tissue", "TISSUE", 49, 60], ["trachea", "ORGAN", 99, 106], ["eyelid", "ORGAN", 114, 120], ["M41-CK", "GENE_OR_GENE_PRODUCT", 129, 135], ["Beau-R", "GENE_OR_GENE_PRODUCT", 237, 243], ["IBV", "ORGANISM", 281, 284], ["M41", "PROTEIN", 129, 132], ["CK", "PROTEIN", 133, 135], ["Infectious Beau-R", "SPECIES", 0, 17], ["IBV", "SPECIES", 281, 284], ["other attenuated IBV isolates", "TREATMENT", 264, 293], ["the vaccine", "TREATMENT", 305, 316], ["temperature sensitivity", "PROBLEM", 395, 418], ["attenuation", "PROBLEM", 451, 462], ["loss of virulence", "PROBLEM", 466, 483], ["harvested", "OBSERVATION", 39, 48], ["beak tissue", "OBSERVATION", 49, 60], ["not detected", "UNCERTAINTY", 79, 91], ["trachea", "ANATOMY", 99, 106], ["eyelid", "ANATOMY", 114, 120], ["attenuation", "OBSERVATION", 451, 462]]], ["More importantly, however, another pathogenic isolate of IBV investigated that can also replicate in primary CK cells, D388(QX) was, in addition to M41-CK, able to replicate at 41 \u2022 C (Figure 4 ).", [["primary CK cells", "ANATOMY", 101, 117], ["IBV", "ORGANISM", 57, 60], ["CK cells", "CELL", 109, 117], ["D388", "SIMPLE_CHEMICAL", 119, 123], ["M41-CK", "GENE_OR_GENE_PRODUCT", 148, 154], ["primary CK cells", "CELL_TYPE", 101, 117], ["M41", "PROTEIN", 148, 151], ["CK", "PROTEIN", 152, 154], ["IBV", "SPECIES", 57, 60], ["IBV", "PROBLEM", 57, 60], ["primary CK cells", "TEST", 101, 117], ["M41", "TEST", 148, 151], ["CK", "TEST", 152, 154]]], ["This may suggest that the ability to replicate at higher temperature may be a shared characteristic of pathogenic isolates of IBV, and in particular nephropathogenic strains that have to disseminate deep into the body of the bird, to infect the kidneys, oviducts and enteric tract.", [["body", "ANATOMY", 213, 217], ["kidneys", "ANATOMY", 245, 252], ["oviducts", "ANATOMY", 254, 262], ["enteric tract", "ANATOMY", 267, 280], ["IBV", "ORGANISM", 126, 129], ["body", "ORGANISM_SUBDIVISION", 213, 217], ["kidneys", "ORGAN", 245, 252], ["oviducts", "MULTI-TISSUE_STRUCTURE", 254, 262], ["enteric tract", "ORGANISM_SUBDIVISION", 267, 280], ["IBV", "SPECIES", 126, 129], ["IBV", "PROBLEM", 126, 129], ["particular nephropathogenic strains", "PROBLEM", 138, 173], ["body", "ANATOMY_MODIFIER", 213, 217], ["bird", "ANATOMY", 225, 229], ["infect", "OBSERVATION", 234, 240], ["kidneys", "ANATOMY", 245, 252], ["oviducts", "ANATOMY", 254, 262], ["enteric tract", "ANATOMY", 267, 280]]], ["This latter point is of particular interest as the replication kinetics of D388(QX) were found to be comparable at 37 \u2022 C and 41 \u2022 C ( Figure 6 ) whereas M41-CK, a classical respiratory strain, was able to replicate at 41 \u2022 C but did experience a moderate reduction in viral titre at the higher temperature.", [["D388", "CHEMICAL", 75, 79], ["QX", "CHEMICAL", 80, 82], ["D388", "CHEMICAL", 75, 79], ["D388", "SIMPLE_CHEMICAL", 75, 79], ["QX", "SIMPLE_CHEMICAL", 80, 82], ["M41-CK", "GENE_OR_GENE_PRODUCT", 154, 160], ["M41", "PROTEIN", 154, 157], ["CK", "PROTEIN", 158, 160], ["C", "TEST", 120, 121], ["Figure", "TEST", 135, 141], ["M41", "TEST", 154, 157], ["CK", "TEST", 158, 160], ["a classical respiratory strain", "PROBLEM", 162, 192], ["a moderate reduction in viral titre", "PROBLEM", 245, 280], ["respiratory strain", "OBSERVATION", 174, 192], ["moderate", "OBSERVATION_MODIFIER", 247, 255], ["reduction", "OBSERVATION_MODIFIER", 256, 265], ["viral titre", "OBSERVATION", 269, 280], ["higher temperature", "OBSERVATION_MODIFIER", 288, 306]]], ["This may, in part, explain why M41 is less often detected in the kidney during in vivo infection.", [["kidney", "ANATOMY", 65, 71], ["infection", "DISEASE", 87, 96], ["M41", "GENE_OR_GENE_PRODUCT", 31, 34], ["kidney", "ORGAN", 65, 71], ["M41", "PROTEIN", 31, 34], ["vivo infection", "PROBLEM", 82, 96], ["less often", "OBSERVATION_MODIFIER", 38, 48], ["kidney", "ANATOMY", 65, 71], ["infection", "OBSERVATION", 87, 96]]], ["To conclusively state that the ability to replicate at higher temperatures is a shared characteristic of pathogenic isolates further investigation of more IBV strains, which is difficult as many IBV pathogenic field strains cannot be propagated in vitro, will be required.DiscussionTemperature sensitivity is not a novel topic in the field of virology and has been widely studied for RNA viruses since the mid-1900s [43, 56, 57] .", [["IBV", "ORGANISM", 155, 158], ["IBV", "ORGANISM", 195, 198], ["IBV", "SPECIES", 155, 158], ["IBV", "SPECIES", 195, 198], ["more IBV strains", "PROBLEM", 150, 166], ["many IBV pathogenic field strains", "PROBLEM", 190, 223], ["Temperature sensitivity", "TEST", 282, 305], ["RNA viruses", "PROBLEM", 384, 395], ["more IBV", "OBSERVATION_MODIFIER", 150, 158]]], ["The analysis of temperature sensitive mutants has been used to identify genes involved in viral replication and pathogenesis as well as aiding in the generation of vaccine viruses [29, 46, 47, 55, [58] [59] [60] [61] [62] [63] .", [["[58] [59] [60] [61] [62] [63]", "SIMPLE_CHEMICAL", 197, 226], ["The analysis", "TEST", 0, 12], ["temperature sensitive mutants", "PROBLEM", 16, 45], ["viral replication", "PROBLEM", 90, 107], ["pathogenesis", "PROBLEM", 112, 124], ["viral replication", "OBSERVATION", 90, 107]]], ["Whilst temperature sensitivity has not been a popular research subject for IBV, [64] [65] [66] , several temperature sensitive mutants of the Betacoronavirus mouse hepatitis virus (MHV) have been generated [55, 62, 67] .", [["hepatitis virus", "DISEASE", 164, 179], ["IBV", "ORGANISM", 75, 78], ["Betacoronavirus", "ORGANISM", 142, 157], ["mouse hepatitis virus", "ORGANISM", 158, 179], ["MHV", "ORGANISM", 181, 184], ["Betacoronavirus", "SPECIES", 142, 157], ["mouse", "SPECIES", 158, 163], ["hepatitis virus", "SPECIES", 164, 179], ["IBV", "SPECIES", 75, 78], ["Betacoronavirus mouse hepatitis virus", "SPECIES", 142, 179], ["MHV", "SPECIES", 181, 184], ["temperature sensitivity", "TEST", 7, 30], ["several temperature sensitive mutants", "PROBLEM", 97, 134], ["the Betacoronavirus mouse hepatitis virus", "PROBLEM", 138, 179]]], ["These mutants all carry mutations within the replicase gene, supporting the data presented in this study that the Beau-R replicase gene is a determinant of temperature sensitivity ( Figure 6 ).", [["Beau-R", "GENE_OR_GENE_PRODUCT", 114, 120], ["replicase gene", "DNA", 45, 59], ["Beau-R replicase gene", "DNA", 114, 135], ["this study", "TEST", 94, 104]]], ["These mutants also have defects in viral RNA synthesis [62] .", [["viral RNA", "RNA", 35, 44], ["defects in viral RNA synthesis", "PROBLEM", 24, 54], ["defects", "OBSERVATION", 24, 31], ["viral RNA synthesis", "OBSERVATION", 35, 54]]], ["The analysis of N protein sgRNA levels indicates that Beau-R also experiences defects in RNA synthesis at higher temperatures ( Figure 7 ) but further research is required to elucidate both the extent of these defects and the mechanism behind them.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 54, 60], ["N protein sgRNA", "PROTEIN", 16, 31], ["Beau-R", "PROTEIN", 54, 60], ["The analysis", "TEST", 0, 12], ["N protein sgRNA levels", "TEST", 16, 38], ["Beau", "TEST", 54, 58], ["defects in RNA synthesis", "PROBLEM", 78, 102], ["these defects", "PROBLEM", 204, 217], ["defects", "OBSERVATION", 78, 85], ["RNA synthesis", "OBSERVATION", 89, 102], ["defects", "OBSERVATION", 210, 217]]], ["The cause of the moderate reduction in M41-CK titres observed at 41 \u2022 C also requires further investigation as the data described here indicates that this is not the result of disrupted RNA synthesis (Figure 7) .", [["M41-CK", "GENE_OR_GENE_PRODUCT", 39, 45], ["M41", "PROTEIN", 39, 42], ["CK", "PROTEIN", 43, 45], ["the moderate reduction", "PROBLEM", 13, 35], ["M41-CK titres", "TEST", 39, 52], ["further investigation", "TEST", 86, 107], ["the data", "TEST", 111, 119], ["disrupted RNA synthesis", "PROBLEM", 176, 199], ["moderate", "OBSERVATION_MODIFIER", 17, 25], ["reduction", "OBSERVATION_MODIFIER", 26, 35]]], ["It is possible that protein-protein interactions, processing of the polyprotein, proteolytic cleavage or protein stability and/or activity are affected [55, [67] [68] [69] or even that the virus-host response has been altered [31, 55, 67] .", [["protein-protein interactions", "PROBLEM", 20, 48], ["the polyprotein", "PROBLEM", 64, 79], ["proteolytic cleavage", "TREATMENT", 81, 101], ["protein stability", "TEST", 105, 122], ["the virus", "TEST", 185, 194]]], ["Interestingly a recent publication examining the effect of temperature on the replication on both SARS-CoV and SARS-CoV-2 has highlighted a temperature dependent type I interferon mediated antiviral response [70] .DiscussionRegardless of the cause of Beau-R temperature sensitivity, the identification of a temperature sensitive replication phenotype, alongside restricted replication in vivo, may have implications for the further development of Beau-R as a vaccine vector.", [["SARS", "DISEASE", 98, 102], ["SARS", "DISEASE", 111, 115], ["Beau-R", "CHEMICAL", 447, 453], ["SARS-CoV", "ORGANISM", 98, 106], ["SARS-CoV-2", "ORGANISM", 111, 121], ["type I interferon", "GENE_OR_GENE_PRODUCT", 162, 179], ["Beau-R", "GENE_OR_GENE_PRODUCT", 251, 257], ["Beau-R", "GENE_OR_GENE_PRODUCT", 447, 453], ["I interferon", "PROTEIN", 167, 179], ["SARS-CoV", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 111, 119], ["the replication", "TREATMENT", 74, 89], ["SARS", "TEST", 111, 115], ["CoV", "TEST", 116, 119], ["a temperature dependent type I interferon mediated antiviral response", "TREATMENT", 138, 207], ["Beau-R temperature sensitivity", "PROBLEM", 251, 281], ["a temperature sensitive replication phenotype", "PROBLEM", 305, 350], ["a vaccine vector", "TREATMENT", 457, 473]]], ["It is well established that the Beaudette strain replicates poorly in vivo, with the molecular clone Beau-R behaving comparably [15] .", [["Beau-R", "GENE_OR_GENE_PRODUCT", 101, 107]]], ["Additionally, vaccination of birds with Beau-R does not induce a protective immune response against M41-CK challenge [15] .", [["Beau-R", "CHEMICAL", 40, 46], ["M41", "CHEMICAL", 100, 103], ["birds", "ORGANISM", 29, 34], ["Beau-R", "GENE_OR_GENE_PRODUCT", 40, 46], ["M41-CK", "GENE_OR_GENE_PRODUCT", 100, 106], ["M41", "TEST", 100, 103]]], ["Although vaccination with Beau-R expressing heterologous S genes can induce a partial protective immune response against homologous challenge, it does not meet the standards set by the European Pharmacopoeia, with one hypothesis reasoning that this is the result of poor levels of in vivo replication [15, 16, 20] .DiscussionBeau-R is, however, a powerful molecular tool for coronavirus research.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 26, 32], ["heterologous S", "GENE_OR_GENE_PRODUCT", 44, 58], ["DiscussionBeau-R", "GENE_OR_GENE_PRODUCT", 315, 331], ["coronavirus", "ORGANISM", 375, 386], ["heterologous S genes", "DNA", 44, 64], ["Beau", "TEST", 26, 30], ["poor levels", "PROBLEM", 266, 277], ["coronavirus research", "PROBLEM", 375, 395]]], ["The temperature sensitive mutants identified for MHV have proved extremely useful in elucidating the specific roles of individual replicase proteins (nsps) as well as protein-protein and protein-RNA interactions during the coronavirus replication cycle [55, 62, 67, 71] .", [["MHV", "ORGANISM", 49, 52], ["nsps", "GENE_OR_GENE_PRODUCT", 150, 154], ["MHV", "PROTEIN", 49, 52], ["replicase proteins", "PROTEIN", 130, 148], ["nsps", "PROTEIN", 150, 154], ["MHV", "SPECIES", 49, 52], ["The temperature sensitive mutants", "PROBLEM", 0, 33], ["MHV", "PROBLEM", 49, 52], ["protein-protein", "TEST", 167, 182], ["protein", "TEST", 187, 194], ["RNA interactions", "PROBLEM", 195, 211], ["the coronavirus replication cycle", "TEST", 219, 252]]], ["Furthermore, temperature sensitive mutants have identified pathogenic determinants within the MHV genome and have also been demonstrated to protect mice against lethal challenge [55, 67] .", [["MHV", "ORGANISM", 94, 97], ["mice", "ORGANISM", 148, 152], ["MHV genome", "DNA", 94, 104], ["mice", "SPECIES", 148, 152], ["MHV", "SPECIES", 94, 97], ["mice", "SPECIES", 148, 152], ["temperature sensitive mutants", "PROBLEM", 13, 42], ["MHV genome", "OBSERVATION", 94, 104]]], ["Temperature sensitivity has been used in development of vaccines against RSV [46] and influenza virus [32, 61] .", [["influenza virus", "DISEASE", 86, 101], ["RSV", "ORGANISM", 73, 76], ["influenza virus", "ORGANISM", 86, 101], ["influenza virus", "SPECIES", 86, 101], ["RSV", "SPECIES", 73, 76], ["Temperature sensitivity", "TEST", 0, 23], ["vaccines", "TREATMENT", 56, 64], ["RSV", "PROBLEM", 73, 76], ["influenza virus", "PROBLEM", 86, 101]]], ["It is therefore possible, with further research into temperature sensitive lesions within the Beau-R replicase gene, that temperature sensitivity could be used to achieve attenuation of other IBV strains for future vaccine development, as well as a research tool to investigate the functions of the IBV replicase proteins.ConclusionsThe Gammacoronavirus IBV is a highly contagious economically important respiratory pathogen of domestic fowl.", [["lesions", "ANATOMY", 75, 82], ["respiratory", "ANATOMY", 404, 415], ["respiratory pathogen of domestic fowl", "DISEASE", 404, 441], ["lesions", "PATHOLOGICAL_FORMATION", 75, 82], ["Beau-R", "GENE_OR_GENE_PRODUCT", 94, 100], ["IBV", "ORGANISM", 192, 195], ["IBV", "ORGANISM", 299, 302], ["Gammacoronavirus IBV", "ORGANISM", 337, 357], ["Beau-R replicase gene", "DNA", 94, 115], ["IBV replicase proteins", "PROTEIN", 299, 321], ["fowl", "SPECIES", 437, 441], ["IBV", "SPECIES", 192, 195], ["IBV", "SPECIES", 299, 302], ["Gammacoronavirus IBV", "SPECIES", 337, 357], ["fowl", "SPECIES", 437, 441], ["temperature sensitive lesions", "PROBLEM", 53, 82], ["temperature sensitivity", "PROBLEM", 122, 145], ["other IBV strains", "TREATMENT", 186, 203], ["future vaccine development", "TREATMENT", 208, 234], ["a research tool", "TEST", 247, 262], ["the IBV replicase proteins", "TREATMENT", 295, 321], ["The Gammacoronavirus IBV", "PROBLEM", 333, 357], ["therefore possible", "UNCERTAINTY", 6, 24], ["lesions", "OBSERVATION", 75, 82], ["highly", "OBSERVATION_MODIFIER", 363, 369], ["contagious", "OBSERVATION_MODIFIER", 370, 380]]], ["Current live attenuated vaccines are generated through serial passage of a virulent isolate through embryonated hens' eggs; the molecular mechanism is unknown.", [["eggs", "ANATOMY", 118, 122], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 118, 122], ["hens", "SPECIES", 112, 116], ["hens", "SPECIES", 112, 116], ["Current live attenuated vaccines", "TREATMENT", 0, 32], ["a virulent isolate", "TREATMENT", 73, 91]]], ["The research described here identifies that the replication of the attenuated IBV strain Beau-R is temperature sensitive and is highly restricted in chickens to the soft tissue within the beak.", [["soft tissue", "ANATOMY", 165, 176], ["Beau-R", "CHEMICAL", 89, 95], ["IBV", "ORGANISM", 78, 81], ["Beau-R", "GENE_OR_GENE_PRODUCT", 89, 95], ["chickens", "ORGANISM", 149, 157], ["soft tissue", "TISSUE", 165, 176], ["beak", "ORGANISM_SUBDIVISION", 188, 192], ["chickens", "SPECIES", 149, 157], ["IBV strain Beau-R", "SPECIES", 78, 95], ["chickens", "SPECIES", 149, 157], ["the attenuated IBV strain", "PROBLEM", 63, 88], ["temperature sensitive", "PROBLEM", 99, 120], ["attenuated", "OBSERVATION_MODIFIER", 67, 77], ["IBV", "OBSERVATION", 78, 81], ["highly", "OBSERVATION_MODIFIER", 128, 134], ["restricted", "OBSERVATION_MODIFIER", 135, 145], ["soft tissue", "ANATOMY_MODIFIER", 165, 176], ["beak", "OBSERVATION_MODIFIER", 188, 192]]], ["The temperature sensitive replication phenotype of Beau-R was found to be associated with the replicase gene and with defects in sub-genomic mRNA synthesis.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 51, 57], ["replicase gene", "DNA", 94, 108], ["Beau-R", "SPECIES", 51, 57], ["The temperature", "TEST", 0, 15], ["defects in sub-genomic mRNA synthesis", "PROBLEM", 118, 155], ["defects", "OBSERVATION", 118, 125], ["sub", "OBSERVATION_MODIFIER", 129, 132], ["genomic mRNA synthesis", "OBSERVATION", 133, 155]]], ["These findings highlight the possibility of utilising temperature sensitivity as a method for rational attenuation and vaccine development as seen with pathogens such as influenza virus.", [["influenza virus", "DISEASE", 170, 185], ["influenza virus", "ORGANISM", 170, 185], ["influenza virus", "SPECIES", 170, 185], ["influenza virus", "SPECIES", 170, 185], ["utilising temperature sensitivity", "PROBLEM", 44, 77], ["a method", "TREATMENT", 81, 89], ["rational attenuation", "PROBLEM", 94, 114], ["vaccine development", "TREATMENT", 119, 138], ["pathogens", "PROBLEM", 152, 161], ["influenza virus", "PROBLEM", 170, 185]]]], "4de1b149eec1f1f357839a56490ed0c025ae5567": [["investigated WHO's perceived failings, it was noted that the organization had, for example, previously cut a substantial proportion of its emergency response capability, and \"lacked the governance needed to coordinate multiple stakeholders\" in the response to a disease outbreak [6] .", [["a disease outbreak", "PROBLEM", 260, 278]]]], "708b99d85508fad46c3981cb0c6a5833f1a03074": [["IntroductionThe presence of highly infectious diseases which have become pandemics, such as COVID-19, create serious health and economic problems because of various global social and environmental transformations which have occurred as a result of economic development.", [["infectious diseases", "DISEASE", 35, 54], ["highly infectious diseases", "PROBLEM", 28, 54], ["pandemics", "PROBLEM", 73, 82], ["COVID", "TEST", 92, 97], ["economic problems", "PROBLEM", 128, 145], ["various global social and environmental transformations", "PROBLEM", 157, 212], ["highly", "OBSERVATION_MODIFIER", 28, 34], ["infectious", "OBSERVATION", 35, 45], ["global", "OBSERVATION_MODIFIER", 165, 171], ["social", "OBSERVATION", 172, 178], ["environmental transformations", "OBSERVATION", 183, 212]]], ["As a consequence of economic development, the world's population has become increasingly urbanized and concentrated in large cities and as well, the global level of human population has risen manifold since the beginning of the Industrial Revolution.", [["human", "ORGANISM", 165, 170], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["human population", "PROBLEM", 165, 181], ["economic", "OBSERVATION_MODIFIER", 20, 28], ["increasingly", "OBSERVATION_MODIFIER", 76, 88], ["urbanized", "OBSERVATION_MODIFIER", 89, 98], ["concentrated", "OBSERVATION_MODIFIER", 103, 115], ["large", "OBSERVATION_MODIFIER", 119, 124], ["cities", "OBSERVATION_MODIFIER", 125, 131]]], ["The density of human populations is greater than ever.", [["human", "ORGANISM", 15, 20], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["human populations", "PROBLEM", 15, 32], ["density", "OBSERVATION", 4, 11], ["human", "OBSERVATION_MODIFIER", 15, 20], ["populations", "OBSERVATION_MODIFIER", 21, 32], ["greater", "OBSERVATION_MODIFIER", 36, 43]]], ["In addition, the mobility of humans in all geographical dimensions has increased tremendously.", [["humans", "ORGANISM", 29, 35], ["humans", "SPECIES", 29, 35], ["humans", "SPECIES", 29, 35], ["mobility", "OBSERVATION_MODIFIER", 17, 25], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["tremendously", "OBSERVATION_MODIFIER", 81, 93]]], ["These factors facilitate the outbreak of new infectious diseases and their spread.", [["infectious diseases", "DISEASE", 45, 64], ["new infectious diseases", "PROBLEM", 41, 64], ["new", "OBSERVATION_MODIFIER", 41, 44], ["infectious", "OBSERVATION", 45, 55]]], ["This is especially evident in the case of the corona viruses, such as different strains of influenza and more recently, COVID-19.", [["influenza", "DISEASE", 91, 100], ["the corona viruses", "PROBLEM", 42, 60], ["influenza", "PROBLEM", 91, 100], ["COVID", "TEST", 120, 125], ["corona", "ANATOMY_MODIFIER", 46, 52], ["viruses", "OBSERVATION", 53, 60], ["influenza", "OBSERVATION", 91, 100]]], ["The incidence of COVID-19 basically involves an environmental health issue because its occurrence depends on the state of the surrounds of individuals.IntroductionDevelopments in the nature of economic activity exacerbate the problem of controlling new infectious diseases which are transmitted as a result of human contact and presence.", [["COVID-19", "CHEMICAL", 17, 25], ["infectious diseases", "DISEASE", 253, 272], ["human", "ORGANISM", 310, 315], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 310, 315], ["COVID", "TEST", 17, 22], ["new infectious diseases", "PROBLEM", 249, 272], ["new", "OBSERVATION_MODIFIER", 249, 252], ["infectious", "OBSERVATION", 253, 263]]], ["Increased economic specialization and greater division of labour accompanied by the expansion of markets and growing economic globalization increase the risk that individuals will come into contact with sources that facilitate the occurrence of highly contagious diseases such as influenza and COVID-19.", [["influenza", "DISEASE", 280, 289], ["Increased economic specialization", "PROBLEM", 0, 33], ["highly contagious diseases", "PROBLEM", 245, 271], ["influenza", "PROBLEM", 280, 289], ["COVID", "TEST", 294, 299], ["economic", "OBSERVATION_MODIFIER", 10, 18], ["greater", "OBSERVATION_MODIFIER", 38, 45], ["division", "OBSERVATION_MODIFIER", 46, 54], ["labour", "OBSERVATION", 58, 64], ["expansion", "OBSERVATION_MODIFIER", 84, 93], ["growing", "OBSERVATION_MODIFIER", 109, 116], ["economic globalization", "OBSERVATION", 117, 139]]], ["The adverse economic consequences of new forms or types of these diseases can be severe given the high degree of interdependence in economic activity in modern economies.", [["these diseases", "PROBLEM", 59, 73], ["adverse", "OBSERVATION_MODIFIER", 4, 11], ["economic", "OBSERVATION_MODIFIER", 12, 20], ["new", "OBSERVATION_MODIFIER", 37, 40], ["diseases", "OBSERVATION", 65, 73], ["high degree", "OBSERVATION_MODIFIER", 98, 109], ["interdependence", "OBSERVATION", 113, 128], ["economic", "OBSERVATION_MODIFIER", 132, 140], ["activity", "OBSERVATION_MODIFIER", 141, 149], ["modern economies", "OBSERVATION", 153, 169]]], ["For example, the absence of workers from work due to such infections, or the risks of these infections, can disrupt production at the workplace level.", [["infections", "DISEASE", 58, 68], ["infections", "DISEASE", 92, 102], ["such infections", "PROBLEM", 53, 68], ["these infections", "PROBLEM", 86, 102], ["infections", "OBSERVATION", 92, 102]]], ["As well, supply chains are liable to be broken or disrupted by these pandemics, and in addition, they usually have negative effects on the aggregate demand for commodities.", [["supply chains", "TREATMENT", 9, 22]]], ["This is evident from the COVID-19 outbreak which has resulted in a major worldwide economic depression.", [["depression", "DISEASE", 92, 102], ["the COVID", "TEST", 21, 30], ["a major worldwide economic depression", "PROBLEM", 65, 102], ["major", "OBSERVATION_MODIFIER", 67, 72], ["worldwide", "OBSERVATION_MODIFIER", 73, 82], ["economic", "OBSERVATION_MODIFIER", 83, 91], ["depression", "OBSERVATION", 92, 102]]], ["A useful coverage of the worldwide economic effects of COVID-19 is available in Fernandez (2020).IntroductionThere is now a very large volume of literature on the economics of COVID-19 and it is growing at a rapid rate.", [["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "CHEMICAL", 176, 184], ["COVID-19", "CHEMICAL", 55, 63], ["COVID-19", "CHEMICAL", 176, 184], ["COVID", "TREATMENT", 55, 60], ["COVID", "TEST", 176, 181], ["very", "OBSERVATION_MODIFIER", 124, 128], ["large", "OBSERVATION_MODIFIER", 129, 134], ["volume", "OBSERVATION_MODIFIER", 135, 141], ["rapid rate", "OBSERVATION", 208, 218]]], ["A relatively comprehensive review of this literature (as at June 2020) is available in Brodeur et al. (2020) and a very useful overview of the economic issues raised at an early stage by COVID-19 is available in Baldwin and Weder di Mauro (2020) .", [["the economic issues", "PROBLEM", 139, 158]]], ["It is important to assess the COVID-19 pandemic in relation to the historical context, impact and nature of previous pandemics.", [["the COVID", "TEST", 26, 35]]], ["Therefore, initially, this article provides a selected brief overview of the history and nature of a variety of pandemics and compares these to the COVID-19 pandemic.", [["pandemics", "PROBLEM", 112, 121], ["the COVID", "TEST", 144, 153], ["pandemic", "PROBLEM", 157, 165]]], ["Subsequently, choice problems involving available hospital capacity and the prioritization of admissions of those with COVID-19 are considered.", [["COVID-19", "CHEMICAL", 119, 127], ["COVID", "TEST", 119, 124]]], ["Then attention turns to considering social choice and economic trade-offs between the incidence of COVID-19 infections and the level of economic activity.", [["COVID", "DISEASE", 99, 104], ["infections", "DISEASE", 108, 118], ["social choice", "TREATMENT", 36, 49], ["COVID-19 infections", "PROBLEM", 99, 118], ["infections", "OBSERVATION", 108, 118]]], ["This is followed up by a critical discussion of the desirability of isolating social groups in order to control the incidence of COVID-19 and possibly reduce economic losses from the pandemic.", [["isolating social groups", "TREATMENT", 68, 91], ["COVID", "TEST", 129, 134], ["economic losses", "PROBLEM", 158, 173], ["the pandemic", "PROBLEM", 179, 191]]], ["The important issue of the extent to which individuals should be permitted freedom in relation to the control of COVID-19 is investigated and brief notes follow on the factors that are likely to hinder economic recovery from COVID-19.The coverage of this sectionThe occurrence of pandemics is by no means new.", [["pandemics", "DISEASE", 280, 289], ["COVID-19", "CHEMICAL", 225, 233], ["COVID", "TEST", 225, 230], ["this section", "TREATMENT", 250, 262], ["pandemics", "PROBLEM", 280, 289], ["new", "OBSERVATION_MODIFIER", 305, 308]]], ["Although communicable diseases were present when humankind relied on hunting and gathering for subsistence, the shift to agriculture, which began some 10,000 years ago and the subsequent growth of urban centres, increased the incidence of epidemics (History.com Editors, 2020) .", [["communicable diseases", "DISEASE", 9, 30], ["communicable diseases", "PROBLEM", 9, 30]]], ["Urbanization (facilitated by the Agricultural Revolution) provided a fertile environment for pandemics to take hold.", [["Urbanization", "DISEASE", 0, 12], ["pandemics", "PROBLEM", 93, 102]]], ["Huremovi\u0107 (2019) provides a well referenced coverage of pandemics both before, including, and following the Black Death but excluding COVID-19.", [["Death", "DISEASE", 114, 119], ["COVID-19", "CHEMICAL", 134, 142], ["the Black Death", "PROBLEM", 104, 119], ["COVID", "TEST", 134, 139]]], ["I'll just give a brief coverage of the Black Death (1348-1400 AD), the 'Spanish' flu (1918) (1919) (1920)The Black Death (1348-1400 AD)The Black Death (also known as the bubonic plague) ravaged Eurasia in the second half of the 14 th century.", [["Death", "DISEASE", 45, 50], ["AD", "DISEASE", 62, 64], ["Death", "DISEASE", 115, 120], ["AD", "DISEASE", 132, 134], ["Death", "DISEASE", 145, 150], ["bubonic", "DISEASE", 170, 177], ["The Black Death", "PROBLEM", 135, 150]]], ["It arrived in the western part of Eurasia and parts of North Africa via the Silk Road trade routes (Frankopan, 2016) .", [["Eurasia", "OBSERVATION", 34, 41]]], ["This disease was spread from oriental rats (which were infected by fleas which hosted the bacteria, Yersinia pestis) to humans (bubonic plague) and it was also transmitted from human to human by droplets from those infected (pneumonia plague).", [["Yersinia pestis", "DISEASE", 100, 115], ["bubonic plague", "DISEASE", 128, 142], ["pneumonia", "DISEASE", 225, 234], ["rats", "ORGANISM", 38, 42], ["Yersinia pestis", "ORGANISM", 100, 115], ["humans", "ORGANISM", 120, 126], ["human", "ORGANISM", 177, 182], ["human", "ORGANISM", 186, 191], ["rats", "SPECIES", 38, 42], ["Yersinia pestis", "SPECIES", 100, 115], ["humans", "SPECIES", 120, 126], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 186, 191], ["Yersinia pestis", "SPECIES", 100, 115], ["humans", "SPECIES", 120, 126], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 186, 191], ["This disease", "PROBLEM", 0, 12], ["oriental rats", "PROBLEM", 29, 42], ["the bacteria", "PROBLEM", 86, 98], ["Yersinia pestis", "PROBLEM", 100, 115], ["those infected (pneumonia plague", "PROBLEM", 209, 241], ["disease", "OBSERVATION", 5, 12], ["infected", "OBSERVATION_MODIFIER", 215, 223], ["pneumonia", "OBSERVATION", 225, 234]]], ["The death rates for these two forms of infection were high (approximately 70% in the former case and around 95% in the latter case) and death usually occurred within 8 days.The Black Death (1348-1400 AD)Some scholars believe that the Black Death may have reduced the European population by up to 60%.", [["death", "DISEASE", 4, 9], ["infection", "DISEASE", 39, 48], ["death", "DISEASE", 136, 141], ["Death", "DISEASE", 183, 188], ["AD", "DISEASE", 200, 202], ["Death", "DISEASE", 240, 245], ["The death rates", "PROBLEM", 0, 15], ["infection", "PROBLEM", 39, 48], ["death", "PROBLEM", 136, 141], ["The Black Death", "PROBLEM", 173, 188], ["the Black Death", "PROBLEM", 230, 245], ["infection", "OBSERVATION", 39, 48], ["high", "OBSERVATION_MODIFIER", 54, 58], ["Black", "OBSERVATION_MODIFIER", 177, 182]]], ["The death rates were especially high in urban areas.The Black Death (1348-1400 AD)The economic and social consequences of this pandemic were severe.", [["death", "DISEASE", 4, 9], ["Death", "DISEASE", 62, 67], ["AD", "DISEASE", 79, 81], ["The death rates", "PROBLEM", 0, 15], ["The Black Death", "PROBLEM", 52, 67], ["high", "OBSERVATION_MODIFIER", 32, 36], ["Black", "OBSERVATION_MODIFIER", 56, 61], ["Death", "OBSERVATION", 62, 67], ["severe", "OBSERVATION_MODIFIER", 141, 147]]], ["Crops could not be harvested, traveling and trade became curtailed, and food and manufactured goods became short.", [["Crops", "TREATMENT", 0, 5], ["harvested", "OBSERVATION", 19, 28]]], ["The plague broke down the normal division between the upper and lower classes and led to the emergences of a new middle class\" (Huremovi\u0107, 2019, p.", [["upper", "ORGANISM_SUBDIVISION", 54, 59], ["normal division", "OBSERVATION_MODIFIER", 26, 41], ["upper", "ANATOMY_MODIFIER", 54, 59], ["lower", "ANATOMY_MODIFIER", 64, 69]]], ["10 ) has argued that due to labour shortages caused by the Black Death, it resulted in the long run in the development of labour-saving technologies and consequently, higher productivity.", [["Death", "DISEASE", 65, 70], ["the Black Death", "PROBLEM", 55, 70], ["labour", "OBSERVATION", 122, 128], ["higher", "OBSERVATION_MODIFIER", 167, 173], ["productivity", "OBSERVATION_MODIFIER", 174, 186]]], ["Frankopan (2016, pp. 191-195) points out that significant economic development and social change occurred in Europe after the Black Death subsided.", [["Death", "DISEASE", 132, 137], ["Frankopan", "TEST", 0, 9], ["significant economic development", "PROBLEM", 46, 78], ["social change", "PROBLEM", 83, 96], ["the Black Death", "PROBLEM", 122, 137], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["economic", "OBSERVATION_MODIFIER", 58, 66], ["social change", "OBSERVATION", 83, 96]]], ["Several scholars have argued that changes wrought by the Black Death subsequently brought about positive long-term social and economic development (see, for example, the references provided by Frankopan, 2016, Ch.", [["Death", "DISEASE", 63, 68]]], ["10) .The Black Death (1348-1400 AD)The Black Death was undoubtedly more catastrophic than COVID-19 has been so far.", [["Death", "DISEASE", 15, 20], ["AD", "DISEASE", 32, 34], ["Death", "DISEASE", 45, 50], ["COVID-19", "CHEMICAL", 90, 98], ["COVID", "TEST", 90, 95], ["Black", "OBSERVATION_MODIFIER", 9, 14], ["Death", "OBSERVATION", 15, 20], ["catastrophic", "OBSERVATION_MODIFIER", 72, 84]]], ["Furthermore, it resulted in a considerably higher death rate than COVID-19 and unlike COVID-19, the mortality rate from it bore little relationship to the age of victims, their socio-economic status, or their healthiness prior to contracting the disease.", [["death", "DISEASE", 50, 55], ["a considerably higher death rate", "PROBLEM", 28, 60], ["COVID", "TEST", 66, 71], ["COVID", "TEST", 86, 91], ["the mortality rate", "TEST", 96, 114], ["the disease", "PROBLEM", 242, 253], ["disease", "OBSERVATION", 246, 253]]], ["In some areas, quarantine of visitors from outside of regions was adopted as a measure to reduce its incidence.", [["some", "OBSERVATION_MODIFIER", 3, 7], ["areas", "OBSERVATION_MODIFIER", 8, 13], ["quarantine", "OBSERVATION_MODIFIER", 15, 25]]], ["For instance, the city of Dubrovnik quarantined visitors on a nearby island for a number of days.The Black Death (1348-1400 AD)Quarantine is also one of the methods used today to limit the geographic spread of COVID-J o u r n a l P r e -p r o o f Journal Pre-proof 19. ' flu Pandemic, 1918 ' flu Pandemic, -1920 This is considered to be the first truly global pandemic and the method of transmission of the disease was similar to that for COVID-19.", [["Death", "DISEASE", 107, 112], ["AD", "DISEASE", 124, 126], ["The Black Death", "PROBLEM", 97, 112], ["the methods", "TREATMENT", 153, 164], ["COVID", "TEST", 210, 215], ["the disease", "PROBLEM", 403, 414], ["COVID", "TEST", 439, 444], ["Black", "OBSERVATION_MODIFIER", 101, 106], ["Death", "OBSERVATION", 107, 112], ["considered to be", "UNCERTAINTY", 320, 336], ["global", "OBSERVATION_MODIFIER", 353, 359], ["pandemic", "OBSERVATION", 360, 368], ["disease", "OBSERVATION", 407, 414]]], ["In the absence of a vaccine, similar methods to those used to limit the occurrence of COVID-19 were adopted such as quarantining those with the disease or those coming from infected areas.", [["a vaccine", "TREATMENT", 18, 27], ["COVID", "TEST", 86, 91], ["the disease", "PROBLEM", 140, 151], ["disease", "OBSERVATION", 144, 151], ["infected", "OBSERVATION", 173, 181]]], ["Unlike COVID-19, it was mostly fatal to younger personsthe elderly seem to have been resistant to the disease.", [["COVID", "TEST", 7, 12], ["the disease", "PROBLEM", 98, 109], ["disease", "OBSERVATION", 102, 109]]], ["It was thought that this was so because they may have been exposed to a similar virus earlier in their lives.", [["a similar virus", "PROBLEM", 70, 85], ["virus", "OBSERVATION", 80, 85]]], ["It has been estimated that around 500 million people contracted the disease, and that as many as 50 million died as a result of it.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["the disease", "PROBLEM", 64, 75], ["disease", "OBSERVATION", 68, 75]]], ["This suggests a 10% mortality rate, a significantly higher rate than in the case of COVID-19.", [["a 10% mortality rate", "PROBLEM", 14, 34], ["COVID", "TEST", 84, 89]]], ["It began in August 1918 and petered out in 1920.The 'SpanishNevertheless, in the case of children in the womb of mothers who contracted this disease, they appear to have suffered long-term adverse affects.", [["children", "ORGANISM", 89, 97], ["womb", "ORGANISM_SUBDIVISION", 105, 109], ["children", "SPECIES", 89, 97], ["this disease", "PROBLEM", 136, 148], ["long-term adverse affects", "PROBLEM", 179, 204]]], ["A study by Almond (2006) published in the Journal of Political Economy reported that these children compared to other cohorts experienced life-long disadvantages.", [["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["A study", "TEST", 0, 7]]], ["Whether or not similar delayed effects will occur in the case of COVID-19 remains to be seen.The HIV/AIDS PandemicThis pandemic began in the early 1980s and it now infects about 40 million people worldwide.", [["HIV/AIDS", "DISEASE", 97, 105], ["COVID-19", "CHEMICAL", 65, 73], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 189, 195], ["HIV", "SPECIES", 97, 100], ["COVID", "TEST", 65, 70], ["The HIV/AIDS PandemicThis pandemic", "PROBLEM", 93, 127]]], ["While around two million died annually from this disease in 2005, this number has now declined to about one million (Wang et al., 2016) due, in part to more effective treatments for this disease and increased knowledge of preventative measures.", [["this disease", "PROBLEM", 44, 56], ["this disease", "PROBLEM", 182, 194], ["preventative measures", "TREATMENT", 222, 243]]], ["Although it is a major economic and social burden on some sub-Saharan African countries, globally it is much less so.", [["major", "OBSERVATION_MODIFIER", 17, 22], ["economic", "OBSERVATION_MODIFIER", 23, 31]]], ["Overall, its annual adverse economic effects are much lower than are those being currently experienced with COVID-19.SARS and the 'Swine' fluThe outbreak of Severe Acute Respiratory Syndrome (SARS) started early in this millennium in China and had the potential to become a global pandemic.", [["SARS", "DISEASE", 117, 121], ["Acute Respiratory Syndrome", "DISEASE", 164, 190], ["SARS", "DISEASE", 192, 196], ["COVID-19", "CHEMICAL", 108, 116], ["Severe Acute Respiratory Syndrome (SARS", "SPECIES", 157, 196], ["its annual adverse economic effects", "PROBLEM", 9, 44], ["COVID", "TEST", 108, 113], ["SARS", "PROBLEM", 117, 121], ["Severe Acute Respiratory Syndrome", "PROBLEM", 157, 190], ["SARS", "PROBLEM", 192, 196], ["a global pandemic", "PROBLEM", 272, 289], ["Severe", "OBSERVATION_MODIFIER", 157, 163], ["Acute", "OBSERVATION_MODIFIER", 164, 169], ["Respiratory Syndrome", "OBSERVATION", 170, 190], ["global", "OBSERVATION_MODIFIER", 274, 280], ["pandemic", "OBSERVATION", 281, 289]]], ["It was virtually stamped out by mid-2003.SARS and the 'Swine' fluSARS was of global concern because, it resulted in a mortality rate of about 10%.", [["SARS", "DISEASE", 41, 45], ["SARS", "PROBLEM", 41, 45], ["a mortality rate", "TEST", 116, 132]]], ["It was also caused by a coronavirus and resulted in similar symptoms to COVID-19.", [["coronavirus", "DISEASE", 24, 35], ["COVID-19", "CHEMICAL", 72, 80], ["a coronavirus", "PROBLEM", 22, 35], ["similar symptoms", "PROBLEM", 52, 68], ["COVID", "TEST", 72, 77], ["coronavirus", "OBSERVATION", 24, 35]]], ["Although it did have some negative global economic effects (mainly on international travel and tourism), these were relatively minor compared to the economic consequences of COVID-19.SARS and the 'Swine' fluThe 'Swine' flu began in Mexico in April 2009 and disappeared by May 2010.", [["SARS", "DISEASE", 183, 187], ["Swine' flu", "DISEASE", 212, 222], ["Swine", "SPECIES", 197, 202], ["Swine", "SPECIES", 212, 217], ["some negative global economic effects", "PROBLEM", 21, 58], ["COVID", "TEST", 174, 179], ["SARS", "PROBLEM", 183, 187], ["negative", "OBSERVATION_MODIFIER", 26, 34], ["global", "OBSERVATION_MODIFIER", 35, 41], ["economic effects", "OBSERVATION", 42, 58]]], ["It spread rapidly.", [["spread", "OBSERVATION_MODIFIER", 3, 9], ["rapidly", "OBSERVATION_MODIFIER", 10, 17]]], ["The worldwide death rate from it is uncertain but seems to have been lower than in the case of COVID-19.", [["death", "DISEASE", 14, 19], ["The worldwide death rate", "PROBLEM", 0, 24], ["COVID", "TEST", 95, 100], ["lower", "OBSERVATION_MODIFIER", 69, 74]]], ["25) states: \"Although its death rate was ultimately lower than the regular influenza death rates, at the time it was perceived as very threatening because it disproportionately affected previously healthy young adults, often leading to severe respiratory compromise\".", [["respiratory", "ANATOMY", 243, 254], ["death", "DISEASE", 26, 31], ["death", "DISEASE", 85, 90], ["respiratory compromise", "DISEASE", 243, 265], ["its death rate", "PROBLEM", 22, 36], ["severe respiratory compromise\"", "PROBLEM", 236, 266]]], ["By comparison, COVID-19 disproportionately is a threat to the elderly, especially those in old-age care facilities.Avian flu, Ebola and ZikaIn February 2004, the avian influenza virus was found in poultry in Vietnam and began to infect workers in the poultry industry.", [["Avian flu", "DISEASE", 115, 124], ["Ebola", "DISEASE", 126, 131], ["avian influenza virus", "DISEASE", 162, 183], ["Avian", "ORGANISM", 115, 120], ["Ebola", "ORGANISM", 126, 131], ["avian influenza virus", "ORGANISM", 162, 183], ["Avian flu", "SPECIES", 115, 124], ["avian influenza virus", "SPECIES", 162, 183], ["poultry", "SPECIES", 197, 204], ["the avian influenza virus", "PROBLEM", 158, 183], ["influenza virus", "OBSERVATION", 168, 183]]], ["It was feared that it could become a pandemic.", [["a pandemic", "PROBLEM", 35, 45], ["pandemic", "OBSERVATION", 37, 45]]], ["However, human to human transmission was low (or possibly did not actually occur) and the death rate was very low.Avian flu, Ebola and ZikaConsequently, Avian flu soon became of little concern.Avian flu, Ebola and ZikaThe Ebola virus is another virus which has the potential to become a global pandemic.", [["death", "DISEASE", 90, 95], ["Avian flu", "DISEASE", 114, 123], ["Ebola", "DISEASE", 125, 130], ["Avian flu", "DISEASE", 153, 162], ["Avian flu", "DISEASE", 193, 202], ["Ebola", "DISEASE", 204, 209], ["Ebola virus", "DISEASE", 222, 233], ["human", "ORGANISM", 9, 14], ["human", "ORGANISM", 18, 23], ["Avian", "ORGANISM", 114, 119], ["Ebola", "ORGANISM", 125, 130], ["Avian flu", "ORGANISM", 153, 162], ["Avian flu", "ORGANISM", 193, 202], ["Ebola", "ORGANISM", 204, 209], ["Zika", "ORGANISM", 214, 218], ["Ebola virus", "ORGANISM", 222, 233], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 18, 23], ["Avian flu", "SPECIES", 114, 123], ["Ebola", "SPECIES", 125, 130], ["Avian flu", "SPECIES", 153, 162], ["Avian flu", "SPECIES", 193, 202], ["Ebola virus", "SPECIES", 222, 233], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 18, 23], ["Avian flu", "SPECIES", 153, 162], ["Avian flu", "SPECIES", 193, 202], ["Ebola virus", "SPECIES", 222, 233], ["the death rate", "TEST", 86, 100], ["Avian flu", "PROBLEM", 193, 202], ["Ebola", "PROBLEM", 204, 209], ["The Ebola virus", "PROBLEM", 218, 233], ["another virus", "PROBLEM", 237, 250], ["a global pandemic", "PROBLEM", 285, 302], ["flu", "OBSERVATION", 120, 123], ["Ebola", "OBSERVATION", 125, 130], ["Ebola", "OBSERVATION", 204, 209], ["Ebola virus", "OBSERVATION", 222, 233], ["global", "OBSERVATION_MODIFIER", 287, 293], ["pandemic", "OBSERVATION", 294, 302]]], ["It is very deadly and does not differentiate between age groups.Avian flu, Ebola and ZikaZika was first recorded in Micronesia and after that in Brazil in 2015.", [["Avian flu", "DISEASE", 64, 73], ["Ebola", "DISEASE", 75, 80], ["Avian", "ORGANISM", 64, 69], ["Ebola", "ORGANISM", 75, 80], ["Avian flu", "SPECIES", 64, 73], ["flu", "OBSERVATION", 70, 73], ["Ebola", "OBSERVATION", 75, 80]]], ["Subsequently, it became more widespread internationally.", [["widespread", "OBSERVATION_MODIFIER", 29, 39]]], ["It is transmitted by mosquitos.", [["mosquitos", "OBSERVATION", 21, 30]]], ["Zika is of considerable concern because it causes severe deformities (microcephalus) in about one percent of the unborn children of infected mothers.", [["Zika", "DISEASE", 0, 4], ["deformities", "DISEASE", 57, 68], ["microcephalus", "DISEASE", 70, 83], ["microcephalus", "CANCER", 70, 83], ["children", "ORGANISM", 120, 128], ["mothers", "ORGANISM", 141, 148], ["children", "SPECIES", 120, 128], ["severe deformities (microcephalus)", "PROBLEM", 50, 84], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["deformities", "OBSERVATION", 57, 68], ["infected", "OBSERVATION", 132, 140]]], ["It has not yet become established globally, unlike COVID-19.COVID-19 in historical contextIt is too early now to determine how eventually COVID-19 will compare with previous pandemics.", [["COVID-19", "DNA", 60, 68], ["COVID", "TEST", 51, 56], ["COVID", "TEST", 60, 65], ["COVID", "TEST", 138, 143], ["not yet", "UNCERTAINTY", 7, 14]]], ["However, like the 'Spanish' flu, it has become a global pandemic.", [["a global pandemic", "PROBLEM", 47, 64], ["global", "OBSERVATION_MODIFIER", 49, 55], ["pandemic", "OBSERVATION", 56, 64]]], ["It was first reported in Wuhan in November, 2019 and by March 2020, WHO declared it to be a J o u r n a l P r e -p r o o f Journal Pre-proof pandemic.", [["pandemic", "PROBLEM", 141, 149]]], ["It was not long before individuals in most nations were infected.COVID-19 in historical contextLike SARS (which is also a closely related coronavirus) and the 'Spanish' flu, it is spread mainly by droplets and by sneezing.", [["SARS", "DISEASE", 100, 104], ["flu", "DISEASE", 169, 172], ["sneezing", "DISEASE", 213, 221], ["coronavirus", "ORGANISM", 138, 149], ["COVID-19", "DNA", 65, 73], ["COVID", "TEST", 65, 70], ["SARS", "PROBLEM", 100, 104], ["a closely related coronavirus", "PROBLEM", 120, 149], ["sneezing", "PROBLEM", 213, 221], ["infected", "OBSERVATION", 56, 64], ["SARS", "OBSERVATION", 100, 104], ["sneezing", "OBSERVATION", 213, 221]]], ["Although it is less deadly than the 'Spanish' flu was (and much less likely to kill younger people), it has already resulted in an alarming number of deaths worldwide.", [["deaths", "DISEASE", 150, 156], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["less", "OBSERVATION_MODIFIER", 15, 19], ["deadly", "OBSERVATION_MODIFIER", 20, 26]]], ["In addition, it has significantly reduced (and disrupted) economic and social activity.", [["significantly", "OBSERVATION_MODIFIER", 20, 33], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["economic", "OBSERVATION_MODIFIER", 58, 66], ["social activity", "OBSERVATION", 71, 86]]], ["This has enabled many individuals (but by no means all) to work from home and has helped to sustain social connectivity.COVID-19 in historical contextAn interesting question is whether the COVID-19 pandemic will bring about permanent economic, social and political changes and what might they be?", [["COVID-19", "DNA", 120, 128], ["COVID", "TEST", 120, 125]]], ["Will it change the course of history as the Black Death is believed to have done?", [["Death", "DISEASE", 50, 55]]], ["It is, of course, too early to say.COVID-19 in historical contextHowever, one possibility is that it will permanently lead to an increase in the incidence of working from home and also considerably accelerate and maintain the greater use of the internet.", [["COVID-19", "DNA", 35, 43], ["COVID", "TEST", 35, 40], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["Although these trends were already under way before COVID-19 and were predicted in the 1980s when ICT was in its infancy (Darton and O'Neill, 2018; Hall, 2018; Suchard, 2018; Weston and Williams, 2018) , COVID-19 has accelerated these trends.", [["COVID-19", "CHEMICAL", 204, 212], ["COVID", "TEST", 52, 57], ["COVID", "TEST", 204, 209]]], ["Whether or not all of these trends are socially and psychologicallyCOVID-19 in historical contextdesirable remains an open question (Tisdell, 2017a ).COVID-19 in historical contextWith the above general historical background in mind, let us consider some of the important economic and social problems associated with management of the COVID-19 pandemic, as well as some relevant political aspects.", [["psychologicallyCOVID", "TEST", 52, 72], ["COVID", "TEST", 150, 155], ["management", "TREATMENT", 317, 327], ["the COVID", "TEST", 331, 340]]], ["Only selected aspects can be covered in this article.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Contagious diseases capable of becoming pandemics can take varied forms and therefore, appropriate policies for controlling them often differ.", [["pandemics", "DISEASE", 170, 179], ["COVID", "TREATMENT", 122, 127]]], ["Determining appropriate economic policies to respond to the outbreak and human-to-human spread of COVID-19 has proven to be extremely challenging because major measures to stem the level of infections and death rates from the disease involve a high economic cost in terms of the levels of income and economic production forgone.", [["COVID-19", "CHEMICAL", 98, 106], ["infections", "DISEASE", 190, 200], ["death", "DISEASE", 205, 210], ["human", "ORGANISM", 73, 78], ["human", "ORGANISM", 82, 87], ["stem", "CELL", 172, 176], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["infections", "PROBLEM", 190, 200], ["death rates", "PROBLEM", 205, 216], ["the disease", "PROBLEM", 222, 233], ["a high economic cost", "PROBLEM", 242, 262], ["economic production forgone", "PROBLEM", 300, 327], ["infections", "OBSERVATION", 190, 200], ["high", "OBSERVATION_MODIFIER", 244, 248]]], ["They were seen as necessary (especially in the early stages of mass infections with COVID-19) to flatten the upward trend in the J o u r n a l P r e -p r o o f Journal Pre-proof curve of infections and reduce the increase in deaths and to enable hospitals to increase their capacity to provide for patients requiring hospitalization.Hospital Capacity and the Prioritization of Admissions of those with COVID-19While it is not possible in this article to consider all economic aspects of responding to the novel virus, COVID-19, Fig. 1 is helpful for conceptualizing one of the economic problems, namely those involved in flattening the infection curve (Anderson et al., 2020) .", [["infections", "DISEASE", 68, 78], ["infections", "DISEASE", 187, 197], ["deaths", "DISEASE", 225, 231], ["infection", "DISEASE", 636, 645], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 298, 306], ["mass infections", "PROBLEM", 63, 78], ["COVID", "TEST", 84, 89], ["infections", "PROBLEM", 187, 197], ["the increase in deaths", "PROBLEM", 209, 231], ["COVID", "TREATMENT", 402, 407], ["the novel virus", "PROBLEM", 501, 516], ["COVID", "TEST", 518, 523], ["the economic problems", "PROBLEM", 573, 594], ["flattening the infection curve", "PROBLEM", 621, 651], ["mass", "OBSERVATION", 63, 67], ["upward", "OBSERVATION_MODIFIER", 109, 115], ["infections", "OBSERVATION", 187, 197], ["increase", "OBSERVATION_MODIFIER", 213, 221], ["infection", "OBSERVATION", 636, 645]]], ["Although many countries have now sufficient capacity to admit COVID-19 patients, many less developed countries do not.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["COVID", "TEST", 62, 67]]], ["In Fig. 1 , curve JKEH represents the capacity of the hospital system to admit and care for patients requiring hospitalization for COVID-19.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["COVID", "TEST", 131, 136]]], ["It might be of a logistic form because the initial expansion of this capacity takes time and once physical capacity ramps up, increasing scarcity of qualified staff to operate hospitals can become a major constraint.", [["this capacity", "PROBLEM", 64, 77]]], ["Three different hypothetical functions correspond to the number of persons requiring hospitalization due to COVID-19 infectionsthe higher the curve, the greater the number needing to be hospitalized.", [["persons", "ORGANISM", 67, 74], ["persons", "SPECIES", 67, 74], ["COVID", "TEST", 108, 113]]], ["Each also corresponds to different levels of social restrictions imposed by the government to limit the spread of COVID-19.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Curves OAB, ODE and OGH correspond respectively to substantial, moderate, and weak social restrictions to limit the spread of this disease.", [["OAB", "DISEASE", 207, 210], ["COVID", "TEST", 114, 119], ["COVID", "TREATMENT", 192, 197], ["OAB", "TREATMENT", 207, 210], ["this disease", "PROBLEM", 326, 338], ["different", "OBSERVATION_MODIFIER", 25, 34], ["levels", "OBSERVATION_MODIFIER", 35, 41], ["substantial", "OBSERVATION_MODIFIER", 251, 262], ["moderate", "OBSERVATION_MODIFIER", 264, 272], ["weak", "OBSERVATION_MODIFIER", 278, 282]]], ["The shape of these curves might differ from those shown.", [["these curves", "TEST", 13, 25], ["shape", "OBSERVATION_MODIFIER", 4, 9]]], ["The ones shown are for illustrative purposes only.", [["illustrative purposes", "TEST", 23, 44]]], ["It can be seen in Fig. 1 that as a result of the most severe restrictions, the hospital system would be able to accommodate all COVID-19 patients requiring hospitalization.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["hospitalization", "TREATMENT", 156, 171]]], ["In the other two cases, hospital capacity is exceeded for a period of time and to a greater extent, the weaker are the social restrictions and precautions designed to reduce the transmission of the disease.", [["hospital capacity", "TEST", 24, 41], ["precautions", "TREATMENT", 143, 154], ["the disease", "PROBLEM", 194, 205], ["greater extent", "OBSERVATION_MODIFIER", 84, 98], ["disease", "OBSERVATION", 198, 205]]], ["For example, in the case of moderate restrictions, hospital capacity is exceeded between t2 and t3 with the number of COVID-19 patients in need of hospitalization but unable to be admitted is equal to the difference between the segment CDE of the curve of COVID-19 patients requiring hospitalization and the segment CKE of the capacity of the hospital system to accommodate these patients.", [["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 265, 273], ["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 380, 388], ["hospital capacity", "TEST", 51, 68], ["COVID", "TEST", 118, 123], ["COVID", "TEST", 256, 261], ["hospitalization", "TREATMENT", 284, 299], ["moderate", "OBSERVATION_MODIFIER", 28, 36], ["restrictions", "OBSERVATION", 37, 49]]], ["If weak restrictions and precautions are taken to limit the occurrence of COVID-19, then the period for which hospital capacity is exceeded increases to t4 -t1.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Consequently, the number of needy cases unable to be hospitalized rises from an amount indicated by the eye-shaped hatched area bounded by CKED in Fig. 1 Then the expected increase in the value of admitting the i-th COVID-19 sufferer to hospital isHospital Capacity and the Prioritization of Admissions of those with COVID-19A challenging moral and valuation issue is how to determine Vi.", [["eye", "ANATOMY", 341, 344], ["eye", "ORGAN", 341, 344], ["t4", "DNA", 153, 155], ["t1", "DNA", 157, 159], ["precautions", "TREATMENT", 25, 36], ["COVID", "TEST", 74, 79], ["COVID", "TREATMENT", 229, 234], ["COVID", "TREATMENT", 554, 559], ["eye", "ANATOMY", 341, 344], ["increase", "OBSERVATION_MODIFIER", 409, 417]]], ["In some circumstances, hospitalization may actually increase the probability of death.", [["death", "DISEASE", 80, 85], ["death", "PROBLEM", 80, 85]]], ["It is, therefore, best avoided in these cases.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Several different possibilities exist for determining Vi.", [["Vi.", "SPECIES", 177, 180], ["COVID", "TREATMENT", 115, 120]]], ["One criterion for prioritizing health J o u r n a l P r e -p r o o f (frequently used by health professionals) is based on the quality of life years (QALYS) available to patients.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178]]], ["This criterion is discussed in Tisdell (forthcoming, Ch.", [["Ch.", "SPECIES", 53, 56]]], ["In order to apply this criterion to prioritizing COVID-19 sufferers for hospitalization (or for treatment of the disease), it is necessary to estimate the quality of life years each sufferer is likely to have left if the individual recovers from the disease.", [["treatment", "TREATMENT", 96, 105], ["the disease", "PROBLEM", 109, 120], ["the disease", "PROBLEM", 246, 257], ["disease", "OBSERVATION", 113, 120], ["left", "ANATOMY_MODIFIER", 209, 213], ["disease", "OBSERVATION", 250, 257]]], ["On this basis, other things being equal, the fewer are the number of years a sufferer is predicted to survive for after recovery from the virus, the lower would be the sufferer's Vi-value.", [["the virus", "PROBLEM", 134, 143]]], ["This approach gives a reduced priority for hospital admissions to the elderly and to those with chronic conditions which are likely to reduce their life span.", [["chronic conditions", "PROBLEM", 96, 114]]], ["In addition, many belonging to these groups have a poor quality of life.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Furthermore, they may have a smaller increase in the probability of recovery if admitted to hospital.", [["COVID", "TREATMENT", 141, 146], ["smaller", "OBSERVATION_MODIFIER", 178, 185], ["increase", "OBSERVATION_MODIFIER", 186, 194]]], ["This approach could discriminate against the elderly and those with chronic health conditions.", [["chronic health conditions", "PROBLEM", 68, 93]]], ["Chronic health problems are more prevalent in some ethnic minority communities also and so this criterion could also discriminate against these groups.Hospital Capacity and the Prioritization of Admissions of those with COVID-19It is necessary however, to bear in mind that categorizing individuals into broad groups for triage purposes has its limitations.", [["Chronic health problems", "PROBLEM", 0, 23], ["COVID", "TREATMENT", 220, 225], ["triage purposes", "TEST", 321, 336], ["more prevalent", "OBSERVATION_MODIFIER", 28, 42]]], ["This is because not all individuals in these groups have an equal chance of recovery if they are provided with hospital care and the remaining QALYS of individuals of the same age can be difficult to determine and can vary considerably.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Furthermore, it should be kept in mind that COVID-19 victims belonging to some groups (such as the young) have a high chance of recovery without hospitalization (or treatment) and on average, hospitalization may do little to increase their probability of recovery.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Consequently, even though their Vi-values are high, the change in their expected Vi-values could be much lower than for those patients (such as the elderly or those with underlying health problems) who contract COVID-19.", [["COVID-19", "CHEMICAL", 865, 873], ["patients", "ORGANISM", 780, 788], ["patients", "SPECIES", 780, 788], ["COVID", "TREATMENT", 305, 310], ["treatment", "TREATMENT", 478, 487], ["COVID", "TREATMENT", 646, 651], ["high", "OBSERVATION", 700, 704]]], ["Therefore, it is probably rational for doctors to monitor individual patients and to be more ready to recommend admission to hospital of those patients who are likely to have the greatest possibility of benefiting from hospitalization.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 143, 151]]], ["Possibly, elderly patients (and those with underlying health problems) should be admitted early when they contract this disease whereas others could be monitored with admission only being recommended when it becomes evident that they will succumb to this disease in the absence of hospitalization.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["this disease", "PROBLEM", 115, 127], ["this disease", "PROBLEM", 250, 262]]], ["If, however, hospital capacity is likely to be exceeded by this policy, further discrimination would be needed.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Another approach to prioritizing hospital admissions of those infected by COVID-19 is to make these admissions dependent on their willingness (and ability) to pay.", [["COVID", "TREATMENT", 180, 185]]], ["For example Giannadaki et al. (2018) , J o u r n a l P r e -p r o o f when estimating the value of a statistical life (VSL), provide evidence that the average willingness to pay to avoid premature death from air pollution has an income elasticity of 0.8.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Therefore, this approach discriminates against the poor, and other socially disadvantaged groups.", [["death", "DISEASE", 197, 202], ["premature death", "PROBLEM", 187, 202], ["COVID", "TREATMENT", 323, 328], ["air pollution", "OBSERVATION", 208, 221]]], ["They are also more likely than the remainder of the population to have chronic health problems.", [["chronic health problems", "PROBLEM", 71, 94], ["more likely", "UNCERTAINTY", 14, 25], ["chronic", "OBSERVATION_MODIFIER", 71, 78]]], ["So there is a high probability that this economic criterion (as well as the use of QALYS) will disadvantage the elderly and some ethnic communities, or more generally the poorer members of society in gaining access to medicine and hospital services.Hospital Capacity and the Prioritization of Admissions of those with COVID-19In addition, consideration should be given to the extent to which patients with health conditions (other than COVID-19) requiring hospital treatment should be prioritized for admission to hospital.", [["COVID-19In", "CHEMICAL", 318, 328], ["COVID-19In", "CHEMICAL", 318, 328], ["patients", "ORGANISM", 392, 400], ["patients", "SPECIES", 392, 400], ["COVID", "TREATMENT", 318, 323], ["hospital treatment", "TREATMENT", 456, 474], ["high probability", "OBSERVATION_MODIFIER", 14, 30]]], ["When hospital capacity is exceeded, a trade-off problem exists between admitting COVID-19 patients and other patients.", [["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 109, 117]]], ["In principle, the type of formula set out in Equation (1) could also be applied to all patients seeking hospitalization.Hospital Capacity and the Prioritization of Admissions of those with COVID-19Decisions also need to be made about the economics of expanding hospital capacity and the period for which this extra capacity is likely to be needed.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["COVID", "TREATMENT", 189, 194], ["this extra capacity", "PROBLEM", 304, 323]]], ["When a quick response is needed, temporary facilities for hospitalization are likely to be economic, such as the tents which were erected in Central Park in New York, the use of train carriages, as was done for holding COVID-19 patients in India and France, and the conversion of convention centres as hospitals as was done in the UK.", [["patients", "ORGANISM", 228, 236], ["UK", "GENE_OR_GENE_PRODUCT", 331, 333], ["patients", "SPECIES", 228, 236], ["hospitalization", "TREATMENT", 58, 73]]], ["Once COVID-19 infections fall, then these facilities are easily dismantled or returned to their original use.Hospital Capacity and the Prioritization of Admissions of those with COVID-19As mentioned above, the shape of the curves shown in Figure 1 of the number of COVID-19Hospital Capacity and the Prioritization of Admissions of those with COVID-19cases which ought to be hospitalized is only adopted for illustrative purposes.", [["infections", "DISEASE", 14, 24], ["19 infections fall", "PROBLEM", 11, 29], ["COVID", "TEST", 178, 183], ["COVID", "TREATMENT", 342, 347]]], ["In the absence of mitigation measures, it is believed that the number of active cases of COVID-19 rises initially at an exponential rate (as a function of time) but eventually reaches a maximum (once a large proportion of the population has been infected).", [["COVID-19", "CHEMICAL", 89, 97], ["mitigation measures", "TREATMENT", 18, 37], ["COVID", "TEST", 89, 94], ["active", "OBSERVATION_MODIFIER", 73, 79], ["large", "OBSERVATION_MODIFIER", 202, 207], ["infected", "OBSERVATION", 246, 254]]], ["It can then be expected to decline at a slower rate than in the upsurge of cases (Anderson et al., 2020; Anon, 2020) .Hospital Capacity and the Prioritization of Admissions of those with COVID-19Consequently, the curve of infections exhibits kurtosis.", [["infections", "DISEASE", 222, 232], ["COVID", "TREATMENT", 187, 192], ["infections", "PROBLEM", 222, 232], ["kurtosis", "PROBLEM", 242, 250], ["infections", "OBSERVATION", 222, 232]]], ["In the absence of mitigation, the initial exponential growth rate in the incidence of COVID-19 is very high.", [["the initial exponential growth rate", "TEST", 30, 65], ["COVID", "TEST", 86, 91], ["mitigation", "OBSERVATION", 18, 28], ["exponential", "OBSERVATION_MODIFIER", 42, 53], ["growth", "OBSERVATION_MODIFIER", 54, 60], ["very", "OBSERVATION_MODIFIER", 98, 102], ["high", "OBSERVATION", 103, 107]]], ["The doubling time of infections is very short.", [["infections", "DISEASE", 21, 31], ["infections", "PROBLEM", 21, 31], ["infections", "OBSERVATION", 21, 31], ["very", "OBSERVATION_MODIFIER", 35, 39], ["short", "OBSERVATION_MODIFIER", 40, 45]]], ["If containment or mitigation is not started early after an initial outbreak, it is very hard to contain the virus because small numbers of infected persons rapidly infect a very large number of individuals, and tracing active cases becomes difficult.Hospital Capacity and the Prioritization of Admissions of those with COVID-19This makes the disease very hard to manage socially.Hospital Capacity and the Prioritization of Admissions of those with COVID-19It is also the case, that early relaxation of mitigation measures can allow a rapid resurgence of J o u r n a l P r e -p r o o f Journal Pre-proof the disease (Anderson et al., 2020; Anon, 2020) .", [["COVID-19This", "CHEMICAL", 319, 331], ["persons", "ORGANISM", 148, 155], ["persons", "SPECIES", 148, 155], ["an initial outbreak", "PROBLEM", 56, 75], ["the virus", "PROBLEM", 104, 113], ["COVID", "TREATMENT", 319, 324], ["the disease", "PROBLEM", 338, 349], ["COVID", "TREATMENT", 448, 453], ["mitigation measures", "TREATMENT", 502, 521], ["small", "OBSERVATION_MODIFIER", 122, 127], ["numbers", "OBSERVATION_MODIFIER", 128, 135], ["infected", "OBSERVATION", 139, 147], ["very", "OBSERVATION_MODIFIER", 173, 177], ["large", "OBSERVATION_MODIFIER", 178, 183], ["disease", "OBSERVATION", 607, 614]]], ["Control measures need to be kept in place to ensure that the basic reproduction rate of infections is less than unity if the number of infections is to be lowered.", [["infections", "DISEASE", 88, 98], ["infections", "DISEASE", 135, 145], ["Control measures", "TREATMENT", 0, 16], ["infections", "PROBLEM", 88, 98], ["infections", "PROBLEM", 135, 145], ["infections", "OBSERVATION", 88, 98], ["infections", "OBSERVATION", 135, 145]]], ["An infection rate of unity corresponds to an approximate stationary state.", [["infection", "DISEASE", 3, 12], ["An infection rate", "TEST", 0, 17], ["infection", "OBSERVATION", 3, 12]]], ["If less than an existing stationary state is desired (because the number of existing infections is deemed to be too high), a hard lockdown may be needed to reduce the numbers infected, that is the adoption of a suppression strategy.", [["infections", "DISEASE", 85, 95], ["existing infections", "PROBLEM", 76, 95], ["a hard lockdown", "TREATMENT", 123, 138], ["the numbers infected", "PROBLEM", 163, 183], ["a suppression strategy", "TREATMENT", 209, 231], ["infections", "OBSERVATION", 85, 95], ["numbers", "OBSERVATION_MODIFIER", 167, 174], ["infected", "OBSERVATION", 175, 183]]], ["The economic and psychiatric costs of this are likely to be high.", [["psychiatric", "DISEASE", 17, 28], ["economic", "OBSERVATION_MODIFIER", 4, 12], ["likely to be", "UNCERTAINTY", 47, 59], ["high", "OBSERVATION", 60, 64]]], ["Let us now consider aspects of the economic cost of the pandemic in relation to the severity of policy measures to control it.Modelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityMost restrictions.", [["policy measures", "TREATMENT", 96, 111], ["COVID", "TREATMENT", 179, 184]]], ["When death rates are high, government action to adopt measures to reduce them become commonplace but once death rates fall, then there are usually strong demands to ease social restrictions.", [["death", "DISEASE", 5, 10], ["death", "DISEASE", 106, 111], ["death rates", "PROBLEM", 5, 16]]], ["This can set off a new wave of infections with the process repeating itself once again.", [["infections", "DISEASE", 31, 41], ["infections", "PROBLEM", 31, 41], ["infections", "OBSERVATION", 31, 41]]], ["This process has been evident in several European countries, e.g. Spain and France.Modelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityThe above discussion can be advanced conceptually by means of some theoretical modelling.", [["COVID", "TREATMENT", 136, 141]]], ["I assume, however, that it is not only deaths from COVID-19 that reduce output but also the incidence of the disease.", [["deaths", "DISEASE", 39, 45], ["COVID-19", "CHEMICAL", 51, 59], ["COVID", "TEST", 51, 56], ["the disease", "PROBLEM", 105, 116], ["disease", "OBSERVATION", 109, 116]]], ["However, I also suppose that the number of deaths are positively related to the number of COVID-19 cases.", [["deaths", "DISEASE", 43, 49], ["COVID", "TEST", 90, 95]]], ["To be more specific, when m represents mortality from the disease and X indicates the number of COVID-19 cases, it is supposed thatModelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityThis relationship will vary from country to country and by social groups depending on the health care available and the healthiness of the different groups.Modelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityThe relationship shown in Fig. 2 is easily related to the loss in output due to COVID-19.", [["COVID-19", "CHEMICAL", 585, 593], ["COVID-19", "DNA", 585, 593], ["the disease", "PROBLEM", 54, 65], ["COVID", "TEST", 96, 101], ["COVID", "TREATMENT", 184, 189], ["COVID", "TREATMENT", 449, 454], ["the loss in output", "PROBLEM", 559, 577], ["COVID", "TEST", 585, 590], ["disease", "OBSERVATION", 58, 65]]], ["The loss in output is equal to the difference between line HJ and the trade-off function ABCD.", [["The loss in output", "PROBLEM", 0, 18], ["line HJ", "TREATMENT", 54, 61], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["output", "OBSERVATION_MODIFIER", 12, 18], ["equal", "OBSERVATION_MODIFIER", 22, 27], ["HJ", "OBSERVATION_MODIFIER", 59, 61]]], ["If Fig. 1 is represented by the functionModelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic Activitythen the loss in output (L) due to COVID-19 can be represented byModelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic Activitywhere Y0 represents the level of output in the absence of COVID-19.Modelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityTaking into account only the above-mentioned variables, it is rational to suppose that there is a social preference for fewer COVID-19 cases and for a higher level of economic activity.Modelling Social Choice Involving Trade-offs between COVID-19 Restrictions and the Level of Economic ActivityTherefore, given this point of view, it is irrational to choose a combination on the segment CDE of the trade-off function, ABCDE.", [["COVID", "TREATMENT", 93, 98], ["the loss in output", "PROBLEM", 154, 172], ["COVID", "TEST", 184, 189], ["COVID", "TREATMENT", 267, 272], ["COVID", "TEST", 381, 386], ["COVID", "TREATMENT", 443, 448], ["COVID", "TREATMENT", 737, 742]]], ["Given the Bergson-type of preference function (Bergson, 1938) represented in Fig. 2 Acemoglu et al. (2020) develop a model from which they conclude that the isolation of individuals belonging to particular social groups is an effective means of limiting the number of deaths from and the incidence of COVID-19 and the economic loss from the virus.", [["deaths", "DISEASE", 268, 274], ["COVID-19", "CHEMICAL", 301, 309], ["COVID", "TEST", 301, 306], ["the economic loss", "PROBLEM", 314, 331], ["the virus", "PROBLEM", 337, 346]]], ["They claim, on the basis of their modelling that a policy of isolating the elderly from other age groups (which they describe as \"group distancing\") is a very efficient means for approaching the trade-off frontier between the incidence of COVID-19 and the loss in output due to the disease.Incidence of COVID-19 and Reducing Economic Losses from the VirusThey investigate the optimal targeted lockdown of social groups.", [["Losses", "DISEASE", 334, 340], ["COVID", "TEST", 239, 244], ["the loss in output", "PROBLEM", 252, 270], ["the disease", "PROBLEM", 278, 289], ["COVID", "TEST", 303, 308], ["Reducing Economic Losses", "PROBLEM", 316, 340], ["disease", "OBSERVATION", 282, 289]]], ["It can be doubted if those aged in the 50-64 group should be appropriately described as middle-aged.", [["middle", "ANATOMY_MODIFIER", 88, 94]]], ["These figures are based on \"There is a sense in which our analysis understates the gains from targeting, because we have focused only on targeting by age.", [["our analysis", "TEST", 54, 66]]], ["The mortality rates of COVID-19 also vary significantly by pre-existing co-morbidities, and targeting lockdown and protection policies to co-morbidities can multiply the benefits from targeting significantly.\"Incidence of COVID-19 and Reducing Economic Losses from the VirusHowever, the poor are more likely to have co-morbidities that make them more vulnerable to COVID-19 than those that are well-off.", [["Losses", "DISEASE", 253, 259], ["COVID-19", "CHEMICAL", 23, 31], ["COVID", "TEST", 23, 28], ["pre-existing co-morbidities", "PROBLEM", 59, 86], ["protection policies", "TREATMENT", 115, 134], ["COVID", "TEST", 222, 227], ["Reducing Economic Losses", "PROBLEM", 235, 259], ["co-morbidities", "PROBLEM", 316, 330], ["COVID", "TEST", 365, 370], ["co-morbidities", "OBSERVATION", 72, 86]]], ["Economically, the poor may not be able to survive a J o u r n a l P r e -p r o o f lockdown unless provided with financial support by the state.", [["lockdown", "TREATMENT", 83, 91], ["financial support", "TREATMENT", 113, 130]]], ["Morbidity tends to increase with poverty and chronic illness is also often a source of poverty.Incidence of COVID-19 and Reducing Economic Losses from the VirusThe possibility of group lockdown policies and the ethical implications of them need to be explicitly considered.", [["chronic illness", "DISEASE", 45, 60], ["Losses", "DISEASE", 139, 145], ["Morbidity", "PROBLEM", 0, 9], ["chronic illness", "PROBLEM", 45, 60], ["COVID", "TEST", 108, 113], ["Reducing Economic Losses", "PROBLEM", 121, 145], ["the Virus", "PROBLEM", 151, 160], ["group lockdown policies", "TREATMENT", 179, 202], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["illness", "OBSERVATION", 53, 60]]], ["Lockdowns of social groups as proposed by Acemoglu et al. (2020) are likely to create serious economic problems for some of the targeted groups.", [["serious economic problems", "PROBLEM", 86, 111]]], ["In the absence of government financial support, most of the poor have little option but to work (if they can) even if they have COVID-19 or are awaiting the results of testing for it.", [["financial support", "TREATMENT", 29, 46], ["testing", "TEST", 168, 175]]], ["In fact, there is a case for government income support to be given for all those infected by COVID-19 or those awaiting test results if they do not have sick leave entitlements.", [["government income support", "TREATMENT", 29, 54]]], ["Otherwise they may fail to remain in isolation or quarantine and spread the virus.Incidence of COVID-19 and Reducing Economic Losses from the VirusLocking down everyone in particular social groups seems to be a very blunt way of reducing COVID-19 deaths and the incidence of the disease.", [["Losses", "DISEASE", 126, 132], ["deaths", "DISEASE", 247, 253], ["quarantine", "TREATMENT", 50, 60], ["the virus", "PROBLEM", 72, 81], ["COVID", "TEST", 95, 100], ["Reducing Economic Losses", "PROBLEM", 108, 132], ["the disease", "PROBLEM", 275, 286], ["Economic", "OBSERVATION_MODIFIER", 117, 125], ["Losses", "OBSERVATION", 126, 132], ["disease", "OBSERVATION", 279, 286]]], ["For example, not everyone of 65 and over is in poor health and highly vulnerable to the disease.", [["the disease", "PROBLEM", 84, 95], ["disease", "OBSERVATION", 88, 95]]], ["Some also hold important positions in societies.", [["important positions", "OBSERVATION_MODIFIER", 15, 34]]], ["Several of the political leaders of nations are well over 65, for example, Mr. DonaldIncidence of COVID-19 and Reducing Economic Losses from the VirusTrump, President of the USA.", [["Losses", "DISEASE", 129, 135], ["COVID", "TEST", 98, 103], ["Economic Losses", "OBSERVATION", 120, 135]]], ["Furthermore, many in the vulnerable social groups identified by Acemoglu et al. (2020) can reduce their likelihood of catching COVID-19 by wearing masks, practicing appropriate hygiene, and by keeping appropriate distance away from others.", [["catching COVID", "TREATMENT", 118, 132]]], ["However, special care is needed to avoid infections in aged care facilities given the vulnerability of residents and the closeness of contact, for example, with staff.", [["infections", "DISEASE", 41, 51], ["infections", "PROBLEM", 41, 51]]], ["The same is true in hospitals.", [["true", "OBSERVATION_MODIFIER", 12, 16]]], ["Moreover, it is not clear how the elderly living in extended families can be easily isolated.Incidence of COVID-19 and Reducing Economic Losses from the VirusAs for isolating those who have underlying health conditions which make them vulnerable to COVID-19, it is not clear how they are to be identified.", [["Losses", "DISEASE", 137, 143], ["COVID-19", "CHEMICAL", 249, 257], ["COVID", "TEST", 106, 111], ["Reducing Economic Losses", "PROBLEM", 119, 143], ["the VirusAs", "TREATMENT", 149, 160], ["underlying health conditions", "PROBLEM", 190, 218], ["COVID", "TEST", 249, 254]]], ["Possibilities include isolating those in areas known to have a high incidence of co-morbidity, or to do likewise with those belonging to particular racial groups in which morbidity is high.", [["co-morbidity", "PROBLEM", 81, 93], ["high", "OBSERVATION_MODIFIER", 184, 188]]], ["Such policies are likely to be viewed as blunt and too discriminating.Incidence of COVID-19 and Reducing Economic Losses from the VirusAlthough the contribution by Acemoglu et al. (2020) is an interesting and worthwhile contribution to the discussion about how to respond to the COVID-19 pandemic, it only concentrates on comparing targeted and uniform isolation policies as a means of limiting the number of COVID-19 deaths and their economic impacts.", [["Losses", "DISEASE", 114, 120], ["deaths", "DISEASE", 418, 424], ["blunt", "PROBLEM", 41, 46], ["COVID", "TEST", 83, 88], ["Reducing Economic Losses", "PROBLEM", 96, 120], ["the COVID", "TEST", 275, 284]]], ["It does not take account of alternative policies such as those mentioned above and fails to take account of many of the J o u r n a l P r e -p r o o f difficulties that arise when particular social groups are to be isolated.", [["difficulties", "PROBLEM", 151, 163]]], ["Some of these (such as the costs of imposing isolation and the possibility of breaches of it) are mentioned by Finechel (2013) .", [["isolation", "TREATMENT", 45, 54]]], ["If liberty is valued, then a choice to the right of point B and even beyond C (such as that corresponding to point D) might be made.", [["right", "ANATOMY_MODIFIER", 43, 48]]], ["In the latter case, the government is prepared to forgo some economic activity and allow a higher number of COVID-19 infections to occur than otherwise in order for individuals to have more freedom.Freedom of Choice IssuesThere are two aspects to be considered in restricting liberty:Freedom of Choice Issues1.", [["infections", "DISEASE", 117, 127], ["COVID", "TREATMENT", 108, 113], ["19 infections", "PROBLEM", 114, 127]]], ["The ability of an individual to spread the occurrence of the virus, that is the negative external effects arising from the individual being permitted liberty.Freedom of Choice IssuesAlthough some restrictions on liberty may be defensible on social grounds, others could be difficult to defend.", [["the virus", "PROBLEM", 57, 66], ["virus", "OBSERVATION", 61, 66]]], ["The latter include restrictions in cases where the behaviour of individuals poses little or no risk to others, but which heighten the risk of those granted greater liberty being infected with the virus.", [["the virus", "PROBLEM", 192, 201]]], ["However, even in these cases, it might be argued that taking this extra risk could pose a burden to society if the individuals involved become infected with the virus.", [["individuals", "ORGANISM", 115, 126], ["the virus", "PROBLEM", 157, 166]]], ["If they need medical care or hospitalization as a result of being infected, this would put extra strain on the medical and hospital system.", [["medical care", "TREATMENT", 13, 25], ["hospitalization", "TREATMENT", 29, 44], ["infected", "OBSERVATION", 66, 74]]], ["If the state subsidizes or provides free medical care or hospital services, this will add to the costs that have to be met by taxpayers.Freedom of Choice IssuesIn addition, if the contacts of an infected person are quarantined for a time, this adds to external costs as does the cost of tracing their contacts.", [["person", "SPECIES", 204, 210], ["infected", "OBSERVATION", 195, 203]]], ["Furthermore, an extra economic burden can be placed on family members if one of its members is infected by COVID-19.", [["an extra economic burden", "PROBLEM", 13, 37], ["extra", "OBSERVATION_MODIFIER", 16, 21], ["economic", "OBSERVATION_MODIFIER", 22, 30], ["burden", "OBSERVATION", 31, 37]]], ["For example, they may be required to quarantine and they may have to meet the extra medical care and other costs incurred by the infected family member.Freedom of Choice IssuesEvery society faces the difficult task of determining how much personal liberty should be afforded to its citizens.", [["the extra medical care", "TREATMENT", 74, 96], ["infected", "OBSERVATION", 129, 137]]], ["Any society which allowed complete personal liberty would be J o u r n a l P r e -p r o o f lawless and lacking in order.", [["lawless", "PROBLEM", 92, 99]]], ["This lack of law and order would have negative economic repercussions due to individuals being allowed to act (without limitation) in ways which have negative effects on others.", [["individuals", "PROBLEM", 77, 88], ["negative", "OBSERVATION", 150, 158]]], ["The negative effects of lack of law and order on the creation of economic wealth were already stressed by Adam Smith in 1776 (Smith, 1776) .", [["negative", "OBSERVATION", 4, 12]]], ["This is particularly relevant to measures to control COVID-19.", [["COVID-19", "CHEMICAL", 53, 61], ["COVID-19", "DNA", 53, 61], ["COVID", "TEST", 53, 58]]], ["For example, some restrictions on the freedom of individuals involve little cost and loss of freedom, such as the wearing of masks in crowded places but the social benefits may be considerable.", [["loss of freedom", "PROBLEM", 85, 100], ["some", "OBSERVATION_MODIFIER", 13, 17], ["restrictions", "OBSERVATION", 18, 30], ["little", "OBSERVATION_MODIFIER", 69, 75], ["cost", "OBSERVATION_MODIFIER", 76, 80], ["loss", "OBSERVATION_MODIFIER", 85, 89], ["freedom", "OBSERVATION_MODIFIER", 93, 100]]], ["On the other hand, some types of blanket lockdowns involve a considerable restriction on personal freedom and the social gains might be small.", [["blanket lockdowns", "TREATMENT", 33, 50], ["blanket", "OBSERVATION", 33, 40], ["small", "OBSERVATION_MODIFIER", 136, 141]]], ["Higher income countries are in a better position to provide social safety nets to their citizens to support them if they are restricted in their ability to work as a result of COVID-19.", [["COVID", "TEST", 176, 181]]], ["There is little scope for cushioning these effects in low-income countries such as India.", [["little", "OBSERVATION_MODIFIER", 9, 15], ["scope", "OBSERVATION", 16, 21]]], ["In these countries, stringent social measures to control COVID-19 impose a heavy burden on the poor who need to work to earn enough income for their survival.Freedom of Choice IssuesThe choice of government policies to control COVID-19 are significantly influenced by political pressures, the nature of which has altered with the duration of the pandemic.Freedom of Choice IssuesInitially, many governments were slow to impose social restrictions to limit the occurrence of COVID-19.", [["stringent social measures", "TREATMENT", 20, 45], ["government policies", "TREATMENT", 196, 215], ["COVID", "TEST", 227, 232], ["political pressures", "TEST", 268, 287], ["the pandemic", "PROBLEM", 342, 354], ["COVID", "TEST", 474, 479]]], ["As infections and the death rate rose, political pressure to impose social restrictions to limit the occurrence of the disease mounted.", [["infections", "DISEASE", 3, 13], ["death", "DISEASE", 22, 27], ["infections", "PROBLEM", 3, 13], ["the death rate", "TEST", 18, 32], ["political pressure", "TREATMENT", 39, 57], ["the disease mounted", "PROBLEM", 115, 134], ["infections", "OBSERVATION", 3, 13], ["disease", "OBSERVATION", 119, 126]]], ["However, political pressure subsequently intensified to ease these restrictions in order to reduce the economic cost of the virus.", [["political pressure", "TREATMENT", 9, 27], ["these restrictions", "TREATMENT", 61, 79], ["the virus", "PROBLEM", 120, 129], ["pressure", "OBSERVATION_MODIFIER", 19, 27], ["virus", "OBSERVATION", 124, 129]]], ["As a result, many governments responded by altering their Bergson-type preference functions to take account of these political pressures.", [["these political pressures", "TEST", 111, 136]]], ["In addition, with better knowledge about COVID-19 and of the means to treat it, greater hospital capacity and the occurrence of fewer cases, shifts in the trade-off function ABCDE favoured less stringent control measures in some countries.Factors Limiting Economic Recovery from COVID-19As is well known, the extent of economic recovery from COVID-19 depends upon medical J o u r n a l P r e -p r o o f treatments to prevent COVID-19 occurring, for example, the discovery and mass production of an effective vaccine, or finding means to reduce the severity of infections.", [["infections", "DISEASE", 560, 570], ["COVID-19", "CHEMICAL", 342, 350], ["COVID-19As", "GENE_OR_GENE_PRODUCT", 279, 289], ["COVID", "TEST", 41, 46], ["COVID", "TEST", 279, 284], ["COVID", "TEST", 342, 347], ["a l P r e -p r o o f treatments", "TREATMENT", 382, 413], ["COVID", "TEST", 425, 430], ["mass production", "PROBLEM", 476, 491], ["an effective vaccine", "TREATMENT", 495, 515], ["infections", "PROBLEM", 560, 570], ["mass", "OBSERVATION", 476, 480], ["infections", "OBSERVATION", 560, 570]]], ["However, it is unlikely that this disease will be eliminated, and like influenza, it may change its form (mutate) with the passage of time.Factors Limiting Economic Recovery from COVID-19The speed and nature of recovery from the pandemic will be hampered both by supply-side and demand-side factors.", [["influenza", "DISEASE", 71, 80], ["COVID-19", "CHEMICAL", 179, 187], ["this disease", "PROBLEM", 29, 41], ["influenza", "PROBLEM", 71, 80], ["COVID", "TEST", 179, 184], ["side factors", "PROBLEM", 286, 298], ["unlikely", "UNCERTAINTY", 15, 23]]], ["On the supply-side, many manufacturers and other businesses depend on international supply chains for sustaining their economic activity.", [["international supply chains", "TREATMENT", 70, 97]]], ["This raises a synchronization problem.", [["a synchronization problem", "PROBLEM", 12, 37], ["synchronization problem", "OBSERVATION", 14, 37]]], ["Nations that are ready to and want to resume production of commodities (but rely on international supply chains for their production) may find that their ability to do so is restricted because their international suppliers cannot meet their demands due to continuing closures or because of their reduced output as a consequence of COVID-19.", [["international supply chains", "TREATMENT", 84, 111], ["continuing closures", "TREATMENT", 256, 275], ["their reduced output", "PROBLEM", 290, 310], ["COVID", "TEST", 331, 336]]], ["China's recovery is likely to be hampered for example, by the disruption in its supply chains as well as a lagged recovery in the demand for its exports.", [["the disruption in its supply chains", "PROBLEM", 58, 93], ["likely to be", "UNCERTAINTY", 20, 32]]], ["In the recent past,Factors Limiting Economic Recovery from COVID-19China has exhibited a high degree of dependence on imported components used in manufacturing its goods (Tisdell, 2007) .", [["COVID-19China", "CHEMICAL", 59, 72], ["COVID", "TEST", 59, 64], ["high degree", "OBSERVATION_MODIFIER", 89, 100], ["dependence", "OBSERVATION", 104, 114]]], ["It was, therefore, quite exposed to supply-side disruptions.", [["side disruptions", "PROBLEM", 43, 59]]], ["This, together with its high dependence on exports (Tisdell, 2009a (Tisdell, , 2009b , created major economic challenges for the Chinese government in responding to COVID-19, not to mention problems created by Trump's 'trade war' with China.Factors Limiting Economic Recovery from COVID-19Many nations have international demand and supply-side constraints on their level of economic activity and its recovery given the presence of COVID-19.", [["COVID-19", "CHEMICAL", 431, 439], ["the Chinese government", "TREATMENT", 125, 147], ["COVID", "TEST", 165, 170], ["COVID", "TEST", 281, 286], ["international demand", "TREATMENT", 307, 327], ["COVID", "TEST", 431, 436], ["high dependence", "OBSERVATION_MODIFIER", 24, 39]]], ["Australian farmers have, for example, faced delays in the supply of spare parts for agricultural machinery and in the supply of agrochemicals, such as weedicides due to transport delays or supply shortages.Factors Limiting Economic Recovery from COVID-19The disruption of supply chains, however, appears to have been more severe in the earlier stages of the pandemic than later.", [["COVID-19", "CHEMICAL", 246, 254], ["agricultural machinery", "TREATMENT", 84, 106], ["COVID", "TEST", 246, 251], ["The disruption of supply chains", "PROBLEM", 254, 285], ["disruption", "OBSERVATION", 258, 268], ["supply chains", "OBSERVATION", 272, 285], ["more", "OBSERVATION_MODIFIER", 317, 321], ["severe", "OBSERVATION_MODIFIER", 322, 328], ["pandemic", "OBSERVATION_MODIFIER", 358, 366]]], ["Just-in-time international supply chains have had to be replaced by others or by increases in domestic production.Factors Limiting Economic Recovery from COVID-19On the demand-side, aggregate consumer expenditure is likely to recover slowly due to lower disposable incomes and because consumers do not purchase commodities that increase their risk of contracting COVID-19 or purchase lots of these commodities.", [["COVID", "TEST", 154, 159], ["contracting COVID", "PROBLEM", 351, 368], ["increases", "OBSERVATION_MODIFIER", 81, 90], ["domestic production", "OBSERVATION", 94, 113]]], ["Similarly, many individuals will continue to avoid activities (for some time) that involve mass gatherings.", [["mass gatherings", "PROBLEM", 91, 106], ["mass", "OBSERVATION", 91, 95]]], ["Demand is only likely to recover slowly for the commodities J o u r n a l P r e -p r o o f produced by those industries that sell discretionary commodities and for which their purchasers face increased risks of contracting COVID-19.", [["COVID-19", "CHEMICAL", 223, 231], ["contracting COVID", "TEST", 211, 228], ["only likely", "UNCERTAINTY", 10, 21]]], ["Consequently, the economic recovery of some industries will be constrained by both of these factors, that is, by reduced discretionary buying and by risk-avoidance in purchasing commodities.Factors Limiting Economic Recovery from COVID-19Of course, those industries that recover slowly after the end of the period of socio-economic hibernation designed to control COVID-19 will also retard the recovery of those industries with which they have a high degree of economic interdependence.", [["COVID", "TEST", 230, 235], ["socio-economic hibernation", "TREATMENT", 317, 343], ["economic interdependence", "PROBLEM", 461, 485], ["high degree", "OBSERVATION_MODIFIER", 446, 457], ["economic interdependence", "OBSERVATION", 461, 485]]], ["Inter-industry analysis (e.g. input-output analysis) could be used to help gauge these flow-on effects.Factors Limiting Economic Recovery from COVID-19A dangerous international situation now exists.", [["industry analysis", "TEST", 6, 23], ["input-output analysis", "TEST", 30, 51], ["these flow", "TEST", 81, 91], ["COVID", "TEST", 143, 148]]], ["Many nations may begin to adopt protectionist policies to counteract a reduction in their level of economic activity and employment brought about by the COVID-19 pandemic.", [["protectionist policies", "TREATMENT", 32, 54], ["a reduction", "TREATMENT", 69, 80]]], ["This could delay global economic recovery.", [["global", "OBSERVATION_MODIFIER", 17, 23], ["economic recovery", "OBSERVATION", 24, 41]]], ["It will disadvantage countries (such as Australia and Germany) which depend heavily on exports to generate their level of economic activity and employment.More on ethics and COVID-19The effects of COVID-19 on mortality raise difficult moral and ethical questions about how human life should be valued as well as significant economic dilemmas.", [["COVID-19", "CHEMICAL", 197, 205], ["COVID-19", "CHEMICAL", 197, 205], ["human", "ORGANISM", 273, 278], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["COVID", "TEST", 174, 179], ["COVID", "TEST", 197, 202], ["significant economic dilemmas", "PROBLEM", 312, 341], ["significant", "OBSERVATION_MODIFIER", 312, 323], ["economic", "OBSERVATION_MODIFIER", 324, 332], ["dilemmas", "OBSERVATION", 333, 341]]], ["The modelling by Acemoglu et al. (2020) , for instance, supposes that it is reasonable to value the lives of social groups or individuals by how much they contribute to economic production, measured by variations in GDP.", [["GDP", "CHEMICAL", 216, 219], ["GDP", "CHEMICAL", 216, 219], ["GDP", "SIMPLE_CHEMICAL", 216, 219]]], ["This results in the lives of the elderly and those of lowincome earners (the poor) being ascribed a low value compared to the lives of others.", [["a low value", "PROBLEM", 98, 109]]], ["This approach would also give a low value to the lives of women as a group who on average earn less (market-related) income than do men.", [["women", "ORGANISM", 58, 63], ["men", "ORGANISM", 132, 135], ["women", "SPECIES", 58, 63], ["men", "SPECIES", 132, 135]]], ["It also ignores the value of the unpaid work of women within the household and their usual roles as the main carers in a family (Tisdell, 2019, Ch.", [["women", "ORGANISM", 48, 53], ["women", "SPECIES", 48, 53]]], ["Also how should one value the lives of those who do unpaid or under paid charitable work?More on ethics and COVID-19It was also found that the QALYS and the willingness to pay approaches tend to assign a lower value of life to the elderly, and possibly to those who are poor and have serious morbidity problems.", [["serious morbidity problems", "PROBLEM", 284, 310]]], ["It is known that individuals are often prepared to pay to save others from death, particularly children.", [["death", "DISEASE", 75, 80], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103]]], ["While sometimes this may be because of a material benefit to the donor, it may also be motivated purely or partly by sympathy or altruism.", [["the donor", "TREATMENT", 61, 70]]], ["By way of example, in George Orwell's Animal Farm (Orwell, 2008) , did the loyal and hard-working horse that contributed so much to his community deserve to be sent to the knackery at the end of his working life?", [["horse", "ORGANISM", 98, 103], ["horse", "SPECIES", 98, 103]]], ["I am not suggesting that technical analysis is not of value, but its ethical implications and limitations should be made clear and debated.A brief r\u00e9sum\u00e9The occurrence and consequences of epidemics and pandemics depend on the nature and stages of economic development.", [["technical analysis", "TEST", 25, 43], ["epidemics", "PROBLEM", 188, 197], ["pandemics", "PROBLEM", 202, 211], ["economic development", "PROBLEM", 247, 267], ["economic", "OBSERVATION_MODIFIER", 247, 255]]], ["The economic and social structure of contemporary societies facilitates the transmission of those diseases which depend on human contact or presence, especially those that involve air-borne germs or which persist on surfaces that are commonly used.", [["germs", "ANATOMY", 190, 195], ["human", "ORGANISM", 123, 128], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 123, 128], ["those diseases", "PROBLEM", 92, 106], ["air-borne germs", "PROBLEM", 180, 195], ["economic", "OBSERVATION_MODIFIER", 4, 12], ["social structure", "OBSERVATION_MODIFIER", 17, 33]]], ["The latter characteristics have facilitated the rapid spread of COVID-19 and left little time to respond to it.", [["COVID", "TEST", 64, 69], ["rapid", "OBSERVATION_MODIFIER", 48, 53], ["spread", "OBSERVATION_MODIFIER", 54, 60], ["left", "ANATOMY_MODIFIER", 77, 81]]], ["Devising appropriate policies to deal with it were also complicated in its early stages by lack of knowledge about its epidemiology and many of its other characteristics.A brief r\u00e9sum\u00e9This article has analysed the types of trade-offs that have required consideration and choices that have to be made at different stages of the COVID-19 pandemic.", [["the COVID", "TEST", 323, 332], ["pandemic", "PROBLEM", 336, 344]]], ["It has done this by means of some simple economic modelling.", [["some simple economic modelling", "PROBLEM", 29, 59], ["simple", "OBSERVATION_MODIFIER", 34, 40], ["economic modelling", "OBSERVATION", 41, 59]]], ["Ethical issues have also received attention.Issues requiring further attention and researchThe occurrence of COVID-19 has raised many important issues which need more attention and research.", [["COVID-19", "CHEMICAL", 109, 117], ["Ethical issues", "PROBLEM", 0, 14], ["further attention", "TREATMENT", 61, 78], ["COVID", "TEST", 109, 114]]], ["It would also be interesting to have more evidence about which social groups support or do not support different policies for managing the COVID-19 pandemic and why they do so.", [["social groups support", "TREATMENT", 63, 84]]], ["Which social groups, for instance, support rapid return-to-work policies and why?Issues requiring further attention and researchProbably, it is not only those who rely on work for their survival who support these policies but also a group of capitalists and investors who are concerned about the falling return on their investments as a result of reduced economic activity.Issues requiring further attention and research6.", [["reduced economic activity", "PROBLEM", 347, 372], ["further attention", "TREATMENT", 390, 407], ["research6", "TREATMENT", 412, 421], ["reduced", "OBSERVATION_MODIFIER", 347, 354], ["economic activity", "OBSERVATION", 355, 372]]], ["A decline in the overall funding of research by universities and similar bodies have occurred (at least in Australia) as a result of financial pressures associated with the occurrence of COVID-19.", [["A decline", "PROBLEM", 0, 9], ["financial pressures", "TEST", 133, 152], ["COVID", "TEST", 187, 192], ["decline", "OBSERVATION_MODIFIER", 2, 9], ["overall", "OBSERVATION_MODIFIER", 17, 24], ["funding", "OBSERVATION", 25, 32]]], ["In many cases, internal recurrent funding by universities for research has been shelved as they try to maintain their financial viability.", [["internal", "OBSERVATION_MODIFIER", 15, 23], ["recurrent", "OBSERVATION_MODIFIER", 24, 33], ["funding", "OBSERVATION", 34, 41]]], ["There is a need to examine the long-term consequences of these changes.Issues requiring further attention and researchThe above is just a small sample of significant issues raised by the COVID-19 pandemic which require further investigation.", [["further attention", "TREATMENT", 88, 105], ["significant issues", "PROBLEM", 154, 172], ["the COVID", "TEST", 183, 192], ["further investigation", "TEST", 219, 240], ["long-term", "OBSERVATION_MODIFIER", 31, 40], ["small", "OBSERVATION_MODIFIER", 138, 143], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["issues", "OBSERVATION", 166, 172]]], ["The pandemic has therefore, resulted in increasing scrutiny of this framework.", [["pandemic", "OBSERVATION", 4, 12], ["increasing", "OBSERVATION_MODIFIER", 40, 50]]]], "61810c29377a4573810dc313f4f5d526e7451c0d": [["IntroductionSince the emergence of the pandemic H1N1pdm09 virus in Mexico and California, biannual increases in the number of cases have been detected in Mexico [1, 2] The first outbreak began from late March to July 2009, followed by a second wave from late August 2009 to March 2010 [1] .", [["H1N1pdm09 virus", "ORGANISM", 48, 63], ["increases", "OBSERVATION_MODIFIER", 99, 108]]], ["The 2010-2011 winter season was characterized by low cases of pandemic virus and a predominance of Influenza A H3N2 and Influenza B [3] .", [["Influenza A H3N2", "DISEASE", 99, 115], ["Influenza B", "DISEASE", 120, 131], ["Influenza A H3N2", "ORGANISM", 99, 115], ["Influenza A H3N2", "SPECIES", 99, 115], ["Influenza", "SPECIES", 120, 129], ["Influenza A H3N2", "SPECIES", 99, 115], ["pandemic virus", "PROBLEM", 62, 76], ["Influenza", "PROBLEM", 99, 108], ["Influenza B", "PROBLEM", 120, 131], ["pandemic virus", "OBSERVATION", 62, 76], ["Influenza", "OBSERVATION", 99, 108]]], ["As Viral genome sequencing 50 clinical samples were positive for AH1N1pdm09 and we obtained the whole viral genome sequence in 23 of these samples.", [["samples", "ANATOMY", 39, 46], ["samples", "ANATOMY", 139, 146], ["samples", "CANCER", 39, 46], ["samples", "CANCER", 139, 146], ["AH1N1pdm09", "DNA", 65, 75], ["whole viral genome sequence", "DNA", 96, 123], ["Viral genome sequencing", "TEST", 3, 26], ["clinical samples", "TEST", 30, 46], ["AH1N1pdm09", "TEST", 65, 75], ["the whole viral genome sequence", "TEST", 92, 123], ["these samples", "TEST", 133, 146]]], ["13 samples were sequenced using high-density oligonuclotides microarrays and 10 samples were sequenced using massive parallel sequencing with the Illumina platform.", [["samples", "ANATOMY", 3, 10], ["samples", "ANATOMY", 80, 87], ["samples", "CANCER", 3, 10], ["high-density oligonuclotides microarrays", "TREATMENT", 32, 72], ["massive parallel sequencing", "TREATMENT", 109, 136]]], ["4 samples were sequenced using both technologies.", [["samples", "ANATOMY", 2, 9], ["4 samples", "TEST", 0, 9]]], ["Additionally, there were 4 samples where we could not achieve whole genome sequences and we only obtained sequences from specific segments (INMEGEN-INER 1Re-sequencing arrayThe whole genome sequences from clinical samples were obtained using high-density oligonuclotides microarrays for re-sequencing, (GIS H1N1 Flu BioSurveillance Array Nimblechip 132k) as previously described [10] Retro transcription (RT) of the influenza AH1N1pdm09 viral genome was carried out from RNA extracted from nasal swabs of clinical samples positive to this viral type.", [["samples", "ANATOMY", 214, 221], ["nasal swabs", "ANATOMY", 490, 501], ["samples", "ANATOMY", 514, 521], ["samples", "CANCER", 214, 221], ["influenza AH1N1pdm09", "ORGANISM", 416, 436], ["nasal swabs", "ORGANISM_SUBSTANCE", 490, 501], ["samples", "CANCER", 514, 521], ["whole genome sequences", "DNA", 62, 84], ["INMEGEN-INER 1Re", "DNA", 140, 156], ["whole genome sequences", "DNA", 177, 199], ["influenza AH1N1pdm09 viral genome", "DNA", 416, 449], ["whole genome sequences", "TEST", 62, 84], ["INMEGEN", "TEST", 140, 147], ["The whole genome sequences", "TEST", 173, 199], ["clinical samples", "TEST", 205, 221], ["high-density oligonuclotides microarrays", "TREATMENT", 242, 282], ["re-sequencing", "TEST", 287, 300], ["Nimblechip", "TEST", 338, 348], ["Retro transcription", "TREATMENT", 384, 403], ["the influenza", "PROBLEM", 412, 425], ["viral genome", "PROBLEM", 437, 449], ["RNA", "PROBLEM", 471, 474], ["nasal swabs", "TEST", 490, 501], ["clinical samples", "TEST", 505, 521], ["viral genome", "OBSERVATION", 437, 449], ["nasal", "ANATOMY", 490, 495]]], ["We used the Invitrogen Super Script III high fidelity enzymes kit (SuperScript III First strand synthesis system for RT-PCR, Cat No. 18080-051) and primers from the Biosurveillance Resequencing Oligo Kit (AITbiotech, AITBH1N1M-50), for RT-PCR.", [["Invitrogen Super Script III high fidelity enzymes", "PROTEIN", 12, 61], ["the Invitrogen", "TREATMENT", 8, 22], ["SuperScript III First strand synthesis system", "TREATMENT", 67, 112], ["RT-PCR", "TEST", 117, 123], ["Oligo Kit", "TEST", 194, 203], ["AITbiotech", "TEST", 205, 215], ["AITBH1N1M", "TEST", 217, 226], ["RT-PCR", "TEST", 236, 242]]], ["Later we used 2 ul of cDNA from the RT for the 8 segments amplification by PCR with Platinum Taq DNA polymerase (Platinum Taq DNA polymerase, Thermo Scientific, Foster City, CA, USA) and cocktail of primers included in the resequencing oligo kit.", [["DNA", "CELLULAR_COMPONENT", 97, 100], ["DNA", "CELLULAR_COMPONENT", 126, 129], ["cDNA", "DNA", 22, 26], ["Platinum Taq DNA polymerase", "PROTEIN", 84, 111], ["Platinum Taq DNA polymerase", "PROTEIN", 113, 140], ["cDNA", "TREATMENT", 22, 26], ["the RT", "TREATMENT", 32, 38], ["the 8 segments amplification", "TREATMENT", 43, 71], ["PCR", "TEST", 75, 78], ["Platinum Taq DNA polymerase", "TREATMENT", 84, 111], ["Platinum Taq DNA polymerase", "TREATMENT", 113, 140], ["cocktail of primers", "TREATMENT", 187, 206]]], ["PCR conditions were 94\u02daC, 2min; 40 cycles (94\u02daC, 30 s; 66\u02daC, 3min); 72\u02daC, 5min.Re-sequencing arrayPCR fragments from each sample were pooled and labeled with CY3 (Nimbelgen Onecolor DNA Labeling Kit, REF 05 223 555 001) independently and 800 ng of the labeled reaction were used for array hybridization, following the manufacturer\u00b4s instructions (NimbleGen Hybridization Kit, REF 05 583 683 001).Re-sequencing arrayMicroarrays were scanned using a GenePix 4000B scanner and processed with the Nimble-Scan and EvolStar softwares to translate the fluorescence intensity into nucleotides and obtain a sequence FASTA file.Re-sequencing arrayIn total, the array contains 8,236 control probes and 121,928 H1N1(2009) probes, which provides 2X coverage of the entire H1N1(2009) genome, and up to 8X coverage of the regions comprising the 36 mutation hotspots and 10 drug-binding sites [11] .Re-sequencing arrayAnother set of 10 clinical samples were sequenced using massive paralleled sequencing (MPS) on an Illumina MiSeq (Illumina, CA, USA), as described below.", [["fragments", "ANATOMY", 102, 111], ["sample", "ANATOMY", 122, 128], ["samples", "ANATOMY", 929, 936], ["nucleotides", "CHEMICAL", 573, 584], ["CY3", "SIMPLE_CHEMICAL", 158, 161], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["samples", "CANCER", 929, 936], ["arrayPCR fragments", "DNA", 93, 111], ["Nimble-Scan and EvolStar softwares", "DNA", 493, 527], ["8,236 control probes", "DNA", 666, 686], ["121,928 H1N1(2009) probes", "DNA", 691, 716], ["H1N1(2009) genome", "DNA", 759, 776], ["36 mutation hotspots", "DNA", 830, 850], ["drug-binding sites", "DNA", 858, 876], ["Illumina MiSeq", "DNA", 1000, 1014], ["PCR conditions", "TEST", 0, 14], ["sequencing arrayPCR fragments", "PROBLEM", 82, 111], ["CY3", "TEST", 158, 161], ["the labeled reaction", "PROBLEM", 248, 268], ["array hybridization", "TEST", 283, 302], ["Re-sequencing arrayMicroarrays", "TEST", 396, 426], ["the Nimble-Scan", "TEST", 489, 504], ["a sequence FASTA file", "TEST", 596, 617], ["the array", "TEST", 647, 656], ["H1N1", "PROBLEM", 699, 703], ["the entire H1N1", "TREATMENT", 748, 763], ["clinical samples", "TEST", 920, 936], ["massive paralleled sequencing", "TREATMENT", 958, 987], ["an Illumina MiSeq", "TREATMENT", 997, 1014]]], ["Four samples were sequenced in parallel by microarrays and (MPS).Re-sequencing arrayMassive parallel sequencing.", [["samples", "ANATOMY", 5, 12], ["Four samples", "TEST", 0, 12]]], ["The 8 viral segments were amplified simultaneously and directly from clinical samples, using MBTuni12 and MBTuni13 primers, as described elsewhere [12] .", [["samples", "ANATOMY", 78, 85], ["MBTuni12", "GENE_OR_GENE_PRODUCT", 93, 101], ["MBTuni12 and MBTuni13 primers", "DNA", 93, 122], ["The 8 viral segments", "TREATMENT", 0, 20], ["clinical samples", "TEST", 69, 85], ["MBTuni12 and MBTuni13 primers", "TREATMENT", 93, 122], ["viral segments", "OBSERVATION", 6, 20]]], ["Amplification products for 10 samples were gel-purified (QIAquick Gel Extraction Kit; QIAGEN, Valencia, CA).", [["samples", "ANATOMY", 30, 37], ["Amplification products", "TREATMENT", 0, 22], ["QIAquick Gel Extraction", "TREATMENT", 57, 80]]], ["Barcoded libraries for NGS were produced using Nextera XT DNA Library Preparation kit and paired-end sequencing (2x250 cycles) was performed using the MiSeq platform (Illumina).", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["MiSeq platform", "DNA", 151, 165], ["Barcoded libraries", "TREATMENT", 0, 18], ["NGS", "TEST", 23, 26], ["Nextera XT DNA Library Preparation kit", "TREATMENT", 47, 85], ["paired-end sequencing (2x250 cycles)", "TREATMENT", 90, 126]]], ["The reads were mapped to A/California/07/2009(H1N1)/2009 (H1N1), data was obtained from the NIAID Influenza Research Database (IRD) [13] (access number of this sequence is presented in S1 Table) using SMALT V.0.7.6.", [["Influenza", "DISEASE", 98, 107], ["California/07/2009(H1N1", "ORGANISM", 27, 50], ["A/California/07/2009(H1N1)/2009 (H1N1)", "SPECIES", 25, 63], ["this sequence", "TEST", 155, 168], ["SMALT", "TEST", 201, 206]]], ["Assembly was performed using Velvet package (Velvet V1.2.10) and visualized with TABLET (V 1.15.09.01).", [["Velvet package (Velvet V1", "TREATMENT", 29, 54]]], ["A 100% coverage was achieved for each virus, with at least 90 depth for HA, NS, NA, M and NP segments (mean coverage: 10).", [["A 100% coverage", "TREATMENT", 0, 15], ["each virus", "PROBLEM", 33, 43], ["HA", "PROBLEM", 72, 74], ["NS", "TREATMENT", 76, 78], ["NA, M and NP segments", "TREATMENT", 80, 101], ["NP segments", "ANATOMY", 90, 101]]], ["The PA, PB1 and PB2 segments had 80% coverage at >10x.", [["PA", "GENE_OR_GENE_PRODUCT", 4, 6], ["PB1", "DNA", 8, 11], ["PB2 segments", "PROTEIN", 16, 28], ["The PA", "TEST", 0, 6], ["PB2", "ANATOMY", 16, 19], ["segments", "ANATOMY_MODIFIER", 20, 28]]], ["The sequences from this study were deposited at the NIAID Influenza Research Database (IRD, http://www.fludb.org) [13] and are available in GenBank (Accesion numbers can be found in S1 Table) Mutation analysisRe-sequencing arrayThe sequences were analyzed using A/California/07/2009(H1N1)/2009 amino acid sequence as reference and compared to global sequences at FluSurver [14] from 2009 to 2016, this for each of the eight viral segments (Access number in S1 Table) , in order to identify novel substitutions and determine how many times reported substitutions have been previously reported.", [["amino acid", "CHEMICAL", 294, 304], ["amino acid", "CHEMICAL", 294, 304], ["amino acid", "AMINO_ACID", 294, 304], ["A/California/07/2009(H1N1", "SPECIES", 262, 287], ["The sequences", "TEST", 0, 13], ["this study", "TEST", 19, 29], ["amino acid sequence", "TEST", 294, 313], ["novel substitutions", "PROBLEM", 490, 509], ["substitutions", "PROBLEM", 548, 561], ["viral segments", "OBSERVATION", 424, 438]]], ["Sequences were aligned using the CLUSTAL W method in Molecular Evolutionary Genetics Analysis (MEGA 6.0) software [15] .", [["the CLUSTAL W method", "TREATMENT", 29, 49]]], ["A maximum likelihood tree was constructed for each influenza segment using MEGA 6.0.", [["each influenza segment", "PROBLEM", 46, 68]]], ["The Tajima-Nei model was selected with 5-parameter gamma distributed rates and 1,000 bootstrap replicates.", [["Tajima", "DNA", 4, 10], ["The Tajima-Nei model", "TREATMENT", 0, 20], ["parameter gamma distributed rates", "TREATMENT", 41, 74]]], ["The mean age of the patients was 45.4 \u00b1 20.8 years and 76.4% of these individuals were male.", [["patients", "ORGANISM", 20, 28], ["individuals", "ORGANISM", 70, 81], ["patients", "SPECIES", 20, 28]]], ["Fatal outcome (%) 5.8ResultsData are means \u00b1 standard deviation (SD), or number and percentage. *2 patients had asthma and 1 COPD.ResultsThe mean BMI (kg/m 2 ) was 29.2, and 23.5% required mechanical ventilation for 15.2 (mean) days.", [["asthma", "DISEASE", 112, 118], ["COPD", "DISEASE", 125, 129], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["Fatal outcome", "TEST", 0, 13], ["standard deviation (SD), or number and percentage", "PROBLEM", 45, 94], ["asthma", "PROBLEM", 112, 118], ["1 COPD", "PROBLEM", 123, 129], ["The mean BMI", "TEST", 137, 149], ["mechanical ventilation", "TREATMENT", 189, 211], ["percentage", "OBSERVATION_MODIFIER", 84, 94], ["asthma", "OBSERVATION", 112, 118], ["COPD", "OBSERVATION", 125, 129]]], ["Patients had 22 days of hospitalization stay, 17.6% of them had co-morbidities such as asthma and chronic obstructive pulmonary disease (COPD), and 5.8% of these patients died.ResultsPatients who required mechanical ventilation displayed a Kirby index (PaO 2 /FiO 2 ) (mean: 104.7).", [["pulmonary", "ANATOMY", 118, 127], ["asthma", "DISEASE", 87, 93], ["chronic obstructive pulmonary disease", "DISEASE", 98, 135], ["COPD", "DISEASE", 137, 141], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 118, 127], ["patients", "ORGANISM", 162, 170], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 162, 170], ["co-morbidities", "PROBLEM", 64, 78], ["asthma", "PROBLEM", 87, 93], ["chronic obstructive pulmonary disease", "PROBLEM", 98, 135], ["COPD)", "PROBLEM", 137, 142], ["mechanical ventilation", "TREATMENT", 205, 227], ["a Kirby index", "TEST", 238, 251], ["PaO", "TEST", 253, 256], ["FiO", "TEST", 260, 263], ["asthma", "OBSERVATION", 87, 93], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["obstructive", "OBSERVATION_MODIFIER", 106, 117], ["pulmonary", "ANATOMY", 118, 127], ["disease", "OBSERVATION", 128, 135], ["COPD", "OBSERVATION", 137, 141], ["mechanical ventilation", "OBSERVATION", 205, 227]]], ["The main signs and symptoms at the start of the illness included fever, myalgia, cough, and headaches, while chest pain, dyspnea, and cyanosis occurred after the third day.", [["chest", "ANATOMY", 109, 114], ["illness", "DISEASE", 48, 55], ["fever", "DISEASE", 65, 70], ["myalgia", "DISEASE", 72, 79], ["cough", "DISEASE", 81, 86], ["headaches", "DISEASE", 92, 101], ["chest pain", "DISEASE", 109, 119], ["dyspnea", "DISEASE", 121, 128], ["cyanosis", "DISEASE", 134, 142], ["chest", "ORGANISM_SUBDIVISION", 109, 114], ["The main signs", "PROBLEM", 0, 14], ["symptoms", "PROBLEM", 19, 27], ["fever", "PROBLEM", 65, 70], ["myalgia", "PROBLEM", 72, 79], ["cough", "PROBLEM", 81, 86], ["headaches", "PROBLEM", 92, 101], ["chest pain", "PROBLEM", 109, 119], ["dyspnea", "PROBLEM", 121, 128], ["cyanosis", "PROBLEM", 134, 142], ["main", "OBSERVATION_MODIFIER", 4, 8], ["myalgia", "OBSERVATION", 72, 79], ["cough", "OBSERVATION", 81, 86], ["chest", "ANATOMY", 109, 114], ["dyspnea", "OBSERVATION", 121, 128], ["cyanosis", "OBSERVATION", 134, 142]]], ["Critically ill patients received oseltamivir (150 mg/day) during the period while they were under mechanical ventilation while non-critically ill patients received 150mg/day of oseltamivir for 5 days.ResultsSubstitutions detected by whole genome sequencing of the AH1N1 09pdm influenza virus 13 of the substitutions we identified were novel, and their potential biological role has not been defined.", [["Critically ill", "DISEASE", 0, 14], ["oseltamivir", "CHEMICAL", 33, 44], ["non-critically ill", "DISEASE", 127, 145], ["oseltamivir", "CHEMICAL", 177, 188], ["oseltamivir", "CHEMICAL", 33, 44], ["oseltamivir", "CHEMICAL", 177, 188], ["patients", "ORGANISM", 15, 23], ["oseltamivir", "SIMPLE_CHEMICAL", 33, 44], ["patients", "ORGANISM", 146, 154], ["oseltamivir", "SIMPLE_CHEMICAL", 177, 188], ["AH1N1 09pdm influenza virus", "ORGANISM", 264, 291], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 146, 154], ["pdm influenza virus", "SPECIES", 272, 291], ["AH1N1 09pdm influenza virus", "SPECIES", 264, 291], ["Critically ill", "PROBLEM", 0, 14], ["oseltamivir", "TREATMENT", 33, 44], ["mechanical ventilation", "TREATMENT", 98, 120], ["oseltamivir", "TREATMENT", 177, 188], ["ResultsSubstitutions", "TEST", 200, 220], ["pdm influenza virus", "PROBLEM", 272, 291], ["the substitutions", "PROBLEM", 298, 315], ["mechanical ventilation", "OBSERVATION", 98, 120]]], ["Substitutions that have been previously reported are involved in host specificity shift, viral oligomerization interfaces (VOI), binding small ligands (BSL), Ab's recognition, binding host proteins (BHP), binding nucleic acids (BNA) and antigenic drift.", [["nucleic acids", "CHEMICAL", 213, 226], ["Ab", "GENE_OR_GENE_PRODUCT", 158, 160], ["BHP", "SIMPLE_CHEMICAL", 199, 202], ["nucleic acids", "SIMPLE_CHEMICAL", 213, 226], ["BNA", "SIMPLE_CHEMICAL", 228, 231], ["viral oligomerization interfaces", "PROTEIN", 89, 121], ["VOI", "PROTEIN", 123, 126], ["binding small ligands", "PROTEIN", 129, 150], ["BSL", "PROTEIN", 152, 155], ["Ab", "PROTEIN", 158, 160], ["binding host proteins", "PROTEIN", 176, 197], ["BHP", "PROTEIN", 199, 202], ["binding nucleic acids", "PROTEIN", 205, 226], ["BNA", "PROTEIN", 228, 231], ["Substitutions", "TREATMENT", 0, 13], ["viral oligomerization interfaces", "PROBLEM", 89, 121], ["binding small ligands", "PROBLEM", 129, 150], ["Ab's recognition", "TEST", 158, 174], ["binding host proteins (BHP)", "PROBLEM", 176, 203], ["binding nucleic acids", "TEST", 205, 226], ["antigenic drift", "PROBLEM", 237, 252], ["small ligands", "OBSERVATION", 137, 150], ["antigenic drift", "OBSERVATION", 237, 252]]], ["VOI is calculated automatically from known structures and captures sites both in viral oligomerization sites as well as crystal contacts.", [["viral oligomerization sites", "PROTEIN", 81, 108], ["VOI", "TEST", 0, 3], ["known structures", "PROBLEM", 37, 53], ["captures sites", "PROBLEM", 58, 72], ["viral oligomerization sites", "TREATMENT", 81, 108], ["viral oligomerization sites", "OBSERVATION", 81, 108]]], ["BHP includes mostly interaction with human immune response proteins.", [["BHP", "CHEMICAL", 0, 3], ["BHP", "CHEMICAL", 0, 3], ["BHP", "SIMPLE_CHEMICAL", 0, 3], ["human", "ORGANISM", 37, 42], ["immune response proteins", "GENE_OR_GENE_PRODUCT", 43, 67], ["human immune response proteins", "PROTEIN", 37, 67], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["human immune response proteins", "TREATMENT", 37, 67]]], ["BSL is derived from small ligands seen in known crystal structures and, in case of influenza surface proteins, often signifies interaction with small glycans which can be in or near a glycosylation site.", [["surface", "ANATOMY", 93, 100], ["BSL", "GENE_OR_GENE_PRODUCT", 0, 3], ["influenza surface proteins", "GENE_OR_GENE_PRODUCT", 83, 109], ["BSL", "PROTEIN", 0, 3], ["influenza surface proteins", "PROTEIN", 83, 109], ["glycosylation site", "PROTEIN", 184, 202], ["small ligands", "PROBLEM", 20, 33], ["known crystal structures", "PROBLEM", 42, 66], ["influenza surface proteins", "PROBLEM", 83, 109], ["small glycans", "PROBLEM", 144, 157], ["small ligands", "OBSERVATION", 20, 33], ["crystal structures", "OBSERVATION", 48, 66], ["influenza", "OBSERVATION", 83, 92], ["small glycans", "OBSERVATION_MODIFIER", 144, 157]]], ["These Mexican sequences clustered next to HA sequences of strains from New York (CY189313, CY189361, bootstrap value 66).", [["HA sequences", "DNA", 42, 54], ["strains", "PROBLEM", 58, 65], ["bootstrap value", "TEST", 101, 116]]], ["These sequences share two substitutions in Signal Peptide of the immature HA at amino acid 7 and 15 (-11 V/I and -3 A/T).", [["amino acid", "CHEMICAL", 80, 90], ["amino acid", "CHEMICAL", 80, 90], ["amino acid", "AMINO_ACID", 80, 90], ["immature HA", "PROTEIN", 65, 76], ["These sequences", "TEST", 0, 15], ["two substitutions", "PROBLEM", 22, 39], ["Signal Peptide", "TEST", 43, 57], ["the immature HA", "PROBLEM", 61, 76], ["amino acid", "TEST", 80, 90], ["V/I", "TEST", 105, 108], ["immature", "OBSERVATION_MODIFIER", 65, 73]]], ["Group 2 (KR271559 and KR1571583) sequences clustered separately and shared a novel substitution in HA H138Q.", [["HA H138Q", "GENE_OR_GENE_PRODUCT", 99, 107], ["Group 2 (KR271559 and KR1571583) sequences", "DNA", 0, 42], ["Group 2 (KR271559 and KR1571583) sequences", "TEST", 0, 42], ["a novel substitution in HA H138Q", "TREATMENT", 75, 107]]], ["Group 3 (KR271599 and KR271567) clustered with strains isolated in New York, Washington and Helsinki.", [["strains", "PROBLEM", 47, 54]]], ["We mapped the amino acid substitutions occurring at the nodes of H1N1/2009 HA phylogeny, revealing amino acid changes at K163Q and A256T for 2013-2014 sequences as reported previously.", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 99, 109], ["amino acid", "AMINO_ACID", 14, 24], ["amino acid", "AMINO_ACID", 99, 109], ["K163Q and A256T for 2013-2014 sequences", "DNA", 121, 160], ["the amino acid substitutions", "PROBLEM", 10, 38], ["H1N1", "PROBLEM", 65, 69], ["amino acid changes", "PROBLEM", 99, 117], ["amino acid substitutions", "OBSERVATION", 14, 38], ["amino acid", "OBSERVATION", 99, 109]]], ["Regarding NA, we observed 3 substitutions that marked sequences from 2013-2014; I34V, I321V and K432E.", [["3 substitutions", "PROBLEM", 26, 41]]], ["To determine whether individual sites were under positive selection, we used the mixed effects model of evolution (MEME) method.", [["individual sites", "PROBLEM", 21, 37]]], ["Only I34V was statistically significant (P = 0.05).", [["significant", "OBSERVATION_MODIFIER", 28, 39]]], ["Additionally we found substitutions that distinguished the three groups mentioned above with HA analyses.", [["substitutions", "PROBLEM", 22, 35], ["HA analyses", "PROBLEM", 93, 104], ["substitutions", "OBSERVATION", 22, 35]]], ["We observed substitution Q308L in group 1, while T452I was found in group 2 and the substitutions N449K, N386K and S82P were present on sequence KR271569 in group 3.", [["substitution Q308L", "TREATMENT", 12, 30], ["the substitutions", "TEST", 80, 97], ["sequence", "TEST", 136, 144]]], ["For NS1 we detected the substitution L36I in group 1, the N127S in group 2 and finally the substitution K131E in group 3.", [["NS1", "GENE_OR_GENE_PRODUCT", 4, 7], ["NS1", "PROTEIN", 4, 7], ["NS1", "PROBLEM", 4, 7], ["the substitution K131E in group", "TREATMENT", 87, 118]]], ["Regarding PA we found the substitution I13V as a signature of the group 1 (statistically significant with P = 0.05), while in group 3 we detected two substitutions F35L and I459T.", [["PA", "GENE_OR_GENE_PRODUCT", 10, 12], ["P", "TEST", 106, 107]]], ["In PB1 we associated the substitution A374T with group 2 and M646I with group 3.", [["PB1", "DNA", 3, 6]]], ["In PB2 T676I was found in group 2 [17] .", [["PB2 T676I", "ORGANISM", 3, 12], ["PB2 T676I", "PROTEIN", 3, 12]]], ["Other substitutions Red dots at nodes show branches with 50% bootstrap support leading to the 2014 sequences described in this work.", [["nodes", "ANATOMY", 32, 37], ["nodes", "MULTI-TISSUE_STRUCTURE", 32, 37], ["2014 sequences", "DNA", 94, 108], ["Other substitutions", "PROBLEM", 0, 19], ["Red dots at nodes", "PROBLEM", 20, 37], ["50% bootstrap support", "TREATMENT", 57, 78], ["dots", "OBSERVATION_MODIFIER", 24, 28], ["nodes", "OBSERVATION", 32, 37], ["branches", "ANATOMY_MODIFIER", 43, 51]]], ["Trees for the rest of the viral genome segments can be found in S1-S7 Figs (S1 Fig NA, S2 Fig PB2, S3 Fig PB2, S4 Fig PA, S5 Fig M, S6 Fig NP, S7 Fig NS) . were found in M1, M2, NS2 and NP but were similar to those reported in other countries ( Table 2 ).DiscussionInfluenza A viruses cause acute respiratory tract infections and represent a significant public health threat [18] .", [["respiratory tract", "ANATOMY", 297, 314], ["Influenza A viruses", "DISEASE", 265, 284], ["acute respiratory tract infections", "DISEASE", 291, 325], ["M2", "GENE_OR_GENE_PRODUCT", 174, 176], ["NS2", "GENE_OR_GENE_PRODUCT", 178, 181], ["Influenza A viruses", "ORGANISM", 265, 284], ["viral genome segments", "DNA", 26, 47], ["S1", "PROTEIN", 64, 66], ["S2", "PROTEIN", 87, 89], ["PB2", "PROTEIN", 94, 97], ["S3", "PROTEIN", 99, 101], ["PB2", "PROTEIN", 106, 109], ["S4", "PROTEIN", 111, 113], ["S5", "PROTEIN", 122, 124], ["S6", "PROTEIN", 132, 134], ["S7 Fig NS", "DNA", 143, 152], ["NS2", "PROTEIN", 178, 181], ["Influenza A viruses", "SPECIES", 265, 284], ["S1", "TEST", 64, 66], ["NA", "TEST", 83, 85], ["S2", "TEST", 87, 89], ["Fig", "TEST", 90, 93], ["PB2", "TEST", 94, 97], ["S3", "TEST", 99, 101], ["Fig PB2", "TEST", 102, 109], ["S4", "TEST", 111, 113], ["Fig PA", "TEST", 114, 120], ["Fig NP", "TREATMENT", 135, 141], ["Influenza A viruses", "PROBLEM", 265, 284], ["acute respiratory tract infections", "PROBLEM", 291, 325], ["M1", "ANATOMY_MODIFIER", 170, 172], ["M2", "ANATOMY", 174, 176], ["respiratory tract", "ANATOMY", 297, 314], ["significant", "OBSERVATION_MODIFIER", 342, 353]]], ["The outbreak strain of swine-origin influenza A/H1N1 virus infection in 2009 is still circulating during the winter season in many countries, and may cause severe pulmonary illness in susceptible individuals [4, 19] .", [["pulmonary", "ANATOMY", 163, 172], ["H1N1 virus infection", "DISEASE", 48, 68], ["pulmonary illness", "DISEASE", 163, 180], ["swine-origin influenza A/H1N1 virus", "ORGANISM", 23, 58], ["pulmonary", "ORGAN", 163, 172], ["swine", "SPECIES", 23, 28], ["influenza A/H1N1 virus", "SPECIES", 36, 58], ["swine-origin influenza A/H1N1 virus", "SPECIES", 23, 58], ["influenza A/H1N1 virus infection", "PROBLEM", 36, 68], ["severe pulmonary illness in susceptible individuals", "PROBLEM", 156, 207], ["may cause", "UNCERTAINTY", 146, 155], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["pulmonary", "ANATOMY", 163, 172], ["illness", "OBSERVATION", 173, 180]]], ["Therefore continuous analysis of the entire genome of these viruses will provide comprehensive information of its molecular evolution in order to maintain effective prevention measures for public health.", [["continuous analysis", "TEST", 10, 29], ["these viruses", "PROBLEM", 54, 67], ["viruses", "OBSERVATION", 60, 67]]], ["It has been extensively demonstrated that pandemic A/H1N1 influenza virus contains a mixture of segments, including HA, NP, PB1, PB2, PA and NS from a triple reassortant virus isolated in north America and segments NA and M from the Eurasian swine influenza virus [20, 21] .", [["influenza virus", "DISEASE", 58, 73], ["influenza virus", "DISEASE", 248, 263], ["pandemic", "ORGANISM", 42, 50], ["A/H1N1 influenza virus", "ORGANISM", 51, 73], ["HA", "GENE_OR_GENE_PRODUCT", 116, 118], ["NP", "GENE_OR_GENE_PRODUCT", 120, 122], ["PB1", "GENE_OR_GENE_PRODUCT", 124, 127], ["PB2", "GENE_OR_GENE_PRODUCT", 129, 132], ["PA", "GENE_OR_GENE_PRODUCT", 134, 136], ["triple reassortant virus", "ORGANISM", 151, 175], ["Eurasian", "ORGANISM", 233, 241], ["swine influenza virus", "ORGANISM", 242, 263], ["PB1", "PROTEIN", 124, 127], ["PB2", "PROTEIN", 129, 132], ["A/H1N1 influenza virus", "SPECIES", 51, 73], ["Eurasian swine influenza virus", "SPECIES", 233, 263], ["A/H1N1 influenza virus", "SPECIES", 51, 73], ["Eurasian swine influenza virus", "SPECIES", 233, 263], ["pandemic A/H1N1 influenza virus", "PROBLEM", 42, 73], ["HA", "TEST", 116, 118], ["NP", "TEST", 120, 122], ["PB1", "TEST", 124, 127], ["PB2", "TEST", 129, 132], ["PA", "TEST", 134, 136], ["NS", "TREATMENT", 141, 143], ["a triple reassortant virus", "PROBLEM", 149, 175], ["the Eurasian swine influenza virus", "PROBLEM", 229, 263], ["Eurasian swine", "OBSERVATION", 233, 247], ["influenza virus", "OBSERVATION", 248, 263]]], ["Due to the differential mutation rates of each viral segment, molecular epidemiology surveillance is important to detect antigenic variations among circulating influenza strains, which can modify the pathogenicity and antiviral resistance patterns of these viral strains.DiscussionIn this study we sequenced the entire genome of pandemic A/H1N1 strains isolated from patients in a reference Hospital in Mexico City (INER) in different years and we compared these sequences with consensus sequences in order to detect mutations that might be associated with viral evolution or might influence the antigenicity of the virus.", [["influenza strains", "ORGANISM", 160, 177], ["pandemic A/H1N1 strains", "ORGANISM", 329, 352], ["patients", "ORGANISM", 367, 375], ["consensus sequences", "DNA", 478, 497], ["patients", "SPECIES", 367, 375], ["A/H1N1 strains", "SPECIES", 338, 352], ["molecular epidemiology surveillance", "TEST", 62, 97], ["antigenic variations", "PROBLEM", 121, 141], ["circulating influenza strains", "PROBLEM", 148, 177], ["the pathogenicity", "PROBLEM", 196, 213], ["antiviral resistance patterns", "TREATMENT", 218, 247], ["these viral strains", "PROBLEM", 251, 270], ["this study", "TEST", 284, 294], ["H1N1 strains", "PROBLEM", 340, 352], ["these sequences", "TEST", 457, 472], ["consensus sequences", "TEST", 478, 497], ["mutations", "PROBLEM", 517, 526], ["viral evolution", "PROBLEM", 557, 572], ["the virus", "PROBLEM", 612, 621], ["antiviral resistance", "OBSERVATION", 218, 238], ["viral strains", "OBSERVATION", 257, 270]]], ["It is important to mention that the sequences were obtained directly from clinical samples, in order to avoid in vitro artificial selection.DiscussionWe found a clear variation of the virus in Mexico from the 2011-2014 season due to different markers and in accordance with previous reports [22, 23] .", [["samples", "ANATOMY", 83, 90], ["the sequences", "TEST", 32, 45], ["the virus", "PROBLEM", 180, 189]]], ["Mutations V344M and I354L of PB2 and N321K of PA, I397M, I435T of PB1, S498N of NP, N44S, V241L, N369K of NA V80I of M1, L90I of NS1 and S185T, S203T, E374K and S451N of HA appeared together during the evolution of influenza virus in Mexico.", [["influenza virus", "DISEASE", 215, 230], ["PA", "GENE_OR_GENE_PRODUCT", 46, 48], ["NA V80I of M1", "GENE_OR_GENE_PRODUCT", 106, 119], ["NS1", "GENE_OR_GENE_PRODUCT", 129, 132], ["S185T", "GENE_OR_GENE_PRODUCT", 137, 142], ["influenza virus", "ORGANISM", 215, 230], ["PB2", "DNA", 29, 32], ["PB1", "DNA", 66, 69], ["M1", "PROTEIN", 117, 119], ["NS1", "PROTEIN", 129, 132], ["S185T", "PROTEIN", 137, 142], ["HA", "PROTEIN", 170, 172], ["Mutations", "TEST", 0, 9], ["PB2", "TEST", 29, 32], ["PA", "TEST", 46, 48], ["PB1", "TEST", 66, 69], ["NP", "TEST", 80, 82], ["N44S", "TEST", 84, 88], ["NA", "TEST", 106, 108], ["M1", "TEST", 117, 119], ["L90I", "TEST", 121, 125], ["NS1", "TEST", 129, 132], ["S185T", "TEST", 137, 142], ["S203T", "TEST", 144, 149], ["E374K", "TEST", 151, 156], ["S451N of HA", "PROBLEM", 161, 172], ["influenza virus", "PROBLEM", 215, 230], ["M1", "ANATOMY", 117, 119], ["influenza virus", "OBSERVATION", 215, 230]]], ["However we found other unique substitutions in PB2 G644R and T676I, PB1 A374T, HA H138Q, NA Q308L, and L36I in NS1 of some Mexican strains that could indicate geographical divergence.", [["PB2 G644R", "ORGANISM", 47, 56], ["HA H138Q", "GENE_OR_GENE_PRODUCT", 79, 87], ["NA Q308L", "GENE_OR_GENE_PRODUCT", 89, 97], ["NS1", "GENE_OR_GENE_PRODUCT", 111, 114], ["PB2", "DNA", 47, 50], ["NS1", "PROTEIN", 111, 114], ["other unique substitutions", "PROBLEM", 17, 43], ["PB2 G644R", "TEST", 47, 56], ["T676I", "TEST", 61, 66], ["PB1", "TEST", 68, 71], ["HA", "TEST", 79, 81], ["NA", "TEST", 89, 91], ["L36I", "TEST", 103, 107], ["some Mexican strains", "PROBLEM", 118, 138], ["substitutions", "OBSERVATION", 30, 43], ["geographical divergence", "OBSERVATION", 159, 182]]], ["Recently a very extensive analysis of sequences of influenza virus in a post-pandemic era showed that different geographical regions generated local epidemic peaks and might act as a potential seed of local virus.", [["influenza virus", "DISEASE", 51, 66], ["influenza virus", "ORGANISM", 51, 66], ["influenza virus", "SPECIES", 51, 66], ["influenza virus", "SPECIES", 51, 66], ["influenza virus", "PROBLEM", 51, 66], ["a post-pandemic era", "TEST", 70, 89], ["local epidemic peaks", "PROBLEM", 143, 163], ["local virus", "PROBLEM", 201, 212], ["local", "OBSERVATION_MODIFIER", 143, 148], ["epidemic peaks", "OBSERVATION", 149, 163], ["local virus", "OBSERVATION", 201, 212]]], ["Further studies would be required in order to determine which of them are fixed in the next generation of influenza virus in Mexico.", [["influenza virus", "DISEASE", 106, 121], ["influenza virus", "ORGANISM", 106, 121], ["Further studies", "TEST", 0, 15], ["influenza virus", "PROBLEM", 106, 121], ["influenza virus", "OBSERVATION", 106, 121]]], ["It is known that influenza viruses undergo positive selection during the process of cross-species transmission and during the initial stages of a human outbreak, followed by purifying (negative) selection, when viruses adapted to the new human host in late epidemic [24] [25] [26] .", [["influenza viruses", "DISEASE", 17, 34], ["influenza viruses", "ORGANISM", 17, 34], ["human", "ORGANISM", 146, 151], ["human", "ORGANISM", 238, 243], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 238, 243], ["influenza viruses", "PROBLEM", 17, 34], ["a human outbreak", "PROBLEM", 144, 160], ["viruses", "PROBLEM", 211, 218]]], ["In this context we still observed positive selection of substitutions of NA I34V and PA I13V in winter season 2013-2014.DiscussionOur data indicate that the polymerase complex appears to have different evolutionary dynamics; probably due to differences in the evolutionary rate among the viral segments.", [["NA", "CHEMICAL", 73, 75], ["NA I34V", "GENE_OR_GENE_PRODUCT", 73, 80], ["PA I13V", "GENE_OR_GENE_PRODUCT", 85, 92], ["NA I34V and PA I13V", "DNA", 73, 92], ["polymerase complex", "PROTEIN", 157, 175], ["NA", "TEST", 73, 75], ["DiscussionOur data", "TEST", 120, 138], ["the polymerase complex", "PROBLEM", 153, 175], ["probably due to", "UNCERTAINTY", 225, 240], ["viral segments", "OBSERVATION", 288, 302]]], ["This might also be a reflection of differences in selective pressure once the virus is in the infected host; regarding the rest of the viral genome segments, all the Mexican isolates from season 2013-2014 clustered with sequences from New York and Helsinki.DiscussionMexican sequences from 2013-2014 belonged to clade 6B characterized by D97N, K163Q, S185T, K283E and A256T substitutions (Fig 1) .", [["D97N", "GENE_OR_GENE_PRODUCT", 338, 342], ["viral genome segments", "DNA", 135, 156], ["selective pressure", "TREATMENT", 50, 68], ["the virus", "PROBLEM", 74, 83], ["selective", "OBSERVATION_MODIFIER", 50, 59], ["pressure", "OBSERVATION_MODIFIER", 60, 68], ["virus", "OBSERVATION", 78, 83], ["infected", "OBSERVATION", 94, 102], ["viral genome segments", "OBSERVATION", 135, 156]]], ["However a different branch was observed with 2 sequences presenting specific substitutions in all segments, including the substitution H138Q which lied in antigenic site in HA, These results suggest that strains could appear temporarily, with different molecular characteristics and potentially with antigenic or pathogenic implications.DiscussionA recently significant change occurred in virus from 2013 to 2014, the substitution K163Q were predominant from these years until now and has been associated with binding prevention of antibodies (Abs) elicited in a larger number of middle-aged humans all over the world [27] .DiscussionIn this study we identified 13 novel substitutions with important biological effects, including virulence, T cell epitope presented by MHC and potential roles in host specificity shifts and it should be noted that although these mutations have not been particularly characterized, they are found to be close to or belong to regions of biological importance previously ( Table 2) .DiscussionSubstitution PB2-R591P is on a position where R has been implicated in a more efficient replication of pandemic H1N1 viruses in mammals [28] while the effect of proline is not known.", [["T cell", "ANATOMY", 741, 747], ["H1N1 viruses", "DISEASE", 1136, 1148], ["proline", "CHEMICAL", 1185, 1192], ["proline", "CHEMICAL", 1185, 1192], ["humans", "ORGANISM", 592, 598], ["T cell", "CELL", 741, 747], ["R", "GENE_OR_GENE_PRODUCT", 1070, 1071], ["pandemic H1N1 viruses", "ORGANISM", 1127, 1148], ["proline", "AMINO_ACID", 1185, 1192], ["antibodies", "PROTEIN", 532, 542], ["Abs", "PROTEIN", 544, 547], ["T cell epitope", "PROTEIN", 741, 755], ["MHC", "PROTEIN", 769, 772], ["PB2", "DNA", 1037, 1040], ["R591P", "DNA", 1041, 1046], ["humans", "SPECIES", 592, 598], ["humans", "SPECIES", 592, 598], ["pandemic H1N1 viruses", "SPECIES", 1127, 1148], ["the substitution H138Q", "TREATMENT", 118, 140], ["HA", "PROBLEM", 173, 175], ["strains", "PROBLEM", 204, 211], ["antigenic or pathogenic implications", "PROBLEM", 300, 336], ["the substitution K163Q", "TREATMENT", 414, 436], ["antibodies (Abs)", "PROBLEM", 532, 548], ["this study", "TEST", 637, 647], ["novel substitutions", "PROBLEM", 665, 684], ["virulence", "PROBLEM", 730, 739], ["T cell epitope", "TREATMENT", 741, 755], ["these mutations", "PROBLEM", 857, 872], ["PB2", "TEST", 1037, 1040], ["pandemic H1N1 viruses", "PROBLEM", 1127, 1148], ["different", "OBSERVATION_MODIFIER", 10, 19], ["branch", "OBSERVATION_MODIFIER", 20, 26], ["all segments", "ANATOMY_MODIFIER", 94, 106], ["potentially with", "UNCERTAINTY", 283, 299], ["significant", "OBSERVATION_MODIFIER", 358, 369], ["change", "OBSERVATION", 370, 376], ["larger", "OBSERVATION_MODIFIER", 563, 569], ["number", "OBSERVATION_MODIFIER", 570, 576], ["middle", "ANATOMY_MODIFIER", 580, 586]]], ["PB1-S704T is part of the H-2K b epitope and might affect the efficiency of antigen processing during cytotoxic T lymphocyte (CTL) response [29, 30] .", [["cytotoxic T lymphocyte", "ANATOMY", 101, 123], ["PB1-S704T", "GENE_OR_GENE_PRODUCT", 0, 9], ["H-2K", "GENE_OR_GENE_PRODUCT", 25, 29], ["cytotoxic T lymphocyte", "CELL", 101, 123], ["CTL", "CELL", 125, 128], ["PB1", "DNA", 0, 3], ["S704T", "PROTEIN", 4, 9], ["H-2K b epitope", "PROTEIN", 25, 39], ["cytotoxic T lymphocyte", "CELL_TYPE", 101, 123], ["PB1", "TEST", 0, 3], ["the H-2K b epitope", "TREATMENT", 21, 39], ["antigen processing", "PROBLEM", 75, 93], ["cytotoxic T lymphocyte", "TEST", 101, 123]]], ["E16A is in the N-terminal ectodomain of M2 at the outside of the viral membrane near to the disulfide bridges connecting the M2 tetramer 18235503] but its specific effect has not been particularly characterized yet [31] .DiscussionOther novel substitutions in this report are involved in VOI, such as PA at position T162P [32, 33] ; BSL in PB2 at V640M [34] and in PA at L109F [32, 33] ; VOI/BNA in NP at G356R [35] and BSL/VOI in NS1 at Q63K [36] .DiscussionRegarding previously observed substitutions, some have been computationally predicted to be linked to host specificity, such as PB2 V613A [37] .", [["membrane", "ANATOMY", 71, 79], ["N", "CHEMICAL", 15, 16], ["disulfide", "CHEMICAL", 92, 101], ["E16A", "GENE_OR_GENE_PRODUCT", 0, 4], ["M2", "GENE_OR_GENE_PRODUCT", 40, 42], ["PA", "GENE_OR_GENE_PRODUCT", 301, 303], ["PA", "GENE_OR_GENE_PRODUCT", 365, 367], ["E16A", "PROTEIN", 0, 4], ["N-terminal ectodomain", "PROTEIN", 15, 36], ["M2", "PROTEIN", 40, 42], ["disulfide bridges", "PROTEIN", 92, 109], ["M2 tetramer 18235503", "PROTEIN", 125, 145], ["BNA", "PROTEIN", 392, 395], ["BSL", "PROTEIN", 420, 423], ["NS1", "PROTEIN", 431, 434], ["PB2 V613A", "PROTEIN", 587, 596], ["BSL in PB2", "TEST", 333, 343], ["PA", "TEST", 365, 367], ["VOI", "TEST", 388, 391], ["BNA", "TEST", 392, 395], ["BSL/VOI in NS1", "TREATMENT", 420, 434], ["viral membrane", "OBSERVATION", 65, 79]]], ["Other roles of residues include VOI, I13V in PA [38] , S482N in NP [35] ; G18S and A33T in M1; A122T in NS1 [39] [40] .", [["PA [38]", "GENE_OR_GENE_PRODUCT", 45, 52], ["I13V", "PROTEIN", 37, 41], ["M1", "PROTEIN", 91, 93], ["NS1", "PROTEIN", 104, 107], ["VOI", "TEST", 32, 35], ["G18S", "TEST", 74, 78], ["A33T", "TEST", 83, 87], ["A122T", "TEST", 95, 100], ["NS1", "TEST", 104, 107], ["M1", "ANATOMY", 91, 93]]], ["BSL, F35L in PA [41] .DiscussionIt was observed before that some substitutions might have more than one biological function, such as HA H25R and E373G, which are implicated in Ab's recognition, BSL, VOI, and BHP [42, 43] .", [["BHP", "CHEMICAL", 208, 211], ["HA H25R", "GENE_OR_GENE_PRODUCT", 133, 140], ["E373G", "GENE_OR_GENE_PRODUCT", 145, 150], ["Ab", "GENE_OR_GENE_PRODUCT", 176, 178], ["BSL", "GENE_OR_GENE_PRODUCT", 194, 197], ["BHP", "SIMPLE_CHEMICAL", 208, 211], ["H25R", "PROTEIN", 136, 140], ["E373G", "PROTEIN", 145, 150], ["Ab", "PROTEIN", 176, 178], ["some substitutions", "PROBLEM", 60, 78]]], ["NA D199N is also associated with antigenic drift [44, 45] ; BSL/VOI in PB2 G644R [46] ; PA T151N and E623D [32, 33, 47] ; NA, V177I [45]; NS1, L36I, Q63K, N127S [40, 48] .", [["NA", "CHEMICAL", 0, 2], ["NA D199N", "GENE_OR_GENE_PRODUCT", 0, 8], ["BSL", "GENE_OR_GENE_PRODUCT", 60, 63], ["PA T151N", "GENE_OR_GENE_PRODUCT", 88, 96], ["NS1", "GENE_OR_GENE_PRODUCT", 138, 141], ["NA D199N", "DNA", 0, 8], ["antigenic drift", "TEST", 33, 48], ["BSL/VOI in PB2 G644R", "TEST", 60, 80], ["PA T151N", "TEST", 88, 96], ["E623D", "TEST", 101, 106], ["NA", "TEST", 122, 124], ["V177I", "TEST", 126, 131], ["NS1", "TEST", 138, 141], ["L36I", "TEST", 143, 147]]], ["BHP in NA T452I involved in BSL [49] and, in NS1 S74T [40, 48] , related to BSL and VOI.", [["BHP", "CHEMICAL", 0, 3], ["NA", "CHEMICAL", 7, 9], ["BHP", "CHEMICAL", 0, 3], ["BHP", "SIMPLE_CHEMICAL", 0, 3], ["NA T452I", "GENE_OR_GENE_PRODUCT", 7, 15], ["BSL [49]", "GENE_OR_GENE_PRODUCT", 28, 36], ["BSL", "GENE_OR_GENE_PRODUCT", 76, 79], ["NA T452I", "DNA", 7, 15], ["NS1", "PROTEIN", 45, 48], ["BSL", "PROTEIN", 76, 79]]], ["BNA in NP G356R [35] and NS1, G45 related with VOI [50].", [["BNA", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["BNA", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 25, 28], ["BNA", "TEST", 0, 3], ["NS1", "TEST", 25, 28], ["VOI", "TEST", 47, 50]]], ["All of these sites have been described by crystalographic or computational analysis ( Table 2 ).DiscussionIn HA we observe changes that could affect immunogenicity of the influenza virus; sequences from 2015 to 2016 had additional mutations (S162N) in antigenic site (Sa) and together with the substitution I276T are defining a new clade 6B.1 [21, 22] .", [["influenza virus", "DISEASE", 171, 186], ["influenza virus", "ORGANISM", 171, 186], ["antigenic site", "DNA", 252, 266], ["Sa", "DNA", 268, 270], ["substitution I276T", "DNA", 294, 312], ["influenza virus", "SPECIES", 171, 186], ["influenza virus", "SPECIES", 171, 186], ["computational analysis", "TEST", 61, 83], ["HA", "PROBLEM", 109, 111], ["the influenza virus", "PROBLEM", 167, 186], ["additional mutations", "PROBLEM", 220, 240]]], ["Importantly S162N may confer an additional glycosylation site in HA that could affect even more the immunogenicity of influenza virus in the future.DiscussionOur results indicate that the pandemic influenza virus changes through the seasons and show how the use of whole genome sequences are able to provide a deeper understanding of virus evolution through time.DiscussionSupporting information S1 Table.", [["S162N", "CHEMICAL", 12, 17], ["influenza virus", "DISEASE", 118, 133], ["influenza", "DISEASE", 197, 206], ["S162N", "GENE_OR_GENE_PRODUCT", 12, 17], ["influenza virus", "ORGANISM", 118, 133], ["influenza virus", "ORGANISM", 197, 212], ["S162N", "PROTEIN", 12, 17], ["whole genome sequences", "DNA", 265, 287], ["influenza virus", "SPECIES", 118, 133], ["an additional glycosylation site", "PROBLEM", 29, 61], ["HA", "PROBLEM", 65, 67], ["influenza virus", "PROBLEM", 118, 133], ["the pandemic influenza virus changes", "PROBLEM", 184, 220], ["whole genome sequences", "TREATMENT", 265, 287], ["virus", "OBSERVATION", 334, 339]]], ["Accession numbers of sequence used as reference and accession numbers of sequences from this study.", [["this study", "TEST", 88, 98]]]], "b5e1d36298a78690140d5ccb9673dbd48a0ddcd3": [["sequences and the inferred amino acid sequences are subject to purifying selection, 27", [["amino acid", "CHEMICAL", 27, 37], ["amino acid", "CHEMICAL", 27, 37], ["amino acid", "AMINO_ACID", 27, 37], ["the inferred amino acid sequences", "TEST", 14, 47], ["purifying selection", "TEST", 63, 82]]]], "7b112a7f35ac2905ba7d47dc492c59d79fa8f6f3": [["IntroductionSince December 2019, many patients with coronavirus disease 2019 (COVID- 19) pneumonia have been discovered in Wuhan, Hubei province, China.", [["coronavirus disease", "DISEASE", 52, 71], ["COVID- 19", "CHEMICAL", 78, 87], ["pneumonia", "DISEASE", 89, 98], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["coronavirus disease", "PROBLEM", 52, 71], ["COVID", "TEST", 78, 83], ["pneumonia", "PROBLEM", 89, 98], ["coronavirus disease", "OBSERVATION", 52, 71], ["pneumonia", "OBSERVATION", 89, 98]]], ["This virus subsequently spread to other provinces in China, and patients have been discovered in other countries [1] [2] [3] .", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["This virus", "PROBLEM", 0, 10]]], ["Novel coronavirus pneumonia is a novel respiratory disease in humans that is caused by the novel coronavirus.", [["respiratory", "ANATOMY", 39, 50], ["coronavirus pneumonia", "DISEASE", 6, 27], ["respiratory disease", "DISEASE", 39, 58], ["coronavirus", "ORGANISM", 6, 17], ["humans", "ORGANISM", 62, 68], ["coronavirus", "ORGANISM", 97, 108], ["humans", "SPECIES", 62, 68], ["coronavirus", "SPECIES", 97, 108], ["humans", "SPECIES", 62, 68], ["Novel coronavirus pneumonia", "PROBLEM", 0, 27], ["a novel respiratory disease in humans", "PROBLEM", 31, 68], ["the novel coronavirus", "PROBLEM", 87, 108], ["coronavirus", "OBSERVATION_MODIFIER", 6, 17], ["pneumonia", "OBSERVATION", 18, 27], ["respiratory disease", "OBSERVATION", 39, 58], ["coronavirus", "OBSERVATION", 97, 108]]], ["The WHO has officially named this disease coronavirus disease 2019 .", [["coronavirus disease", "DISEASE", 42, 61], ["this disease coronavirus disease", "PROBLEM", 29, 61]]], ["Currently, six coronaviruses that can infect humans have been discovered (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, and MERS-CoV).", [["coronaviruses", "ORGANISM", 15, 28], ["humans", "ORGANISM", 45, 51], ["HCoV-229E", "ORGANISM", 74, 83], ["HCoV-OC43", "CELL", 85, 94], ["HCoV-NL63", "CELL", 96, 105], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 107, 116], ["SARS-CoV", "ORGANISM", 118, 126], ["MERS-CoV", "ORGANISM", 132, 140], ["humans", "SPECIES", 45, 51], ["humans", "SPECIES", 45, 51], ["SARS-CoV", "SPECIES", 118, 126], ["MERS-CoV", "SPECIES", 132, 140], ["six coronaviruses", "PROBLEM", 11, 28], ["HCoV", "TEST", 74, 78], ["HCoV", "TEST", 85, 89], ["OC43", "TEST", 90, 94], ["HCoV", "TEST", 96, 100], ["NL63", "TEST", 101, 105], ["HCoV", "TEST", 107, 111], ["HKU1", "TEST", 112, 116], ["SARS", "TEST", 118, 122], ["CoV", "TEST", 123, 126], ["MERS", "TEST", 132, 136]]], ["The first four viruses mainly cause the common cold, whereas the SARS-CoV and MERS-CoV viruses cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), respectively.", [["SARS", "DISEASE", 65, 69], ["acute respiratory syndrome", "DISEASE", 108, 134], ["SARS", "DISEASE", 136, 140], ["Middle East respiratory syndrome", "DISEASE", 146, 178], ["SARS-CoV", "ORGANISM", 65, 73], ["MERS-CoV viruses", "ORGANISM", 78, 94], ["MERS-CoV", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 65, 73], ["MERS-CoV viruses", "SPECIES", 78, 94], ["Middle East respiratory syndrome (MERS)", "SPECIES", 146, 185], ["The first four viruses", "PROBLEM", 0, 22], ["the common cold", "PROBLEM", 36, 51], ["the SARS", "TEST", 61, 69], ["CoV viruses", "PROBLEM", 83, 94], ["severe acute respiratory syndrome", "PROBLEM", 101, 134], ["SARS", "PROBLEM", 136, 140], ["Middle East respiratory syndrome", "PROBLEM", 146, 178], ["viruses", "OBSERVATION", 15, 22], ["common", "OBSERVATION_MODIFIER", 40, 46], ["cold", "OBSERVATION", 47, 51], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory syndrome", "OBSERVATION", 114, 134], ["Middle", "ANATOMY_MODIFIER", 146, 152], ["respiratory syndrome", "OBSERVATION", 158, 178]]], ["The newly discovered coronavirus is a \u03b2-coronavirus that has enveloped virus particles that are spherical or oval in shape.", [["coronavirus", "ORGANISM", 21, 32], ["\u03b2-coronavirus", "CANCER", 38, 51], ["coronavirus", "SPECIES", 21, 32], ["coronavirus", "PROBLEM", 21, 32], ["a \u03b2-coronavirus", "PROBLEM", 36, 51], ["coronavirus", "OBSERVATION", 21, 32], ["enveloped", "OBSERVATION_MODIFIER", 61, 70], ["virus particles", "OBSERVATION", 71, 86], ["spherical", "OBSERVATION_MODIFIER", 96, 105], ["oval", "OBSERVATION_MODIFIER", 109, 113], ["shape", "OBSERVATION_MODIFIER", 117, 122]]], ["Although it belongs to the same genus as SARS-CoV and MERS-CoV, its genetic characteristics show significant differences compared with SARS-CoV and MERS-CoV [4] .", [["SARS-CoV", "ORGANISM", 41, 49], ["MERS-CoV", "ORGANISM", 54, 62], ["SARS-CoV", "ORGANISM", 135, 143], ["MERS-CoV", "ORGANISM", 148, 156], ["SARS-CoV", "SPECIES", 41, 49], ["MERS-CoV", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 135, 143], ["MERS-CoV", "SPECIES", 148, 156], ["SARS", "PROBLEM", 41, 45], ["significant differences", "PROBLEM", 97, 120], ["SARS", "TEST", 135, 139], ["significant", "OBSERVATION_MODIFIER", 97, 108]]], ["After assessment of the virus, the Coronavirus Study Group of the International Committee on Virus Taxonomy recommended naming this virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 145, 183], ["severe acute respiratory syndrome coronavirus", "SPECIES", 138, 183], ["SARS-CoV-2", "SPECIES", 187, 197], ["assessment", "TEST", 6, 16], ["the virus", "PROBLEM", 20, 29], ["the Coronavirus Study", "TEST", 31, 52], ["Virus Taxonomy", "TREATMENT", 93, 107], ["this virus severe acute respiratory syndrome coronavirus", "PROBLEM", 127, 183], ["CoV", "TEST", 192, 195], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory syndrome", "OBSERVATION", 151, 171]]], ["The epidemiological data provided by Huang et al. showed that the Huanan Seafood Wholesale Market in Wuhan was the source of the zoonosis.", [["zoonosis", "DISEASE", 129, 137], ["the zoonosis", "PROBLEM", 125, 137], ["zoonosis", "OBSERVATION", 129, 137]]], ["The appearance of disease clusters proved that human-to-human transmission is present [5] .", [["human", "ORGANISM", 47, 52], ["human", "ORGANISM", 56, 61], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 56, 61], ["disease clusters", "PROBLEM", 18, 34], ["disease", "OBSERVATION", 18, 25]]], ["Some researchers found that the fulllength genome sequence of SARS-CoV-2 obtained from earlier patients had a homology of 79.5% with the SARS-CoV sequence and a homology of 96% with the whole genome of bat coronaviruses [6] .", [["SARS-CoV-2", "ORGANISM", 62, 72], ["patients", "ORGANISM", 95, 103], ["bat coronaviruses", "ORGANISM", 202, 219], ["fulllength genome sequence", "DNA", 32, 58], ["SARS-CoV-2", "DNA", 62, 72], ["SARS-CoV sequence", "DNA", 137, 154], ["patients", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 137, 145], ["bat coronaviruses", "SPECIES", 202, 219], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["a homology", "TEST", 108, 118], ["the SARS", "TEST", 133, 141], ["CoV sequence", "TEST", 142, 154], ["a homology", "TEST", 159, 169]]], ["This provided valuable clues for examining the pathogenesis and clinical treatment of COVID-19.Thrombocytopenia in patients with COVID-19The most common symptoms seen in COVID-19 patients are fever, fatigue, and dry cough, and dyspnea gradually develops.", [["Thrombocytopenia", "DISEASE", 95, 111], ["fever", "DISEASE", 192, 197], ["fatigue", "DISEASE", 199, 206], ["dry cough", "DISEASE", 212, 221], ["dyspnea", "DISEASE", 227, 234], ["patients", "ORGANISM", 115, 123], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 115, 123], ["patients", "SPECIES", 179, 187], ["COVID", "TEST", 86, 91], ["Thrombocytopenia", "PROBLEM", 95, 111], ["COVID", "TEST", 129, 134], ["The most common symptoms", "PROBLEM", 137, 161], ["COVID", "TEST", 170, 175], ["fever", "PROBLEM", 192, 197], ["fatigue", "PROBLEM", 199, 206], ["dry cough", "PROBLEM", 212, 221], ["dyspnea", "PROBLEM", 227, 234], ["fever", "OBSERVATION", 192, 197], ["dry", "OBSERVATION_MODIFIER", 212, 215], ["cough", "OBSERVATION", 216, 221]]], ["Some patients have mild symptoms at disease onset and may not present with apparent fever.", [["fever", "DISEASE", 84, 89], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["mild symptoms at disease onset", "PROBLEM", 19, 49], ["apparent fever", "PROBLEM", 75, 89], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["symptoms", "OBSERVATION", 24, 32], ["fever", "OBSERVATION", 84, 89]]], ["Uncommon symptoms include abdominal pain, headache, palpitations, and chest pain.", [["abdominal", "ANATOMY", 26, 35], ["chest", "ANATOMY", 70, 75], ["abdominal pain", "DISEASE", 26, 40], ["headache", "DISEASE", 42, 50], ["palpitations", "DISEASE", 52, 64], ["chest pain", "DISEASE", 70, 80], ["abdominal", "ORGANISM_SUBDIVISION", 26, 35], ["chest", "ORGANISM_SUBDIVISION", 70, 75], ["Uncommon symptoms", "PROBLEM", 0, 17], ["abdominal pain", "PROBLEM", 26, 40], ["headache", "PROBLEM", 42, 50], ["palpitations", "PROBLEM", 52, 64], ["chest pain", "PROBLEM", 70, 80], ["abdominal", "ANATOMY", 26, 35], ["pain", "OBSERVATION", 36, 40], ["headache", "OBSERVATION", 42, 50], ["chest", "ANATOMY", 70, 75]]], ["Hematological changes are common in patients with COVID-19, which include reduced lymphocyte count and platelet count but normal white blood cell count.", [["lymphocyte", "ANATOMY", 82, 92], ["platelet", "ANATOMY", 103, 111], ["white blood cell", "ANATOMY", 129, 145], ["patients", "ORGANISM", 36, 44], ["lymphocyte", "CELL", 82, 92], ["platelet", "CELL", 103, 111], ["white blood cell", "CELL", 129, 145], ["patients", "SPECIES", 36, 44], ["Hematological changes", "PROBLEM", 0, 21], ["COVID", "TEST", 50, 55], ["reduced lymphocyte count", "PROBLEM", 74, 98], ["platelet count", "TEST", 103, 117], ["white blood cell count", "TEST", 129, 151], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["lymphocyte count", "OBSERVATION", 82, 98], ["platelet count", "OBSERVATION", 103, 117]]], ["Prolonged activated partial thromboplastin time, 26% had elevated D-dimer levels, and most patients had normal prothrombin time (PT) [7] .", [["thromboplastin", "GENE_OR_GENE_PRODUCT", 28, 42], ["D-dimer", "GENE_OR_GENE_PRODUCT", 66, 73], ["patients", "ORGANISM", 91, 99], ["prothrombin", "GENE_OR_GENE_PRODUCT", 111, 122], ["D-dimer", "PROTEIN", 66, 73], ["prothrombin", "PROTEIN", 111, 122], ["patients", "SPECIES", 91, 99], ["Prolonged activated partial thromboplastin time", "PROBLEM", 0, 47], ["elevated D-dimer levels", "PROBLEM", 57, 80], ["partial thromboplastin", "OBSERVATION", 20, 42]]], ["Of seven patients in the University of Hong Kong-Shenzhen Hospital (Shenzhen, Guangdong province, China), two had thrombocytopenia, and two had elevated D-dimer levels [8] .", [["thrombocytopenia", "DISEASE", 114, 130], ["D-dimer", "CHEMICAL", 153, 160], ["patients", "ORGANISM", 9, 17], ["D-dimer", "SIMPLE_CHEMICAL", 153, 160], ["patients", "SPECIES", 9, 17], ["thrombocytopenia", "PROBLEM", 114, 130], ["elevated D-dimer levels", "PROBLEM", 144, 167], ["thrombocytopenia", "OBSERVATION", 114, 130]]], ["A study involving 1099 patients from 31 provinces/direct-controlled municipalities in China showed that 82.1% of patients had lymphopenia, 36.2% had thrombocytopenia, and 33.7% had leukopenia [9] .", [["lymphopenia", "DISEASE", 126, 137], ["thrombocytopenia", "DISEASE", 149, 165], ["leukopenia", "DISEASE", 181, 191], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 113, 121], ["A study", "TEST", 0, 7], ["lymphopenia", "PROBLEM", 126, 137], ["thrombocytopenia", "PROBLEM", 149, 165], ["leukopenia", "PROBLEM", 181, 191], ["lymphopenia", "OBSERVATION", 126, 137]]], ["These laboratory marker abnormalities were more significant in severe cases [9] .", [["These laboratory marker abnormalities", "TEST", 0, 37]]], ["In 13 patients from 3 hospitals in Beijing, 72.5% developed thrombocytopenia [10] .", [["thrombocytopenia", "DISEASE", 60, 76], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["thrombocytopenia", "PROBLEM", 60, 76], ["thrombocytopenia", "OBSERVATION", 60, 76]]], ["Statistics from 41 patients in a designated hospital in Wuhan showed that 5% of patients had thrombocytopenia on admission [11] .", [["thrombocytopenia", "DISEASE", 93, 109], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 80, 88], ["thrombocytopenia", "PROBLEM", 93, 109], ["thrombocytopenia", "OBSERVATION", 93, 109]]], ["In most cases, the platelet count did not decrease to a level at which bleeding occurs.", [["platelet", "ANATOMY", 19, 27], ["bleeding", "DISEASE", 71, 79], ["platelet", "CELL", 19, 27], ["the platelet count", "TEST", 15, 33], ["bleeding", "PROBLEM", 71, 79], ["bleeding", "OBSERVATION", 71, 79]]], ["However, the mechanisms by which this coronavirus interferes with the hematopoietic system are unclear.", [["hematopoietic system", "ANATOMY", 70, 90], ["coronavirus", "ORGANISM", 38, 49], ["this coronavirus", "PROBLEM", 33, 49], ["the hematopoietic system", "PROBLEM", 66, 90], ["hematopoietic system", "OBSERVATION", 70, 90]]], ["In this paper, we summarized the hematological changes of thrombocytopenia in patients with COVID-19 and proposed possible mechanisms by which COVID-19 causes thrombocytopenia (Fig. 1 ).The possible mechanism of thrombocytopenia in COVID-19SARS-CoV-2 may reduce platelet production Coronaviruses are able to infect bone marrow cells, resulting in abnormal hematopoiesis [12] .", [["platelet", "ANATOMY", 262, 270], ["bone marrow cells", "ANATOMY", 315, 332], ["thrombocytopenia", "DISEASE", 58, 74], ["COVID-19", "CHEMICAL", 92, 100], ["COVID-19", "CHEMICAL", 143, 151], ["thrombocytopenia", "DISEASE", 159, 175], ["thrombocytopenia", "DISEASE", 212, 228], ["COVID-19SARS-CoV-2", "CHEMICAL", 232, 250], ["abnormal hematopoiesis", "DISEASE", 347, 369], ["COVID-19", "CHEMICAL", 92, 100], ["COVID-19", "CHEMICAL", 143, 151], ["patients", "ORGANISM", 78, 86], ["COVID-19SARS-CoV-2", "ORGANISM", 232, 250], ["platelet", "CELL", 262, 270], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 282, 295], ["bone marrow cells", "CELL", 315, 332], ["bone marrow cells", "CELL_TYPE", 315, 332], ["patients", "SPECIES", 78, 86], ["the hematological changes", "PROBLEM", 29, 54], ["thrombocytopenia", "PROBLEM", 58, 74], ["COVID", "TEST", 92, 97], ["COVID", "TEST", 143, 148], ["thrombocytopenia", "PROBLEM", 159, 175], ["thrombocytopenia", "PROBLEM", 212, 228], ["COVID", "TEST", 232, 237], ["CoV", "TEST", 245, 248], ["platelet production Coronaviruses", "PROBLEM", 262, 295], ["abnormal hematopoiesis", "PROBLEM", 347, 369], ["thrombocytopenia", "OBSERVATION", 58, 74], ["thrombocytopenia", "OBSERVATION", 159, 175], ["possible mechanism of", "UNCERTAINTY", 190, 211], ["thrombocytopenia", "OBSERVATION", 212, 228], ["abnormal", "OBSERVATION_MODIFIER", 347, 355], ["hematopoiesis", "OBSERVATION", 356, 369]]], ["SARS-CoV-2 and human SARS-CoV have 82% nucleotide homology [13] .", [["SARS", "DISEASE", 0, 4], ["nucleotide", "CHEMICAL", 39, 49], ["nucleotide", "CHEMICAL", 39, 49], ["SARS-CoV-2", "ORGANISM", 0, 10], ["human", "ORGANISM", 15, 20], ["SARS-CoV", "ORGANISM", 21, 29], ["human SARS-CoV", "DNA", 15, 29], ["human", "SPECIES", 15, 20], ["SARS-CoV", "SPECIES", 0, 8], ["human SARS-CoV", "SPECIES", 15, 29], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["human SARS", "TEST", 15, 25], ["CoV", "TEST", 26, 29]]], ["Because SARS-CoVand HCoV-229E have identical antigen characteristics, it is speculated that SARS-CoV-2 and HCoV-229E antigens have some similarity.", [["HCoV-229E", "GENE_OR_GENE_PRODUCT", 20, 29], ["SARS-CoV-2", "ORGANISM", 92, 102], ["HCoV-229E antigens", "GENE_OR_GENE_PRODUCT", 107, 125], ["SARS-CoVand HCoV-229E", "DNA", 8, 29], ["SARS-CoV-2 and HCoV-229E antigens", "PROTEIN", 92, 125], ["SARS-CoVand HCoV-229E", "SPECIES", 8, 29], ["SARS", "PROBLEM", 8, 12], ["HCoV", "TEST", 20, 24], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["HCoV", "TEST", 107, 111]]], ["Human aminopeptidase N (CD13) is a metalloprotease that is present on the cell surfaces of epithelial cells in the intestine, kidneys, and lungs and is a receptor for HCoV-229E [14] .", [["cell surfaces", "ANATOMY", 74, 87], ["epithelial cells", "ANATOMY", 91, 107], ["intestine", "ANATOMY", 115, 124], ["kidneys", "ANATOMY", 126, 133], ["lungs", "ANATOMY", 139, 144], ["Human", "ORGANISM", 0, 5], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 6, 22], ["CD13", "GENE_OR_GENE_PRODUCT", 24, 28], ["cell surfaces", "CELLULAR_COMPONENT", 74, 87], ["epithelial cells", "CELL", 91, 107], ["intestine", "ORGAN", 115, 124], ["kidneys", "ORGAN", 126, 133], ["lungs", "ORGAN", 139, 144], ["HCoV", "GENE_OR_GENE_PRODUCT", 167, 171], ["Human aminopeptidase N", "PROTEIN", 0, 22], ["CD13", "PROTEIN", 24, 28], ["metalloprotease", "PROTEIN", 35, 50], ["epithelial cells", "CELL_TYPE", 91, 107], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["HCoV-229E", "SPECIES", 167, 176], ["Human aminopeptidase N (CD13)", "TREATMENT", 0, 29], ["a metalloprotease", "TREATMENT", 33, 50], ["HCoV", "TEST", 167, 171], ["epithelial cells", "OBSERVATION", 91, 107], ["intestine", "ANATOMY", 115, 124], ["kidneys", "ANATOMY", 126, 133], ["lungs", "ANATOMY", 139, 144]]], ["CD13 is a marker of granulocytes and monocytes and is ubiquitous in respiratory tract epithelial cells, smooth muscle cells, fibroblasts, epithelial cells in the kidneys and small intestine, activated endothelial cells, lymphocytes, and platelets.", [["granulocytes", "ANATOMY", 20, 32], ["monocytes", "ANATOMY", 37, 46], ["respiratory tract epithelial cells", "ANATOMY", 68, 102], ["smooth muscle cells", "ANATOMY", 104, 123], ["fibroblasts", "ANATOMY", 125, 136], ["epithelial cells", "ANATOMY", 138, 154], ["kidneys", "ANATOMY", 162, 169], ["small intestine", "ANATOMY", 174, 189], ["endothelial cells", "ANATOMY", 201, 218], ["lymphocytes", "ANATOMY", 220, 231], ["platelets", "ANATOMY", 237, 246], ["CD13", "GENE_OR_GENE_PRODUCT", 0, 4], ["granulocytes", "CELL", 20, 32], ["monocytes", "CELL", 37, 46], ["respiratory tract epithelial cells", "CELL", 68, 102], ["smooth muscle cells", "CELL", 104, 123], ["fibroblasts", "CELL", 125, 136], ["epithelial cells", "CELL", 138, 154], ["kidneys", "ORGAN", 162, 169], ["small intestine", "ORGAN", 174, 189], ["endothelial cells", "CELL", 201, 218], ["lymphocytes", "CELL", 220, 231], ["platelets", "CELL", 237, 246], ["CD13", "PROTEIN", 0, 4], ["granulocytes", "CELL_TYPE", 20, 32], ["monocytes", "CELL_TYPE", 37, 46], ["respiratory tract epithelial cells", "CELL_TYPE", 68, 102], ["smooth muscle cells", "CELL_TYPE", 104, 123], ["fibroblasts", "CELL_TYPE", 125, 136], ["epithelial cells", "CELL_TYPE", 138, 154], ["activated endothelial cells", "CELL_TYPE", 191, 218], ["lymphocytes", "CELL_TYPE", 220, 231], ["platelets", "CELL_TYPE", 237, 246], ["CD13", "TEST", 0, 4], ["granulocytes", "TEST", 20, 32], ["monocytes", "TEST", 37, 46], ["ubiquitous in respiratory tract epithelial cells", "PROBLEM", 54, 102], ["epithelial cells in the kidneys and small intestine", "PROBLEM", 138, 189], ["activated endothelial cells", "PROBLEM", 191, 218], ["lymphocytes", "TEST", 220, 231], ["platelets", "TEST", 237, 246], ["granulocytes", "OBSERVATION", 20, 32], ["monocytes", "OBSERVATION", 37, 46], ["respiratory tract", "ANATOMY", 68, 85], ["epithelial cells", "OBSERVATION", 86, 102], ["smooth muscle cells", "OBSERVATION", 104, 123], ["fibroblasts", "OBSERVATION_MODIFIER", 125, 136], ["epithelial cells", "OBSERVATION", 138, 154], ["kidneys", "ANATOMY", 162, 169], ["small intestine", "ANATOMY", 174, 189], ["endothelial cells", "OBSERVATION", 201, 218], ["lymphocytes", "ANATOMY", 220, 231]]], ["HCoV-229E enters bone marrow cells and platelets through CD13 receptors and induces growth inhibition and apoptosis in the bone marrow, leading to aberrant hematopoiesis and thrombocytopenia [14] .", [["bone marrow cells", "ANATOMY", 17, 34], ["platelets", "ANATOMY", 39, 48], ["bone marrow", "ANATOMY", 123, 134], ["HCoV-229E", "CHEMICAL", 0, 9], ["thrombocytopenia", "DISEASE", 174, 190], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 0, 9], ["bone marrow cells", "CELL", 17, 34], ["platelets", "CELL", 39, 48], ["CD13", "GENE_OR_GENE_PRODUCT", 57, 61], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 123, 134], ["bone marrow cells", "CELL_TYPE", 17, 34], ["platelets", "CELL_TYPE", 39, 48], ["CD13 receptors", "PROTEIN", 57, 71], ["HCoV-229E", "SPECIES", 0, 9], ["HCoV", "TEST", 0, 4], ["bone marrow cells", "TEST", 17, 34], ["platelets", "TEST", 39, 48], ["CD13 receptors", "TEST", 57, 71], ["growth inhibition", "PROBLEM", 84, 101], ["apoptosis in the bone marrow", "PROBLEM", 106, 134], ["aberrant hematopoiesis", "PROBLEM", 147, 169], ["thrombocytopenia", "PROBLEM", 174, 190], ["bone", "ANATOMY", 17, 21], ["marrow cells", "OBSERVATION", 22, 34], ["growth inhibition", "OBSERVATION", 84, 101], ["bone marrow", "ANATOMY", 123, 134], ["aberrant", "OBSERVATION_MODIFIER", 147, 155], ["hematopoiesis", "OBSERVATION", 156, 169], ["thrombocytopenia", "OBSERVATION", 174, 190]]], ["Thrombocytopenia caused by SARS-CoV-2 infection is similar to that caused by SARS-CoV and HCoV-229E infection.", [["Thrombocytopenia", "DISEASE", 0, 16], ["SARS-CoV-2 infection", "DISEASE", 27, 47], ["infection", "DISEASE", 100, 109], ["SARS-CoV-2", "ORGANISM", 27, 37], ["SARS-CoV", "ORGANISM", 77, 85], ["HCoV-229E", "ORGANISM", 90, 99], ["CoV-2", "SPECIES", 32, 37], ["SARS-CoV-2", "SPECIES", 27, 37], ["SARS-CoV", "SPECIES", 77, 85], ["HCoV-229E", "SPECIES", 90, 99], ["Thrombocytopenia", "PROBLEM", 0, 16], ["SARS", "PROBLEM", 27, 31], ["CoV", "PROBLEM", 32, 35], ["2 infection", "PROBLEM", 36, 47], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["HCoV", "PROBLEM", 90, 94], ["229E infection", "PROBLEM", 95, 109], ["SARS", "OBSERVATION", 27, 31], ["CoV", "OBSERVATION_MODIFIER", 32, 35], ["infection", "OBSERVATION", 38, 47], ["SARS", "OBSERVATION", 77, 81], ["infection", "OBSERVATION", 100, 109]]], ["Based on this phenomenon, it is speculated that SARS-CoV-2 similarly inhibits hematopoiesis in the bone marrow through certain receptors to cause decreased primary platelet formation and lead to thrombocytopenia.The possible mechanism of thrombocytopenia in COVID-19Secondary hemophagocytic lymphohistiocytosis (sHLH) is caused by excessive proliferation and activation of mononuclear macrophage system, in which a large number of inflammatory cytokines are released and a large number of blood cells are swallowed.", [["bone marrow", "ANATOMY", 99, 110], ["primary platelet", "ANATOMY", 156, 172], ["mononuclear macrophage system", "ANATOMY", 373, 402], ["blood cells", "ANATOMY", 489, 500], ["SARS", "DISEASE", 48, 52], ["thrombocytopenia", "DISEASE", 195, 211], ["thrombocytopenia", "DISEASE", 238, 254], ["hemophagocytic lymphohistiocytosis", "DISEASE", 276, 310], ["sHLH", "DISEASE", 312, 316], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 99, 110], ["platelet", "CELL", 164, 172], ["COVID-19Secondary hemophagocytic lymphohistiocytosis", "CANCER", 258, 310], ["sHLH", "CANCER", 312, 316], ["mononuclear macrophage", "CELL", 373, 395], ["blood cells", "CELL", 489, 500], ["inflammatory cytokines", "PROTEIN", 431, 453], ["blood cells", "CELL_TYPE", 489, 500], ["SARS-CoV", "TEST", 48, 56], ["hematopoiesis in the bone marrow", "PROBLEM", 78, 110], ["decreased primary platelet formation", "PROBLEM", 146, 182], ["thrombocytopenia", "PROBLEM", 195, 211], ["thrombocytopenia", "PROBLEM", 238, 254], ["COVID", "TEST", 258, 263], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 276, 310], ["excessive proliferation", "PROBLEM", 331, 354], ["activation of mononuclear macrophage system", "PROBLEM", 359, 402], ["inflammatory cytokines", "PROBLEM", 431, 453], ["hematopoiesis", "OBSERVATION", 78, 91], ["bone marrow", "ANATOMY", 99, 110], ["decreased", "OBSERVATION_MODIFIER", 146, 155], ["primary platelet formation", "OBSERVATION", 156, 182], ["thrombocytopenia", "OBSERVATION", 195, 211], ["possible mechanism of", "UNCERTAINTY", 216, 237], ["thrombocytopenia", "OBSERVATION", 238, 254], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 276, 310], ["excessive", "OBSERVATION_MODIFIER", 331, 340], ["proliferation", "OBSERVATION", 341, 354], ["mononuclear macrophage system", "OBSERVATION", 373, 402], ["large", "OBSERVATION_MODIFIER", 415, 420], ["number", "OBSERVATION_MODIFIER", 421, 427], ["inflammatory cytokines", "OBSERVATION", 431, 453], ["large", "OBSERVATION_MODIFIER", 473, 478], ["number", "OBSERVATION_MODIFIER", 479, 485]]], ["This reactive disease has a rapid response with high mortality, and its basic features include persistent fever, hyperferremia, cytopenia, and lung involvement.", [["lung", "ANATOMY", 143, 147], ["fever", "DISEASE", 106, 111], ["hyperferremia", "DISEASE", 113, 126], ["cytopenia", "DISEASE", 128, 137], ["lung", "ORGAN", 143, 147], ["This reactive disease", "PROBLEM", 0, 21], ["high mortality", "PROBLEM", 48, 62], ["persistent fever", "PROBLEM", 95, 111], ["hyperferremia", "PROBLEM", 113, 126], ["cytopenia", "PROBLEM", 128, 137], ["lung involvement", "PROBLEM", 143, 159], ["reactive", "OBSERVATION_MODIFIER", 5, 13], ["disease", "OBSERVATION", 14, 21], ["rapid", "OBSERVATION_MODIFIER", 28, 33], ["response", "OBSERVATION_MODIFIER", 34, 42], ["high mortality", "OBSERVATION_MODIFIER", 48, 62], ["persistent", "OBSERVATION_MODIFIER", 95, 105], ["fever", "OBSERVATION", 106, 111], ["cytopenia", "OBSERVATION", 128, 137], ["lung", "ANATOMY", 143, 147], ["involvement", "OBSERVATION", 148, 159]]], ["In the retrospective analysis of 150 patients with COVID-19 in Wuhan, China, it was found that elevated ferritin was one of the predictors of death [15] .", [["death", "DISEASE", 142, 147], ["patients", "ORGANISM", 37, 45], ["ferritin", "GENE_OR_GENE_PRODUCT", 104, 112], ["ferritin", "PROTEIN", 104, 112], ["patients", "SPECIES", 37, 45], ["COVID", "TEST", 51, 56], ["elevated ferritin", "PROBLEM", 95, 112]]], ["After analyzing the blood samples of 33 severe and critical type ill COVID-19 patients, Wei Haiming's team found that after novel coronavirus infection, T cells were overactivated to produce granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-6 (IL-6).", [["blood samples", "ANATOMY", 20, 33], ["T cells", "ANATOMY", 153, 160], ["coronavirus infection", "DISEASE", 130, 151], ["blood samples", "ORGANISM_SUBSTANCE", 20, 33], ["patients", "ORGANISM", 78, 86], ["coronavirus", "ORGANISM", 130, 141], ["T cells", "CELL", 153, 160], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 191, 239], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 241, 247], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 253, 266], ["IL-6", "GENE_OR_GENE_PRODUCT", 268, 272], ["T cells", "CELL_TYPE", 153, 160], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 191, 239], ["GM", "PROTEIN", 241, 243], ["CSF", "PROTEIN", 244, 247], ["interleukin-6 (IL-6", "PROTEIN", 253, 272], ["patients", "SPECIES", 78, 86], ["coronavirus", "SPECIES", 130, 141], ["the blood samples", "TEST", 16, 33], ["novel coronavirus infection", "PROBLEM", 124, 151], ["T cells", "PROBLEM", 153, 160], ["granulocyte", "TEST", 191, 202], ["macrophage colony", "TEST", 203, 220], ["stimulating factor", "TEST", 221, 239], ["CSF", "TEST", 244, 247], ["interleukin", "TEST", 253, 264], ["IL", "TEST", 268, 270]]], ["GM-CSF stimulated CD14+ CD16+, inflammatory mononuclear macrophages to produce more interleukin-6 (IL-6), and other inflammatory factors, thus forming an inflammatory storm and causing immune damage to the lungs and other organs [16] .", [["CD14+ CD16+", "ANATOMY", 18, 29], ["inflammatory mononuclear macrophages", "ANATOMY", 31, 67], ["lungs", "ANATOMY", 206, 211], ["organs", "ANATOMY", 222, 228], ["GM", "CHEMICAL", 0, 2], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["CD14", "GENE_OR_GENE_PRODUCT", 18, 22], ["CD16", "GENE_OR_GENE_PRODUCT", 24, 28], ["mononuclear macrophages", "CELL", 44, 67], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 84, 97], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["lungs", "ORGAN", 206, 211], ["organs", "ORGAN", 222, 228], ["CSF", "PROTEIN", 3, 6], ["CD14", "PROTEIN", 18, 22], ["CD16", "PROTEIN", 24, 28], ["inflammatory mononuclear macrophages", "CELL_TYPE", 31, 67], ["interleukin-6 (IL-6", "PROTEIN", 84, 103], ["inflammatory factors", "PROTEIN", 116, 136], ["GM", "TEST", 0, 2], ["CSF stimulated CD14", "TEST", 3, 22], ["CD16", "TEST", 24, 28], ["inflammatory mononuclear macrophages", "PROBLEM", 31, 67], ["interleukin", "TEST", 84, 95], ["IL", "TEST", 99, 101], ["other inflammatory factors", "PROBLEM", 110, 136], ["an inflammatory storm", "PROBLEM", 151, 172], ["immune damage to the lungs", "PROBLEM", 185, 211], ["inflammatory mononuclear macrophages", "OBSERVATION", 31, 67], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128], ["inflammatory storm", "OBSERVATION", 154, 172], ["immune damage", "OBSERVATION", 185, 198], ["lungs", "ANATOMY", 206, 211]]], ["This is similar to the clinical manifestation and laboratory examination of patients with sHLH.", [["sHLH", "DISEASE", 90, 94], ["patients", "ORGANISM", 76, 84], ["sHLH", "CANCER", 90, 94], ["patients", "SPECIES", 76, 84], ["laboratory examination", "TEST", 50, 72]]], ["In addition, studies have shown [15] that the cytokine spectrum similar to sHLH is related to the severity of COVID-19 disease.", [["sHLH", "DISEASE", 75, 79], ["sHLH", "CANCER", 75, 79], ["cytokine", "PROTEIN", 46, 54], ["studies", "TEST", 13, 20], ["the cytokine spectrum", "TEST", 42, 63], ["COVID-19 disease", "PROBLEM", 110, 126], ["19 disease", "OBSERVATION", 116, 126]]], ["It is speculated that after the cytokine storm, the hematopoietic progenitor cells in bone marrow of patients with pneumonia infected by novel coronavirus were destroyed, the primary production of platelets decreased, and at the same time, too many blood cells were swallowed, which led to the decrease of peripheral blood platelet count.The possible mechanism of thrombocytopenia in COVID-19Evidence [17] has shown that a large number of megakaryocytes dynamically release platelets during pulmonary circulation.", [["hematopoietic progenitor cells", "ANATOMY", 52, 82], ["bone marrow", "ANATOMY", 86, 97], ["platelets", "ANATOMY", 197, 206], ["blood cells", "ANATOMY", 249, 260], ["peripheral blood platelet", "ANATOMY", 306, 331], ["megakaryocytes", "ANATOMY", 439, 453], ["platelets", "ANATOMY", 474, 483], ["pulmonary", "ANATOMY", 491, 500], ["pneumonia", "DISEASE", 115, 124], ["thrombocytopenia", "DISEASE", 364, 380], ["COVID-19Evidence", "CHEMICAL", 384, 400], ["hematopoietic progenitor cells", "CELL", 52, 82], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 86, 97], ["patients", "ORGANISM", 101, 109], ["coronavirus", "ORGANISM", 143, 154], ["platelets", "CELL", 197, 206], ["blood cells", "CELL", 249, 260], ["peripheral blood", "ORGANISM_SUBSTANCE", 306, 322], ["platelet", "CELL", 323, 331], ["megakaryocytes", "CELL", 439, 453], ["platelets", "CELL", 474, 483], ["pulmonary", "ORGAN", 491, 500], ["cytokine", "PROTEIN", 32, 40], ["hematopoietic progenitor cells", "CELL_TYPE", 52, 82], ["platelets", "CELL_TYPE", 197, 206], ["blood cells", "CELL_TYPE", 249, 260], ["megakaryocytes", "CELL_TYPE", 439, 453], ["platelets", "CELL_TYPE", 474, 483], ["patients", "SPECIES", 101, 109], ["the cytokine storm", "TREATMENT", 28, 46], ["the hematopoietic progenitor cells", "TREATMENT", 48, 82], ["pneumonia", "PROBLEM", 115, 124], ["novel coronavirus", "PROBLEM", 137, 154], ["platelets", "TEST", 197, 206], ["too many blood cells", "PROBLEM", 240, 260], ["peripheral blood platelet count", "TEST", 306, 337], ["thrombocytopenia", "PROBLEM", 364, 380], ["COVID", "TEST", 384, 389], ["megakaryocytes dynamically release platelets", "PROBLEM", 439, 483], ["hematopoietic progenitor cells", "OBSERVATION", 52, 82], ["bone", "ANATOMY", 86, 90], ["pneumonia", "OBSERVATION", 115, 124], ["decreased", "OBSERVATION_MODIFIER", 207, 216], ["decrease", "OBSERVATION_MODIFIER", 294, 302], ["peripheral", "ANATOMY_MODIFIER", 306, 316], ["blood", "ANATOMY", 317, 322], ["platelet count", "OBSERVATION", 323, 337], ["possible mechanism of", "UNCERTAINTY", 342, 363], ["thrombocytopenia", "OBSERVATION", 364, 380], ["large", "OBSERVATION_MODIFIER", 423, 428], ["megakaryocytes dynamically", "OBSERVATION", 439, 465], ["release platelets", "OBSERVATION", 466, 483], ["pulmonary", "ANATOMY", 491, 500], ["circulation", "ANATOMY_MODIFIER", 501, 512]]], ["Persistent hypertension and oxygen toxicity exacerbate lung injury, resulting in consolidation changes such as fibrosis.", [["lung", "ANATOMY", 55, 59], ["hypertension", "DISEASE", 11, 23], ["oxygen", "CHEMICAL", 28, 34], ["toxicity", "DISEASE", 35, 43], ["lung injury", "DISEASE", 55, 66], ["fibrosis", "DISEASE", 111, 119], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["lung", "ORGAN", 55, 59], ["Persistent hypertension", "PROBLEM", 0, 23], ["oxygen toxicity", "PROBLEM", 28, 43], ["lung injury", "PROBLEM", 55, 66], ["consolidation changes", "PROBLEM", 81, 102], ["fibrosis", "PROBLEM", 111, 119], ["hypertension", "OBSERVATION", 11, 23], ["oxygen toxicity", "OBSERVATION", 28, 43], ["lung", "ANATOMY", 55, 59], ["injury", "OBSERVATION", 60, 66], ["consolidation", "OBSERVATION", 81, 94], ["fibrosis", "OBSERVATION", 111, 119]]], ["Damaged pulmonary capillary beds cause the process of megakaryocyte rupture and platelet release to be blocked, which affects the release of platelets into the pulmonary circulation and indirectly leads to reduced platelet synthesis in the systemic circulation.SARS-CoV-2 infection may increase platelet destructionCOVID-19 may increase levels of autoantibodies and immune complexes, resulting in specific destruction of platelets by the immune system.", [["pulmonary capillary beds", "ANATOMY", 8, 32], ["megakaryocyte", "ANATOMY", 54, 67], ["platelet", "ANATOMY", 80, 88], ["platelets", "ANATOMY", 141, 150], ["pulmonary", "ANATOMY", 160, 169], ["platelet", "ANATOMY", 214, 222], ["platelet", "ANATOMY", 295, 303], ["platelets", "ANATOMY", 421, 430], ["immune system", "ANATOMY", 438, 451], ["megakaryocyte rupture", "DISEASE", 54, 75], ["SARS", "DISEASE", 261, 265], ["infection", "DISEASE", 272, 281], ["pulmonary capillary", "TISSUE", 8, 27], ["megakaryocyte", "CELL", 54, 67], ["platelet", "CELL", 80, 88], ["platelets", "CELL", 141, 150], ["pulmonary", "ORGAN", 160, 169], ["platelet", "CELL", 214, 222], ["SARS-CoV-2", "ORGANISM", 261, 271], ["platelet", "CELL", 295, 303], ["platelets", "CELL", 421, 430], ["platelets", "CELL_TYPE", 141, 150], ["autoantibodies", "PROTEIN", 347, 361], ["immune complexes", "PROTEIN", 366, 382], ["platelets", "CELL_TYPE", 421, 430], ["Damaged pulmonary capillary beds", "TREATMENT", 0, 32], ["megakaryocyte rupture", "PROBLEM", 54, 75], ["platelet release", "PROBLEM", 80, 96], ["reduced platelet synthesis in the systemic circulation", "PROBLEM", 206, 260], ["SARS", "TEST", 261, 265], ["CoV-2 infection", "PROBLEM", 266, 281], ["platelet destructionCOVID", "TEST", 295, 320], ["autoantibodies", "PROBLEM", 347, 361], ["immune complexes", "PROBLEM", 366, 382], ["specific destruction of platelets", "PROBLEM", 397, 430], ["pulmonary", "ANATOMY", 8, 17], ["capillary beds", "OBSERVATION", 18, 32], ["megakaryocyte rupture", "OBSERVATION", 54, 75], ["pulmonary circulation", "ANATOMY", 160, 181], ["reduced", "OBSERVATION_MODIFIER", 206, 213], ["platelet synthesis", "OBSERVATION", 214, 232], ["systemic circulation", "ANATOMY", 240, 260], ["infection", "OBSERVATION", 272, 281], ["destruction", "OBSERVATION", 406, 417]]], ["A study reported that the phenomenon of immune-mediated thrombocytopenia in patients infected with HIV-1 is widespread [18] .", [["thrombocytopenia", "DISEASE", 56, 72], ["patients", "ORGANISM", 76, 84], ["HIV-1", "ORGANISM", 99, 104], ["patients", "SPECIES", 76, 84], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 99, 104], ["A study", "TEST", 0, 7], ["immune-mediated thrombocytopenia", "PROBLEM", 40, 72], ["HIV", "PROBLEM", 99, 102], ["thrombocytopenia", "OBSERVATION", 56, 72], ["infected", "OBSERVATION_MODIFIER", 85, 93]]], ["Although the pathogenesis is unknown, this was proven to be associated with circulating immune complexes containing platelet membrane components and the anti-platelet membrane GPIIIa49-66 IgG antibodies [18] .", [["platelet membrane", "ANATOMY", 116, 133], ["membrane", "ANATOMY", 167, 175], ["platelet", "CELL", 116, 124], ["circulating immune complexes", "PROTEIN", 76, 104], ["platelet membrane components", "PROTEIN", 116, 144], ["anti-platelet membrane GPIIIa49-66 IgG antibodies", "PROTEIN", 153, 202], ["circulating immune complexes", "PROBLEM", 76, 104], ["platelet membrane components", "PROBLEM", 116, 144], ["the anti-platelet membrane GPIIIa49", "TEST", 149, 184], ["IgG antibodies", "TEST", 188, 202], ["platelet membrane components", "OBSERVATION", 116, 144]]], ["Anti-platelet membrane GPIIIa49-66 IgG antibodies can cross-react with the HIV-1GP 160/120 antigen.", [["membrane", "ANATOMY", 14, 22], ["Anti-platelet membrane GPIIIa49-66", "GENE_OR_GENE_PRODUCT", 0, 34], ["Anti-platelet membrane GPIIIa49-66 IgG antibodies", "PROTEIN", 0, 49], ["HIV-1GP 160/120 antigen", "PROTEIN", 75, 98], ["HIV", "SPECIES", 75, 78], ["HIV-1GP 160/120", "SPECIES", 75, 90], ["Anti-platelet membrane GPIIIa49", "TEST", 0, 31], ["IgG antibodies", "TEST", 35, 49], ["the HIV", "TEST", 71, 78]]], ["Antibodies and immune complexes deposited on the surfaces of platelets will be recognized by reticuloendothelial cells, and the platelets will be destroyed as target tissues, resulting in excessive platelet destruction.", [["platelets", "ANATOMY", 61, 70], ["reticuloendothelial cells", "ANATOMY", 93, 118], ["platelets", "ANATOMY", 128, 137], ["tissues", "ANATOMY", 166, 173], ["platelet", "ANATOMY", 198, 206], ["platelet destruction", "DISEASE", 198, 218], ["platelets", "CELL", 61, 70], ["reticuloendothelial cells", "CELL", 93, 118], ["platelets", "CELL", 128, 137], ["tissues", "TISSUE", 166, 173], ["platelet", "CELL", 198, 206], ["immune complexes", "PROTEIN", 15, 31], ["platelets", "CELL_TYPE", 61, 70], ["reticuloendothelial cells", "CELL_TYPE", 93, 118], ["platelets", "CELL_TYPE", 128, 137], ["Antibodies", "TEST", 0, 10], ["immune complexes", "PROBLEM", 15, 31], ["platelets", "TREATMENT", 61, 70], ["the platelets", "TEST", 124, 137], ["excessive platelet destruction", "PROBLEM", 188, 218], ["immune complexes", "OBSERVATION", 15, 31], ["reticuloendothelial cells", "OBSERVATION", 93, 118], ["excessive", "OBSERVATION_MODIFIER", 188, 197], ["platelet destruction", "OBSERVATION", 198, 218]]], ["Platelets with similar antigens may be coated by anti-platelet antibodies and immune complexes, which may result in immune-mediated damage.", [["Platelets", "ANATOMY", 0, 9], ["Platelets", "CELL", 0, 9], ["anti-platelet antibodies", "GENE_OR_GENE_PRODUCT", 49, 73], ["Platelets", "CELL_TYPE", 0, 9], ["anti-platelet antibodies", "PROTEIN", 49, 73], ["immune complexes", "PROTEIN", 78, 94], ["Platelets", "TEST", 0, 9], ["similar antigens", "PROBLEM", 15, 31], ["anti-platelet antibodies", "TEST", 49, 73], ["immune complexes", "PROBLEM", 78, 94], ["immune-mediated damage", "PROBLEM", 116, 138], ["damage", "OBSERVATION", 132, 138]]], ["In addition, antibodies produced during viral infection may specifically bind to antigens on platelets through molecular mimicry, resulting in increased platelet destruction.SARS-CoV-2 infection may increase platelet consumptionViral infection and inflammation result in lung damage.", [["platelets", "ANATOMY", 93, 102], ["platelet", "ANATOMY", 153, 161], ["platelet", "ANATOMY", 208, 216], ["lung", "ANATOMY", 271, 275], ["viral infection", "DISEASE", 40, 55], ["platelet destruction", "DISEASE", 153, 173], ["SARS", "DISEASE", 174, 178], ["infection", "DISEASE", 185, 194], ["infection", "DISEASE", 234, 243], ["inflammation", "DISEASE", 248, 260], ["lung damage", "DISEASE", 271, 282], ["platelets", "CELL", 93, 102], ["platelet", "CELL", 153, 161], ["SARS-CoV-2", "ORGANISM", 174, 184], ["platelet", "CELL", 208, 216], ["lung", "ORGAN", 271, 275], ["antibodies", "PROTEIN", 13, 23], ["platelets", "CELL_TYPE", 93, 102], ["antibodies", "PROBLEM", 13, 23], ["viral infection", "PROBLEM", 40, 55], ["platelets", "TEST", 93, 102], ["increased platelet destruction", "PROBLEM", 143, 173], ["SARS", "PROBLEM", 174, 178], ["CoV-2 infection", "PROBLEM", 179, 194], ["increase platelet consumptionViral infection", "PROBLEM", 199, 243], ["inflammation", "PROBLEM", 248, 260], ["lung damage", "PROBLEM", 271, 282], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["platelet destruction", "OBSERVATION", 153, 173], ["infection", "OBSERVATION", 185, 194], ["increase", "OBSERVATION_MODIFIER", 199, 207], ["platelet consumptionViral infection", "OBSERVATION", 208, 243], ["inflammation", "OBSERVATION", 248, 260], ["lung", "ANATOMY", 271, 275], ["damage", "OBSERVATION", 276, 282]]], ["Damaged lung tissues and pulmonary endothelial cells may activate platelets in the lungs, resulting in aggregation and formation of microthrombi, which increases platelet consumption.", [["lung tissues", "ANATOMY", 8, 20], ["pulmonary endothelial cells", "ANATOMY", 25, 52], ["platelets", "ANATOMY", 66, 75], ["lungs", "ANATOMY", 83, 88], ["microthrombi", "ANATOMY", 132, 144], ["platelet", "ANATOMY", 162, 170], ["microthrombi", "DISEASE", 132, 144], ["lung tissues", "TISSUE", 8, 20], ["pulmonary endothelial cells", "CELL", 25, 52], ["platelets", "CELL", 66, 75], ["lungs", "ORGAN", 83, 88], ["platelet", "CELL", 162, 170], ["pulmonary endothelial cells", "CELL_TYPE", 25, 52], ["platelets", "CELL_TYPE", 66, 75], ["Damaged lung tissues", "PROBLEM", 0, 20], ["pulmonary endothelial cells", "PROBLEM", 25, 52], ["platelets in the lungs", "PROBLEM", 66, 88], ["aggregation", "PROBLEM", 103, 114], ["microthrombi", "PROBLEM", 132, 144], ["platelet consumption", "TEST", 162, 182], ["lung tissues", "ANATOMY", 8, 20], ["pulmonary", "ANATOMY", 25, 34], ["endothelial cells", "OBSERVATION", 35, 52], ["platelets", "OBSERVATION", 66, 75], ["lungs", "ANATOMY", 83, 88], ["aggregation", "OBSERVATION", 103, 114], ["microthrombi", "OBSERVATION", 132, 144], ["increases", "OBSERVATION_MODIFIER", 152, 161], ["platelet consumption", "OBSERVATION", 162, 182]]], ["Most patients with COVID-19 who have thrombocytopenia have elevated D-dimer levels and impaired coagulation time, which further proves the above hypothesis that there is low intravascular coagulation.", [["intravascular", "ANATOMY", 174, 187], ["thrombocytopenia", "DISEASE", 37, 53], ["impaired coagulation", "DISEASE", 87, 107], ["intravascular coagulation", "DISEASE", 174, 199], ["patients", "ORGANISM", 5, 13], ["D-dimer", "GENE_OR_GENE_PRODUCT", 68, 75], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 187], ["D-dimer", "PROTEIN", 68, 75], ["patients", "SPECIES", 5, 13], ["COVID", "TEST", 19, 24], ["thrombocytopenia", "PROBLEM", 37, 53], ["elevated D-dimer levels", "PROBLEM", 59, 82], ["impaired coagulation time", "PROBLEM", 87, 112], ["low intravascular coagulation", "PROBLEM", 170, 199], ["thrombocytopenia", "OBSERVATION", 37, 53], ["coagulation time", "OBSERVATION_MODIFIER", 96, 112], ["low", "OBSERVATION_MODIFIER", 170, 173], ["intravascular coagulation", "OBSERVATION", 174, 199]]], ["Therefore, it is still unclear which drugs used for the treatment of patients with COVID-19 having thrombocytopenia resulted in recovery.", [["COVID", "DISEASE", 83, 88], ["thrombocytopenia", "DISEASE", 99, 115], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["COVID", "TEST", 83, 88], ["thrombocytopenia", "PROBLEM", 99, 115], ["thrombocytopenia", "OBSERVATION", 99, 115]]], ["SARS-CoV-2, MERS-CoV, and SARS-CoV are all \u03b2-coronaviruses.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 26, 30], ["SARS-CoV-2", "ORGANISM", 0, 10], ["MERS-CoV", "ORGANISM", 12, 20], ["SARS-CoV", "ORGANISM", 26, 34], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "PROBLEM", 26, 30]]], ["Previously, a patient with MERS received large doses of corticosteroids by intravenous infusion to treat thrombocytopenia, and their platelet counts improved [19] .", [["intravenous", "ANATOMY", 75, 86], ["platelet", "ANATOMY", 133, 141], ["MERS", "DISEASE", 27, 31], ["thrombocytopenia", "DISEASE", 105, 121], ["corticosteroids", "CHEMICAL", 56, 71], ["patient", "ORGANISM", 14, 21], ["corticosteroids", "SIMPLE_CHEMICAL", 56, 71], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["platelet", "CELL", 133, 141], ["patient", "SPECIES", 14, 21], ["corticosteroids", "TREATMENT", 56, 71], ["intravenous infusion", "TREATMENT", 75, 95], ["thrombocytopenia", "PROBLEM", 105, 121], ["their platelet counts", "TEST", 127, 148], ["thrombocytopenia", "OBSERVATION", 105, 121]]], ["This classical method has been shown to correct thrombocytopenia in patients infected with HIV [20] .", [["thrombocytopenia", "DISEASE", 48, 64], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 91, 94], ["thrombocytopenia", "PROBLEM", 48, 64], ["HIV", "PROBLEM", 91, 94], ["thrombocytopenia", "OBSERVATION", 48, 64]]], ["Therefore, it is speculated that the intravenous injection of human immunoglobulin, corticosteroids, and platelets may be effective in patients under certain circumstances.", [["intravenous", "ANATOMY", 37, 48], ["platelets", "ANATOMY", 105, 114], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 48], ["human", "ORGANISM", 62, 67], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 68, 82], ["corticosteroids", "SIMPLE_CHEMICAL", 84, 99], ["platelets", "CELL", 105, 114], ["patients", "ORGANISM", 135, 143], ["human immunoglobulin", "PROTEIN", 62, 82], ["platelets", "CELL_TYPE", 105, 114], ["human", "SPECIES", 62, 67], ["patients", "SPECIES", 135, 143], ["human", "SPECIES", 62, 67], ["the intravenous injection of human immunoglobulin", "TREATMENT", 33, 82], ["corticosteroids", "TREATMENT", 84, 99], ["platelets", "TREATMENT", 105, 114]]], ["In the treatment measures of Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) [21] , it is pointed out that for patients with excessive activation of inflammatory response, the recommended dose of glucocorticoid can be used in a short period of time.", [["COVID-19", "CHEMICAL", 66, 74], ["patients", "ORGANISM", 127, 135], ["glucocorticoid", "SIMPLE_CHEMICAL", 212, 226], ["patients", "SPECIES", 127, 135], ["Treatment Protocol", "TREATMENT", 43, 61], ["COVID", "TEST", 66, 71], ["inflammatory response", "PROBLEM", 165, 186], ["glucocorticoid", "TREATMENT", 212, 226], ["inflammatory", "OBSERVATION", 165, 177]]], ["This is consistent with the above studies to improve the thrombocytopenia.", [["thrombocytopenia", "DISEASE", 57, 73], ["the above studies", "TEST", 24, 41], ["the thrombocytopenia", "PROBLEM", 53, 73], ["consistent with", "UNCERTAINTY", 8, 23], ["thrombocytopenia", "OBSERVATION", 57, 73]]], ["Reverse transcriptase inhibitors are effective in the treatment of HIV-related thrombocytopenia.", [["thrombocytopenia", "DISEASE", 79, 95], ["HIV", "ORGANISM", 67, 70], ["HIV", "SPECIES", 67, 70], ["Reverse transcriptase inhibitors", "TREATMENT", 0, 32], ["HIV", "PROBLEM", 67, 70], ["thrombocytopenia", "PROBLEM", 79, 95], ["HIV", "OBSERVATION", 67, 70], ["thrombocytopenia", "OBSERVATION", 79, 95]]], ["For example, zidovudine increased platelet synthesis.", [["platelet", "ANATOMY", 34, 42], ["zidovudine", "CHEMICAL", 13, 23], ["zidovudine", "CHEMICAL", 13, 23], ["zidovudine", "SIMPLE_CHEMICAL", 13, 23], ["platelet", "CELL", 34, 42], ["zidovudine increased platelet synthesis", "TREATMENT", 13, 52], ["zidovudine", "OBSERVATION_MODIFIER", 13, 23], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["platelet synthesis", "OBSERVATION", 34, 52]]], ["In addition, drug stimulation of megakaryocyte synthesis can increase platelet synthesis.", [["megakaryocyte", "ANATOMY", 33, 46], ["platelet", "ANATOMY", 70, 78], ["megakaryocyte", "CELL", 33, 46], ["platelet", "CELL", 70, 78], ["drug stimulation of megakaryocyte synthesis", "TREATMENT", 13, 56], ["platelet synthesis", "TREATMENT", 70, 88], ["megakaryocyte synthesis", "OBSERVATION", 33, 56], ["platelet synthesis", "OBSERVATION", 70, 88]]], ["Evidence shows that the chemokine CXCR4 can be expressed in megakaryocytes.", [["megakaryocytes", "ANATOMY", 60, 74], ["CXCR4", "GENE_OR_GENE_PRODUCT", 34, 39], ["megakaryocytes", "CELL", 60, 74], ["chemokine", "PROTEIN", 24, 33], ["CXCR4", "PROTEIN", 34, 39], ["megakaryocytes", "CELL_TYPE", 60, 74], ["the chemokine CXCR4", "TEST", 20, 39], ["megakaryocytes", "PROBLEM", 60, 74], ["megakaryocytes", "OBSERVATION", 60, 74]]], ["Because SARS-CoV-2 and HIV are both RNA viruses, reverse transcriptase inhibitors and chemokine receptor antagonists may improve the disease course of COVID-19.", [["COVID-19", "CHEMICAL", 151, 159], ["SARS-CoV-2", "ORGANISM", 8, 18], ["HIV", "ORGANISM", 23, 26], ["reverse transcriptase", "PROTEIN", 49, 70], ["chemokine receptor", "PROTEIN", 86, 104], ["HIV", "SPECIES", 23, 26], ["SARS-CoV", "SPECIES", 8, 16], ["HIV", "SPECIES", 23, 26], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["HIV", "PROBLEM", 23, 26], ["both RNA viruses", "PROBLEM", 31, 47], ["reverse transcriptase inhibitors", "TREATMENT", 49, 81], ["chemokine receptor antagonists", "TREATMENT", 86, 116], ["COVID", "TEST", 151, 156], ["RNA viruses", "OBSERVATION", 36, 47]]], ["At the same time, it is suggested that Shenmai injection can be used to treat immunosuppression in the treatment of traditional Chinese medicine in Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) [21] .", [["Shenmai", "CHEMICAL", 39, 46], ["Shenmai", "SIMPLE_CHEMICAL", 39, 46], ["Shenmai injection", "TREATMENT", 39, 56], ["immunosuppression", "TREATMENT", 78, 95], ["traditional Chinese medicine", "TREATMENT", 116, 144], ["Treatment Protocol", "TREATMENT", 162, 180], ["COVID", "TEST", 185, 190]]], ["Shenmai injection has a scavenging effect on all kinds of pathological substances.", [["Shenmai", "CHEMICAL", 0, 7], ["Shenmai", "SIMPLE_CHEMICAL", 0, 7], ["Shenmai injection", "TREATMENT", 0, 17], ["pathological substances", "PROBLEM", 58, 81], ["scavenging effect", "OBSERVATION", 24, 41], ["pathological substances", "OBSERVATION", 58, 81]]], ["It can improve anticoagulation and thrombocytopenia in patients with COVID-19 effectively.", [["thrombocytopenia", "DISEASE", 35, 51], ["COVID-19", "CHEMICAL", 69, 77], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["anticoagulation", "TREATMENT", 15, 30], ["thrombocytopenia", "PROBLEM", 35, 51], ["COVID", "TEST", 69, 74], ["anticoagulation", "OBSERVATION", 15, 30], ["thrombocytopenia", "OBSERVATION", 35, 51]]], ["Additionally, the immunotherapy scheme of \"monoclonal antibody drug topirazumab + routine therapy\" is also included in the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) [21] as an valid option treating severe and critical COVID-19 cases.", [["topirazumab", "CHEMICAL", 68, 79], ["COVID-19", "CHEMICAL", 160, 168], ["topirazumab", "SIMPLE_CHEMICAL", 68, 79], ["the immunotherapy scheme", "TREATMENT", 14, 38], ["\"monoclonal antibody drug topirazumab", "TREATMENT", 42, 79], ["routine therapy", "TREATMENT", 82, 97], ["Treatment Protocol", "TREATMENT", 137, 155], ["COVID", "TEST", 160, 165], ["an valid option", "TREATMENT", 195, 210], ["critical COVID", "TEST", 231, 245]]], ["The monoclonal antibody against IL-6 receptor tocilizumab can effectively block COVID-19's inflammatory storm, thus improving the prognosis of the patients.SummaryThere are very few reports of the mechanisms of thrombocytopenia in patients with COVID-19, but thrombocytopenia is very common.", [["tocilizumab", "CHEMICAL", 46, 57], ["thrombocytopenia", "DISEASE", 211, 227], ["COVID-19", "CHEMICAL", 245, 253], ["thrombocytopenia", "DISEASE", 259, 275], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 32, 45], ["tocilizumab", "SIMPLE_CHEMICAL", 46, 57], ["patients", "ORGANISM", 147, 155], ["patients", "ORGANISM", 231, 239], ["monoclonal antibody", "PROTEIN", 4, 23], ["IL-6 receptor", "PROTEIN", 32, 45], ["patients", "SPECIES", 147, 155], ["patients", "SPECIES", 231, 239], ["The monoclonal antibody", "TREATMENT", 0, 23], ["IL-6 receptor tocilizumab", "TREATMENT", 32, 57], ["inflammatory storm", "PROBLEM", 91, 109], ["thrombocytopenia", "PROBLEM", 211, 227], ["COVID", "TEST", 245, 250], ["thrombocytopenia", "PROBLEM", 259, 275], ["inflammatory storm", "OBSERVATION", 91, 109], ["very", "OBSERVATION_MODIFIER", 173, 177], ["few", "OBSERVATION_MODIFIER", 178, 181], ["thrombocytopenia", "OBSERVATION", 211, 227], ["thrombocytopenia", "OBSERVATION", 259, 275]]], ["Through analogy, three mechanisms of thrombocytopenia are hypothesized in this review:1) Direct infection of bone marrow cells by the virus andinhibition of platelet synthesis.", [["bone marrow cells", "ANATOMY", 109, 126], ["platelet", "ANATOMY", 157, 165], ["thrombocytopenia", "DISEASE", 37, 53], ["infection", "DISEASE", 96, 105], ["bone marrow cells", "CELL", 109, 126], ["platelet", "CELL", 157, 165], ["bone marrow cells", "CELL_TYPE", 109, 126], ["thrombocytopenia", "PROBLEM", 37, 53], ["Direct infection of bone marrow cells", "PROBLEM", 89, 126], ["the virus", "PROBLEM", 130, 139], ["platelet synthesis", "PROBLEM", 157, 175], ["thrombocytopenia", "OBSERVATION", 37, 53], ["infection", "OBSERVATION", 96, 105], ["bone", "ANATOMY", 109, 113], ["marrow cells", "OBSERVATION", 114, 126], ["platelet synthesis", "OBSERVATION", 157, 175]]], ["Following virus infection, cytokine storm destroys bone marrow progenitor cells and leads to the decrease of platelet production.", [["bone marrow progenitor cells", "ANATOMY", 51, 79], ["platelet", "ANATOMY", 109, 117], ["infection", "DISEASE", 16, 25], ["bone marrow progenitor cells", "CELL", 51, 79], ["platelet", "CELL", 109, 117], ["cytokine", "PROTEIN", 27, 35], ["bone marrow progenitor cells", "CELL_TYPE", 51, 79], ["virus infection", "PROBLEM", 10, 25], ["cytokine storm destroys bone marrow progenitor cells", "TREATMENT", 27, 79], ["the decrease of platelet production", "PROBLEM", 93, 128], ["marrow progenitor cells", "OBSERVATION", 56, 79], ["decrease", "OBSERVATION_MODIFIER", 97, 105], ["platelet production", "OBSERVATION", 109, 128]]], ["Lung injury indirectly results in reduction of platelet synthesis.", [["Lung", "ANATOMY", 0, 4], ["platelet", "ANATOMY", 47, 55], ["Lung injury", "DISEASE", 0, 11], ["Lung", "ORGAN", 0, 4], ["platelet", "CELL", 47, 55], ["Lung injury", "PROBLEM", 0, 11], ["platelet synthesis", "PROBLEM", 47, 65], ["injury", "OBSERVATION", 5, 11], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["platelet synthesis", "OBSERVATION", 47, 65]]], ["2) Platelet destruction by the immune system.1) Direct infection of bone marrow cells by the virus and3) Platelet aggregation in the lungs, resulting in microthrombi and platelet consumption.1) Direct infection of bone marrow cells by the virus andFurther investigation of the mechanisms of thrombocytopenia can provide a valuable theoretical basis for timely clinical treatment and provide us with a more comprehensive understanding of this disease.Compliance with ethical standardsConflict of interest The authors declare there they have no conflict of interest.Compliance with ethical standardsEthical approval This article does not contain any studies with human participants performed by any of the authors.Compliance with ethical standardsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["Platelet", "ANATOMY", 3, 11], ["immune system", "ANATOMY", 31, 44], ["bone marrow cells", "ANATOMY", 68, 85], ["Platelet", "ANATOMY", 105, 113], ["lungs", "ANATOMY", 133, 138], ["microthrombi", "ANATOMY", 153, 165], ["platelet", "ANATOMY", 170, 178], ["bone marrow cells", "ANATOMY", 214, 231], ["infection", "DISEASE", 55, 64], ["Platelet aggregation", "DISEASE", 105, 125], ["infection", "DISEASE", 201, 210], ["thrombocytopenia", "DISEASE", 291, 307], ["Platelet", "CELL", 3, 11], ["bone marrow cells", "CELL", 68, 85], ["Platelet", "CELL", 105, 113], ["lungs", "ORGAN", 133, 138], ["platelet", "CELL", 170, 178], ["bone marrow cells", "CELL", 214, 231], ["human", "ORGANISM", 661, 666], ["bone marrow cells", "CELL_TYPE", 68, 85], ["bone marrow cells", "CELL_TYPE", 214, 231], ["human", "SPECIES", 661, 666], ["participants", "SPECIES", 667, 679], ["human", "SPECIES", 661, 666], ["Platelet destruction", "PROBLEM", 3, 23], ["Direct infection of bone marrow cells", "PROBLEM", 48, 85], ["Platelet aggregation in the lungs", "PROBLEM", 105, 138], ["microthrombi", "PROBLEM", 153, 165], ["platelet consumption", "TEST", 170, 190], ["Direct infection of bone marrow cells", "PROBLEM", 194, 231], ["the virus", "PROBLEM", 235, 244], ["Further investigation", "TEST", 248, 269], ["thrombocytopenia", "PROBLEM", 291, 307], ["timely clinical treatment", "TREATMENT", 353, 378], ["this disease", "PROBLEM", 437, 449], ["ethical standards", "TREATMENT", 466, 483], ["ethical standards", "TREATMENT", 580, 597], ["Ethical approval", "TREATMENT", 597, 613], ["ethical standards", "TREATMENT", 728, 745], ["Open Access", "TREATMENT", 745, 756], ["Platelet destruction", "OBSERVATION", 3, 23], ["immune system", "OBSERVATION", 31, 44], ["infection", "OBSERVATION", 55, 64], ["bone", "ANATOMY", 68, 72], ["marrow cells", "OBSERVATION", 73, 85], ["aggregation", "OBSERVATION", 114, 125], ["lungs", "ANATOMY", 133, 138], ["microthrombi", "OBSERVATION", 153, 165], ["platelet consumption", "OBSERVATION", 170, 190], ["infection", "OBSERVATION", 201, 210], ["bone", "ANATOMY", 214, 218], ["marrow cells", "OBSERVATION", 219, 231], ["thrombocytopenia", "OBSERVATION", 291, 307]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]], "93aab5344693c6df1630f5dcd54b16ad82d7966a": [["IntroductionFoot-and-mouth disease (FMD) is one of the most economically and socially devastating diseases affecting cloven-hoofed animals [1] .", [["IntroductionFoot-and-mouth disease", "DISEASE", 0, 34], ["FMD", "DISEASE", 36, 39], ["mouth", "ORGAN", 21, 26], ["IntroductionFoot-and-mouth", "SPECIES", 0, 26], ["FMD", "SPECIES", 36, 39], ["IntroductionFoot", "TEST", 0, 16], ["mouth disease", "PROBLEM", 21, 34], ["mouth", "ANATOMY", 21, 26], ["disease", "OBSERVATION", 27, 34]]], ["The infectious agent, foot-and-mouth disease virus (FMDV), is a member of the Aphthovirus genus of the Picornaviridae family, and contains single-stranded positive-sense RNA genomes of about 8,500 nucleotides [2] .", [["foot-and-mouth disease", "DISEASE", 22, 44], ["nucleotides", "CHEMICAL", 197, 208], ["foot-and-mouth disease virus", "ORGANISM", 22, 50], ["FMDV", "ORGANISM", 52, 56], ["Aphthovirus genus", "ORGANISM", 78, 95], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 103, 117], ["single-stranded positive-sense RNA genomes", "DNA", 139, 181], ["foot-and-mouth disease virus", "SPECIES", 22, 50], ["FMDV", "SPECIES", 52, 56], ["foot-and-mouth disease virus", "SPECIES", 22, 50], ["FMDV", "SPECIES", 52, 56], ["The infectious agent", "PROBLEM", 0, 20], ["mouth disease virus", "PROBLEM", 31, 50], ["infectious", "OBSERVATION", 4, 14], ["foot", "ANATOMY", 22, 26], ["mouth", "ANATOMY", 31, 36], ["disease", "OBSERVATION", 37, 44]]], ["As an antigenically variable virus, FMDV consists of seven serotypes (A, O, C, Asia 1, and South African Territories 1, 2, and 3) and a large number of subtypes.", [["FMDV", "ORGANISM", 36, 40], ["FMDV", "SPECIES", 36, 40], ["FMDV", "SPECIES", 36, 40], ["an antigenically variable virus", "PROBLEM", 3, 34], ["FMDV", "PROBLEM", 36, 40], ["seven serotypes", "PROBLEM", 53, 68], ["large", "OBSERVATION_MODIFIER", 136, 141], ["number", "OBSERVATION_MODIFIER", 142, 148]]], ["In general, slaughtering FMDV-infected/exposed or FMDV-susceptible animals, restricting animal movement, and, in some cases, vaccinating against FMDV and then slaughtering these animals are used as control measures for potential outbreaks in disease-free areas [3] .", [["FMDV-infected", "DISEASE", 25, 38], ["FMDV", "ORGANISM", 25, 29], ["FMDV", "ORGANISM", 50, 54], ["FMDV", "ORGANISM", 145, 149], ["FMDV", "SPECIES", 25, 29], ["FMDV", "SPECIES", 50, 54], ["FMDV", "SPECIES", 145, 149], ["FMDV", "SPECIES", 25, 29], ["FMDV", "SPECIES", 50, 54], ["FMDV", "SPECIES", 145, 149], ["infected", "PROBLEM", 30, 38], ["FMDV", "PROBLEM", 50, 54], ["susceptible animals", "PROBLEM", 55, 74], ["FMDV", "PROBLEM", 145, 149], ["potential outbreaks in disease-free areas", "PROBLEM", 219, 260]]], ["Although inactivated FMD vaccines have been available since the early 1900s and new novel vaccines are being continuously developed, they offer little or no cross-protection against various serotypes and subtypes of FMDV.", [["FMDV", "DISEASE", 216, 220], ["FMDV", "ORGANISM", 216, 220], ["FMDV", "SPECIES", 216, 220], ["FMD", "SPECIES", 21, 24], ["FMDV", "SPECIES", 216, 220], ["inactivated FMD vaccines", "TREATMENT", 9, 33], ["new novel vaccines", "TREATMENT", 80, 98], ["FMDV", "PROBLEM", 216, 220]]], ["In addition, these vaccines do not provide complete clinical protection until seven days post-vaccination.", [["these vaccines", "TREATMENT", 13, 27]]], ["Therefore, there is a need for developing effective and safe alternative antiviral strategies against FMDV [4] [5] [6] .IntroductionMizoribine, an imidazole nucleoside ( Figure 1A ) [7] , has been used as an immunosuppressive agent for the treatment of renal transplantation, autoimmune diseases, and steroid-resistant nephrotic syndrome in some countries owing to its antiproliferative activity against T and B lymphocytes [7] .", [["renal", "ANATOMY", 253, 258], ["T", "ANATOMY", 404, 405], ["B lymphocytes", "ANATOMY", 410, 423], ["Mizoribine", "CHEMICAL", 132, 142], ["imidazole nucleoside", "CHEMICAL", 147, 167], ["autoimmune diseases", "DISEASE", 276, 295], ["steroid", "CHEMICAL", 301, 308], ["nephrotic syndrome", "DISEASE", 319, 337], ["Mizoribine", "CHEMICAL", 132, 142], ["imidazole nucleoside", "CHEMICAL", 147, 167], ["steroid", "CHEMICAL", 301, 308], ["FMDV", "ORGANISM", 102, 106], ["[4] [5] [6]", "SIMPLE_CHEMICAL", 107, 118], ["Mizoribine", "SIMPLE_CHEMICAL", 132, 142], ["imidazole nucleoside", "SIMPLE_CHEMICAL", 147, 167], ["Figure 1A ) [7]", "SIMPLE_CHEMICAL", 170, 185], ["renal", "ORGAN", 253, 258], ["T", "CELL", 404, 405], ["B lymphocytes", "CELL", 410, 423], ["T and B lymphocytes", "CELL_TYPE", 404, 423], ["FMDV", "SPECIES", 102, 106], ["FMDV", "SPECIES", 102, 106], ["safe alternative antiviral strategies", "TREATMENT", 56, 93], ["IntroductionMizoribine", "TREATMENT", 120, 142], ["an imidazole nucleoside ( Figure 1A )", "TREATMENT", 144, 181], ["an immunosuppressive agent", "TREATMENT", 205, 231], ["the treatment", "TREATMENT", 236, 249], ["renal transplantation", "TREATMENT", 253, 274], ["autoimmune diseases", "PROBLEM", 276, 295], ["steroid", "TREATMENT", 301, 308], ["resistant nephrotic syndrome", "PROBLEM", 309, 337], ["renal", "ANATOMY", 253, 258], ["transplantation", "OBSERVATION", 259, 274], ["autoimmune diseases", "OBSERVATION", 276, 295], ["nephrotic syndrome", "OBSERVATION", 319, 337]]], ["This drug could be phosphorylated by adenosine kinase and converted to mizoribine 5 -monophosphate, replication of some DNA and RNA viruses, such as cytomegalovirus [9] , respiratory syncytial virus [10] , severe acute respiratory syndrome-associated coronavirus (SARS-CoV) [11] , bovine viral diarrhea virus (BVDV) [12] , vaccinia virus [13] , influenza virus types A and B, and herpesviruses, in combination with acyclovir [14, 15] .", [["adenosine", "CHEMICAL", 37, 46], ["mizoribine 5 -monophosphate", "CHEMICAL", 71, 98], ["respiratory syncytial virus", "DISEASE", 171, 198], ["acute respiratory syndrome-associated coronavirus", "DISEASE", 213, 262], ["SARS-CoV)", "DISEASE", 264, 273], ["bovine viral diarrhea virus", "DISEASE", 281, 308], ["vaccinia virus", "DISEASE", 323, 337], ["influenza virus", "DISEASE", 345, 360], ["herpesviruses", "DISEASE", 380, 393], ["acyclovir", "CHEMICAL", 415, 424], ["adenosine", "CHEMICAL", 37, 46], ["mizoribine 5 -monophosphate", "CHEMICAL", 71, 98], ["acyclovir", "CHEMICAL", 415, 424], ["adenosine", "SIMPLE_CHEMICAL", 37, 46], ["mizoribine 5 -monophosphate", "SIMPLE_CHEMICAL", 71, 98], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["cytomegalovirus [9] ,", "ORGANISM", 149, 170], ["respiratory syncytial virus", "ORGANISM", 171, 198], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 206, 262], ["SARS-CoV", "ORGANISM", 264, 272], ["bovine viral diarrhea virus", "ORGANISM", 281, 308], ["BVDV", "ORGANISM", 310, 314], ["vaccinia virus [13", "ORGANISM", 323, 341], ["influenza virus", "ORGANISM", 345, 360], ["B", "CANCER", 373, 374], ["herpesviruses", "ORGANISM", 380, 393], ["acyclovir", "SIMPLE_CHEMICAL", 415, 424], ["adenosine kinase", "PROTEIN", 37, 53], ["respiratory syncytial virus", "SPECIES", 171, 198], ["associated coronavirus", "SPECIES", 240, 262], ["bovine", "SPECIES", 281, 287], ["viral diarrhea virus", "SPECIES", 288, 308], ["BVDV", "SPECIES", 310, 314], ["vaccinia virus", "SPECIES", 323, 337], ["influenza virus", "SPECIES", 345, 360], ["respiratory syncytial virus", "SPECIES", 171, 198], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 206, 262], ["SARS-CoV", "SPECIES", 264, 272], ["bovine viral diarrhea virus", "SPECIES", 281, 308], ["BVDV", "SPECIES", 310, 314], ["vaccinia virus", "SPECIES", 323, 337], ["adenosine kinase", "TREATMENT", 37, 53], ["mizoribine", "TREATMENT", 71, 81], ["monophosphate", "TREATMENT", 85, 98], ["some DNA", "PROBLEM", 115, 123], ["RNA viruses", "PROBLEM", 128, 139], ["cytomegalovirus", "PROBLEM", 149, 164], ["respiratory syncytial virus", "PROBLEM", 171, 198], ["severe acute respiratory syndrome", "PROBLEM", 206, 239], ["associated coronavirus (SARS", "PROBLEM", 240, 268], ["bovine viral diarrhea virus (BVDV)", "PROBLEM", 281, 315], ["vaccinia virus", "PROBLEM", 323, 337], ["influenza virus types A and B", "PROBLEM", 345, 374], ["herpesviruses", "PROBLEM", 380, 393], ["acyclovir", "TREATMENT", 415, 424], ["RNA viruses", "OBSERVATION", 128, 139], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["acute", "OBSERVATION_MODIFIER", 213, 218], ["respiratory syndrome", "OBSERVATION", 219, 239]]], ["However, the antiviral activity of mizoribine against FMDV has not yet been investigated.", [["mizoribine", "CHEMICAL", 35, 45], ["mizoribine", "CHEMICAL", 35, 45], ["mizoribine", "SIMPLE_CHEMICAL", 35, 45], ["FMDV", "ORGANISM", 54, 58], ["FMDV", "SPECIES", 54, 58], ["FMDV", "SPECIES", 54, 58], ["mizoribine", "TREATMENT", 35, 45], ["FMDV", "PROBLEM", 54, 58]]], ["Hence, in this study, the antiviral effect of mizoribine against FMDV was evaluated in vitro using IBRS-2 cells and confirmed in vivo using suckling mice.", [["IBRS-2 cells", "ANATOMY", 99, 111], ["mizoribine", "CHEMICAL", 46, 56], ["mizoribine", "CHEMICAL", 46, 56], ["mizoribine", "SIMPLE_CHEMICAL", 46, 56], ["FMDV", "ORGANISM", 65, 69], ["IBRS-2 cells", "CELL", 99, 111], ["mice", "ORGANISM", 149, 153], ["IBRS-2 cells", "CELL_LINE", 99, 111], ["FMDV", "SPECIES", 65, 69], ["mice", "SPECIES", 149, 153], ["FMDV", "SPECIES", 65, 69], ["mice", "SPECIES", 149, 153], ["this study", "TEST", 10, 20], ["mizoribine", "TREATMENT", 46, 56], ["FMDV", "PROBLEM", 65, 69], ["IBRS", "TEST", 99, 103]]], ["Figure 1B illustrates the results of the MTS assay.", [["the MTS assay", "TEST", 37, 50]]], ["As is shown in Figure 1B , mizoribine presented little or no cytotoxicity to the cells.", [["cells", "ANATOMY", 81, 86], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "SIMPLE_CHEMICAL", 27, 37], ["cells", "CELL", 81, 86], ["mizoribine", "TREATMENT", 27, 37], ["cytotoxicity to the cells", "PROBLEM", 61, 86], ["no", "UNCERTAINTY", 58, 60]]], ["The cell viability was 95.14%, 100.74%, 100.19%, 95.71%, 97.22%, and 99.51% at mizoribine concentrations of 6, 12, 25, 50, 75, and 100 \u03bcM, respectively, and the 50% cytotoxic concentration (CC50) of mizoribine was estimated to be more than 100 \u03bcM on IBRS-2 cells.Antiviral Effect of Mizoribine on FMDV Replication in IBRS-2 CellsThe inhibitory effect of mizoribine on FMDV infection in IBRS-2 cells was calculated by measuring cell viability using the results of MTS assay.", [["cell", "ANATOMY", 4, 8], ["IBRS-2 cells", "ANATOMY", 250, 262], ["IBRS-2 Cells", "ANATOMY", 317, 329], ["IBRS-2 cells", "ANATOMY", 386, 398], ["cell", "ANATOMY", 427, 431], ["mizoribine", "CHEMICAL", 79, 89], ["mizoribine", "CHEMICAL", 199, 209], ["Mizoribine", "CHEMICAL", 283, 293], ["mizoribine", "CHEMICAL", 354, 364], ["infection", "DISEASE", 373, 382], ["mizoribine", "CHEMICAL", 199, 209], ["Mizoribine", "CHEMICAL", 283, 293], ["mizoribine", "CHEMICAL", 354, 364], ["cell", "CELL", 4, 8], ["mizoribine", "SIMPLE_CHEMICAL", 79, 89], ["mizoribine", "SIMPLE_CHEMICAL", 199, 209], ["IBRS-2 cells", "CELL", 250, 262], ["Mizoribine", "SIMPLE_CHEMICAL", 283, 293], ["FMDV", "ORGANISM", 297, 301], ["IBRS-2 Cells", "CELL", 317, 329], ["mizoribine", "SIMPLE_CHEMICAL", 354, 364], ["FMDV", "ORGANISM", 368, 372], ["IBRS-2 cells", "CELL", 386, 398], ["cell", "CELL", 427, 431], ["IBRS-2 cells", "CELL_LINE", 250, 262], ["IBRS-2 cells", "CELL_LINE", 386, 398], ["FMDV", "SPECIES", 297, 301], ["FMDV", "SPECIES", 368, 372], ["FMDV", "SPECIES", 297, 301], ["FMDV", "SPECIES", 368, 372], ["The cell viability", "TEST", 0, 18], ["mizoribine concentrations", "TEST", 79, 104], ["mizoribine", "TEST", 199, 209], ["IBRS", "TEST", 250, 254], ["Antiviral Effect", "TREATMENT", 263, 279], ["Mizoribine", "TREATMENT", 283, 293], ["FMDV Replication", "TREATMENT", 297, 313], ["IBRS", "TEST", 317, 321], ["mizoribine", "TREATMENT", 354, 364], ["FMDV infection", "PROBLEM", 368, 382], ["IBRS", "TEST", 386, 390], ["MTS assay", "TEST", 463, 472], ["cell viability", "OBSERVATION", 4, 18]]], ["As indicated in Figure 2A , the inhibition rates were approximately 63.01%, 82.03%, 90.89%, and 90.41% in cells treated with 25, 50, 75, and 100 \u03bcM mizoribine, respectively, whereas other lower mizoribine concentrations demonstrated limited or no inhibitory effect on FMDV.", [["cells", "ANATOMY", 106, 111], ["mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 194, 204], ["mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 194, 204], ["cells", "CELL", 106, 111], ["mizoribine", "SIMPLE_CHEMICAL", 148, 158], ["mizoribine", "SIMPLE_CHEMICAL", 194, 204], ["FMDV", "ORGANISM", 268, 272], ["FMDV", "SPECIES", 268, 272], ["FMDV", "SPECIES", 268, 272], ["the inhibition rates", "TEST", 28, 48], ["mizoribine", "TREATMENT", 148, 158], ["other lower mizoribine concentrations", "PROBLEM", 182, 219], ["inhibitory effect on FMDV", "PROBLEM", 247, 272]]], ["The IC50 and SI values were calculated to be 21.39 \u03bcM and 4.67, respectively.", [["The IC50 and SI values", "TEST", 0, 22]]], ["Interestingly, mizoribine also displayed activity against another FMDV strain, A/GD/MM/2013, with an IC50 of 6.57 \u03bcM and SI value of 15.20 ( Figure 2C ).", [["mizoribine", "CHEMICAL", 15, 25], ["mizoribine", "CHEMICAL", 15, 25], ["mizoribine", "SIMPLE_CHEMICAL", 15, 25], ["FMDV", "ORGANISM", 66, 70], ["FMDV", "SPECIES", 66, 70], ["FMDV", "SPECIES", 66, 70], ["A/GD/MM/2013", "SPECIES", 79, 91], ["mizoribine", "TREATMENT", 15, 25], ["another FMDV strain", "PROBLEM", 58, 77], ["an IC50", "TEST", 98, 105], ["SI value", "TEST", 121, 129]]], ["These data supported the potential broad-spectrum activity of mizoribine against RNA viruses.", [["mizoribine", "CHEMICAL", 62, 72], ["mizoribine", "CHEMICAL", 62, 72], ["mizoribine", "SIMPLE_CHEMICAL", 62, 72], ["mizoribine", "TREATMENT", 62, 72], ["RNA viruses", "PROBLEM", 81, 92]]], ["Figure 1B illustrates the results of the MTS assay.", [["the MTS assay", "TEST", 37, 50]]], ["As is shown in Figure 1B , mizoribine presented little or no cytotoxicity to the cells.", [["cells", "ANATOMY", 81, 86], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "SIMPLE_CHEMICAL", 27, 37], ["cells", "CELL", 81, 86], ["mizoribine", "TREATMENT", 27, 37], ["cytotoxicity to the cells", "PROBLEM", 61, 86], ["no", "UNCERTAINTY", 58, 60]]], ["The cell viability was 95.14%, 100.74%, 100.19%, 95.71%, 97.22%, and 99.51% at mizoribine concentrations of 6, 12, 25, 50, 75, and 100 \u00b5M, respectively, and the 50% cytotoxic concentration (CC 50 ) of mizoribine was estimated to be more than 100 \u00b5M on IBRS-2 cells.Antiviral Effect of Mizoribine on FMDV Replication in IBRS-2 CellsThe inhibitory effect of mizoribine on FMDV infection in IBRS-2 cells was calculated by measuring cell viability using the results of MTS assay.", [["cell", "ANATOMY", 4, 8], ["IBRS-2 cells", "ANATOMY", 252, 264], ["IBRS-2 Cells", "ANATOMY", 319, 331], ["IBRS-2 cells", "ANATOMY", 388, 400], ["cell", "ANATOMY", 429, 433], ["mizoribine", "CHEMICAL", 79, 89], ["CC", "CHEMICAL", 190, 192], ["mizoribine", "CHEMICAL", 201, 211], ["Mizoribine", "CHEMICAL", 285, 295], ["mizoribine", "CHEMICAL", 356, 366], ["infection", "DISEASE", 375, 384], ["mizoribine", "CHEMICAL", 201, 211], ["Mizoribine", "CHEMICAL", 285, 295], ["mizoribine", "CHEMICAL", 356, 366], ["cell", "CELL", 4, 8], ["mizoribine", "SIMPLE_CHEMICAL", 79, 89], ["mizoribine", "SIMPLE_CHEMICAL", 201, 211], ["IBRS-2 cells", "CELL", 252, 264], ["Mizoribine", "SIMPLE_CHEMICAL", 285, 295], ["FMDV", "ORGANISM", 299, 303], ["IBRS-2 Cells", "CELL", 319, 331], ["mizoribine", "SIMPLE_CHEMICAL", 356, 366], ["FMDV", "ORGANISM", 370, 374], ["IBRS-2 cells", "CELL", 388, 400], ["cell", "CELL", 429, 433], ["IBRS-2 cells", "CELL_LINE", 252, 264], ["IBRS-2 cells", "CELL_LINE", 388, 400], ["FMDV", "SPECIES", 299, 303], ["FMDV", "SPECIES", 370, 374], ["FMDV", "SPECIES", 299, 303], ["FMDV", "SPECIES", 370, 374], ["The cell viability", "TEST", 0, 18], ["mizoribine concentrations", "TEST", 79, 104], ["CC", "TEST", 190, 192], ["mizoribine", "TEST", 201, 211], ["IBRS", "TEST", 252, 256], ["Antiviral Effect", "TREATMENT", 265, 281], ["Mizoribine", "TREATMENT", 285, 295], ["FMDV Replication", "TREATMENT", 299, 315], ["IBRS", "TEST", 319, 323], ["mizoribine", "TREATMENT", 356, 366], ["FMDV infection", "PROBLEM", 370, 384], ["IBRS", "TEST", 388, 392], ["MTS assay", "TEST", 465, 474], ["cell viability", "OBSERVATION", 4, 18]]], ["As indicated in Figure 2A , the inhibition rates were approximately 63.01%, 82.03%, 90.89%, and 90.41% in cells treated with 25, 50, 75, and 100 \u00b5M mizoribine, respectively, whereas other lower mizoribine concentrations demonstrated limited or no inhibitory effect on FMDV.", [["cells", "ANATOMY", 106, 111], ["mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 194, 204], ["mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 194, 204], ["cells", "CELL", 106, 111], ["mizoribine", "SIMPLE_CHEMICAL", 148, 158], ["mizoribine", "SIMPLE_CHEMICAL", 194, 204], ["FMDV", "ORGANISM", 268, 272], ["FMDV", "SPECIES", 268, 272], ["FMDV", "SPECIES", 268, 272], ["the inhibition rates", "TEST", 28, 48], ["mizoribine", "TREATMENT", 148, 158], ["other lower mizoribine concentrations", "PROBLEM", 182, 219], ["inhibitory effect on FMDV", "PROBLEM", 247, 272]]], ["The IC 50 and SI values were calculated to be 21.39 \u00b5M and 4.67, respectively.", [["The IC", "TEST", 0, 6]]], ["Interestingly, mizoribine also displayed activity against another FMDV strain, A/GD/MM/2013, with an IC 50 of 6.57 \u00b5M and SI value of 15.20 ( Figure 2C ).", [["mizoribine", "CHEMICAL", 15, 25], ["mizoribine", "CHEMICAL", 15, 25], ["mizoribine", "SIMPLE_CHEMICAL", 15, 25], ["FMDV", "ORGANISM", 66, 70], ["FMDV", "SPECIES", 66, 70], ["FMDV", "SPECIES", 66, 70], ["A/GD/MM/2013", "SPECIES", 79, 91], ["mizoribine", "TREATMENT", 15, 25], ["another FMDV strain", "PROBLEM", 58, 77], ["an IC", "TEST", 98, 103], ["SI value", "TEST", 122, 130]]], ["These data supported the potential broad-spectrum activity of mizoribine against RNA viruses.Antiviral Effect of Mizoribine on FMDV Replication in IBRS-2 CellsThe transcription of FMDV mRNA was significantly reduced with 25, 50, 75, and 100 \u00b5M mizoribine treatments relative to the DMSO control group ( Figure 2B ).", [["IBRS-2 Cells", "ANATOMY", 147, 159], ["mizoribine", "CHEMICAL", 62, 72], ["Mizoribine", "CHEMICAL", 113, 123], ["mizoribine", "CHEMICAL", 244, 254], ["DMSO", "CHEMICAL", 282, 286], ["mizoribine", "CHEMICAL", 62, 72], ["Mizoribine", "CHEMICAL", 113, 123], ["mizoribine", "CHEMICAL", 244, 254], ["DMSO", "CHEMICAL", 282, 286], ["mizoribine", "SIMPLE_CHEMICAL", 62, 72], ["Mizoribine", "SIMPLE_CHEMICAL", 113, 123], ["FMDV", "ORGANISM", 127, 131], ["IBRS-2 Cells", "CELL", 147, 159], ["FMDV", "ORGANISM", 180, 184], ["mizoribine", "SIMPLE_CHEMICAL", 244, 254], ["FMDV mRNA", "RNA", 180, 189], ["FMDV", "SPECIES", 127, 131], ["FMDV", "SPECIES", 180, 184], ["FMDV", "SPECIES", 127, 131], ["FMDV", "SPECIES", 180, 184], ["mizoribine", "TREATMENT", 62, 72], ["RNA viruses", "PROBLEM", 81, 92], ["Antiviral Effect", "TREATMENT", 93, 109], ["Mizoribine", "TREATMENT", 113, 123], ["FMDV Replication", "TREATMENT", 127, 143], ["IBRS", "TEST", 147, 151], ["The transcription of FMDV mRNA", "TEST", 159, 189], ["100 \u00b5M mizoribine treatments", "TREATMENT", 237, 265], ["the DMSO control", "TREATMENT", 278, 294]]], ["Consistent with mRNA expression, immunofluorescence assay (IFA) revealed that mizoribine inhibited the expression of FMDV protein in a dose-dependent manner ( Figure 3 ).", [["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "SIMPLE_CHEMICAL", 78, 88], ["FMDV", "ORGANISM", 117, 121], ["FMDV protein", "PROTEIN", 117, 129], ["FMDV", "SPECIES", 117, 121], ["FMDV", "SPECIES", 117, 121], ["mRNA expression", "TEST", 16, 31], ["immunofluorescence assay", "TEST", 33, 57], ["IFA", "TEST", 59, 62], ["mizoribine", "TREATMENT", 78, 88], ["FMDV protein", "PROBLEM", 117, 129]]], ["The concentration of 75 \u00b5M, which showed more protection against CPE than other concentration, was chosen for the further study.", [["CPE", "CHEMICAL", 65, 68], ["CPE", "PROBLEM", 65, 68], ["the further study", "TEST", 110, 127]]], ["The transcription of FMDV mRNA was significantly reduced with 25, 50, 75, and 100 \u03bcM mizoribine treatments relative to the DMSO control group ( Figure 2B ).", [["mizoribine", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 123, 127], ["mizoribine", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 123, 127], ["FMDV", "ORGANISM", 21, 25], ["mizoribine", "SIMPLE_CHEMICAL", 85, 95], ["FMDV mRNA", "RNA", 21, 30], ["FMDV", "SPECIES", 21, 25], ["FMDV", "SPECIES", 21, 25], ["The transcription of FMDV mRNA", "TEST", 0, 30], ["100 \u03bcM mizoribine treatments", "TREATMENT", 78, 106], ["the DMSO control", "TREATMENT", 119, 135]]], ["Consistent with mRNA expression, immunofluorescence assay (IFA) revealed that mizoribine inhibited the expression of FMDV protein in a dose-dependent manner ( Figure 3 ).", [["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "SIMPLE_CHEMICAL", 78, 88], ["FMDV", "ORGANISM", 117, 121], ["FMDV protein", "PROTEIN", 117, 129], ["FMDV", "SPECIES", 117, 121], ["FMDV", "SPECIES", 117, 121], ["mRNA expression", "TEST", 16, 31], ["immunofluorescence assay", "TEST", 33, 57], ["IFA", "TEST", 59, 62], ["mizoribine", "TREATMENT", 78, 88], ["FMDV protein", "PROBLEM", 117, 129]]], ["The concentration of 75 \u03bcM, which showed more protection against CPE than other concentration, was chosen for the further study.Antiviral Effect of Mizoribine on FMDV Replication in IBRS-2 CellsSubsequently, the antiviral efficacy of mizoribine was further evaluated at various intervals post-FMDV infection, we found that the viral 2B mRNA and protein expressions were continuously inhibited at different time points (0, 2, 4, and 8 h) after treatment with 75 \u03bcM mizoribine; however, no significant differences were observed between 16 h post-infection (hpi) and the control group ( Figure 4 ).", [["CPE", "CHEMICAL", 65, 68], ["Mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 234, 244], ["FMDV infection", "DISEASE", 293, 307], ["mizoribine", "CHEMICAL", 464, 474], ["infection", "DISEASE", 544, 553], ["Mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 234, 244], ["mizoribine", "CHEMICAL", 464, 474], ["Mizoribine", "SIMPLE_CHEMICAL", 148, 158], ["FMDV", "ORGANISM", 162, 166], ["IBRS-2 CellsSubsequently", "CELL", 182, 206], ["mizoribine", "SIMPLE_CHEMICAL", 234, 244], ["viral 2B", "GENE_OR_GENE_PRODUCT", 327, 335], ["mizoribine", "SIMPLE_CHEMICAL", 464, 474], ["viral 2B mRNA", "RNA", 327, 340], ["FMDV", "SPECIES", 162, 166], ["FMDV", "SPECIES", 293, 297], ["FMDV", "SPECIES", 162, 166], ["FMDV", "SPECIES", 293, 297], ["CPE", "PROBLEM", 65, 68], ["the further study", "TEST", 110, 127], ["Antiviral Effect", "TREATMENT", 128, 144], ["Mizoribine", "TREATMENT", 148, 158], ["FMDV Replication", "TREATMENT", 162, 178], ["IBRS", "TEST", 182, 186], ["mizoribine", "TREATMENT", 234, 244], ["FMDV infection", "PROBLEM", 293, 307], ["the viral 2B mRNA", "TEST", 323, 340], ["protein expressions", "TEST", 345, 364], ["treatment", "TREATMENT", 443, 452], ["75 \u03bcM mizoribine", "TREATMENT", 458, 474], ["significant differences", "PROBLEM", 488, 511], ["infection", "PROBLEM", 544, 553], ["Mizoribine", "OBSERVATION_MODIFIER", 148, 158], ["FMDV infection", "OBSERVATION", 293, 307], ["viral 2B", "OBSERVATION", 327, 335], ["infection", "OBSERVATION", 544, 553]]], ["Taken together, these results suggested that mizoribine exhibited potent antiviral activity against FMDV in IBRS-2 cells at the early stages of viral infection.", [["IBRS-2 cells", "ANATOMY", 108, 120], ["mizoribine", "CHEMICAL", 45, 55], ["viral infection", "DISEASE", 144, 159], ["mizoribine", "CHEMICAL", 45, 55], ["mizoribine", "SIMPLE_CHEMICAL", 45, 55], ["FMDV", "ORGANISM", 100, 104], ["IBRS-2 cells", "CELL", 108, 120], ["IBRS-2 cells", "CELL_LINE", 108, 120], ["FMDV", "SPECIES", 100, 104], ["FMDV", "SPECIES", 100, 104], ["mizoribine", "TREATMENT", 45, 55], ["FMDV", "PROBLEM", 100, 104], ["viral infection", "PROBLEM", 144, 159], ["antiviral activity", "OBSERVATION", 73, 91], ["early stages", "OBSERVATION_MODIFIER", 128, 140], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159]]], ["The supernatants were used for viral RNA quantification using qPCR.", [["supernatants", "ANATOMY", 4, 16], ["viral RNA", "RNA", 31, 40], ["The supernatants", "TREATMENT", 0, 16], ["viral RNA quantification", "TEST", 31, 55], ["qPCR", "TEST", 62, 66]]], ["The expression values relative to that of \u03b2-actin were calculated using the 2 \u2212\u2206\u2206Ct method.", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 42, 49], ["\u03b2-actin", "PROTEIN", 42, 49], ["The expression values", "PROBLEM", 0, 21], ["the 2 \u2212\u2206\u2206Ct method", "TREATMENT", 72, 90]]], ["CPE, cytopathic effect.", [["CPE", "PROBLEM", 0, 3], ["cytopathic effect", "PROBLEM", 5, 22], ["cytopathic effect", "OBSERVATION", 5, 22]]], ["Statistically significant differences are indicated by asterisks (* p < 0.05, *** p < 0.001).", [["asterisks", "TEST", 55, 64]]], ["The transcription of FMDV mRNA was significantly reduced with 25, 50, 75, and 100 \u03bcM mizoribine treatments relative to the DMSO control group ( Figure 2B ).", [["mizoribine", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 123, 127], ["mizoribine", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 123, 127], ["FMDV", "ORGANISM", 21, 25], ["mizoribine", "SIMPLE_CHEMICAL", 85, 95], ["FMDV mRNA", "RNA", 21, 30], ["FMDV", "SPECIES", 21, 25], ["FMDV", "SPECIES", 21, 25], ["The transcription of FMDV mRNA", "TEST", 0, 30], ["100 \u03bcM mizoribine treatments", "TREATMENT", 78, 106], ["the DMSO control", "TREATMENT", 119, 135]]], ["Consistent with mRNA expression, immunofluorescence assay (IFA) revealed that mizoribine inhibited the expression of FMDV protein in a dose-dependent manner ( Figure 3 ).", [["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "CHEMICAL", 78, 88], ["mizoribine", "SIMPLE_CHEMICAL", 78, 88], ["FMDV", "ORGANISM", 117, 121], ["FMDV protein", "PROTEIN", 117, 129], ["FMDV", "SPECIES", 117, 121], ["FMDV", "SPECIES", 117, 121], ["mRNA expression", "TEST", 16, 31], ["immunofluorescence assay", "TEST", 33, 57], ["IFA", "TEST", 59, 62], ["mizoribine", "TREATMENT", 78, 88], ["FMDV protein", "PROBLEM", 117, 129]]], ["The concentration of 75 \u03bcM, which showed more protection against CPE than other concentration, was chosen for the further study.Antiviral Effect of Mizoribine on FMDV Replication in IBRS-2 CellsSubsequently, the antiviral efficacy of mizoribine was further evaluated at various intervals post-FMDV infection, we found that the viral 2B mRNA and protein expressions were continuously inhibited at different time points (0, 2, 4, and 8 h) after treatment with 75 \u03bcM mizoribine; however, no significant differences were observed between 16 h post-infection (hpi) and the control group ( Figure 4 ).", [["CPE", "CHEMICAL", 65, 68], ["Mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 234, 244], ["FMDV infection", "DISEASE", 293, 307], ["mizoribine", "CHEMICAL", 464, 474], ["infection", "DISEASE", 544, 553], ["Mizoribine", "CHEMICAL", 148, 158], ["mizoribine", "CHEMICAL", 234, 244], ["mizoribine", "CHEMICAL", 464, 474], ["Mizoribine", "SIMPLE_CHEMICAL", 148, 158], ["FMDV", "ORGANISM", 162, 166], ["IBRS-2 CellsSubsequently", "CELL", 182, 206], ["mizoribine", "SIMPLE_CHEMICAL", 234, 244], ["viral 2B", "GENE_OR_GENE_PRODUCT", 327, 335], ["mizoribine", "SIMPLE_CHEMICAL", 464, 474], ["viral 2B mRNA", "RNA", 327, 340], ["FMDV", "SPECIES", 162, 166], ["FMDV", "SPECIES", 293, 297], ["FMDV", "SPECIES", 162, 166], ["FMDV", "SPECIES", 293, 297], ["CPE", "PROBLEM", 65, 68], ["the further study", "TEST", 110, 127], ["Antiviral Effect", "TREATMENT", 128, 144], ["Mizoribine", "TREATMENT", 148, 158], ["FMDV Replication", "TREATMENT", 162, 178], ["IBRS", "TEST", 182, 186], ["mizoribine", "TREATMENT", 234, 244], ["FMDV infection", "PROBLEM", 293, 307], ["the viral 2B mRNA", "TEST", 323, 340], ["protein expressions", "TEST", 345, 364], ["treatment", "TREATMENT", 443, 452], ["75 \u03bcM mizoribine", "TREATMENT", 458, 474], ["significant differences", "PROBLEM", 488, 511], ["infection", "PROBLEM", 544, 553], ["Mizoribine", "OBSERVATION_MODIFIER", 148, 158], ["FMDV infection", "OBSERVATION", 293, 307], ["viral 2B", "OBSERVATION", 327, 335], ["infection", "OBSERVATION", 544, 553]]], ["Taken together, these results suggested that mizoribine exhibited potent antiviral activity against FMDV in IBRS-2 cells at the early stages of viral infection.", [["IBRS-2 cells", "ANATOMY", 108, 120], ["mizoribine", "CHEMICAL", 45, 55], ["viral infection", "DISEASE", 144, 159], ["mizoribine", "CHEMICAL", 45, 55], ["mizoribine", "SIMPLE_CHEMICAL", 45, 55], ["FMDV", "ORGANISM", 100, 104], ["IBRS-2 cells", "CELL", 108, 120], ["IBRS-2 cells", "CELL_LINE", 108, 120], ["FMDV", "SPECIES", 100, 104], ["FMDV", "SPECIES", 100, 104], ["mizoribine", "TREATMENT", 45, 55], ["FMDV", "PROBLEM", 100, 104], ["viral infection", "PROBLEM", 144, 159], ["antiviral activity", "OBSERVATION", 73, 91], ["early stages", "OBSERVATION_MODIFIER", 128, 140], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159]]], ["Subsequently, the antiviral efficacy of mizoribine was further evaluated at various intervals post-FMDV infection, we found that the viral 2B mRNA and protein expressions were continuously inhibited at different time points (0, 2, 4, and 8 h) after treatment with 75 \u00b5M mizoribine; however, no significant differences were observed between 16 h post-infection (hpi) and the control group ( Figure 4 ).", [["mizoribine", "CHEMICAL", 40, 50], ["FMDV infection", "DISEASE", 99, 113], ["mizoribine", "CHEMICAL", 270, 280], ["infection", "DISEASE", 350, 359], ["mizoribine", "CHEMICAL", 40, 50], ["mizoribine", "CHEMICAL", 270, 280], ["mizoribine", "SIMPLE_CHEMICAL", 40, 50], ["viral 2B", "GENE_OR_GENE_PRODUCT", 133, 141], ["mizoribine", "SIMPLE_CHEMICAL", 270, 280], ["viral 2B mRNA", "RNA", 133, 146], ["FMDV", "SPECIES", 99, 103], ["FMDV", "SPECIES", 99, 103], ["mizoribine", "TREATMENT", 40, 50], ["FMDV infection", "PROBLEM", 99, 113], ["the viral 2B mRNA", "TEST", 129, 146], ["protein expressions", "TEST", 151, 170], ["treatment", "TREATMENT", 249, 258], ["75 \u00b5M mizoribine", "TREATMENT", 264, 280], ["significant differences", "PROBLEM", 294, 317], ["infection", "PROBLEM", 350, 359], ["FMDV infection", "OBSERVATION", 99, 113], ["viral 2B", "OBSERVATION", 133, 141], ["infection", "OBSERVATION", 350, 359]]], ["Taken together, these results suggested that mizoribine exhibited potent antiviral activity against FMDV in IBRS-2 cells at the early stages of viral infection.", [["IBRS-2 cells", "ANATOMY", 108, 120], ["mizoribine", "CHEMICAL", 45, 55], ["viral infection", "DISEASE", 144, 159], ["mizoribine", "CHEMICAL", 45, 55], ["mizoribine", "SIMPLE_CHEMICAL", 45, 55], ["FMDV", "ORGANISM", 100, 104], ["IBRS-2 cells", "CELL", 108, 120], ["IBRS-2 cells", "CELL_LINE", 108, 120], ["FMDV", "SPECIES", 100, 104], ["FMDV", "SPECIES", 100, 104], ["mizoribine", "TREATMENT", 45, 55], ["FMDV", "PROBLEM", 100, 104], ["viral infection", "PROBLEM", 144, 159], ["antiviral activity", "OBSERVATION", 73, 91], ["early stages", "OBSERVATION_MODIFIER", 128, 140], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159]]], ["''VC'' represents those cells treated with 1% DMSO without mizoribine.", [["cells", "ANATOMY", 24, 29], ["DMSO", "CHEMICAL", 46, 50], ["mizoribine", "CHEMICAL", 59, 69], ["DMSO", "CHEMICAL", 46, 50], ["mizoribine", "CHEMICAL", 59, 69], ["cells", "CELL", 24, 29], ["DMSO", "SIMPLE_CHEMICAL", 46, 50], ["mizoribine", "SIMPLE_CHEMICAL", 59, 69], ["those cells", "PROBLEM", 18, 29], ["1% DMSO", "TREATMENT", 43, 50], ["mizoribine", "TREATMENT", 59, 69]]], ["Values represent the mean \u00b1 standard deviation for three independent experiments.", [["Values", "TEST", 0, 6], ["standard deviation", "OBSERVATION", 28, 46]]], ["The asterisks indicate significant differences between mock-treated and drug-treated cells (** p < 0.01).Effect of Mizoribine on Purine Synthesis in FMDVInosine-5\u2032-monophosphate dehydrogenase (IMPDH) is required for de novo purine nucleotide synthesis and its inhibition can lead to depletion of intracellular GTP pools.", [["cells", "ANATOMY", 85, 90], ["intracellular", "ANATOMY", 296, 309], ["Mizoribine", "CHEMICAL", 115, 125], ["Purine", "CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate", "CHEMICAL", 149, 177], ["IMPDH", "CHEMICAL", 193, 198], ["purine nucleotide", "CHEMICAL", 224, 241], ["GTP", "CHEMICAL", 310, 313], ["Mizoribine", "CHEMICAL", 115, 125], ["Purine", "CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate", "CHEMICAL", 149, 177], ["purine nucleotide", "CHEMICAL", 224, 241], ["GTP", "CHEMICAL", 310, 313], ["cells", "CELL", 85, 90], ["Mizoribine", "SIMPLE_CHEMICAL", 115, 125], ["Purine", "SIMPLE_CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 149, 191], ["IMPDH", "GENE_OR_GENE_PRODUCT", 193, 198], ["purine nucleotide", "SIMPLE_CHEMICAL", 224, 241], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 296, 309], ["GTP", "SIMPLE_CHEMICAL", 310, 313], ["drug-treated cells", "CELL_LINE", 72, 90], ["FMDVInosine-5\u2032-monophosphate dehydrogenase", "PROTEIN", 149, 191], ["IMPDH", "PROTEIN", 193, 198], ["significant differences between mock-treated and drug-treated cells", "PROBLEM", 23, 90], ["Mizoribine", "TREATMENT", 115, 125], ["Purine Synthesis", "TREATMENT", 129, 145], ["FMDVInosine", "TEST", 149, 160], ["monophosphate dehydrogenase (IMPDH)", "TREATMENT", 164, 199], ["de novo purine nucleotide synthesis", "TREATMENT", 216, 251], ["intracellular GTP pools", "PROBLEM", 296, 319], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["intracellular GTP pools", "OBSERVATION", 296, 319]]], ["To investigate the effect of mizoribine on purine synthesis in FMDV, serially diluted guanosine was added to the infected cells treated with mizoribine.", [["cells", "ANATOMY", 122, 127], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "SIMPLE_CHEMICAL", 29, 39], ["purine", "SIMPLE_CHEMICAL", 43, 49], ["FMDV", "ORGANISM", 63, 67], ["guanosine", "SIMPLE_CHEMICAL", 86, 95], ["cells", "CELL", 122, 127], ["mizoribine", "SIMPLE_CHEMICAL", 141, 151], ["infected cells", "CELL_TYPE", 113, 127], ["FMDV", "SPECIES", 63, 67], ["FMDV", "SPECIES", 63, 67], ["mizoribine", "TREATMENT", 29, 39], ["purine synthesis", "TREATMENT", 43, 59], ["FMDV", "TREATMENT", 63, 67], ["serially diluted guanosine", "TREATMENT", 69, 95], ["the infected cells", "PROBLEM", 109, 127], ["mizoribine", "TREATMENT", 141, 151], ["infected cells", "OBSERVATION", 113, 127]]], ["While guanosine had no effect on mizoribine, it significantly attenuated the anti-FMDV effect of mizoribine in a dose-dependent manner ( Figure 5 ).", [["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "SIMPLE_CHEMICAL", 6, 15], ["mizoribine", "SIMPLE_CHEMICAL", 33, 43], ["mizoribine", "SIMPLE_CHEMICAL", 97, 107], ["guanosine", "TREATMENT", 6, 15], ["mizoribine", "TREATMENT", 33, 43], ["mizoribine", "TREATMENT", 97, 107]]], ["These data indicated that mizoribine activity against FMDV involved inhibition of IMPDH-dependent purine synthesis.Effect of Mizoribine on Purine Synthesis in FMDVInosine-5 -monophosphate dehydrogenase (IMPDH) is required for de novo purine nucleotide synthesis and its inhibition can lead to depletion of intracellular GTP pools.", [["intracellular", "ANATOMY", 306, 319], ["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["Mizoribine", "CHEMICAL", 125, 135], ["Purine", "CHEMICAL", 139, 145], ["FMDVInosine-5 -monophosphate", "CHEMICAL", 159, 187], ["IMPDH", "CHEMICAL", 203, 208], ["purine nucleotide", "CHEMICAL", 234, 251], ["GTP", "CHEMICAL", 320, 323], ["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["Mizoribine", "CHEMICAL", 125, 135], ["Purine", "CHEMICAL", 139, 145], ["FMDVInosine-5 -monophosphate", "CHEMICAL", 159, 187], ["purine nucleotide", "CHEMICAL", 234, 251], ["GTP", "CHEMICAL", 320, 323], ["mizoribine", "SIMPLE_CHEMICAL", 26, 36], ["FMDV", "ORGANISM", 54, 58], ["IMPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["purine", "SIMPLE_CHEMICAL", 98, 104], ["Mizoribine", "SIMPLE_CHEMICAL", 125, 135], ["Purine", "SIMPLE_CHEMICAL", 139, 145], ["FMDVInosine-5 -monophosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 159, 201], ["IMPDH", "GENE_OR_GENE_PRODUCT", 203, 208], ["purine nucleotide", "SIMPLE_CHEMICAL", 234, 251], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 306, 319], ["GTP", "SIMPLE_CHEMICAL", 320, 323], ["IMPDH", "PROTEIN", 82, 87], ["FMDVInosine-5 -monophosphate dehydrogenase", "PROTEIN", 159, 201], ["IMPDH", "PROTEIN", 203, 208], ["FMDV", "SPECIES", 54, 58], ["FMDV", "SPECIES", 54, 58], ["These data", "TEST", 0, 10], ["mizoribine activity", "TREATMENT", 26, 45], ["FMDV", "PROBLEM", 54, 58], ["IMPDH", "PROBLEM", 82, 87], ["dependent purine synthesis", "PROBLEM", 88, 114], ["Mizoribine", "TREATMENT", 125, 135], ["Purine Synthesis", "TREATMENT", 139, 155], ["FMDVInosine", "TEST", 159, 170], ["monophosphate dehydrogenase (IMPDH)", "TREATMENT", 174, 209], ["de novo purine nucleotide synthesis", "TREATMENT", 226, 261], ["intracellular GTP pools", "PROBLEM", 306, 329], ["purine synthesis", "OBSERVATION", 98, 114], ["intracellular GTP pools", "OBSERVATION", 306, 329]]], ["To investigate the effect of mizoribine on purine synthesis in FMDV, serially diluted guanosine was added to the infected cells treated with mizoribine.", [["cells", "ANATOMY", 122, 127], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "SIMPLE_CHEMICAL", 29, 39], ["purine", "SIMPLE_CHEMICAL", 43, 49], ["FMDV", "ORGANISM", 63, 67], ["guanosine", "SIMPLE_CHEMICAL", 86, 95], ["cells", "CELL", 122, 127], ["mizoribine", "SIMPLE_CHEMICAL", 141, 151], ["infected cells", "CELL_TYPE", 113, 127], ["FMDV", "SPECIES", 63, 67], ["FMDV", "SPECIES", 63, 67], ["mizoribine", "TREATMENT", 29, 39], ["purine synthesis", "TREATMENT", 43, 59], ["FMDV", "TREATMENT", 63, 67], ["serially diluted guanosine", "TREATMENT", 69, 95], ["the infected cells", "PROBLEM", 109, 127], ["mizoribine", "TREATMENT", 141, 151], ["infected cells", "OBSERVATION", 113, 127]]], ["While guanosine had no effect on mizoribine, it significantly attenuated the anti-FMDV effect of mizoribine in a dose-dependent manner ( Figure 5 ).", [["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "SIMPLE_CHEMICAL", 6, 15], ["mizoribine", "SIMPLE_CHEMICAL", 33, 43], ["mizoribine", "SIMPLE_CHEMICAL", 97, 107], ["guanosine", "TREATMENT", 6, 15], ["mizoribine", "TREATMENT", 33, 43], ["mizoribine", "TREATMENT", 97, 107]]], ["These data indicated that mizoribine activity against FMDV involved inhibition of IMPDH-dependent purine synthesis.", [["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["mizoribine", "SIMPLE_CHEMICAL", 26, 36], ["FMDV", "ORGANISM", 54, 58], ["IMPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["purine", "SIMPLE_CHEMICAL", 98, 104], ["IMPDH", "PROTEIN", 82, 87], ["FMDV", "SPECIES", 54, 58], ["FMDV", "SPECIES", 54, 58], ["These data", "TEST", 0, 10], ["mizoribine activity", "TREATMENT", 26, 45], ["FMDV", "PROBLEM", 54, 58], ["IMPDH", "PROBLEM", 82, 87], ["dependent purine synthesis", "PROBLEM", 88, 114], ["purine synthesis", "OBSERVATION", 98, 114]]], ["''VC'' represents those cells treated with 1% DMSO without mizoribine.", [["cells", "ANATOMY", 24, 29], ["DMSO", "CHEMICAL", 46, 50], ["mizoribine", "CHEMICAL", 59, 69], ["DMSO", "CHEMICAL", 46, 50], ["mizoribine", "CHEMICAL", 59, 69], ["cells", "CELL", 24, 29], ["DMSO", "SIMPLE_CHEMICAL", 46, 50], ["mizoribine", "SIMPLE_CHEMICAL", 59, 69], ["those cells", "PROBLEM", 18, 29], ["1% DMSO", "TREATMENT", 43, 50], ["mizoribine", "TREATMENT", 59, 69]]], ["Values represent the mean \u00b1 standard deviation for three independent experiments.", [["Values", "TEST", 0, 6], ["standard deviation", "OBSERVATION", 28, 46]]], ["The asterisks indicate significant differences between mock-treated and drug-treated cells (** p < 0.01).Effect of Mizoribine on Purine Synthesis in FMDVInosine-5\u2032-monophosphate dehydrogenase (IMPDH) is required for de novo purine nucleotide synthesis and its inhibition can lead to depletion of intracellular GTP pools.", [["cells", "ANATOMY", 85, 90], ["intracellular", "ANATOMY", 296, 309], ["Mizoribine", "CHEMICAL", 115, 125], ["Purine", "CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate", "CHEMICAL", 149, 177], ["IMPDH", "CHEMICAL", 193, 198], ["purine nucleotide", "CHEMICAL", 224, 241], ["GTP", "CHEMICAL", 310, 313], ["Mizoribine", "CHEMICAL", 115, 125], ["Purine", "CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate", "CHEMICAL", 149, 177], ["purine nucleotide", "CHEMICAL", 224, 241], ["GTP", "CHEMICAL", 310, 313], ["cells", "CELL", 85, 90], ["Mizoribine", "SIMPLE_CHEMICAL", 115, 125], ["Purine", "SIMPLE_CHEMICAL", 129, 135], ["FMDVInosine-5\u2032-monophosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 149, 191], ["IMPDH", "GENE_OR_GENE_PRODUCT", 193, 198], ["purine nucleotide", "SIMPLE_CHEMICAL", 224, 241], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 296, 309], ["GTP", "SIMPLE_CHEMICAL", 310, 313], ["drug-treated cells", "CELL_LINE", 72, 90], ["FMDVInosine-5\u2032-monophosphate dehydrogenase", "PROTEIN", 149, 191], ["IMPDH", "PROTEIN", 193, 198], ["significant differences between mock-treated and drug-treated cells", "PROBLEM", 23, 90], ["Mizoribine", "TREATMENT", 115, 125], ["Purine Synthesis", "TREATMENT", 129, 145], ["FMDVInosine", "TEST", 149, 160], ["monophosphate dehydrogenase (IMPDH)", "TREATMENT", 164, 199], ["de novo purine nucleotide synthesis", "TREATMENT", 216, 251], ["intracellular GTP pools", "PROBLEM", 296, 319], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["intracellular GTP pools", "OBSERVATION", 296, 319]]], ["To investigate the effect of mizoribine on purine synthesis in FMDV, serially diluted guanosine was added to the infected cells treated with mizoribine.", [["cells", "ANATOMY", 122, 127], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "CHEMICAL", 29, 39], ["purine", "CHEMICAL", 43, 49], ["guanosine", "CHEMICAL", 86, 95], ["mizoribine", "CHEMICAL", 141, 151], ["mizoribine", "SIMPLE_CHEMICAL", 29, 39], ["purine", "SIMPLE_CHEMICAL", 43, 49], ["FMDV", "ORGANISM", 63, 67], ["guanosine", "SIMPLE_CHEMICAL", 86, 95], ["cells", "CELL", 122, 127], ["mizoribine", "SIMPLE_CHEMICAL", 141, 151], ["infected cells", "CELL_TYPE", 113, 127], ["FMDV", "SPECIES", 63, 67], ["FMDV", "SPECIES", 63, 67], ["mizoribine", "TREATMENT", 29, 39], ["purine synthesis", "TREATMENT", 43, 59], ["FMDV", "TREATMENT", 63, 67], ["serially diluted guanosine", "TREATMENT", 69, 95], ["the infected cells", "PROBLEM", 109, 127], ["mizoribine", "TREATMENT", 141, 151], ["infected cells", "OBSERVATION", 113, 127]]], ["While guanosine had no effect on mizoribine, it significantly attenuated the anti-FMDV effect of mizoribine in a dose-dependent manner ( Figure 5 ).", [["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "CHEMICAL", 6, 15], ["mizoribine", "CHEMICAL", 33, 43], ["mizoribine", "CHEMICAL", 97, 107], ["guanosine", "SIMPLE_CHEMICAL", 6, 15], ["mizoribine", "SIMPLE_CHEMICAL", 33, 43], ["mizoribine", "SIMPLE_CHEMICAL", 97, 107], ["guanosine", "TREATMENT", 6, 15], ["mizoribine", "TREATMENT", 33, 43], ["mizoribine", "TREATMENT", 97, 107]]], ["These data indicated that mizoribine activity against FMDV involved inhibition of IMPDH-dependent purine synthesis.Antiviral Activity of Mizoribine in VivoThe suckling mice pretreated by subcutaneous injection of mizoribine or PBS in the neck were infected with FMDV to determine the antiviral activity of mizoribine in vivo.", [["subcutaneous", "ANATOMY", 187, 199], ["neck", "ANATOMY", 238, 242], ["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["Mizoribine", "CHEMICAL", 137, 147], ["mizoribine", "CHEMICAL", 213, 223], ["mizoribine", "CHEMICAL", 306, 316], ["mizoribine", "CHEMICAL", 26, 36], ["purine", "CHEMICAL", 98, 104], ["Mizoribine", "CHEMICAL", 137, 147], ["mizoribine", "CHEMICAL", 213, 223], ["mizoribine", "CHEMICAL", 306, 316], ["mizoribine", "SIMPLE_CHEMICAL", 26, 36], ["FMDV", "ORGANISM", 54, 58], ["IMPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["purine", "SIMPLE_CHEMICAL", 98, 104], ["Mizoribine", "SIMPLE_CHEMICAL", 137, 147], ["suckling mice", "ORGANISM", 159, 172], ["mizoribine", "SIMPLE_CHEMICAL", 213, 223], ["PBS", "SIMPLE_CHEMICAL", 227, 230], ["neck", "ORGAN", 238, 242], ["FMDV", "ORGANISM", 262, 266], ["mizoribine", "SIMPLE_CHEMICAL", 306, 316], ["IMPDH", "PROTEIN", 82, 87], ["FMDV", "SPECIES", 54, 58], ["mice", "SPECIES", 168, 172], ["FMDV", "SPECIES", 262, 266], ["FMDV", "SPECIES", 54, 58], ["mice", "SPECIES", 168, 172], ["FMDV", "SPECIES", 262, 266], ["These data", "TEST", 0, 10], ["mizoribine activity", "TREATMENT", 26, 45], ["FMDV", "PROBLEM", 54, 58], ["IMPDH", "PROBLEM", 82, 87], ["dependent purine synthesis", "PROBLEM", 88, 114], ["Antiviral", "TREATMENT", 115, 124], ["Mizoribine", "TREATMENT", 137, 147], ["mizoribine", "TREATMENT", 213, 223], ["PBS in the neck", "TREATMENT", 227, 242], ["FMDV", "TREATMENT", 262, 266], ["mizoribine in vivo", "TREATMENT", 306, 324], ["purine synthesis", "OBSERVATION", 98, 114], ["neck", "ANATOMY", 238, 242], ["infected", "OBSERVATION", 248, 256]]], ["All the solvent-treated mice died within 60 h after 100 LD 50 of O/MY98/BY/2010 challenge.", [["mice", "ORGANISM", 24, 28], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28]]], ["In contrast, a 48-h delay in death post-infection was noted in the mizoribine-treated group, and all the mice died within 108 h after the viral challenge.", [["death", "DISEASE", 29, 34], ["mizoribine", "CHEMICAL", 67, 77], ["mizoribine", "CHEMICAL", 67, 77], ["mizoribine", "SIMPLE_CHEMICAL", 67, 77], ["mice", "ORGANISM", 105, 109], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["a 48-h delay in death post-infection", "PROBLEM", 13, 49], ["the mizoribine", "TREATMENT", 63, 77], ["the viral challenge", "TREATMENT", 134, 153], ["48-", "OBSERVATION_MODIFIER", 15, 18]]], ["The overall death time of mice treated with mizoribine was delayed by 48 h, when compared with the control, and a significant difference in mouse survival was noted between the treatment group and control (p = 0.0014) ( Figure 6A ).", [["death", "DISEASE", 12, 17], ["mizoribine", "CHEMICAL", 44, 54], ["mizoribine", "CHEMICAL", 44, 54], ["mice", "ORGANISM", 26, 30], ["mizoribine", "SIMPLE_CHEMICAL", 44, 54], ["mouse", "ORGANISM", 140, 145], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 140, 145], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 140, 145], ["mizoribine", "TREATMENT", 44, 54], ["a significant difference in mouse survival", "PROBLEM", 112, 154], ["the treatment group", "TREATMENT", 173, 192], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["difference", "OBSERVATION_MODIFIER", 126, 136], ["mouse survival", "OBSERVATION", 140, 154]]], ["The suckling mice pretreated by subcutaneous injection of mizoribine or PBS in the neck were infected with FMDV to determine the antiviral activity of mizoribine in vivo.", [["subcutaneous", "ANATOMY", 32, 44], ["neck", "ANATOMY", 83, 87], ["mizoribine", "CHEMICAL", 58, 68], ["mizoribine", "CHEMICAL", 151, 161], ["mizoribine", "CHEMICAL", 58, 68], ["mizoribine", "CHEMICAL", 151, 161], ["suckling mice", "ORGANISM", 4, 17], ["mizoribine", "SIMPLE_CHEMICAL", 58, 68], ["PBS", "SIMPLE_CHEMICAL", 72, 75], ["neck", "ORGAN", 83, 87], ["FMDV", "ORGANISM", 107, 111], ["mizoribine", "SIMPLE_CHEMICAL", 151, 161], ["mice", "SPECIES", 13, 17], ["FMDV", "SPECIES", 107, 111], ["mice", "SPECIES", 13, 17], ["FMDV", "SPECIES", 107, 111], ["mizoribine", "TREATMENT", 58, 68], ["PBS in the neck", "TREATMENT", 72, 87], ["FMDV", "TREATMENT", 107, 111], ["mizoribine in vivo", "TREATMENT", 151, 169], ["neck", "ANATOMY", 83, 87], ["infected", "OBSERVATION", 93, 101]]], ["All the solvent-treated mice died within 60 h after 100 LD50 of O/MY98/BY/2010 challenge.", [["mice", "ORGANISM", 24, 28], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28]]], ["In contrast, a 48-h delay in death post-infection was noted in the mizoribine-treated group, and all the mice died within 108 h after the viral challenge.", [["death", "DISEASE", 29, 34], ["mizoribine", "CHEMICAL", 67, 77], ["mizoribine", "CHEMICAL", 67, 77], ["mizoribine", "SIMPLE_CHEMICAL", 67, 77], ["mice", "ORGANISM", 105, 109], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["a 48-h delay in death post-infection", "PROBLEM", 13, 49], ["the mizoribine", "TREATMENT", 63, 77], ["the viral challenge", "TREATMENT", 134, 153], ["48-", "OBSERVATION_MODIFIER", 15, 18]]], ["The overall death time of mice treated with mizoribine was delayed by 48 h, when compared with the control, and a significant difference in mouse survival was noted between the treatment group and control (p = 0.0014) ( Figure 6A ).", [["death", "DISEASE", 12, 17], ["mizoribine", "CHEMICAL", 44, 54], ["mizoribine", "CHEMICAL", 44, 54], ["mice", "ORGANISM", 26, 30], ["mizoribine", "SIMPLE_CHEMICAL", 44, 54], ["mouse", "ORGANISM", 140, 145], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 140, 145], ["mice", "SPECIES", 26, 30], ["mouse", "SPECIES", 140, 145], ["mizoribine", "TREATMENT", 44, 54], ["a significant difference in mouse survival", "PROBLEM", 112, 154], ["the treatment group", "TREATMENT", 173, 192], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["difference", "OBSERVATION_MODIFIER", 126, 136], ["mouse survival", "OBSERVATION", 140, 154]]], ["Furthermore, significant histopathological damage was observed in the heart tissue of FMDV-infected mice, including considerable myocardial interstitial hemorrhage, myocardial fibronectin degeneration, and extensive inflammatory cell infiltration, as indicated by black arrows ( Figure 7A ).", [["heart tissue", "ANATOMY", 70, 82], ["myocardial interstitial", "ANATOMY", 129, 152], ["myocardial", "ANATOMY", 165, 175], ["inflammatory cell", "ANATOMY", 216, 233], ["FMDV-infected", "DISEASE", 86, 99], ["myocardial interstitial hemorrhage", "DISEASE", 129, 163], ["heart tissue", "TISSUE", 70, 82], ["FMDV", "ORGANISM", 86, 90], ["mice", "ORGANISM", 100, 104], ["myocardial interstitial", "PATHOLOGICAL_FORMATION", 129, 152], ["myocardial", "MULTI-TISSUE_STRUCTURE", 165, 175], ["fibronectin", "GENE_OR_GENE_PRODUCT", 176, 187], ["inflammatory cell", "CELL", 216, 233], ["fibronectin", "PROTEIN", 176, 187], ["FMDV", "SPECIES", 86, 90], ["mice", "SPECIES", 100, 104], ["FMDV", "SPECIES", 86, 90], ["mice", "SPECIES", 100, 104], ["significant histopathological damage", "PROBLEM", 13, 49], ["FMDV", "PROBLEM", 86, 90], ["infected mice", "PROBLEM", 91, 104], ["considerable myocardial interstitial hemorrhage", "PROBLEM", 116, 163], ["myocardial fibronectin degeneration", "PROBLEM", 165, 200], ["extensive inflammatory cell infiltration", "PROBLEM", 206, 246], ["black arrows", "PROBLEM", 264, 276], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["histopathological", "OBSERVATION_MODIFIER", 25, 42], ["damage", "OBSERVATION", 43, 49], ["heart", "ANATOMY", 70, 75], ["tissue", "ANATOMY_MODIFIER", 76, 82], ["FMDV", "OBSERVATION", 86, 90], ["infected mice", "OBSERVATION", 91, 104], ["considerable", "OBSERVATION_MODIFIER", 116, 128], ["myocardial", "ANATOMY", 129, 139], ["interstitial", "ANATOMY_MODIFIER", 140, 152], ["hemorrhage", "OBSERVATION", 153, 163], ["myocardial", "ANATOMY", 165, 175], ["fibronectin degeneration", "OBSERVATION", 176, 200], ["extensive", "OBSERVATION_MODIFIER", 206, 215], ["inflammatory cell infiltration", "OBSERVATION", 216, 246], ["black arrows", "OBSERVATION", 264, 276]]], ["In addition, myocardial fiber edema and incomplete fibrous structure were also observed.", [["myocardial fiber", "ANATOMY", 13, 29], ["fibrous structure", "ANATOMY", 51, 68], ["myocardial fiber edema", "DISEASE", 13, 35], ["myocardial fiber edema", "PATHOLOGICAL_FORMATION", 13, 35], ["myocardial fiber edema", "PROBLEM", 13, 35], ["incomplete fibrous structure", "PROBLEM", 40, 68], ["myocardial", "ANATOMY", 13, 23], ["fiber edema", "OBSERVATION", 24, 35], ["incomplete", "OBSERVATION_MODIFIER", 40, 50], ["fibrous structure", "OBSERVATION", 51, 68]]], ["However, mice treated with mizoribine showed mild histopathological changes and only a small amount of inflammatory cell infiltration in the heart ( Figure 7B ).", [["inflammatory cell", "ANATOMY", 103, 120], ["heart", "ANATOMY", 141, 146], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "CHEMICAL", 27, 37], ["mice", "ORGANISM", 9, 13], ["mizoribine", "SIMPLE_CHEMICAL", 27, 37], ["inflammatory cell", "CELL", 103, 120], ["heart", "ORGAN", 141, 146], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["mizoribine", "TREATMENT", 27, 37], ["mild histopathological changes", "PROBLEM", 45, 75], ["inflammatory cell infiltration in the heart", "PROBLEM", 103, 146], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["histopathological", "OBSERVATION", 50, 67], ["small", "OBSERVATION_MODIFIER", 87, 92], ["amount", "OBSERVATION_MODIFIER", 93, 99], ["inflammatory cell infiltration", "OBSERVATION", 103, 133], ["heart", "ANATOMY", 141, 146]]], ["Intriguingly, although FMDV antigen was detected in the heart tissue of both mizoribine-treated and control mice, it was not statistically significant ( Figure 7C,D) .", [["heart tissue", "ANATOMY", 56, 68], ["mizoribine", "CHEMICAL", 77, 87], ["mizoribine", "CHEMICAL", 77, 87], ["FMDV antigen", "GENE_OR_GENE_PRODUCT", 23, 35], ["heart tissue", "TISSUE", 56, 68], ["mizoribine", "SIMPLE_CHEMICAL", 77, 87], ["mice", "ORGANISM", 108, 112], ["FMDV antigen", "PROTEIN", 23, 35], ["FMDV", "SPECIES", 23, 27], ["mice", "SPECIES", 108, 112], ["FMDV", "SPECIES", 23, 27], ["mice", "SPECIES", 108, 112], ["FMDV antigen", "TEST", 23, 35], ["mizoribine", "TREATMENT", 77, 87], ["FMDV", "OBSERVATION", 23, 27], ["heart", "ANATOMY", 56, 61], ["tissue", "ANATOMY_MODIFIER", 62, 68]]], ["These findings suggested that histopathological damage may be the main cause of death resulting from FMDV infection, and mizoribine can effectively alleviate these effects.", [["histopathological damage", "DISEASE", 30, 54], ["death", "DISEASE", 80, 85], ["FMDV infection", "DISEASE", 101, 115], ["mizoribine", "CHEMICAL", 121, 131], ["mizoribine", "CHEMICAL", 121, 131], ["FMDV", "ORGANISM", 101, 105], ["mizoribine", "SIMPLE_CHEMICAL", 121, 131], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 101, 105], ["histopathological damage", "PROBLEM", 30, 54], ["death", "PROBLEM", 80, 85], ["FMDV infection", "PROBLEM", 101, 115], ["mizoribine", "TREATMENT", 121, 131], ["FMDV", "OBSERVATION_MODIFIER", 101, 105], ["infection", "OBSERVATION", 106, 115]]], ["Furthermore, significant histopathological damage was observed in the heart tissue of FMDV-infected mice, including considerable myocardial interstitial hemorrhage, myocardial fibronectin degeneration, and extensive inflammatory cell infiltration, as indicated by black arrows ( Figure 7A ).", [["heart tissue", "ANATOMY", 70, 82], ["myocardial interstitial", "ANATOMY", 129, 152], ["myocardial", "ANATOMY", 165, 175], ["inflammatory cell", "ANATOMY", 216, 233], ["FMDV-infected", "DISEASE", 86, 99], ["myocardial interstitial hemorrhage", "DISEASE", 129, 163], ["heart tissue", "TISSUE", 70, 82], ["FMDV", "ORGANISM", 86, 90], ["mice", "ORGANISM", 100, 104], ["myocardial interstitial", "PATHOLOGICAL_FORMATION", 129, 152], ["myocardial", "MULTI-TISSUE_STRUCTURE", 165, 175], ["fibronectin", "GENE_OR_GENE_PRODUCT", 176, 187], ["inflammatory cell", "CELL", 216, 233], ["fibronectin", "PROTEIN", 176, 187], ["FMDV", "SPECIES", 86, 90], ["mice", "SPECIES", 100, 104], ["FMDV", "SPECIES", 86, 90], ["mice", "SPECIES", 100, 104], ["significant histopathological damage", "PROBLEM", 13, 49], ["FMDV", "PROBLEM", 86, 90], ["infected mice", "PROBLEM", 91, 104], ["considerable myocardial interstitial hemorrhage", "PROBLEM", 116, 163], ["myocardial fibronectin degeneration", "PROBLEM", 165, 200], ["extensive inflammatory cell infiltration", "PROBLEM", 206, 246], ["black arrows", "PROBLEM", 264, 276], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["histopathological", "OBSERVATION_MODIFIER", 25, 42], ["damage", "OBSERVATION", 43, 49], ["heart", "ANATOMY", 70, 75], ["tissue", "ANATOMY_MODIFIER", 76, 82], ["FMDV", "OBSERVATION", 86, 90], ["infected mice", "OBSERVATION", 91, 104], ["considerable", "OBSERVATION_MODIFIER", 116, 128], ["myocardial", "ANATOMY", 129, 139], ["interstitial", "ANATOMY_MODIFIER", 140, 152], ["hemorrhage", "OBSERVATION", 153, 163], ["myocardial", "ANATOMY", 165, 175], ["fibronectin degeneration", "OBSERVATION", 176, 200], ["extensive", "OBSERVATION_MODIFIER", 206, 215], ["inflammatory cell infiltration", "OBSERVATION", 216, 246], ["black arrows", "OBSERVATION", 264, 276]]], ["In addition, myocardial fiber edema and incomplete fibrous structure were also observed.", [["myocardial fiber", "ANATOMY", 13, 29], ["fibrous structure", "ANATOMY", 51, 68], ["myocardial fiber edema", "DISEASE", 13, 35], ["myocardial fiber edema", "PATHOLOGICAL_FORMATION", 13, 35], ["myocardial fiber edema", "PROBLEM", 13, 35], ["incomplete fibrous structure", "PROBLEM", 40, 68], ["myocardial", "ANATOMY", 13, 23], ["fiber edema", "OBSERVATION", 24, 35], ["incomplete", "OBSERVATION_MODIFIER", 40, 50], ["fibrous structure", "OBSERVATION", 51, 68]]], ["However, mice treated with mizoribine showed mild histopathological changes and only a small amount of inflammatory cell infiltration in the heart ( Figure 7B ).", [["inflammatory cell", "ANATOMY", 103, 120], ["heart", "ANATOMY", 141, 146], ["mizoribine", "CHEMICAL", 27, 37], ["mizoribine", "CHEMICAL", 27, 37], ["mice", "ORGANISM", 9, 13], ["mizoribine", "SIMPLE_CHEMICAL", 27, 37], ["inflammatory cell", "CELL", 103, 120], ["heart", "ORGAN", 141, 146], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["mizoribine", "TREATMENT", 27, 37], ["mild histopathological changes", "PROBLEM", 45, 75], ["inflammatory cell infiltration in the heart", "PROBLEM", 103, 146], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["histopathological", "OBSERVATION", 50, 67], ["small", "OBSERVATION_MODIFIER", 87, 92], ["amount", "OBSERVATION_MODIFIER", 93, 99], ["inflammatory cell infiltration", "OBSERVATION", 103, 133], ["heart", "ANATOMY", 141, 146]]], ["Intriguingly, although FMDV antigen was detected in the heart tissue of both mizoribine-treated and control mice, it was not statistically significant ( Figure 7C,D) .", [["heart tissue", "ANATOMY", 56, 68], ["mizoribine", "CHEMICAL", 77, 87], ["mizoribine", "CHEMICAL", 77, 87], ["FMDV antigen", "GENE_OR_GENE_PRODUCT", 23, 35], ["heart tissue", "TISSUE", 56, 68], ["mizoribine", "SIMPLE_CHEMICAL", 77, 87], ["mice", "ORGANISM", 108, 112], ["FMDV antigen", "PROTEIN", 23, 35], ["FMDV", "SPECIES", 23, 27], ["mice", "SPECIES", 108, 112], ["FMDV", "SPECIES", 23, 27], ["mice", "SPECIES", 108, 112], ["FMDV antigen", "TEST", 23, 35], ["mizoribine", "TREATMENT", 77, 87], ["FMDV", "OBSERVATION", 23, 27], ["heart", "ANATOMY", 56, 61], ["tissue", "ANATOMY_MODIFIER", 62, 68]]], ["These findings suggested that histopathological damage may be the main cause of death resulting from FMDV infection, and mizoribine can effectively alleviate these effects.DiscussionAs FMDV exhibits high mutation rates and produces significant economic loss in affected countries, it is important to adopt effective measures to control this virus.", [["histopathological damage", "DISEASE", 30, 54], ["death", "DISEASE", 80, 85], ["FMDV infection", "DISEASE", 101, 115], ["mizoribine", "CHEMICAL", 121, 131], ["mizoribine", "CHEMICAL", 121, 131], ["FMDV", "ORGANISM", 101, 105], ["mizoribine", "SIMPLE_CHEMICAL", 121, 131], ["FMDV", "ORGANISM", 185, 189], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 185, 189], ["FMDV", "SPECIES", 101, 105], ["FMDV", "SPECIES", 185, 189], ["histopathological damage", "PROBLEM", 30, 54], ["death", "PROBLEM", 80, 85], ["FMDV infection", "PROBLEM", 101, 115], ["mizoribine", "TREATMENT", 121, 131], ["high mutation rates", "PROBLEM", 199, 218], ["significant economic loss in affected countries", "PROBLEM", 232, 279], ["effective measures", "TREATMENT", 306, 324], ["this virus", "PROBLEM", 336, 346], ["FMDV", "OBSERVATION_MODIFIER", 101, 105], ["infection", "OBSERVATION", 106, 115], ["significant", "OBSERVATION_MODIFIER", 232, 243], ["economic", "OBSERVATION_MODIFIER", 244, 252], ["loss", "OBSERVATION", 253, 257]]], ["It has been demonstrated that mizoribine does not produce tumorigenic and gonadal suppression effects, and exerts low bone marrow inhibition and hepatotoxic outcomes, and has been used for the treatment of renal diseases in humans [8, 16] .", [["gonadal", "ANATOMY", 74, 81], ["bone marrow", "ANATOMY", 118, 129], ["renal", "ANATOMY", 206, 211], ["mizoribine", "CHEMICAL", 30, 40], ["low bone marrow inhibition", "DISEASE", 114, 140], ["hepatotoxic", "DISEASE", 145, 156], ["renal diseases", "DISEASE", 206, 220], ["mizoribine", "CHEMICAL", 30, 40], ["mizoribine", "SIMPLE_CHEMICAL", 30, 40], ["gonadal", "ORGAN", 74, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 118, 129], ["renal", "ORGAN", 206, 211], ["humans", "ORGANISM", 224, 230], ["humans", "SPECIES", 224, 230], ["humans", "SPECIES", 224, 230], ["mizoribine", "TREATMENT", 30, 40], ["tumorigenic and gonadal suppression effects", "PROBLEM", 58, 101], ["low bone marrow inhibition", "PROBLEM", 114, 140], ["renal diseases in humans", "PROBLEM", 206, 230], ["mizoribine", "OBSERVATION", 30, 40], ["gonadal suppression", "OBSERVATION", 74, 93], ["low", "OBSERVATION_MODIFIER", 114, 117], ["bone", "ANATOMY", 118, 122], ["marrow inhibition", "OBSERVATION", 123, 140], ["renal", "ANATOMY", 206, 211], ["diseases", "OBSERVATION", 212, 220]]], ["Thus, considering the safe, reliable, and acceptable efficacy of mizoribine in humans, it might also be employed for the treatment of animal diseases.DiscussionAs FMDV exhibits high mutation rates and produces significant economic loss in affected countries, it is important to adopt effective measures to control this virus.", [["mizoribine", "CHEMICAL", 65, 75], ["animal diseases", "DISEASE", 134, 149], ["mizoribine", "CHEMICAL", 65, 75], ["mizoribine", "SIMPLE_CHEMICAL", 65, 75], ["humans", "ORGANISM", 79, 85], ["FMDV", "ORGANISM", 163, 167], ["humans", "SPECIES", 79, 85], ["FMDV", "SPECIES", 163, 167], ["humans", "SPECIES", 79, 85], ["FMDV", "SPECIES", 163, 167], ["mizoribine", "TREATMENT", 65, 75], ["animal diseases", "PROBLEM", 134, 149], ["high mutation rates", "PROBLEM", 177, 196], ["significant economic loss in affected countries", "PROBLEM", 210, 257], ["effective measures", "TREATMENT", 284, 302], ["this virus", "PROBLEM", 314, 324], ["significant", "OBSERVATION_MODIFIER", 210, 221], ["economic", "OBSERVATION_MODIFIER", 222, 230], ["loss", "OBSERVATION", 231, 235]]], ["It has been demonstrated that mizoribine does not produce tumorigenic and gonadal suppression effects, and exerts low bone marrow inhibition and hepatotoxic outcomes, and has been used for the treatment of renal diseases in humans [8, 16] .", [["gonadal", "ANATOMY", 74, 81], ["bone marrow", "ANATOMY", 118, 129], ["renal", "ANATOMY", 206, 211], ["mizoribine", "CHEMICAL", 30, 40], ["low bone marrow inhibition", "DISEASE", 114, 140], ["hepatotoxic", "DISEASE", 145, 156], ["renal diseases", "DISEASE", 206, 220], ["mizoribine", "CHEMICAL", 30, 40], ["mizoribine", "SIMPLE_CHEMICAL", 30, 40], ["gonadal", "ORGAN", 74, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 118, 129], ["renal", "ORGAN", 206, 211], ["humans", "ORGANISM", 224, 230], ["humans", "SPECIES", 224, 230], ["humans", "SPECIES", 224, 230], ["mizoribine", "TREATMENT", 30, 40], ["tumorigenic and gonadal suppression effects", "PROBLEM", 58, 101], ["low bone marrow inhibition", "PROBLEM", 114, 140], ["renal diseases in humans", "PROBLEM", 206, 230], ["mizoribine", "OBSERVATION", 30, 40], ["gonadal suppression", "OBSERVATION", 74, 93], ["low", "OBSERVATION_MODIFIER", 114, 117], ["bone", "ANATOMY", 118, 122], ["marrow inhibition", "OBSERVATION", 123, 140], ["renal", "ANATOMY", 206, 211], ["diseases", "OBSERVATION", 212, 220]]], ["Thus, considering the safe, reliable, and acceptable efficacy of mizoribine in humans, it might also be employed for the treatment of animal diseases.DiscussionTo the best of our knowledge, the present study is the first to report on the antiviral effect of mizoribine on FMDV both in vitro and in vivo.", [["mizoribine", "CHEMICAL", 65, 75], ["animal diseases", "DISEASE", 134, 149], ["mizoribine", "CHEMICAL", 258, 268], ["mizoribine", "CHEMICAL", 65, 75], ["mizoribine", "CHEMICAL", 258, 268], ["mizoribine", "SIMPLE_CHEMICAL", 65, 75], ["humans", "ORGANISM", 79, 85], ["mizoribine", "SIMPLE_CHEMICAL", 258, 268], ["FMDV", "ORGANISM", 272, 276], ["humans", "SPECIES", 79, 85], ["FMDV", "SPECIES", 272, 276], ["humans", "SPECIES", 79, 85], ["FMDV", "SPECIES", 272, 276], ["mizoribine", "TREATMENT", 65, 75], ["animal diseases", "PROBLEM", 134, 149], ["the present study", "TEST", 190, 207], ["mizoribine", "TREATMENT", 258, 268], ["FMDV", "TREATMENT", 272, 276]]], ["By using MTS assay, the cytotoxicity of mizoribine was determined to be very weak, with a CC 50 value higher than 100 \u00b5M.", [["mizoribine", "CHEMICAL", 40, 50], ["CC", "CHEMICAL", 90, 92], ["mizoribine", "CHEMICAL", 40, 50], ["mizoribine", "SIMPLE_CHEMICAL", 40, 50], ["MTS assay", "TEST", 9, 18], ["mizoribine", "TREATMENT", 40, 50], ["very weak", "PROBLEM", 72, 81], ["a CC 50 value", "TEST", 88, 101]]], ["Furthermore, mizoribine showed significant anti-FMDV activity, not only against type O FMDV O/MY98/BY/2010 strain, but also against type A FMDV A/GD/MM/2013, with SI values of 4.67 and 15.20, respectively.", [["mizoribine", "CHEMICAL", 13, 23], ["mizoribine", "CHEMICAL", 13, 23], ["mizoribine", "SIMPLE_CHEMICAL", 13, 23], ["anti-FMDV", "CANCER", 43, 52], ["type O FMDV O/MY98", "ORGANISM", 80, 98], ["FMDV", "SPECIES", 87, 91], ["FMDV", "SPECIES", 139, 143], ["O FMDV O/MY98/BY/2010 strain", "SPECIES", 85, 113], ["type A FMDV A/GD/MM/2013", "SPECIES", 132, 156], ["mizoribine", "TREATMENT", 13, 23], ["SI values", "TEST", 163, 172], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["anti-FMDV activity", "OBSERVATION", 43, 61]]], ["These results indicated that mizoribine could be a better drug to prevent FMDV A/GD/MM/2013 infection.", [["mizoribine", "CHEMICAL", 29, 39], ["infection", "DISEASE", 92, 101], ["mizoribine", "CHEMICAL", 29, 39], ["mizoribine", "SIMPLE_CHEMICAL", 29, 39], ["FMDV", "SPECIES", 74, 78], ["FMDV A/GD/MM/2013", "SPECIES", 74, 91], ["mizoribine", "TREATMENT", 29, 39], ["FMDV", "PROBLEM", 74, 78], ["MM", "PROBLEM", 84, 86], ["infection", "PROBLEM", 92, 101], ["infection", "OBSERVATION", 92, 101]]], ["Moreover, qPCR and IFA findings revealed that mizoribine can significantly inhibit the viral mRNA and FMDV protein levels.", [["mizoribine", "CHEMICAL", 46, 56], ["mizoribine", "CHEMICAL", 46, 56], ["mizoribine", "SIMPLE_CHEMICAL", 46, 56], ["viral mRNA", "RNA", 87, 97], ["FMDV protein", "PROTEIN", 102, 114], ["FMDV", "SPECIES", 102, 106], ["FMDV", "SPECIES", 102, 106], ["qPCR", "TEST", 10, 14], ["IFA findings", "TEST", 19, 31], ["mizoribine", "TREATMENT", 46, 56], ["the viral mRNA", "TEST", 83, 97], ["FMDV protein levels", "TEST", 102, 121], ["viral mRNA", "OBSERVATION", 87, 97]]], ["To understand the preliminary antiviral mechanism of mizoribine, time-of-drug-addition assay was performed, and the results demonstrated that mizoribine mainly functions at the early stages of infection.", [["mizoribine", "CHEMICAL", 53, 63], ["mizoribine", "CHEMICAL", 142, 152], ["infection", "DISEASE", 193, 202], ["mizoribine", "CHEMICAL", 53, 63], ["mizoribine", "CHEMICAL", 142, 152], ["mizoribine", "SIMPLE_CHEMICAL", 53, 63], ["mizoribine", "SIMPLE_CHEMICAL", 142, 152], ["mizoribine", "TREATMENT", 53, 63], ["mizoribine", "TREATMENT", 142, 152], ["infection", "PROBLEM", 193, 202], ["early stages", "OBSERVATION_MODIFIER", 177, 189], ["infection", "OBSERVATION", 193, 202]]], ["It has been reported that the antiviral activity of mizoribine involves inhibition of IMPDH [7] , an essential enzyme for the synthesis of guanosine monophosphate from inosine monophosphate through de novo pathway [8, 17] .", [["mizoribine", "CHEMICAL", 52, 62], ["guanosine monophosphate", "CHEMICAL", 139, 162], ["inosine monophosphate", "CHEMICAL", 168, 189], ["mizoribine", "CHEMICAL", 52, 62], ["guanosine monophosphate", "CHEMICAL", 139, 162], ["inosine monophosphate", "CHEMICAL", 168, 189], ["mizoribine", "SIMPLE_CHEMICAL", 52, 62], ["IMPDH [7]", "GENE_OR_GENE_PRODUCT", 86, 95], ["guanosine monophosphate", "SIMPLE_CHEMICAL", 139, 162], ["inosine monophosphate", "SIMPLE_CHEMICAL", 168, 189], ["IMPDH [7]", "PROTEIN", 86, 95], ["mizoribine", "TREATMENT", 52, 62], ["IMPDH", "TEST", 86, 91], ["an essential enzyme", "TEST", 98, 117], ["guanosine monophosphate", "TREATMENT", 139, 162], ["inosine monophosphate", "TREATMENT", 168, 189]]], ["Similarly, in the present study, the antiviral activity of mizoribine against FMDV was found to be attenuated by guanosine supplementation.", [["mizoribine", "CHEMICAL", 59, 69], ["guanosine", "CHEMICAL", 113, 122], ["mizoribine", "CHEMICAL", 59, 69], ["guanosine", "CHEMICAL", 113, 122], ["mizoribine", "SIMPLE_CHEMICAL", 59, 69], ["FMDV", "ORGANISM", 78, 82], ["guanosine", "SIMPLE_CHEMICAL", 113, 122], ["FMDV", "SPECIES", 78, 82], ["FMDV", "SPECIES", 78, 82], ["the present study", "TEST", 14, 31], ["mizoribine", "TREATMENT", 59, 69], ["FMDV", "PROBLEM", 78, 82], ["guanosine supplementation", "TREATMENT", 113, 138], ["guanosine supplementation", "OBSERVATION", 113, 138]]], ["The animal experiment demonstrated that mizoribine had an inhibitory effect on FMDV in vivo, and treatment with 50 \u00b5g of mizoribine significantly prolonged the survival of FMDV-infected suckling mice.", [["mizoribine", "CHEMICAL", 40, 50], ["mizoribine", "CHEMICAL", 121, 131], ["mizoribine", "CHEMICAL", 40, 50], ["mizoribine", "CHEMICAL", 121, 131], ["mizoribine", "SIMPLE_CHEMICAL", 40, 50], ["FMDV", "ORGANISM", 79, 83], ["mizoribine", "SIMPLE_CHEMICAL", 121, 131], ["FMDV", "ORGANISM", 172, 176], ["suckling mice", "ORGANISM", 186, 199], ["FMDV", "SPECIES", 79, 83], ["FMDV", "SPECIES", 172, 176], ["mice", "SPECIES", 195, 199], ["FMDV", "SPECIES", 79, 83], ["FMDV", "SPECIES", 172, 176], ["mice", "SPECIES", 195, 199], ["mizoribine", "TREATMENT", 40, 50], ["FMDV in vivo", "TREATMENT", 79, 91], ["treatment", "TREATMENT", 97, 106], ["mizoribine", "TREATMENT", 121, 131], ["FMDV", "PROBLEM", 172, 176]]], ["Although the in vivo results did not show a significant increase in the survival rates of infected mice, the delay in death and alleviated histopathological changes suggested the inhibitory effect of mizoribine on viral replication.", [["death", "DISEASE", 118, 123], ["mizoribine", "CHEMICAL", 200, 210], ["mizoribine", "CHEMICAL", 200, 210], ["mice", "ORGANISM", 99, 103], ["mizoribine", "SIMPLE_CHEMICAL", 200, 210], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["infected mice", "PROBLEM", 90, 103], ["the delay in death", "PROBLEM", 105, 123], ["alleviated histopathological changes", "PROBLEM", 128, 164], ["mizoribine", "TREATMENT", 200, 210], ["viral replication", "TREATMENT", 214, 231], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["increase", "OBSERVATION_MODIFIER", 56, 64]]], ["Overall, the weak cytotoxicity and strong antiviral activities of mizoribine both in vitro and in vivo favored its further potential clinical applications in the treatment of viral infection.DiscussionCombination treatment strategies have been proposed to enhance the efficacy of antiviral agents, because of their advantages in overcoming viral mechanisms of resistance to antiviral treatments [18] .", [["mizoribine", "CHEMICAL", 66, 76], ["viral infection", "DISEASE", 175, 190], ["mizoribine", "CHEMICAL", 66, 76], ["mizoribine", "SIMPLE_CHEMICAL", 66, 76], ["the weak cytotoxicity", "PROBLEM", 9, 30], ["mizoribine", "TREATMENT", 66, 76], ["clinical applications", "TREATMENT", 133, 154], ["viral infection", "PROBLEM", 175, 190], ["DiscussionCombination treatment strategies", "TREATMENT", 191, 233], ["antiviral agents", "TREATMENT", 280, 296], ["antiviral treatments", "TREATMENT", 374, 394], ["weak", "OBSERVATION_MODIFIER", 13, 17], ["cytotoxicity", "OBSERVATION", 18, 30], ["viral", "OBSERVATION_MODIFIER", 175, 180], ["infection", "OBSERVATION", 181, 190]]], ["It has been demonstrated that mizoribine enhances the anti-caprine-herpesvirus-1 activity of acyclovir, and the combination of mizoribine and acyclovir resulted in an almost complete inhibition of viral replication.", [["mizoribine", "CHEMICAL", 30, 40], ["acyclovir", "CHEMICAL", 93, 102], ["mizoribine", "CHEMICAL", 127, 137], ["acyclovir", "CHEMICAL", 142, 151], ["mizoribine", "CHEMICAL", 30, 40], ["acyclovir", "CHEMICAL", 93, 102], ["mizoribine", "CHEMICAL", 127, 137], ["acyclovir", "CHEMICAL", 142, 151], ["mizoribine", "SIMPLE_CHEMICAL", 30, 40], ["anti-caprine-herpesvirus-1", "GENE_OR_GENE_PRODUCT", 54, 80], ["acyclovir", "SIMPLE_CHEMICAL", 93, 102], ["mizoribine", "SIMPLE_CHEMICAL", 127, 137], ["acyclovir", "SIMPLE_CHEMICAL", 142, 151], ["mizoribine", "TREATMENT", 30, 40], ["the anti-caprine", "TREATMENT", 50, 66], ["herpesvirus", "TREATMENT", 67, 78], ["acyclovir", "TREATMENT", 93, 102], ["mizoribine", "TREATMENT", 127, 137], ["acyclovir", "TREATMENT", 142, 151], ["viral replication", "TREATMENT", 197, 214], ["mizoribine", "OBSERVATION_MODIFIER", 30, 40], ["viral replication", "OBSERVATION", 197, 214]]], ["Thus, combined therapy of acyclovir and mizoribine could be exploited for the treatment of genital infection by herpesviruses [19] .", [["genital", "ANATOMY", 91, 98], ["acyclovir", "CHEMICAL", 26, 35], ["mizoribine", "CHEMICAL", 40, 50], ["genital infection", "DISEASE", 91, 108], ["acyclovir", "CHEMICAL", 26, 35], ["mizoribine", "CHEMICAL", 40, 50], ["acyclovir", "SIMPLE_CHEMICAL", 26, 35], ["mizoribine", "SIMPLE_CHEMICAL", 40, 50], ["genital", "ORGANISM_SUBDIVISION", 91, 98], ["herpesviruses", "ORGANISM", 112, 125], ["combined therapy", "TREATMENT", 6, 22], ["acyclovir", "TREATMENT", 26, 35], ["mizoribine", "TREATMENT", 40, 50], ["genital infection", "PROBLEM", 91, 108], ["herpesviruses", "PROBLEM", 112, 125], ["genital", "ANATOMY", 91, 98], ["infection", "OBSERVATION", 99, 108]]], ["Moreover, mizoribine has been reported to be active against the replication of BVDV in Madin-Darby bovine kidney (MDBK) cells, and a combination of interferons (IFNs) and mizoribine had been noted to synergistically inhibit BVDV replication in bovine kidney cells [17] .", [["kidney (MDBK) cells", "ANATOMY", 106, 125], ["kidney cells", "ANATOMY", 251, 263], ["mizoribine", "CHEMICAL", 10, 20], ["mizoribine", "CHEMICAL", 171, 181], ["mizoribine", "CHEMICAL", 10, 20], ["mizoribine", "CHEMICAL", 171, 181], ["mizoribine", "SIMPLE_CHEMICAL", 10, 20], ["BVDV", "ORGANISM", 79, 83], ["Madin-Darby bovine kidney (MDBK) cells", "CELL", 87, 125], ["interferons", "GENE_OR_GENE_PRODUCT", 148, 159], ["IFNs", "GENE_OR_GENE_PRODUCT", 161, 165], ["mizoribine", "SIMPLE_CHEMICAL", 171, 181], ["BVDV", "ORGANISM", 224, 228], ["bovine", "ORGANISM", 244, 250], ["kidney cells", "CELL", 251, 263], ["Madin-Darby bovine kidney (MDBK) cells", "CELL_LINE", 87, 125], ["interferons", "PROTEIN", 148, 159], ["IFNs", "PROTEIN", 161, 165], ["bovine kidney cells", "CELL_TYPE", 244, 263], ["bovine", "SPECIES", 99, 105], ["bovine", "SPECIES", 244, 250], ["BVDV", "SPECIES", 79, 83], ["MDBK", "SPECIES", 114, 118], ["BVDV", "SPECIES", 224, 228], ["bovine", "SPECIES", 244, 250], ["mizoribine", "TREATMENT", 10, 20], ["BVDV", "PROBLEM", 79, 83], ["Madin", "TREATMENT", 87, 92], ["Darby bovine kidney (MDBK) cells", "TREATMENT", 93, 125], ["interferons (IFNs)", "TREATMENT", 148, 166], ["mizoribine", "TREATMENT", 171, 181], ["BVDV replication in bovine kidney cells", "PROBLEM", 224, 263], ["kidney", "ANATOMY", 106, 112], ["kidney", "ANATOMY", 251, 257]]], ["With regard to FMD, FMDV have been demonstrated to be very sensitive to IFNs, and IFN-based strategies have been established to be an efficient biotherapeutic option against FMDV [20] .", [["IFN", "CHEMICAL", 82, 85], ["FMDV", "ORGANISM", 20, 24], ["IFNs", "GENE_OR_GENE_PRODUCT", 72, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["FMDV", "ORGANISM", 174, 178], ["IFNs", "PROTEIN", 72, 76], ["IFN", "PROTEIN", 82, 85], ["FMDV", "SPECIES", 20, 24], ["FMDV", "SPECIES", 174, 178], ["FMD", "SPECIES", 15, 18], ["FMDV", "SPECIES", 20, 24], ["FMDV", "SPECIES", 174, 178], ["FMD", "PROBLEM", 15, 18], ["FMDV", "PROBLEM", 20, 24], ["IFNs", "TREATMENT", 72, 76], ["IFN", "TREATMENT", 82, 85]]], ["Similarly, the combination of antiviral agents, such as siRNA, ribavirin, and IFNs, has been determined to produce enhanced antiviral effect against FMDV [18] .", [["ribavirin", "CHEMICAL", 63, 72], ["ribavirin", "CHEMICAL", 63, 72], ["ribavirin", "SIMPLE_CHEMICAL", 63, 72], ["FMDV", "ORGANISM", 149, 153], ["IFNs", "PROTEIN", 78, 82], ["FMDV", "SPECIES", 149, 153], ["FMDV", "SPECIES", 149, 153], ["antiviral agents", "TREATMENT", 30, 46], ["siRNA", "TREATMENT", 56, 61], ["ribavirin", "TREATMENT", 63, 72], ["IFNs", "TREATMENT", 78, 82], ["FMDV", "PROBLEM", 149, 153], ["antiviral agents", "OBSERVATION", 30, 46]]], ["Therefore, future studies must investigate whether a combination of IFNs and mizoribine could produce increased inhibitory effect on FMDV replication both in vitro and in vivo.DiscussionIn conclusion, to the best of the authors' knowledge, the present study is the first to demonstrate that mizoribine can suppress FMDV replication in vitro as well as prolong the survival of suckling mice in vivo, suggesting the potential applications of this drug in antiviral regimens for FMD treatment.", [["IFNs", "CHEMICAL", 68, 72], ["mizoribine", "CHEMICAL", 77, 87], ["mizoribine", "CHEMICAL", 291, 301], ["FMD", "DISEASE", 476, 479], ["mizoribine", "CHEMICAL", 77, 87], ["mizoribine", "CHEMICAL", 291, 301], ["IFNs", "GENE_OR_GENE_PRODUCT", 68, 72], ["mizoribine", "SIMPLE_CHEMICAL", 77, 87], ["FMDV", "ORGANISM", 133, 137], ["mizoribine", "SIMPLE_CHEMICAL", 291, 301], ["FMDV", "ORGANISM", 315, 319], ["mice", "ORGANISM", 385, 389], ["FMD", "SIMPLE_CHEMICAL", 476, 479], ["IFNs", "PROTEIN", 68, 72], ["FMDV", "SPECIES", 133, 137], ["FMDV", "SPECIES", 315, 319], ["mice", "SPECIES", 385, 389], ["FMDV", "SPECIES", 133, 137], ["FMDV", "SPECIES", 315, 319], ["mice", "SPECIES", 385, 389], ["FMD", "SPECIES", 476, 479], ["future studies", "TEST", 11, 25], ["IFNs", "TREATMENT", 68, 72], ["mizoribine", "TREATMENT", 77, 87], ["increased inhibitory effect", "PROBLEM", 102, 129], ["FMDV replication", "TREATMENT", 133, 149], ["the present study", "TEST", 240, 257], ["mizoribine", "TREATMENT", 291, 301], ["this drug", "TREATMENT", 440, 449], ["antiviral regimens", "TREATMENT", 453, 471], ["FMD treatment", "TREATMENT", 476, 489], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["inhibitory effect", "OBSERVATION", 112, 129]]], ["The findings of this study may warrant further investigations on the efficacy and safety of combined use of mizoribine and other antiviral agents in vitro and in vivo.Laboratory AnimalsThirty-two (32) two-and three-day-old BALB/c mice weighing 3-4 g were used to investigate the efficacy of mizoribine in vivo.", [["mizoribine", "CHEMICAL", 108, 118], ["mizoribine", "CHEMICAL", 291, 301], ["mizoribine", "CHEMICAL", 108, 118], ["mizoribine", "CHEMICAL", 291, 301], ["mizoribine", "SIMPLE_CHEMICAL", 108, 118], ["BALB/c mice", "ORGANISM", 223, 234], ["mizoribine", "SIMPLE_CHEMICAL", 291, 301], ["mice", "SPECIES", 230, 234], ["mice", "SPECIES", 230, 234], ["this study", "TEST", 16, 26], ["further investigations", "TEST", 39, 61], ["mizoribine", "TREATMENT", 108, 118], ["other antiviral agents", "TREATMENT", 123, 145], ["vitro", "TREATMENT", 149, 154], ["Laboratory Animals", "TEST", 167, 185], ["old BALB/c mice weighing", "TREATMENT", 219, 243], ["mizoribine in vivo", "TREATMENT", 291, 309]]], ["LVRIAEC2018-007).", [["LVRIAEC2018-007", "CHEMICAL", 0, 15]]], ["FMDV type O (O/MYA98/BY/2010) strain was used for viral challenge.Cytotoxicity AssayThe cytotoxicity of mizoribine was evaluated using MTS assay.", [["mizoribine", "CHEMICAL", 104, 114], ["mizoribine", "CHEMICAL", 104, 114], ["FMDV", "ORGANISM", 0, 4], ["mizoribine", "SIMPLE_CHEMICAL", 104, 114], ["FMDV", "SPECIES", 0, 4], ["FMDV type O (O/MYA98/BY/2010)", "SPECIES", 0, 29], ["viral challenge", "TREATMENT", 50, 65], ["Cytotoxicity Assay", "TEST", 66, 84], ["mizoribine", "TREATMENT", 104, 114], ["MTS assay", "TEST", 135, 144]]], ["Briefly, 3 \u00d7 10 4 cells were seeded into each well of a 96-well plate containing 100 \u00b5L of complete medium.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["a 96-well plate", "TREATMENT", 54, 69]]], ["On the following day, the cells were incubated with 100 \u00b5L of mizoribine at various concentrations (6, 12, 25, 50, 75 , and 100 \u00b5M) for 72 h.", [["cells", "ANATOMY", 26, 31], ["mizoribine", "CHEMICAL", 62, 72], ["mizoribine", "CHEMICAL", 62, 72], ["cells", "CELL", 26, 31], ["mizoribine", "SIMPLE_CHEMICAL", 62, 72], ["mizoribine", "TREATMENT", 62, 72]]], ["As a control, cells were treated with 1% DMSO.", [["cells", "ANATOMY", 14, 19], ["DMSO", "CHEMICAL", 41, 45], ["DMSO", "CHEMICAL", 41, 45], ["cells", "CELL", 14, 19], ["DMSO", "SIMPLE_CHEMICAL", 41, 45], ["1% DMSO", "TREATMENT", 38, 45]]], ["After treatment, the supernatants were discarded, and the cells were washed three times.", [["supernatants", "ANATOMY", 21, 33], ["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["treatment", "TREATMENT", 6, 15], ["the supernatants", "TREATMENT", 17, 33], ["the cells", "TREATMENT", 54, 63]]], ["Then, 100 \u00b5L of DMEM were added to each well along with 20 \u00b5L of MTS solution and incubated for an additional 3 h at 37 \u2022 C. The optical density of each well at 490 nm was determined using a microplate reader (Bio-Rad, Hercules, CA, USA).", [["DMEM", "CHEMICAL", 16, 20], ["MTS", "CHEMICAL", 65, 68], ["MTS", "CHEMICAL", 65, 68], ["DMEM", "TREATMENT", 16, 20], ["MTS solution", "TREATMENT", 65, 77], ["a microplate", "TEST", 189, 201]]], ["The cell viability was expressed as the percentage of absorbance of the treated cells to that of the control cells.Antiviral AssayThe antiviral activity of mizoribine against FMDV was determined using an MTS-based cytopathic effect (CPE) inhibition assay.", [["cell", "ANATOMY", 4, 8], ["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 109, 114], ["mizoribine", "CHEMICAL", 156, 166], ["mizoribine", "CHEMICAL", 156, 166], ["cell", "CELL", 4, 8], ["cells", "CELL", 80, 85], ["cells", "CELL", 109, 114], ["mizoribine", "SIMPLE_CHEMICAL", 156, 166], ["FMDV", "ORGANISM", 175, 179], ["treated cells", "CELL_LINE", 72, 85], ["control cells", "CELL_TYPE", 101, 114], ["FMDV", "SPECIES", 175, 179], ["FMDV", "SPECIES", 175, 179], ["the treated cells", "TREATMENT", 68, 85], ["Antiviral Assay", "TREATMENT", 115, 130], ["The antiviral activity", "TREATMENT", 130, 152], ["mizoribine", "TREATMENT", 156, 166], ["FMDV", "PROBLEM", 175, 179], ["an MTS-based cytopathic effect", "TREATMENT", 201, 231], ["inhibition assay", "TEST", 238, 254], ["cell viability", "OBSERVATION", 4, 18], ["antiviral activity", "OBSERVATION", 134, 152], ["cytopathic", "OBSERVATION_MODIFIER", 214, 224]]], ["Briefly, the viral suspension (100 TCID 50 O/MY98/BY/2010) was added to the IBRS-2 cell monolayers.", [["IBRS-2 cell monolayers", "ANATOMY", 76, 98], ["IBRS-2 cell monolayers", "CELL", 76, 98], ["IBRS-2 cell monolayers", "CELL_LINE", 76, 98], ["the viral suspension", "TREATMENT", 9, 29], ["the IBRS", "TEST", 72, 80], ["cell monolayers", "OBSERVATION", 83, 98]]], ["After incubation for 1 h, the cells were washed three times with DMEM, and serially diluted mizoribine solution was added to the wells (eight wells for each concentration).", [["cells", "ANATOMY", 30, 35], ["mizoribine", "CHEMICAL", 92, 102], ["mizoribine", "CHEMICAL", 92, 102], ["cells", "CELL", 30, 35], ["mizoribine", "SIMPLE_CHEMICAL", 92, 102], ["the cells", "TREATMENT", 26, 35], ["DMEM", "TREATMENT", 65, 69], ["serially diluted mizoribine solution", "TREATMENT", 75, 111]]], ["Then, the plates were incubated at 37 \u2022 C in 5% CO 2 .", [["CO 2", "CHEMICAL", 48, 52], ["the plates", "TEST", 6, 16]]], ["After 48 h, when maximum CPE was noted in the virus control group (VC), the cell viability was measured using MTS assay as described earlier, and the percentage of inhibition associated with each mizoribine concentration was normalized with respect to the VC.", [["cell", "ANATOMY", 76, 80], ["mizoribine", "CHEMICAL", 196, 206], ["mizoribine", "CHEMICAL", 196, 206], ["cell", "CELL", 76, 80], ["mizoribine", "SIMPLE_CHEMICAL", 196, 206], ["maximum CPE", "PROBLEM", 17, 28], ["the cell viability", "TEST", 72, 90], ["MTS assay", "TEST", 110, 119], ["each mizoribine concentration", "TREATMENT", 191, 220], ["cell viability", "OBSERVATION", 76, 90]]], ["The virus inhibition rate was calculated as follows: inhibition rate = (optical density of mizoribine group \u2212 optical density of VC)/(optical density of cell control group \u2212 optical density of VC) \u00d7 100%.", [["cell", "ANATOMY", 153, 157], ["mizoribine", "CHEMICAL", 91, 101], ["cell", "CELL", 153, 157], ["The virus inhibition rate", "TEST", 0, 25], ["inhibition rate", "TEST", 53, 68], ["mizoribine group", "TREATMENT", 91, 107]]], ["The supernatant of each well was collected and the viral 2B mRNA was analyzed using Q-PCR.", [["supernatant", "ANATOMY", 4, 15], ["viral 2B mRNA", "RNA", 51, 64], ["the viral 2B mRNA", "TEST", 47, 64], ["Q-PCR", "TEST", 84, 89]]], ["The 50% inhibitory concentration (IC 50 ) values were calculated with GraphPad software (version 7.04, La Jolla, CA, USA).Guanosine Supplementation ExperimentThe monolayers of cells were seeded in 96-well plates infected with 100 TCID 50 FMDV O/MY98/BY/2010 at 37 \u2022 C for 1 h.", [["monolayers", "ANATOMY", 162, 172], ["cells", "ANATOMY", 176, 181], ["Guanosine", "CHEMICAL", 122, 131], ["Guanosine", "CHEMICAL", 122, 131], ["Guanosine", "SIMPLE_CHEMICAL", 122, 131], ["monolayers", "CELL", 162, 172], ["cells", "CELL", 176, 181], ["FMDV", "SPECIES", 238, 242], ["FMDV O/MY98/BY/2010", "SPECIES", 238, 257], ["The 50% inhibitory concentration (IC", "TREATMENT", 0, 36], ["GraphPad software", "TEST", 70, 87], ["version", "TEST", 89, 96], ["La Jolla", "TEST", 103, 111], ["Guanosine Supplementation", "TREATMENT", 122, 147], ["The monolayers of cells", "TREATMENT", 158, 181]]], ["Then, a 75 \u00b5M portion of mizoribine supplemented with serial dilutions of guanosine (from 100 to 25 \u00b5M) was added and incubated for 48 h.", [["mizoribine", "CHEMICAL", 25, 35], ["guanosine", "CHEMICAL", 74, 83], ["mizoribine", "CHEMICAL", 25, 35], ["guanosine", "CHEMICAL", 74, 83], ["mizoribine", "SIMPLE_CHEMICAL", 25, 35], ["guanosine", "SIMPLE_CHEMICAL", 74, 83], ["mizoribine", "TREATMENT", 25, 35], ["serial dilutions of guanosine", "TREATMENT", 54, 83]]], ["After incubation, the viral protein and gene expressions were assessed by Western blot analysis and Q-PCR, respectively.Time-of-Drug-Addition AssayThe IBRS-2 cells were incubated with 100 TCID 50 O/MY98/BY/2010 for 1 h.", [["IBRS-2 cells", "ANATOMY", 151, 163], ["IBRS-2 cells", "CELL", 151, 163], ["viral protein", "PROTEIN", 22, 35], ["IBRS-2 cells", "CELL_LINE", 151, 163], ["the viral protein", "TEST", 18, 35], ["gene expressions", "TEST", 40, 56], ["blot analysis", "TEST", 82, 95], ["Q-PCR", "TEST", 100, 105], ["viral protein", "OBSERVATION", 22, 35]]], ["Subsequently, the viruses were removed and the medium was replaced.", [["the viruses", "TREATMENT", 14, 25], ["viruses", "OBSERVATION", 18, 25]]], ["Mizoribine (75 \u00b5M) was added to the cells during infection (co) or post-infection (2, 4, 8 and 16 h).", [["cells", "ANATOMY", 36, 41], ["Mizoribine", "CHEMICAL", 0, 10], ["infection", "DISEASE", 49, 58], ["Mizoribine", "CHEMICAL", 0, 10], ["Mizoribine", "SIMPLE_CHEMICAL", 0, 10], ["cells", "CELL", 36, 41], ["Mizoribine", "TREATMENT", 0, 10], ["infection", "PROBLEM", 49, 58], ["post-infection", "PROBLEM", 67, 81], ["infection", "OBSERVATION", 49, 58]]], ["After 48 h incubation, the FMDV 2B mRNA and VP1 protein in the cells were determined by Q-PCR and Western blot analysis, respectively.Q-PCRThe expression levels of FMDV 2B mRNA and \u03b2-actin were determined by real-time PCR as previously reported [21] .", [["cells", "ANATOMY", 63, 68], ["FMDV 2B", "GENE_OR_GENE_PRODUCT", 27, 34], ["VP1", "GENE_OR_GENE_PRODUCT", 44, 47], ["cells", "CELL", 63, 68], ["Q-PCRThe", "GENE_OR_GENE_PRODUCT", 134, 142], ["FMDV 2B", "GENE_OR_GENE_PRODUCT", 164, 171], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 181, 188], ["FMDV 2B mRNA", "RNA", 27, 39], ["VP1 protein", "PROTEIN", 44, 55], ["FMDV 2B mRNA", "RNA", 164, 176], ["\u03b2-actin", "PROTEIN", 181, 188], ["FMDV", "SPECIES", 27, 31], ["FMDV", "SPECIES", 164, 168], ["FMDV", "SPECIES", 27, 31], ["FMDV", "SPECIES", 164, 168], ["the FMDV 2B mRNA", "TEST", 23, 39], ["VP1 protein", "TEST", 44, 55], ["Q-PCR", "TEST", 88, 93], ["Western blot analysis", "TEST", 98, 119], ["FMDV 2B mRNA", "TEST", 164, 176], ["\u03b2-actin", "TREATMENT", 181, 188]]], ["Briefly, the total RNA from the IBRS-2 cells was extracted using TRizol reagent, and 1 \u00b5g of RNA was used in reverse transcription reaction using a PrimeScript\u2122 RT reagent kit containing gDNA Eraser, following the manufacturer's instructions.", [["IBRS-2 cells", "ANATOMY", 32, 44], ["IBRS-2 cells", "CELL", 32, 44], ["IBRS-2 cells", "CELL_LINE", 32, 44], ["the total RNA", "TEST", 9, 22], ["the IBRS", "TEST", 28, 36], ["TRizol reagent", "TREATMENT", 65, 79], ["RNA", "TREATMENT", 93, 96], ["a PrimeScript\u2122 RT reagent kit", "TREATMENT", 146, 175], ["gDNA Eraser", "TREATMENT", 187, 198], ["gDNA Eraser", "OBSERVATION", 187, 198]]], ["The reaction mixture for real-time PCR comprised diluted cDNA (1 \u00b5L), 10 \u00b5M primers, and 12.5 \u00b5L of SYBR Green Master Mix to a final volume of 25 \u00b5L.", [["diluted cDNA", "DNA", 49, 61], ["The reaction mixture", "PROBLEM", 0, 20], ["real-time PCR", "TEST", 25, 38], ["diluted cDNA", "TEST", 49, 61], ["a final volume", "TEST", 125, 139]]], ["The amplification conditions were as follows: 95 \u2022 C for 30 s, followed by 40 cycles of 95 \u2022 C for 5 s, 56 \u2022 C for 30 s, and 72 \u2022 C for 30 s.", [["The amplification conditions", "TEST", 0, 28]]], ["Dissociation curves were generated to analyze the individual PCR products after 40 cycles.", [["Dissociation curves", "TEST", 0, 19]]], ["The expression levels of FMDV mRNA genes were normalized against those of porcine \u03b2-actin mRNA.", [["FMDV", "ORGANISM", 25, 29], ["porcine", "ORGANISM", 74, 81], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 82, 89], ["FMDV mRNA", "RNA", 25, 34], ["porcine \u03b2-actin mRNA", "RNA", 74, 94], ["FMDV", "SPECIES", 25, 29], ["FMDV", "SPECIES", 25, 29], ["porcine", "SPECIES", 74, 81], ["FMDV mRNA genes", "PROBLEM", 25, 40], ["porcine \u03b2-actin mRNA", "TREATMENT", 74, 94]]], ["The analyses of the relative gene expression data were performed using the 2 \u2212\u2206\u2206CT method [22] .Western Blot AnalysisFor Western blot analysis, the cells were lysed with Pierce RIPA, and the cell lysates were resolved and separated by 12% SDS-PAGE and transferred to polyvinylidene fluoride membrane.", [["cells", "ANATOMY", 148, 153], ["cell lysates", "ANATOMY", 191, 203], ["polyvinylidene fluoride", "CHEMICAL", 267, 290], ["polyvinylidene fluoride", "CHEMICAL", 267, 290], ["cells", "CELL", 148, 153], ["cell lysates", "CELL", 191, 203], ["polyvinylidene fluoride membrane", "SIMPLE_CHEMICAL", 267, 299], ["CT method", "TEST", 80, 89], ["Blot Analysis", "TEST", 104, 117], ["Western blot analysis", "TEST", 121, 142], ["Pierce RIPA", "TREATMENT", 170, 181], ["the cell lysates", "TEST", 187, 203], ["polyvinylidene fluoride membrane", "TREATMENT", 267, 299]]], ["The membranes were probed with primary antibodies against FMDV VP1 protein (dilution, 1:1000) to detect virus replication.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["FMDV", "ORGANISM", 58, 62], ["primary antibodies", "PROTEIN", 31, 49], ["FMDV VP1 protein", "PROTEIN", 58, 74], ["FMDV", "SPECIES", 58, 62], ["FMDV", "SPECIES", 58, 62], ["primary antibodies", "TREATMENT", 31, 49], ["FMDV VP1 protein", "TEST", 58, 74], ["virus replication", "PROBLEM", 104, 121]]], ["A monoclonal antibody to \u03b2-actin (dilution, 1:4000) was used as a loading control.", [["\u03b2-actin", "CHEMICAL", 25, 32], ["\u03b2-actin", "SIMPLE_CHEMICAL", 25, 32], ["monoclonal antibody", "PROTEIN", 2, 21], ["\u03b2-actin", "PROTEIN", 25, 32], ["A monoclonal antibody to \u03b2-actin (dilution", "TREATMENT", 0, 42], ["a loading control", "TREATMENT", 64, 81]]], ["The membranes were incubated with goat anti-mouse and anti-rabbit conjugated with horseradish peroxidase for 1 h at room temperature and examined by Pierce\u2122 ECL Western Blotting Substrate.Indirect Immunofluorescence AssayTo determine the antiviral activity of mizoribine, indirect immunofluorescence assay (IFA) was performed as previously described with minor modifications [23] .", [["membranes", "ANATOMY", 4, 13], ["mizoribine", "CHEMICAL", 260, 270], ["mizoribine", "CHEMICAL", 260, 270], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["goat", "ORGANISM", 34, 38], ["anti-mouse", "GENE_OR_GENE_PRODUCT", 39, 49], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 82, 104], ["mizoribine", "SIMPLE_CHEMICAL", 260, 270], ["goat anti-mouse", "PROTEIN", 34, 49], ["horseradish peroxidase", "PROTEIN", 82, 104], ["goat", "SPECIES", 34, 38], ["anti-mouse", "SPECIES", 39, 49], ["anti-rabbit", "SPECIES", 54, 65], ["horseradish", "SPECIES", 82, 93], ["goat", "SPECIES", 34, 38], ["anti-rabbit", "SPECIES", 54, 65], ["goat anti-mouse and anti-rabbit conjugated", "TREATMENT", 34, 76], ["horseradish peroxidase", "TREATMENT", 82, 104], ["Indirect Immunofluorescence", "TEST", 188, 215], ["mizoribine", "TREATMENT", 260, 270], ["indirect immunofluorescence assay", "TEST", 272, 305]]], ["The IBRS-2 cells were seeded into a 12-well plate at a concentration of 3 \u00d7 10 5 cells/well and incubated for one day.", [["IBRS-2 cells", "ANATOMY", 4, 16], ["cells", "ANATOMY", 81, 86], ["IBRS-2 cells", "CELL", 4, 16], ["cells", "CELL", 81, 86], ["IBRS-2 cells", "CELL_LINE", 4, 16], ["The IBRS", "TEST", 0, 8]]], ["Subsequently, the cells were incubated with 100 TCID 50 FMDV for 1 h, and mizoribine diluted at indicated concentrations was added to the cells after removal of the viral inoculum.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 138, 143], ["mizoribine", "CHEMICAL", 74, 84], ["mizoribine", "CHEMICAL", 74, 84], ["cells", "CELL", 18, 23], ["mizoribine", "SIMPLE_CHEMICAL", 74, 84], ["cells", "CELL", 138, 143], ["FMDV", "SPECIES", 56, 60], ["FMDV", "SPECIES", 56, 60], ["mizoribine", "TREATMENT", 74, 84], ["removal", "TREATMENT", 150, 157], ["the viral inoculum", "PROBLEM", 161, 179], ["viral inoculum", "OBSERVATION", 165, 179]]], ["After 12 h of incubation, the IBRS-2 cells were washed thrice with PBS and fixed with 4% paraformaldehyde for 10 min.", [["IBRS-2 cells", "ANATOMY", 30, 42], ["paraformaldehyde", "CHEMICAL", 89, 105], ["IBRS-2 cells", "CELL", 30, 42], ["paraformaldehyde", "SIMPLE_CHEMICAL", 89, 105], ["IBRS-2 cells", "CELL_LINE", 30, 42], ["incubation", "TREATMENT", 14, 24], ["the IBRS-2 cells", "TREATMENT", 26, 42], ["PBS", "TREATMENT", 67, 70], ["4% paraformaldehyde", "TREATMENT", 86, 105]]], ["Then, paraformaldehyde was removed and absolute methanol was added to the cells and incubated for 5 min.", [["cells", "ANATOMY", 74, 79], ["methanol", "CHEMICAL", 48, 56], ["paraformaldehyde", "CHEMICAL", 6, 22], ["methanol", "CHEMICAL", 48, 56], ["paraformaldehyde", "SIMPLE_CHEMICAL", 6, 22], ["methanol", "SIMPLE_CHEMICAL", 48, 56], ["cells", "CELL", 74, 79], ["paraformaldehyde", "TREATMENT", 6, 22], ["absolute methanol", "TREATMENT", 39, 56]]], ["Subsequently, the cells were washed with PBS and blocked using blocking buffer (PBS supplemented with 0.3% Triton X-100 and 10% FBS).", [["cells", "ANATOMY", 18, 23], ["Triton X-100", "CHEMICAL", 107, 119], ["cells", "CELL", 18, 23], ["Triton X-100", "SIMPLE_CHEMICAL", 107, 119], ["FBS", "ORGANISM_SUBSTANCE", 128, 131], ["the cells", "TREATMENT", 14, 23], ["PBS", "TREATMENT", 41, 44], ["blocking buffer (PBS", "TREATMENT", 63, 83]]], ["Rabbit hyperimmune serum raised against type O FMDV (O/MY98/BY/2010) was used to probe type O FMDV, and peroxidase-conjugated goat anti-rabbit IgG (H + L) was employed as secondary antibody.", [["serum", "ANATOMY", 19, 24], ["Rabbit", "ORGANISM", 0, 6], ["hyperimmune", "ORGANISM", 7, 18], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["type O FMDV", "ORGANISM", 40, 51], ["FMDV", "ORGANISM", 94, 98], ["peroxidase", "GENE_OR_GENE_PRODUCT", 104, 114], ["goat", "ORGANISM", 126, 130], ["anti-rabbit IgG", "SIMPLE_CHEMICAL", 131, 146], ["H + L", "SIMPLE_CHEMICAL", 148, 153], ["peroxidase", "PROTEIN", 104, 114], ["conjugated goat anti-rabbit IgG", "PROTEIN", 115, 146], ["H + L", "PROTEIN", 148, 153], ["secondary antibody", "PROTEIN", 171, 189], ["Rabbit", "SPECIES", 0, 6], ["hyperimmune", "SPECIES", 7, 18], ["FMDV", "SPECIES", 47, 51], ["FMDV", "SPECIES", 94, 98], ["goat", "SPECIES", 126, 130], ["anti-rabbit", "SPECIES", 131, 142], ["Rabbit", "SPECIES", 0, 6], ["O FMDV (O/MY98/BY/2010)", "SPECIES", 45, 68], ["FMDV", "SPECIES", 94, 98], ["goat", "SPECIES", 126, 130], ["anti-rabbit", "SPECIES", 131, 142], ["Rabbit hyperimmune serum", "TEST", 0, 24], ["peroxidase", "TEST", 104, 114], ["conjugated goat anti-rabbit IgG", "TREATMENT", 115, 146], ["secondary antibody", "PROBLEM", 171, 189]]], ["Finally, the cells were counterstained with 4 , 6-diamidino-2-phenylindole (DAPI) and viewed under fluorescence microscope (Nikon ECLIPSE TS100 fluorescence microscope, Yokagawa Electric Corporation, Tokyo, Japan).Antiviral Activity of Mizoribine in VivoSpecific-pathogen-free three-day-old Kunming suckling mice were inoculated with 50 \u00b5g of mizoribine dissolved in 10 \u00b5M DMSO, 5% Tween 80, and 0.1 mL of PBS by subcutaneous neck injection.", [["cells", "ANATOMY", 13, 18], ["subcutaneous neck", "ANATOMY", 413, 430], ["4 , 6-diamidino-2-phenylindole", "CHEMICAL", 44, 74], ["Mizoribine", "CHEMICAL", 236, 246], ["mizoribine", "CHEMICAL", 343, 353], ["DMSO", "CHEMICAL", 373, 377], ["4 , 6-diamidino-2-phenylindole", "CHEMICAL", 44, 74], ["DAPI", "CHEMICAL", 76, 80], ["Mizoribine", "CHEMICAL", 236, 246], ["mizoribine", "CHEMICAL", 343, 353], ["DMSO", "CHEMICAL", 373, 377], ["Tween 80", "CHEMICAL", 382, 390], ["cells", "CELL", 13, 18], ["4 , 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 44, 74], ["DAPI", "SIMPLE_CHEMICAL", 76, 80], ["Mizoribine", "SIMPLE_CHEMICAL", 236, 246], ["VivoSpecific-pathogen", "ORGANISM", 250, 271], ["Kunming", "ORGANISM", 291, 298], ["suckling", "ORGANISM", 299, 307], ["mice", "ORGANISM", 308, 312], ["mizoribine", "SIMPLE_CHEMICAL", 343, 353], ["DMSO", "SIMPLE_CHEMICAL", 373, 377], ["neck", "ORGANISM_SUBDIVISION", 426, 430], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 308, 312], ["diamidino", "TREATMENT", 50, 59], ["fluorescence microscope", "TEST", 99, 122], ["Antiviral", "TREATMENT", 214, 223], ["Mizoribine", "TREATMENT", 236, 246], ["mizoribine dissolved", "TREATMENT", 343, 363], ["10 \u00b5M DMSO", "TREATMENT", 367, 377], ["PBS", "TREATMENT", 406, 409], ["subcutaneous neck injection", "TREATMENT", 413, 440], ["subcutaneous neck", "ANATOMY", 413, 430]]], ["The negative control was inoculated with PBS.", [["PBS", "TREATMENT", 41, 44], ["negative", "OBSERVATION", 4, 12]]], ["After 2 h, viral challenge was performed by intradermal injection with 100 50% lethal dose (LD 50 ) FMDV serotype O O/MY98/BY/2010 into the subcutaneous neck region of the mice.", [["intradermal", "ANATOMY", 44, 55], ["subcutaneous neck region", "ANATOMY", 140, 164], ["subcutaneous neck", "ORGAN", 140, 157], ["mice", "ORGANISM", 172, 176], ["FMDV", "SPECIES", 100, 104], ["mice", "SPECIES", 172, 176], ["FMDV", "SPECIES", 100, 104], ["O O/MY98/BY/2010", "SPECIES", 114, 130], ["mice", "SPECIES", 172, 176], ["viral challenge", "TREATMENT", 11, 26], ["subcutaneous neck", "ANATOMY", 140, 157]]], ["The animals were monitored for five days, and a log-rank test was performed for statistical analysis using GraphPad software.", [["animals", "ORGANISM", 4, 11], ["a log-rank test", "TEST", 46, 61], ["statistical analysis", "TEST", 80, 100], ["GraphPad software", "TEST", 107, 124]]], ["At 34 h post-infection, the suckling mice were euthanized and processed for histological and immunohistochemical investigations.Antiviral Activity of Mizoribine in VivoFor histopathological analysis, the heart tissues were fixed in 4% paraformaldehyde solution, embedded in paraffin, and cut into 4 \u00b5m thick sections for standard hematoxylin and eosin (H & E) staining.", [["heart tissues", "ANATOMY", 204, 217], ["sections", "ANATOMY", 308, 316], ["infection", "DISEASE", 13, 22], ["Mizoribine", "CHEMICAL", 150, 160], ["Mizoribine", "CHEMICAL", 150, 160], ["paraformaldehyde", "CHEMICAL", 235, 251], ["paraffin", "CHEMICAL", 274, 282], ["hematoxylin", "CHEMICAL", 330, 341], ["eosin", "CHEMICAL", 346, 351], ["mice", "ORGANISM", 37, 41], ["Mizoribine", "SIMPLE_CHEMICAL", 150, 160], ["heart tissues", "TISSUE", 204, 217], ["paraformaldehyde", "SIMPLE_CHEMICAL", 235, 251], ["sections", "MULTI-TISSUE_STRUCTURE", 308, 316], ["hematoxylin", "SIMPLE_CHEMICAL", 330, 341], ["H & E", "SIMPLE_CHEMICAL", 353, 358], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["infection", "PROBLEM", 13, 22], ["histological and immunohistochemical investigations", "TEST", 76, 127], ["Antiviral", "TREATMENT", 128, 137], ["Mizoribine", "TREATMENT", 150, 160], ["histopathological analysis", "TEST", 172, 198], ["4% paraformaldehyde solution", "TREATMENT", 232, 260], ["standard hematoxylin", "TREATMENT", 321, 341], ["infection", "OBSERVATION", 13, 22], ["heart tissues", "ANATOMY", 204, 217]]], ["With regard to immunohistochemical (IHC) studies, the FMDV antigen was detected as follows: 5 \u00b5m thick paraffin-embedded tissue sections were deparaffinized and treated with methanol-hydrogen peroxide for 10 min before heat-induced antigen retrieval in 0.01 M sodium citrate buffer (pH = 6) for 30 min.", [["tissue sections", "ANATOMY", 121, 136], ["methanol-hydrogen peroxide", "CHEMICAL", 174, 200], ["sodium citrate", "CHEMICAL", 260, 274], ["methanol", "CHEMICAL", 174, 182], ["hydrogen peroxide", "CHEMICAL", 183, 200], ["sodium citrate", "CHEMICAL", 260, 274], ["FMDV", "ORGANISM", 54, 58], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 121, 136], ["methanol-hydrogen peroxide", "SIMPLE_CHEMICAL", 174, 200], ["sodium citrate", "SIMPLE_CHEMICAL", 260, 274], ["FMDV antigen", "PROTEIN", 54, 66], ["FMDV", "SPECIES", 54, 58], ["FMDV", "SPECIES", 54, 58], ["immunohistochemical (IHC) studies", "TEST", 15, 48], ["the FMDV antigen", "TEST", 50, 66], ["methanol-hydrogen peroxide", "TREATMENT", 174, 200], ["heat-induced antigen retrieval", "TREATMENT", 219, 249], ["0.01 M sodium citrate buffer", "TREATMENT", 253, 281]]], ["Rabbit hyperimmune serum raised against type O FMDV (O/MY98/BY/2010) was used as primary antibody.", [["serum", "ANATOMY", 19, 24], ["Rabbit", "ORGANISM", 0, 6], ["hyperimmune", "ORGANISM", 7, 18], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["type O FMDV", "ORGANISM", 40, 51], ["primary antibody", "PROTEIN", 81, 97], ["Rabbit", "SPECIES", 0, 6], ["FMDV", "SPECIES", 47, 51], ["Rabbit", "SPECIES", 0, 6], ["O FMDV (O/MY98/BY/2010)", "SPECIES", 45, 68], ["Rabbit hyperimmune serum", "TEST", 0, 24], ["type O FMDV", "PROBLEM", 40, 51]]], ["The tissue sections were processed with a SPlink detection kit for 30 min and stained with DAB for 2 min at room temperature.", [["tissue sections", "ANATOMY", 4, 19], ["DAB", "CHEMICAL", 91, 94], ["tissue sections", "CANCER", 4, 19], ["DAB", "SIMPLE_CHEMICAL", 91, 94], ["a SPlink detection kit", "TEST", 40, 62]]], ["After washing, the tissue sections were counterstained, mounted, examined under a digital microscope (BA400Digital, Motic, Xiamen, China), and photographed.", [["tissue sections", "ANATOMY", 19, 34], ["tissue sections", "CANCER", 19, 34], ["the tissue sections", "TEST", 15, 34], ["a digital microscope", "TEST", 80, 100]]], ["The optical density of each tissue section was determined by Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).Statistical AnalysisAll the data are expressed as mean \u00b1 standard deviation (SD) for at least three independent experiments.", [["tissue section", "ANATOMY", 28, 42], ["tissue", "TISSUE", 28, 34], ["Statistical Analysis", "TEST", 129, 149], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19], ["each tissue", "OBSERVATION_MODIFIER", 23, 34]]], ["One-way ANOVA was used to analyze the difference between mizoribine and control groups using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA), version 7.04, and significant differences were defined at p < 0.05.", [["mizoribine", "CHEMICAL", 57, 67], ["mizoribine", "CHEMICAL", 57, 67], ["mizoribine", "SIMPLE_CHEMICAL", 57, 67], ["mizoribine", "TREATMENT", 57, 67], ["GraphPad Prism", "TEST", 93, 107], ["Software", "TEST", 120, 128], ["version", "TEST", 156, 163], ["significant", "OBSERVATION_MODIFIER", 174, 185]]], ["Selective index (SI) = CC 50 /EC 50 .", [["Selective index (SI", "TREATMENT", 0, 19]]]], "50f57239c1628ad65df4731082f46f3bea07d957": [["Introduction, reported its isolation from porcine duodenal extracts, Miklos Bodanszky successfully synthesized the Vasoactive Intestinal Peptide (VIP), and characterized its chemical nature.", [["duodenal extracts", "ANATOMY", 50, 67], ["porcine", "ORGANISM", 42, 49], ["duodenal extracts", "ORGANISM_SUBSTANCE", 50, 67], ["VIP", "GENE_OR_GENE_PRODUCT", 146, 149], ["porcine", "SPECIES", 42, 49], ["porcine", "SPECIES", 42, 49], ["porcine duodenal extracts", "TREATMENT", 42, 67], ["Miklos Bodanszky", "TREATMENT", 69, 85], ["the Vasoactive Intestinal Peptide", "TREATMENT", 111, 144], ["duodenal", "ANATOMY", 50, 58], ["Vasoactive Intestinal", "OBSERVATION", 115, 136], ["chemical nature", "OBSERVATION", 174, 189]]], ["Intensive research by numerous investigators over the years since has revealed VIP to have multiple biological effects, important physiological infl uence in many organ systems, and strong promise as a therapeutic agent for a number of varied human disorders.", [["organ", "ANATOMY", 163, 168], ["VIP", "GENE_OR_GENE_PRODUCT", 79, 82], ["organ", "ORGAN", 163, 168], ["human", "ORGANISM", 243, 248], ["human", "SPECIES", 243, 248], ["human", "SPECIES", 243, 248], ["VIP", "PROBLEM", 79, 82], ["multiple biological effects", "PROBLEM", 91, 118], ["a therapeutic agent", "TREATMENT", 200, 219], ["varied human disorders", "PROBLEM", 236, 258]]], ["Produced mainly in neurons of the central and peripheral nervous systems, VIP is therefore widely distributed throughout the body.", [["neurons", "ANATOMY", 19, 26], ["peripheral nervous systems", "ANATOMY", 46, 72], ["body", "ANATOMY", 125, 129], ["neurons", "CELL", 19, 26], ["central", "ANATOMICAL_SYSTEM", 34, 41], ["peripheral nervous systems", "ANATOMICAL_SYSTEM", 46, 72], ["VIP", "GENE_OR_GENE_PRODUCT", 74, 77], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["neurons", "ANATOMY_MODIFIER", 19, 26], ["central", "ANATOMY_MODIFIER", 34, 41], ["peripheral", "ANATOMY_MODIFIER", 46, 56], ["nervous systems", "ANATOMY", 57, 72], ["widely", "OBSERVATION_MODIFIER", 91, 97], ["body", "ANATOMY", 125, 129]]], ["Its biological actions include: Relaxation of vascular and non-vascular smooth muscle, inhibition of smooth muscle cell proliferation, suppression of infl ammation, modulation of immune function, and antiapoptotic, pro-survival effects.", [["vascular", "ANATOMY", 46, 54], ["non-vascular smooth muscle", "ANATOMY", 59, 85], ["smooth muscle cell", "ANATOMY", 101, 119], ["vascular", "MULTI-TISSUE_STRUCTURE", 46, 54], ["non-vascular smooth muscle", "TISSUE", 59, 85], ["smooth muscle cell", "CELL", 101, 119], ["infl ammation", "GENE_OR_GENE_PRODUCT", 150, 163], ["smooth muscle cell", "CELL_TYPE", 101, 119], ["smooth muscle cell proliferation", "PROBLEM", 101, 133], ["infl ammation", "PROBLEM", 150, 163], ["immune function", "PROBLEM", 179, 194], ["vascular", "ANATOMY", 46, 54], ["non-vascular", "ANATOMY_MODIFIER", 59, 71], ["smooth muscle", "ANATOMY", 72, 85], ["smooth muscle cell proliferation", "OBSERVATION", 101, 133], ["immune function", "OBSERVATION", 179, 194]]], ["Among its likely physiological roles, deduced in part from studies of mice lacking the VIP gene and the use of specifi c antibodies, VIP serves as: A co-transmitter, with NO and CO, of non-adrenergic, non-cholinergic smooth muscle relaxation; a modulator of infl ammation, apoptosis, and smooth muscle cell proliferation; and a promoter of cell survival.", [["non-cholinergic smooth muscle", "ANATOMY", 201, 230], ["smooth muscle cell", "ANATOMY", 288, 306], ["cell", "ANATOMY", 340, 344], ["NO", "CHEMICAL", 171, 173], ["NO", "CHEMICAL", 171, 173], ["CO", "CHEMICAL", 178, 180], ["mice", "ORGANISM", 70, 74], ["VIP", "GENE_OR_GENE_PRODUCT", 87, 90], ["specifi c antibodies", "GENE_OR_GENE_PRODUCT", 111, 131], ["VIP", "GENE_OR_GENE_PRODUCT", 133, 136], ["NO", "SIMPLE_CHEMICAL", 171, 173], ["CO", "SIMPLE_CHEMICAL", 178, 180], ["smooth muscle", "TISSUE", 217, 230], ["infl", "GENE_OR_GENE_PRODUCT", 258, 262], ["smooth muscle cell", "CELL", 288, 306], ["cell", "CELL", 340, 344], ["VIP gene", "DNA", 87, 95], ["specifi c antibodies", "PROTEIN", 111, 131], ["smooth muscle cell", "CELL_TYPE", 288, 306], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["specifi c antibodies", "TREATMENT", 111, 131], ["non-adrenergic", "PROBLEM", 185, 199], ["non-cholinergic smooth muscle relaxation", "PROBLEM", 201, 241], ["infl ammation", "PROBLEM", 258, 271], ["apoptosis", "PROBLEM", 273, 282], ["smooth muscle cell proliferation", "PROBLEM", 288, 320], ["a promoter of cell survival", "TREATMENT", 326, 353], ["likely", "UNCERTAINTY", 10, 16], ["non-cholinergic", "OBSERVATION", 201, 216], ["smooth muscle relaxation", "OBSERVATION", 217, 241], ["smooth muscle cell proliferation", "OBSERVATION", 288, 320], ["cell survival", "OBSERVATION", 340, 353]]], ["Based on the preceding information, as well as on the use of the peptide in experimental models of disease, and in some instances on early clinical trials, VIP and its analogs may prove to be novel and effective agents for the treatment of a variety of human disorders.", [["VIP", "GENE_OR_GENE_PRODUCT", 156, 159], ["human", "ORGANISM", 253, 258], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258], ["the peptide", "TREATMENT", 61, 72], ["disease", "PROBLEM", 99, 106], ["VIP", "TREATMENT", 156, 159], ["effective agents", "TREATMENT", 202, 218], ["the treatment", "TREATMENT", 223, 236], ["human disorders", "PROBLEM", 253, 268], ["disease", "OBSERVATION", 99, 106]]], ["These include: Bronchial asthma; pulmonary hypertension; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Multi-Organ Dysfunction Syndrome (MODS); infl ammatory/auto-immune disorders, such as rheumatoid arthritis and infl ammatory bowel disease; cardiovascular disorders; neurodegenerative diseases, including Alzheimer's disease; and small-cell lung cancer.", [["pulmonary", "ANATOMY", 33, 42], ["Lung", "ANATOMY", 63, 67], ["bowel", "ANATOMY", 244, 249], ["cardiovascular", "ANATOMY", 259, 273], ["small-cell lung cancer", "ANATOMY", 348, 370], ["Bronchial asthma", "DISEASE", 15, 31], ["pulmonary hypertension", "DISEASE", 33, 55], ["Lung Injury", "DISEASE", 63, 74], ["Acute Respiratory Distress Syndrome", "DISEASE", 75, 110], ["ARDS", "DISEASE", 112, 116], ["Multi-Organ Dysfunction Syndrome", "DISEASE", 119, 151], ["MODS", "DISEASE", 153, 157], ["auto-immune disorders", "DISEASE", 174, 195], ["rheumatoid arthritis", "DISEASE", 205, 225], ["infl ammatory bowel disease", "DISEASE", 230, 257], ["cardiovascular disorders", "DISEASE", 259, 283], ["neurodegenerative diseases", "DISEASE", 285, 311], ["Alzheimer's disease", "DISEASE", 323, 342], ["small-cell lung cancer", "DISEASE", 348, 370], ["pulmonary", "ORGAN", 33, 42], ["Lung", "ORGAN", 63, 67], ["bowel", "ORGAN", 244, 249], ["small-cell lung cancer", "CANCER", 348, 370], ["Bronchial asthma", "PROBLEM", 15, 31], ["pulmonary hypertension", "PROBLEM", 33, 55], ["Acute Lung Injury", "PROBLEM", 57, 74], ["Acute Respiratory Distress Syndrome", "PROBLEM", 75, 110], ["ARDS)", "PROBLEM", 112, 117], ["Multi-Organ Dysfunction Syndrome", "PROBLEM", 119, 151], ["MODS", "PROBLEM", 153, 157], ["infl ammatory", "PROBLEM", 160, 173], ["auto-immune disorders", "PROBLEM", 174, 195], ["rheumatoid arthritis", "PROBLEM", 205, 225], ["infl ammatory bowel disease", "PROBLEM", 230, 257], ["cardiovascular disorders", "PROBLEM", 259, 283], ["neurodegenerative diseases", "PROBLEM", 285, 311], ["Alzheimer's disease", "PROBLEM", 323, 342], ["small-cell lung cancer", "PROBLEM", 348, 370], ["Bronchial", "ANATOMY", 15, 24], ["asthma", "OBSERVATION", 25, 31], ["pulmonary", "ANATOMY", 33, 42], ["hypertension", "OBSERVATION", 43, 55], ["Acute", "OBSERVATION_MODIFIER", 57, 62], ["Lung", "ANATOMY", 63, 67], ["Injury", "OBSERVATION", 68, 74], ["Acute", "OBSERVATION_MODIFIER", 75, 80], ["Respiratory Distress Syndrome", "OBSERVATION", 81, 110], ["ARDS", "OBSERVATION", 112, 116], ["Organ", "ANATOMY", 125, 130], ["Dysfunction", "OBSERVATION", 131, 142], ["rheumatoid arthritis", "OBSERVATION", 205, 225], ["bowel", "ANATOMY", 244, 249], ["disease", "OBSERVATION", 250, 257], ["neurodegenerative diseases", "OBSERVATION", 285, 311], ["small", "OBSERVATION_MODIFIER", 348, 353], ["-cell", "OBSERVATION", 353, 358], ["lung", "ANATOMY", 359, 363], ["cancer", "OBSERVATION", 364, 370]]], ["After some delay, the pace of progress in this area seems to be accelerating.", [["some delay", "PROBLEM", 6, 16], ["delay", "OBSERVATION_MODIFIER", 11, 16]]], ["There is thus reason to hope that the promise fueled by much work, inspired and supported by Viktor Mutt and Miklos Bodanszky, will soon be fulfi lled.Potent and selective peptide agonists for human melanocortin receptors 1b and 5Bednarek, Maria A Merck Research Laboratories, UNITED STATES -Melanocyte-stimulating hormones ( MSH), through interactions with the cell surface receptors (melanocortin receptors 1, 3, 4 and 5; MC1,3-5R), elicits numerous physiological functions in the CNS and periphery.", [["cell surface", "ANATOMY", 362, 374], ["CNS", "ANATOMY", 483, 486], ["human", "ORGANISM", 193, 198], ["melanocortin receptors 1b", "GENE_OR_GENE_PRODUCT", 199, 224], ["STATES -Melanocyte-stimulating hormones", "GENE_OR_GENE_PRODUCT", 284, 323], ["MSH", "GENE_OR_GENE_PRODUCT", 326, 329], ["cell", "CELL", 362, 366], ["melanocortin receptors 1", "GENE_OR_GENE_PRODUCT", 386, 410], ["3", "GENE_OR_GENE_PRODUCT", 412, 413], ["4", "GENE_OR_GENE_PRODUCT", 415, 416], ["5", "GENE_OR_GENE_PRODUCT", 421, 422], ["MC1,3-5R", "GENE_OR_GENE_PRODUCT", 424, 432], ["CNS", "ANATOMICAL_SYSTEM", 483, 486], ["cell surface receptors", "PROTEIN", 362, 384], ["melanocortin receptors 1, 3, 4 and 5", "PROTEIN", 386, 422], ["MC1,3", "PROTEIN", 424, 429], ["5R", "PROTEIN", 430, 432], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["Potent and selective peptide agonists", "TREATMENT", 151, 188], ["human melanocortin receptors", "TREATMENT", 193, 221], ["the cell surface receptors", "TREATMENT", 358, 384], ["melanocortin receptors", "TREATMENT", 386, 408], ["physiological functions", "OBSERVATION", 452, 475], ["CNS", "ANATOMY", 483, 486], ["periphery", "ANATOMY_MODIFIER", 491, 500]]], ["Of those receptors, MC1R and MC5R have been predominantly found on the surface of several types of skin and immune cells, in a number of endocrine and exocrine glands, and others.", [["surface", "ANATOMY", 71, 78], ["skin", "ANATOMY", 99, 103], ["immune cells", "ANATOMY", 108, 120], ["endocrine", "ANATOMY", 137, 146], ["exocrine glands", "ANATOMY", 151, 166], ["MC1R", "GENE_OR_GENE_PRODUCT", 20, 24], ["MC5R", "GENE_OR_GENE_PRODUCT", 29, 33], ["surface", "CELLULAR_COMPONENT", 71, 78], ["skin", "ORGAN", 99, 103], ["immune cells", "CELL", 108, 120], ["endocrine", "ANATOMICAL_SYSTEM", 137, 146], ["exocrine glands", "ORGAN", 151, 166], ["MC1R", "PROTEIN", 20, 24], ["MC5R", "PROTEIN", 29, 33], ["skin and immune cells", "CELL_TYPE", 99, 120], ["those receptors", "TEST", 3, 18], ["MC1R and MC5R", "TEST", 20, 33], ["skin and immune cells", "PROBLEM", 99, 120], ["predominantly", "OBSERVATION_MODIFIER", 44, 57], ["several types", "OBSERVATION_MODIFIER", 82, 95], ["skin", "ANATOMY", 99, 103], ["immune cells", "OBSERVATION", 108, 120], ["exocrine glands", "ANATOMY", 151, 166]]], ["To elucidate and differentiate the role of MC1R and MC5R in some skin disorders, and immunomodulatory and anti-infl ammatory actions of MSH, selective ligands for are necessary.", [["skin", "ANATOMY", 65, 69], ["skin disorders", "DISEASE", 65, 79], ["MC1R", "GENE_OR_GENE_PRODUCT", 43, 47], ["MC5R", "GENE_OR_GENE_PRODUCT", 52, 56], ["skin", "ORGAN", 65, 69], ["MSH", "GENE_OR_GENE_PRODUCT", 136, 139], ["MC1R", "PROTEIN", 43, 47], ["MC5R", "PROTEIN", 52, 56], ["MC5R", "TREATMENT", 52, 56], ["some skin disorders", "PROBLEM", 60, 79], ["immunomodulatory", "TREATMENT", 85, 101], ["anti-infl ammatory actions", "TREATMENT", 106, 132], ["MSH", "PROBLEM", 136, 139], ["skin", "ANATOMY", 65, 69], ["disorders", "OBSERVATION", 70, 79]]], ["In the structure of the endogenous agonist -MSH, the His 6 -Phe 7 -Arg 8 -Trp 9 segment has been recognized as critical to molecular recognition at hMC5R and hMC1bR (an isoform of the human MC1aR with virtually identical pharmacological properties).", [["His 6 -Phe 7 -Arg 8 -Trp 9", "CHEMICAL", 53, 79], ["His 6 -Phe 7 -Arg 8 -Trp", "CHEMICAL", 53, 77], ["MSH", "GENE_OR_GENE_PRODUCT", 44, 47], ["hMC5R", "GENE_OR_GENE_PRODUCT", 148, 153], ["hMC1bR", "GENE_OR_GENE_PRODUCT", 158, 164], ["human", "ORGANISM", 184, 189], ["MC1aR", "GENE_OR_GENE_PRODUCT", 190, 195], ["hMC5R", "PROTEIN", 148, 153], ["hMC1bR", "PROTEIN", 158, 164], ["human MC1aR", "PROTEIN", 184, 195], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["Phe", "TEST", 60, 63], ["Arg", "TEST", 67, 70], ["hMC5R", "TEST", 148, 153], ["hMC1bR", "TEST", 158, 164], ["endogenous agonist", "OBSERVATION", 24, 42]]], ["The same segment has also been crucial for potency of various synthetic analogs of MSH at hMC1b,5R.", [["MSH", "GENE_OR_GENE_PRODUCT", 83, 86], ["hMC1b", "GENE_OR_GENE_PRODUCT", 90, 95]]], ["One of the most broadly used analogs of MSH is a cyclic peptide, Ac-Nle 4 -cyclo-(Asp 5 -His 6 -D-Phe 7 -Arg 8 -Trp 9 -Lys 10 )-NH 2 , designated MTII.", [["MSH", "CHEMICAL", 40, 43], ["Ac-Nle 4 -cyclo-(Asp 5 -His 6 -D-Phe 7 -Arg 8 -Trp 9 -Lys", "CHEMICAL", 65, 122], ["Ac-Nle 4 -cyclo-(Asp 5 -His 6 -D-Phe 7 -Arg 8 -Trp 9 -Lys 10 )-NH 2", "CHEMICAL", 65, 132], ["MSH", "GENE_OR_GENE_PRODUCT", 40, 43], ["cyclic peptide", "SIMPLE_CHEMICAL", 49, 63], ["Ac-Nle 4 -cyclo-(Asp 5 -His 6 -D-Phe 7 -Arg 8 -Trp 9 -Lys 10 )-NH 2", "SIMPLE_CHEMICAL", 65, 132], ["MTII", "SIMPLE_CHEMICAL", 146, 150], ["MTII", "PROTEIN", 146, 150], ["a cyclic peptide", "TEST", 47, 63], ["Ac", "TEST", 65, 67], ["Nle", "TEST", 68, 71], ["cyclo", "TEST", 75, 80], ["Asp", "TEST", 82, 85], ["Phe", "TEST", 98, 101], ["Arg", "TEST", 105, 108], ["Trp", "TEST", 112, 115], ["Lys", "TEST", 119, 122]]], ["Herein, the role of Trp 9 in the interactions of MTII with the hMC1b,5R was examined through the ligand structure -function studies.", [["Trp 9", "CHEMICAL", 20, 25], ["Trp", "CHEMICAL", 20, 23], ["Trp 9", "GENE_OR_GENE_PRODUCT", 20, 25], ["MTII", "GENE_OR_GENE_PRODUCT", 49, 53], ["hMC1b", "GENE_OR_GENE_PRODUCT", 63, 68], ["5R", "GENE_OR_GENE_PRODUCT", 69, 71], ["Trp 9", "PROTEIN", 20, 25], ["MTII", "PROTEIN", 49, 53], ["hMC1b,5R", "PROTEIN", 63, 71]]], ["The side chain of Trp 9 was found to be not critical for high agonist potency at the hMC1b,5R; however, it was essential for potency of the MTII peptides at the human melanocortin receptors 3 and 4 (hMC3, 4R) .", [["Trp 9", "CHEMICAL", 18, 23], ["Trp", "CHEMICAL", 18, 21], ["Trp", "AMINO_ACID", 18, 21], ["9", "GENE_OR_GENE_PRODUCT", 22, 23], ["MTII peptides", "GENE_OR_GENE_PRODUCT", 140, 153], ["human", "ORGANISM", 161, 166], ["melanocortin receptors 3", "GENE_OR_GENE_PRODUCT", 167, 191], ["4", "GENE_OR_GENE_PRODUCT", 196, 197], ["hMC3", "GENE_OR_GENE_PRODUCT", 199, 203], ["hMC1b", "PROTEIN", 85, 90], ["human melanocortin receptors 3 and 4", "PROTEIN", 161, 197], ["hMC3", "PROTEIN", 199, 203], ["4R", "PROTEIN", 205, 207], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["The side chain of Trp 9", "TEST", 0, 23], ["high agonist potency", "PROBLEM", 57, 77], ["the MTII peptides", "TREATMENT", 136, 153], ["the human melanocortin receptors", "TREATMENT", 157, 189]]], ["Several analogs of MTII are reported which are potent agonists at hMC1bR or hMC5R, and of high receptor subtype selectivity.Potent and selective peptide agonists for human melanocortin receptors 1b and 5The lantibiotics are a family of antimicrobial peptides, characterised by complex structures featuring multiple thioether bridges (from the residues lanthionine and methyl lanthionine) and other residues, such as dehydro amino acids and other bridges (1) .", [["MTII", "CHEMICAL", 19, 23], ["thioether", "CHEMICAL", 315, 324], ["lanthionine", "CHEMICAL", 352, 363], ["methyl lanthionine", "CHEMICAL", 368, 386], ["dehydro amino acids", "CHEMICAL", 416, 435], ["MTII", "CHEMICAL", 19, 23], ["thioether", "CHEMICAL", 315, 324], ["lanthionine", "CHEMICAL", 352, 363], ["methyl lanthionine", "CHEMICAL", 368, 386], ["dehydro amino acids", "CHEMICAL", 416, 435], ["MTII", "SIMPLE_CHEMICAL", 19, 23], ["hMC1bR", "GENE_OR_GENE_PRODUCT", 66, 72], ["hMC5R", "GENE_OR_GENE_PRODUCT", 76, 81], ["human", "ORGANISM", 166, 171], ["melanocortin receptors 1b", "GENE_OR_GENE_PRODUCT", 172, 197], ["lanthionine", "SIMPLE_CHEMICAL", 352, 363], ["methyl lanthionine", "SIMPLE_CHEMICAL", 368, 386], ["dehydro amino acids", "SIMPLE_CHEMICAL", 416, 435], ["hMC1bR", "PROTEIN", 66, 72], ["hMC5R", "PROTEIN", 76, 81], ["human melanocortin receptors 1b and 5", "PROTEIN", 166, 203], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["Several analogs of MTII", "TREATMENT", 0, 23], ["Potent and selective peptide agonists", "TREATMENT", 124, 161], ["human melanocortin receptors", "TREATMENT", 166, 194], ["The lantibiotics", "TREATMENT", 203, 219], ["antimicrobial peptides", "TREATMENT", 236, 258], ["multiple thioether bridges", "PROBLEM", 306, 332], ["the residues lanthionine", "TREATMENT", 339, 363], ["methyl lanthionine)", "TREATMENT", 368, 387], ["other residues", "PROBLEM", 392, 406], ["dehydro amino acids", "TREATMENT", 416, 435], ["multiple", "OBSERVATION_MODIFIER", 306, 314], ["thioether bridges", "OBSERVATION", 315, 332]]], ["Nisin is the best studied Type I lantibiotic.", [["Nisin", "CHEMICAL", 0, 5], ["Nisin", "CHEMICAL", 0, 5], ["Nisin", "SIMPLE_CHEMICAL", 0, 5], ["Type I lantibiotic", "PROTEIN", 26, 44], ["Type I", "SPECIES", 26, 32], ["Nisin", "TREATMENT", 0, 5], ["Type I lantibiotic", "TREATMENT", 26, 44]]], ["It has a dual mode of action on bacterial membranes.", [["membranes", "ANATOMY", 42, 51], ["bacterial membranes", "CELLULAR_COMPONENT", 32, 51], ["bacterial membranes", "TREATMENT", 32, 51], ["dual mode", "OBSERVATION_MODIFIER", 9, 18], ["bacterial membranes", "OBSERVATION", 32, 51]]], ["NMR studies have shown that the C-terminus (rings A and B) recognises and specifi cally bind lipid II (a key component of the biosynthesis of bacterial membranes) (2) , this is then followed by pore formation by the nisin/lipid II complex, mediated by C-terminus (rings C, D/E).", [["membranes", "ANATOMY", 152, 161], ["pore", "ANATOMY", 194, 198], ["lipid II", "CHEMICAL", 93, 101], ["C", "CHEMICAL", 32, 33], ["C", "CHEMICAL", 252, 253], ["C-terminus", "GENE_OR_GENE_PRODUCT", 32, 42], ["rings A", "GENE_OR_GENE_PRODUCT", 44, 51], ["B", "GENE_OR_GENE_PRODUCT", 56, 57], ["lipid II", "GENE_OR_GENE_PRODUCT", 93, 101], ["pore", "CELLULAR_COMPONENT", 194, 198], ["nisin/lipid II", "GENE_OR_GENE_PRODUCT", 216, 230], ["rings C", "SIMPLE_CHEMICAL", 264, 271], ["C-terminus", "PROTEIN", 32, 42], ["lipid II", "PROTEIN", 93, 101], ["nisin", "PROTEIN", 216, 221], ["lipid II complex", "PROTEIN", 222, 238], ["C-terminus", "PROTEIN", 252, 262], ["rings C, D/E", "PROTEIN", 264, 276], ["NMR studies", "TEST", 0, 11], ["the C-terminus (rings A and B) recognises", "PROBLEM", 28, 69], ["bacterial membranes", "PROBLEM", 142, 161], ["the nisin/lipid II complex", "TREATMENT", 212, 238], ["bacterial membranes", "OBSERVATION", 142, 161]]], ["Both parts of nisin appear to possess antimicrobial action, both separately and in synergy, and the structure of the intermediate hinge region also affects the activity.", [["nisin", "CHEMICAL", 14, 19], ["nisin", "GENE_OR_GENE_PRODUCT", 14, 19], ["intermediate hinge region", "PROTEIN", 117, 142], ["nisin", "TREATMENT", 14, 19], ["antimicrobial action", "TREATMENT", 38, 58], ["antimicrobial", "OBSERVATION", 38, 51], ["intermediate hinge", "OBSERVATION", 117, 135], ["activity", "OBSERVATION_MODIFIER", 160, 168]]], ["The biosynthetic pathways responsible for the production of the lantibiotics are now well understood (1) : Ser or Thr residues in a precursor peptide are dehydrated to give Dha or Dhb residues, which are then cyclised with Cys residues to form the thioether bridges.", [["Thr", "CHEMICAL", 114, 117], ["Cys", "CHEMICAL", 223, 226], ["thioether", "CHEMICAL", 248, 257], ["Ser", "CHEMICAL", 107, 110], ["Thr", "CHEMICAL", 114, 117], ["Dha", "CHEMICAL", 173, 176], ["Dhb", "CHEMICAL", 180, 183], ["Cys", "CHEMICAL", 223, 226], ["thioether", "CHEMICAL", 248, 257], ["Ser", "AMINO_ACID", 107, 110], ["Thr residues", "AMINO_ACID", 114, 126], ["Dha", "GENE_OR_GENE_PRODUCT", 173, 176], ["Dha", "PROTEIN", 173, 176], ["the lantibiotics", "TREATMENT", 60, 76], ["Ser or Thr residues", "PROBLEM", 107, 126], ["a precursor peptide", "PROBLEM", 130, 149], ["dehydrated", "PROBLEM", 154, 164], ["Dhb residues", "PROBLEM", 180, 192], ["Cys residues", "PROBLEM", 223, 235], ["the thioether bridges", "TREATMENT", 244, 265]]], ["Based on these pathways, a number of biomimetic strategies for the synthesis of lantibiotics have been used, however these are not always suitable for the synthesis of multiply bridged peptides (3) .", [["lantibiotics", "SIMPLE_CHEMICAL", 80, 92], ["biomimetic strategies", "TREATMENT", 37, 58], ["the synthesis of lantibiotics", "TREATMENT", 63, 92]]], ["We have recently developed methodology for the synthesis of lanthionine-bridged peptides based on the use of orthogonally protected lanthionine, and have previously reported the synthesis of analogues of ring C of nisin ( 4) .", [["lanthionine", "CHEMICAL", 60, 71], ["lanthionine", "CHEMICAL", 132, 143], ["lanthionine", "CHEMICAL", 60, 71], ["lanthionine", "CHEMICAL", 132, 143], ["lanthionine", "SIMPLE_CHEMICAL", 60, 71], ["lanthionine", "SIMPLE_CHEMICAL", 132, 143], ["ring C", "SIMPLE_CHEMICAL", 204, 210], ["nisin ( 4)", "SIMPLE_CHEMICAL", 214, 224], ["the synthesis of lanthionine", "TREATMENT", 43, 71], ["bridged peptides", "TREATMENT", 72, 88], ["orthogonally protected lanthionine", "TREATMENT", 109, 143], ["analogues of ring C of nisin", "TREATMENT", 191, 219]]], ["In this presentation we now report the extension of this approach to give lanthionine-containing peptides with multiple bridges, and present the synthesis and structure of analogues of the C-terminus of nisin (rings A and B).", [["lanthionine", "CHEMICAL", 74, 85], ["lanthionine", "CHEMICAL", 74, 85], ["C", "CHEMICAL", 189, 190], ["lanthionine", "SIMPLE_CHEMICAL", 74, 85], ["nisin", "SIMPLE_CHEMICAL", 203, 208], ["C-terminus", "PROTEIN", 189, 199], ["nisin", "PROTEIN", 203, 208], ["B", "PROTEIN", 222, 223], ["this approach", "TREATMENT", 52, 65], ["lanthionine-containing peptides", "TREATMENT", 74, 105], ["multiple bridges", "TREATMENT", 111, 127], ["the synthesis", "TREATMENT", 141, 154], ["the C-terminus of nisin (rings A and B)", "TREATMENT", 185, 224]]], ["References: 1 C. Chatterjee, M. Paul, L. Xie, W. A. van der Donk Chem Rev., 105, 633-683 (2005S02-3Solid phase synthesis of alkene dipeptidosulfonamide isosteres using olefi n cross metathesis and the incorporation into amyloidogenic amylin(20-29) 1 Brouwer, Arwin J.; Elgersma, Ronald C.; Rijkers, Dirk T. S.; Liskamp, Rob M. J. Department of Medicinal Chemistry and Chemical Biology, Faculty of Science, Utrecht University, NETHERLANDS The replacement of a backbone amide bond in peptides is a strategy which has been widely used to study peptide backbone interactions as well as for stabilization of peptides towards enzymatic degradation.", [["2005S02-3Solid", "CHEMICAL", 90, 104], ["alkene dipeptidosulfonamide", "CHEMICAL", 124, 151], ["olefi", "CHEMICAL", 168, 173], ["alkene dipeptidosulfonamide", "CHEMICAL", 124, 151], ["olefi n", "CHEMICAL", 168, 175], ["amide", "CHEMICAL", 468, 473], ["alkene dipeptidosulfonamide isosteres", "SIMPLE_CHEMICAL", 124, 161], ["alkene dipeptidosulfonamide isosteres", "TREATMENT", 124, 161], ["olefi n cross metathesis", "TREATMENT", 168, 192], ["the incorporation into amyloidogenic amylin", "TREATMENT", 197, 240], ["The replacement of a backbone amide bond in peptides", "TREATMENT", 438, 490], ["a strategy", "TREATMENT", 494, 504], ["stabilization of peptides", "TREATMENT", 586, 611], ["enzymatic degradation", "PROBLEM", 620, 641], ["replacement", "OBSERVATION", 442, 453]]], ["Two amide bond surrogates that mimic the amide bond are the (E)-alkene dipeptide isostere and the sulfonamide.", [["sulfonamide", "CHEMICAL", 98, 109], ["amide", "CHEMICAL", 4, 9], ["amide", "CHEMICAL", 41, 46], ["(E)-alkene dipeptide", "CHEMICAL", 60, 80], ["sulfonamide", "CHEMICAL", 98, 109], ["(E)-alkene dipeptide isostere", "SIMPLE_CHEMICAL", 60, 89], ["sulfonamide", "SIMPLE_CHEMICAL", 98, 109], ["Two amide bond surrogates", "TREATMENT", 0, 25], ["the amide bond", "PROBLEM", 37, 51], ["the (E)-alkene dipeptide isostere", "TREATMENT", 56, 89], ["the sulfonamide", "TREATMENT", 94, 109]]], ["The sulfonamide increases the fl exibility of the backbone, is resistant to enzymatic degradation and is conveniently accessible.", [["sulfonamide", "CHEMICAL", 4, 15], ["sulfonamide", "CHEMICAL", 4, 15], ["sulfonamide", "SIMPLE_CHEMICAL", 4, 15], ["The sulfonamide", "TREATMENT", 0, 15], ["enzymatic degradation", "PROBLEM", 76, 97], ["fl exibility", "OBSERVATION", 30, 42], ["backbone", "ANATOMY_MODIFIER", 50, 58], ["resistant", "OBSERVATION_MODIFIER", 63, 72], ["enzymatic degradation", "OBSERVATION", 76, 97]]], ["2 A disadvantage of peptidosulfonamides might be the presence of an additional carbon atom in each amino sulfonic acid residue, which is needed for stability reasons.", [["peptidosulfonamides", "CHEMICAL", 20, 39], ["amino sulfonic acid", "CHEMICAL", 99, 118], ["peptidosulfonamides", "CHEMICAL", 20, 39], ["carbon", "CHEMICAL", 79, 85], ["amino sulfonic acid", "CHEMICAL", 99, 118], ["peptidosulfonamides", "SIMPLE_CHEMICAL", 20, 39], ["carbon atom", "SIMPLE_CHEMICAL", 79, 90], ["amino sulfonic acid", "SIMPLE_CHEMICAL", 99, 118], ["peptidosulfonamides", "TREATMENT", 20, 39], ["an additional carbon atom", "TREATMENT", 65, 90], ["each amino sulfonic acid residue", "TREATMENT", 94, 126], ["carbon atom", "OBSERVATION", 79, 90], ["sulfonic acid residue", "OBSERVATION", 105, 126]]], ["As a result, there is no exact match of a peptidosulfonamide and its parent peptide.", [["peptidosulfonamide", "CHEMICAL", 42, 60], ["peptidosulfonamide", "CHEMICAL", 42, 60], ["peptidosulfonamide", "SIMPLE_CHEMICAL", 42, 60], ["a peptidosulfonamide", "TREATMENT", 40, 60], ["no", "UNCERTAINTY", 22, 24]]], ["By combining the alkene dipeptide isostere with the sulfonamide a new peptidomimetic was designed and synthesized: the alkene dipeptidosulfonamide isostere.", [["alkene dipeptide", "CHEMICAL", 17, 33], ["sulfonamide", "CHEMICAL", 52, 63], ["dipeptidosulfonamide", "CHEMICAL", 126, 146], ["alkene dipeptide", "CHEMICAL", 17, 33], ["sulfonamide", "CHEMICAL", 52, 63], ["alkene dipeptidosulfonamide", "CHEMICAL", 119, 146], ["alkene dipeptide isostere", "SIMPLE_CHEMICAL", 17, 42], ["sulfonamide", "SIMPLE_CHEMICAL", 52, 63], ["alkene dipeptidosulfonamide isostere", "SIMPLE_CHEMICAL", 119, 155], ["the alkene dipeptide isostere", "TREATMENT", 13, 42], ["the sulfonamide", "TREATMENT", 48, 63], ["a new peptidomimetic", "TREATMENT", 64, 84], ["the alkene dipeptidosulfonamide isostere", "TREATMENT", 115, 155]]], ["This isostere has the same backbone length as the parent (di)peptide, and also contains a sulfonamide moiety.", [["isostere", "CHEMICAL", 5, 13], ["sulfonamide", "CHEMICAL", 90, 101], ["sulfonamide", "CHEMICAL", 90, 101], ["sulfonamide moiety", "SIMPLE_CHEMICAL", 90, 108], ["This isostere", "TREATMENT", 0, 13], ["a sulfonamide moiety", "TREATMENT", 88, 108]]], ["The synthesis is based on a cross metathesis (CM) reaction between two allylic building blocks, which can be performed either in solution or on the solid phase.", [["CM", "DISEASE", 46, 48], ["a cross metathesis (CM) reaction", "TREATMENT", 26, 58], ["two allylic building blocks", "TREATMENT", 67, 94]]], ["This CM method was found to be also applicable to the solid phase synthesis of alkene dipeptide isosteres.", [["CM", "DISEASE", 5, 7], ["alkene dipeptide", "CHEMICAL", 79, 95], ["alkene dipeptide", "CHEMICAL", 79, 95], ["alkene dipeptide isosteres", "SIMPLE_CHEMICAL", 79, 105], ["This CM method", "TEST", 0, 14], ["alkene dipeptide isosteres", "TREATMENT", 79, 105]]], ["It was decided to incorporate a leucine-derived alkene dipeptidosulfonamide into the peptide sequence of human amylin(20-29) (SNNFGAILSS), a highly amyloidogenic peptide.", [["leucine", "CHEMICAL", 32, 39], ["dipeptidosulfonamide", "CHEMICAL", 55, 75], ["amylin(20-29)", "CHEMICAL", 111, 124], ["leucine", "CHEMICAL", 32, 39], ["alkene dipeptidosulfonamide", "CHEMICAL", 48, 75], ["leucine-derived alkene dipeptidosulfonamide", "SIMPLE_CHEMICAL", 32, 75], ["human", "ORGANISM", 105, 110], ["amylin", "GENE_OR_GENE_PRODUCT", 111, 117], ["SNNFGAILSS", "GENE_OR_GENE_PRODUCT", 126, 136], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["a leucine-derived alkene dipeptidosulfonamide", "TREATMENT", 30, 75], ["human amylin", "TREATMENT", 105, 117], ["a highly amyloidogenic peptide", "TREATMENT", 139, 169]]], ["Previously it was shown that aggregation phenomena of this sequence are highly sensitive toward modifi cation of the peptide backbone.", [["modifi cation", "SIMPLE_CHEMICAL", 96, 109], ["aggregation phenomena of this sequence", "PROBLEM", 29, 67], ["modifi cation of the peptide backbone", "TREATMENT", 96, 133], ["aggregation phenomena", "OBSERVATION", 29, 50]]], ["3 It was found that the alkene dipeptidosulfonamide isostere delayed the fi bril formation and altered the secondary structure.", [["dipeptidosulfonamide", "CHEMICAL", 31, 51], ["alkene dipeptidosulfonamide", "CHEMICAL", 24, 51], ["alkene dipeptidosulfonamide isostere", "SIMPLE_CHEMICAL", 24, 60], ["fi bril", "SIMPLE_CHEMICAL", 73, 80], ["the alkene dipeptidosulfonamide isostere", "TREATMENT", 20, 60], ["secondary structure", "OBSERVATION", 107, 126]]], ["In the present contribution the synthesis as well as a structure-aggregation behavior study of this class of amylin derivatives will be presented.", [["amylin derivatives", "SIMPLE_CHEMICAL", 109, 127], ["amylin derivatives", "TREATMENT", 109, 127]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["R.C. Elgersma et al., Org.", [["Org", "CHEMICAL", 22, 25]]], ["Biomol.", [["Biomol", "GENE_OR_GENE_PRODUCT", 0, 6]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["2006 Dixon, Mark 1 ; Nathubhai, Amit 1 ; Andersen, Ole 2 ; van Aalten, Daan 2 ; Eggleston, Ian 1 1 University of Bath, UNITED KINGDOM; 2 University of Dundee, UNITED KINGDOM Many pathogenic organisms need to hydrolyse chitin, a homopolymer of (1, 4) -linked N-acetyl-D-glucosamine, at key points in their life cycles.", [["chitin", "CHEMICAL", 218, 224], ["homopolymer of (1, 4", "CHEMICAL", 228, 248], ["N-acetyl-D-glucosamine", "CHEMICAL", 258, 280], ["N-acetyl-D-glucosamine", "CHEMICAL", 258, 280], ["chitin", "SIMPLE_CHEMICAL", 218, 224], ["(1, 4) -linked N-acetyl-D-glucosamine", "SIMPLE_CHEMICAL", 243, 280], ["pathogenic organisms", "PROBLEM", 179, 199], ["hydrolyse chitin", "TREATMENT", 208, 224], ["N-acetyl", "TREATMENT", 258, 266], ["D-glucosamine", "TREATMENT", 267, 280]]], ["Chitin is the main structural component of insect exoskeletons, the cell walls of fungi, and is also found in the eggshells of parasitic nematodes.", [["exoskeletons", "ANATOMY", 50, 62], ["cell walls", "ANATOMY", 68, 78], ["Chitin", "CHEMICAL", 0, 6], ["Chitin", "GENE_OR_GENE_PRODUCT", 0, 6], ["cell walls", "CELLULAR_COMPONENT", 68, 78], ["Chitin", "TREATMENT", 0, 6], ["insect exoskeletons", "PROBLEM", 43, 62], ["fungi", "PROBLEM", 82, 87], ["main", "OBSERVATION_MODIFIER", 14, 18], ["structural", "OBSERVATION_MODIFIER", 19, 29], ["component", "OBSERVATION_MODIFIER", 30, 39], ["insect exoskeletons", "OBSERVATION", 43, 62], ["cell", "OBSERVATION_MODIFIER", 68, 72], ["walls", "OBSERVATION_MODIFIER", 73, 78], ["fungi", "OBSERVATION", 82, 87], ["eggshells", "OBSERVATION_MODIFIER", 114, 123], ["parasitic nematodes", "OBSERVATION", 127, 146]]], ["Molecules able to inhibit chitinase enzymes in these organisms have considerable potential as novel fungicides, insecticides, and nematocides.", [["nematocides", "CHEMICAL", 130, 141], ["chitinase enzymes", "GENE_OR_GENE_PRODUCT", 26, 43], ["nematocides", "SIMPLE_CHEMICAL", 130, 141], ["chitinase enzymes", "PROTEIN", 26, 43], ["chitinase enzymes", "TEST", 26, 43], ["novel fungicides", "PROBLEM", 94, 110]]], ["The recent discovery of the human acidic mammalian chitinase and its apparent role in infl ammatory disorders such as asthma has led to renewed interest in this fi eld, but the lack of readily available broad spectrum inhibitors has until now severely limited research in this area.", [["ammatory disorders", "DISEASE", 91, 109], ["asthma", "DISEASE", 118, 124], ["human", "ORGANISM", 28, 33], ["chitinase", "GENE_OR_GENE_PRODUCT", 51, 60], ["human acidic mammalian chitinase", "PROTEIN", 28, 60], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["the human acidic mammalian chitinase", "PROBLEM", 24, 60], ["infl ammatory disorders", "PROBLEM", 86, 109], ["asthma", "PROBLEM", 118, 124], ["broad spectrum inhibitors", "TREATMENT", 203, 228]]], ["We will describe new, effi cient and fl exible solid phase syntheses of two families of potent chitinase inhibitors, derived from the cyclic pentapeptide natural products, argifi n and argadin.", [["argadin", "CHEMICAL", 185, 192], ["cyclic pentapeptide", "CHEMICAL", 134, 153], ["argadin", "CHEMICAL", 185, 192], ["argifi n", "SIMPLE_CHEMICAL", 172, 180], ["argadin", "SIMPLE_CHEMICAL", 185, 192], ["potent chitinase inhibitors", "TREATMENT", 88, 115], ["the cyclic pentapeptide natural products", "TREATMENT", 130, 170], ["argifi n", "TREATMENT", 172, 180], ["argadin", "TREATMENT", 185, 192]]], ["[1, 2] These permit assembly, cyclisation, and key side chain derivatisations to be performed entirely upon the solid phase.", [["cyclisation", "TEST", 30, 41], ["key side chain derivatisations", "PROBLEM", 47, 77]]], ["The unusual modifi ed Arg residues of both peptides are installed via an orthogonally protected Orn, thus avoiding side reactions observed on fi nal deprotection in previous combined solid phase/solution approaches.", [["Orn", "CHEMICAL", 96, 99], ["Arg", "CHEMICAL", 22, 25], ["Orn", "CHEMICAL", 96, 99], ["Orn", "SIMPLE_CHEMICAL", 96, 99], ["fi nal", "SIMPLE_CHEMICAL", 142, 148], ["side reactions", "PROBLEM", 115, 129], ["fi nal deprotection", "TREATMENT", 142, 161], ["previous combined solid phase/solution approaches", "TREATMENT", 165, 214]]], ["SAR data for designed analogues vs typical fungal and mammalian chitinases will be presented, along with recent data on the X-ray structure-led dissection of the argifi n scaffold.", [["mammalian chitinases", "PROTEIN", 54, 74], ["argifi n scaffold", "PROTEIN", 162, 179], ["SAR data", "TEST", 0, 8], ["designed analogues", "PROBLEM", 13, 31], ["typical fungal and mammalian chitinases", "PROBLEM", 35, 74], ["the X-ray structure", "TREATMENT", 120, 139], ["dissection of the argifi n scaffold", "TREATMENT", 144, 179], ["fungal", "OBSERVATION", 43, 49], ["mammalian chitinases", "OBSERVATION", 54, 74], ["dissection", "OBSERVATION", 144, 154]]], ["(3) This has allowed us to identify, synthesise and evaluate, minimal active fragments from argifi n which may serve as starting points for a new generation of drug-like, peptidomimetic inhibitors.S03-1Dynamic ligations with peptide electrophiles allow to identify protein-binding fragments and to develop protein ligands Rademann, J\u00f6rg; Schmidt, Marco; El-Dahshan, Adeeb Leibniz Institute for Molecular Pharmacology, GERMANY Specifi c protein ligands are crucial for the modulation of protein activities in medicinal chemistry and chemical biology.", [["protein-binding fragments", "PROTEIN", 265, 290], ["minimal active fragments", "PROBLEM", 62, 86], ["argifi n", "TREATMENT", 92, 100], ["a new generation of drug", "TREATMENT", 140, 164], ["peptidomimetic inhibitors", "TREATMENT", 171, 196], ["1Dynamic ligations", "TREATMENT", 201, 219], ["peptide electrophiles", "TREATMENT", 225, 246], ["protein-binding fragments", "PROBLEM", 265, 290], ["protein ligands", "TEST", 306, 321], ["GERMANY Specifi c protein ligands", "TREATMENT", 418, 451], ["minimal", "OBSERVATION_MODIFIER", 62, 69], ["active", "OBSERVATION_MODIFIER", 70, 76], ["fragments", "OBSERVATION", 77, 86]]], ["Recently, we have prepared various peptidyl bis-and tris-electrophiles from amino acids using of phosphoranes as polymeric carbanion equivalents.", [["peptidyl bis-and tris-electrophiles", "CHEMICAL", 35, 70], ["amino acids", "CHEMICAL", 76, 87], ["phosphoranes", "CHEMICAL", 97, 109], ["tris", "CHEMICAL", 52, 56], ["amino acids", "CHEMICAL", 76, 87], ["phosphoranes", "CHEMICAL", 97, 109], ["carbanion", "CHEMICAL", 123, 132], ["peptidyl bis-", "SIMPLE_CHEMICAL", 35, 48], ["tris-electrophiles", "SIMPLE_CHEMICAL", 52, 70], ["amino acids", "AMINO_ACID", 76, 87], ["phosphoranes", "SIMPLE_CHEMICAL", 97, 109], ["polymeric carbanion", "SIMPLE_CHEMICAL", 113, 132], ["various peptidyl bis", "TREATMENT", 27, 47], ["amino acids", "TREATMENT", 76, 87], ["phosphoranes", "TREATMENT", 97, 109], ["polymeric carbanion equivalents", "TREATMENT", 113, 144], ["carbanion equivalents", "OBSERVATION", 123, 144]]], ["(1) We now found such peptidyl electrophiles useful in Dynamic Ligation Screening (DLS), enabling the rapid and site-directed identifi cation of protein binders by template-assisted fragment assembly.", [["peptidyl electrophiles", "SIMPLE_CHEMICAL", 22, 44], ["cation", "SIMPLE_CHEMICAL", 135, 141], ["such peptidyl electrophiles", "PROBLEM", 17, 44], ["Dynamic Ligation Screening", "TREATMENT", 55, 81], ["directed identifi cation of protein binders", "TREATMENT", 117, 160], ["template-assisted fragment assembly", "TREATMENT", 164, 199]]], ["(2) DLS was conducted with libraries of 200-6000 fragments.", [["libraries", "TREATMENT", 27, 36]]], ["A fl uorogenic substrate competed with an equilibrium of nucleophilic fragments and the directing peptide electrophile.", [["A fl uorogenic substrate", "PROBLEM", 0, 24], ["an equilibrium of nucleophilic fragments", "PROBLEM", 39, 79], ["fl uorogenic", "OBSERVATION", 2, 14], ["nucleophilic fragments", "OBSERVATION", 57, 79]]], ["(2) Decreased initial rates of product formation in the enzyme assay indicated the inhibitory activity of the reversibly formed ligation product.", [["Decreased initial rates of product formation", "PROBLEM", 4, 48], ["the enzyme assay", "TEST", 52, 68], ["the reversibly formed ligation product", "TREATMENT", 106, 144], ["Decreased", "OBSERVATION_MODIFIER", 4, 13], ["ligation", "OBSERVATION", 128, 136]]], ["Via an iterative scanning of different binding sites on the protein surface, moderately active peptide ligands could be transformed into entirely non-peptidic inhibitors with low M inhibition (KI).", [["surface", "ANATOMY", 68, 75], ["an iterative scanning", "TEST", 4, 25], ["different binding sites", "PROBLEM", 29, 52], ["the protein surface", "TEST", 56, 75], ["moderately active peptide ligands", "PROBLEM", 77, 110], ["non-peptidic inhibitors", "TREATMENT", 146, 169], ["binding sites", "OBSERVATION", 39, 52], ["moderately", "OBSERVATION_MODIFIER", 77, 87], ["active", "OBSERVATION", 88, 94]]], ["The concept was established for the development of a non-peptidic SARS coronavirus main protease (SARS-CoV Mpro) inhibitor.", [["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 98, 111], ["non-peptidic SARS coronavirus main protease", "PROTEIN", 53, 96], ["SARS-CoV Mpro", "PROTEIN", 98, 111], ["SARS coronavirus", "SPECIES", 66, 82], ["SARS-CoV", "SPECIES", 98, 106], ["a non-peptidic SARS coronavirus main protease", "TREATMENT", 51, 96], ["SARS-CoV Mpro) inhibitor", "TREATMENT", 98, 122]]], ["This enzyme has been identifi ed as a drug target of SARS being essential for replication of the virus inside the infected host cell.", [["cell", "ANATOMY", 128, 132], ["SARS", "DISEASE", 53, 57], ["host cell", "CELL", 123, 132], ["infected host cell", "CELL_TYPE", 114, 132], ["This enzyme", "TEST", 0, 11], ["SARS", "PROBLEM", 53, 57], ["the virus", "PROBLEM", 93, 102], ["virus", "OBSERVATION", 97, 102], ["infected", "OBSERVATION_MODIFIER", 114, 122], ["host cell", "OBSERVATION", 123, 132]]], ["The thermodynamics of protein-assisted fragment ligation were studied for caspase 3, a cellular switch for apoptosis, the programmed cell death.", [["cellular", "ANATOMY", 87, 95], ["cell", "ANATOMY", 133, 137], ["death", "DISEASE", 138, 143], ["caspase 3", "GENE_OR_GENE_PRODUCT", 74, 83], ["cellular", "CELL", 87, 95], ["cell", "CELL", 133, 137], ["caspase 3", "PROTEIN", 74, 83], ["protein-assisted fragment ligation", "TREATMENT", 22, 56], ["caspase", "TREATMENT", 74, 81], ["a cellular switch", "TREATMENT", 85, 102], ["apoptosis", "PROBLEM", 107, 116], ["the programmed cell death", "PROBLEM", 118, 143], ["programmed cell death", "OBSERVATION", 122, 143]]], ["As a result, a model for the additivity of binding contributions of ligated fragments is proposed.", [["fragments", "ANATOMY", 76, 85], ["ligated fragments", "PROBLEM", 68, 85], ["ligated fragments", "OBSERVATION", 68, 85]]], ["The method can be further extended to other protein targets such as phosphatases4. and to protein-protein interactions.", [["phosphatases4", "GENE_OR_GENE_PRODUCT", 68, 81], ["phosphatases4", "PROTEIN", 68, 81], ["The method", "TREATMENT", 0, 10], ["phosphatases4", "TREATMENT", 68, 81]]], ["References: 1. a) A. El-Dahshan, S. Weik, J. Rademann Org.", [["Org", "CHEMICAL", 54, 57]]], ["Lett.", [["Lett", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["2007, 9, 949-952 1. bSemisynthesis of Membrane-Associated Prion ProteinsOlschewski, Diana 1 ; Seidel, Ralf 1 ; Becker, Christian F.W. 2 1 Max-Planck Institut f\u00fcr molekulare Physiologie, GERMANY; 2Technische Universit\u00e4t M\u00fcnchen, GERMANYTransmissible spongiform encephalopathies (TSEs) such as Creutzfeld Jakob disease (CJD) are rare fatal neurodegenerative disorders that are characterized by the accumulation of a misfolded isoform (PrPsc) of the cellular prion protein (PrPC).", [["cellular", "ANATOMY", 447, 455], ["GERMANYTransmissible spongiform encephalopathies", "DISEASE", 228, 276], ["TSEs", "DISEASE", 278, 282], ["Creutzfeld Jakob disease", "DISEASE", 292, 316], ["CJD", "DISEASE", 318, 321], ["neurodegenerative disorders", "DISEASE", 338, 365], ["GERMANYTransmissible spongiform", "ORGANISM", 228, 259], ["PrPsc", "GENE_OR_GENE_PRODUCT", 433, 438], ["cellular prion protein", "GENE_OR_GENE_PRODUCT", 447, 469], ["PrPC", "GENE_OR_GENE_PRODUCT", 471, 475], ["misfolded isoform", "PROTEIN", 414, 431], ["PrPsc", "PROTEIN", 433, 438], ["cellular prion protein", "PROTEIN", 447, 469], ["PrPC", "PROTEIN", 471, 475], ["bSemisynthesis of Membrane", "PROBLEM", 20, 46], ["GERMANYTransmissible spongiform encephalopathies (TSEs)", "PROBLEM", 228, 283], ["Creutzfeld Jakob disease (CJD", "PROBLEM", 292, 321], ["rare fatal neurodegenerative disorders", "PROBLEM", 327, 365], ["Prion ProteinsOlschewski", "OBSERVATION", 58, 82], ["spongiform encephalopathies", "OBSERVATION", 249, 276], ["rare", "OBSERVATION_MODIFIER", 327, 331], ["fatal", "OBSERVATION_MODIFIER", 332, 337], ["neurodegenerative disorders", "OBSERVATION", 338, 365]]], ["PrPC is an N-glycosylated protein attached to the outer leafl et of the plasma membrane by a C-terminal glycosylphosphatidylinositol (GPI)-anchor, where it segregates into cholesterol-and spingomyelin-rich microdomains (1) .", [["plasma membrane", "ANATOMY", 72, 87], ["cholesterol", "CHEMICAL", 172, 183], ["N", "CHEMICAL", 11, 12], ["C", "CHEMICAL", 93, 94], ["glycosylphosphatidylinositol", "CHEMICAL", 104, 132], ["cholesterol", "CHEMICAL", 172, 183], ["spingomyelin", "CHEMICAL", 188, 200], ["PrPC", "GENE_OR_GENE_PRODUCT", 0, 4], ["plasma membrane", "CELLULAR_COMPONENT", 72, 87], ["cholesterol", "SIMPLE_CHEMICAL", 172, 183], ["spingomyelin", "SIMPLE_CHEMICAL", 188, 200], ["PrPC", "PROTEIN", 0, 4], ["N-glycosylated protein", "PROTEIN", 11, 33], ["C-terminal glycosylphosphatidylinositol (GPI)-anchor", "PROTEIN", 93, 145], ["spingomyelin", "PROTEIN", 188, 200], ["an N-glycosylated protein", "TREATMENT", 8, 33], ["a C-terminal glycosylphosphatidylinositol (GPI)-anchor", "TREATMENT", 91, 145], ["cholesterol", "TEST", 172, 183]]], ["This membrane localization seems to be crucial for the de novo generation of infectious PrPsc (2) .", [["membrane", "ANATOMY", 5, 13], ["PrPsc (2)", "CHEMICAL", 88, 97], ["membrane", "CELLULAR_COMPONENT", 5, 13], ["infectious", "OBSERVATION", 77, 87]]], ["In order to mimic the infl uence of membrane attachment on folding and conversion, synthesis strategies based on expressed protein ligation (EPL) and the process of protein trans-splicing (3) were devised that allowed incorporation of palmitoylated and fl uorescently labeled peptides as well as of glycosylphosphatidylinositol (GPI) anchors at the C-terminus of PrP.", [["membrane", "ANATOMY", 36, 44], ["glycosylphosphatidylinositol", "CHEMICAL", 299, 327], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["EPL", "PROTEIN", 141, 144], ["glycosylphosphatidylinositol (GPI) anchors", "PROTEIN", 299, 341], ["C-terminus", "PROTEIN", 349, 359], ["membrane attachment", "PROBLEM", 36, 55], ["synthesis strategies", "TREATMENT", 83, 103], ["expressed protein ligation", "TREATMENT", 113, 139], ["palmitoylated and fl uorescently labeled peptides", "TREATMENT", 235, 284], ["glycosylphosphatidylinositol (GPI) anchors", "TREATMENT", 299, 341]]], ["Following these synthesis strategies, murine PrP was modifi ed with chemically synthesized peptides containing lipid moieties that mimic the GPI anchor and fl uorescent labels for localization studies.", [["murine", "ORGANISM", 38, 44], ["PrP", "GENE_OR_GENE_PRODUCT", 45, 48], ["lipid moieties", "SIMPLE_CHEMICAL", 111, 125], ["murine PrP", "PROTEIN", 38, 48], ["GPI anchor", "PROTEIN", 141, 151], ["murine", "SPECIES", 38, 44], ["these synthesis strategies", "TREATMENT", 10, 36], ["murine PrP", "TREATMENT", 38, 48], ["chemically synthesized peptides containing lipid moieties", "TREATMENT", 68, 125], ["localization studies", "TEST", 180, 200]]], ["Synthesis of these peptides was accomplished by solid phase peptide synthesis (SPPS) The resulting C-terminally modifi ed mPrP variants were successfully folded and transferred into liposomes as well as N2a cells (4) .", [["liposomes", "ANATOMY", 182, 191], ["N2a cells", "ANATOMY", 203, 212], ["C", "CHEMICAL", 99, 100], ["mPrP", "GENE_OR_GENE_PRODUCT", 122, 126], ["liposomes", "SIMPLE_CHEMICAL", 182, 191], ["N2a cells", "CELL", 203, 212], ["C-terminally modifi ed mPrP variants", "CELL_LINE", 99, 135], ["N2a cells", "CELL_LINE", 203, 212], ["these peptides", "TREATMENT", 13, 27], ["solid phase peptide synthesis", "TREATMENT", 48, 77], ["The resulting C-terminally modifi ed mPrP variants", "TREATMENT", 85, 135], ["N2a cells", "OBSERVATION", 203, 212]]], ["Chemically synthesized, native GPI anchors are currently tested for incorporation into mPrP via EPL as well.", [["GPI", "GENE_OR_GENE_PRODUCT", 31, 34], ["mPrP", "SIMPLE_CHEMICAL", 87, 91], ["EPL", "SIMPLE_CHEMICAL", 96, 99], ["mPrP", "PROTEIN", 87, 91], ["EPL", "PROTEIN", 96, 99], ["native GPI anchors", "TREATMENT", 24, 42], ["incorporation into mPrP via EPL", "TREATMENT", 68, 99], ["GPI anchors", "OBSERVATION", 31, 42], ["EPL", "ANATOMY", 96, 99]]], ["The most versatile approach uses a modifi cation of Kenner's safety catch linker which requires a very strong activation using trimethylsilandiazomethane followed by a thiol displacement.", [["trimethylsilandiazomethane", "CHEMICAL", 127, 153], ["thiol", "CHEMICAL", 168, 173], ["trimethylsilandiazomethane", "CHEMICAL", 127, 153], ["thiol", "CHEMICAL", 168, 173], ["Kenner", "SIMPLE_CHEMICAL", 52, 58], ["trimethylsilandiazomethane", "SIMPLE_CHEMICAL", 127, 153], ["thiol", "SIMPLE_CHEMICAL", 168, 173], ["a modifi cation", "TREATMENT", 33, 48], ["Kenner's safety catch linker", "TREATMENT", 52, 80], ["trimethylsilandiazomethane", "TREATMENT", 127, 153], ["a thiol displacement", "TREATMENT", 166, 186], ["thiol displacement", "OBSERVATION", 168, 186]]], ["Here we present a novel method for the synthesis of C-terminal peptide thioesters.", [["C", "CHEMICAL", 52, 53], ["thioesters", "CHEMICAL", 71, 81], ["C-terminal peptide thioesters", "SIMPLE_CHEMICAL", 52, 81], ["a novel method", "TREATMENT", 16, 30], ["C-terminal peptide thioesters", "TREATMENT", 52, 81]]], ["A C-terminal glutamic acid residue with a highly acid-labile side-chain protecting group is fi rst anchored to a solid support.", [["glutamic acid", "CHEMICAL", 13, 26], ["glutamic acid", "CHEMICAL", 13, 26], ["glutamic acid", "AMINO_ACID", 13, 26], ["A C-terminal glutamic acid residue", "PROBLEM", 0, 34], ["a solid support", "TREATMENT", 111, 126], ["glutamic acid residue", "OBSERVATION", 13, 34]]], ["The desired peptide is then assembled on-resin, followed by selective removal of the glutamic acid side-chain protecting group with dilute TFA.", [["glutamic acid", "CHEMICAL", 85, 98], ["TFA", "CHEMICAL", 139, 142], ["glutamic acid", "CHEMICAL", 85, 98], ["TFA", "CHEMICAL", 139, 142], ["glutamic acid", "SIMPLE_CHEMICAL", 85, 98], ["TFA", "SIMPLE_CHEMICAL", 139, 142], ["selective removal", "TREATMENT", 60, 77], ["the glutamic acid side-chain", "TREATMENT", 81, 109], ["dilute TFA", "TREATMENT", 132, 142]]], ["Activation of the deprotected carboxylic acid, e.g. PyBrop/DIEA in NMP, resulted in formation of the pyroglutamyl imide moiety on-resin.", [["carboxylic acid", "CHEMICAL", 30, 45], ["PyBrop", "CHEMICAL", 52, 58], ["DIEA", "CHEMICAL", 59, 63], ["NMP", "CHEMICAL", 67, 70], ["pyroglutamyl imide", "CHEMICAL", 101, 119], ["carboxylic acid", "CHEMICAL", 30, 45], ["PyBrop", "CHEMICAL", 52, 58], ["DIEA", "CHEMICAL", 59, 63], ["NMP", "CHEMICAL", 67, 70], ["pyroglutamyl imide", "CHEMICAL", 101, 119], ["carboxylic acid", "SIMPLE_CHEMICAL", 30, 45], ["PyBrop", "SIMPLE_CHEMICAL", 52, 58], ["DIEA", "SIMPLE_CHEMICAL", 59, 63], ["NMP", "SIMPLE_CHEMICAL", 67, 70], ["pyroglutamyl imide moiety", "SIMPLE_CHEMICAL", 101, 126], ["the deprotected carboxylic acid", "TREATMENT", 14, 45], ["PyBrop/DIEA in NMP", "TREATMENT", 52, 70], ["the pyroglutamyl imide moiety", "TREATMENT", 97, 126]]], ["Nucleophilic displacement of the pyroglutamyl imide leaving group by treatment with thiol released the peptide as the thioester from the solid support.", [["pyroglutamyl imide", "CHEMICAL", 33, 51], ["thiol", "CHEMICAL", 84, 89], ["pyroglutamyl imide", "CHEMICAL", 33, 51], ["thiol", "CHEMICAL", 84, 89], ["thioester", "CHEMICAL", 118, 127], ["pyroglutamyl imide", "SIMPLE_CHEMICAL", 33, 51], ["thiol", "SIMPLE_CHEMICAL", 84, 89], ["Nucleophilic displacement of the pyroglutamyl imide", "TREATMENT", 0, 51], ["thiol", "TREATMENT", 84, 89], ["the peptide", "TREATMENT", 99, 110], ["the solid support", "TREATMENT", 133, 150], ["solid support", "OBSERVATION", 137, 150]]], ["We have successfully used this method for the synthesis of a range of peptide thioesters.", [["thioesters", "CHEMICAL", 78, 88], ["this method", "TREATMENT", 26, 37], ["a range of peptide thioesters", "TREATMENT", 59, 88]]], ["We believe this new method has the potential to become a general tool for the synthesis of peptide thioesters.S03-4Doubling of cyclopeptides and cyclodepsipeptides: a new topological approach towards more active compounds Ru\u00edz-Rodr\u00edguez, Javier; Albericio, Fernando; Spengler, Jan Institute for Research in Biomedicine (IRB Barcelona) , SPAIN Cyclization is the most common geometrical manipulation in peptide chemistry.", [["cyclodepsipeptides", "CHEMICAL", 145, 163], ["thioesters", "CHEMICAL", 99, 109], ["cyclopeptides", "CHEMICAL", 127, 140], ["cyclodepsipeptides", "CHEMICAL", 145, 163], ["peptide thioesters", "SIMPLE_CHEMICAL", 91, 109], ["cyclopeptides", "SIMPLE_CHEMICAL", 127, 140], ["cyclodepsipeptides", "SIMPLE_CHEMICAL", 145, 163], ["the synthesis of peptide thioesters", "TREATMENT", 74, 109], ["cyclopeptides", "TREATMENT", 127, 140], ["cyclodepsipeptides", "TREATMENT", 145, 163], ["a new topological approach", "TREATMENT", 165, 191], ["SPAIN Cyclization", "TREATMENT", 337, 354]]], ["Two functional groups (e.g. N-and C-terminus) of a peptide are connected by a new bond.", [["N", "CHEMICAL", 28, 29], ["C", "CHEMICAL", 34, 35], ["N-and C-terminus", "PROTEIN", 28, 44], ["a peptide", "TREATMENT", 49, 58]]], ["The cyclized peptide obtained can exhibit much higher receptor affi nity and better stability towards degrading enzymes.", [["degrading enzymes", "PROTEIN", 102, 119], ["The cyclized peptide", "TEST", 0, 20]]], ["Thus, what about other types of peptide geometry manipulation?", [["peptide geometry manipulation", "TREATMENT", 32, 61]]], ["Both halves A and B of a cyclic peptides type cyclo-AB can interact with macromolecules to the same degree.", [["cyclo-AB", "CHEMICAL", 46, 54], ["cyclo-AB", "SIMPLE_CHEMICAL", 46, 54], ["a cyclic peptides type cyclo-AB", "PROBLEM", 23, 54]]], ["A connection of two cycles via a C-C single bond to the double cyclic structure, AB-BA, should result in a differentiation of the topology into a \"buried region\" (B-B) and a \"solvent-exposed region\" (the A-ends of AB-BA).", [["AB-BA", "CHEMICAL", 81, 86], ["B-B", "CHEMICAL", 163, 166], ["C-C", "CHEMICAL", 33, 36], ["C-C", "SIMPLE_CHEMICAL", 33, 36], ["AB-BA", "SIMPLE_CHEMICAL", 81, 86], ["buried region", "PROTEIN", 147, 160], ["B", "PROTEIN", 163, 164], ["B", "PROTEIN", 165, 166], ["a C-C single bond", "TREATMENT", 31, 48], ["AB-BA", "TEST", 81, 86], ["a \"buried region\"", "PROBLEM", 144, 161], ["a \"solvent-exposed region", "PROBLEM", 172, 197]]], ["When A represents a receptor-interacting sequence and B a conformationally constraining peptidic sequence, the A-sequence should consequently have the capacity to interact with higher propensity with macromolecules (receptors) than the B-sequence, which should be less available for catabolising macromolecules (proteases).", [["receptor-interacting sequence", "PROTEIN", 20, 49], ["A-sequence", "DNA", 111, 121], ["B-sequence", "DNA", 236, 246], ["proteases", "PROTEIN", 312, 321], ["the capacity", "PROBLEM", 147, 159], ["the B-sequence", "TEST", 232, 246]]], ["The test this hypothesis, we performed a fi rst synthesis for \"doubled\" sansalvamides, and a fi rst depsipeptide synthesis of double-cycles with S,S-tartaric acid and S,S-hydroxy aspartic acid as core building blocks. the cyclic 5-membered anticancer depsipeptide sansalvamide A (1) was chosen as a model compound.", [["sansalvamides", "CHEMICAL", 72, 85], ["S,S-tartaric acid", "CHEMICAL", 145, 162], ["S,S-hydroxy aspartic acid", "CHEMICAL", 167, 192], ["depsipeptide", "CHEMICAL", 251, 263], ["sansalvamide A", "CHEMICAL", 264, 278], ["sansalvamides", "CHEMICAL", 72, 85], ["fi rst depsipeptide", "CHEMICAL", 93, 112], ["S", "CHEMICAL", 145, 146], ["S-tartaric acid", "CHEMICAL", 147, 162], ["S", "CHEMICAL", 167, 168], ["S-hydroxy aspartic acid", "CHEMICAL", 169, 192], ["sansalvamide A", "CHEMICAL", 264, 278], ["sansalvamides", "SIMPLE_CHEMICAL", 72, 85], ["fi rst depsipeptide", "SIMPLE_CHEMICAL", 93, 112], ["S-tartaric acid", "SIMPLE_CHEMICAL", 147, 162], ["S,S-hydroxy aspartic acid", "SIMPLE_CHEMICAL", 167, 192], ["5-membered anticancer depsipeptide", "SIMPLE_CHEMICAL", 229, 263], ["sansalvamide A (1)", "SIMPLE_CHEMICAL", 264, 282], ["a fi rst synthesis", "TREATMENT", 39, 57], ["doubled\" sansalvamides", "TREATMENT", 63, 85], ["a fi rst depsipeptide synthesis", "TREATMENT", 91, 122], ["double-cycles", "TREATMENT", 126, 139], ["S-tartaric acid", "TREATMENT", 147, 162], ["hydroxy aspartic acid", "TREATMENT", 171, 192], ["core building blocks", "TREATMENT", 196, 216], ["the cyclic 5-membered anticancer", "TREATMENT", 218, 250]]], ["The structures of these \"bi-cycles\" were confi rmed by NMR and the anticancer activity of the tartaric acid derivative was found to be one order of magnitude higher than the single cycle natural product.Brik, Ashraf Ben-Gurion University, ISRAELPeptide ligation strategies that rely on intramolecular acyl transfer to form an amide bond have been of great interest for accessing synthetic proteins.", [["anticancer", "ANATOMY", 67, 77], ["tartaric acid", "CHEMICAL", 94, 107], ["acyl", "CHEMICAL", 301, 305], ["tartaric acid", "CHEMICAL", 94, 107], ["acyl", "CHEMICAL", 301, 305], ["amide", "CHEMICAL", 326, 331], ["anticancer", "CANCER", 67, 77], ["tartaric acid derivative", "SIMPLE_CHEMICAL", 94, 118], ["synthetic proteins", "PROTEIN", 379, 397], ["NMR", "TEST", 55, 58], ["the tartaric acid derivative", "TREATMENT", 90, 118], ["ISRAELPeptide ligation strategies", "TREATMENT", 239, 272], ["intramolecular acyl transfer", "TREATMENT", 286, 314], ["an amide bond", "TREATMENT", 323, 336], ["accessing synthetic proteins", "TREATMENT", 369, 397], ["natural product", "OBSERVATION", 187, 202]]], ["Unarguably, Native Chemical Ligation (NCL), assisted by the N-terminal cysteine residue to facilitate S N acyl transfer, is the most effective method for protein synthesis.", [["S N acyl", "CHEMICAL", 102, 110], ["N", "CHEMICAL", 60, 61], ["cysteine", "CHEMICAL", 71, 79], ["S N acyl", "CHEMICAL", 102, 110], ["S N acyl", "SIMPLE_CHEMICAL", 102, 110], ["Native Chemical Ligation", "TREATMENT", 12, 36], ["the N-terminal cysteine residue", "TREATMENT", 56, 87], ["S N acyl transfer", "TREATMENT", 102, 119], ["protein synthesis", "TREATMENT", 154, 171], ["Chemical Ligation", "OBSERVATION", 19, 36]]], ["However, the requirement of cysteine at the ligation junction hampers its use in a variety of protein systems.", [["cysteine", "CHEMICAL", 28, 36], ["cysteine", "CHEMICAL", 28, 36], ["cysteine", "AMINO_ACID", 28, 36], ["cysteine at the ligation junction", "TREATMENT", 28, 61], ["a variety of protein systems", "TREATMENT", 81, 109]]], ["Mimicking the cysteine function in the ligation pathway with a removable auxiliary is a promising approach to assist S N acyl transfer at various amino acid junctions.", [["cysteine", "CHEMICAL", 14, 22], ["S N acyl", "CHEMICAL", 117, 125], ["amino acid", "CHEMICAL", 146, 156], ["cysteine", "CHEMICAL", 14, 22], ["S N acyl", "CHEMICAL", 117, 125], ["amino acid", "CHEMICAL", 146, 156], ["cysteine", "AMINO_ACID", 14, 22], ["S N acyl", "SIMPLE_CHEMICAL", 117, 125], ["amino acid", "AMINO_ACID", 146, 156], ["the ligation pathway", "TREATMENT", 35, 55], ["S N acyl transfer at various amino acid junctions", "TREATMENT", 117, 166], ["acid junctions", "OBSERVATION", 152, 166]]], ["Presented here is a new peptide ligation method that uses an auxiliary attached to the side-chains of different amino acids (Ser, Thr, Asp, Glu) to facilitate an effi cient ligation at non-cysteinyl junction.", [["amino acids", "CHEMICAL", 112, 123], ["Ser, Thr, Asp, Glu", "CHEMICAL", 125, 143], ["amino acids", "CHEMICAL", 112, 123], ["Ser", "CHEMICAL", 125, 128], ["Thr", "CHEMICAL", 130, 133], ["Asp", "CHEMICAL", 135, 138], ["Glu", "CHEMICAL", 140, 143], ["non-cysteinyl", "CHEMICAL", 185, 198], ["amino acids", "AMINO_ACID", 112, 123], ["Ser,", "AMINO_ACID", 125, 129], ["Thr,", "AMINO_ACID", 130, 134], ["Asp, Glu", "AMINO_ACID", 135, 143], ["side-chains", "PROTEIN", 87, 98], ["a new peptide ligation method", "TREATMENT", 18, 47], ["different amino acids", "TREATMENT", 102, 123], ["Asp", "TEST", 135, 138], ["an effi cient ligation at non-cysteinyl junction", "TREATMENT", 159, 207], ["ligation", "OBSERVATION", 32, 40], ["ligation", "OBSERVATION", 173, 181]]], ["Following the ligation reaction, without product isolation, the auxiliary can be rapidly removed under basic conditions to generate the unmodifi ed peptide. * Marina-Yamit Lutsky, Natalia Nepomniaschiy and Ashraf Brik, Chemical Communications, 2008.Modulating Biology with Cryptic Cell Penetrating PeptidesHowl, John; Jones, Sarah Research Institute in Healthcare Science, School of Applied Sciences, University of Wolverhampton, UNITED KINGDOM Numerous cell penetrating peptides (CPP) have been utilised as vectors for the intracellular delivery of diverse bioactive cargoes.", [["Cell", "ANATOMY", 281, 285], ["cell", "ANATOMY", 454, 458], ["intracellular", "ANATOMY", 524, 537], ["cell penetrating peptides", "GENE_OR_GENE_PRODUCT", 454, 479], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 524, 537], ["the ligation reaction", "TREATMENT", 10, 31], ["product isolation", "TREATMENT", 41, 58], ["the unmodifi ed peptide", "TREATMENT", 132, 155], ["Cryptic Cell Penetrating Peptides", "TREATMENT", 273, 306], ["Numerous cell penetrating peptides", "TREATMENT", 445, 479], ["the intracellular delivery", "TREATMENT", 520, 546], ["diverse bioactive cargoes", "TREATMENT", 550, 575], ["ligation", "OBSERVATION", 14, 22], ["without", "UNCERTAINTY", 33, 40], ["Cryptic Cell", "OBSERVATION", 273, 285], ["Penetrating Peptides", "OBSERVATION", 286, 306], ["bioactive cargoes", "OBSERVATION", 558, 575]]], ["The utility of this strategy requires highly effi cient CPP with minimal toxicity and negligible biological activity.", [["toxicity", "DISEASE", 73, 81], ["this strategy", "TREATMENT", 15, 28], ["minimal toxicity", "PROBLEM", 65, 81], ["minimal", "OBSERVATION_MODIFIER", 65, 72], ["toxicity", "OBSERVATION", 73, 81], ["negligible", "OBSERVATION_MODIFIER", 86, 96], ["biological activity", "OBSERVATION", 97, 116]]], ["However, general consideration of the multi-domain architecture of many human proteins indicates that cell penetrant cryptic sequences could mimic and/or modulate their functions.", [["cell", "ANATOMY", 102, 106], ["human", "ORGANISM", 72, 77], ["cell", "CELL", 102, 106], ["human proteins", "PROTEIN", 72, 86], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["many human proteins", "PROBLEM", 67, 86], ["cell penetrant cryptic sequences", "PROBLEM", 102, 134]]], ["Our starting point for the development of biologically-active cryptic CPP was the QSAR-based prediction algorithm recently described by \u00dclo Langel's group.", [["active cryptic CPP", "PROBLEM", 55, 73], ["the QSAR", "TEST", 78, 86], ["active", "OBSERVATION_MODIFIER", 55, 61], ["cryptic CPP", "OBSERVATION", 62, 73]]], ["This strategy has enabled the study of cryptic CPP in which multiple pharmacophores for cellular penetration and biological activities are discontinuously organised within the primary sequence.", [["cellular", "ANATOMY", 88, 96], ["cellular", "CELL", 88, 96], ["the study", "TEST", 26, 35], ["cryptic CPP", "TEST", 39, 50], ["cellular penetration", "PROBLEM", 88, 108], ["cellular penetration", "OBSERVATION", 88, 108]]], ["The term rhegnylogic is used to distinguish this class of CPP from the more usual sychnologic combination of CPP and cargo.", [["CPP", "CHEMICAL", 109, 112], ["CPP", "SIMPLE_CHEMICAL", 109, 112], ["cargo", "CELLULAR_COMPONENT", 117, 122], ["CPP", "PROBLEM", 109, 112]]], ["Cryptic CPP sequences are located within both amino and carboxyl helical domains of cytochrome c (Cyt c), a signalling protein integral to apoptotic events.", [["amino", "CHEMICAL", 46, 51], ["carboxyl", "CHEMICAL", 56, 64], ["amino", "AMINO_ACID", 46, 51], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 84, 96], ["Cyt c", "GENE_OR_GENE_PRODUCT", 98, 103], ["Cryptic CPP sequences", "DNA", 0, 21], ["amino and carboxyl helical domains", "PROTEIN", 46, 80], ["cytochrome c", "PROTEIN", 84, 96], ["Cyt c", "PROTEIN", 98, 103], ["signalling protein", "PROTEIN", 108, 126], ["Cryptic CPP sequences", "TEST", 0, 21], ["cytochrome c (Cyt c", "PROBLEM", 84, 103], ["a signalling protein integral", "PROBLEM", 106, 135], ["apoptotic events", "PROBLEM", 139, 155], ["apoptotic events", "OBSERVATION", 139, 155]]], ["Detailed characterisation of these peptides has identifi ed a series of effi cient CPP vectors that differentially target intracellular organelles.", [["intracellular organelles", "ANATOMY", 122, 146], ["intracellular organelles", "CELLULAR_COMPONENT", 122, 146], ["effi cient CPP vectors", "TREATMENT", 72, 94], ["intracellular organelles", "OBSERVATION", 122, 146]]], ["These molecular properties mimic the propensity of Cyt c to translocate biological membranes as a mediator of both mitochondrial apoptosis and infl ammation.", [["membranes", "ANATOMY", 83, 92], ["mitochondrial", "ANATOMY", 115, 128], ["Cyt c", "GENE_OR_GENE_PRODUCT", 51, 56], ["membranes", "CELLULAR_COMPONENT", 83, 92], ["mitochondrial", "CELLULAR_COMPONENT", 115, 128], ["Cyt c", "PROTEIN", 51, 56], ["Cyt c", "PROBLEM", 51, 56], ["both mitochondrial apoptosis", "PROBLEM", 110, 138], ["mitochondrial apoptosis", "OBSERVATION", 115, 138]]], ["Moreover, chimeric combination of Cyt c-derived CPP and other biologically-active sequences has generated potent apoptogenic peptides.", [["Cyt c", "GENE_OR_GENE_PRODUCT", 34, 39], ["Cyt c", "PROTEIN", 34, 39], ["Cyt c", "TEST", 34, 39], ["CPP", "TEST", 48, 51], ["potent apoptogenic peptides", "TREATMENT", 106, 133]]], ["Related studies have identifi ed a cryptic CPP within nitric oxide synthase, eNOS 492-507 , located within a helical domain known to tightly bind calmodulin.", [["nitric oxide", "CHEMICAL", 54, 66], ["eNOS 492-507", "CHEMICAL", 77, 89], ["nitric oxide", "CHEMICAL", 54, 66], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 54, 75], ["eNOS 492-507", "GENE_OR_GENE_PRODUCT", 77, 89], ["calmodulin", "GENE_OR_GENE_PRODUCT", 146, 156], ["nitric oxide synthase", "PROTEIN", 54, 75], ["eNOS 492-507", "PROTEIN", 77, 89], ["helical domain", "PROTEIN", 109, 123], ["calmodulin", "PROTEIN", 146, 156], ["Related studies", "TEST", 0, 15], ["a cryptic CPP", "TEST", 33, 46], ["nitric oxide synthase", "TREATMENT", 54, 75], ["eNOS", "TEST", 77, 81]]], ["Signifi cantly, this peptide potently inhibits the proliferation, migration and tube-forming capacity of primary endothelial cells and displays anti-angiogenic properties in vivo.", [["tube", "ANATOMY", 80, 84], ["primary endothelial cells", "ANATOMY", 105, 130], ["tube", "TISSUE", 80, 84], ["endothelial cells", "CELL", 113, 130], ["primary endothelial cells", "CELL_TYPE", 105, 130], ["the proliferation", "PROBLEM", 47, 64], ["migration", "PROBLEM", 66, 75], ["tube", "TREATMENT", 80, 84], ["primary endothelial cells", "PROBLEM", 105, 130], ["anti-angiogenic properties in vivo", "TREATMENT", 144, 178], ["proliferation", "OBSERVATION_MODIFIER", 51, 64], ["migration", "OBSERVATION_MODIFIER", 66, 75], ["primary endothelial cells", "OBSERVATION", 105, 130], ["anti-angiogenic", "OBSERVATION_MODIFIER", 144, 159]]], ["In summary, these and other data confi rm that cryptic CPP can modulate many aspects of cell biology and are, therefore, a valuable new class of bioactive peptide. .", [["cell", "ANATOMY", 88, 92], ["CPP", "CHEMICAL", 55, 58], ["cell", "CELL", 88, 92], ["cryptic CPP", "PROBLEM", 47, 58], ["bioactive peptide", "TREATMENT", 145, 162], ["bioactive peptide", "OBSERVATION", 145, 162]]], ["In a preliminary study, we ensured that grafting of an oxorhenium core on reference substrates did not alter signifi cantly their affi nity for hCyp-18.", [["oxorhenium", "CHEMICAL", 55, 65], ["hCyp-18", "CHEMICAL", 144, 151], ["oxorhenium", "CHEMICAL", 55, 65], ["hCyp-18", "CHEMICAL", 144, 151], ["oxorhenium", "SIMPLE_CHEMICAL", 55, 65], ["hCyp-18", "GENE_OR_GENE_PRODUCT", 144, 151], ["hCyp-18", "PROTEIN", 144, 151], ["a preliminary study", "TEST", 3, 22], ["grafting", "TREATMENT", 40, 48], ["hCyp", "TEST", 144, 148], ["grafting", "OBSERVATION", 40, 48]]], ["Firstly, two libraries of 112 and 176 peptideoxorhenium complexes were synthesized and systematically screened as ligands of hCyp-18.", [["peptideoxorhenium", "CHEMICAL", 38, 55], ["peptideoxorhenium", "CHEMICAL", 38, 55], ["hCyp-18", "CHEMICAL", 125, 132], ["hCyp-18", "GENE_OR_GENE_PRODUCT", 125, 132], ["hCyp-18", "PROTEIN", 125, 132], ["two libraries", "TEST", 9, 22], ["hCyp", "TEST", 125, 129]]], ["Two coordinates were shown to bind specifi cally to cyclophilin with affi nities higher by one order of magnitude relative to a reference substrate.", [["cyclophilin", "GENE_OR_GENE_PRODUCT", 52, 63], ["cyclophilin", "PROTEIN", 52, 63], ["affi nities", "PROTEIN", 69, 80], ["cyclophilin", "TREATMENT", 52, 63]]], ["We also demonstrated that the self-assembly of mixtures of peptide-oxorhenium coordinates can be carried out in various solvents including buffers.", [["peptide-oxorhenium", "CHEMICAL", 59, 77], ["oxorhenium", "CHEMICAL", 67, 77], ["peptide-oxorhenium", "SIMPLE_CHEMICAL", 59, 77], ["oxorhenium coordinates", "PROBLEM", 67, 89]]], ["As anticipated, these complexes were sensitive to high concentrations in glutathione (GSH) which substitutes de B-SH moiety.", [["glutathione", "CHEMICAL", 73, 84], ["GSH", "CHEMICAL", 86, 89], ["de B-SH", "CHEMICAL", 109, 116], ["glutathione", "CHEMICAL", 73, 84], ["GSH", "CHEMICAL", 86, 89], ["de B-SH", "CHEMICAL", 109, 116], ["glutathione", "SIMPLE_CHEMICAL", 73, 84], ["GSH", "SIMPLE_CHEMICAL", 86, 89], ["B-SH moiety", "SIMPLE_CHEMICAL", 112, 123], ["high concentrations in glutathione (GSH)", "PROBLEM", 50, 90]]], ["In a second step, we explored the cyclophilin-mediated selection of new oxorhenium coordinates from a set of 192 possible complexes.", [["oxorhenium", "CHEMICAL", 72, 82], ["oxorhenium", "CHEMICAL", 72, 82], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 34, 45], ["oxorhenium", "SIMPLE_CHEMICAL", 72, 82], ["cyclophilin", "PROTEIN", 34, 45], ["the cyclophilin", "TREATMENT", 30, 45], ["new oxorhenium coordinates", "PROBLEM", 68, 94], ["new", "OBSERVATION_MODIFIER", 68, 71], ["oxorhenium", "OBSERVATION", 72, 82]]], ["For this purpose, 12 modules A-N(SH)2 and 16 modules B-SH were incubated with [ReO\u2022(gluconate)2] and hCyp-18, together with increasing concentrations in GSH.", [["gluconate", "CHEMICAL", 84, 93], ["hCyp-18", "CHEMICAL", 101, 108], ["GSH", "CHEMICAL", 153, 156], ["[ReO\u2022(gluconate)2", "CHEMICAL", 78, 95], ["hCyp-18", "CHEMICAL", 101, 108], ["GSH", "CHEMICAL", 153, 156], ["B-SH", "SIMPLE_CHEMICAL", 53, 57], ["[ReO\u2022(gluconate)2]", "SIMPLE_CHEMICAL", 78, 96], ["hCyp-18", "SIMPLE_CHEMICAL", 101, 108], ["GSH", "SIMPLE_CHEMICAL", 153, 156], ["A-N(SH)", "TREATMENT", 29, 36], ["ReO\u2022(gluconate)", "TREATMENT", 79, 94], ["hCyp", "TEST", 101, 105], ["increasing concentrations in GSH", "PROBLEM", 124, 156]]], ["LC-MS analysis of the mixtures showed that oxorhenium coordinates, which tightly bind to cyclophilin, were partially protected against GSH substitution, whereas complexes, which do not bind to the enzyme, readily dissociated.", [["oxorhenium", "CHEMICAL", 43, 53], ["GSH", "CHEMICAL", 135, 138], ["oxorhenium", "CHEMICAL", 43, 53], ["GSH", "CHEMICAL", 135, 138], ["oxorhenium", "SIMPLE_CHEMICAL", 43, 53], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 89, 100], ["GSH", "SIMPLE_CHEMICAL", 135, 138], ["cyclophilin", "PROTEIN", 89, 100], ["enzyme", "PROTEIN", 197, 203], ["LC", "TEST", 0, 2], ["MS analysis", "TEST", 3, 14], ["the mixtures", "TEST", 18, 30], ["oxorhenium coordinates", "PROBLEM", 43, 65], ["cyclophilin", "TREATMENT", 89, 100], ["GSH substitution", "PROBLEM", 135, 151], ["the enzyme", "TEST", 193, 203]]], ["These complexes bind to the cyclophilin active site 1000-fold better than the reference peptide and are able to inhibit the PPIase activity with IC50 up to 0.2 M. A kinetic study of the assembly of these complexes strongly suggests the existence of two distinct modes of selection by the enzyme.", [["cyclophilin", "GENE_OR_GENE_PRODUCT", 28, 39], ["PPIase", "GENE_OR_GENE_PRODUCT", 124, 130], ["cyclophilin active site", "DNA", 28, 51], ["PPIase", "PROTEIN", 124, 130], ["enzyme", "PROTEIN", 288, 294], ["These complexes bind", "PROBLEM", 0, 20], ["the cyclophilin active site", "PROBLEM", 24, 51], ["IC50", "TEST", 145, 149], ["A kinetic study", "TEST", 163, 178], ["the enzyme", "TEST", 284, 294], ["active", "OBSERVATION_MODIFIER", 40, 46], ["site", "OBSERVATION_MODIFIER", 47, 51]]], ["Carbohydrates are involved in a broad variety of physiological or pathological processes, which basically rely on molecular recognition events.", [["Carbohydrates", "TREATMENT", 0, 13], ["physiological or pathological processes", "PROBLEM", 49, 88]]], ["Despite the tremendous methodological advancements in carbohydrate synthesis, the development of carbohydrate-based therapeutics comprises multi-step syntheses and always has to cope with unfavourable ADME parameters of oligosaccharides.", [["carbohydrate", "CHEMICAL", 54, 66], ["carbohydrate", "CHEMICAL", 97, 109], ["carbohydrate", "SIMPLE_CHEMICAL", 54, 66], ["carbohydrate", "SIMPLE_CHEMICAL", 97, 109], ["carbohydrate synthesis", "TREATMENT", 54, 76], ["carbohydrate", "TREATMENT", 97, 109], ["multi-step syntheses", "TREATMENT", 139, 159], ["unfavourable ADME parameters of oligosaccharides", "PROBLEM", 188, 236], ["tremendous", "OBSERVATION_MODIFIER", 12, 22]]], ["Peptides in general do not display any similarities to carbohydrates, but can be synthesized in a straightforward fashion by solid phase synthesis.", [["carbohydrates", "CHEMICAL", 55, 68], ["carbohydrates", "SIMPLE_CHEMICAL", 55, 68]]], ["Structural variations can easily be introduced in a combinatorial way.", [["Structural variations", "PROBLEM", 0, 21]]], ["Peptides that functionally and/or structurally mimic oligosaccharides provide a straightforward and elegant approach to interfere with the interaction between complex carbohydrates and their receptors.", [["carbohydrates", "CHEMICAL", 167, 180], ["structurally mimic oligosaccharides", "PROBLEM", 34, 69]]], ["A cyclopeptide library was synthesized on the basis of the linear sequences TFKLSETTLEYY and TFQLSTRTLPFS previously discovered in phage display studies as functional mimetics of the HNK-1 trisaccharide.", [["trisaccharide", "CHEMICAL", 189, 202], ["HNK-1 trisaccharide", "GENE_OR_GENE_PRODUCT", 183, 202], ["cyclopeptide library", "DNA", 2, 22], ["linear sequences", "DNA", 59, 75], ["TFQLSTRTLPFS", "DNA", 93, 105], ["HNK", "PROTEIN", 183, 186], ["A cyclopeptide library", "TREATMENT", 0, 22], ["TFQLSTRTLPFS", "TREATMENT", 93, 105], ["the HNK", "TEST", 179, 186]]], ["This oligosaccharide plays a major role e.g in developmental processes in the nervous system.", [["nervous system", "ANATOMY", 78, 92], ["nervous system", "ANATOMICAL_SYSTEM", 78, 92], ["nervous system", "ANATOMY", 78, 92]]], ["The cyclopeptide library comprised cyclic hexapeptides based on the partial sequences TFKLSE, LSETTL, TTLEYY, TFQLST, LSTRTL, and RTLPFS in a spatial screening approach.", [["cyclopeptide", "CHEMICAL", 4, 16], ["cyclic hexapeptides", "CHEMICAL", 35, 54], ["cyclic hexapeptides", "SIMPLE_CHEMICAL", 35, 54], ["cyclopeptide library", "DNA", 4, 24], ["partial sequences TFKLSE, LSETTL, TTLEYY, TFQLST, LSTRTL, and RTLPFS", "DNA", 68, 136], ["The cyclopeptide library", "TREATMENT", 0, 24], ["cyclic hexapeptides", "TREATMENT", 35, 54], ["the partial sequences TFKLSE", "TEST", 64, 92], ["TFQLST", "TREATMENT", 110, 116], ["LSTRTL", "TREATMENT", 118, 124], ["RTLPFS", "TREATMENT", 130, 136], ["a spatial screening approach", "TREATMENT", 140, 168]]], ["Cyclic peptides can be designed in such a way that conformation and three-dimensional orientation of the side chain functional groups that are responsible for the contacts to a receptor is highly predictable.", [["Cyclic peptides", "PROBLEM", 0, 15]]], ["The affi nity of all peptides to the selection antibody recognizing HNK-1 was determined in surface plasmon resonance studies.", [["HNK-1", "GENE_OR_GENE_PRODUCT", 68, 73], ["HNK-1", "PROTEIN", 68, 73], ["all peptides", "TREATMENT", 17, 29], ["the selection antibody", "TEST", 33, 55], ["surface plasmon resonance studies", "TEST", 92, 125]]], ["For some peptides considerably increased affi nity compared to the linear control was observed with K D values in the low micromolar range.", [["affi", "CHEMICAL", 41, 45], ["K", "CHEMICAL", 100, 101], ["affi", "SIMPLE_CHEMICAL", 41, 45], ["K D", "SIMPLE_CHEMICAL", 100, 103], ["some peptides", "PROBLEM", 4, 17], ["increased affi nity", "PROBLEM", 31, 50], ["K D values", "TEST", 100, 110], ["considerably", "OBSERVATION_MODIFIER", 18, 30], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["low micromolar", "OBSERVATION_MODIFIER", 118, 132]]], ["The most active peptides also signifi cantly stimulate neurite outgrowth of murine motoneurons.", [["neurite", "ANATOMY", 55, 62], ["motoneurons", "ANATOMY", 83, 94], ["neurite", "CELL", 55, 62], ["murine", "ORGANISM", 76, 82], ["motoneurons", "CELL", 83, 94], ["murine", "SPECIES", 76, 82], ["murine motoneurons", "OBSERVATION", 76, 94]]], ["This proves that they act as functional mimics of the HNK-1 oligosaccharide.Sivonen, Kaarina Department of Applied Chemistry and Microbiology, Viikki Biocenter, University of Helsinki, FINLANDCyanobacteria produce a wide variety of toxins as well as biomedically interesting bioactive compounds.", [["HNK-1 oligosaccharide", "GENE_OR_GENE_PRODUCT", 54, 75], ["HNK", "PROTEIN", 54, 57], ["the HNK", "TEST", 50, 57], ["FINLANDCyanobacteria", "TREATMENT", 185, 205], ["toxins", "PROBLEM", 232, 238], ["bioactive compounds", "OBSERVATION", 275, 294]]], ["The cyclic hepatotoxic peptides microcystins and nodularins are the best known.", [["microcystins", "CHEMICAL", 32, 44], ["microcystins", "CHEMICAL", 32, 44], ["nodularins", "CHEMICAL", 49, 59], ["microcystins", "SIMPLE_CHEMICAL", 32, 44], ["nodularins", "SIMPLE_CHEMICAL", 49, 59], ["The cyclic hepatotoxic peptides microcystins", "PROBLEM", 0, 44], ["nodularins", "PROBLEM", 49, 59], ["cyclic", "OBSERVATION_MODIFIER", 4, 10], ["hepatotoxic", "OBSERVATION_MODIFIER", 11, 22], ["peptides microcystins", "OBSERVATION", 23, 44]]], ["These toxins have caused number of animal poisonings and are a risk for human health.", [["poisonings", "DISEASE", 42, 52], ["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77]]], ["Microcystins and nodularins are specifi c inhibitors of eykaryotic protein phosphatases and act as tumour promoters.", [["tumour", "ANATOMY", 99, 105], ["Microcystins", "CHEMICAL", 0, 12], ["tumour", "DISEASE", 99, 105], ["Microcystins", "CHEMICAL", 0, 12], ["nodularins", "CHEMICAL", 17, 27], ["Microcystins", "GENE_OR_GENE_PRODUCT", 0, 12], ["nodularins", "SIMPLE_CHEMICAL", 17, 27], ["tumour", "CANCER", 99, 105], ["eykaryotic protein phosphatases", "PROTEIN", 56, 87], ["tumour promoters", "DNA", 99, 115], ["Microcystins", "PROBLEM", 0, 12], ["nodularins", "PROBLEM", 17, 27], ["eykaryotic protein phosphatases", "TREATMENT", 56, 87]]], ["In addition, several bioactive cyclic and linear peptides have been characterized from cyanobacteria and display a number of bioactivities including serine protease inhibition and cytotoxicity.", [["serine", "CHEMICAL", 149, 155], ["serine", "AMINO_ACID", 149, 155], ["several bioactive cyclic and linear peptides", "PROBLEM", 13, 57], ["cyanobacteria", "PROBLEM", 87, 100], ["serine protease inhibition", "TREATMENT", 149, 175], ["cytotoxicity", "PROBLEM", 180, 192], ["several", "OBSERVATION_MODIFIER", 13, 20], ["bioactive cyclic", "OBSERVATION", 21, 37], ["linear peptides", "OBSERVATION_MODIFIER", 42, 57], ["cyanobacteria", "OBSERVATION", 87, 100]]], ["Many of these compounds contain non-proteinogenic amino acids and are synthesised on non-ribosomal peptide synthetases.", [["amino acids", "CHEMICAL", 50, 61], ["amino acids", "CHEMICAL", 50, 61], ["non-proteinogenic", "SIMPLE_CHEMICAL", 32, 49], ["amino acids", "AMINO_ACID", 50, 61], ["non-ribosomal peptide synthetases", "GENE_OR_GENE_PRODUCT", 85, 118], ["non-ribosomal peptide synthetases", "PROTEIN", 85, 118], ["non-proteinogenic amino acids", "PROBLEM", 32, 61], ["non-ribosomal peptide synthetases", "TREATMENT", 85, 118], ["non-proteinogenic", "OBSERVATION_MODIFIER", 32, 49], ["amino acids", "OBSERVATION", 50, 61], ["non-ribosomal peptide synthetases", "OBSERVATION", 85, 118]]], ["Microcystins and nodularin are products of a mixed non-ribosomal peptide and polyketide synthetase.", [["Microcystins", "CHEMICAL", 0, 12], ["nodularin", "CHEMICAL", 17, 26], ["Microcystins", "CHEMICAL", 0, 12], ["nodularin", "CHEMICAL", 17, 26], ["Microcystins", "GENE_OR_GENE_PRODUCT", 0, 12], ["nodularin", "SIMPLE_CHEMICAL", 17, 26], ["polyketide synthetase", "GENE_OR_GENE_PRODUCT", 77, 98], ["nodularin", "PROTEIN", 17, 26], ["polyketide synthetase", "PROTEIN", 77, 98], ["Microcystins", "PROBLEM", 0, 12], ["nodularin", "PROBLEM", 17, 26], ["a mixed non-ribosomal peptide", "TREATMENT", 43, 72], ["polyketide synthetase", "TREATMENT", 77, 98], ["nodularin", "OBSERVATION", 17, 26], ["mixed", "OBSERVATION_MODIFIER", 45, 50], ["non-ribosomal peptide", "OBSERVATION", 51, 72], ["polyketide synthetase", "OBSERVATION", 77, 98]]], ["The microcystins and nodularin gene clusters encode peptide synthetases, polyketide synthatases and tailoring enzymes.", [["microcystins", "CHEMICAL", 4, 16], ["microcystins", "SIMPLE_CHEMICAL", 4, 16], ["nodularin", "GENE_OR_GENE_PRODUCT", 21, 30], ["polyketide synthatases", "SIMPLE_CHEMICAL", 73, 95], ["nodularin gene clusters", "DNA", 21, 44], ["peptide synthetases", "PROTEIN", 52, 71], ["polyketide synthatases", "PROTEIN", 73, 95], ["enzymes", "PROTEIN", 110, 117], ["The microcystins", "PROBLEM", 0, 16], ["nodularin gene clusters encode peptide synthetases", "PROBLEM", 21, 71], ["polyketide synthatases", "TEST", 73, 95], ["tailoring enzymes", "TEST", 100, 117], ["microcystins", "OBSERVATION", 4, 16], ["nodularin gene clusters", "OBSERVATION", 21, 44], ["peptide synthetases", "OBSERVATION", 52, 71]]], ["Studies on the evolution of microcystin/nodularin synthetase genes suggest that these genes are ancient and that present non-toxic strains have lost the genes and toxin production.", [["microcystin", "CHEMICAL", 28, 39], ["microcystin", "CHEMICAL", 28, 39], ["microcystin", "GENE_OR_GENE_PRODUCT", 28, 39], ["nodularin synthetase", "GENE_OR_GENE_PRODUCT", 40, 60], ["microcystin/nodularin synthetase genes", "DNA", 28, 66], ["microcystin/nodularin synthetase genes", "PROBLEM", 28, 66], ["non-toxic strains", "PROBLEM", 121, 138], ["nodularin synthetase", "OBSERVATION", 40, 60]]], ["The cyclic anabenopeptilides, and anabaenopeptins as well as linear spumigins are synthesised on non-ribosomal peptide synthetases.", [["cyclic anabenopeptilides", "CHEMICAL", 4, 28], ["anabaenopeptins", "CHEMICAL", 34, 49], ["cyclic anabenopeptilides", "CHEMICAL", 4, 28], ["anabaenopeptins", "CHEMICAL", 34, 49], ["cyclic anabenopeptilides", "SIMPLE_CHEMICAL", 4, 28], ["anabaenopeptins", "SIMPLE_CHEMICAL", 34, 49], ["spumigins", "SIMPLE_CHEMICAL", 68, 77], ["non-ribosomal peptide synthetases", "PROTEIN", 97, 130], ["The cyclic anabenopeptilides", "TREATMENT", 0, 28], ["anabaenopeptins", "TREATMENT", 34, 49], ["linear spumigins", "TREATMENT", 61, 77], ["non-ribosomal peptide synthetases", "TREATMENT", 97, 130], ["cyclic anabenopeptilides", "OBSERVATION", 4, 28], ["non-ribosomal peptide synthetases", "OBSERVATION", 97, 130]]], ["Recently the complete genome of Anabaena sp. strain 90 revealed ribosomal peptide synthesis of a novel family of cyclic peptides by planktonic cyanobacteria.", [["ribosomal", "ANATOMY", 64, 73], ["Anabaena sp", "ORGANISM", 32, 43], ["Anabaena sp", "PROBLEM", 32, 43], ["strain", "PROBLEM", 45, 51], ["ribosomal peptide synthesis", "PROBLEM", 64, 91], ["cyclic peptides", "PROBLEM", 113, 128], ["planktonic cyanobacteria", "PROBLEM", 132, 156], ["Anabaena sp", "OBSERVATION", 32, 43], ["ribosomal peptide synthesis", "OBSERVATION", 64, 91]]], ["This genome project also showed that 5% of the genome was dedicated to biosynthesis of bioactive compounds and that all the gene clusters are carried on the chromosome.", [["chromosome", "ANATOMY", 157, 167], ["chromosome", "CELLULAR_COMPONENT", 157, 167], ["chromosome", "DNA", 157, 167], ["bioactive compounds", "PROBLEM", 87, 106], ["bioactive compounds", "OBSERVATION", 87, 106]]], ["Cyanobacteria are a rich source of bioactive compounds for drug leads.", [["Cyanobacteria", "CHEMICAL", 0, 13], ["Cyanobacteria", "SIMPLE_CHEMICAL", 0, 13], ["Cyanobacteria", "PROBLEM", 0, 13], ["drug leads", "TREATMENT", 59, 69], ["bioactive compounds", "OBSERVATION", 35, 54]]], ["They produce peptides by ribosomal and non-ribosomal peptide synthesis pathways and could provide enzymes to be used in combinatorial biosynthesis or semisynthesis to produce novel compounds in future.S05-2The biosynthesis and evolution of cyclotides: macrocyclic peptides from plants, with applications in drug design The cyclotides [1, 2] are a recently discovered family of plant-derived proteins that have applications in drug design and agriculture.", [["ribosomal", "ANATOMY", 25, 34], ["cyclotides", "CHEMICAL", 240, 250], ["cyclotides [1, 2]", "CHEMICAL", 323, 340], ["cyclotides", "CHEMICAL", 240, 250], ["cyclotides", "CHEMICAL", 323, 333], ["ribosomal", "CELLULAR_COMPONENT", 25, 34], ["cyclotides", "SIMPLE_CHEMICAL", 240, 250], ["macrocyclic peptides", "SIMPLE_CHEMICAL", 252, 272], ["cyclotides [1, 2]", "SIMPLE_CHEMICAL", 323, 340], ["ribosomal and non-ribosomal peptide synthesis pathways", "TREATMENT", 25, 79], ["enzymes", "TEST", 98, 105], ["combinatorial biosynthesis", "TREATMENT", 120, 146], ["semisynthesis", "TREATMENT", 150, 163], ["macrocyclic peptides", "TREATMENT", 252, 272]]], ["They occur in plants from the Violaceae (violet), Rubiaceae (coffee) and Cucurbitaceae (cucurbit) families and have a diverse range of biological activities, including uterotonic, anti-HIV, antimicrobial, and insecticidal activities, the latter suggesting that their natural function is in plant defense.", [["cucurbit", "CHEMICAL", 88, 96], ["Violaceae", "SIMPLE_CHEMICAL", 30, 39], ["violet", "SIMPLE_CHEMICAL", 41, 47], ["coffee", "ORGANISM_SUBDIVISION", 61, 67], ["Cucurbitaceae", "SIMPLE_CHEMICAL", 73, 86], ["the Violaceae (violet", "TREATMENT", 26, 47], ["Rubiaceae (coffee)", "TREATMENT", 50, 68], ["Cucurbitaceae (cucurbit)", "TREATMENT", 73, 97], ["uterotonic, anti-HIV", "TREATMENT", 168, 188], ["antimicrobial", "TREATMENT", 190, 203], ["Rubiaceae", "ANATOMY", 50, 59]]], ["Individual plants express suites of 10-100 cyclotides at high levels (2g/kg wet plant weight).", [["cyclotides", "CHEMICAL", 43, 53], ["cyclotides", "SIMPLE_CHEMICAL", 43, 53], ["cyclotides", "TREATMENT", 43, 53]]], ["Cyclotides typically comprise 30 amino acids, have a head-to-tail cyclized backbone and incorporate three disulfi de bonds arranged in a cystine knot topology.", [["head", "ANATOMY", 53, 57], ["Cyclotides", "CHEMICAL", 0, 10], ["amino acids", "CHEMICAL", 33, 44], ["disulfi", "CHEMICAL", 106, 113], ["cystine", "CHEMICAL", 137, 144], ["Cyclotides", "CHEMICAL", 0, 10], ["amino acids", "CHEMICAL", 33, 44], ["disulfi", "CHEMICAL", 106, 113], ["cystine", "CHEMICAL", 137, 144], ["Cyclotides", "SIMPLE_CHEMICAL", 0, 10], ["amino acids", "AMINO_ACID", 33, 44], ["disulfi de bonds", "SIMPLE_CHEMICAL", 106, 122], ["Cyclotides", "TREATMENT", 0, 10], ["amino acids", "TEST", 33, 44], ["a head-to-tail cyclized backbone", "TREATMENT", 51, 83], ["a cystine knot topology", "TREATMENT", 135, 158]]], ["In this motif an embedded ring in the structure formed by two disulfi de bonds and their connecting backbone segments is penetrated by a third disulfi de bond.", [["disulfi", "CHEMICAL", 62, 69], ["disulfi", "CHEMICAL", 143, 150], ["disulfi", "CHEMICAL", 62, 69], ["disulfi", "CHEMICAL", 143, 150], ["disulfi de bonds", "SIMPLE_CHEMICAL", 62, 78], ["disulfi de bond", "SIMPLE_CHEMICAL", 143, 158], ["connecting backbone segments", "PROTEIN", 89, 117], ["this motif an embedded ring in the structure", "TREATMENT", 3, 47], ["embedded ring", "OBSERVATION", 17, 30], ["two", "OBSERVATION_MODIFIER", 58, 61], ["disulfi", "OBSERVATION_MODIFIER", 62, 69], ["de bonds", "OBSERVATION", 70, 78], ["backbone", "ANATOMY_MODIFIER", 100, 108], ["segments", "ANATOMY_MODIFIER", 109, 117], ["penetrated", "OBSERVATION_MODIFIER", 121, 131]]], ["The combination of this knotted and strongly braced structure with a circular backbone renders the cyclotides impervious to enzymatic breakdown and makes them exceptionally stable.", [["cyclotides", "SIMPLE_CHEMICAL", 99, 109], ["this knotted and strongly braced structure", "PROBLEM", 19, 61], ["a circular backbone", "TREATMENT", 67, 86], ["the cyclotides", "TREATMENT", 95, 109], ["enzymatic breakdown", "PROBLEM", 124, 143], ["braced structure", "OBSERVATION", 45, 61], ["circular", "OBSERVATION_MODIFIER", 69, 77], ["enzymatic", "OBSERVATION_MODIFIER", 124, 133], ["breakdown", "OBSERVATION", 134, 143], ["exceptionally", "OBSERVATION_MODIFIER", 159, 172], ["stable", "OBSERVATION_MODIFIER", 173, 179]]], ["The cyclotides are the largest of several groups of naturally occurring circular proteins that have been discovered over recent years (2) .", [["cyclotides", "CHEMICAL", 4, 14], ["cyclotides", "SIMPLE_CHEMICAL", 4, 14], ["circular proteins", "PROTEIN", 72, 89], ["The cyclotides", "TREATMENT", 0, 14], ["circular proteins", "PROBLEM", 72, 89], ["cyclotides", "OBSERVATION", 4, 14], ["largest", "OBSERVATION_MODIFIER", 23, 30], ["several", "OBSERVATION_MODIFIER", 34, 41], ["groups", "OBSERVATION_MODIFIER", 42, 48], ["naturally", "OBSERVATION_MODIFIER", 52, 61], ["circular proteins", "OBSERVATION", 72, 89]]], ["Their stability and compact structure makes them an attractive protein framework onto which bioactive peptide epitopes can be grafted to stabilize them.", [["an attractive protein framework", "TREATMENT", 49, 80], ["bioactive peptide epitopes", "TREATMENT", 92, 118], ["stability", "OBSERVATION_MODIFIER", 6, 15]]], ["Cyclotides are matured from larger precursor proteins via a series of processing events, including excision, and head-to-tail peptide ligation via an asparaginyl endoproteinase.", [["head", "ANATOMY", 113, 117], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "CHEMICAL", 0, 10], ["Cyclotides", "SIMPLE_CHEMICAL", 0, 10], ["asparaginyl endoproteinase", "GENE_OR_GENE_PRODUCT", 150, 176], ["precursor proteins", "PROTEIN", 35, 53], ["asparaginyl endoproteinase", "PROTEIN", 150, 176], ["Cyclotides", "TREATMENT", 0, 10], ["larger precursor proteins", "PROBLEM", 28, 53], ["processing events", "PROBLEM", 70, 87], ["excision", "TREATMENT", 99, 107], ["head-to-tail peptide ligation", "TREATMENT", 113, 142], ["an asparaginyl endoproteinase", "TREATMENT", 147, 176], ["larger", "OBSERVATION_MODIFIER", 28, 34], ["precursor proteins", "OBSERVATION", 35, 53], ["excision", "OBSERVATION", 99, 107], ["head", "ANATOMY", 113, 117], ["tail", "ANATOMY", 121, 125], ["ligation", "OBSERVATION", 134, 142], ["asparaginyl endoproteinase", "OBSERVATION", 150, 176]]], ["Folding is facilitated by a protein disulfi de isomerase (PDI).", [["disulfi de isomerase", "GENE_OR_GENE_PRODUCT", 36, 56], ["PDI", "GENE_OR_GENE_PRODUCT", 58, 61], ["protein disulfi de isomerase", "PROTEIN", 28, 56], ["PDI", "PROTEIN", 58, 61]]], ["This presentation will describe the discovery and characterization of the precursor proteins, PDI and the biosynthetic process.", [["PDI", "GENE_OR_GENE_PRODUCT", 94, 97], ["precursor proteins", "PROTEIN", 74, 92], ["PDI", "PROTEIN", 94, 97], ["the precursor proteins", "PROBLEM", 70, 92], ["PDI", "PROBLEM", 94, 97], ["the biosynthetic process", "PROBLEM", 102, 126], ["biosynthetic process", "OBSERVATION", 106, 126]]], ["The venom of cone snails is a remarkable source of bioactive peptides.ReferencesHere we describe the fi rst example of an exogenous CCAP peptide as part of the venom of Conus villepinii, a deep-water Western Atlantic cone snail species.", [["venom", "ANATOMY", 4, 9], ["venom", "ANATOMY", 160, 165], ["venom", "ORGANISM_SUBSTANCE", 4, 9], ["CCAP", "GENE_OR_GENE_PRODUCT", 132, 136], ["venom", "ORGANISM_SUBSTANCE", 160, 165], ["Conus villepinii", "ORGANISM", 169, 185], ["Conus villepinii", "SPECIES", 169, 185], ["Conus villepinii", "SPECIES", 169, 185], ["bioactive peptides", "TREATMENT", 51, 69], ["an exogenous CCAP peptide", "PROBLEM", 119, 144], ["Conus villepinii", "PROBLEM", 169, 185], ["bioactive peptides", "OBSERVATION", 51, 69], ["Conus villepinii", "ANATOMY", 169, 185], ["deep", "ANATOMY_MODIFIER", 189, 193], ["snail species", "OBSERVATION", 222, 235]]], ["Cardioactive peptides (CCAPs) were fi rst isolated from the shore crab Carcinus maenas.", [["CCAPs", "GENE_OR_GENE_PRODUCT", 23, 28], ["crab", "ORGANISM", 66, 70], ["Carcinus maenas", "ORGANISM", 71, 86], ["Carcinus maenas", "SPECIES", 71, 86], ["shore crab", "SPECIES", 60, 70], ["Carcinus maenas", "SPECIES", 71, 86], ["Cardioactive peptides (CCAPs)", "PROBLEM", 0, 29], ["peptides", "OBSERVATION", 13, 21], ["Carcinus maenas", "OBSERVATION", 71, 86]]], ["These endogenous peptides have been isolated from other invertebrates and insects.", [["These endogenous peptides", "PROBLEM", 0, 25]]], ["CCAP's are multifunctional neuropeptides involved in circulatory function, ecdysis behavior and visceral organ activity.", [["circulatory", "ANATOMY", 53, 64], ["visceral organ", "ANATOMY", 96, 110], ["CCAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["circulatory", "ANATOMICAL_SYSTEM", 53, 64], ["visceral", "ORGAN", 96, 104], ["organ", "ORGAN", 105, 110], ["CCAP", "PROTEIN", 0, 4], ["CCAP's", "TEST", 0, 6], ["multifunctional neuropeptides", "PROBLEM", 11, 40], ["ecdysis behavior", "PROBLEM", 75, 91], ["visceral organ activity", "PROBLEM", 96, 119], ["circulatory function", "OBSERVATION", 53, 73], ["visceral organ", "ANATOMY", 96, 110]]], ["One of the principal roles of the CCAP neuropeptide is that it has a cardioacceleratory effect when it is applied in vitro and a cardiotonic effect when it is applied in vivo.", [["CCAP neuropeptide", "GENE_OR_GENE_PRODUCT", 34, 51], ["CCAP neuropeptide", "PROTEIN", 34, 51], ["a cardioacceleratory effect", "PROBLEM", 67, 94], ["a cardiotonic effect", "TREATMENT", 127, 147], ["cardiotonic effect", "OBSERVATION", 129, 147]]], ["This discrepancy may result from the modulation of the cardiac CCAP signaling pathway by other molecules that are present in the whole organism but absent in the isolated cardiac tissue or cells.", [["cardiac", "ANATOMY", 55, 62], ["cardiac tissue", "ANATOMY", 171, 185], ["cells", "ANATOMY", 189, 194], ["cardiac", "ORGAN", 55, 62], ["CCAP", "GENE_OR_GENE_PRODUCT", 63, 67], ["cardiac tissue", "TISSUE", 171, 185], ["cells", "CELL", 189, 194], ["CCAP", "PROTEIN", 63, 67], ["other molecules", "PROBLEM", 89, 104], ["the whole organism", "PROBLEM", 125, 143], ["the isolated cardiac tissue", "PROBLEM", 158, 185], ["cardiac CCAP", "ANATOMY", 55, 67], ["cardiac tissue", "ANATOMY", 171, 185]]], ["We initially isolated a peptide from the venom of Conus villepinii whose precursor we determined that belong to the CCAP family (CCAP-vil).", [["venom", "ANATOMY", 41, 46], ["venom", "ORGANISM_SUBSTANCE", 41, 46], ["Conus villepinii", "ORGANISM", 50, 66], ["CCAP", "GENE_OR_GENE_PRODUCT", 116, 120], ["CCAP-vil", "GENE_OR_GENE_PRODUCT", 129, 137], ["CCAP family", "PROTEIN", 116, 127], ["CCAP", "PROTEIN", 129, 133], ["vil", "PROTEIN", 134, 137], ["Conus villepinii", "SPECIES", 50, 66], ["Conus villepinii", "SPECIES", 50, 66], ["CCAP", "TEST", 129, 133]]], ["We determined the 3D structure of the CCAP-vil peptide by NMR, which was shown to be a loop fl anked by the disulfi de bridge, with two turns and several intermolecular hydrogen bonds.", [["disulfi", "CHEMICAL", 108, 115], ["disulfi", "CHEMICAL", 108, 115], ["hydrogen", "CHEMICAL", 169, 177], ["CCAP-vil peptide", "GENE_OR_GENE_PRODUCT", 38, 54], ["CCAP", "PROTEIN", 38, 42], ["disulfi de bridge", "PROTEIN", 108, 125], ["the CCAP", "TEST", 34, 42], ["several intermolecular hydrogen bonds", "PROBLEM", 146, 183], ["loop fl", "OBSERVATION", 87, 94], ["intermolecular", "OBSERVATION", 154, 168], ["hydrogen bonds", "OBSERVATION", 169, 183]]], ["This structure suggests potential cellpenetrating features that might be important for the peptide activity.", [["potential cellpenetrating features", "PROBLEM", 24, 58]]], ["Assays using mammalian myocytes show that CCAP-vil is cardiotonic, as it decreases hearts contraction by 58%.", [["myocytes", "ANATOMY", 23, 31], ["hearts", "ANATOMY", 83, 89], ["CCAP-vil", "CHEMICAL", 42, 50], ["myocytes", "CELL", 23, 31], ["CCAP-vil", "GENE_OR_GENE_PRODUCT", 42, 50], ["hearts", "ORGAN", 83, 89], ["Assays", "TEST", 0, 6], ["mammalian myocytes", "TEST", 13, 31], ["CCAP", "TEST", 42, 46], ["cardiotonic", "PROBLEM", 54, 65], ["contraction", "OBSERVATION_MODIFIER", 90, 101]]], ["No other studies on the cardiac effects of CCAPs in mammals have been reported so far.", [["cardiac", "ANATOMY", 24, 31], ["CCAPs", "CHEMICAL", 43, 48], ["cardiac", "ANATOMICAL_SYSTEM", 24, 31], ["CCAPs", "GENE_OR_GENE_PRODUCT", 43, 48], ["other studies", "TEST", 3, 16], ["CCAPs", "TEST", 43, 48]]], ["These results suggest that the effects on systolic Ca2+ and contraction may be due to the action of the peptide on the ryanodine receptor (RyR) activity.", [["Ca2", "CHEMICAL", 51, 54], ["ryanodine", "CHEMICAL", 119, 128], ["Ca2+", "CHEMICAL", 51, 55], ["ryanodine", "CHEMICAL", 119, 128], ["Ca2+", "SIMPLE_CHEMICAL", 51, 55], ["ryanodine receptor", "GENE_OR_GENE_PRODUCT", 119, 137], ["RyR", "GENE_OR_GENE_PRODUCT", 139, 142], ["ryanodine receptor", "PROTEIN", 119, 137], ["RyR", "PROTEIN", 139, 142], ["systolic Ca2", "TEST", 42, 54], ["the peptide", "TREATMENT", 100, 111], ["the ryanodine receptor", "TREATMENT", 115, 137]]], ["The fact that these effects are time-dependent also suggests that the peptide action may require binding to a target protein that affects Ca2+ release via RyR.S05-4A novel nucleolar localization signal sequence derived by structural minimization of an animal toxin Localization sequences are specifi c sorting signals present in proteins, which direct them to precise cellular compartments.", [["nucleolar", "ANATOMY", 172, 181], ["cellular compartments", "ANATOMY", 368, 389], ["Ca2", "CHEMICAL", 138, 141], ["Ca2+", "CHEMICAL", 138, 142], ["Ca2+", "SIMPLE_CHEMICAL", 138, 142], ["RyR.S05-4", "GENE_OR_GENE_PRODUCT", 155, 164], ["nucleolar", "CELLULAR_COMPONENT", 172, 181], ["cellular", "CELL", 368, 376], ["Ca2", "PROTEIN", 138, 141], ["RyR.S05", "PROTEIN", 155, 162], ["nucleolar localization signal sequence", "PROTEIN", 172, 210], ["the peptide action", "PROBLEM", 66, 84], ["RyR.S05", "TEST", 155, 162], ["A novel nucleolar localization signal sequence", "TEST", 164, 210], ["an animal toxin Localization sequences", "TEST", 249, 287]]], ["For instance, nuclear localization signals (NLSs), typifi ed by cluster(s) of basic residues (e.g.S05-4-KKKRK-), are found in nuclear proteins selectively recognized by nuclear import machinery.", [["nuclear", "ANATOMY", 14, 21], ["nuclear", "ANATOMY", 126, 133], ["nuclear", "ANATOMY", 169, 176], ["nuclear", "CELLULAR_COMPONENT", 14, 21], ["S05-4", "GENE_OR_GENE_PRODUCT", 98, 103], ["KKKRK", "GENE_OR_GENE_PRODUCT", 104, 109], ["nuclear", "CELLULAR_COMPONENT", 126, 133], ["nuclear", "CELLULAR_COMPONENT", 169, 176], ["NLSs", "PROTEIN", 44, 48], ["basic residues", "PROTEIN", 78, 92], ["S05", "PROTEIN", 98, 101], ["KKKRK", "PROTEIN", 104, 109], ["nuclear proteins", "PROTEIN", 126, 142], ["nuclear localization signals", "TEST", 14, 42], ["basic residues", "TEST", 78, 92], ["S05", "TEST", 98, 101], ["nuclear proteins", "OBSERVATION", 126, 142]]], ["Cell penetrating peptides (CPPs), on the other hand, are natural or synthetic sequences, also cationic and usually amphipathic, capable of translocating cell membranes and often localizing to the nucleus of eucaryotic cells.", [["Cell", "ANATOMY", 0, 4], ["cell membranes", "ANATOMY", 153, 167], ["nucleus", "ANATOMY", 196, 203], ["cells", "ANATOMY", 218, 223], ["Cell penetrating peptides", "GENE_OR_GENE_PRODUCT", 0, 25], ["cell membranes", "CELLULAR_COMPONENT", 153, 167], ["nucleus", "CELLULAR_COMPONENT", 196, 203], ["eucaryotic cells", "CELL", 207, 223], ["eucaryotic cells", "CELL_TYPE", 207, 223], ["Cell penetrating peptides", "PROBLEM", 0, 25], ["translocating cell membranes", "PROBLEM", 139, 167], ["translocating cell membranes", "OBSERVATION", 139, 167], ["nucleus", "ANATOMY_MODIFIER", 196, 203], ["eucaryotic cells", "OBSERVATION", 207, 223]]], ["Although cationic and amphipathic peptides are plentiful in animal venoms, the number of reported examples of animal toxins with membrane translocating properties is limited.", [["membrane", "ANATOMY", 129, 137], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["cationic and amphipathic peptides", "PROBLEM", 9, 42], ["animal toxins", "PROBLEM", 110, 123], ["amphipathic peptides", "OBSERVATION", 22, 42], ["plentiful", "OBSERVATION_MODIFIER", 47, 56]]], ["In one of such cases, we have dissected the highly folded, 3disulfi de native structure of an amphiphatic toxin with a view to defi ning the pharmacophore responsible for membrane translocation and nuclear localization.", [["membrane", "ANATOMY", 171, 179], ["nuclear", "ANATOMY", 198, 205], ["membrane", "CELLULAR_COMPONENT", 171, 179], ["nuclear", "CELLULAR_COMPONENT", 198, 205], ["amphiphatic toxin", "PROTEIN", 94, 111], ["membrane translocation", "PROBLEM", 171, 193], ["nuclear localization", "TEST", 198, 218], ["highly", "OBSERVATION_MODIFIER", 44, 50], ["folded", "OBSERVATION", 51, 57]]], ["Using a minimalist synthetic approach in conjunction with in vivo time-lapse confocal microscopy, we have successfully identifi ed a novel 13-residue peptide sequence with exquisite nucleolar localization (NrL) properties.", [["nucleolar", "ANATOMY", 182, 191], ["NrL", "PROTEIN", 206, 209], ["a minimalist synthetic approach", "TREATMENT", 6, 37], ["confocal microscopy", "TEST", 77, 96], ["a novel 13-residue peptide sequence", "TREATMENT", 131, 166], ["nucleolar localization", "OBSERVATION", 182, 204]]], ["Fluorescent tagged peptide initiates uptake as early as 15 min, reaching maximal penetration rate and compartmentalization at 45-60 min.", [["maximal penetration rate", "TEST", 73, 97]]], ["In addition, the uptake process and nucleolar localization are shown to be cell cycle-dependent.", [["nucleolar", "ANATOMY", 36, 45], ["cell", "ANATOMY", 75, 79], ["nucleolar", "CELLULAR_COMPONENT", 36, 45], ["cell", "CELL", 75, 79], ["the uptake process", "PROBLEM", 13, 31], ["nucleolar localization", "TEST", 36, 58], ["cell cycle-dependent", "PROBLEM", 75, 95], ["uptake process", "OBSERVATION", 17, 31], ["nucleolar localization", "OBSERVATION", 36, 58], ["cell cycle-dependent", "OBSERVATION", 75, 95]]], ["Cytotoxicity assay with 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) shows the peptide to be not harmful for HeLa cells up to 100 M. These results are interesting as the nucleolus is a preeminent nuclear compartment that, aside from its role in ribosomal RNA biogenesis, contains a number of proteins involved in cell cycle regulation.S05-5The We have purifi ed and identifi ed a 5.6 KDa Kazal-type trypsin inhibitor (P12) in mouse seminal vesicle fl uid.", [["HeLa cells", "ANATOMY", 130, 140], ["nucleolus", "ANATOMY", 191, 200], ["nuclear compartment", "ANATOMY", 217, 236], ["ribosomal", "ANATOMY", 266, 275], ["cell", "ANATOMY", 334, 338], ["seminal vesicle", "ANATOMY", 453, 468], ["3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 24, 83], ["MTT", "CHEMICAL", 85, 88], ["3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "CHEMICAL", 24, 83], ["MTT", "CHEMICAL", 85, 88], ["3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide", "SIMPLE_CHEMICAL", 24, 83], ["MTT", "SIMPLE_CHEMICAL", 85, 88], ["HeLa cells", "CELL", 130, 140], ["nucleolus", "CELLULAR_COMPONENT", 191, 200], ["nuclear", "CELLULAR_COMPONENT", 217, 224], ["ribosomal", "CELLULAR_COMPONENT", 266, 275], ["cell", "CELL", 334, 338], ["Kazal-type trypsin", "GENE_OR_GENE_PRODUCT", 409, 427], ["mouse", "ORGANISM", 447, 452], ["seminal vesicle fl uid", "CELL", 453, 475], ["HeLa cells", "CELL_LINE", 130, 140], ["ribosomal RNA", "RNA", 266, 279], ["mouse", "SPECIES", 447, 452], ["mouse", "SPECIES", 447, 452], ["Cytotoxicity assay", "TEST", 0, 18], ["4,5dimethylthiazol", "TEST", 27, 45], ["diphenyltetrazolium bromide", "TREATMENT", 56, 83], ["HeLa cells", "TEST", 130, 140], ["ribosomal RNA biogenesis", "PROBLEM", 266, 290], ["cell cycle regulation", "TREATMENT", 334, 355], ["a 5.6 KDa Kazal-type trypsin inhibitor", "TREATMENT", 399, 437], ["ribosomal RNA biogenesis", "OBSERVATION", 266, 290], ["cell cycle", "OBSERVATION", 334, 344], ["seminal vesicle", "ANATOMY", 453, 468], ["fl uid", "OBSERVATION", 469, 475]]], ["It shows high affi nity to the plasma membrane overlaying the anterior acrosome of mouse spermatozoa (Kd = 70nM, 1.49x106 sites/cell) to suppress the spermatozoal Ca2+-uptake.", [["plasma membrane", "ANATOMY", 31, 46], ["anterior acrosome", "ANATOMY", 62, 79], ["spermatozoa", "ANATOMY", 89, 100], ["cell", "ANATOMY", 128, 132], ["spermatozoal", "ANATOMY", 150, 162], ["Ca2", "CHEMICAL", 163, 166], ["Ca2+-", "CHEMICAL", 163, 168], ["plasma membrane", "CELLULAR_COMPONENT", 31, 46], ["anterior acrosome", "CELLULAR_COMPONENT", 62, 79], ["mouse", "ORGANISM", 83, 88], ["spermatozoa", "DEVELOPING_ANATOMICAL_STRUCTURE", 89, 100], ["spermatozoal", "SIMPLE_CHEMICAL", 150, 162], ["Ca2+-", "SIMPLE_CHEMICAL", 163, 168], ["mouse spermatozoa", "CELL_TYPE", 83, 100], ["Ca2", "PROTEIN", 163, 166], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 83, 88], ["Kd", "TEST", 102, 104], ["high affi", "OBSERVATION", 9, 18], ["plasma membrane", "ANATOMY", 31, 46], ["anterior", "ANATOMY_MODIFIER", 62, 70], ["acrosome", "ANATOMY_MODIFIER", 71, 79], ["mouse spermatozoa", "OBSERVATION", 83, 100], ["spermatozoal Ca2", "ANATOMY", 150, 166]]], ["It gives very slight impact on the spermatozoal status represented by the cell population in uncapacitated, capacitated and acrosome-reacted stages.", [["spermatozoal", "ANATOMY", 35, 47], ["cell", "ANATOMY", 74, 78], ["acrosome", "ANATOMY", 124, 132], ["spermatozoal", "CELL", 35, 47], ["cell", "CELL", 74, 78], ["acrosome", "CELLULAR_COMPONENT", 124, 132], ["very slight impact on the spermatozoal status", "PROBLEM", 9, 54], ["the cell population", "PROBLEM", 70, 89], ["very", "OBSERVATION_MODIFIER", 9, 13], ["slight", "OBSERVATION_MODIFIER", 14, 20], ["impact", "OBSERVATION", 21, 27], ["cell population", "OBSERVATION", 74, 89]]], ["Arg19 is the reactive site for protease inhibitor, and Tyr21 or/ and Asp22 is essential for the sperm-binding.", [["sperm", "ANATOMY", 96, 101], ["Arg19", "GENE_OR_GENE_PRODUCT", 0, 5], ["Tyr21", "GENE_OR_GENE_PRODUCT", 55, 60], ["Asp22", "GENE_OR_GENE_PRODUCT", 69, 74], ["sperm", "CELLULAR_COMPONENT", 96, 101], ["Arg19", "DNA", 0, 5], ["Tyr21", "PROTEIN", 55, 60], ["Asp22", "PROTEIN", 69, 74], ["sperm", "CELL_TYPE", 96, 101], ["protease inhibitor", "TREATMENT", 31, 49], ["Tyr21", "TREATMENT", 55, 60], ["Asp22", "TREATMENT", 69, 74], ["reactive", "OBSERVATION_MODIFIER", 13, 21]]], ["There are three epitopes located in residues 5-10, residues 41-47, and residues 51-56, and they are three-dimensional distant from both Arg19 and Tyr21/Asp22.", [["Arg19", "CHEMICAL", 136, 141], ["Tyr21", "CHEMICAL", 146, 151], ["Asp", "CHEMICAL", 152, 155], ["Arg19", "GENE_OR_GENE_PRODUCT", 136, 141], ["Tyr21", "GENE_OR_GENE_PRODUCT", 146, 151], ["Asp22", "AMINO_ACID", 152, 157], ["epitopes", "PROTEIN", 16, 24], ["Arg19", "PROTEIN", 136, 141], ["Tyr21", "PROTEIN", 146, 151], ["Asp22", "PROTEIN", 152, 157], ["Asp", "TEST", 152, 155], ["three", "OBSERVATION_MODIFIER", 10, 15], ["epitopes", "OBSERVATION", 16, 24]]], ["Recently, we have succeeded in specifi cally crosslinking P12 to its binding site on mouse spermatozoa by the photo affi nity technique, using P12 conjugated with Sulfo-HSAB (N-Hydroxysulfosuccinimidyle-4-azidobenzoate), a photo affi nity labeling reagent.", [["spermatozoa", "ANATOMY", 91, 102], ["Sulfo-HSAB", "CHEMICAL", 163, 173], ["N-Hydroxysulfosuccinimidyle-4-azidobenzoate", "CHEMICAL", 175, 218], ["Sulfo-HSAB", "CHEMICAL", 163, 173], ["N-Hydroxysulfosuccinimidyle-4-azidobenzoate", "CHEMICAL", 175, 218], ["P12", "SIMPLE_CHEMICAL", 58, 61], ["mouse", "ORGANISM", 85, 90], ["spermatozoa", "DEVELOPING_ANATOMICAL_STRUCTURE", 91, 102], ["Sulfo-HSAB", "SIMPLE_CHEMICAL", 163, 173], ["N-Hydroxysulfosuccinimidyle-4-azidobenzoate", "SIMPLE_CHEMICAL", 175, 218], ["mouse spermatozoa", "CELL_TYPE", 85, 102], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["mouse spermatozoa", "TREATMENT", 85, 102], ["Sulfo-HSAB", "TREATMENT", 163, 173], ["Hydroxysulfosuccinimidyle", "TREATMENT", 177, 202], ["azidobenzoate", "TREATMENT", 205, 218], ["a photo affi nity labeling reagent", "TREATMENT", 221, 255]]], ["The spermatozoal protein complexed with P12 has been demonstrated to be \u00a3-enolase by proteomic study.", [["spermatozoal", "ANATOMY", 4, 16], ["spermatozoal protein", "GENE_OR_GENE_PRODUCT", 4, 24], ["P12", "GENE_OR_GENE_PRODUCT", 40, 43], ["spermatozoal protein", "PROTEIN", 4, 24], ["P12", "PROTEIN", 40, 43], ["\u00a3-enolase", "PROTEIN", 72, 81], ["proteomic study", "TEST", 85, 100], ["spermatozoal protein", "OBSERVATION", 4, 24]]], ["The presence of \u00a3-enolase on the sperm surface has been also confi rmed by immunocytochemical staining using the antibody against enolase.", [["sperm surface", "ANATOMY", 33, 46], ["\u00a3-enolase", "GENE_OR_GENE_PRODUCT", 16, 25], ["sperm surface", "CELLULAR_COMPONENT", 33, 46], ["enolase", "GENE_OR_GENE_PRODUCT", 130, 137], ["\u00a3-enolase", "PROTEIN", 16, 25], ["enolase", "PROTEIN", 130, 137], ["\u00a3-enolase on the sperm surface", "PROBLEM", 16, 46], ["immunocytochemical staining", "TEST", 75, 102], ["the antibody", "TEST", 109, 121], ["enolase", "PROBLEM", 130, 137], ["\u00a3-enolase", "OBSERVATION", 16, 25]]], ["In addition, we have found that the \u00a3-enolase antibody is able to inhibit the P12-sperm binding.", [["sperm", "ANATOMY", 82, 87], ["\u00a3-enolase antibody", "GENE_OR_GENE_PRODUCT", 36, 54], ["P12", "GENE_OR_GENE_PRODUCT", 78, 81], ["sperm", "CELLULAR_COMPONENT", 82, 87], ["\u00a3-enolase antibody", "PROTEIN", 36, 54], ["the \u00a3-enolase antibody", "TEST", 32, 54]]], ["Meanwhile, we have resolved the protein components of mouse uterine fl uid into three fractions, Fr I-III by gel chromatography on a G-100 Sephadex column, and demonstrated predominant distribution of trypsin-like proteases in Fr III.", [["uterine fl uid", "ANATOMY", 60, 74], ["fractions", "ANATOMY", 86, 95], ["mouse", "ORGANISM", 54, 59], ["uterine fl uid", "CELL", 60, 74], ["trypsin-like proteases", "GENE_OR_GENE_PRODUCT", 201, 223], ["Fr III", "GENE_OR_GENE_PRODUCT", 227, 233], ["trypsin-like proteases", "PROTEIN", 201, 223], ["Fr III", "PROTEIN", 227, 233], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["gel chromatography", "TEST", 109, 127], ["a G-100 Sephadex column", "TEST", 131, 154], ["trypsin", "PROBLEM", 201, 208], ["mouse uterine fl", "OBSERVATION", 54, 70], ["predominant", "OBSERVATION_MODIFIER", 173, 184], ["distribution", "OBSERVATION_MODIFIER", 185, 197], ["trypsin", "OBSERVATION", 201, 208]]], ["Hydrolysis of the trypsin substrate N-benzoyl-phe-Val-Arg p-nitroanilide by Fr III can be inhibited to a certain extent by P12, indicating that mouse uterine fl uid contains trypsin-like protease which can be specially inhibited by P12.", [["uterine", "ANATOMY", 150, 157], ["N-benzoyl-phe-Val-Arg p-nitroanilide", "CHEMICAL", 36, 72], ["N-benzoyl-phe-Val-Arg p-nitroanilide", "CHEMICAL", 36, 72], ["Fr III", "CHEMICAL", 76, 82], ["trypsin", "GENE_OR_GENE_PRODUCT", 18, 25], ["N-benzoyl-phe-Val-Arg p-nitroanilide", "SIMPLE_CHEMICAL", 36, 72], ["Fr III", "GENE_OR_GENE_PRODUCT", 76, 82], ["P12", "SIMPLE_CHEMICAL", 123, 126], ["mouse", "ORGANISM", 144, 149], ["uterine fl uid", "GENE_OR_GENE_PRODUCT", 150, 164], ["trypsin-like protease", "GENE_OR_GENE_PRODUCT", 174, 195], ["mouse uterine fl uid", "PROTEIN", 144, 164], ["trypsin", "PROTEIN", 174, 181], ["protease", "PROTEIN", 187, 195], ["mouse", "SPECIES", 144, 149], ["mouse", "SPECIES", 144, 149], ["Hydrolysis", "TEST", 0, 10], ["the trypsin substrate", "TEST", 14, 35], ["benzoyl", "TREATMENT", 38, 45], ["phe-Val", "TREATMENT", 46, 53], ["Arg p-nitroanilide", "TREATMENT", 54, 72], ["trypsin-like protease", "TREATMENT", 174, 195], ["uterine", "ANATOMY", 150, 157]]], ["Finally, the ability of Fr III to remove P12 on the sperm surface has been demonstrated.Pl\u00fcckthun, Andreas University of Z\u00fcrich, Department of Biochemistry, SWITZERLANDArmadillo repeat proteins are abundant eukaryotic proteins involved in several cellular processes, including cellular signaling and cytoskeletal regulation.", [["sperm surface", "ANATOMY", 52, 65], ["cellular", "ANATOMY", 247, 255], ["cellular", "ANATOMY", 277, 285], ["cytoskeletal", "ANATOMY", 300, 312], ["Fr III", "GENE_OR_GENE_PRODUCT", 24, 30], ["P12", "GENE_OR_GENE_PRODUCT", 41, 44], ["sperm surface", "CELLULAR_COMPONENT", 52, 65], ["cellular", "CELL", 247, 255], ["cellular", "CELL", 277, 285], ["cytoskeletal", "CELLULAR_COMPONENT", 300, 312], ["Fr III", "PROTEIN", 24, 30], ["SWITZERLANDArmadillo repeat proteins", "PROTEIN", 157, 193], ["eukaryotic proteins", "PROTEIN", 207, 226], ["Fr III", "TREATMENT", 24, 30], ["SWITZERLANDArmadillo repeat proteins", "TEST", 157, 193], ["eukaryotic proteins", "PROBLEM", 207, 226], ["several cellular processes", "PROBLEM", 239, 265], ["cellular signaling and cytoskeletal regulation", "PROBLEM", 277, 323], ["eukaryotic proteins", "OBSERVATION", 207, 226], ["several", "OBSERVATION_MODIFIER", 239, 246], ["cellular processes", "OBSERVATION", 247, 265], ["cellular signaling", "OBSERVATION", 277, 295], ["cytoskeletal regulation", "OBSERVATION", 300, 323]]], ["They are characterized by an armadillo domain, composed of tandem armadillo repeats of approximately 42 amino acids, which mediate interactions with peptides or parts of proteins in extended conformation.", [["amino acids", "CHEMICAL", 104, 115], ["amino acids", "CHEMICAL", 104, 115], ["amino acids", "AMINO_ACID", 104, 115], ["armadillo domain", "PROTEIN", 29, 45], ["tandem armadillo repeats", "PROTEIN", 59, 83], ["an armadillo domain", "TEST", 26, 45], ["tandem armadillo repeats", "TREATMENT", 59, 83], ["42 amino acids", "TREATMENT", 101, 115]]], ["The conserved binding mode, observed for different targets, makes armadillo repeat proteins attractive candidates for the generation of modular peptide binding scaffolds.", [["armadillo repeat proteins", "PROTEIN", 66, 91], ["armadillo repeat proteins", "TREATMENT", 66, 91], ["modular peptide binding scaffolds", "TREATMENT", 136, 169]]], ["Taking advantage of the large number of repeat sequences available, a consensus-based approach combined with a computational optimization of the hydrophobic core was used to derive soluble, highly expressed, stable, monomeric designed proteins with improved characteristics in comparison with natural armadillo proteins.", [["armadillo", "ORGANISM", 301, 310], ["repeat sequences", "DNA", 40, 56], ["monomeric designed proteins", "PROTEIN", 216, 243], ["natural armadillo proteins", "PROTEIN", 293, 319], ["repeat sequences", "TEST", 40, 56], ["the hydrophobic core", "TREATMENT", 141, 161], ["natural armadillo proteins", "TREATMENT", 293, 319], ["stable", "OBSERVATION_MODIFIER", 208, 214]]], ["The designed sequences constitute then the starting point for the generation of designed armadillo repeat protein libraries for the selection of peptide binders, taking advantage of their modular structure and their conserved binding mode.", [["armadillo repeat protein libraries", "DNA", 89, 123], ["armadillo repeat protein libraries", "TREATMENT", 89, 123], ["the selection of peptide binders", "TREATMENT", 128, 160]]], ["The release of ammonia upon urea hydrolysis by urease causes the increase of local pH providing microenvironment suitable for bacterial existence.", [["ammonia", "CHEMICAL", 15, 22], ["urea", "CHEMICAL", 28, 32], ["ammonia", "CHEMICAL", 15, 22], ["urea", "CHEMICAL", 28, 32], ["ammonia", "SIMPLE_CHEMICAL", 15, 22], ["urea", "SIMPLE_CHEMICAL", 28, 32], ["urease", "SIMPLE_CHEMICAL", 47, 53], ["ammonia upon urea hydrolysis", "TREATMENT", 15, 43], ["local pH", "TREATMENT", 77, 85], ["bacterial existence", "PROBLEM", 126, 145], ["increase", "OBSERVATION_MODIFIER", 65, 73]]], ["Helicobacter pylori may cause stomach ulcers and fi nally stomach cancer, while Proteus species are responsible for urinal tracts infl ammations.", [["stomach ulcers", "ANATOMY", 30, 44], ["stomach cancer", "ANATOMY", 58, 72], ["urinal tracts", "ANATOMY", 116, 129], ["Helicobacter pylori", "DISEASE", 0, 19], ["ulcers", "DISEASE", 38, 44], ["stomach cancer", "DISEASE", 58, 72], ["Helicobacter pylori", "ORGANISM", 0, 19], ["stomach ulcers", "PATHOLOGICAL_FORMATION", 30, 44], ["stomach cancer", "CANCER", 58, 72], ["Proteus species", "ORGANISM", 80, 95], ["Helicobacter pylori", "SPECIES", 0, 19], ["Helicobacter pylori", "SPECIES", 0, 19], ["Helicobacter pylori", "PROBLEM", 0, 19], ["stomach ulcers", "PROBLEM", 30, 44], ["fi nally stomach cancer", "PROBLEM", 49, 72], ["Proteus species", "PROBLEM", 80, 95], ["urinal tracts infl ammations", "PROBLEM", 116, 144], ["stomach", "ANATOMY", 30, 37], ["ulcers", "OBSERVATION", 38, 44], ["stomach", "ANATOMY", 58, 65], ["cancer", "OBSERVATION", 66, 72]]], ["Thus, inhibitors of urease are potential drugs against these diseases.", [["urease", "GENE_OR_GENE_PRODUCT", 20, 26], ["urease", "PROTEIN", 20, 26], ["inhibitors of urease", "TREATMENT", 6, 26], ["potential drugs", "TREATMENT", 31, 46], ["these diseases", "PROBLEM", 55, 69]]], ["Among several known inhibitors of urease, phosphoramidates are the most potent.", [["phosphoramidates", "CHEMICAL", 42, 58], ["phosphoramidates", "CHEMICAL", 42, 58], ["urease", "GENE_OR_GENE_PRODUCT", 34, 40], ["phosphoramidates", "SIMPLE_CHEMICAL", 42, 58], ["urease", "PROTEIN", 34, 40], ["urease", "PROBLEM", 34, 40], ["phosphoramidates", "TREATMENT", 42, 58], ["most potent", "OBSERVATION_MODIFIER", 67, 78]]], ["Phosphorus acid diamide -enzymatic reaction transition state analogue is the simplest example of this group of compounds.", [["Phosphorus acid diamide", "CHEMICAL", 0, 23], ["Phosphorus acid diamide", "CHEMICAL", 0, 23], ["Phosphorus acid diamide", "SIMPLE_CHEMICAL", 0, 23], ["Phosphorus acid diamide -enzymatic reaction", "PROBLEM", 0, 43], ["transition state analogue", "PROBLEM", 44, 69]]], ["The main disadvantages of this class of compounds are their low stability in aqueous solutions and low selectivity.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["low stability", "OBSERVATION_MODIFIER", 60, 73], ["low selectivity", "OBSERVATION_MODIFIER", 99, 114]]], ["On the basis of crystal structure of Helicobacter pylori urease novel class of urease inhibitors -phosphonic and phosphinic peptides were designed.", [["phosphonic", "CHEMICAL", 98, 108], ["phosphonic", "CHEMICAL", 98, 108], ["Helicobacter pylori", "ORGANISM", 37, 56], ["urease inhibitors -phosphonic", "SIMPLE_CHEMICAL", 79, 108], ["phosphinic peptides", "SIMPLE_CHEMICAL", 113, 132], ["Helicobacter pylori", "SPECIES", 37, 56], ["Helicobacter pylori", "SPECIES", 37, 56], ["Helicobacter pylori urease", "PROBLEM", 37, 63], ["urease inhibitors", "TREATMENT", 79, 96], ["phosphonic and phosphinic peptides", "TREATMENT", 98, 132], ["Helicobacter pylori", "OBSERVATION", 37, 56]]], ["Proposed scaffold gives the possibility of several modifi cations in order to enhance both inhibitory activity and selectivity towards pathogen protein.", [["cations", "SIMPLE_CHEMICAL", 58, 65], ["pathogen protein", "PROTEIN", 135, 151], ["several modifi cations", "TREATMENT", 43, 65], ["pathogen protein", "TEST", 135, 151]]], ["Subsequently, several phosphonic, P-methyland P-hydroxymethyl-phosphinic compounds were synthesized.", [["phosphonic, P-methyland P-hydroxymethyl-phosphinic", "CHEMICAL", 22, 72], ["phosphonic, P-methyland P-hydroxymethyl-phosphinic", "CHEMICAL", 22, 72], ["phosphonic, P-methyland P-hydroxymethyl-phosphinic compounds", "SIMPLE_CHEMICAL", 22, 82], ["several phosphonic", "TEST", 14, 32], ["P-methyland P-hydroxymethyl-phosphinic compounds", "TREATMENT", 34, 82]]], ["Evaluation of their potency in vitro against bacterial ureases showed high activity, with inhibitory constants for most active compounds being in nanomolar range.Kunz, Christian; Wei\u00df, Astrid; Groner, Bernd; Heinz, Corina Insitute for Biomedical Research, GERMANYSignal transduction events often involve the assembly of protein complexes dependent upon modular interactions.", [["protein complexes", "PROTEIN", 320, 337], ["Evaluation", "TEST", 0, 10], ["bacterial ureases", "TEST", 45, 62], ["high activity", "PROBLEM", 70, 83], ["inhibitory constants", "PROBLEM", 90, 110], ["most active compounds", "PROBLEM", 115, 136], ["Wei\u00df", "TEST", 179, 183], ["Astrid", "TEST", 185, 191], ["Biomedical Research", "TREATMENT", 235, 254], ["GERMANYSignal transduction events", "PROBLEM", 256, 289], ["high activity", "OBSERVATION", 70, 83], ["nanomolar range", "OBSERVATION", 146, 161], ["modular", "OBSERVATION_MODIFIER", 353, 360]]], ["The inappropriate assembly of modular components plays a role in oncogenic transformation and can be exploited for therapeutic purposes.", [["modular components", "PROBLEM", 30, 48], ["oncogenic transformation", "PROBLEM", 65, 89], ["modular", "OBSERVATION_MODIFIER", 30, 37], ["oncogenic transformation", "OBSERVATION", 65, 89]]], ["Selected peptides embedded in a scaffold protein, so-called peptide aptamers, can serve as competitive inhibitors of intracellular protein functions in cancer cells.", [["intracellular", "ANATOMY", 117, 130], ["cancer cells", "ANATOMY", 152, 164], ["cancer", "DISEASE", 152, 158], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["cancer cells", "CELL", 152, 164], ["scaffold protein", "PROTEIN", 32, 48], ["cancer cells", "CELL_TYPE", 152, 164], ["Selected peptides", "TREATMENT", 0, 17], ["a scaffold protein", "TREATMENT", 30, 48], ["peptide aptamers", "TREATMENT", 60, 76], ["intracellular protein functions in cancer cells", "PROBLEM", 117, 164], ["cancer cells", "OBSERVATION", 152, 164]]], ["Therapeutic application depends on binding specifi cities and affi nities, as well as on the production and purifi cation characteristics of the peptide aptamers and their delivery into cells.", [["cells", "ANATOMY", 186, 191], ["affi nities", "SIMPLE_CHEMICAL", 62, 73], ["cells", "CELL", 186, 191], ["Therapeutic application", "TREATMENT", 0, 23], ["purifi cation", "TREATMENT", 108, 121], ["the peptide aptamers", "TREATMENT", 141, 161], ["their delivery into cells", "TREATMENT", 166, 191]]], ["We found that the commonly employed bacterial thioredoxin scaffold is suboptimal for therapeutic purposes, since it aggregates during purifi cation and is most likely immunogenic in humans.", [["thioredoxin", "GENE_OR_GENE_PRODUCT", 46, 57], ["cation", "SIMPLE_CHEMICAL", 141, 147], ["humans", "ORGANISM", 182, 188], ["humans", "SPECIES", 182, 188], ["humans", "SPECIES", 182, 188], ["bacterial thioredoxin scaffold", "TREATMENT", 36, 66], ["purifi cation", "TREATMENT", 134, 147], ["most likely", "UNCERTAINTY", 155, 166], ["immunogenic", "OBSERVATION", 167, 178]]], ["In contrast, a modifi ed version of the human thioredoxin (hTrx) can be effi ciently produced in bacteria and purifi ed with high yield.", [["human", "ORGANISM", 40, 45], ["thioredoxin", "GENE_OR_GENE_PRODUCT", 46, 57], ["hTrx", "GENE_OR_GENE_PRODUCT", 59, 63], ["human thioredoxin", "PROTEIN", 40, 57], ["hTrx", "PROTEIN", 59, 63], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["the human thioredoxin (hTrx)", "TREATMENT", 36, 64], ["bacteria", "PROBLEM", 97, 105], ["bacteria", "OBSERVATION", 97, 105]]], ["We removed fi ve internal cysteines of hTrx to circumvent aggregation during purifi cation, which, we found, is a prerequisite for effi cient uptake into cells.", [["cells", "ANATOMY", 154, 159], ["cysteines", "CHEMICAL", 26, 35], ["hTrx", "GENE_OR_GENE_PRODUCT", 39, 43], ["purifi cation", "SIMPLE_CHEMICAL", 77, 90], ["cells", "CELL", 154, 159], ["hTrx", "PROTEIN", 39, 43], ["internal cysteines of hTrx", "TREATMENT", 17, 43], ["circumvent aggregation", "PROBLEM", 47, 69], ["purifi cation", "TREATMENT", 77, 90], ["effi cient uptake into cells", "PROBLEM", 131, 159], ["internal cysteines", "OBSERVATION", 17, 35]]], ["By inserting our previously characterised peptide aptamer DD3 into the modifi ed hTrx scaffold, binding properties of the aptamer to the dimerization domain of the transcription factor Stat3 were retained.", [["Stat3", "GENE_OR_GENE_PRODUCT", 185, 190], ["DD3", "PROTEIN", 58, 61], ["modifi ed hTrx scaffold", "PROTEIN", 71, 94], ["dimerization domain", "PROTEIN", 137, 156], ["transcription factor", "PROTEIN", 164, 184], ["Stat3", "PROTEIN", 185, 190], ["the modifi ed hTrx scaffold", "TREATMENT", 67, 94]]], ["Addition of a protein transduction domain (PTD), consisting of nine arginines, results in a fusion protein, which is taken up by cultured cells.", [["cells", "ANATOMY", 138, 143], ["arginines", "CHEMICAL", 68, 77], ["cells", "CELL", 138, 143], ["protein transduction domain", "PROTEIN", 14, 41], ["PTD", "PROTEIN", 43, 46], ["fusion protein", "PROTEIN", 92, 106], ["cultured cells", "CELL_LINE", 129, 143], ["a protein transduction domain", "TREATMENT", 12, 41], ["a fusion protein", "TEST", 90, 106]]], ["We show that the transduced aptamers prevent nuclear import of phosphorylated Stat3.", [["nuclear", "ANATOMY", 45, 52], ["nuclear", "CELLULAR_COMPONENT", 45, 52], ["Stat3", "GENE_OR_GENE_PRODUCT", 78, 83], ["phosphorylated Stat3", "PROTEIN", 63, 83], ["the transduced aptamers", "TREATMENT", 13, 36], ["phosphorylated Stat3", "TREATMENT", 63, 83], ["phosphorylated Stat3", "OBSERVATION", 63, 83]]], ["As a result, treatment of various cancer cells, expressing constitutively activated Stat3, with purifi ed peptide aptamers strongly inhibits Stat3 signalling, causing cell growth arrest and inducing apoptosis.", [["cancer cells", "ANATOMY", 34, 46], ["cell", "ANATOMY", 167, 171], ["cancer", "DISEASE", 34, 40], ["cancer cells", "CELL", 34, 46], ["Stat3", "GENE_OR_GENE_PRODUCT", 84, 89], ["Stat3", "GENE_OR_GENE_PRODUCT", 141, 146], ["cell", "CELL", 167, 171], ["cancer cells", "CELL_TYPE", 34, 46], ["Stat3", "PROTEIN", 84, 89], ["Stat3", "PROTEIN", 141, 146], ["various cancer cells", "PROBLEM", 26, 46], ["constitutively activated Stat3", "PROBLEM", 59, 89], ["purifi ed peptide aptamers", "TREATMENT", 96, 122], ["Stat3 signalling", "PROBLEM", 141, 157], ["cell growth arrest", "PROBLEM", 167, 185], ["inducing apoptosis", "PROBLEM", 190, 208], ["cancer cells", "OBSERVATION", 34, 46], ["cell", "OBSERVATION", 167, 171], ["growth arrest", "OBSERVATION", 172, 185], ["apoptosis", "OBSERVATION_MODIFIER", 199, 208]]], ["Our data show, that optimization of the scaffold offers new perspectives to overcome the technical diffi culties encountered with the development of therapeutically active peptide aptamers.Title Abs NoDesigned armadillo repeat protein libraries for the selection of peptide binders Pl\u00fcckthun, Andreas (1).", [["Title Abs", "PROTEIN", 189, 198], ["armadillo repeat protein libraries", "DNA", 210, 244], ["Our data", "TEST", 0, 8], ["therapeutically active peptide aptamers", "TREATMENT", 149, 188], ["Title Abs", "TEST", 189, 198], ["armadillo repeat protein libraries", "TREATMENT", 210, 244], ["the selection of peptide binders", "TREATMENT", 249, 281]]], ["This compound is specifi c for calpain even in cell lysate, but unfortunately has poor cell-uptake.", [["cell lysate", "ANATOMY", 47, 58], ["cell", "ANATOMY", 87, 91], ["specifi c", "GENE_OR_GENE_PRODUCT", 17, 26], ["calpain", "GENE_OR_GENE_PRODUCT", 31, 38], ["cell", "CELL", 47, 51], ["cell", "CELL", 87, 91], ["calpain", "PROTEIN", 31, 38], ["calpain", "PROBLEM", 31, 38], ["cell lysate", "TEST", 47, 58], ["poor cell-uptake", "PROBLEM", 82, 98], ["cell lysate", "OBSERVATION", 47, 58], ["poor cell", "OBSERVATION", 82, 91]]], ["Thus we have designed its new dervivatives with cell-penetrating capacity.", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["cell-penetrating capacity", "TREATMENT", 48, 73], ["penetrating capacity", "OBSERVATION", 53, 73]]], ["In order to achieve this we have elongated the sequence at the C-terminal with heptaarginine unit, Dabcyl-TPLKSPPPSPRE(EDANS)R7.", [["heptaarginine", "CHEMICAL", 79, 92], ["C", "CHEMICAL", 63, 64], ["heptaarginine", "CHEMICAL", 79, 92], ["Dabcyl-TPLKSPPPSPRE", "CHEMICAL", 99, 118], ["heptaarginine", "SIMPLE_CHEMICAL", 79, 92], ["Dabcyl-TPLKSPPPSPRE", "SIMPLE_CHEMICAL", 99, 118], ["C-terminal", "DNA", 63, 73], ["heptaarginine unit", "DNA", 79, 97], ["Dabcyl-TPLKSPPPSPRE(EDANS)R7", "PROTEIN", 99, 127], ["heptaarginine unit", "TREATMENT", 79, 97]]], ["For preservation the necessary distance between the two FRET partners, we inserted a Glu residue between the substrate and heptaarginine (2) .", [["Glu", "CHEMICAL", 85, 88], ["heptaarginine", "CHEMICAL", 123, 136], ["Glu", "CHEMICAL", 85, 88], ["heptaarginine", "CHEMICAL", 123, 136], ["heptaarginine", "SIMPLE_CHEMICAL", 123, 136], ["a Glu residue", "TREATMENT", 83, 96], ["the substrate and heptaarginine", "TREATMENT", 105, 136]]], ["We found that this conjugate was even better substrate of Calpain B than the unconjugated one and could enters COS-7 cells effi ciently.", [["COS-7 cells", "ANATOMY", 111, 122], ["Calpain B", "GENE_OR_GENE_PRODUCT", 58, 67], ["COS-7 cells", "CELL", 111, 122], ["Calpain B", "PROTEIN", 58, 67], ["COS-7 cells", "CELL_LINE", 111, 122], ["this conjugate", "PROBLEM", 14, 28]]], ["Specifi c activation of intracellular calpain may be a suitable tools to study its function.", [["intracellular", "ANATOMY", 24, 37], ["Specifi c", "GENE_OR_GENE_PRODUCT", 0, 9], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 37], ["calpain", "GENE_OR_GENE_PRODUCT", 38, 45], ["intracellular calpain", "PROTEIN", 24, 45], ["intracellular calpain", "PROBLEM", 24, 45], ["intracellular calpain", "OBSERVATION", 24, 45]]], ["For this, we synthesised a new group of cell-penetrating calpastatin-peptide conjugates.", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["calpastatin", "GENE_OR_GENE_PRODUCT", 57, 68], ["calpastatin", "PROTEIN", 57, 68], ["penetrating calpastatin-peptide conjugates", "TREATMENT", 45, 87]]], ["The calpastatin A or C subunit related peptides with calpain activatory effect were covalently conjugated to penetratin via amide, thioether, or disulfi de bond (3).", [["penetratin", "CHEMICAL", 109, 119], ["thioether", "CHEMICAL", 131, 140], ["disulfi", "CHEMICAL", 145, 152], ["penetratin", "CHEMICAL", 109, 119], ["amide", "CHEMICAL", 124, 129], ["thioether", "CHEMICAL", 131, 140], ["disulfi", "CHEMICAL", 145, 152], ["calpastatin A", "GENE_OR_GENE_PRODUCT", 4, 17], ["C subunit", "GENE_OR_GENE_PRODUCT", 21, 30], ["calpain", "GENE_OR_GENE_PRODUCT", 53, 60], ["penetratin", "SIMPLE_CHEMICAL", 109, 119], ["amide, thioether", "SIMPLE_CHEMICAL", 124, 140], ["disulfi de bond", "SIMPLE_CHEMICAL", 145, 160], ["calpastatin A", "PROTEIN", 4, 17], ["C subunit", "PROTEIN", 21, 30], ["calpain", "PROTEIN", 53, 60], ["The calpastatin A", "TREATMENT", 0, 17], ["C subunit related peptides", "TREATMENT", 21, 47], ["calpain activatory effect", "TREATMENT", 53, 78]]], ["Our results show that conjugates with different bond possess essentially the same level of activation and also could internalise into COS-7 cells.", [["COS-7 cells", "ANATOMY", 134, 145], ["COS-7 cells", "CELL", 134, 145], ["COS-7 cells", "CELL_LINE", 134, 145]]], ["We also noticed that even the conjugate with disulfi de linkage are stable and activate m-calpain after intracellular translocation under the conditions studied.", [["intracellular", "ANATOMY", 104, 117], ["disulfi", "CHEMICAL", 45, 52], ["disulfi", "CHEMICAL", 45, 52], ["disulfi", "SIMPLE_CHEMICAL", 45, 52], ["m-calpain", "GENE_OR_GENE_PRODUCT", 88, 97], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["m-calpain", "PROTEIN", 88, 97], ["stable", "OBSERVATION_MODIFIER", 68, 74]]], ["Thus, these conjugates seem to be appropriate as molecular tools to activate intracellular m-calpain and to study calpain functions in living cells.", [["intracellular", "ANATOMY", 77, 90], ["cells", "ANATOMY", 142, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["m-calpain", "GENE_OR_GENE_PRODUCT", 91, 100], ["calpain", "GENE_OR_GENE_PRODUCT", 114, 121], ["cells", "CELL", 142, 147], ["m-calpain", "PROTEIN", 91, 100], ["calpain", "PROTEIN", 114, 121], ["intracellular m-calpain", "TREATMENT", 77, 100]]], ["Leptin, a hormone produced by adipose tissue, regulates energy balance in the hypothalamus and is involved in fertility, immune response and carcinogenesis.", [["adipose tissue", "ANATOMY", 30, 44], ["hypothalamus", "ANATOMY", 78, 90], ["carcinogenesis", "DISEASE", 141, 155], ["Leptin", "GENE_OR_GENE_PRODUCT", 0, 6], ["adipose tissue", "TISSUE", 30, 44], ["hypothalamus", "ORGAN", 78, 90], ["Leptin", "PROTEIN", 0, 6], ["Leptin", "TREATMENT", 0, 6], ["a hormone", "TREATMENT", 8, 17], ["carcinogenesis", "PROBLEM", 141, 155], ["energy balance", "OBSERVATION", 56, 70], ["hypothalamus", "ANATOMY", 78, 90]]], ["The existence of disorders related to leptin defi cit or overabundance calls for the development of drugs acting on the leptin receptor (ObR).", [["leptin", "GENE_OR_GENE_PRODUCT", 38, 44], ["leptin receptor", "GENE_OR_GENE_PRODUCT", 120, 135], ["ObR", "GENE_OR_GENE_PRODUCT", 137, 140], ["leptin receptor", "PROTEIN", 120, 135], ["ObR", "PROTEIN", 137, 140], ["disorders", "PROBLEM", 17, 26], ["leptin defi cit", "TREATMENT", 38, 53], ["drugs", "TREATMENT", 100, 105], ["the leptin receptor", "TREATMENT", 116, 135]]], ["We synthesized individual arms of three proposed ObR-binding leptin fragments (sites I-III), their reportedly antagonist analogs, and a peptide chimera composed of two site II arms.", [["ObR", "SIMPLE_CHEMICAL", 49, 52], ["leptin", "GENE_OR_GENE_PRODUCT", 61, 67], ["ObR-binding leptin fragments", "DNA", 49, 77], ["sites I-III", "DNA", 79, 90], ["site II arms", "PROTEIN", 168, 180], ["binding leptin fragments", "PROBLEM", 53, 77], ["antagonist analogs", "TREATMENT", 110, 128], ["a peptide chimera", "TREATMENT", 134, 151], ["binding leptin fragments", "OBSERVATION", 53, 77]]], ["To assess the pharmacological utility of leptin fragments, we studied their ability to stimulate the growth of ObR-positive and ObR-negative cells.", [["ObR-negative cells", "ANATOMY", 128, 146], ["leptin", "GENE_OR_GENE_PRODUCT", 41, 47], ["ObR", "GENE_OR_GENE_PRODUCT", 111, 114], ["ObR", "GENE_OR_GENE_PRODUCT", 128, 131], ["cells", "CELL", 141, 146], ["leptin fragments", "DNA", 41, 57], ["ObR-positive and ObR-negative cells", "CELL_LINE", 111, 146], ["leptin fragments", "PROBLEM", 41, 57], ["ObR", "TEST", 111, 114], ["ObR", "TEST", 128, 131], ["negative cells", "OBSERVATION", 132, 146]]], ["The combined site II construct and site III derivatives selectively reversed leptin-induced growth of ObR-positive cells at mid-nM concentrations.", [["ObR-positive cells", "ANATOMY", 102, 120], ["leptin", "CHEMICAL", 77, 83], ["leptin", "GENE_OR_GENE_PRODUCT", 77, 83], ["ObR", "GENE_OR_GENE_PRODUCT", 102, 105], ["cells", "CELL", 115, 120], ["site II construct", "DNA", 13, 30], ["leptin", "PROTEIN", 77, 83], ["ObR-positive cells", "CELL_LINE", 102, 120], ["The combined site II construct", "TREATMENT", 0, 30], ["site III derivatives", "TREATMENT", 35, 55], ["leptin", "TEST", 77, 83], ["ObR", "TEST", 102, 105], ["positive cells", "PROBLEM", 106, 120], ["growth", "OBSERVATION_MODIFIER", 92, 98], ["positive cells", "OBSERVATION", 106, 120]]], ["However, these peptides appeared to be partial agonists as they activated cell growth in the absence of exogenous leptin.", [["cell", "ANATOMY", 74, 78], ["cell", "CELL", 74, 78], ["leptin", "GENE_OR_GENE_PRODUCT", 114, 120], ["partial agonists", "PROBLEM", 39, 55], ["they activated cell growth", "PROBLEM", 59, 85], ["exogenous leptin", "TREATMENT", 104, 120], ["exogenous leptin", "OBSERVATION", 104, 120]]], ["A designer site III analog, featuring non-natural amino acids at terminal positions to decrease proteolysis and a blood-brain barrier (BBB) penetration-enhancing carbohydrate moiety, proved to be a full agonist to ObR, i.e., it stimulated proliferation of different ObR-positive but not ObR-negative cells in the presence or absence of leptin.", [["blood", "ANATOMY", 114, 119], ["ObR-negative cells", "ANATOMY", 287, 305], ["amino acids", "CHEMICAL", 50, 61], ["amino acids", "CHEMICAL", 50, 61], ["carbohydrate", "CHEMICAL", 162, 174], ["amino acids", "AMINO_ACID", 50, 61], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 120, 133], ["BBB", "MULTI-TISSUE_STRUCTURE", 135, 138], ["ObR", "GENE_OR_GENE_PRODUCT", 214, 217], ["ObR", "GENE_OR_GENE_PRODUCT", 266, 269], ["ObR", "GENE_OR_GENE_PRODUCT", 287, 290], ["cells", "CELL", 300, 305], ["leptin", "GENE_OR_GENE_PRODUCT", 336, 342], ["ObR", "PROTEIN", 214, 217], ["ObR-positive but not ObR-negative cells", "CELL_LINE", 266, 305], ["leptin", "PROTEIN", 336, 342], ["A designer site III analog", "PROBLEM", 0, 26], ["featuring non-natural amino acids", "TREATMENT", 28, 61], ["decrease proteolysis", "PROBLEM", 87, 107], ["a blood-brain barrier", "TREATMENT", 112, 133], ["enhancing carbohydrate moiety", "PROBLEM", 152, 181], ["different ObR", "TEST", 256, 269], ["ObR", "TEST", 287, 290], ["absence of leptin", "PROBLEM", 325, 342], ["decrease", "OBSERVATION_MODIFIER", 87, 95], ["proteolysis", "OBSERVATION", 96, 107], ["brain", "ANATOMY", 120, 125], ["negative cells", "OBSERVATION", 291, 305]]], ["This glycopeptide bound to isolated ObR and activated ERK 1/2 signaling in ObR-positive MCF-7 cells at 200 -500 nM concentrations.", [["ObR-positive MCF-7 cells", "ANATOMY", 75, 99], ["ObR", "GENE_OR_GENE_PRODUCT", 36, 39], ["ERK 1/2", "GENE_OR_GENE_PRODUCT", 54, 61], ["ObR", "GENE_OR_GENE_PRODUCT", 75, 78], ["MCF-7 cells", "CELL", 88, 99], ["ObR", "PROTEIN", 36, 39], ["ERK 1/2", "PROTEIN", 54, 61], ["ObR-positive MCF-7 cells", "CELL_LINE", 75, 99], ["This glycopeptide bound", "PROBLEM", 0, 23], ["isolated ObR", "PROBLEM", 27, 39], ["activated ERK", "TEST", 44, 57], ["ObR", "TEST", 75, 78], ["MCF", "TEST", 88, 91], ["cells", "TEST", 94, 99], ["positive MCF", "OBSERVATION_MODIFIER", 79, 91]]], ["The glycopeptide was stable in mouse serum, readily crossed epithelial/astrocyte cell layers, and was distributed into the brain of Balb/c mice after intraperitoneal administration.", [["serum", "ANATOMY", 37, 42], ["epithelial", "ANATOMY", 60, 70], ["astrocyte cell layers", "ANATOMY", 71, 92], ["brain", "ANATOMY", 123, 128], ["intraperitoneal", "ANATOMY", 150, 165], ["mouse", "ORGANISM", 31, 36], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["epithelial", "CELL", 60, 70], ["astrocyte cell layers", "TISSUE", 71, 92], ["brain", "ORGAN", 123, 128], ["Balb/c mice", "ORGANISM", 132, 143], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 150, 165], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 139, 143], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 139, 143], ["The glycopeptide", "TREATMENT", 0, 16], ["intraperitoneal administration", "TREATMENT", 150, 180], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["epithelial", "ANATOMY_MODIFIER", 60, 70], ["astrocyte cell layers", "OBSERVATION", 71, 92], ["brain", "ANATOMY", 123, 128]]], ["Finally the effi cacy of the glycopeptide was tested on typical leptin functions in sheep.", [["leptin", "GENE_OR_GENE_PRODUCT", 64, 70], ["sheep", "ORGANISM", 84, 89], ["sheep", "SPECIES", 84, 89], ["sheep", "SPECIES", 84, 89], ["the glycopeptide", "TREATMENT", 25, 41]]], ["Voluntary food intake of program-fed animals was reduced by 25% and central infusion increased post-prandial thermogenesis in muscle by 3 degrees C without an effect on core body temperature.", [["muscle", "ANATOMY", 126, 132], ["body", "ANATOMY", 174, 178], ["post-prandial", "ORGANISM_SUBDIVISION", 95, 108], ["muscle", "ORGAN", 126, 132], ["body", "ORGANISM_SUBDIVISION", 174, 178], ["central infusion increased post-prandial thermogenesis", "TREATMENT", 68, 122], ["core body temperature", "TEST", 169, 190], ["muscle", "ANATOMY", 126, 132]]], ["These characteristics suggest a potential pharmaceutical utility of the designer site III glycopeptide in leptin-defi cient diseases.Aeterna-Zentaris, GERMANYThe central actions of ghrelin include stimulation of appetite and GH secretion.", [["ghrelin", "CHEMICAL", 181, 188], ["leptin", "GENE_OR_GENE_PRODUCT", 106, 112], ["ghrelin", "GENE_OR_GENE_PRODUCT", 181, 188], ["GH", "GENE_OR_GENE_PRODUCT", 225, 227], ["III glycopeptide", "TREATMENT", 86, 102], ["diseases", "PROBLEM", 124, 132], ["Aeterna", "TREATMENT", 133, 140], ["Zentaris", "TREATMENT", 141, 149], ["GERMANYThe central actions of ghrelin", "TREATMENT", 151, 188], ["stimulation of appetite", "TREATMENT", 197, 220], ["GH secretion", "PROBLEM", 225, 237]]], ["Such properties support the hope that ghrelin receptor antagonists could be useful for the treatment of obesity.", [["obesity", "DISEASE", 104, 111], ["ghrelin receptor antagonists", "GENE_OR_GENE_PRODUCT", 38, 66], ["ghrelin receptor antagonists", "TREATMENT", 38, 66], ["obesity", "PROBLEM", 104, 111], ["obesity", "OBSERVATION", 104, 111]]], ["However for an effi cient anti-obesity activity, a ghrelin antagonist should counteract the orexigenic effect of ghrelin but not the GH secretagogue effect, since GH defi ciency is frequently associated with increased adiposity.", [["ghrelin", "GENE_OR_GENE_PRODUCT", 51, 58], ["ghrelin", "GENE_OR_GENE_PRODUCT", 113, 120], ["GH", "GENE_OR_GENE_PRODUCT", 133, 135], ["GH", "GENE_OR_GENE_PRODUCT", 163, 165], ["an effi cient anti-obesity activity", "TREATMENT", 12, 47], ["a ghrelin antagonist", "TREATMENT", 49, 69], ["ghrelin", "TREATMENT", 113, 120], ["the GH secretagogue effect", "PROBLEM", 129, 155], ["GH defi ciency", "PROBLEM", 163, 177], ["increased adiposity", "PROBLEM", 208, 227], ["increased", "OBSERVATION_MODIFIER", 208, 217], ["adiposity", "OBSERVATION", 218, 227]]], ["Starting from a triazole scaffold, we have designed and prepared a series of novel small molecules with high binding affi nity for the cloned human GHS-R1a and we have investigated their effects on food intake and GH secretion in animal models.", [["triazole", "CHEMICAL", 16, 24], ["triazole", "CHEMICAL", 16, 24], ["affi", "GENE_OR_GENE_PRODUCT", 117, 121], ["human", "ORGANISM", 142, 147], ["GHS-R1a", "GENE_OR_GENE_PRODUCT", 148, 155], ["food", "ORGANISM_SUBDIVISION", 198, 202], ["GH", "GENE_OR_GENE_PRODUCT", 214, 216], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["a triazole scaffold", "TREATMENT", 14, 33], ["GH secretion in animal models", "PROBLEM", 214, 243]]], ["The systematic screening of over 250 novel compounds for their ability to displace radiolabelled ghrelin and to activate or to inhibit calcium uptake in cells transiently expressing GHS-R1a led to the characterization of several compounds acting as GHS-R1a ghrelin full agonists, partial agonists or antagonists.", [["cells", "ANATOMY", 153, 158], ["ghrelin", "CHEMICAL", 97, 104], ["calcium", "CHEMICAL", 135, 142], ["calcium", "CHEMICAL", 135, 142], ["ghrelin", "GENE_OR_GENE_PRODUCT", 97, 104], ["calcium", "SIMPLE_CHEMICAL", 135, 142], ["cells", "CELL", 153, 158], ["GHS-R1a", "GENE_OR_GENE_PRODUCT", 182, 189], ["GHS-R1a", "SIMPLE_CHEMICAL", 249, 256], ["ghrelin", "GENE_OR_GENE_PRODUCT", 257, 264], ["GHS-R1a", "PROTEIN", 182, 189], ["The systematic screening", "TEST", 0, 24], ["radiolabelled ghrelin", "TREATMENT", 83, 104], ["calcium uptake in cells", "PROBLEM", 135, 158], ["the characterization", "TEST", 197, 217], ["GHS", "TEST", 249, 252], ["R1a ghrelin full agonists", "TREATMENT", 253, 278], ["partial agonists", "TREATMENT", 280, 296], ["antagonists", "TREATMENT", 300, 311]]], ["Our results showed that non-peptide compounds characterized as in vitro GHS-R1a ghrelin antagonist or partial agonist were able to inhibit food intake without altering in vivo GH secretion.", [["GHS-R1a ghrelin", "GENE_OR_GENE_PRODUCT", 72, 87], ["GH", "GENE_OR_GENE_PRODUCT", 176, 178], ["non-peptide compounds", "PROBLEM", 24, 45], ["vitro GHS", "TEST", 66, 75], ["R1a ghrelin antagonist", "TREATMENT", 76, 98], ["altering in vivo GH secretion", "PROBLEM", 159, 188]]], ["The dissociated effect of the novel ghrelin receptor ligands on food intake and GH secretion supports the role of different subtypes or signaling pathways of the ghrelin receptor in the control of these functions.", [["ghrelin receptor", "GENE_OR_GENE_PRODUCT", 36, 52], ["food", "ORGANISM_SUBDIVISION", 64, 68], ["GH", "GENE_OR_GENE_PRODUCT", 80, 82], ["ghrelin receptor", "GENE_OR_GENE_PRODUCT", 162, 178], ["ghrelin receptor", "PROTEIN", 36, 52], ["ghrelin receptor", "PROTEIN", 162, 178], ["the novel ghrelin receptor ligands", "TREATMENT", 26, 60], ["GH secretion", "PROBLEM", 80, 92], ["the ghrelin receptor", "TREATMENT", 158, 178]]], ["Thus this report supports the feasibility of a specifi c pharmacological modulation of the ghrelin effect on appetite.Title Abs NoA leptin receptor glycopeptide agonist for leptin replacement therapy Otvos, Laszlo Structure-activity relationship studies of native proline-rich antimicrobial peptides together with biochemical evidence points to a multiple mode of action including disintegration of bacterial membranes and inhibition of the bacterial heat shock protein, DnaK.", [["membranes", "ANATOMY", 409, 418], ["leptin", "CHEMICAL", 173, 179], ["proline", "CHEMICAL", 264, 271], ["proline", "CHEMICAL", 264, 271], ["ghrelin", "GENE_OR_GENE_PRODUCT", 91, 98], ["leptin", "GENE_OR_GENE_PRODUCT", 173, 179], ["membranes", "CELLULAR_COMPONENT", 409, 418], ["bacterial heat shock protein", "GENE_OR_GENE_PRODUCT", 441, 469], ["DnaK", "GENE_OR_GENE_PRODUCT", 471, 475], ["Title Abs", "PROTEIN", 118, 127], ["bacterial heat shock protein", "PROTEIN", 441, 469], ["DnaK", "PROTEIN", 471, 475], ["Title Abs NoA leptin receptor glycopeptide agonist", "TREATMENT", 118, 168], ["leptin replacement therapy", "TREATMENT", 173, 199], ["Otvos", "TREATMENT", 200, 205], ["native proline-rich antimicrobial peptides", "TREATMENT", 257, 299], ["disintegration of bacterial membranes", "TREATMENT", 381, 418], ["the bacterial heat shock protein", "TREATMENT", 437, 469], ["DnaK", "PROBLEM", 471, 475], ["bacterial membranes", "OBSERVATION", 399, 418]]], ["Molecular modeling of the bioactive protein indicates that the peptide binding site is located at the D-E helix region of the carboxy-terminal multihelical lid, a domain directly involved in dimer formation and needed for the protein refolding activity of DnaK.", [["carboxy", "CHEMICAL", 126, 133], ["DnaK", "GENE_OR_GENE_PRODUCT", 256, 260], ["D-E helix region", "PROTEIN", 102, 118], ["carboxy-terminal multihelical lid", "PROTEIN", 126, 159], ["DnaK", "PROTEIN", 256, 260], ["Molecular modeling of the bioactive protein", "PROBLEM", 0, 43], ["the peptide binding site", "PROBLEM", 59, 83], ["the protein refolding activity of DnaK", "TREATMENT", 222, 260], ["bioactive protein", "OBSERVATION", 26, 43], ["carboxy", "ANATOMY_MODIFIER", 126, 133], ["terminal", "ANATOMY_MODIFIER", 134, 142], ["multihelical lid", "ANATOMY", 143, 159]]], ["A series of peptide dimers were designed from which A3-APO was selected for its highest effi cacy against several Enterobacteriaceae as well as a few Gram-positives such as Staphylococcus saprophyticus.", [["A3-APO", "CHEMICAL", 52, 58], ["Staphylococcus saprophyticus", "DISEASE", 173, 201], ["APO", "CHEMICAL", 55, 58], ["A3-APO", "SIMPLE_CHEMICAL", 52, 58], ["Gram", "GENE_OR_GENE_PRODUCT", 150, 154], ["Staphylococcus saprophyticus", "ORGANISM", 173, 201], ["Staphylococcus saprophyticus", "SPECIES", 173, 201], ["Staphylococcus saprophyticus", "SPECIES", 173, 201], ["A series of peptide dimers", "TEST", 0, 26], ["several Enterobacteriaceae", "PROBLEM", 106, 132], ["a few Gram", "TEST", 144, 154], ["Staphylococcus saprophyticus", "PROBLEM", 173, 201], ["Enterobacteriaceae", "OBSERVATION", 114, 132], ["Staphylococcus saprophyticus", "OBSERVATION", 173, 201]]], ["The Minimal Inhibitory Concentrations of A3-APO in undiluted broth ranged from 1 to 8 mg/L for E. coli, K. pneumoniae, S. typhimurium and S. saprophyticus strains, and was independent of Multi-Drug Resistance (MDR) status.", [["strains", "ANATOMY", 155, 162], ["A3-APO", "CHEMICAL", 41, 47], ["A3-APO", "CHEMICAL", 41, 47], ["A3-APO", "SIMPLE_CHEMICAL", 41, 47], ["E. coli", "ORGANISM", 95, 102], ["K. pneumoniae", "ORGANISM", 104, 117], ["S. typhimurium", "ORGANISM", 119, 133], ["S. saprophyticus", "ORGANISM", 138, 154], ["strains", "ORGANISM", 155, 162], ["Multi-Drug", "SIMPLE_CHEMICAL", 187, 197], ["E. coli", "SPECIES", 95, 102], ["K. pneumoniae", "SPECIES", 104, 117], ["S. typhimurium", "SPECIES", 119, 133], ["S. saprophyticus", "SPECIES", 138, 154], ["E. coli", "SPECIES", 95, 102], ["K. pneumoniae", "SPECIES", 104, 117], ["S. typhimurium", "SPECIES", 119, 133], ["S. saprophyticus", "SPECIES", 138, 154], ["A3-APO in undiluted broth", "TREATMENT", 41, 66], ["E. coli", "PROBLEM", 95, 102], ["K. pneumoniae", "PROBLEM", 104, 117], ["S. typhimurium", "PROBLEM", 119, 133], ["S. saprophyticus strains", "PROBLEM", 138, 162], ["Minimal", "OBSERVATION_MODIFIER", 4, 11], ["Inhibitory", "OBSERVATION_MODIFIER", 12, 22], ["Concentrations", "OBSERVATION_MODIFIER", 23, 37], ["pneumoniae", "OBSERVATION", 107, 117]]], ["A3-APO was tested in CD-1 female mice pre-treated with 18 mg/kg cisplatin for four days then infected intraperitoneally (ip) with LD90 amount of the extended spectrum \u00df-lactamase producing, fl uoroquinolone-resistant E. coli 5770 strain.", [["intraperitoneally", "ANATOMY", 102, 119], ["A3-APO", "CHEMICAL", 0, 6], ["cisplatin", "CHEMICAL", 64, 73], ["uoroquinolone", "CHEMICAL", 193, 206], ["APO", "CHEMICAL", 3, 6], ["cisplatin", "CHEMICAL", 64, 73], ["uoroquinolone", "CHEMICAL", 193, 206], ["A3-APO", "SIMPLE_CHEMICAL", 0, 6], ["CD-1", "CELL", 21, 25], ["mice", "ORGANISM", 33, 37], ["cisplatin", "SIMPLE_CHEMICAL", 64, 73], ["LD90", "SIMPLE_CHEMICAL", 130, 134], ["fl uoroquinolone", "SIMPLE_CHEMICAL", 190, 206], ["E. coli 5770", "ORGANISM", 217, 229], ["mice", "SPECIES", 33, 37], ["E. coli", "SPECIES", 217, 224], ["mice", "SPECIES", 33, 37], ["E. coli", "SPECIES", 217, 224], ["18 mg/kg cisplatin", "TREATMENT", 55, 73], ["the extended spectrum \u00df-lactamase", "TEST", 145, 178], ["fl uoroquinolone", "TEST", 190, 206], ["resistant E. coli", "PROBLEM", 207, 224], ["E. coli", "OBSERVATION", 217, 224]]], ["A total ip dose of 3x10 mg/kg each in four hour intervals led to blood sterilization and survival improvement, similar to imipenem added at a higher dose.", [["blood", "ANATOMY", 65, 70], ["imipenem", "CHEMICAL", 122, 130], ["imipenem", "CHEMICAL", 122, 130], ["ip", "SIMPLE_CHEMICAL", 8, 10], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["imipenem", "SIMPLE_CHEMICAL", 122, 130], ["A total ip dose", "TREATMENT", 0, 15], ["blood sterilization", "TREATMENT", 65, 84], ["imipenem", "TREATMENT", 122, 130]]], ["Through inactivating of resistance enzymes, A3-APO was able to recover in vitro the lost activity of conventional antibiotics including chloramphenicol, -lactams, sulfonamides or trimethoprim with a partial or full synergic effect.", [["A3-APO", "CHEMICAL", 44, 50], ["chloramphenicol", "CHEMICAL", 136, 151], ["-lactams", "CHEMICAL", 153, 161], ["sulfonamides", "CHEMICAL", 163, 175], ["trimethoprim", "CHEMICAL", 179, 191], ["APO", "CHEMICAL", 47, 50], ["chloramphenicol", "CHEMICAL", 136, 151], ["-lactams", "CHEMICAL", 153, 161], ["sulfonamides", "CHEMICAL", 163, 175], ["trimethoprim", "CHEMICAL", 179, 191], ["A3-APO", "SIMPLE_CHEMICAL", 44, 50], ["chloramphenicol", "SIMPLE_CHEMICAL", 136, 151], ["-lactams", "SIMPLE_CHEMICAL", 153, 161], ["sulfonamides", "SIMPLE_CHEMICAL", 163, 175], ["trimethoprim", "SIMPLE_CHEMICAL", 179, 191], ["resistance enzymes", "PROTEIN", 24, 42], ["A3", "PROTEIN", 44, 46], ["resistance enzymes", "TEST", 24, 42], ["conventional antibiotics", "TREATMENT", 101, 125], ["chloramphenicol", "TREATMENT", 136, 151], ["-lactams", "TREATMENT", 153, 161], ["sulfonamides", "TREATMENT", 163, 175], ["trimethoprim", "TREATMENT", 179, 191], ["synergic effect", "OBSERVATION", 215, 230]]], ["However, the synergy appeared to be individual strain and drug combination-dependent.", [["individual strain", "PROBLEM", 36, 53]]], ["While A3-APO remains the most effective amongst the many designer dimers studied, a single chain, natural metabolite identifi ed in vivo showed a 2-4 fold increase in activity against some test strains, and appears to be an ideal candidate for preclinical development based on its microbiological, pharmacological and cost/benefi t.", [["A3-APO", "CHEMICAL", 6, 12], ["APO", "CHEMICAL", 9, 12], ["A3-APO", "SIMPLE_CHEMICAL", 6, 12], ["a 2-4 fold increase in activity", "PROBLEM", 144, 175], ["some test strains", "PROBLEM", 184, 201], ["increase", "OBSERVATION_MODIFIER", 155, 163]]], ["Many cancers including pancreatic cancer and melanoma cancer are highly resistant to treatment especially following metathesis.", [["cancers", "ANATOMY", 5, 12], ["pancreatic cancer", "ANATOMY", 23, 40], ["melanoma cancer", "ANATOMY", 45, 60], ["cancers", "DISEASE", 5, 12], ["pancreatic cancer", "DISEASE", 23, 40], ["melanoma cancer", "DISEASE", 45, 60], ["cancers", "CANCER", 5, 12], ["pancreatic cancer", "CANCER", 23, 40], ["melanoma cancer", "CANCER", 45, 60], ["Many cancers", "PROBLEM", 0, 12], ["pancreatic cancer", "PROBLEM", 23, 40], ["melanoma cancer", "PROBLEM", 45, 60], ["treatment", "TREATMENT", 85, 94], ["metathesis", "TREATMENT", 116, 126], ["cancers", "OBSERVATION", 5, 12], ["pancreatic", "ANATOMY", 23, 33], ["cancer", "OBSERVATION", 34, 40], ["melanoma", "OBSERVATION", 45, 53]]], ["Furthermore, it has become increasingly clear that essentially all cancers have multiple phenotypes so any single approach to treatment will fail for many persons with that cancer.", [["cancers", "ANATOMY", 67, 74], ["cancer", "ANATOMY", 173, 179], ["cancers", "DISEASE", 67, 74], ["cancer", "DISEASE", 173, 179], ["cancers", "CANCER", 67, 74], ["persons", "ORGANISM", 155, 162], ["cancer", "CANCER", 173, 179], ["persons", "SPECIES", 155, 162], ["essentially all cancers", "PROBLEM", 51, 74], ["multiple phenotypes", "PROBLEM", 80, 99], ["treatment", "TREATMENT", 126, 135], ["that cancer", "PROBLEM", 168, 179], ["increasingly", "OBSERVATION_MODIFIER", 27, 39], ["clear", "OBSERVATION", 40, 45], ["all", "OBSERVATION_MODIFIER", 63, 66], ["cancers", "OBSERVATION", 67, 74], ["cancer", "OBSERVATION", 173, 179]]], ["To overcome these problems we are taking a novel approach which directly addresses the cancer state.", [["cancer", "ANATOMY", 87, 93], ["cancer", "DISEASE", 87, 93], ["cancer", "CANCER", 87, 93], ["these problems", "PROBLEM", 12, 26], ["a novel approach", "TREATMENT", 41, 57], ["the cancer state", "PROBLEM", 83, 99], ["cancer", "OBSERVATION", 87, 93]]], ["In particular we are targeting cancer cells with a single ligand that contains an imaging agent and/or a therapeutic agent and two or more different ligands that target two or more cell surface proteins (receptors, cytokines, ion channels, enzymes, etc.) that distinguish a cancer cell from normal cells.", [["cancer cells", "ANATOMY", 31, 43], ["cell surface", "ANATOMY", 181, 193], ["cancer cell", "ANATOMY", 274, 285], ["cells", "ANATOMY", 298, 303], ["cancer", "DISEASE", 31, 37], ["cancer", "DISEASE", 274, 280], ["cancer cells", "CELL", 31, 43], ["cell", "CELL", 181, 185], ["cancer cell", "CELL", 274, 285], ["cells", "CELL", 298, 303], ["cancer cells", "CELL_TYPE", 31, 43], ["cell surface proteins", "PROTEIN", 181, 202], ["receptors", "PROTEIN", 204, 213], ["cytokines", "PROTEIN", 215, 224], ["ion channels", "PROTEIN", 226, 238], ["enzymes", "PROTEIN", 240, 247], ["cancer cell", "CELL_TYPE", 274, 285], ["normal cells", "CELL_TYPE", 291, 303], ["cancer cells", "PROBLEM", 31, 43], ["an imaging agent", "TEST", 79, 95], ["a therapeutic agent", "TREATMENT", 103, 122], ["cytokines, ion channels", "TEST", 215, 238], ["enzymes", "TEST", 240, 247], ["a cancer cell", "PROBLEM", 272, 285], ["cancer cells", "OBSERVATION", 31, 43], ["more cell", "OBSERVATION_MODIFIER", 176, 185], ["cancer cell", "OBSERVATION", 274, 285], ["normal cells", "OBSERVATION", 291, 303]]], ["This requires the development of scaffolds that will place the ligands at suffi cient distance from each other so as to crosslink two or more different cell surface proteins, and imaging and/ or therapeutic agents such that it (they) will not interfere with binding.", [["cell surface", "ANATOMY", 152, 164], ["cell", "CELL", 152, 156], ["cell surface proteins", "PROTEIN", 152, 173], ["scaffolds", "TREATMENT", 33, 42], ["imaging", "TEST", 179, 186], ["therapeutic agents", "TREATMENT", 195, 213], ["scaffolds", "OBSERVATION", 33, 42]]], ["Both thermodynamic and kinetic considerations are critical for obtaining useful ligands.", [["kinetic", "OBSERVATION_MODIFIER", 23, 30]]], ["We will report on the design, synthesis, biochemical, biophysical and imaging of several multimeric, multiheterovalent ligands which demonstrate for the fi rst time crosslinking of two different cell surface proteins and the viability of this approach.S07-5Can biotherapeutics ever be cheap enough for developing countries?", [["cell surface", "ANATOMY", 195, 207], ["cell", "CELL", 195, 199], ["cell surface proteins", "PROTEIN", 195, 216], ["biophysical and imaging", "TEST", 54, 77], ["several multimeric, multiheterovalent ligands", "PROBLEM", 81, 126], ["two different", "OBSERVATION_MODIFIER", 181, 194], ["cell", "OBSERVATION", 195, 199], ["surface", "OBSERVATION_MODIFIER", 200, 207]]], ["Anti-HIV chemokines as a case study Women and girls in developing countries, the group now most at risk from HIV infection, urgently need substances (wrongly but universally called 'microbicides') for intravaginal application before intercourse to prevent transmission of the disease.", [["HIV infection", "DISEASE", 109, 122], ["Women", "ORGANISM", 36, 41], ["HIV", "ORGANISM", 109, 112], ["HIV chemokines", "PROTEIN", 5, 19], ["HIV", "SPECIES", 5, 8], ["Women", "SPECIES", 36, 41], ["girls", "SPECIES", 46, 51], ["HIV", "SPECIES", 109, 112], ["HIV", "SPECIES", 5, 8], ["HIV", "SPECIES", 109, 112], ["a case study", "TEST", 23, 35], ["HIV infection", "PROBLEM", 109, 122], ["intravaginal application", "TREATMENT", 201, 225], ["intercourse", "TREATMENT", 233, 244], ["the disease", "PROBLEM", 272, 283], ["infection", "OBSERVATION", 113, 122], ["disease", "OBSERVATION", 276, 283]]], ["We developed a potent microbicide lead known as PSC-RANTES, a 69-residue protein based on the CCR5 ligand RANTES (CCL5).", [["PSC-RANTES", "GENE_OR_GENE_PRODUCT", 48, 58], ["CCR5", "GENE_OR_GENE_PRODUCT", 94, 98], ["RANTES", "GENE_OR_GENE_PRODUCT", 106, 112], ["CCL5", "GENE_OR_GENE_PRODUCT", 114, 118], ["PSC", "PROTEIN", 48, 51], ["RANTES", "PROTEIN", 52, 58], ["69-residue protein", "PROTEIN", 62, 80], ["CCR5 ligand", "PROTEIN", 94, 105], ["RANTES", "PROTEIN", 106, 112], ["CCL5", "PROTEIN", 114, 118], ["a potent microbicide lead", "PROBLEM", 13, 38], ["potent", "OBSERVATION_MODIFIER", 15, 21]]], ["It is still the only published example of a substance tested in the standard macaque vaginal challenge model to protect all animals in a dose group even when used alone.", [["vaginal", "ANATOMY", 85, 92], ["macaque", "ORGANISM", 77, 84], ["vaginal", "ORGANISM_SUBDIVISION", 85, 92], ["a substance", "TREATMENT", 42, 53], ["the standard macaque vaginal challenge model", "TREATMENT", 64, 108]]], ["However, it contains non-coded amino acids, and its manufacture requires synthetic steps.", [["amino acids", "CHEMICAL", 31, 42], ["amino acids", "CHEMICAL", 31, 42], ["amino acids", "AMINO_ACID", 31, 42], ["non-coded amino acids", "TREATMENT", 21, 42], ["amino acids", "OBSERVATION", 31, 42]]], ["Total synthesis would never permit its production at a cost per dose low enough to permit worldwide use.", [["Total synthesis", "TREATMENT", 0, 15]]], ["Using a novel phage-display technique we have identifi ed new RANTES analogues that show equivalent potency to PSC-RANTES but, consisting only of coded residues, can be produced by microbial fermentation or other biological routes.", [["RANTES", "GENE_OR_GENE_PRODUCT", 62, 68], ["PSC-RANTES", "GENE_OR_GENE_PRODUCT", 111, 121], ["RANTES", "PROTEIN", 62, 68], ["RANTES", "PROTEIN", 115, 121], ["a novel phage", "TREATMENT", 6, 19], ["new RANTES analogues", "TREATMENT", 58, 78]]], ["For a Phase I trial, where some tens of grams only are required and cost would not yet be the determining issue, it would be quite practical to express the wanted molecules intracellularly, as soluble protein or inclusion bodies.", [["soluble protein", "PROTEIN", 193, 208], ["soluble protein or inclusion bodies", "PROBLEM", 193, 228]]], ["Downstream processing is normally the principal element that determines cost, and for the multi-ton production that would be required if these molecules came into general use, an expression system that leads to secretion of the product into the culture medium would probably be best.", [["Downstream processing", "PROBLEM", 0, 21], ["an expression system", "PROBLEM", 176, 196]]], ["This is done at the scale of hundreds of thousands of tons every year in the production of food-grade GMP enzymes for the detergent industry.", [["GMP", "CHEMICAL", 102, 105], ["GMP", "CHEMICAL", 102, 105], ["GMP", "SIMPLE_CHEMICAL", 102, 105], ["food-grade GMP enzymes", "PROTEIN", 91, 113], ["the detergent industry", "TREATMENT", 118, 140]]], ["This fi gure seems at fi rst sight to be wildly discrepant with the perceived cost of common biotherapeutics, but we will present experimental results tending to correct that perception.", [["common biotherapeutics", "TREATMENT", 86, 108]]], ["Multidrug therapies became routine approach in modern medical treatment protocols.", [["Multidrug therapies", "TREATMENT", 0, 19], ["routine approach", "TREATMENT", 27, 43], ["modern medical treatment protocols", "TREATMENT", 47, 81]]], ["However, using combinations of drugs has disadvantages, including differences in pharmacological profi les of single drug component.", [["drugs", "TREATMENT", 31, 36], ["single drug component", "PROBLEM", 110, 131]]], ["Therefore, over twenty years ago we have proposed development of multitarget medicines as a new avenue of drug discovery.", [["multitarget medicines", "TREATMENT", 65, 86]]], ["Identifi cation of numerous endogenous components that participate in the formation, transmission, modulation and perception of pain signals offers numerous strategies for the development of new analgesics.", [["pain", "DISEASE", 128, 132], ["cation", "SIMPLE_CHEMICAL", 9, 15], ["numerous endogenous components", "PROBLEM", 19, 49], ["pain signals", "PROBLEM", 128, 140], ["numerous strategies", "TREATMENT", 148, 167], ["new analgesics", "TREATMENT", 191, 205], ["numerous", "OBSERVATION_MODIFIER", 19, 27], ["endogenous components", "OBSERVATION", 28, 49]]], ["One of them is hybridization of opioid pharmacophores with tachykinin receptor ligands.", [["tachykinin", "CHEMICAL", 59, 69], ["tachykinin receptor", "GENE_OR_GENE_PRODUCT", 59, 78], ["opioid pharmacophores", "TREATMENT", 32, 53], ["tachykinin receptor ligands", "TREATMENT", 59, 86], ["opioid pharmacophores", "OBSERVATION", 32, 53]]], ["Tachykinins, like substance P (SP) produces both hyperalgesia and, at low doses, a naloxone-sensitive analgesia.", [["Tachykinins", "CHEMICAL", 0, 11], ["SP", "CHEMICAL", 31, 33], ["hyperalgesia", "DISEASE", 49, 61], ["naloxone", "CHEMICAL", 83, 91], ["Tachykinins", "CHEMICAL", 0, 11], ["naloxone", "CHEMICAL", 83, 91], ["Tachykinins", "SIMPLE_CHEMICAL", 0, 11], ["substance P", "SIMPLE_CHEMICAL", 18, 29], ["SP", "SIMPLE_CHEMICAL", 31, 33], ["naloxone", "SIMPLE_CHEMICAL", 83, 91], ["Tachykinins", "PROBLEM", 0, 11], ["both hyperalgesia", "PROBLEM", 44, 61], ["a naloxone", "TREATMENT", 81, 91], ["sensitive analgesia", "TREATMENT", 92, 111], ["hyperalgesia", "OBSERVATION", 49, 61]]], ["Very likely, these opposite effects of SP in the spinal cord, are mediated through activation of various self-regulatory mechanisms.", [["spinal cord", "ANATOMY", 49, 60], ["SP", "CHEMICAL", 39, 41], ["SP", "GENE_OR_GENE_PRODUCT", 39, 41], ["spinal cord", "ORGAN", 49, 60], ["SP", "PROTEIN", 39, 41], ["SP in the spinal cord", "PROBLEM", 39, 60], ["SP", "OBSERVATION", 39, 41], ["spinal cord", "ANATOMY", 49, 60]]], ["Modulation of tachykinin receptor system is probably signifi cant component of tolerance and dependence development.", [["tachykinin", "CHEMICAL", 14, 24], ["tachykinin receptor", "GENE_OR_GENE_PRODUCT", 14, 33], ["tachykinin receptor", "PROTEIN", 14, 33], ["Modulation of tachykinin receptor system", "PROBLEM", 0, 40], ["signifi cant component of tolerance", "PROBLEM", 53, 88], ["dependence development", "PROBLEM", 93, 115], ["probably", "UNCERTAINTY", 44, 52], ["signifi cant", "OBSERVATION_MODIFIER", 53, 65], ["component", "OBSERVATION_MODIFIER", 66, 75], ["tolerance", "OBSERVATION", 79, 88]]], ["Therefore, various new opioid agonist-tachykinin antagonist and opioid agonist-tachykinin agonist have been synthesized and tested to develop new medicines for chronic pain treatment.", [["chronic pain", "DISEASE", 160, 172], ["opioid", "SIMPLE_CHEMICAL", 64, 70], ["various new opioid agonist", "TREATMENT", 11, 37], ["tachykinin antagonist", "TREATMENT", 38, 59], ["opioid agonist", "TREATMENT", 64, 78], ["tachykinin agonist", "TREATMENT", 79, 97], ["new medicines", "TREATMENT", 142, 155], ["chronic pain treatment", "TREATMENT", 160, 182], ["chronic", "OBSERVATION_MODIFIER", 160, 167], ["pain", "OBSERVATION", 168, 172]]], ["The communication will present new group of opioid agonist-tachykinin agonist that express strong analgesic activity even after peripheral application.", [["opioid agonist", "TREATMENT", 44, 58], ["tachykinin agonist", "TREATMENT", 59, 77], ["peripheral application", "TREATMENT", 128, 150]]], ["These new compounds are interesting candidates for treatment of chronic pain because they express very low tolerance development properties.", [["chronic pain", "DISEASE", 64, 76], ["chronic pain", "PROBLEM", 64, 76], ["very low tolerance development properties", "PROBLEM", 98, 139], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["pain", "OBSERVATION", 72, 76]]], ["Acknowledgements: Presented studies have been supported in part with EU grant Normolife (LSHC-CT-2006-037733)S08-2Determination of GPCR structures and activation mechanisms with reactive peptide probes.", [["activation mechanisms", "PROBLEM", 151, 172], ["reactive peptide probes", "TREATMENT", 178, 201], ["reactive peptide", "OBSERVATION", 178, 194]]], ["The G-protein coupled receptor family is the most important family of regulatory proteins in the genome and, hence, the most important drug target family of conventional and future drug therapy.", [["G-protein coupled receptor", "GENE_OR_GENE_PRODUCT", 4, 30], ["G-protein coupled receptor family", "PROTEIN", 4, 37], ["regulatory proteins", "PROTEIN", 70, 89], ["conventional and future drug therapy", "TREATMENT", 157, 193]]], ["In spite of this, structure-based or target derived drug design is still hampered for GPCRs since their structures are extremely diffi cult to access and their activation mechanisms even more.", [["GPCRs", "PROBLEM", 86, 91]]], ["Thus far, reactive peptides probes have allowed identifying the immediate receptor environment of the ligands of aminergic, proteinergic and peptidergic GPCRs, among them, the human Angiotensin II receptor AT1.", [["Angiotensin II", "CHEMICAL", 182, 196], ["human", "ORGANISM", 176, 181], ["Angiotensin II receptor AT1", "GENE_OR_GENE_PRODUCT", 182, 209], ["aminergic, proteinergic and peptidergic GPCRs", "PROTEIN", 113, 158], ["human Angiotensin II receptor AT1", "PROTEIN", 176, 209], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["reactive peptides probes", "PROBLEM", 10, 34], ["peptidergic GPCRs", "PROBLEM", 141, 158], ["the human Angiotensin II receptor AT1", "TREATMENT", 172, 209], ["reactive peptides", "OBSERVATION", 10, 27], ["peptidergic GPCRs", "OBSERVATION", 141, 158]]], ["The determination of several such contact points in this receptor has allowed proposing the fi rst molecular structures of this receptor but also in others.", [["several", "OBSERVATION_MODIFIER", 21, 28]]], ["In the present contribution, the combined application of different photochemical probes, together with the chemical selectivity of such probes, their introduction in several positions of a peptide ligand, as well as iterative mutagenesis approaches, have allowed to obtain not only molecular structures of such peptide ligand bound receptors but also the thermodynamic behaviour and information about structural changes associated to GPCR activation.", [["GPCR", "GENE_OR_GENE_PRODUCT", 434, 438], ["peptide ligand bound receptors", "PROTEIN", 311, 341], ["GPCR", "PROTEIN", 434, 438], ["different photochemical probes", "TREATMENT", 57, 87], ["such probes", "TREATMENT", 131, 142], ["a peptide ligand", "TREATMENT", 187, 203], ["iterative mutagenesis approaches", "TREATMENT", 216, 248], ["structural changes", "PROBLEM", 401, 419], ["GPCR activation", "PROBLEM", 434, 449], ["GPCR activation", "OBSERVATION", 434, 449]]], ["These activation mechanisms are addressed with constitutively active and constitutively inactive receptor mutants and reactive peptide ligands of agonistic as well as antagonistic nature.", [["constitutively inactive receptor mutants", "PROTEIN", 73, 113], ["constitutively inactive receptor mutants", "PROBLEM", 73, 113], ["reactive peptide ligands", "TREATMENT", 118, 142], ["reactive", "OBSERVATION_MODIFIER", 118, 126]]], ["Supported by grants from CIHR.Title Abs NoChimeric opioid-tachykinin ligands as a new prospective analgesics in chronic pain Lipkowski, Andrzej W 3D-chemical featured based pharmacophores were developed and used for screening several compound databases with the aim of identifying active molecules targeted for G-protein coupled opioid receptors.", [["tachykinin", "CHEMICAL", 58, 68], ["pain", "DISEASE", 120, 124], ["G-protein coupled opioid receptors", "GENE_OR_GENE_PRODUCT", 311, 345], ["G-protein coupled opioid receptors", "PROTEIN", 311, 345], ["NoChimeric opioid", "TREATMENT", 40, 57], ["tachykinin ligands", "TREATMENT", 58, 76], ["a new prospective analgesics", "TREATMENT", 80, 108], ["chronic pain", "PROBLEM", 112, 124], ["Lipkowski", "TEST", 125, 134], ["Andrzej W 3D", "TREATMENT", 136, 148], ["screening several compound databases", "TEST", 216, 252], ["G-protein coupled opioid receptors", "TREATMENT", 311, 345], ["chronic", "OBSERVATION_MODIFIER", 112, 119]]], ["Previously developed models proposing bioactive conformations of potent opioid ligands containing 2',6'-dimethyltyrosine (Dmt), 1,2,3,4tetrahydroisoquinoline carboxylic acid (Tic) and Dmt-Tic-Bid (1Hbenzimidazole-2-yl) were utilized to develop various pharmacophores based on previously designed molecular models and using the program LigandScout.", [["2',6'-dimethyltyrosine", "CHEMICAL", 98, 120], ["Dmt", "CHEMICAL", 122, 125], ["1,2,3,4tetrahydroisoquinoline carboxylic acid", "CHEMICAL", 128, 173], ["Tic", "CHEMICAL", 175, 178], ["Dmt-Tic-Bid", "CHEMICAL", 184, 195], ["1Hbenzimidazole-2-yl", "CHEMICAL", 197, 217], ["2',6'-dimethyltyrosine", "CHEMICAL", 98, 120], ["Dmt", "CHEMICAL", 122, 125], ["1,2,3,4tetrahydroisoquinoline carboxylic acid", "CHEMICAL", 128, 173], ["Tic", "CHEMICAL", 175, 178], ["Dmt-Tic-Bid", "CHEMICAL", 184, 195], ["1Hbenzimidazole-2-yl", "CHEMICAL", 197, 217], ["2',6'-dimethyltyrosine", "SIMPLE_CHEMICAL", 98, 120], ["Dmt", "SIMPLE_CHEMICAL", 122, 125], ["1,2,3,4tetrahydroisoquinoline carboxylic acid", "SIMPLE_CHEMICAL", 128, 173], ["Tic", "SIMPLE_CHEMICAL", 175, 178], ["Dmt-Tic-Bid", "SIMPLE_CHEMICAL", 184, 195], ["1Hbenzimidazole-2-yl", "SIMPLE_CHEMICAL", 197, 217], ["potent opioid ligands", "TREATMENT", 65, 86], ["dimethyltyrosine (Dmt", "TREATMENT", 104, 125], ["tetrahydroisoquinoline carboxylic acid (Tic)", "TREATMENT", 135, 179], ["Dmt", "TREATMENT", 184, 187], ["Tic", "TREATMENT", 188, 191], ["1Hbenzimidazole", "TREATMENT", 197, 212], ["various pharmacophores", "PROBLEM", 244, 266], ["bioactive conformations", "OBSERVATION", 38, 61]]], ["The pharmacophores were deployed as 3D-search queries using Catalyst to screen the Derwent World Drug Index, National Cancer Institute and ChemDiv databases.", [["Cancer", "DISEASE", 118, 124], ["Catalyst", "TREATMENT", 60, 68]]], ["One exhibited high -opioid receptor affi nity (Ki = 0.075 nM); the others displayed moderate -affi nities (Ki = 4.26 & 6.03 M) and no competitive binding to -opioid receptors.", [["-opioid receptors", "GENE_OR_GENE_PRODUCT", 157, 174], ["-opioid receptors", "PROTEIN", 157, 174], ["Ki", "TEST", 47, 49], ["moderate -affi nities", "PROBLEM", 84, 105], ["Ki", "TEST", 107, 109], ["competitive binding", "PROBLEM", 134, 153], ["high", "OBSERVATION_MODIFIER", 14, 18], ["moderate", "OBSERVATION_MODIFIER", 84, 92]]], ["This approach enabled the validation of the proposed Dmt-Tic opioid pharmacophore as well as identifi cation of lead compounds for development of opioid therapeutics.", [["cation", "SIMPLE_CHEMICAL", 102, 108], ["opioid", "SIMPLE_CHEMICAL", 146, 152], ["the proposed Dmt", "TREATMENT", 40, 56], ["Tic opioid pharmacophore", "TREATMENT", 57, 81], ["identifi cation of lead compounds", "TREATMENT", 93, 126], ["opioid therapeutics", "TREATMENT", 146, 165]]], ["Furthermore, 3D-chemical featured based virtual screening offers a rapid and effective means to identify new lead compounds when the bioactive forms of ligands and protein target structures are unknown.", [["virtual screening", "TEST", 40, 57], ["new lead compounds", "PROBLEM", 105, 123], ["the bioactive forms of ligands and protein target structures", "PROBLEM", 129, 189]]], ["Compared to high through-put screening the hit rate for identifying active compound leads using 3D-chemical featured based pharmacophore virtual screening was increased 1000-fold.", [["active compound leads", "TREATMENT", 68, 89], ["pharmacophore virtual screening", "TEST", 123, 154]]], ["(1) (2) (3) (4) and found it to be a selective agonist of non-opioid (naloxone-insensitive) beta-endorphin receptor on human T lymphocytes, mouse peritoneal macrophages, rat brain synaptic membranes, and human T-lymphoblastoid cell line Jurkat.", [["T lymphocytes", "ANATOMY", 125, 138], ["peritoneal macrophages", "ANATOMY", 146, 168], ["brain synaptic membranes", "ANATOMY", 174, 198], ["T-lymphoblastoid cell line Jurkat", "ANATOMY", 210, 243], ["naloxone", "CHEMICAL", 70, 78], ["beta-endorphin", "CHEMICAL", 92, 106], ["naloxone", "CHEMICAL", 70, 78], ["(1) (2) (3) (4", "SIMPLE_CHEMICAL", 0, 14], ["naloxone", "SIMPLE_CHEMICAL", 70, 78], ["beta-endorphin receptor", "GENE_OR_GENE_PRODUCT", 92, 115], ["human", "ORGANISM", 119, 124], ["T lymphocytes", "CELL", 125, 138], ["mouse", "ORGANISM", 140, 145], ["peritoneal macrophages", "CELL", 146, 168], ["rat", "ORGANISM", 170, 173], ["brain synaptic membranes", "MULTI-TISSUE_STRUCTURE", 174, 198], ["human", "ORGANISM", 204, 209], ["T-lymphoblastoid cell line Jurkat", "CELL", 210, 243], ["beta-endorphin receptor", "PROTEIN", 92, 115], ["human T lymphocytes", "CELL_TYPE", 119, 138], ["mouse peritoneal macrophages", "CELL_TYPE", 140, 168], ["human T-lymphoblastoid cell line Jurkat", "CELL_LINE", 204, 243], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 140, 145], ["rat", "SPECIES", 170, 173], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 140, 145], ["rat", "SPECIES", 170, 173], ["human", "SPECIES", 204, 209], ["non-opioid (naloxone", "TREATMENT", 58, 78], ["beta-endorphin receptor", "TEST", 92, 115], ["human T lymphocytes", "TEST", 119, 138], ["mouse peritoneal macrophages", "PROBLEM", 140, 168], ["rat brain synaptic membranes", "PROBLEM", 170, 198], ["human T-lymphoblastoid cell line Jurkat", "TREATMENT", 204, 243], ["peritoneal", "ANATOMY", 146, 156], ["macrophages", "OBSERVATION", 157, 168], ["brain", "ANATOMY", 174, 179], ["synaptic membranes", "OBSERVATION", 180, 198], ["lymphoblastoid cell", "OBSERVATION", 212, 231], ["line Jurkat", "OBSERVATION", 232, 243]]], ["The study of biologic activity of IMN has revealed that it enhances the concanavalin A-induced proliferation of human T lymphocytes in vitro, activates mouse peritoneal macrophages in vitro and in vivo, and stimulates the growth of human T-lymphoblastoid cell lines Jurkat and MT-4.", [["T lymphocytes", "ANATOMY", 118, 131], ["peritoneal macrophages", "ANATOMY", 158, 180], ["T-lymphoblastoid cell lines Jurkat", "ANATOMY", 238, 272], ["MT-4", "ANATOMY", 277, 281], ["IMN", "CHEMICAL", 34, 37], ["IMN", "SIMPLE_CHEMICAL", 34, 37], ["human", "ORGANISM", 112, 117], ["T lymphocytes", "CELL", 118, 131], ["mouse", "ORGANISM", 152, 157], ["peritoneal macrophages", "CELL", 158, 180], ["human", "ORGANISM", 232, 237], ["T-lymphoblastoid cell lines Jurkat", "CELL", 238, 272], ["MT-4", "CELL", 277, 281], ["human T lymphocytes", "CELL_TYPE", 112, 131], ["mouse peritoneal macrophages", "CELL_TYPE", 152, 180], ["human T-lymphoblastoid cell lines", "CELL_LINE", 232, 265], ["Jurkat", "CELL_LINE", 266, 272], ["MT-4", "CELL_LINE", 277, 281], ["human", "SPECIES", 112, 117], ["mouse", "SPECIES", 152, 157], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 112, 117], ["mouse", "SPECIES", 152, 157], ["human", "SPECIES", 232, 237], ["The study", "TEST", 0, 9], ["human T lymphocytes", "PROBLEM", 112, 131], ["mouse peritoneal macrophages", "TREATMENT", 152, 180], ["MT", "TEST", 277, 279], ["concanavalin A-induced proliferation", "OBSERVATION", 72, 108], ["human T lymphocytes", "OBSERVATION", 112, 131], ["peritoneal macrophages", "OBSERVATION", 158, 180], ["lymphoblastoid cell lines Jurkat", "OBSERVATION", 240, 272]]], ["We have recently identifi ed non-opioid beta-endorphin receptors on the membranes isolated from rat adrenal cortex.", [["membranes", "ANATOMY", 72, 81], ["adrenal cortex", "ANATOMY", 100, 114], ["beta-endorphin", "CHEMICAL", 40, 54], ["beta-endorphin receptors", "GENE_OR_GENE_PRODUCT", 40, 64], ["membranes", "CELLULAR_COMPONENT", 72, 81], ["rat", "ORGANISM", 96, 99], ["adrenal cortex", "MULTI-TISSUE_STRUCTURE", 100, 114], ["non-opioid beta-endorphin receptors", "PROTEIN", 29, 64], ["rat", "SPECIES", 96, 99], ["recently identifi ed non-opioid beta-endorphin receptors", "TREATMENT", 8, 64], ["adrenal", "ANATOMY", 100, 107], ["cortex", "ANATOMY_MODIFIER", 108, 114]]], ["IMN at concentrations of 0.1-1000 nM was found to inhibit the adenylate cyclase activity in adrenocortical membranes, while intramuscular injection of IMN at doses of 1-100 g/kg was found to reduce the secretion of corticosterone from the adrenals to the bloodstream.", [["adrenocortical membranes", "ANATOMY", 92, 116], ["intramuscular", "ANATOMY", 124, 137], ["adrenals", "ANATOMY", 239, 247], ["bloodstream", "ANATOMY", 255, 266], ["IMN", "CHEMICAL", 0, 3], ["IMN", "CHEMICAL", 151, 154], ["corticosterone", "CHEMICAL", 215, 229], ["adenylate", "CHEMICAL", 62, 71], ["corticosterone", "CHEMICAL", 215, 229], ["IMN", "SIMPLE_CHEMICAL", 0, 3], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 62, 79], ["adrenocortical membranes", "MULTI-TISSUE_STRUCTURE", 92, 116], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 137], ["IMN", "SIMPLE_CHEMICAL", 151, 154], ["corticosterone", "SIMPLE_CHEMICAL", 215, 229], ["adrenals", "ORGAN", 239, 247], ["adenylate cyclase", "PROTEIN", 62, 79], ["IMN at concentrations", "TEST", 0, 21], ["the adenylate cyclase activity in adrenocortical membranes", "PROBLEM", 58, 116], ["IMN", "TREATMENT", 151, 154], ["the secretion of corticosterone", "PROBLEM", 198, 229], ["adrenocortical membranes", "ANATOMY", 92, 116], ["adrenals", "ANATOMY", 239, 247], ["bloodstream", "ANATOMY", 255, 266]]], ["Approximately 60 % of all drugs currently on the market act on GPCRs.", [["all drugs", "TREATMENT", 22, 31], ["GPCRs", "TEST", 63, 68]]], ["Up to now, the three-dimensional structures of only two GPCRs have been experimentally elucidated: bovine rhodopsin(1) and the human 2-adrenergic receptor (2) .", [["bovine", "ORGANISM", 99, 105], ["rhodopsin(1)", "GENE_OR_GENE_PRODUCT", 106, 118], ["human", "ORGANISM", 127, 132], ["2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 133, 154], ["GPCRs", "PROTEIN", 56, 61], ["bovine rhodopsin", "PROTEIN", 99, 115], ["human 2-adrenergic receptor", "PROTEIN", 127, 154], ["bovine", "SPECIES", 99, 105], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["bovine rhodopsin", "TREATMENT", 99, 115], ["the human 2-adrenergic receptor", "TREATMENT", 123, 154]]], ["Both structures were crystallised with a (covalently) bound inverse agonist, that shows no interaction with the ECLs.", [["ECLs", "ANATOMY", 112, 116], ["ECLs", "PATHOLOGICAL_FORMATION", 112, 116], ["ECLs", "PROTEIN", 112, 116], ["a (covalently) bound inverse agonist", "TREATMENT", 39, 75], ["the ECLs", "TREATMENT", 108, 116], ["structures", "ANATOMY_MODIFIER", 5, 15], ["no", "UNCERTAINTY", 88, 90]]], ["The vast majority of endogenous ligands of GPCRs most likely interact with the receptors via the extracellular regions.", [["extracellular regions", "ANATOMY", 97, 118], ["GPCRs", "GENE_OR_GENE_PRODUCT", 43, 48], ["extracellular regions", "CELLULAR_COMPONENT", 97, 118], ["GPCRs", "PROTEIN", 43, 48], ["extracellular regions", "PROTEIN", 97, 118], ["endogenous ligands of GPCRs", "PROBLEM", 21, 48], ["endogenous ligands", "OBSERVATION", 21, 39], ["extracellular", "ANATOMY_MODIFIER", 97, 110], ["regions", "ANATOMY_MODIFIER", 111, 118]]], ["Thus, profound knowledge on the structure of the fl exible ECLs is desired in order to understand the mechanism of GPCR signalling.", [["GPCR", "GENE_OR_GENE_PRODUCT", 115, 119], ["fl exible ECLs", "PROTEIN", 49, 63], ["GPCR", "PROTEIN", 115, 119], ["GPCR signalling", "PROBLEM", 115, 130], ["profound", "OBSERVATION_MODIFIER", 6, 14]]], ["Based on the 3-dimensional structure of rhodopsin and the recently published crystal structure of the 2-adrenergic receptor, we present a 3D-model of a GPCR with special focus on the fl exible ECLs.", [["rhodopsin", "GENE_OR_GENE_PRODUCT", 40, 49], ["2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 102, 123], ["rhodopsin", "PROTEIN", 40, 49], ["2-adrenergic receptor", "PROTEIN", 102, 123], ["GPCR", "PROTEIN", 152, 156], ["fl exible ECLs", "PROTEIN", 183, 197], ["rhodopsin", "TREATMENT", 40, 49], ["a GPCR", "TEST", 150, 156], ["the fl exible ECLs", "TREATMENT", 179, 197]]], ["Signifi cant similarities with the loop structures of rhodopsin and the 2-adrenergic receptor were found.", [["rhodopsin", "GENE_OR_GENE_PRODUCT", 54, 63], ["2-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 72, 93], ["rhodopsin", "PROTEIN", 54, 63], ["2-adrenergic receptor", "PROTEIN", 72, 93], ["Signifi cant similarities", "PROBLEM", 0, 25], ["rhodopsin", "TREATMENT", 54, 63], ["the 2-adrenergic receptor", "TREATMENT", 68, 93], ["loop", "OBSERVATION", 35, 39]]], ["Our novel 3-dimensional model of the GPCR (Y-receptor) will be discussed in light of recent experimental data.", [["GPCR", "GENE_OR_GENE_PRODUCT", 37, 41], ["GPCR", "PROTEIN", 37, 41], ["Y-receptor", "PROTEIN", 43, 53]]], ["To study such a multi-receptor/multi-ligand system we investigated the Y-receptor family.", [["Y-receptor", "GENE_OR_GENE_PRODUCT", 71, 81], ["Y-receptor family", "PROTEIN", 71, 88]]], ["This family consists of four G protein coupled Y receptors in human (hY1R, hY2R, hY4R, and hY5R) and is activated by the so-called NPY hormone family, which itself consists of three native peptide ligands named neuropeptide Y (NPY), pancreatic polypeptide (PP), and peptide YY (PYY).", [["G protein coupled Y receptors", "GENE_OR_GENE_PRODUCT", 29, 58], ["human", "ORGANISM", 62, 67], ["hY1R", "GENE_OR_GENE_PRODUCT", 69, 73], ["hY2R", "GENE_OR_GENE_PRODUCT", 75, 79], ["hY4R", "GENE_OR_GENE_PRODUCT", 81, 85], ["hY5R", "GENE_OR_GENE_PRODUCT", 91, 95], ["NPY hormone", "GENE_OR_GENE_PRODUCT", 131, 142], ["neuropeptide Y", "GENE_OR_GENE_PRODUCT", 211, 225], ["NPY", "GENE_OR_GENE_PRODUCT", 227, 230], ["pancreatic polypeptide", "GENE_OR_GENE_PRODUCT", 233, 255], ["PP", "GENE_OR_GENE_PRODUCT", 257, 259], ["peptide YY", "GENE_OR_GENE_PRODUCT", 266, 276], ["PYY", "GENE_OR_GENE_PRODUCT", 278, 281], ["G protein coupled Y receptors", "PROTEIN", 29, 58], ["hY1R", "PROTEIN", 69, 73], ["hY2R", "PROTEIN", 75, 79], ["hY4R", "PROTEIN", 81, 85], ["hY5R", "PROTEIN", 91, 95], ["NPY hormone family", "PROTEIN", 131, 149], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["pancreatic polypeptide (PP)", "TREATMENT", 233, 260], ["pancreatic", "ANATOMY", 233, 243]]], ["We recently could show that one conserved Asp-residue is essential for ligand binding in all four Y-receptors, but binds the endogenous ligands in a different mode by interacting with different ligand Arg-residues (1).", [["Asp", "CHEMICAL", 42, 45], ["Arg-", "CHEMICAL", 201, 205], ["Y-receptors", "PROTEIN", 98, 109], ["ligand binding", "PROBLEM", 71, 85]]], ["As the hY5R shows high affi nity for all ligands, we performed an extensive mutagenesis study and identifi ed several novel important residues.", [["hY5R", "GENE_OR_GENE_PRODUCT", 7, 11], ["hY5R", "PROTEIN", 7, 11], ["an extensive mutagenesis study", "TEST", 63, 93]]], ["By matching them with the important ligand residues we were able to discover a novel interaction point between hY5R and NPY, and tested whether PP and PYY bind to the receptor in the same manner.", [["hY5R", "GENE_OR_GENE_PRODUCT", 111, 115], ["NPY", "GENE_OR_GENE_PRODUCT", 120, 123], ["PP", "GENE_OR_GENE_PRODUCT", 144, 146], ["PYY", "GENE_OR_GENE_PRODUCT", 151, 154], ["hY5R", "PROTEIN", 111, 115], ["NPY", "PROTEIN", 120, 123], ["PP", "PROTEIN", 144, 146]]], ["The interaction between NPY(Arg25) and hY5R(Asp2.68) as well as between NPY(Arg33) and hY5R(Asp6.59) is maintained in the binding of PYY and PP to hY5R, but different to the PP-hY4R and NPY-hY1R contact points.", [["Asp", "CHEMICAL", 92, 95], ["NPY(Arg25)", "GENE_OR_GENE_PRODUCT", 24, 34], ["hY5R(Asp2.68)", "GENE_OR_GENE_PRODUCT", 39, 52], ["NPY(Arg33)", "GENE_OR_GENE_PRODUCT", 72, 82], ["hY5R", "GENE_OR_GENE_PRODUCT", 87, 91], ["PYY", "GENE_OR_GENE_PRODUCT", 133, 136], ["PP", "GENE_OR_GENE_PRODUCT", 141, 143], ["hY5R", "GENE_OR_GENE_PRODUCT", 147, 151], ["PP-hY4R", "GENE_OR_GENE_PRODUCT", 174, 181], ["NPY-hY1R", "GENE_OR_GENE_PRODUCT", 186, 194], ["hY5R", "PROTEIN", 39, 43], ["Asp2.68", "PROTEIN", 44, 51], ["hY5R", "PROTEIN", 87, 91], ["PP", "PROTEIN", 141, 143], ["hY5R", "PROTEIN", 147, 151], ["hY4R", "PROTEIN", 177, 181], ["hY1R", "PROTEIN", 190, 194], ["Asp", "TEST", 92, 95], ["PP", "TEST", 141, 143], ["the PP", "TEST", 170, 176], ["NPY", "TEST", 186, 189]]], ["Furthermore, the fi rst hY5R model was set up on the basis of the crystal structure of bovine rhodopsin.", [["bovine", "ORGANISM", 87, 93], ["rhodopsin", "GENE_OR_GENE_PRODUCT", 94, 103], ["fi rst hY5R model", "DNA", 17, 34], ["bovine rhodopsin", "PROTEIN", 87, 103], ["bovine", "SPECIES", 87, 93], ["the fi rst hY5R model", "TEST", 13, 34], ["bovine rhodopsin", "TREATMENT", 87, 103], ["bovine rhodopsin", "OBSERVATION", 87, 103]]], ["We can show that most of the residues identifi ed to be critical for ligand binding are located within the now postulated binding pocket.", [["ligand binding", "PROBLEM", 69, 83], ["binding pocket", "OBSERVATION", 122, 136]]], ["This talk will draw together some of the ideas that are emerging from recent work in our laboratory including evidence for the extremely narrow boundary between normal and aberrant behaviour [Tartaglia et al., Trends Biochem.", [["aberrant behaviour", "PROBLEM", 172, 190], ["normal", "OBSERVATION", 161, 167]]], ["32, 204-206 (2007) ], and how this concept sheds light on the origin, current proliferation and potential means of prevention of many of the diseases associated with misfolding.S09-2 InvElucidating molecular mechanisms on and off the pathway to amyloid depositionMiranker, Andrew Yale University, UNITED STATESPolypeptide chains have a generic capacity to self-associate into linear, non-covalent assemblies termed amyloid fi bers.", [["amyloid", "GENE_OR_GENE_PRODUCT", 245, 252], ["amyloid fi bers", "GENE_OR_GENE_PRODUCT", 415, 430], ["amyloid fi bers", "PROTEIN", 415, 430], ["the diseases", "PROBLEM", 137, 149], ["misfolding", "PROBLEM", 166, 176], ["proliferation", "OBSERVATION", 78, 91], ["diseases", "OBSERVATION", 141, 149], ["amyloid fi", "OBSERVATION", 415, 425]]], ["Such fi bers give the appearance of violating basic principles of protein folding because they can serve as templates of their own propagation.", [["protein folding", "PROBLEM", 66, 81], ["protein folding", "OBSERVATION", 66, 81]]], ["Regardless of the identity of the starting precursor, the resultant amyloid structures share a number of properties.", [["the resultant amyloid structures", "PROBLEM", 54, 86], ["resultant", "OBSERVATION_MODIFIER", 58, 67], ["amyloid", "OBSERVATION", 68, 75], ["number", "OBSERVATION_MODIFIER", 95, 101]]], ["These include insolubility, protease resistance, chemical resistance and cytotoxicity.", [["protease resistance", "TREATMENT", 28, 47], ["chemical resistance", "TREATMENT", 49, 68], ["cytotoxicity", "PROBLEM", 73, 85], ["protease resistance", "OBSERVATION", 28, 47], ["chemical resistance", "OBSERVATION", 49, 68]]], ["Proteins are therefore under selective pressure to avoid this phenomenon and are most commonly associated with diseases of advancing age, such as Alzheimer's, and diseases associated with medical therapy, such as dialysis related amyloidosis (DRA).", [["Alzheimer's, and diseases", "DISEASE", 146, 171], ["amyloidosis", "DISEASE", 230, 241], ["selective pressure", "TREATMENT", 29, 47], ["this phenomenon", "PROBLEM", 57, 72], ["Alzheimer's", "PROBLEM", 146, 157], ["diseases", "PROBLEM", 163, 171], ["medical therapy", "TREATMENT", 188, 203], ["dialysis", "TREATMENT", 213, 221], ["amyloidosis", "PROBLEM", 230, 241], ["amyloidosis", "OBSERVATION", 230, 241]]], ["In our laboratory, we investigate fi brillogenesis as a biologically relevant chemical reaction.", [["a biologically relevant chemical reaction", "PROBLEM", 54, 95]]], ["Therefore, understanding the mechanism of assembly requires insight into the structures, energetics and pathways which relate different intermediate states.", [["intermediate states", "OBSERVATION", 136, 155]]], ["In general, insights are elusive due to the transient and heterogeneous nature of fi brillogenesis.", [["the transient and heterogeneous nature of fi brillogenesis", "PROBLEM", 40, 98], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71], ["fi brillogenesis", "OBSERVATION", 82, 98]]], ["We are nevertheless able to shed light by combining a range of biophysical approaches and focusing on protein systems ranging from peptide models to globular proteins.", [["globular proteins", "PROTEIN", 149, 166], ["protein systems", "TEST", 102, 117], ["globular proteins", "PROBLEM", 149, 166], ["globular proteins", "OBSERVATION", 149, 166]]], ["The commonality among such investigations reveals the rules governing this class of polymeric assembly.Title Abs NoLife on the Edge: The Nature and Origins of Protein Misfolding Diseases Dobson, ChrisS09-1 InvElucidating molecular mechanisms on and off the pathway to amyloid deposition Miranker, AndrewS09-2 InvAlzheimer Peptides.", [["amyloid", "GENE_OR_GENE_PRODUCT", 268, 275], ["such investigations", "TEST", 22, 41], ["Protein Misfolding Diseases", "PROBLEM", 159, 186], ["Dobson", "TEST", 187, 193], ["ChrisS09", "TEST", 195, 203], ["amyloid deposition", "TEST", 268, 286], ["Miranker", "TEST", 287, 295], ["AndrewS09", "TEST", 297, 306], ["Protein Misfolding", "OBSERVATION", 159, 177]]], ["The membrane-induced random coil-to--structure transition Seelig, JoachimS09-3 InvRetro-Enantio N-Methylated Peptides as -Amyloid Aggregation Inhibitors Giralt, ErnestS09-4 InvOral sessionsSeelig, Joachim University of Basel, SWITZERLANDBiologically important peptides such as the Alzheimer peptide A (1-40) display a reversible random coil-to--structure transition at anionic membrane surfaces.", [["membrane", "ANATOMY", 4, 12], ["membrane surfaces", "ANATOMY", 377, 394], ["Alzheimer peptide A (1-40)", "CHEMICAL", 281, 307], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["membrane surfaces", "CELLULAR_COMPONENT", 377, 394], ["The membrane", "TREATMENT", 0, 12], ["random coil", "TREATMENT", 21, 32], ["Seelig", "TEST", 58, 64], ["JoachimS09", "TEST", 66, 76], ["Enantio N", "TREATMENT", 88, 97], ["Methylated Peptides", "TREATMENT", 98, 117], ["Amyloid Aggregation Inhibitors", "TREATMENT", 122, 152], ["ErnestS09", "TEST", 161, 170], ["the Alzheimer peptide", "TEST", 277, 298], ["a reversible random coil", "PROBLEM", 316, 340], ["reversible", "OBSERVATION_MODIFIER", 318, 328], ["random coil", "OBSERVATION", 329, 340], ["anionic membrane", "OBSERVATION", 369, 385]]], ["We present a new method to quantitatively analyze the thermodynamic parameters of the membrane-induced -structure formation.", [["membrane", "ANATOMY", 86, 94], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["structure formation", "OBSERVATION", 104, 123]]], ["We have used the model peptide (KIGAKI) 3 and eight analogues in which two adjacent amino acids were substituted by their d-enantiomers.", [["amino acids", "CHEMICAL", 84, 95], ["amino acids", "CHEMICAL", 84, 95], ["amino acids", "AMINO_ACID", 84, 95], ["the model peptide (KIGAKI)", "TREATMENT", 13, 39], ["two adjacent amino acids", "TREATMENT", 71, 95], ["amino acids", "OBSERVATION", 84, 95]]], ["The positions of the d,d pairs were shifted systematically along the three identical segments of the peptide chain.", [["the d,d pairs", "PROBLEM", 17, 30], ["positions", "OBSERVATION_MODIFIER", 4, 13], ["three", "ANATOMY_MODIFIER", 69, 74], ["segments", "ANATOMY_MODIFIER", 85, 93], ["peptide chain", "ANATOMY_MODIFIER", 101, 114]]], ["The -structure content of the peptides was measured in solution and when bound to anionic lipid membranes with CD spectroscopy and isothermal titration calorimetry.", [["lipid membranes", "ANATOMY", 90, 105], ["CD spectroscopy", "TEST", 111, 126], ["isothermal titration calorimetry", "TREATMENT", 131, 163], ["structure", "OBSERVATION_MODIFIER", 5, 14], ["content", "OBSERVATION_MODIFIER", 15, 22]]], ["The thermodynamic parameters were found to be linearly correlated with the extent of -structure formation, characterized by an enthalpy change of DH = 0.23 kcal/mol per residue, an entropy change of DS = 0.24 cal/molK per residue and a free energy change of DG = 0.15 kcal/mol residue.", [["DG", "SIMPLE_CHEMICAL", 258, 260], ["The thermodynamic parameters", "TEST", 0, 28], ["an enthalpy change of DH", "TREATMENT", 124, 148], ["an entropy change of DS", "TREATMENT", 178, 201], ["a free energy change of DG", "TREATMENT", 234, 260], ["extent", "OBSERVATION_MODIFIER", 75, 81], ["structure formation", "OBSERVATION", 86, 105], ["enthalpy change", "OBSERVATION", 127, 142]]], ["(1) We have further synthesized peptides containing the KIGAKI module with a chain length varying between n = 6 to 30.", [["KIGAKI module", "DNA", 56, 69], ["further synthesized peptides", "TREATMENT", 12, 40], ["the KIGAKI module", "TREATMENT", 52, 69], ["a chain length", "TEST", 75, 89]]], ["The above parameters are valid for peptides with a chain length of n >12.", [["The above parameters", "TEST", 0, 20], ["peptides", "TEST", 35, 43], ["a chain length", "TEST", 49, 63]]], ["For short chains with n = 12 -structure formation becomes unfavorable with DG = 0.08 kcal/mol per residue,DH = 0.23 kcal/ mol andDS = 0.24 cal/molK.", [["DG", "SIMPLE_CHEMICAL", 75, 77], ["short chains", "PROBLEM", 4, 16]]], ["The residual free energy of membraneinduced -structure formation for long peptides is close to that of membrane-induced -helix formation.", [["membrane", "ANATOMY", 103, 111], ["membrane", "CELLULAR_COMPONENT", 103, 111], ["The residual free energy of membraneinduced -structure formation", "PROBLEM", 0, 64], ["long peptides", "PROBLEM", 69, 82], ["helix formation", "PROBLEM", 121, 136], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["free", "OBSERVATION_MODIFIER", 13, 17], ["energy", "OBSERVATION_MODIFIER", 18, 24], ["helix formation", "OBSERVATION", 121, 136]]], ["Current treatments for Alzheimer's disease (AD) offer only symptomatic benefi ts to patients.", [["Alzheimer's disease", "DISEASE", 23, 42], ["AD", "DISEASE", 44, 46], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Current treatments", "TREATMENT", 0, 18], ["Alzheimer's disease", "PROBLEM", 23, 42]]], ["Thus, the development of new treatments to actually slow, stop or cure the disease is greatly needed.", [["new treatments", "TREATMENT", 25, 39], ["the disease", "PROBLEM", 71, 82], ["new", "OBSERVATION_MODIFIER", 25, 28]]], ["The fact that -amyloid peptide ( A) aggregation is central to AD, together with an increasing knowledge on amyloid fi bril structure and dynamics, makes inhibition of the aggregation process of A an attractive and promising target for AD therapy.", [["-amyloid peptide", "CHEMICAL", 14, 30], ["AD", "DISEASE", 62, 64], ["AD", "DISEASE", 235, 237], ["-amyloid peptide", "SIMPLE_CHEMICAL", 14, 30], ["A", "GENE_OR_GENE_PRODUCT", 33, 34], ["amyloid fi bril", "GENE_OR_GENE_PRODUCT", 107, 122], ["-amyloid peptide", "PROBLEM", 14, 30], ["the aggregation process", "PROBLEM", 167, 190], ["AD therapy", "TREATMENT", 235, 245], ["increasing", "OBSERVATION_MODIFIER", 83, 93]]], ["Here we present a new peptide, inrD, designed using the retro-enantio approach in tandem with the use of N-methylated amino acids and show that disrupts -amyloid aggregation and decreases A cytotoxicity while proteolytically stable.", [["amino acids", "CHEMICAL", 118, 129], ["N-methylated amino acids", "CHEMICAL", 105, 129], ["inrD", "SIMPLE_CHEMICAL", 31, 35], ["amino acids", "AMINO_ACID", 118, 129], ["amyloid", "GENE_OR_GENE_PRODUCT", 154, 161], ["the retro-enantio approach", "TREATMENT", 52, 78], ["N-methylated amino acids", "TREATMENT", 105, 129], ["amyloid aggregation", "PROBLEM", 154, 173], ["A cytotoxicity", "PROBLEM", 188, 202], ["amyloid aggregation", "OBSERVATION", 154, 173], ["stable", "OBSERVATION_MODIFIER", 225, 231]]], ["In vitro and in silico studies have revealed that our strategy could be very promising not only for designing molecules to treat Alzheimer's disease, but also for designing ligands for a protein surface having a -sheet surface-patch.Retro-Enantio N-Methylated Peptides as -Amyloid Aggregation InhibitorsIn conclusion, inrD is a very promising lead compound to treat AD, owing to its ability to interfere with A aggregation and decrease A cytotoxicity, while being stable to proteases.", [["surface", "ANATOMY", 195, 202], ["surface", "ANATOMY", 219, 226], ["Alzheimer's disease", "DISEASE", 129, 148], ["inrD", "CHEMICAL", 318, 322], ["AD", "DISEASE", 366, 368], ["inrD", "SIMPLE_CHEMICAL", 318, 322], ["proteases", "PROTEIN", 474, 483], ["silico studies", "TEST", 16, 30], ["Alzheimer's disease", "PROBLEM", 129, 148], ["a protein surface", "TREATMENT", 185, 202], ["a -sheet surface-patch", "TREATMENT", 210, 232], ["Retro-Enantio N-Methylated Peptides", "TREATMENT", 233, 268], ["Amyloid Aggregation Inhibitors", "TREATMENT", 273, 303], ["AD", "PROBLEM", 366, 368], ["A aggregation", "PROBLEM", 409, 422], ["A cytotoxicity", "PROBLEM", 436, 450]]], ["Docking and molecular dynamics calculations indicate that although inrD does not maintain the native side-chain pairing observed in A molecules within the fi bril, it can establish an effective hydrogen-bonding pattern with the fi bril.Retro-Enantio N-Methylated Peptides as -Amyloid Aggregation InhibitorsOur results with inrD are testament of the value that the retro-enantio approach can have for obtaining peptides able to interact with -sheet proteins.", [["hydrogen", "CHEMICAL", 194, 202], ["inrD", "PROTEIN", 67, 71], ["A molecules", "PROTEIN", 132, 143], ["fi bril", "PROTEIN", 155, 162], ["inrD", "PROTEIN", 323, 327], ["-sheet proteins", "PROTEIN", 441, 456], ["molecular dynamics calculations", "TEST", 12, 43], ["the fi bril", "TREATMENT", 224, 235], ["Retro-Enantio N-Methylated Peptides", "TREATMENT", 236, 271], ["Amyloid Aggregation Inhibitors", "TREATMENT", 276, 306], ["the retro-enantio approach", "TREATMENT", 360, 386]]], ["This observation may have major implications for the design of bioactive peptides for myriad therapeutic indications, including those targeted at disrupting protein-protein interactions.Title Abs NoOxidatively stressed lipids and polypeptide misfolding in human disease Axelsen, Paul S10-1 InvTitle Abs NoHairpin Peptide Inhibitors of Amyloid Fibril Formation Andersen, Niels S10-2Title Abs NoPrP(106-126) does not interact with membranes in physiological conditions.", [["membranes", "ANATOMY", 429, 438], ["polypeptide misfolding", "DISEASE", 230, 252], ["NoPrP", "CHEMICAL", 391, 396], ["lipids", "SIMPLE_CHEMICAL", 219, 225], ["human", "ORGANISM", 256, 261], ["membranes", "CELLULAR_COMPONENT", 429, 438], ["Title Abs", "PROTEIN", 186, 195], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["bioactive peptides", "TREATMENT", 63, 81], ["myriad therapeutic indications", "TREATMENT", 86, 116], ["stressed lipids", "TREATMENT", 210, 225], ["polypeptide misfolding in human disease", "PROBLEM", 230, 269], ["Axelsen", "TEST", 270, 277], ["InvTitle Abs NoHairpin Peptide Inhibitors", "TREATMENT", 290, 331], ["Amyloid Fibril Formation", "PROBLEM", 335, 359], ["Niels", "TEST", 370, 375], ["NoPrP", "TEST", 391, 396], ["Amyloid Fibril", "OBSERVATION", 335, 349]]], ["A biophysical study with model membranes.Title Abs NoHenriques, S\u00f3nia S10-3Title Abs NoHuman cystatin C interactions with amyloidogenic molecules Juszczyk, Paulina S10-4Axelsen, Paul Departments of Pharmacology, Biochemistry, Biophysics, and Medicine, University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USAEvidence of elevated oxidative stress has been found in many human diseases, including all forms of Alzheimer's Disease.", [["membranes", "ANATOMY", 31, 40], ["human diseases", "DISEASE", 390, 404], ["Alzheimer's Disease", "DISEASE", 429, 448], ["membranes", "CELLULAR_COMPONENT", 31, 40], ["cystatin C", "SIMPLE_CHEMICAL", 93, 103], ["human", "ORGANISM", 390, 395], ["S\u00f3nia S10-3Title Abs", "PROTEIN", 64, 84], ["cystatin C", "PROTEIN", 93, 103], ["amyloidogenic molecules", "PROTEIN", 122, 145], ["human", "SPECIES", 390, 395], ["human", "SPECIES", 390, 395], ["A biophysical study", "TEST", 0, 19], ["model membranes", "TREATMENT", 25, 40], ["Title Abs", "TEST", 41, 50], ["NoHenriques", "TEST", 51, 62], ["S\u00f3nia", "TEST", 64, 69], ["cystatin C interactions", "PROBLEM", 93, 116], ["amyloidogenic molecules", "TEST", 122, 145], ["elevated oxidative stress", "PROBLEM", 341, 366], ["many human diseases", "PROBLEM", 385, 404], ["Alzheimer's Disease", "PROBLEM", 429, 448], ["oxidative stress", "OBSERVATION", 350, 366], ["many human", "OBSERVATION_MODIFIER", 385, 395], ["diseases", "OBSERVATION", 396, 404], ["Alzheimer", "OBSERVATION", 429, 438]]], ["The substances in the brain most vulnerable to oxidative stress are ordinary membrane lipids, and they yield highly reactive metabolic products when subjected to oxidative stress.", [["brain", "ANATOMY", 22, 27], ["membrane", "ANATOMY", 77, 85], ["brain", "ORGAN", 22, 27], ["membrane lipids", "CELLULAR_COMPONENT", 77, 92], ["The substances in the brain", "PROBLEM", 0, 27], ["oxidative stress", "PROBLEM", 47, 63], ["membrane lipids", "TEST", 77, 92], ["oxidative stress", "PROBLEM", 162, 178], ["substances", "OBSERVATION", 4, 14], ["brain", "ANATOMY", 22, 27], ["reactive metabolic products", "OBSERVATION", 116, 143]]], ["Recent investigations have demonstrated that polypeptides known as amyloid beta (Abeta) proteins can dramatically accelerate oxidative stress and lipid damage in membranes.", [["membranes", "ANATOMY", 162, 171], ["amyloid beta", "GENE_OR_GENE_PRODUCT", 67, 79], ["Abeta", "GENE_OR_GENE_PRODUCT", 81, 86], ["lipid", "SIMPLE_CHEMICAL", 146, 151], ["membranes", "CELLULAR_COMPONENT", 162, 171], ["amyloid beta (Abeta) proteins", "PROTEIN", 67, 96], ["Recent investigations", "TEST", 0, 21], ["polypeptides", "PROBLEM", 45, 57], ["amyloid beta (Abeta) proteins", "PROBLEM", 67, 96], ["oxidative stress", "PROBLEM", 125, 141], ["lipid damage in membranes", "PROBLEM", 146, 171], ["oxidative stress", "OBSERVATION", 125, 141], ["lipid damage", "OBSERVATION", 146, 158]]], ["In turn, the reactive products of oxidative lipid damage covalently modify Abeta proteins, converting them into a form that promotes the aggregation of unmodifi ed Abeta proteins and accelerates amyloid fi bril formation.", [["lipid", "SIMPLE_CHEMICAL", 44, 49], ["Abeta", "GENE_OR_GENE_PRODUCT", 75, 80], ["unmodifi ed Abeta proteins", "GENE_OR_GENE_PRODUCT", 152, 178], ["amyloid fi bril", "GENE_OR_GENE_PRODUCT", 195, 210], ["Abeta proteins", "PROTEIN", 75, 89], ["unmodifi", "PROTEIN", 152, 160], ["Abeta proteins", "PROTEIN", 164, 178], ["oxidative lipid damage covalently", "TREATMENT", 34, 67], ["Abeta proteins", "TREATMENT", 75, 89], ["unmodifi ed Abeta proteins", "TREATMENT", 152, 178], ["amyloid fi bril formation", "PROBLEM", 195, 220], ["reactive", "OBSERVATION_MODIFIER", 13, 21], ["oxidative lipid damage", "OBSERVATION", 34, 56], ["amyloid fi bril", "OBSERVATION", 195, 210]]], ["As a consequence, the normal metabolic degradation pathways for membrane lipids become key components of a chemical amplifi cation mechanism that is triggered by Abeta proteins and that results in a reduction of Abeta protein solubility and accelerated fi brillogenesis.", [["membrane lipids", "ANATOMY", 64, 79], ["membrane lipids", "CELLULAR_COMPONENT", 64, 79], ["cation", "SIMPLE_CHEMICAL", 124, 130], ["Abeta", "GENE_OR_GENE_PRODUCT", 162, 167], ["Abeta", "GENE_OR_GENE_PRODUCT", 212, 217], ["Abeta proteins", "PROTEIN", 162, 176], ["Abeta protein", "PROTEIN", 212, 225], ["membrane lipids", "TREATMENT", 64, 79], ["a chemical amplifi cation mechanism", "TREATMENT", 105, 140], ["Abeta proteins", "PROBLEM", 162, 176], ["a reduction of Abeta protein solubility", "TREATMENT", 197, 236], ["accelerated fi brillogenesis", "PROBLEM", 241, 269], ["metabolic degradation", "OBSERVATION", 29, 50], ["Abeta protein solubility", "OBSERVATION", 212, 236], ["fi brillogenesis", "OBSERVATION", 253, 269]]], ["In addition to promoting the formation of amyloid fi brils, this amplifi cation mechanism can exert multifaceted neurotoxicity by generating free radicals, depleting antioxidant reserves, altering transmembrane signals, and elaborating compounds with known propensities to cause chemical modifi cation of proteins and nucleic acids.", [["transmembrane", "ANATOMY", 197, 210], ["neurotoxicity", "DISEASE", 113, 126], ["nucleic acids", "CHEMICAL", 318, 331], ["amyloid fi brils", "GENE_OR_GENE_PRODUCT", 42, 58], ["nucleic acids", "SIMPLE_CHEMICAL", 318, 331], ["amyloid fi brils", "TREATMENT", 42, 58], ["this amplifi cation mechanism", "TREATMENT", 60, 89], ["multifaceted neurotoxicity", "PROBLEM", 100, 126], ["depleting antioxidant reserves", "TREATMENT", 156, 186], ["altering transmembrane signals", "PROBLEM", 188, 218], ["chemical modifi cation of proteins", "TREATMENT", 279, 313], ["nucleic acids", "TREATMENT", 318, 331]]], ["Because this type of mechanism is inhibited by free sulfhydryl groups, it may explain the well-known inverse relationship between the risk of Alzheimer's disease and the number of Cys residues in isoforms of lipoprotein E.Andersen, Niels University of Washington, UNITED STATESAmyloid fi bril formation is associated with at least 17 human diseases; among these, the human-amylin(hAM)-derived deposits in type II diabetes were the discovery system and hAM aggregation is one of the more thoroughly studied systems.", [["sulfhydryl", "CHEMICAL", 52, 62], ["Alzheimer's disease", "DISEASE", 142, 161], ["hAM", "CHEMICAL", 380, 383], ["type II diabetes", "DISEASE", 405, 421], ["sulfhydryl", "CHEMICAL", 52, 62], ["Cys", "CHEMICAL", 180, 183], ["sulfhydryl", "SIMPLE_CHEMICAL", 52, 62], ["human", "ORGANISM", 334, 339], ["human", "ORGANISM", 367, 372], ["amylin", "GENE_OR_GENE_PRODUCT", 373, 379], ["hAM", "GENE_OR_GENE_PRODUCT", 380, 383], ["hAM", "GENE_OR_GENE_PRODUCT", 452, 455], ["human", "SPECIES", 334, 339], ["human", "SPECIES", 367, 372], ["human", "SPECIES", 334, 339], ["human", "SPECIES", 367, 372], ["Alzheimer's disease", "PROBLEM", 142, 161], ["Cys residues", "PROBLEM", 180, 192], ["17 human diseases", "PROBLEM", 331, 348], ["the human-amylin(hAM)", "TREATMENT", 363, 384], ["derived deposits", "PROBLEM", 385, 401], ["type II diabetes", "PROBLEM", 405, 421], ["Alzheimer", "OBSERVATION", 142, 151]]], ["To date, inhibitors of beta-aggregate and fi bril formation have been polyphenols, mutants of hAM, or short peptide related to the hAM(22-29) sequence, NFGAILSS.", [["polyphenols", "CHEMICAL", 70, 81], ["beta-aggregate", "SIMPLE_CHEMICAL", 23, 37], ["fi bril", "SIMPLE_CHEMICAL", 42, 49], ["polyphenols", "SIMPLE_CHEMICAL", 70, 81], ["hAM", "GENE_OR_GENE_PRODUCT", 94, 97], ["hAM", "PROTEIN", 94, 97], ["hAM(22-29) sequence", "DNA", 131, 150], ["NFGAILSS", "PROTEIN", 152, 160], ["inhibitors", "TREATMENT", 9, 19], ["beta-aggregate and fi bril formation", "TREATMENT", 23, 59], ["mutants of hAM", "PROBLEM", 83, 97], ["short peptide", "PROBLEM", 102, 115]]], ["We now report that stable beta-hairpin scaffolds displaying Trp and Tyr residues are effective inhibitors, delaying the onset of both the CD changes associated with beta structure formation and the nucleation time and net enhancement of the fl uorescence observed with added Thiofl avin-T (ThT).", [["Trp", "CHEMICAL", 60, 63], ["Tyr", "CHEMICAL", 68, 71], ["CD", "DISEASE", 138, 140], ["Thiofl avin-T", "CHEMICAL", 275, 288], ["Trp", "CHEMICAL", 60, 63], ["Tyr", "CHEMICAL", 68, 71], ["Trp", "AMINO_ACID", 60, 63], ["Tyr", "AMINO_ACID", 68, 71], ["stable beta-hairpin scaffolds", "TREATMENT", 19, 48], ["Trp and Tyr residues", "TREATMENT", 60, 80], ["effective inhibitors", "TREATMENT", 85, 105], ["the CD changes", "PROBLEM", 134, 148], ["beta structure formation", "PROBLEM", 165, 189], ["stable", "OBSERVATION_MODIFIER", 19, 25], ["beta-hairpin scaffolds", "OBSERVATION", 26, 48], ["Tyr residues", "OBSERVATION", 68, 80], ["CD", "OBSERVATION", 138, 140], ["beta structure", "OBSERVATION_MODIFIER", 165, 179]]], ["Under our test conditions (8 microM hAM, 2% HFIP in 5mM phosphate buffer, pH 7), hAM begins to display an increase in beta structure by CD at 40 min with a constant maximal value from 85 -220 min.", [["HFIP", "CHEMICAL", 44, 48], ["phosphate", "CHEMICAL", 56, 65], ["phosphate", "CHEMICAL", 56, 65], ["hAM", "SIMPLE_CHEMICAL", 81, 84], ["beta", "GENE_OR_GENE_PRODUCT", 118, 122], ["our test conditions", "TEST", 6, 25], ["8 microM hAM", "TREATMENT", 27, 39], ["2% HFIP", "TREATMENT", 41, 48], ["5mM phosphate buffer", "TREATMENT", 52, 72], ["pH", "TEST", 74, 76], ["an increase in beta structure", "PROBLEM", 103, 132], ["a constant maximal value", "TEST", 154, 178], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["beta structure", "OBSERVATION_MODIFIER", 118, 132]]], ["Inhibition (delayed onset and reduction in the maximal fl uorescence enhancement) has been observed with a number of hairpins; those with two Trp residues on a single face of the hairpin are more potent.", [["Trp", "CHEMICAL", 142, 145], ["Trp", "CHEMICAL", 142, 145], ["Inhibition (delayed onset", "PROBLEM", 0, 25], ["reduction", "TREATMENT", 30, 39], ["the maximal fl uorescence enhancement", "TREATMENT", 43, 80], ["hairpins", "TREATMENT", 117, 125], ["two Trp residues", "PROBLEM", 138, 154], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["hairpin", "OBSERVATION", 179, 186], ["more potent", "OBSERVATION_MODIFIER", 191, 202]]], ["Of these, our best inhibitor to date, KKLTVWIpGKWITVSA (p = D-Pro), increases the onset time more than 2-fold at equimolar concentrations.", [["D-Pro", "CHEMICAL", 60, 65], ["KKLTVWIpGKWITVSA", "TEST", 38, 54]]], ["At 4 molar equiv., the onset time is greater than 320 min and ThT fl uorescence levels out at < 40% of the control value.", [["ThT fl uorescence levels", "TEST", 62, 86]]], ["14456 ) that a beta-sheet protein with added Tyr and Trp residues inhibits fi bril formation by the Alzheimer-related Abeta peptide; we expect that designed beta-hairpin scaffolds will be more generally applicable and will afford new insights into the recognition phenomena of amyloidogenesis.", [["amyloidogenesis", "DISEASE", 277, 292], ["Tyr", "CHEMICAL", 45, 48], ["Trp", "CHEMICAL", 53, 56], ["Tyr", "AMINO_ACID", 45, 48], ["Trp", "AMINO_ACID", 53, 56], ["fi bril", "GENE_OR_GENE_PRODUCT", 75, 82], ["beta-sheet protein", "PROTEIN", 15, 33], ["a beta-sheet protein", "TREATMENT", 13, 33], ["added Tyr", "TREATMENT", 39, 48], ["Trp residues", "TREATMENT", 53, 65], ["fi bril formation", "PROBLEM", 75, 92], ["the Alzheimer-related Abeta peptide", "PROBLEM", 96, 131], ["beta-hairpin scaffolds", "TREATMENT", 157, 179], ["amyloidogenesis", "PROBLEM", 277, 292]]], ["Prion diseases result from a post-translational modifi cation of the physiological Prion Protein (PrPC) into a scrapie isoform (PrPSc), which accumulates in the central nervous system and is responsible by progressive neuronal loss.", [["central nervous system", "ANATOMY", 161, 183], ["neuronal", "ANATOMY", 218, 226], ["Prion diseases", "DISEASE", 0, 14], ["neuronal loss", "DISEASE", 218, 231], ["PrPC", "GENE_OR_GENE_PRODUCT", 98, 102], ["PrPSc", "GENE_OR_GENE_PRODUCT", 128, 133], ["central nervous system", "ANATOMICAL_SYSTEM", 161, 183], ["neuronal", "CELL", 218, 226], ["Prion Protein", "PROTEIN", 83, 96], ["PrPC", "PROTEIN", 98, 102], ["scrapie isoform", "PROTEIN", 111, 126], ["PrPSc", "PROTEIN", 128, 133], ["Prion diseases", "PROBLEM", 0, 14], ["a post-translational modifi cation", "TREATMENT", 27, 61], ["the physiological Prion Protein (PrPC)", "TREATMENT", 65, 103], ["a scrapie isoform", "TREATMENT", 109, 126], ["progressive neuronal loss", "PROBLEM", 206, 231], ["central", "ANATOMY_MODIFIER", 161, 168], ["nervous system", "ANATOMY", 169, 183], ["progressive", "OBSERVATION_MODIFIER", 206, 217], ["neuronal loss", "OBSERVATION", 218, 231]]], ["Its fragment 106-126 was reported to be the most amyloidogenic region and to maintain pathological features of PrPSc.", [["PrPSc", "GENE_OR_GENE_PRODUCT", 111, 116], ["amyloidogenic region", "PROTEIN", 49, 69], ["Its fragment", "TEST", 0, 12], ["fragment", "OBSERVATION_MODIFIER", 4, 12], ["amyloidogenic", "OBSERVATION", 49, 62]]], ["A role in neurodegeneration was proposed based on the modulation of membrane properties and channel formation.", [["membrane", "ANATOMY", 68, 76], ["neurodegeneration", "DISEASE", 10, 27], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["neurodegeneration", "PROBLEM", 10, 27], ["the modulation of membrane properties", "TREATMENT", 50, 87], ["neurodegeneration", "OBSERVATION", 10, 27]]], ["If these processes are important, peptide-membrane interactions would be a key feature to the toxicity of PrPSc.", [["membrane", "ANATOMY", 42, 50], ["toxicity", "DISEASE", 94, 102], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["PrPSc", "GENE_OR_GENE_PRODUCT", 106, 111], ["peptide-membrane interactions", "PROBLEM", 34, 63], ["the toxicity of PrPSc", "PROBLEM", 90, 111]]], ["The interaction of PrP(106-126) with model membranes were examined using surface plasmon resonance and fl uorescence methodologies.", [["membranes", "ANATOMY", 43, 52], ["PrP", "GENE_OR_GENE_PRODUCT", 19, 22], ["membranes", "CELLULAR_COMPONENT", 43, 52], ["PrP", "PROTEIN", 19, 22], ["PrP", "TEST", 19, 22], ["model membranes", "TREATMENT", 37, 52], ["surface plasmon resonance", "TEST", 73, 98]]], ["Different parameters relevant to characterisation of peptide-membrane interactions including: membrane charge, viscosity, lipid composition, pH and ionic strength, were studied.", [["membrane", "ANATOMY", 61, 69], ["membrane", "ANATOMY", 94, 102], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["lipid", "SIMPLE_CHEMICAL", 122, 127], ["Different parameters", "TEST", 0, 20], ["peptide-membrane interactions", "PROBLEM", 53, 82], ["membrane charge", "TREATMENT", 94, 109], ["lipid composition", "TEST", 122, 139]]], ["We report that PrP(106-126) has a low affi nity for lipid membranes under physiological conditions without evidence for membrane disturbances.Membrane insertion and permeabilization only occurs under conditionswhere strong electrostatic interactions operate.", [["lipid membranes", "ANATOMY", 52, 67], ["membrane", "ANATOMY", 120, 128], ["Membrane", "ANATOMY", 142, 150], ["PrP(106-126", "CHEMICAL", 15, 26], ["PrP", "GENE_OR_GENE_PRODUCT", 15, 18], ["lipid membranes", "CELLULAR_COMPONENT", 52, 67], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["Membrane", "CELLULAR_COMPONENT", 142, 150], ["PrP", "TEST", 15, 18], ["lipid membranes", "TREATMENT", 52, 67], ["membrane disturbances", "PROBLEM", 120, 141], ["Membrane insertion", "TREATMENT", 142, 160], ["permeabilization", "TREATMENT", 165, 181], ["without evidence for", "UNCERTAINTY", 99, 119], ["membrane disturbances", "OBSERVATION", 120, 141]]], ["These results show that toxic effects of PrP(106-126) cannot be explained by cell membrane leakage and support the hypothesis that the physiological prion protein, PrPC, mediates PrP(106-126) toxic effects in neuronal cells.", [["cell membrane", "ANATOMY", 77, 90], ["neuronal cells", "ANATOMY", 209, 223], ["PrP(106-126", "CHEMICAL", 41, 52], ["PrP(106-126", "CHEMICAL", 179, 190], ["PrP", "GENE_OR_GENE_PRODUCT", 41, 44], ["cell membrane", "CELLULAR_COMPONENT", 77, 90], ["PrPC", "GENE_OR_GENE_PRODUCT", 164, 168], ["PrP", "GENE_OR_GENE_PRODUCT", 179, 182], ["neuronal cells", "CELL", 209, 223], ["prion protein", "PROTEIN", 149, 162], ["PrPC", "PROTEIN", 164, 168], ["neuronal cells", "CELL_TYPE", 209, 223], ["PrP", "TEST", 41, 44], ["cell membrane leakage", "PROBLEM", 77, 98], ["the hypothesis", "PROBLEM", 111, 125], ["the physiological prion protein", "TEST", 131, 162], ["PrPC", "TEST", 164, 168], ["PrP", "TEST", 179, 182], ["toxic effects in neuronal cells", "PROBLEM", 192, 223], ["toxic", "OBSERVATION_MODIFIER", 24, 29], ["cell membrane leakage", "OBSERVATION", 77, 98], ["neuronal cells", "OBSERVATION", 209, 223]]], ["The devastating effect of amyloidogenic proteins and peptides is still not fully understood.", [["amyloidogenic proteins", "PROTEIN", 26, 48], ["amyloidogenic proteins and peptides", "PROBLEM", 26, 61], ["devastating", "OBSERVATION_MODIFIER", 4, 15], ["amyloidogenic proteins", "OBSERVATION", 26, 48]]], ["Numerous experiments determined many physiological ligands of amyloidogenic proteins.", [["amyloidogenic proteins", "PROTEIN", 62, 84], ["amyloidogenic proteins", "PROBLEM", 62, 84], ["amyloidogenic proteins", "OBSERVATION", 62, 84]]], ["The search for the new molecules binding to amyloids could help to understand the aggregation pathway, cellular toxicity of amyloids or neuroprotective properties of protein ligands.", [["cellular", "ANATOMY", 103, 111], ["toxicity", "DISEASE", 112, 120], ["cellular", "CELL", 103, 111], ["the new molecules binding", "PROBLEM", 15, 40], ["amyloids", "TREATMENT", 44, 52], ["the aggregation pathway", "PROBLEM", 78, 101], ["cellular toxicity of amyloids", "PROBLEM", 103, 132], ["protein ligands", "PROBLEM", 166, 181]]], ["Therefore, it necessitates the development of sensitive analytical methods that enable to clarify details of interactions between amyloidogenic molecules.", [["amyloidogenic molecules", "PROTEIN", 130, 153], ["amyloidogenic molecules", "PROBLEM", 130, 153]]], ["Recent developments show that selective proteolytic excision combined with mass spectrometric peptide mapping (Epitope-Excision-MS) present high potential for the determination of epitope for antigen-epitope mapping and for the identifi cation of antibody paratope sequences.", [["antibody paratope sequences", "DNA", 247, 274], ["selective proteolytic excision", "TREATMENT", 30, 60], ["mass spectrometric peptide mapping", "TREATMENT", 75, 109], ["Epitope-Excision", "TREATMENT", 111, 127], ["antigen-epitope mapping", "TREATMENT", 192, 215], ["the identifi cation of antibody paratope sequences", "TEST", 224, 274], ["selective", "OBSERVATION_MODIFIER", 30, 39], ["proteolytic", "OBSERVATION_MODIFIER", 40, 51], ["excision", "OBSERVATION", 52, 60]]], ["In this work we present a novel affi nity method for protein-peptide interaction studies that enabled identifi cation of the interactions between ), serum amyloid A (SAA) and human cystatin C and the amyloid beta peptide (A anti-cystatin C antibody.", [["serum", "ANATOMY", 149, 154], ["cation", "SIMPLE_CHEMICAL", 111, 117], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["amyloid A", "SIMPLE_CHEMICAL", 155, 164], ["SAA", "GENE_OR_GENE_PRODUCT", 166, 169], ["human", "ORGANISM", 175, 180], ["cystatin C", "GENE_OR_GENE_PRODUCT", 181, 191], ["amyloid beta peptide", "GENE_OR_GENE_PRODUCT", 200, 220], ["A anti-cystatin C antibody", "GENE_OR_GENE_PRODUCT", 222, 248], ["serum amyloid A", "PROTEIN", 149, 164], ["SAA", "PROTEIN", 166, 169], ["human cystatin C", "PROTEIN", 175, 191], ["amyloid beta peptide (A anti-cystatin C antibody", "PROTEIN", 200, 248], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["protein-peptide", "TREATMENT", 53, 68], ["human cystatin C", "TREATMENT", 175, 191], ["the amyloid beta peptide", "TREATMENT", 196, 220], ["A anti-cystatin C antibody", "TREATMENT", 222, 248]]], ["We report here the identifi cation of the molecular interaction, epitope binding sites and primary structure of recognized by SAA and cystatin C fragments.", [["cation", "SIMPLE_CHEMICAL", 28, 34], ["SAA", "GENE_OR_GENE_PRODUCT", 126, 129], ["cystatin C", "GENE_OR_GENE_PRODUCT", 134, 144], ["epitope binding sites", "PROTEIN", 65, 86], ["SAA", "PROTEIN", 126, 129], ["cystatin C fragments", "PROTEIN", 134, 154], ["the molecular interaction", "PROBLEM", 38, 63], ["epitope binding sites", "PROBLEM", 65, 86], ["cystatin C fragments", "PROBLEM", 134, 154]]], ["For the identifi cation of the epitope from A antibody and its paratope binding structure on cystatin C, proteolytic epitope extraction/excision-MS protocols were applied using different proteolytic enzymes.", [["cation", "SIMPLE_CHEMICAL", 17, 23], ["paratope", "SIMPLE_CHEMICAL", 63, 71], ["cystatin C", "SIMPLE_CHEMICAL", 93, 103], ["epitope", "PROTEIN", 31, 38], ["A antibody", "PROTEIN", 44, 54], ["cystatin C", "PROTEIN", 93, 103], ["proteolytic enzymes", "PROTEIN", 187, 206], ["the epitope", "PROBLEM", 27, 38], ["A antibody", "TREATMENT", 44, 54], ["its paratope binding structure", "PROBLEM", 59, 89], ["cystatin C", "TREATMENT", 93, 103], ["proteolytic epitope extraction", "TREATMENT", 105, 135], ["excision", "TREATMENT", 136, 144], ["MS protocols", "TREATMENT", 145, 157], ["different proteolytic enzymes", "TEST", 177, 206]]], ["Our results might be of paramount importance for the development of new inhibitors for aggregation processes of all examined cystatin C ligands.", [["cystatin C ligands", "GENE_OR_GENE_PRODUCT", 125, 143], ["cystatin C ligands", "PROTEIN", 125, 143], ["new inhibitors", "TREATMENT", 68, 82], ["aggregation processes", "PROBLEM", 87, 108], ["cystatin C ligands", "TEST", 125, 143]]], ["The determination of the interacting sites could also be useful in designing new tools for diagnostics in many neurodegenerative disorders.", [["neurodegenerative disorders", "DISEASE", 111, 138], ["many neurodegenerative disorders", "PROBLEM", 106, 138], ["neurodegenerative disorders", "OBSERVATION", 111, 138]]], ["Our studies will allow to speculate whether amyloidogenic molecules association is bona fi de phenomenon or just accident.", [["amyloidogenic molecules", "PROTEIN", 44, 67], ["Our studies", "TEST", 0, 11], ["amyloidogenic molecules", "PROBLEM", 44, 67]]], ["Acknowledgement: University of Gdansk grant BW to Paulina Juszczyk.Structural Studies of Large Fragments of G-Protein Coupled ReceptorsZerbe, Oliver S11-1Structural Studies of Large Fragments of G-Protein Coupled ReceptorsInformatics-based structure design for obtaining hypolipidemic short peptides Ryuji, Kato S11-2Structural Studies of Large Fragments of G-Protein Coupled ReceptorsMembrane Interaction of NPY in the Presence of Negatively Charged and Zwitterionic Phospholipids Zsch\u00f6rnig, Olaf S11-3Structural Studies of Large Fragments of G-Protein Coupled ReceptorsUnintended human exposure to toxic microbial ionophoric peptides Salkinoja-Salonen, Mirja S11-4Structural Studies of Large Fragments of G-Protein Coupled ReceptorsThe synthesis of covalent assemblies of model peptides to study membrane proteins Meijneke, Tania S11-5 S11-1Institute of Organic Chemistry, University of Zurich, SWITZERLANDWe present our structural studies of larger fragment of G-protein coupled receptors.", [["membrane", "ANATOMY", 798, 806], ["NPY", "GENE_OR_GENE_PRODUCT", 409, 412], ["human", "ORGANISM", 582, 587], ["membrane", "CELLULAR_COMPONENT", 798, 806], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 964, 991], ["G-Protein Coupled Receptors", "PROTEIN", 707, 734], ["membrane proteins", "PROTEIN", 798, 815], ["G-protein coupled receptors", "PROTEIN", 964, 991], ["human", "SPECIES", 582, 587], ["human", "SPECIES", 582, 587], ["Structural Studies", "TEST", 67, 85], ["Large Fragments of G-Protein", "PROBLEM", 89, 117], ["Large Fragments of G-Protein", "PROBLEM", 176, 204], ["hypolipidemic short peptides", "TREATMENT", 271, 299], ["Large Fragments of G-Protein", "PROBLEM", 339, 367], ["Zwitterionic Phospholipids Zsch\u00f6rnig", "TREATMENT", 455, 491], ["Olaf S11", "TREATMENT", 493, 501], ["Large Fragments of G-Protein Coupled Receptors", "TREATMENT", 525, 571], ["human exposure", "PROBLEM", 582, 596], ["toxic microbial ionophoric peptides", "TREATMENT", 600, 635], ["Salkinoja", "TREATMENT", 636, 645], ["Salonen", "TREATMENT", 646, 653], ["Mirja S11", "TREATMENT", 655, 664], ["Large Fragments of G-Protein", "TREATMENT", 688, 716], ["The synthesis of covalent assemblies of model peptides", "TREATMENT", 734, 788], ["study membrane proteins", "TEST", 792, 815], ["Meijneke", "TEST", 816, 824], ["Tania", "TEST", 826, 831], ["larger fragment of G-protein coupled receptors", "PROBLEM", 945, 991], ["Large", "OBSERVATION_MODIFIER", 89, 94], ["Fragments", "OBSERVATION", 95, 104], ["Large", "OBSERVATION_MODIFIER", 176, 181], ["Fragments", "OBSERVATION", 182, 191], ["Large", "OBSERVATION_MODIFIER", 339, 344], ["Fragments", "OBSERVATION", 345, 354], ["Large", "OBSERVATION_MODIFIER", 525, 530], ["Fragments", "OBSERVATION", 531, 540], ["Large", "OBSERVATION_MODIFIER", 688, 693], ["Fragments", "OBSERVATION", 694, 703], ["larger", "OBSERVATION_MODIFIER", 945, 951]]], ["One system of interest is the Ste2p receptor, for which fragments containing the 7th TM helix as well as TM1-C1-TM2_E1 have been biosynthetically produced by our collaborators Prof. Naider and Becker.", [["Ste2p receptor", "GENE_OR_GENE_PRODUCT", 30, 44], ["TM1-C1-TM2_E1", "GENE_OR_GENE_PRODUCT", 105, 118], ["Ste2p receptor", "PROTEIN", 30, 44], ["7th TM helix", "PROTEIN", 81, 93], ["TM1", "PROTEIN", 105, 108], ["C1", "PROTEIN", 109, 111], ["TM2_E1", "PROTEIN", 112, 118], ["TM1", "TEST", 105, 108], ["fragments", "OBSERVATION", 56, 65], ["C1", "ANATOMY", 109, 111]]], ["The second system to be presented comprises constructs derived from the Y4 receptor, a GPCR targeted by peptides from the NPY family.", [["Y4 receptor", "GENE_OR_GENE_PRODUCT", 72, 83], ["GPCR", "GENE_OR_GENE_PRODUCT", 87, 91], ["NPY", "GENE_OR_GENE_PRODUCT", 122, 125], ["Y4 receptor", "PROTEIN", 72, 83], ["GPCR", "PROTEIN", 87, 91], ["NPY family", "PROTEIN", 122, 132], ["a GPCR", "TEST", 85, 91]]], ["Herein, we present data on constructs comprising the Nterminal (extracellular) domain and on a construct that contains the Nterminal domain fused to TM1-C1-TM2.", [["extracellular", "ANATOMY", 64, 77], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["Nterminal (extracellular) domain", "PROTEIN", 53, 85], ["Nterminal domain", "PROTEIN", 123, 139], ["TM1", "PROTEIN", 149, 152], ["C1", "PROTEIN", 153, 155], ["TM2", "PROTEIN", 156, 159], ["C1", "ANATOMY", 153, 155], ["TM2", "ANATOMY", 156, 159]]], ["The polypeptides have been expressed in isotopically labelled form in E. Coli.", [["E. Coli.", "SPECIES", 70, 78], ["The polypeptides", "PROBLEM", 0, 16], ["E. Coli.", "OBSERVATION", 70, 78]]], ["Their structures in solution are determined in the presence of phospholipid micelles using high-resolution NMR techniques.", [["phospholipid micelles", "SIMPLE_CHEMICAL", 63, 84], ["phospholipid micelles", "TREATMENT", 63, 84], ["high-resolution NMR techniques", "TREATMENT", 91, 121]]], ["The resonances of both backbone and sidechain resonances have been almost completely assigned using triple-resonance NMR experiments.", [["triple-resonance NMR experiments", "TREATMENT", 100, 132], ["both", "ANATOMY_MODIFIER", 18, 22], ["backbone", "ANATOMY_MODIFIER", 23, 31]]], ["This challenging work needed optimization of procedures in all aspects of the work, e.g. in in labeling procedures but also in the spectroscopic work.Institute of Organic Chemistry, University of Zurich, SWITZERLANDIn particular sample conditions and the detergent had to be extensively optimized.", [["optimization of procedures", "TREATMENT", 29, 55], ["Organic Chemistry", "TEST", 163, 180], ["the detergent", "TREATMENT", 251, 264]]], ["The present data now reveal secondary structure, and details of tertiary structure start to emerge.", [["The present data", "TEST", 0, 16], ["secondary structure", "PROBLEM", 28, 47], ["tertiary structure", "PROBLEM", 64, 82], ["secondary structure", "OBSERVATION", 28, 47]]], ["Progress and problems of the spectroscopy of large GPCR fragments in membrane mimetics will be reviewed.", [["membrane", "ANATOMY", 69, 77], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["GPCR fragments", "PROTEIN", 51, 65], ["the spectroscopy", "TEST", 25, 41], ["large GPCR fragments", "PROBLEM", 45, 65], ["membrane mimetics", "TREATMENT", 69, 86], ["large", "OBSERVATION_MODIFIER", 45, 50], ["GPCR fragments", "OBSERVATION", 51, 65]]], ["Naturally derived peptides with hypolipidemic effects are one of the most ideal biocompatible ingredients for designing preventative functional food for patients suffer from cardiovascular diseases.", [["cardiovascular", "ANATOMY", 174, 188], ["cardiovascular diseases", "DISEASE", 174, 197], ["patients", "ORGANISM", 153, 161], ["cardiovascular", "ANATOMICAL_SYSTEM", 174, 188], ["patients", "SPECIES", 153, 161], ["hypolipidemic effects", "PROBLEM", 32, 53], ["cardiovascular diseases", "PROBLEM", 174, 197], ["hypolipidemic", "OBSERVATION_MODIFIER", 32, 45], ["cardiovascular", "ANATOMY", 174, 188], ["diseases", "OBSERVATION", 189, 197]]], ["One strategy to design hypolipidemic peptide is to increase the affi nity to bile acid, which result in the inhibition of cholesterol absorption in small intestine.", [["small intestine", "ANATOMY", 148, 163], ["bile acid", "CHEMICAL", 77, 86], ["cholesterol", "CHEMICAL", 122, 133], ["bile acid", "CHEMICAL", 77, 86], ["cholesterol", "CHEMICAL", 122, 133], ["affi", "SIMPLE_CHEMICAL", 64, 68], ["bile acid", "SIMPLE_CHEMICAL", 77, 86], ["cholesterol", "SIMPLE_CHEMICAL", 122, 133], ["small intestine", "ORGAN", 148, 163], ["design hypolipidemic peptide", "TREATMENT", 16, 44], ["bile acid", "TEST", 77, 86], ["cholesterol absorption in small intestine", "PROBLEM", 122, 163], ["bile", "ANATOMY", 77, 81], ["cholesterol absorption", "OBSERVATION", 122, 144], ["small intestine", "ANATOMY", 148, 163]]], ["Several peptides had already been reported to suppress cholesterol absorption in vitro and in vivo by having greater binding affi nity to bile acids.", [["cholesterol", "CHEMICAL", 55, 66], ["bile acids", "CHEMICAL", 138, 148], ["cholesterol", "CHEMICAL", 55, 66], ["bile acids", "CHEMICAL", 138, 148], ["cholesterol", "SIMPLE_CHEMICAL", 55, 66], ["affi", "SIMPLE_CHEMICAL", 125, 129], ["bile acids", "SIMPLE_CHEMICAL", 138, 148], ["Several peptides", "PROBLEM", 0, 16], ["cholesterol absorption", "PROBLEM", 55, 77], ["bile", "ANATOMY", 138, 142]]], ["However, classical approaches to screen candidate peptides from some selected natural products require greater time and expense.", [["peptides", "TREATMENT", 50, 58], ["some selected natural products", "TREATMENT", 64, 94], ["greater", "OBSERVATION_MODIFIER", 103, 110]]], ["If we could previously understand the common structural rule among objective peptides, we could concentrate and reduce the expense of screening by searching specifi c products that involve the investigated peptide rules in their proteins.", [["specifi c products", "PROTEIN", 157, 175], ["screening", "TEST", 134, 143], ["searching specifi c products", "TREATMENT", 147, 175]]], ["For this purpose, we combined peptide array technique with bioinformatic methodologies (hierarchical clustering / prediction models) to understand the common physicochemical structural rule hidden in short peptides that strongly binds to bile acid.", [["bile acid", "CHEMICAL", 238, 247], ["bile acid", "CHEMICAL", 238, 247], ["bile acid", "SIMPLE_CHEMICAL", 238, 247], ["peptide array technique", "TREATMENT", 30, 53], ["bioinformatic methodologies", "TEST", 59, 86], ["hierarchical clustering / prediction models", "TREATMENT", 88, 131], ["short peptides", "PROBLEM", 200, 214], ["bile", "ANATOMY", 238, 242]]], ["Both in clustering and prediction, we effectively introduced amino acid indices to understand the common physicochemical properties of short peptides.", [["amino acid", "CHEMICAL", 61, 71], ["amino acid", "CHEMICAL", 61, 71], ["amino acid", "AMINO_ACID", 61, 71], ["amino acid indices", "TREATMENT", 61, 79], ["short peptides", "PROBLEM", 135, 149]]], ["As a result, by extracting the physicochemical rules that discriminates peptides with greater affi nity and no affi nity to bile acid, we succeeded in fi nding novel peptide sequences and rules to design hypolipidemic short peptide ingredients for functional food.S11-4Unintended human exposure to toxic microbial ionophoric peptides Many microbially produced substances are known to affect the functioning of mitochondria.", [["mitochondria", "ANATOMY", 410, 422], ["bile acid", "CHEMICAL", 124, 133], ["bile acid", "CHEMICAL", 124, 133], ["affi", "SIMPLE_CHEMICAL", 111, 115], ["bile acid", "SIMPLE_CHEMICAL", 124, 133], ["human", "ORGANISM", 280, 285], ["mitochondria", "CELLULAR_COMPONENT", 410, 422], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 280, 285], ["bile acid", "TEST", 124, 133], ["hypolipidemic short peptide ingredients", "TREATMENT", 204, 243], ["toxic microbial ionophoric peptides", "TREATMENT", 298, 333], ["toxic", "OBSERVATION_MODIFIER", 298, 303], ["substances", "OBSERVATION", 360, 370]]], ["Unintended human exposure to such substances has received little attention inspite of the potential great infl uence of mitochondrial functioning on health.", [["mitochondrial", "ANATOMY", 120, 133], ["human", "ORGANISM", 11, 16], ["mitochondrial", "CELLULAR_COMPONENT", 120, 133], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["mitochondrial functioning", "OBSERVATION", 120, 145]]], ["Cereulide is a cyclic peptide, 1153 g/mol, causing emetic food poisonings at concentrations of 0.01 to 1 g/g food.", [["Cereulide", "CHEMICAL", 0, 9], ["emetic food poisonings", "DISEASE", 51, 73], ["Cereulide", "CHEMICAL", 0, 9], ["cyclic peptide", "CHEMICAL", 15, 29], ["Cereulide", "SIMPLE_CHEMICAL", 0, 9], ["a cyclic peptide", "TREATMENT", 13, 29]]], ["It is a lipophilic (log Kow > 6) ionophore specifi c to K+, driving electrogenic infl ux of K ions into mitochondria at exposure concentrations of 1 ng/ml.", [["mitochondria", "ANATOMY", 104, 116], ["K", "CHEMICAL", 56, 57], ["K", "CHEMICAL", 92, 93], ["K+", "CHEMICAL", 56, 58], ["K", "CHEMICAL", 92, 93], ["ionophore specifi c", "SIMPLE_CHEMICAL", 33, 52], ["K+", "SIMPLE_CHEMICAL", 56, 58], ["K ions", "SIMPLE_CHEMICAL", 92, 98], ["mitochondria", "CELLULAR_COMPONENT", 104, 116], ["K", "TEST", 56, 57]]], ["This leads to depolarisation of mitochondria in primary cells (porcine pancreatic beta cells, boar spermatozoa, human NK-cells and T-cells) and many cell lines.S11-4Enniatin, a cyclic peptide produced by several species of Fusarium fungi is K+ ionophore like cereulide but about 100 \u00d7 less potent.", [["mitochondria", "ANATOMY", 32, 44], ["primary cells", "ANATOMY", 48, 61], ["pancreatic beta cells", "ANATOMY", 71, 92], ["spermatozoa", "ANATOMY", 99, 110], ["NK-cells", "ANATOMY", 118, 126], ["T-cells", "ANATOMY", 131, 138], ["cell lines", "ANATOMY", 149, 159], ["S11-4Enniatin", "CHEMICAL", 160, 173], ["cyclic peptide", "CHEMICAL", 177, 191], ["K", "CHEMICAL", 241, 242], ["cereulide", "CHEMICAL", 259, 268], ["cyclic peptide", "CHEMICAL", 177, 191], ["K+", "CHEMICAL", 241, 243], ["cereulide", "CHEMICAL", 259, 268], ["mitochondria", "CELLULAR_COMPONENT", 32, 44], ["cells", "CELL", 56, 61], ["porcine", "ORGANISM", 63, 70], ["pancreatic beta cells", "CELL", 71, 92], ["boar", "ORGANISM", 94, 98], ["spermatozoa", "CELL", 99, 110], ["human", "ORGANISM", 112, 117], ["NK-cells", "CELL", 118, 126], ["T-cells", "CELL", 131, 138], ["cell lines", "CELL", 149, 159], ["S11-4Enniatin", "GENE_OR_GENE_PRODUCT", 160, 173], ["cyclic peptide", "SIMPLE_CHEMICAL", 177, 191], ["Fusarium fungi", "ORGANISM", 223, 237], ["K+ ionophore", "SIMPLE_CHEMICAL", 241, 253], ["cereulide", "SIMPLE_CHEMICAL", 259, 268], ["primary cells", "CELL_TYPE", 48, 61], ["porcine pancreatic beta cells", "CELL_TYPE", 63, 92], ["boar spermatozoa", "CELL_TYPE", 94, 110], ["human NK-cells", "CELL_TYPE", 112, 126], ["T-cells", "CELL_TYPE", 131, 138], ["cell lines", "CELL_LINE", 149, 159], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["depolarisation of mitochondria", "PROBLEM", 14, 44], ["primary cells", "PROBLEM", 48, 61], ["porcine pancreatic beta cells", "TEST", 63, 92], ["boar spermatozoa", "TEST", 94, 110], ["many cell lines", "PROBLEM", 144, 159], ["a cyclic peptide", "PROBLEM", 175, 191], ["Fusarium fungi", "PROBLEM", 223, 237], ["primary cells", "OBSERVATION", 48, 61], ["pancreatic", "ANATOMY", 71, 81], ["cell lines", "OBSERVATION", 149, 159], ["Fusarium fungi", "OBSERVATION", 223, 237], ["less potent", "OBSERVATION_MODIFIER", 285, 296]]], ["Enniatin occurs in Finnish grains at concentrations from 0 to up to 50 mg/kg.", [["grains", "ANATOMY", 27, 33], ["Enniatin", "CHEMICAL", 0, 8], ["Enniatin", "CHEMICAL", 0, 8], ["Enniatin", "SIMPLE_CHEMICAL", 0, 8], ["Enniatin", "TREATMENT", 0, 8]]], ["Cereulide producing Bacillus cereus were commonly found in infant food formulas and potatoes purchased from consumer markets.", [["Cereulide", "CHEMICAL", 0, 9], ["Cereulide", "SIMPLE_CHEMICAL", 0, 9], ["Bacillus cereus", "ORGANISM", 20, 35], ["potatoes", "ORGANISM_SUBDIVISION", 84, 92], ["Bacillus cereus", "SPECIES", 20, 35], ["infant", "SPECIES", 59, 65], ["potatoes", "SPECIES", 84, 92], ["Bacillus cereus", "SPECIES", 20, 35], ["potatoes", "SPECIES", 84, 92], ["Bacillus cereus", "PROBLEM", 20, 35], ["Bacillus cereus", "OBSERVATION", 20, 35]]], ["Neither the toxin, nor the producer strains, are inactivated by cooking.", [["the toxin", "TEST", 8, 17]]], ["Producers of cereulide also occurred in indoor materials of buildings that suffered from aged moisture damage, together with Bacillus amyloliquefaciens, highly toxic in cell assays.", [["cell", "ANATOMY", 169, 173], ["cereulide", "CHEMICAL", 13, 22], ["moisture damage", "DISEASE", 94, 109], ["cereulide", "CHEMICAL", 13, 22], ["cereulide", "SIMPLE_CHEMICAL", 13, 22], ["Bacillus amyloliquefaciens", "ORGANISM", 125, 151], ["cell", "CELL", 169, 173], ["Bacillus amyloliquefaciens", "SPECIES", 125, 151], ["Bacillus amyloliquefaciens", "SPECIES", 125, 151], ["moisture damage", "PROBLEM", 94, 109], ["Bacillus amyloliquefaciens", "PROBLEM", 125, 151], ["highly toxic in cell assays", "PROBLEM", 153, 180], ["toxic", "OBSERVATION_MODIFIER", 160, 165]]], ["These contained a novel lipopeptide, 1197 g/ mol, amylosin.", [["amylosin", "CHEMICAL", 50, 58], ["amylosin", "SIMPLE_CHEMICAL", 50, 58], ["a novel lipopeptide", "TREATMENT", 16, 35], ["amylosin", "TREATMENT", 50, 58]]], ["This contains a polyene tail that may anchor the peptide into biological membranes.", [["membranes", "ANATOMY", 73, 82], ["polyene", "CHEMICAL", 16, 23], ["polyene", "CHEMICAL", 16, 23], ["membranes", "CELLULAR_COMPONENT", 73, 82], ["a polyene tail", "TREATMENT", 14, 28], ["polyene tail", "OBSERVATION", 16, 28], ["biological membranes", "OBSERVATION", 62, 82]]], ["It forms cation channels in biological membranes, with selectivity to K+:Na+:Ca2+ of 26:15:3.5.", [["membranes", "ANATOMY", 39, 48], ["K", "CHEMICAL", 70, 71], ["Na", "CHEMICAL", 73, 75], ["Ca2", "CHEMICAL", 77, 80], ["K+", "CHEMICAL", 70, 72], ["Na+", "CHEMICAL", 73, 76], ["Ca2+", "CHEMICAL", 77, 81], ["cation", "SIMPLE_CHEMICAL", 9, 15], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["K+", "SIMPLE_CHEMICAL", 70, 72], ["Na+", "SIMPLE_CHEMICAL", 73, 76], ["Ca2+", "SIMPLE_CHEMICAL", 77, 81], ["K", "TEST", 70, 71], ["Na", "TEST", 73, 75], ["Ca2", "TEST", 77, 80], ["cation channels", "OBSERVATION", 9, 24]]], ["Exposure to 250 ng/ml of amylosin collapsed the mitochondrial membrane potential in somatic cells and spermatozoa.", [["mitochondrial membrane", "ANATOMY", 48, 70], ["somatic cells", "ANATOMY", 84, 97], ["spermatozoa", "ANATOMY", 102, 113], ["amylosin", "CHEMICAL", 25, 33], ["amylosin", "CHEMICAL", 25, 33], ["amylosin", "SIMPLE_CHEMICAL", 25, 33], ["mitochondrial membrane", "CELLULAR_COMPONENT", 48, 70], ["somatic cells", "CELL", 84, 97], ["spermatozoa", "CELL", 102, 113], ["somatic cells", "CELL_TYPE", 84, 97], ["spermatozoa", "CELL_TYPE", 102, 113], ["amylosin", "TREATMENT", 25, 33], ["somatic cells", "PROBLEM", 84, 97], ["spermatozoa", "PROBLEM", 102, 113], ["mitochondrial membrane", "OBSERVATION", 48, 70], ["somatic cells", "OBSERVATION", 84, 97]]], ["Amylosin was produced by several Bacillus species connected to food poisoning.", [["Amylosin", "CHEMICAL", 0, 8], ["food poisoning", "DISEASE", 63, 77], ["Amylosin", "CHEMICAL", 0, 8], ["Amylosin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Amylosin", "TREATMENT", 0, 8], ["several Bacillus species", "PROBLEM", 25, 49], ["Bacillus species", "OBSERVATION", 33, 49]]], ["Mitochondriotoxic peptaibols were also present in water damaged buildings contaminated with Trichoderma harzianum, T. longibrachiatum or Acremonium sp.", [["peptaibols", "CHEMICAL", 18, 28], ["peptaibols", "SIMPLE_CHEMICAL", 18, 28], ["water", "SIMPLE_CHEMICAL", 50, 55], ["Trichoderma harzianum", "ORGANISM", 92, 113], ["T. longibrachiatum", "ORGANISM", 115, 133], ["Acremonium sp", "ORGANISM", 137, 150], ["Trichoderma harzianum", "SPECIES", 92, 113], ["T. longibrachiatum", "SPECIES", 115, 133], ["Trichoderma harzianum", "SPECIES", 92, 113], ["T. longibrachiatum", "SPECIES", 115, 133], ["Mitochondriotoxic peptaibols", "TREATMENT", 0, 28], ["Trichoderma harzianum", "TREATMENT", 92, 113]]], ["Thus human exposure to toxic microbial peptides may occur via indoor air as well as via bacterially contaminated food.S11-5The synthesis of covalent assemblies of model peptides to study membrane proteins Membrane proteins play a major role in health and disease.", [["membrane", "ANATOMY", 187, 195], ["Membrane", "ANATOMY", 205, 213], ["human", "ORGANISM", 5, 10], ["membrane", "CELLULAR_COMPONENT", 187, 195], ["Membrane proteins", "GENE_OR_GENE_PRODUCT", 205, 222], ["membrane proteins", "PROTEIN", 187, 204], ["Membrane proteins", "PROTEIN", 205, 222], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["toxic microbial peptides", "PROBLEM", 23, 47], ["model peptides", "TREATMENT", 163, 177], ["disease", "PROBLEM", 255, 262], ["disease", "OBSERVATION", 255, 262]]], ["Since their structure and function is highly infl uenced by the surrounding lipids, often simple model systems are used to study the general principles of protein-lipid interactions.", [["lipids", "SIMPLE_CHEMICAL", 76, 82], ["lipid", "SIMPLE_CHEMICAL", 163, 168], ["protein-lipid interactions", "TREATMENT", 155, 181], ["function", "OBSERVATION", 26, 34]]], ["Examples of a system in which properties of both peptide and lipids can be systematically varied are the WALP peptides (Ac-GW2(LA)8LW2A-NH2) in vesicles of varying lipidcontent.", [["vesicles", "ANATOMY", 144, 152], ["LA", "CHEMICAL", 127, 129], ["Ac-GW2(LA)8LW2A-NH2", "CHEMICAL", 120, 139], ["lipids", "SIMPLE_CHEMICAL", 61, 67], ["Ac-GW2", "SIMPLE_CHEMICAL", 120, 126], ["vesicles", "CELLULAR_COMPONENT", 144, 152], ["NH2", "PROTEIN", 136, 139], ["both peptide and lipids", "TREATMENT", 44, 67], ["the WALP peptides", "TEST", 101, 118], ["Ac", "TEST", 120, 122], ["varying lipidcontent", "PROBLEM", 156, 176], ["varying lipidcontent", "OBSERVATION", 156, 176]]], ["The well-defi ned \u00e1-helical WALP peptides mimic the features of natural membrane proteins, nicely incorporate in membranes and can be characterized by various biophysical methods (e.g. solid state 2H-NMR).", [["membrane", "ANATOMY", 72, 80], ["membranes", "ANATOMY", 113, 122], ["2H", "CHEMICAL", 197, 199], ["membranes", "CELLULAR_COMPONENT", 113, 122], ["natural membrane proteins", "PROTEIN", 64, 89], ["natural membrane proteins", "PROBLEM", 64, 89], ["natural membrane proteins", "OBSERVATION", 64, 89]]], ["However, most proteins have multiple membrane spanning segments.", [["membrane", "ANATOMY", 37, 45], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["multiple membrane spanning segments", "PROTEIN", 28, 63], ["multiple membrane spanning segments", "PROBLEM", 28, 63], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["membrane", "OBSERVATION_MODIFIER", 37, 45], ["spanning", "OBSERVATION_MODIFIER", 46, 54], ["segments", "OBSERVATION_MODIFIER", 55, 63]]], ["To mimic such systems and to study the effect of oligomerization on peptide-lipid interactions we decided to design WALP dimers and tetramers.", [["lipid", "SIMPLE_CHEMICAL", 76, 81], ["WALP dimers", "PROTEIN", 116, 127], ["tetramers", "PROTEIN", 132, 141], ["oligomerization", "TREATMENT", 49, 64], ["peptide-lipid interactions", "TREATMENT", 68, 94], ["tetramers", "TREATMENT", 132, 141]]], ["Firstly, three cysteine-containing WALP analogs, that can be oxidized to form covalent dimers, were synthesized.", [["cysteine", "CHEMICAL", 15, 23], ["WALP", "CHEMICAL", 35, 39], ["cysteine", "CHEMICAL", 15, 23], ["cysteine", "AMINO_ACID", 15, 23], ["WALP analogs", "SIMPLE_CHEMICAL", 35, 47], ["three cysteine-containing WALP analogs", "TREATMENT", 9, 47], ["covalent dimers", "OBSERVATION", 78, 93]]], ["Several experiments were performed, using SDS-PAGE or HPLC to monitor the dimerization reaction.", [["HPLC", "TEST", 54, 58], ["the dimerization reaction", "PROBLEM", 70, 95]]], ["Secondly we synthesized a tetrameric assembly of the WALP peptide, based on the TASP approach of Mutter and using 'click' chemistry to attach the helices to a scaffold.", [["WALP peptide", "SIMPLE_CHEMICAL", 53, 65], ["the WALP peptide", "TREATMENT", 49, 65], ["'click' chemistry", "TREATMENT", 114, 131]]], ["The scaffold was a cyclic peptide with four alkyne-functionalized lysines.", [["alkyne", "CHEMICAL", 44, 50], ["lysines", "CHEMICAL", 66, 73], ["alkyne-functionalized lysines", "SIMPLE_CHEMICAL", 44, 73], ["a cyclic peptide", "TREATMENT", 17, 33], ["four alkyne-functionalized lysines", "TREATMENT", 39, 73], ["functionalized lysines", "OBSERVATION", 51, 73]]], ["The WALP peptide was equipped with an N-terminal azide and a C-terminal tail to facilitate solubilisation and characterization of the reaction product.", [["N-terminal azide", "CHEMICAL", 38, 54], ["N", "CHEMICAL", 38, 39], ["azide", "CHEMICAL", 49, 54], ["C", "CHEMICAL", 61, 62], ["WALP peptide", "SIMPLE_CHEMICAL", 4, 16], ["azide", "SIMPLE_CHEMICAL", 49, 54], ["C-terminal tail", "PROTEIN", 61, 76], ["The WALP peptide", "TEST", 0, 16], ["an N-terminal azide", "TREATMENT", 35, 54], ["a C-terminal tail", "TREATMENT", 59, 76], ["the reaction product", "PROBLEM", 130, 150]]], ["A tetramer (MW=14 kDa) was obtained, as shown by SDS-PAGE, GPC and MALDI.", [["A tetramer (MW", "TEST", 0, 14], ["SDS", "TEST", 49, 52], ["GPC", "TEST", 59, 62], ["MALDI", "PROBLEM", 67, 72]]], ["The properties of the dimers and tetramers will be tested in a membrane environment (e.g. secondary structure and mode of incorporation).", [["membrane", "ANATOMY", 63, 71], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["tetramers", "PROTEIN", 33, 42], ["the dimers and tetramers", "TREATMENT", 18, 42], ["a membrane environment", "TREATMENT", 61, 83]]], ["Next their interactions with lipids will be compared to those of monomers (e.g. effi ciency of lipid fl ip-fl op and lipid chain order) The increasing emergence of multidrug-resistant microbes has urgently required the discovery of new antibiotics with a new mode of action, and naturally occurring antimicrobial peptides (AMPs), which are produced by almost all forms of life, represent promising candidates.", [["lipids", "SIMPLE_CHEMICAL", 29, 35], ["lipids", "TREATMENT", 29, 35], ["multidrug-resistant microbes", "TREATMENT", 164, 192], ["new antibiotics", "TREATMENT", 232, 247], ["antimicrobial peptides", "TREATMENT", 299, 321], ["increasing", "OBSERVATION_MODIFIER", 140, 150], ["new", "OBSERVATION_MODIFIER", 232, 235]]], ["There is compelling evidence that unlike conventional antibiotics, most AMPs interact and increase the permeability of the bacterial membrane as part of their killing mechanism.", [["membrane", "ANATOMY", 133, 141], ["AMPs", "GENE_OR_GENE_PRODUCT", 72, 76], ["bacterial membrane", "CELLULAR_COMPONENT", 123, 141], ["conventional antibiotics", "TREATMENT", 41, 65], ["the bacterial membrane", "PROBLEM", 119, 141], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["permeability", "OBSERVATION_MODIFIER", 103, 115], ["bacterial membrane", "OBSERVATION", 123, 141]]], ["However, before reaching it, they need to cross their cell wall that, in Gram-negative bacteria, is surrounded by the lipopolysaccharide (LPS)-outer membrane, which forms a very effi cient barrier against a variety of hydrophilic and hydrophobic molecules.", [["cell wall", "ANATOMY", 54, 63], ["outer membrane", "ANATOMY", 143, 157], ["lipopolysaccharide", "CHEMICAL", 118, 136], ["LPS", "CHEMICAL", 138, 141], ["cell wall", "TISSUE", 54, 63], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 118, 136], ["LPS", "SIMPLE_CHEMICAL", 138, 141], ["outer membrane", "CELLULAR_COMPONENT", 143, 157], ["hydrophilic and hydrophobic molecules", "PROTEIN", 218, 255], ["Gram-negative bacteria", "PROBLEM", 73, 95], ["hydrophilic and hydrophobic molecules", "PROBLEM", 218, 255], ["negative bacteria", "OBSERVATION_MODIFIER", 78, 95], ["outer membrane", "ANATOMY", 143, 157], ["hydrophobic molecules", "OBSERVATION", 234, 255]]], ["LPS also possesses infl ammatory properties which can result in a fatal phenomenon known as septic shock.", [["LPS", "CHEMICAL", 0, 3], ["septic shock", "DISEASE", 92, 104], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["LPS", "TEST", 0, 3], ["a fatal phenomenon", "PROBLEM", 64, 82], ["septic shock", "PROBLEM", 92, 104], ["fatal", "OBSERVATION_MODIFIER", 66, 71], ["septic shock", "OBSERVATION", 92, 104]]], ["Therefore, the ability of a peptide to display both antimicrobial and anti-endotoxin activities makes it an attractive compound for therapeutic application.", [["antimicrobial and anti-endotoxin activities", "TREATMENT", 52, 95], ["therapeutic application", "TREATMENT", 132, 155]]], ["In Amphibia, temporins are among the shortest (10 to 14 residues) AMPs, with up to ten isoforms within the same specimen.", [["specimen", "ANATOMY", 112, 120], ["temporins", "GENE_OR_GENE_PRODUCT", 13, 22], ["AMPs", "GENE_OR_GENE_PRODUCT", 66, 70], ["AMPs", "TEST", 66, 70]]], ["Recently, we have shown that some of the temporins have a synergistic effect in killing of bacteria, suggesting an important strategy to overcome bacterial resistance imposed by the LPS layer.", [["LPS", "CHEMICAL", 182, 185], ["temporins", "GENE_OR_GENE_PRODUCT", 41, 50], ["the temporins", "PROBLEM", 37, 50], ["bacteria", "PROBLEM", 91, 99], ["bacterial resistance", "PROBLEM", 146, 166], ["bacterial resistance", "OBSERVATION", 146, 166], ["LPS layer", "OBSERVATION_MODIFIER", 182, 191]]], ["Here we show that this effect is highly dependent on the type of LPS composing the bacterial outer layer.", [["outer layer", "ANATOMY", 93, 104], ["LPS", "CHEMICAL", 65, 68], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["LPS", "TREATMENT", 65, 68], ["highly", "OBSERVATION_MODIFIER", 33, 39], ["dependent", "OBSERVATION_MODIFIER", 40, 49], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["outer", "OBSERVATION_MODIFIER", 93, 98], ["layer", "OBSERVATION_MODIFIER", 99, 104]]], ["In addition, we show that the same temporins synergize in neutralizing the endotoxin effects of LPS, by inhibition of TNF-release (considered to be a primary mediator of endotoxemia) from macrophages stimulated with LPS from various species of Escherichia coli.", [["macrophages", "ANATOMY", 188, 199], ["LPS", "CHEMICAL", 96, 99], ["endotoxemia", "DISEASE", 170, 181], ["LPS", "CHEMICAL", 216, 219], ["temporins", "CHEMICAL", 35, 44], ["temporins", "SIMPLE_CHEMICAL", 35, 44], ["LPS", "SIMPLE_CHEMICAL", 96, 99], ["TNF", "GENE_OR_GENE_PRODUCT", 118, 121], ["macrophages", "CELL", 188, 199], ["LPS", "SIMPLE_CHEMICAL", 216, 219], ["Escherichia coli", "ORGANISM", 244, 260], ["TNF", "PROTEIN", 118, 121], ["macrophages", "CELL_TYPE", 188, 199], ["Escherichia coli", "SPECIES", 244, 260], ["Escherichia coli", "SPECIES", 244, 260], ["the same temporins synergize", "PROBLEM", 26, 54], ["LPS", "TREATMENT", 96, 99], ["TNF", "TEST", 118, 121], ["endotoxemia", "PROBLEM", 170, 181], ["macrophages", "PROBLEM", 188, 199], ["LPS", "TREATMENT", 216, 219], ["Escherichia coli", "PROBLEM", 244, 260], ["endotoxemia", "OBSERVATION", 170, 181], ["Escherichia coli", "OBSERVATION", 244, 260]]], ["Furthermore, we show the potential mechanism of this synergism by means of spectroscopic and thermodynamic studies.", [["this synergism", "PROBLEM", 48, 62], ["spectroscopic and thermodynamic studies", "TEST", 75, 114]]], ["Besides improving our knowledge on the peptide-LPS interaction, such studies should contribute to the development of new peptide-based anti-infective and/or antisepsis therapeutics.Title Abs NoSynergism Between Temporins in Killing of Gram-negative bacteria and in Neutralizing Lipopolysaccharide-Activation of Macrophages Mangoni, Maria Luisa S12-1Title Abs NoBiochemical characterization and strong in vivo activity of a novel antimicrobial peptide specifi c for Gramnegative bacteria Pini, Alessandro S12-2Title Abs NoSynergistic pore-formation in lipid membranes by the antimicrobial peptides PGLa and magainin 2 studied with solid-state NMR Strandberg, Erik S12-3Title Abs NoAntimicrobial peptides mode of action through spectrocopic techniques and molecular simulation Jean-Francois, Frantz S12-4Title Abs NoDesign of highly active and protease resistant antibacterial peptides as well as identifi cation of their bacterial targets.", [["lipid membranes", "ANATOMY", 551, 566], ["LPS", "CHEMICAL", 47, 50], ["Lipopolysaccharide", "CHEMICAL", 278, 296], ["PGLa", "CHEMICAL", 597, 601], ["LPS", "SIMPLE_CHEMICAL", 47, 50], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 278, 296], ["lipid membranes", "CELLULAR_COMPONENT", 551, 566], ["PGLa", "SIMPLE_CHEMICAL", 597, 601], ["magainin 2", "SIMPLE_CHEMICAL", 606, 616], ["Strandberg", "SIMPLE_CHEMICAL", 646, 656], ["cation", "SIMPLE_CHEMICAL", 904, 910], ["such studies", "TEST", 64, 76], ["new peptide", "PROBLEM", 117, 128], ["based anti-infective", "TREATMENT", 129, 149], ["antisepsis therapeutics", "TREATMENT", 157, 180], ["Temporins", "TEST", 211, 220], ["Gram", "TEST", 235, 239], ["bacteria", "PROBLEM", 249, 257], ["Neutralizing Lipopolysaccharide", "TEST", 265, 296], ["Macrophages", "PROBLEM", 311, 322], ["NoBiochemical characterization", "TEST", 359, 389], ["a novel antimicrobial peptide", "TREATMENT", 421, 450], ["Gramnegative bacteria", "PROBLEM", 465, 486], ["Pini", "TEST", 487, 491], ["Alessandro", "TEST", 493, 503], ["2Title Abs NoSynergistic pore-formation in lipid membranes", "TREATMENT", 508, 566], ["the antimicrobial peptides PGLa", "TREATMENT", 570, 601], ["magainin", "TREATMENT", 606, 614], ["NMR", "TEST", 642, 645], ["Strandberg", "TEST", 646, 656], ["Erik", "TEST", 658, 662], ["spectrocopic techniques", "TEST", 726, 749], ["protease resistant antibacterial peptides", "TREATMENT", 842, 883], ["negative bacteria", "OBSERVATION_MODIFIER", 240, 257]]], ["The branched peptide M6 was characterized for its activity against a number of bacteria showing a strong specifi city for Gram negative species.", [["Gram negative species", "PROTEIN", 122, 143], ["bacteria", "PROBLEM", 79, 87], ["Gram negative species", "PROBLEM", 122, 143], ["branched", "OBSERVATION_MODIFIER", 4, 12], ["bacteria", "OBSERVATION", 79, 87], ["negative species", "OBSERVATION", 127, 143]]], ["The peptide resulted particularly active against Escherichia coli, Pseudomonas Aeruginosa, Klebsiella pneumoniae and some other enterobacteriacee, including many multidrug resistant isolates.", [["enterobacteriacee", "CHEMICAL", 128, 145], ["Escherichia coli", "ORGANISM", 49, 65], ["Pseudomonas Aeruginosa", "ORGANISM", 67, 89], ["Klebsiella pneumoniae", "ORGANISM", 91, 112], ["enterobacteriacee", "CANCER", 128, 145], ["Escherichia coli", "SPECIES", 49, 65], ["Pseudomonas Aeruginosa", "SPECIES", 67, 89], ["Klebsiella pneumoniae", "SPECIES", 91, 112], ["Escherichia coli", "SPECIES", 49, 65], ["Pseudomonas Aeruginosa", "SPECIES", 67, 89], ["Klebsiella pneumoniae", "SPECIES", 91, 112], ["The peptide", "TEST", 0, 11], ["Escherichia coli", "PROBLEM", 49, 65], ["Pseudomonas Aeruginosa", "PROBLEM", 67, 89], ["Klebsiella pneumoniae", "PROBLEM", 91, 112], ["some other enterobacteriacee", "PROBLEM", 117, 145], ["many multidrug resistant isolates", "PROBLEM", 157, 190], ["Pseudomonas Aeruginosa", "OBSERVATION", 67, 89], ["Klebsiella pneumoniae", "OBSERVATION", 91, 112], ["multidrug resistant isolates", "OBSERVATION", 162, 190]]], ["M6 showed a poor toxicity for eukaryotic cells, it bound LPS and DNA and it did not produce appreciable haemolysis even upon prolonged incubation.", [["cells", "ANATOMY", 41, 46], ["toxicity", "DISEASE", 17, 25], ["haemolysis", "DISEASE", 104, 114], ["cells", "CELL", 41, 46], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["eukaryotic cells", "CELL_TYPE", 30, 46], ["a poor toxicity", "PROBLEM", 10, 25], ["eukaryotic cells", "PROBLEM", 30, 46], ["DNA", "PROBLEM", 65, 68], ["appreciable haemolysis", "PROBLEM", 92, 114], ["prolonged incubation", "TREATMENT", 125, 145], ["poor toxicity", "OBSERVATION", 12, 25], ["eukaryotic cells", "OBSERVATION", 30, 46], ["haemolysis", "OBSERVATION", 104, 114]]], ["We also evaluated M6 acute toxicity (LD50 around 125 mg/Kg for i.p. administration) and we demonstrated that it is not immunogenic upon repeated injections in animals (Pini et al., 2007, J Pept Sci) .", [["toxicity", "DISEASE", 27, 35], ["acute toxicity", "PROBLEM", 21, 35], ["immunogenic", "PROBLEM", 119, 130], ["repeated injections", "TREATMENT", 136, 155]]], ["The peptide was also analysed for its secondary structure by Nuclear Magnetic Resonance in the presence of SDS micelles that mimic negatively charged bacterial membranes.", [["membranes", "ANATOMY", 160, 169], ["SDS", "CHEMICAL", 107, 110], ["SDS micelles", "SIMPLE_CHEMICAL", 107, 119], ["bacterial membranes", "CELLULAR_COMPONENT", 150, 169], ["The peptide", "TREATMENT", 0, 11], ["Nuclear Magnetic Resonance", "TEST", 61, 87], ["SDS micelles", "PROBLEM", 107, 119], ["bacterial membranes", "PROBLEM", 150, 169], ["bacterial membranes", "OBSERVATION", 150, 169]]], ["M6 folds as an -helix interacting with membranes essentially with a side of the helix.", [["membranes", "ANATOMY", 39, 48], ["membranes", "CELLULAR_COMPONENT", 39, 48], ["M6", "PROTEIN", 0, 2]]], ["We also report results on M6 in vivo activity in models of sepsis induced by E. coli and P. aeruginosa.", [["sepsis", "DISEASE", 59, 65], ["E. coli", "ORGANISM", 77, 84], ["P. aeruginosa", "ORGANISM", 89, 102], ["E. coli", "SPECIES", 77, 84], ["P. aeruginosa", "SPECIES", 89, 102], ["E. coli", "SPECIES", 77, 84], ["P. aeruginosa", "SPECIES", 89, 102], ["sepsis", "PROBLEM", 59, 65], ["E. coli", "PROBLEM", 77, 84], ["P. aeruginosa", "PROBLEM", 89, 102], ["sepsis", "OBSERVATION", 59, 65], ["E. coli", "OBSERVATION", 77, 84]]], ["These experiments, carried out with i.p. administration of M6, showed that the peptide is able to prevent animal death and to neutralize sepsis symptoms when used in doses comparable to traditional antibiotics and compatible with a clinical use.", [["death", "DISEASE", 113, 118], ["sepsis", "DISEASE", 137, 143], ["These experiments", "TEST", 0, 17], ["animal death", "PROBLEM", 106, 118], ["neutralize sepsis symptoms", "PROBLEM", 126, 152], ["traditional antibiotics", "TREATMENT", 186, 209]]], ["These results make the branched M6 peptide a strong candidate for the development of a new antibacterial drug.S12-3Synergistic pore-formation in lipid membranes by the antimicrobial peptides PGLa and magainin 2 studied with solid-state NMR Strandberg, Erik; Tremouilhac, Pierre; Wadhwani, Parvesh; Ulrich, Anne S.Karlsruhe Institute of Technology, GERMANYA solid-state NMR method has been used to study the orientation in a lipid membrane of the cationic -helical antimicrobial peptides PGLa and magainin 2 (MAG).", [["lipid membranes", "ANATOMY", 145, 160], ["lipid membrane", "ANATOMY", 424, 438], ["magainin 2", "CHEMICAL", 496, 506], ["magainin 2", "CHEMICAL", 200, 210], ["lipid membranes", "CELLULAR_COMPONENT", 145, 160], ["PGLa", "SIMPLE_CHEMICAL", 191, 195], ["magainin 2", "GENE_OR_GENE_PRODUCT", 200, 210], ["lipid membrane", "CELLULAR_COMPONENT", 424, 438], ["PGLa", "SIMPLE_CHEMICAL", 487, 491], ["magainin 2", "GENE_OR_GENE_PRODUCT", 496, 506], ["MAG", "GENE_OR_GENE_PRODUCT", 508, 511], ["S12", "PROTEIN", 110, 113], ["MAG", "PROTEIN", 508, 511], ["a new antibacterial drug", "TREATMENT", 85, 109], ["3Synergistic pore-formation in lipid membranes", "TREATMENT", 114, 160], ["the antimicrobial peptides", "TREATMENT", 164, 190], ["magainin", "TREATMENT", 200, 208], ["the cationic", "TREATMENT", 442, 454], ["helical antimicrobial peptides PGLa", "TREATMENT", 456, 491], ["magainin 2 (MAG)", "TREATMENT", 496, 512], ["new", "OBSERVATION_MODIFIER", 87, 90], ["antibacterial drug", "OBSERVATION", 91, 109], ["3Synergistic pore", "OBSERVATION_MODIFIER", 114, 131], ["lipid membranes", "OBSERVATION", 145, 160]]], ["These peptides, found in the skin of the African frog Xenopus laevis, have broad spectrum antimicrobial activity.", [["skin", "ANATOMY", 29, 33], ["skin", "ORGAN", 29, 33], ["frog", "ORGANISM", 49, 53], ["Xenopus laevis", "ORGANISM", 54, 68], ["frog", "SPECIES", 49, 53], ["Xenopus laevis", "SPECIES", 54, 68], ["African frog", "SPECIES", 41, 53], ["Xenopus laevis", "SPECIES", 54, 68], ["These peptides", "TEST", 0, 14], ["broad spectrum antimicrobial activity", "TREATMENT", 75, 112], ["skin", "ANATOMY", 29, 33], ["Xenopus laevis", "OBSERVATION", 54, 68], ["broad spectrum", "OBSERVATION_MODIFIER", 75, 89], ["antimicrobial activity", "OBSERVATION", 90, 112]]], ["It has been observed that the activity is synergistically enhanced in mixtures of both peptides, and the formation of PGLa/MAG heterodimers has been proposed.", [["PGLa", "GENE_OR_GENE_PRODUCT", 118, 122], ["MAG", "GENE_OR_GENE_PRODUCT", 123, 126], ["PGLa", "PROTEIN", 118, 122], ["MAG heterodimers", "PROTEIN", 123, 139], ["PGLa/MAG heterodimers", "TREATMENT", 118, 139], ["activity", "OBSERVATION_MODIFIER", 30, 38], ["synergistically", "OBSERVATION_MODIFIER", 42, 57], ["enhanced", "OBSERVATION_MODIFIER", 58, 66]]], ["Using solid-state 2 H-NMR on 3,3,3-2 H-alanine labeled PGLa and MAG, the orientation of the peptides in a lipid membrane was determined with high accuracy.", [["lipid membrane", "ANATOMY", 106, 120], ["3,3,3-2", "CHEMICAL", 29, 36], ["H-alanine", "CHEMICAL", 37, 46], ["PGLa", "CHEMICAL", 55, 59], ["H", "CHEMICAL", 20, 21], ["H-alanine", "CHEMICAL", 37, 46], ["PGLa", "CHEMICAL", 55, 59], ["3,3,3-2", "SIMPLE_CHEMICAL", 29, 36], ["H-alanine", "SIMPLE_CHEMICAL", 37, 46], ["PGLa", "SIMPLE_CHEMICAL", 55, 59], ["MAG", "GENE_OR_GENE_PRODUCT", 64, 67], ["lipid membrane", "CELLULAR_COMPONENT", 106, 120], ["PGLa", "PROTEIN", 55, 59], ["MAG", "PROTEIN", 64, 67], ["H-alanine labeled PGLa", "TREATMENT", 37, 59], ["MAG", "TREATMENT", 64, 67]]], ["We fi nd that each peptide alone binds fl at to the membrane surface at low concentration.", [["membrane surface", "ANATOMY", 52, 68], ["membrane surface", "CELLULAR_COMPONENT", 52, 68], ["fl", "PROTEIN", 39, 41], ["low concentration", "OBSERVATION_MODIFIER", 72, 89]]], ["For PGLa at higher concentration a somewhat more tilted orientation is found, which is attributed to homodimer formation, but the tilt is not large enough to let the peptide span the lipid bilayer.", [["lipid bilayer", "ANATOMY", 183, 196], ["PGLa", "CHEMICAL", 4, 8], ["PGLa", "SIMPLE_CHEMICAL", 4, 8], ["lipid bilayer", "CELLULAR_COMPONENT", 183, 196], ["PGLa", "PROTEIN", 4, 8], ["PGLa", "TREATMENT", 4, 8], ["homodimer formation", "PROBLEM", 101, 120], ["more tilted", "OBSERVATION_MODIFIER", 44, 55], ["attributed to", "UNCERTAINTY", 87, 100], ["homodimer formation", "OBSERVATION", 101, 120]]], ["However, in a PGLa/MAG (1:1) mixture both peptides obtain a more upright orientation, spanning the membrane.", [["membrane", "ANATOMY", 99, 107], ["PGLa", "CHEMICAL", 14, 18], ["PGLa", "SIMPLE_CHEMICAL", 14, 18], ["MAG", "GENE_OR_GENE_PRODUCT", 19, 22], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["PGLa/MAG (1:1) mixture", "CELL_LINE", 14, 36], ["a PGLa/MAG", "TREATMENT", 12, 22]]], ["This suggests that PGLa/MAG heterodimers form stable pores through the membrane, which can explain the synergistic activity.", [["membrane", "ANATOMY", 71, 79], ["PGLa", "GENE_OR_GENE_PRODUCT", 19, 23], ["MAG", "GENE_OR_GENE_PRODUCT", 24, 27], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["PGLa", "PROTEIN", 19, 23], ["MAG heterodimers", "PROTEIN", 24, 40], ["PGLa/MAG heterodimers", "TREATMENT", 19, 40], ["stable", "OBSERVATION_MODIFIER", 46, 52], ["synergistic activity", "OBSERVATION", 103, 123]]], ["The antimicrobial peptide Cateslytin (bCGA-344-RSMRLSFRARGYGF R-358) is a fi ve-positively charged arginin rich peptide known to inhibit the release of catecholamine in chromaffi n granules.", [["chromaffi n granules", "ANATOMY", 169, 189], ["Cateslytin", "CHEMICAL", 26, 36], ["bCGA-344-RSMRLSFRARGYGF R-358", "CHEMICAL", 38, 67], ["catecholamine", "CHEMICAL", 152, 165], ["Cateslytin", "CHEMICAL", 26, 36], ["bCGA-344-RSMRLSFRARGYGF R-358", "CHEMICAL", 38, 67], ["arginin", "CHEMICAL", 99, 106], ["catecholamine", "CHEMICAL", 152, 165], ["Cateslytin", "SIMPLE_CHEMICAL", 26, 36], ["bCGA", "SIMPLE_CHEMICAL", 38, 42], ["fi ve-positively charged arginin rich peptide", "SIMPLE_CHEMICAL", 74, 119], ["catecholamine", "SIMPLE_CHEMICAL", 152, 165], ["granules", "ORGANISM_SUBSTANCE", 181, 189], ["The antimicrobial peptide Cateslytin", "TEST", 0, 36], ["bCGA", "TEST", 38, 42], ["catecholamine in chromaffi n granules", "PROBLEM", 152, 189], ["granules", "OBSERVATION", 181, 189]]], ["Although it is able to rapidly cross the bacterial membrane and stop the bacterial growth, the mechanism of action has not been studied yet.", [["membrane", "ANATOMY", 51, 59], ["bacterial membrane", "CELLULAR_COMPONENT", 41, 59], ["the bacterial growth", "PROBLEM", 69, 89], ["bacterial membrane", "OBSERVATION", 41, 59], ["bacterial growth", "OBSERVATION", 73, 89]]], ["In order to better understand both targeting and selectivity of this peptide towards microorganisms, model membranes with neutral or negative global net charge have been chosen to respectively mimic bacterial or mammalian membranes.", [["membranes", "ANATOMY", 107, 116], ["membranes", "ANATOMY", 222, 231], ["membranes", "CELLULAR_COMPONENT", 107, 116], ["mammalian membranes", "CELLULAR_COMPONENT", 212, 231], ["neutral or negative global net charge", "PROBLEM", 122, 159], ["bacterial or mammalian membranes", "PROBLEM", 199, 231], ["net charge", "OBSERVATION", 149, 159], ["mammalian membranes", "OBSERVATION", 212, 231]]], ["Structural studies have been performed using polarised ATR-FTIR, circular dichro\u00efsm and high resolution NMR.", [["Structural studies", "TEST", 0, 18], ["polarised ATR", "TEST", 45, 58], ["circular dichro\u00efsm", "PROBLEM", 65, 83], ["high resolution", "OBSERVATION_MODIFIER", 88, 103]]], ["Membrane dynamics has been followed using deuterium labelled lipids and solid state NMR.", [["Membrane", "ANATOMY", 0, 8], ["deuterium", "CHEMICAL", 42, 51], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["deuterium", "SIMPLE_CHEMICAL", 42, 51], ["lipids", "SIMPLE_CHEMICAL", 61, 67], ["Membrane dynamics", "TEST", 0, 17]]], ["Patch clamp experiments were also performed on lipid vesicles to measure channel conductivity.", [["lipid vesicles", "ANATOMY", 47, 61], ["Patch clamp experiments", "TREATMENT", 0, 23], ["lipid vesicles", "TREATMENT", 47, 61], ["channel conductivity", "OBSERVATION", 73, 93]]], ["All-atom molecular dynamics on hydrated peptide-lipid membrane systems was also used to assess the interaction from the atomic level.", [["hydrated peptide", "TREATMENT", 31, 47], ["lipid membrane systems", "TREATMENT", 48, 70]]], ["Main results from this interdisciplinary approach are three-fold. i) Electric current passages through membranes demonstrate permeation akin to pore formation. ii) Peptide-induced formation of rigid domains mainly made of negatively charged lipids is found. iii) Peptide antiparallel -sheets are observed preferentially with negatively charged lipids.", [["membranes", "ANATOMY", 103, 112], ["pore", "ANATOMY", 144, 148], ["membranes", "CELLULAR_COMPONENT", 103, 112], ["pore", "CELLULAR_COMPONENT", 144, 148], ["lipids", "SIMPLE_CHEMICAL", 344, 350], ["rigid domains", "PROTEIN", 193, 206], ["this interdisciplinary approach", "TREATMENT", 18, 49], ["Electric current passages through membranes", "TREATMENT", 69, 112], ["Peptide", "TREATMENT", 164, 171], ["rigid domains", "PROBLEM", 193, 206], ["negatively charged lipids", "PROBLEM", 222, 247], ["Peptide antiparallel -sheets", "TREATMENT", 263, 291], ["negatively charged lipids", "TREATMENT", 325, 350], ["permeation akin", "OBSERVATION", 125, 140], ["pore formation", "OBSERVATION", 144, 158], ["rigid domains", "OBSERVATION", 193, 206]]], ["The general picture leads to the proposal that membrane destabilization/permeation is promoted by rigid domains stabilised by peptide -sheets.S12-5Design of highly active and protease resistant antibacterial peptides as well as identifi cation of their bacterial targets.", [["membrane", "ANATOMY", 47, 55], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["S12", "PROTEIN", 142, 145], ["membrane destabilization/permeation", "TREATMENT", 47, 82], ["protease resistant antibacterial peptides", "TREATMENT", 175, 216], ["their bacterial targets", "TREATMENT", 247, 270], ["highly", "OBSERVATION_MODIFIER", 157, 163], ["active", "OBSERVATION", 164, 170], ["antibacterial peptides", "OBSERVATION", 194, 216], ["bacterial targets", "OBSERVATION", 253, 270]]], ["The incidence of serious bacterial and fungal infections is increasing despite remarkable advances in antibiotic therapy.", [["bacterial and fungal infections", "DISEASE", 25, 56], ["serious bacterial and fungal infections", "PROBLEM", 17, 56], ["antibiotic therapy", "TREATMENT", 102, 120], ["serious", "OBSERVATION_MODIFIER", 17, 24], ["bacterial", "OBSERVATION_MODIFIER", 25, 34], ["fungal", "OBSERVATION_MODIFIER", 39, 45], ["infections", "OBSERVATION", 46, 56], ["antibiotic therapy", "OBSERVATION", 102, 120]]], ["At a time of the rapid emergence of drug-resistant bacterial strains, there is an urgent need to develop new antimicrobial compounds with novel modes of action.", [["drug-resistant bacterial strains", "PROBLEM", 36, 68], ["new antimicrobial compounds", "PROBLEM", 105, 132], ["bacterial strains", "OBSERVATION", 51, 68], ["new", "OBSERVATION_MODIFIER", 105, 108], ["antimicrobial compounds", "OBSERVATION", 109, 132]]], ["Thus antimicrobial peptides (AMPs) as part of the innate immune system appear very promising.", [["antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 5, 27], ["AMPs", "GENE_OR_GENE_PRODUCT", 29, 33], ["antimicrobial peptides (AMPs)", "TREATMENT", 5, 34], ["the innate immune system", "TREATMENT", 46, 70]]], ["Among these proline-rich antibacterial peptides are potential therapeutic molecules as they act stereospecifi cally on bacterial targets by a bacteriostatic rather than a lytic process.S12-5Here, we describe the design of novel peptidomimetics to (i) obtain superior antimicrobial activities against pathogenic, multi-resistant Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium, Pseudomonas aeruginosa), (ii) increase the resistance against proteases and peptidases, and (iii) reduce the eukaryotic cell toxicity.", [["cell", "ANATOMY", 537, 541], ["proline", "CHEMICAL", 12, 19], ["toxicity", "DISEASE", 542, 550], ["proline", "CHEMICAL", 12, 19], ["Escherichia coli", "ORGANISM", 352, 368], ["Klebsiella pneumoniae", "ORGANISM", 370, 391], ["Salmonella typhimurium", "ORGANISM", 393, 415], ["Pseudomonas aeruginosa", "ORGANISM", 417, 439], ["cell", "CELL", 537, 541], ["proteases", "PROTEIN", 479, 488], ["peptidases", "PROTEIN", 493, 503], ["Escherichia coli", "SPECIES", 352, 368], ["Klebsiella pneumoniae", "SPECIES", 370, 391], ["Salmonella typhimurium", "SPECIES", 393, 415], ["Pseudomonas aeruginosa", "SPECIES", 417, 439], ["Escherichia coli", "SPECIES", 352, 368], ["Klebsiella pneumoniae", "SPECIES", 370, 391], ["Salmonella typhimurium", "SPECIES", 393, 415], ["Pseudomonas aeruginosa", "SPECIES", 417, 439], ["these proline-rich antibacterial peptides", "TREATMENT", 6, 47], ["potential therapeutic molecules", "PROBLEM", 52, 83], ["a lytic process", "PROBLEM", 169, 184], ["novel peptidomimetics", "TREATMENT", 222, 243], ["superior antimicrobial activities", "TEST", 258, 291], ["pathogenic", "PROBLEM", 300, 310], ["multi-resistant Gram-negative bacteria", "PROBLEM", 312, 350], ["Escherichia coli", "PROBLEM", 352, 368], ["Klebsiella pneumoniae", "PROBLEM", 370, 391], ["Salmonella typhimurium", "PROBLEM", 393, 415], ["Pseudomonas aeruginosa", "PROBLEM", 417, 439], ["the resistance against proteases", "PROBLEM", 456, 488], ["peptidases", "PROBLEM", 493, 503], ["the eukaryotic cell toxicity", "PROBLEM", 522, 550], ["lytic", "OBSERVATION", 171, 176], ["negative bacteria", "OBSERVATION", 333, 350], ["Escherichia coli", "OBSERVATION", 352, 368], ["eukaryotic cell toxicity", "OBSERVATION", 526, 550]]], ["The best peptide derivatives had minimal inhibitory concentrations (MIC) in the ng/mL range against several Gram-negative bacteria.", [["Gram", "GENE_OR_GENE_PRODUCT", 108, 112], ["The best peptide derivatives", "TREATMENT", 0, 28], ["minimal inhibitory concentrations", "PROBLEM", 33, 66], ["several Gram-negative bacteria", "PROBLEM", 100, 130], ["ng", "ANATOMY", 80, 82], ["negative bacteria", "OBSERVATION", 113, 130]]], ["Interestingly, the MIC-values were independent of antibiotic resistances indicating a novel mode of action.", [["antibiotic resistances", "TREATMENT", 50, 72], ["antibiotic resistances", "OBSERVATION", 50, 72]]], ["Additionally, the newly designed analogs killed the bacteria much faster than the native AMPs but still in a non-lytic process.", [["AMPs", "GENE_OR_GENE_PRODUCT", 89, 93], ["the bacteria", "PROBLEM", 48, 60], ["a non-lytic process", "PROBLEM", 107, 126], ["non-lytic process", "OBSERVATION", 109, 126]]], ["We could even extend the activity spectrum to Gram-positive bacteria and design peptides that enter Staphylococcus aureus for example.", [["Staphylococcus aureus", "ORGANISM", 100, 121], ["Staphylococcus aureus", "SPECIES", 100, 121], ["Staphylococcus aureus", "SPECIES", 100, 121], ["Gram-positive bacteria", "PROBLEM", 46, 68], ["design peptides", "PROBLEM", 73, 88], ["Staphylococcus aureus", "PROBLEM", 100, 121], ["Staphylococcus aureus", "OBSERVATION", 100, 121]]], ["Whereas the native peptides were metabolized in serum relatively fast, we could stabilize all labile bonds and thereby increase the half-lives up to 6 hours (25% aqueous serum) without losing the antimicrobial activity.", [["serum", "ANATOMY", 48, 53], ["serum", "ANATOMY", 170, 175], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["all labile bonds", "PROBLEM", 90, 106], ["the antimicrobial activity", "TREATMENT", 192, 218], ["labile bonds", "OBSERVATION", 94, 106], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["antimicrobial activity", "OBSERVATION", 196, 218]]], ["All chemical modifi cations had no effect on the eukaryotic cell toxicity, as studied for COS-7 and HeLa cells and the hemolytic rate of red blood cells for example.", [["cell", "ANATOMY", 60, 64], ["COS-7", "ANATOMY", 90, 95], ["HeLa cells", "ANATOMY", 100, 110], ["red blood cells", "ANATOMY", 137, 152], ["toxicity", "DISEASE", 65, 73], ["hemolytic", "DISEASE", 119, 128], ["modifi cations", "SIMPLE_CHEMICAL", 13, 27], ["cell", "CELL", 60, 64], ["COS-7", "CELL", 90, 95], ["HeLa cells", "CELL", 100, 110], ["red blood cells", "CELL", 137, 152], ["COS-7", "CELL_LINE", 90, 95], ["HeLa cells", "CELL_LINE", 100, 110], ["red blood cells", "CELL_TYPE", 137, 152], ["All chemical modifi cations", "TREATMENT", 0, 27], ["the eukaryotic cell toxicity", "PROBLEM", 45, 73], ["COS", "TEST", 90, 93], ["HeLa cells", "TEST", 100, 110], ["the hemolytic rate", "TEST", 115, 133], ["red blood cells", "TEST", 137, 152], ["eukaryotic cell toxicity", "OBSERVATION", 49, 73]]], ["Furthermore, we could identify two bacterial targets that nicely explain the activity spectrum and non-toxicity towards mammalian cells.Naposomes: A new class of peptide containing supramolecular aggregates as target selective delivery systemsAccardo, Antonella; Tesauro, Diego; Benedetti, Ettore; Pedone, Carlo; Morelli, Giancarlo CIRPeB -Center for Research on Bioactive peptides -Univeristy of Naples \"Federico II\", ITALYNaposomes: A new class of peptide containing supramolecular aggregates as target selective delivery systemsThe use of peptides as targeting tools has been validated in a wide number of applications.", [["cells", "ANATOMY", 130, 135], ["mammalian cells", "CELL", 120, 135], ["mammalian cells", "CELL_TYPE", 120, 135], ["two bacterial targets", "PROBLEM", 31, 52], ["the activity spectrum", "PROBLEM", 73, 94], ["non-toxicity towards mammalian cells", "PROBLEM", 99, 135], ["A new class of peptide", "TREATMENT", 147, 169], ["supramolecular aggregates", "PROBLEM", 181, 206], ["target selective delivery systems", "TREATMENT", 210, 243], ["Pedone", "TREATMENT", 298, 304], ["Research on Bioactive peptides", "TREATMENT", 351, 381], ["A new class of peptide containing supramolecular aggregates", "TREATMENT", 435, 494], ["target selective delivery systems", "TREATMENT", 498, 531], ["peptides", "TREATMENT", 542, 550], ["bacterial targets", "OBSERVATION", 35, 52], ["mammalian cells", "OBSERVATION", 120, 135], ["supramolecular aggregates", "OBSERVATION", 181, 206]]], ["Radiolabeled peptides are used in nuclear medicine techniques to perform imaging or to deliver radiotherapeutic doses to cancer tissues, overexpressing cell membrane receptors such as those for somatostatin.", [["nuclear", "ANATOMY", 34, 41], ["cancer tissues", "ANATOMY", 121, 135], ["cell membrane", "ANATOMY", 152, 165], ["cancer", "DISEASE", 121, 127], ["somatostatin", "CHEMICAL", 194, 206], ["cancer tissues", "TISSUE", 121, 135], ["cell", "CELL", 152, 156], ["somatostatin", "GENE_OR_GENE_PRODUCT", 194, 206], ["overexpressing cell membrane receptors", "PROTEIN", 137, 175], ["Radiolabeled peptides", "TEST", 0, 21], ["imaging", "TEST", 73, 80], ["radiotherapeutic doses", "TREATMENT", 95, 117], ["cancer tissues", "PROBLEM", 121, 135], ["overexpressing cell membrane receptors", "TREATMENT", 137, 175], ["somatostatin", "TREATMENT", 194, 206]]], ["A more complex and challenging objective would be to adopt a similar scheme to deliver supramolecular aggregates, such as micelles or liposomes, to a tissue of interest.", [["tissue", "ANATOMY", 150, 156], ["micelles", "SIMPLE_CHEMICAL", 122, 130], ["liposomes", "SIMPLE_CHEMICAL", 134, 143], ["tissue", "TISSUE", 150, 156], ["liposomes", "TREATMENT", 134, 143], ["more complex", "OBSERVATION_MODIFIER", 2, 14]]], ["We have developed new mixed aggregates with enhanced properties(1,2) (Naposomes) as potential target selective nanovectors of drugs and/or contrast agents.", [["Naposomes", "SIMPLE_CHEMICAL", 70, 79], ["new mixed aggregates", "PROBLEM", 18, 38], ["selective nanovectors of drugs", "TREATMENT", 101, 131], ["contrast agents", "TREATMENT", 139, 154], ["new", "OBSERVATION_MODIFIER", 18, 21], ["mixed", "OBSERVATION_MODIFIER", 22, 27], ["aggregates", "OBSERVATION", 28, 38]]], ["Naposomes are obtained by supramolecular aggregation of two monomers.", [["Naposomes", "SIMPLE_CHEMICAL", 0, 9], ["Naposomes", "TREATMENT", 0, 9], ["supramolecular aggregation", "OBSERVATION", 26, 52]]], ["The fi rst monomer containing a chelating agent able to coordinate a paramagnetic or a radioactive metal ion and bearing a lipophilic tail and a second monomer containing a bioactive peptide linked to a similar lipophilic tail.", [["fi rst monomer", "PROTEIN", 4, 18], ["The fi rst monomer", "TREATMENT", 0, 18], ["a chelating agent", "TREATMENT", 30, 47], ["a paramagnetic", "TREATMENT", 67, 81], ["a radioactive metal ion", "TREATMENT", 85, 108], ["a lipophilic tail", "TREATMENT", 121, 138], ["a second monomer", "TREATMENT", 143, 159], ["a bioactive peptide", "TREATMENT", 171, 190], ["lipophilic tail", "ANATOMY", 123, 138], ["bioactive peptide", "OBSERVATION", 173, 190], ["lipophilic tail", "OBSERVATION", 211, 226]]], ["The aggregates are selectively driven by the exposed bioactive peptide on the chosen biological target.", [["the exposed bioactive peptide", "TREATMENT", 41, 70], ["bioactive peptide", "OBSERVATION", 53, 70]]], ["The aggregates (micelles, vesicles or liposomes) entrap on their inner compartment or in the phospholipid bilayer, a pharmaceutical active principle.", [["vesicles", "ANATOMY", 26, 34], ["inner compartment", "ANATOMY", 65, 82], ["phospholipid bilayer", "ANATOMY", 93, 113], ["micelles", "SIMPLE_CHEMICAL", 16, 24], ["vesicles", "CELLULAR_COMPONENT", 26, 34], ["liposomes", "SIMPLE_CHEMICAL", 38, 47], ["phospholipid", "SIMPLE_CHEMICAL", 93, 105], ["The aggregates (micelles, vesicles or liposomes)", "TREATMENT", 0, 48], ["phospholipid bilayer", "ANATOMY", 93, 113], ["pharmaceutical", "OBSERVATION_MODIFIER", 117, 131], ["active principle", "OBSERVATION", 132, 148]]], ["Naposomes could act as: i) Target-selective vehicles for drugdelivery; ii) Target-selective vehicles of contrast agents for imaging techniques; iii) Target-selective vehicles for simultaneous delivery of a drug (in the inner compartment) and a contrast agent (on the aggregate surface, for its visualization); iv) Target-selective delivery of a drug and a therapeutic active radionuclide.", [["inner compartment", "ANATOMY", 219, 236], ["surface", "ANATOMY", 277, 284], ["Naposomes", "SIMPLE_CHEMICAL", 0, 9], ["inner compartment", "MULTI-TISSUE_STRUCTURE", 219, 236], ["contrast agents", "TREATMENT", 104, 119], ["imaging techniques", "TEST", 124, 142], ["simultaneous delivery", "TREATMENT", 179, 200], ["a drug (in the inner compartment", "TREATMENT", 204, 236], ["a contrast agent", "TREATMENT", 242, 258], ["a drug", "TREATMENT", 343, 349], ["a therapeutic active radionuclide", "TREATMENT", 354, 387], ["selective", "OBSERVATION_MODIFIER", 156, 165]]], ["Supramolecular aggregates exposing peptides such as CCK-8, 7-14 Bombesin and Octreotide, on their external surface have been developed.", [["external surface", "ANATOMY", 98, 114], ["CCK-8, 7-14 Bombesin", "CHEMICAL", 52, 72], ["Octreotide", "CHEMICAL", 77, 87], ["Octreotide", "CHEMICAL", 77, 87], ["CCK-8", "SIMPLE_CHEMICAL", 52, 57], ["7-14 Bombesin", "SIMPLE_CHEMICAL", 59, 72], ["Octreotide", "SIMPLE_CHEMICAL", 77, 87], ["Supramolecular aggregates exposing peptides", "PROBLEM", 0, 43], ["CCK", "TEST", 52, 55], ["Bombesin", "TREATMENT", 64, 72], ["Octreotide", "TREATMENT", 77, 87], ["aggregates", "OBSERVATION", 15, 25]]], ["A complete characterization of their chemical-physical properties and the in vitro and in vivo behaviour as target selective delivery systems for drugs and contrast agents is presented.Title Abs NoNaposomes: A new class of peptide containing supramolecular aggregates as target selective delivery systems Morelli, Giancarlo S13-1Title Abs NoPhotocurrent Generation in Peptide-based Self-Assembled Monolayers Functionalized with Electron Transfer Antenna Chromophores Venanzi, Mariano S13-2Title Abs NoCell Adhesive Laminin Peptides for Tissue Engineering Nomizu, Motoyoshi S13-3Title Abs NoPeptides as Nanomaterials: Self-Assembly and Technological Applications of Peptide Nanotubes, Nanospheres, Hydrogels and other Nanostructures Gazit, Ehud S13-4Title Abs NoSolid phase peptide-carbene and peptide-phosphine transition metal catalysts in asymmetric synthesis and \"Green\" chemistry Meldal, Morten S13-5 S13-2 Bio-hybrid devices based on the integration of biological molecules and metal substrates are currently actively explored for potential applications in the areas of molecular recognition, biological sensing, and molecular electronics.", [["peptide-carbene", "CHEMICAL", 773, 788], ["peptide-phosphine", "CHEMICAL", 793, 810], ["carbene", "CHEMICAL", 781, 788], ["phosphine", "CHEMICAL", 801, 810], ["Peptide Nanotubes", "SIMPLE_CHEMICAL", 665, 682], ["Nanospheres", "SIMPLE_CHEMICAL", 684, 695], ["Hydrogels", "SIMPLE_CHEMICAL", 697, 706], ["Ehud S13-4Title Abs NoSolid phase peptide-carbene", "SIMPLE_CHEMICAL", 739, 788], ["peptide-phosphine transition metal catalysts", "SIMPLE_CHEMICAL", 793, 837], ["metal substrates", "SIMPLE_CHEMICAL", 983, 999], ["Peptide-based Self-Assembled Monolayers", "CELL_LINE", 368, 407], ["target selective delivery systems", "TREATMENT", 108, 141], ["drugs", "TREATMENT", 146, 151], ["contrast agents", "TREATMENT", 156, 171], ["supramolecular aggregates", "PROBLEM", 242, 267], ["target selective delivery systems", "TREATMENT", 271, 304], ["Morelli", "TEST", 305, 312], ["Giancarlo S13", "TREATMENT", 314, 327], ["NoPhotocurrent Generation in Peptide", "TREATMENT", 339, 375], ["Electron Transfer Antenna Chromophores", "TREATMENT", 428, 466], ["Venanzi", "TREATMENT", 467, 474], ["Mariano S13", "TREATMENT", 476, 487], ["2Title Abs NoCell", "TREATMENT", 488, 505], ["Adhesive Laminin Peptides", "TREATMENT", 506, 531], ["Tissue Engineering", "TREATMENT", 536, 554], ["Peptide Nanotubes, Nanospheres", "TREATMENT", 665, 695], ["Hydrogels", "TREATMENT", 697, 706], ["other Nanostructures", "TREATMENT", 711, 731], ["Gazit", "TEST", 732, 737], ["Ehud", "TEST", 739, 743], ["NoSolid phase peptide", "TREATMENT", 759, 780], ["carbene and peptide", "TREATMENT", 781, 800], ["phosphine transition metal catalysts", "TREATMENT", 801, 837], ["asymmetric synthesis", "PROBLEM", 841, 861], ["Meldal", "TEST", 884, 890], ["Morten S13", "TREATMENT", 892, 902], ["Bio-hybrid devices", "TREATMENT", 911, 929], ["biological molecules", "TREATMENT", 958, 978], ["metal substrates", "TREATMENT", 983, 999]]], ["Among the various types of available biomaterials, helical oligopeptides have shown peculiar properties in terms of long-range effi ciency and directional character of the electron transfer process.", [["electron", "SIMPLE_CHEMICAL", 172, 180], ["available biomaterials", "TREATMENT", 27, 49], ["helical oligopeptides", "TREATMENT", 51, 72], ["peculiar properties", "OBSERVATION_MODIFIER", 84, 103]]], ["We have recently demonstrated that self-assembled monolayers (SAM) formed by conformationally-constrained hexapeptides suitably functionalized with antenna chromophores and covalently linked on gold microelectrodes are able to generate electronic current after photoexcitation (1) .", [["monolayers", "CELL", 50, 60], ["hexapeptides", "SIMPLE_CHEMICAL", 106, 118], ["antenna chromophores", "SIMPLE_CHEMICAL", 148, 168], ["self-assembled monolayers", "CELL_LINE", 35, 60], ["self-assembled monolayers (SAM)", "PROBLEM", 35, 66], ["conformationally-constrained hexapeptides", "TREATMENT", 77, 118], ["antenna chromophores", "TREATMENT", 148, 168], ["gold microelectrodes", "TREATMENT", 194, 214]]], ["The deposition of the peptide layer modifi es the gold surface potential, allowing for fi ne tuning of the electronic conduction properties of the substrate.", [["The deposition of the peptide layer modifi", "TREATMENT", 0, 42], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["layer", "OBSERVATION_MODIFIER", 30, 35], ["gold", "OBSERVATION_MODIFIER", 50, 54], ["surface", "OBSERVATION_MODIFIER", 55, 62], ["electronic conduction", "OBSERVATION", 107, 128]]], ["In particular the electrostatic fi eld associated to the helix macrodipole strongly affects the effi ciency and the direction of the electron transfer along the peptide chain and the response of the electrode to the applied potential through the peptide/gold heterojunction.", [["electron", "SIMPLE_CHEMICAL", 133, 141], ["electrostatic fi eld", "PROTEIN", 18, 38], ["helix macrodipole", "PROTEIN", 57, 74], ["the peptide/gold heterojunction", "TREATMENT", 242, 273], ["electrostatic fi", "OBSERVATION", 18, 34], ["gold heterojunction", "OBSERVATION", 254, 273]]], ["Furthemore, a new approach has been employed for the construction of a mixed SAM, exploiting favorable helix-helix dipolar interaction.", [["a mixed SAM", "TREATMENT", 69, 80]]], ["By use of this approach, a helical peptide has been intercalated into an alreadyformed helical peptide SAM covalently linked to the substrate.", [["this approach", "TREATMENT", 10, 23], ["a helical peptide", "TREATMENT", 25, 42], ["an alreadyformed helical peptide SAM", "TREATMENT", 70, 106]]], ["The two peptides are both functionalized, but with different photoactive groups, so that it is possible to switch the direction of the generated current by selective excitation of each of the two chromophores.", [["selective excitation of each of the two chromophores", "TREATMENT", 156, 208], ["functionalized", "OBSERVATION_MODIFIER", 26, 40]]], ["All of these results confi rm the very good electron mediating properties of helical peptides and make them very promising materials for the development of molecular devices based on peptide wires.", [["electron", "SIMPLE_CHEMICAL", 44, 52], ["helical peptides", "TREATMENT", 77, 93], ["molecular devices", "TREATMENT", 156, 173], ["peptide wires", "TREATMENT", 183, 196], ["molecular devices", "OBSERVATION", 156, 173], ["peptide wires", "OBSERVATION", 183, 196]]], ["Tissue engineering aims to create functional tissues or organreplacements using materials and cells.", [["Tissue", "ANATOMY", 0, 6], ["tissues", "ANATOMY", 45, 52], ["cells", "ANATOMY", 94, 99], ["Tissue", "TISSUE", 0, 6], ["tissues", "TISSUE", 45, 52], ["cells", "CELL", 94, 99], ["Tissue engineering", "TREATMENT", 0, 18], ["functional tissues", "OBSERVATION", 34, 52]]], ["Materials provide a support or scaffold for tissue formation.", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["Materials", "TREATMENT", 0, 9], ["a support or scaffold for tissue formation", "TREATMENT", 18, 60]]], ["Extracellular matrix components including laminin, collagen, and fi bronectin, and their active peptides are potential candidates for affording the cell binding activities to materials.", [["Extracellular matrix", "ANATOMY", 0, 20], ["cell", "ANATOMY", 148, 152], ["Extracellular matrix", "CELLULAR_COMPONENT", 0, 20], ["laminin", "GENE_OR_GENE_PRODUCT", 42, 49], ["collagen", "GENE_OR_GENE_PRODUCT", 51, 59], ["fi bronectin", "GENE_OR_GENE_PRODUCT", 65, 77], ["cell", "CELL", 148, 152], ["laminin", "PROTEIN", 42, 49], ["collagen", "PROTEIN", 51, 59], ["fi bronectin", "PROTEIN", 65, 77], ["Extracellular matrix components", "TREATMENT", 0, 31], ["laminin, collagen", "TREATMENT", 42, 59], ["fi bronectin", "TREATMENT", 65, 77], ["matrix", "OBSERVATION", 14, 20], ["laminin", "OBSERVATION_MODIFIER", 42, 49]]], ["Laminin, a major of the basement membrane matrix component, has diverse biological activities including promotion of cell adhesion, migration, neurite outgrowth, and angiogenesis.", [["basement membrane matrix", "ANATOMY", 24, 48], ["cell", "ANATOMY", 117, 121], ["neurite", "ANATOMY", 143, 150], ["Laminin", "GENE_OR_GENE_PRODUCT", 0, 7], ["basement membrane matrix", "CELLULAR_COMPONENT", 24, 48], ["cell", "CELL", 117, 121], ["Laminin", "PROTEIN", 0, 7], ["Laminin", "TREATMENT", 0, 7], ["the basement membrane matrix component", "TREATMENT", 20, 58], ["cell adhesion", "PROBLEM", 117, 130], ["neurite outgrowth", "PROBLEM", 143, 160], ["angiogenesis", "PROBLEM", 166, 178], ["basement", "ANATOMY_MODIFIER", 24, 32], ["membrane matrix", "OBSERVATION", 33, 48], ["diverse", "OBSERVATION_MODIFIER", 64, 71], ["biological activities", "OBSERVATION", 72, 93], ["cell adhesion", "OBSERVATION", 117, 130], ["migration", "OBSERVATION_MODIFIER", 132, 141], ["neurite outgrowth", "OBSERVATION", 143, 160]]], ["Our goal is to identify cell typespecifi c active sequences from the laminins and to use the biologically active peptides for biomaterials.", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28], ["laminins", "GENE_OR_GENE_PRODUCT", 69, 77], ["laminins", "PROTEIN", 69, 77], ["the laminins", "TREATMENT", 65, 77], ["the biologically active peptides", "TREATMENT", 89, 121]]], ["We have identifi ed various active peptides in the laminins using a systematic screening with more than 2,000 synthetic peptides.", [["laminins", "GENE_OR_GENE_PRODUCT", 51, 59], ["laminins", "PROTEIN", 51, 59], ["a systematic screening", "TEST", 66, 88], ["active peptides", "OBSERVATION", 28, 43]]], ["These peptides recognized various cellular receptors and have the potential ability to serve as bio-adhesiveness for tissue engineering.", [["cellular", "ANATOMY", 34, 42], ["tissue", "ANATOMY", 117, 123], ["cellular", "CELL", 34, 42], ["tissue", "TISSUE", 117, 123], ["cellular receptors", "PROTEIN", 34, 52], ["tissue engineering", "TREATMENT", 117, 135]]], ["We have previously demonstrated that several active laminin peptide-conjugated chitosan membranes enhanced the biological activity and promoted cell adhesion in a cell-type specifi c manner.", [["membranes", "ANATOMY", 88, 97], ["cell", "ANATOMY", 144, 148], ["cell", "ANATOMY", 163, 167], ["chitosan", "CHEMICAL", 79, 87], ["laminin", "GENE_OR_GENE_PRODUCT", 52, 59], ["cell", "CELL", 144, 148], ["cell", "CELL", 163, 167], ["specifi c", "GENE_OR_GENE_PRODUCT", 173, 182], ["several active laminin peptide", "TREATMENT", 37, 67], ["conjugated chitosan membranes", "TREATMENT", 68, 97], ["promoted cell adhesion", "TREATMENT", 135, 157], ["several", "OBSERVATION_MODIFIER", 37, 44], ["active", "OBSERVATION_MODIFIER", 45, 51], ["biological activity", "OBSERVATION_MODIFIER", 111, 130], ["cell adhesion", "OBSERVATION", 144, 157]]], ["Here, we demonstrate that a most active laminin peptide (AG73: RKRLQVQLSIRT)-conjugated chitosan membrane can deriver cells and is applicable for keratinocyte transferring to wound bed.", [["membrane", "ANATOMY", 97, 105], ["deriver cells", "ANATOMY", 110, 123], ["keratinocyte", "ANATOMY", 146, 158], ["wound bed", "ANATOMY", 175, 184], ["chitosan", "CHEMICAL", 88, 96], ["laminin", "GENE_OR_GENE_PRODUCT", 40, 47], ["AG73", "SIMPLE_CHEMICAL", 57, 61], ["deriver cells", "CELL", 110, 123], ["keratinocyte", "CELL", 146, 158], ["wound bed", "PATHOLOGICAL_FORMATION", 175, 184], ["deriver cells", "CELL_LINE", 110, 123], ["a most active laminin peptide", "PROBLEM", 26, 55], ["RKRLQVQLSIRT)", "TREATMENT", 63, 76], ["conjugated chitosan membrane", "TREATMENT", 77, 105]]], ["When human keratinocytes were seeded onto the membranes, more than 70% of the cells attached within 2 hrs.", [["keratinocytes", "ANATOMY", 11, 24], ["membranes", "ANATOMY", 46, 55], ["cells", "ANATOMY", 78, 83], ["human", "ORGANISM", 5, 10], ["keratinocytes", "CELL", 11, 24], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["cells", "CELL", 78, 83], ["human keratinocytes", "CELL_TYPE", 5, 24], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["human keratinocytes", "PROBLEM", 5, 24]]], ["The membranes carrying keratinocytes were stable enough for handling with forceps and were inverted onto the muscle fascia exposed on the trunk of nude mice.", [["membranes", "ANATOMY", 4, 13], ["keratinocytes", "ANATOMY", 23, 36], ["forceps", "ANATOMY", 74, 81], ["muscle fascia", "ANATOMY", 109, 122], ["trunk", "ANATOMY", 138, 143], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["keratinocytes", "CELL", 23, 36], ["muscle fascia", "TISSUE", 109, 122], ["trunk", "ORGANISM_SUBDIVISION", 138, 143], ["nude mice", "ORGANISM", 147, 156], ["keratinocytes", "CELL_TYPE", 23, 36], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["forceps", "TREATMENT", 74, 81], ["stable", "OBSERVATION_MODIFIER", 42, 48], ["muscle fascia", "ANATOMY", 109, 122], ["trunk", "ANATOMY", 138, 143]]], ["Keratinocyte sheets were observed after 3 days and colonies appeared after 7 days on the fascia of host mice.", [["Keratinocyte sheets", "ANATOMY", 0, 19], ["colonies", "ANATOMY", 51, 59], ["fascia", "ANATOMY", 89, 95], ["Keratinocyte sheets", "CELL", 0, 19], ["fascia", "TISSUE", 89, 95], ["mice", "ORGANISM", 104, 108], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["Keratinocyte sheets", "TREATMENT", 0, 19], ["fascia", "ANATOMY", 89, 95], ["host mice", "OBSERVATION", 99, 108]]], ["These cells were multilayered on day-3 and expressed various keratinocyte markers.", [["cells", "ANATOMY", 6, 11], ["keratinocyte", "ANATOMY", 61, 73], ["cells", "CELL", 6, 11], ["keratinocyte", "CELL", 61, 73], ["keratinocyte markers", "PROTEIN", 61, 81], ["These cells", "PROBLEM", 0, 11], ["keratinocyte markers", "OBSERVATION", 61, 81]]], ["These results suggest that the AG73-conjugated chitosan membrane is useful as a therapeutic formulation and is applicable as a cell delivery system.", [["membrane", "ANATOMY", 56, 64], ["cell", "ANATOMY", 127, 131], ["AG73", "CHEMICAL", 31, 35], ["chitosan", "CHEMICAL", 47, 55], ["AG73", "CHEMICAL", 31, 35], ["AG73", "SIMPLE_CHEMICAL", 31, 35], ["chitosan", "SIMPLE_CHEMICAL", 47, 55], ["cell", "CELL", 127, 131], ["the AG73-conjugated chitosan membrane", "TREATMENT", 27, 64], ["a therapeutic formulation", "TREATMENT", 78, 103], ["a cell delivery system", "TREATMENT", 125, 147]]], ["The peptidechitosan approach may be a powerful tool for tissue engineering.S13-4Peptides as Nanomaterials: Self-Assembly and Technological Applications of Peptide Nanotubes, Nanospheres, Hydrogels and other NanostructuresGazit, Ehud Tel Aviv University, ISRAELOur works on the mechanism of aromatic peptide self-assembly, lead to the discovery that the diphenylalanine recognition motif of the Alzheimer's \"nano-forests\".", [["tissue", "ANATOMY", 56, 62], ["peptidechitosan", "CHEMICAL", 4, 19], ["diphenylalanine", "CHEMICAL", 353, 368], ["peptidechitosan", "CHEMICAL", 4, 19], ["diphenylalanine", "CHEMICAL", 353, 368], ["peptidechitosan", "SIMPLE_CHEMICAL", 4, 19], ["tissue", "TISSUE", 56, 62], ["Peptide Nanotubes", "SIMPLE_CHEMICAL", 155, 172], ["diphenylalanine", "SIMPLE_CHEMICAL", 353, 368], ["diphenylalanine recognition motif", "PROTEIN", 353, 386], ["The peptidechitosan approach", "TREATMENT", 0, 28], ["tissue engineering", "TREATMENT", 56, 74], ["Peptide Nanotubes, Nanospheres", "TREATMENT", 155, 185], ["Hydrogels", "TREATMENT", 187, 196]]], ["Carny O, Shalev D, and Gazit E (2006) Fabrication of Coaxial Metal Nanowires Using Self-Assembled Peptide Nanotube Scaffold.", [["Coaxial Metal Nanowires Using Self-Assembled Peptide Nanotube Scaffold", "PROTEIN", 53, 123], ["Shalev D, and Gazit E", "TREATMENT", 9, 30], ["Coaxial Metal Nanowires", "TREATMENT", 53, 76], ["Self-Assembled Peptide Nanotube Scaffold", "TREATMENT", 83, 123], ["Nanotube Scaffold", "OBSERVATION", 106, 123]]], ["6, 1594 Reches M and Gazit E (2006) Controlled Patterning of Aligned Self-Assembled Peptide Nanotubes.", [["Peptide Nanotubes", "TREATMENT", 84, 101]]], ["Nature Nanotechnol.", [["Nanotechnol", "CHEMICAL", 7, 18], ["Nanotechnol", "CHEMICAL", 7, 18], ["Nanotechnol", "SIMPLE_CHEMICAL", 7, 18]]], ["Adler-Abramovich L & Gazit E (2008) Controlled pattering of peptide nanotubes and nanospheres using inkjet printing technology.", [["Abramovich L & Gazit E", "TREATMENT", 6, 28], ["peptide nanotubes and nanospheres", "TREATMENT", 60, 93]]], ["14, 217.S13-5Solid phase peptide-carbene and peptide-phosphine transition metal catalysts in asymmetric synthesis and \"Green\" chemistry Meldal, Morten; Worm-Leonhard, Kasper; Christensen, Christian A. Carlsberg Laboratory, DENMARK In Nature metalloproteins play a crucial role in complex biochemical transformations while displaying exquisite regio-and enantio-selectivity.", [["S13-5Solid phase peptide-carbene", "CHEMICAL", 8, 40], ["peptide-phosphine", "CHEMICAL", 45, 62], ["carbene", "CHEMICAL", 33, 40], ["phosphine", "CHEMICAL", 53, 62], ["5Solid phase peptide-carbene", "SIMPLE_CHEMICAL", 12, 40], ["peptide-phosphine transition metal catalysts", "SIMPLE_CHEMICAL", 45, 89], ["5Solid phase peptide", "TREATMENT", 12, 32], ["carbene and peptide-phosphine transition metal catalysts", "TREATMENT", 33, 89], ["asymmetric synthesis", "PROBLEM", 93, 113]]], ["More importantly the protein framework coordinates the catalytic metal and ensure substrate match and lower activation energy of the reaction to provide very high turnovers, which in turn facilitates the effi cient biochemical transformation at low concentration of the catalytic protein.S13-5These properties can advantageously be mimicked in the fi eld peptide and peptide-organic chemistry to putatively create catalysts for \"green\" chemistry.", [["catalytic protein", "PROTEIN", 270, 287], ["the catalytic metal", "TREATMENT", 51, 70], ["the reaction", "PROBLEM", 129, 141], ["very high turnovers", "PROBLEM", 153, 172], ["the effi cient biochemical transformation", "PROBLEM", 200, 241], ["the catalytic protein", "TREATMENT", 266, 287], ["the fi eld peptide", "TREATMENT", 344, 362], ["organic chemistry", "TEST", 375, 392]]], ["By engineering the peptide scaffold with one or several ideal ligands for a variety of transition metals, e. g.", [["the peptide scaffold", "TREATMENT", 15, 35], ["a variety of transition metals", "TREATMENT", 74, 104]]], ["Pd, Cu, Rh, Fe, Ni, Ru etc. artifi cial enzyme like compounds, displaying selectivity and turnover for general organic chemistry transformations may be obtained.", [["Pd", "CHEMICAL", 0, 2], ["Cu", "CHEMICAL", 4, 6], ["Fe", "CHEMICAL", 12, 14], ["Ni", "CHEMICAL", 16, 18], ["Pd", "CHEMICAL", 0, 2], ["Cu", "CHEMICAL", 4, 6], ["Rh", "CHEMICAL", 8, 10], ["Fe", "CHEMICAL", 12, 14], ["Ni", "CHEMICAL", 16, 18], ["Ru", "CHEMICAL", 20, 22], ["Pd", "SIMPLE_CHEMICAL", 0, 2], ["Cu", "SIMPLE_CHEMICAL", 4, 6], ["Rh", "GENE_OR_GENE_PRODUCT", 8, 10], ["Fe", "SIMPLE_CHEMICAL", 12, 14], ["Ni", "SIMPLE_CHEMICAL", 16, 18], ["artifi cial enzyme", "TEST", 28, 46], ["general organic chemistry transformations", "TEST", 103, 144], ["Ni", "ANATOMY", 16, 18]]], ["This presentation describes the synthesis and application of carbene-and phosphine-precursors for incorporation into peptide frameworks that folds around a transition metal and forms relatively compact and stable globular structures with an enzyme like binding cavity for substrate binding and catalysis.", [["carbene", "CHEMICAL", 61, 68], ["phosphine", "CHEMICAL", 73, 82], ["carbene", "CHEMICAL", 61, 68], ["phosphine", "CHEMICAL", 73, 82], ["transition metal", "CHEMICAL", 156, 172], ["phosphine", "SIMPLE_CHEMICAL", 73, 82], ["the synthesis", "TREATMENT", 28, 41], ["carbene", "TREATMENT", 61, 68], ["phosphine", "TREATMENT", 73, 82], ["precursors", "TREATMENT", 83, 93], ["incorporation into peptide frameworks", "TREATMENT", 98, 135], ["a transition metal", "TREATMENT", 154, 172], ["an enzyme like binding cavity", "PROBLEM", 238, 267], ["substrate binding", "PROBLEM", 272, 289], ["stable", "OBSERVATION_MODIFIER", 206, 212], ["globular", "OBSERVATION", 213, 221]]], ["The strategy is modular and well suited for a Split/ Mix approach where a large number of catalysts may be generated in a single combinatorial synthesis.", [["a Split/ Mix approach", "TREATMENT", 44, 65], ["a large number of catalysts", "TREATMENT", 72, 99], ["a single combinatorial synthesis", "TREATMENT", 120, 152], ["modular", "OBSERVATION", 16, 23], ["large", "OBSERVATION_MODIFIER", 74, 79]]], ["Backbone phosphinylated peptides were synthesized on polar PEGA supports and in solution and the catalytic activity was compared.", [["PEGA", "CHEMICAL", 59, 63], ["PEGA", "SIMPLE_CHEMICAL", 59, 63], ["Backbone phosphinylated peptides", "TREATMENT", 0, 32], ["polar PEGA supports", "TREATMENT", 53, 72]]], ["The solid supported catalysts were very effi cient and could be recycled at least 5 times without loss of activity.", [["The solid supported catalysts", "TREATMENT", 0, 29], ["loss of activity", "PROBLEM", 98, 114]]], ["The palladium coordination of the phosphine could furthermore be combined with folding and complexation with other dedicated functional groups in the peptide.", [["palladium", "CHEMICAL", 4, 13], ["phosphine", "CHEMICAL", 34, 43], ["palladium", "CHEMICAL", 4, 13], ["phosphine", "CHEMICAL", 34, 43], ["palladium", "SIMPLE_CHEMICAL", 4, 13], ["phosphine", "SIMPLE_CHEMICAL", 34, 43], ["the phosphine", "TREATMENT", 30, 43]]], ["Backbone carbenes formed extremely stable palladiumpeptido carbene complexes that did not loose any activity with time or use.", [["carbenes", "CHEMICAL", 9, 17], ["palladiumpeptido carbene", "CHEMICAL", 42, 66], ["carbenes", "CHEMICAL", 9, 17], ["palladiumpeptido carbene", "CHEMICAL", 42, 66], ["Backbone carbenes", "SIMPLE_CHEMICAL", 0, 17], ["palladiumpeptido carbene complexes", "SIMPLE_CHEMICAL", 42, 76], ["Backbone carbenes", "TREATMENT", 0, 17], ["stable", "OBSERVATION_MODIFIER", 35, 41]]], ["These solid phase catalysts could be used in microwave assisted C-C and C-N couplings in water with good selectivities and quantitative yields.S14-1 InvProfi ling SH2 and tyrosine phosphatases target specifi city Residues cycling between a phosphorylated and a non-phosphorylated form play a key role in the modulation of signal transduction.", [["tyrosine", "CHEMICAL", 171, 179], ["C-C", "CHEMICAL", 64, 67], ["C-N", "CHEMICAL", 72, 75], ["tyrosine", "CHEMICAL", 171, 179], ["C-C", "SIMPLE_CHEMICAL", 64, 67], ["C-N", "SIMPLE_CHEMICAL", 72, 75], ["water", "SIMPLE_CHEMICAL", 89, 94], ["S14-1", "GENE_OR_GENE_PRODUCT", 143, 148], ["SH2", "GENE_OR_GENE_PRODUCT", 163, 166], ["tyrosine", "AMINO_ACID", 171, 179], ["S14-1 InvProfi ling SH2 and tyrosine phosphatases", "PROTEIN", 143, 192], ["non-phosphorylated form", "PROTEIN", 261, 284], ["These solid phase catalysts", "TREATMENT", 0, 27], ["C-N couplings in water", "TREATMENT", 72, 94], ["S14", "TEST", 143, 146], ["InvProfi ling SH2", "TREATMENT", 149, 166], ["tyrosine phosphatases", "TREATMENT", 171, 192], ["a phosphorylated", "TREATMENT", 238, 254]]], ["Over the past few years, we have designed and implemented a strategy to describe the network of interactions linking phosphorylated peptides to their binding domains and to the enzymes that control their phosphorylation levels.", [["binding domains", "PROTEIN", 150, 165], ["phosphorylated peptides", "TREATMENT", 117, 140], ["the enzymes", "TEST", 173, 184], ["their phosphorylation levels", "TEST", 198, 226]]], ["We will report the results of the characterization of the substrate specifi city of the SH2 domain family and of the family of tyrosine phosphatases.", [["tyrosine", "CHEMICAL", 127, 135], ["tyrosine", "CHEMICAL", 127, 135], ["SH2", "GENE_OR_GENE_PRODUCT", 88, 91], ["tyrosine", "AMINO_ACID", 127, 135], ["substrate specifi city", "PROTEIN", 58, 80], ["SH2 domain family", "PROTEIN", 88, 105], ["tyrosine phosphatases", "PROTEIN", 127, 148], ["the characterization", "TEST", 30, 50], ["tyrosine phosphatases", "TREATMENT", 127, 148]]], ["We have cloned and expressed all the 120 human SH2 domains and for 72 of them we have been able to purify soluble GST fusions.", [["human", "ORGANISM", 41, 46], ["SH2", "GENE_OR_GENE_PRODUCT", 47, 50], ["GST", "GENE_OR_GENE_PRODUCT", 114, 117], ["120 human SH2 domains", "PROTEIN", 37, 58], ["GST fusions", "PROTEIN", 114, 125], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["soluble GST fusions", "TREATMENT", 106, 125]]], ["Similarly we succeeded in expressing 34 of the 37 tyrosine phosphates in a mutant form (trapping mutants) that still binds to substrate peptides but does not carry the de-phosphorylation reaction through.", [["tyrosine", "CHEMICAL", 50, 58], ["tyrosine phosphates", "CHEMICAL", 50, 69], ["tyrosine phosphates", "SIMPLE_CHEMICAL", 50, 69], ["mutant form", "PROTEIN", 75, 86], ["the 37 tyrosine phosphates", "TREATMENT", 43, 69], ["the de-phosphorylation reaction", "PROBLEM", 164, 195]]], ["We have then probed their recognition specifi city by incubating the GST fusions with a glass chip containing approximately 6000 phospho-peptides covering most of the human phospho-proteome.", [["phospho", "CHEMICAL", 129, 136], ["phospho", "CHEMICAL", 173, 180], ["GST", "GENE_OR_GENE_PRODUCT", 69, 72], ["human", "ORGANISM", 167, 172], ["GST fusions", "DNA", 69, 80], ["human phospho", "PROTEIN", 167, 180], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["the GST fusions", "TREATMENT", 65, 80], ["a glass chip", "TREATMENT", 86, 98], ["phospho-peptides", "TREATMENT", 129, 145]]], ["The results have been used to train domain specifi c Neural Networks and to draw a global \"na\u00efve\" phospho-tyrosine specifi c interaction network that only takes into account the ability to bind phospho-peptides in an in vitro system.", [["tyrosine", "CHEMICAL", 106, 114], ["phospho", "CHEMICAL", 98, 105], ["tyrosine", "CHEMICAL", 106, 114], ["phospho", "CHEMICAL", 194, 201], ["phospho-peptides", "GENE_OR_GENE_PRODUCT", 194, 210], ["phospho", "PROTEIN", 98, 105], ["phospho-peptides", "TREATMENT", 194, 210]]], ["Next we have used a context score that combines in a Bayesian approach orthogonal information, namely tissue co-expression, subcellular localization, target sequence conservation in evolution, vicinity in the protein interaction network etc , to rank interaction according to the probability of being functionally relevant.Title Abs NoProfi ling SH2 and tyrosine phosphatases target specifi city Cesareni, Gianni S14-1 InvTitle Abs NoPeptide microarrays for detecting signal transduction-dependent changes in the pattern of molecular interactions Brock, Roland S14-2Title Abs NoArtifi cial intelligence delivers superb antibiotics for superbugs Jenssen, H\u00e5vard S14-3Title Abs NoThe use of plasma proteomics to study disease pathogenesis Hancock, William S14-4 S14-2 Multiprotein complexes play an essential role in the propagation and integration of cellular signals.", [["tissue", "ANATOMY", 102, 108], ["subcellular", "ANATOMY", 124, 135], ["plasma", "ANATOMY", 689, 695], ["cellular", "ANATOMY", 850, 858], ["tyrosine", "CHEMICAL", 354, 362], ["tyrosine", "CHEMICAL", 354, 362], ["tissue", "TISSUE", 102, 108], ["NoProfi ling SH2", "GENE_OR_GENE_PRODUCT", 333, 349], ["tyrosine", "AMINO_ACID", 354, 362], ["plasma", "ORGANISM_SUBSTANCE", 689, 695], ["cellular", "CELL", 850, 858], ["protein interaction network", "PROTEIN", 209, 236], ["Title Abs NoProfi ling SH2 and tyrosine phosphatases", "PROTEIN", 323, 375], ["specifi city Cesareni, Gianni S14-1 InvTitle Abs NoPeptide microarrays", "DNA", 383, 453], ["William S14-4 S14-2 Multiprotein complexes", "PROTEIN", 746, 788], ["subcellular localization", "TEST", 124, 148], ["Title Abs", "TEST", 323, 332], ["tyrosine phosphatases", "TEST", 354, 375], ["specifi", "TEST", 383, 390], ["Cesareni", "TEST", 396, 404], ["Gianni", "TEST", 406, 412], ["signal transduction", "TEST", 468, 487], ["dependent changes", "PROBLEM", 488, 505], ["Brock", "TEST", 547, 552], ["Roland S14", "TEST", 554, 564], ["superb antibiotics", "TREATMENT", 612, 630], ["superbugs", "TEST", 635, 644], ["plasma proteomics", "TEST", 689, 706], ["cellular signals", "OBSERVATION", 850, 866]]], ["However, systems level analyses of signaling-dependent changes in the pattern of molecular interactions are still missing.", [["signaling-dependent changes", "PROBLEM", 35, 62], ["molecular interactions", "PROBLEM", 81, 103], ["dependent", "OBSERVATION_MODIFIER", 45, 54], ["molecular interactions", "OBSERVATION", 81, 103]]], ["Signaling in T lymphocytes is one prominent example, in which multiprotein complexes orchestrate signal transduction.", [["T lymphocytes", "ANATOMY", 13, 26], ["T lymphocytes", "CELL", 13, 26], ["T lymphocytes", "CELL_TYPE", 13, 26], ["multiprotein complexes", "PROTEIN", 62, 84], ["Signaling in T lymphocytes", "PROBLEM", 0, 26], ["T lymphocytes", "OBSERVATION", 13, 26], ["one prominent", "OBSERVATION_MODIFIER", 30, 43], ["multiprotein complexes", "OBSERVATION", 62, 84], ["signal transduction", "OBSERVATION", 97, 116]]], ["We have implemented peptide microarrays comprising a set of interaction motifs of signaling proteins for network-based analyses of signaling-dependent changes in molecular interactions.", [["interaction motifs", "PROTEIN", 60, 78], ["signaling proteins", "PROTEIN", 82, 100], ["peptide microarrays", "TREATMENT", 20, 39], ["signaling proteins", "PROBLEM", 82, 100], ["dependent changes", "PROBLEM", 141, 158], ["dependent", "OBSERVATION_MODIFIER", 141, 150], ["molecular interactions", "OBSERVATION", 162, 184]]], ["Lysates of resting or stimulated cells are incubated on these arrays and the binding of signaling proteins is detected by immunofl uorescence.", [["Lysates", "ANATOMY", 0, 7], ["cells", "ANATOMY", 33, 38], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["cells", "CELL", 33, 38], ["resting or stimulated cells", "CELL_TYPE", 11, 38], ["signaling proteins", "PROTEIN", 88, 106], ["resting or stimulated cells", "PROBLEM", 11, 38], ["these arrays", "TREATMENT", 56, 68], ["signaling proteins", "PROBLEM", 88, 106], ["signaling proteins", "OBSERVATION", 88, 106]]], ["Signaling-dependent changes in molecular interactions are refl ected by changes of signals on the microarrays.", [["Signaling-dependent changes in molecular interactions", "PROBLEM", 0, 53], ["the microarrays", "TEST", 94, 109], ["dependent", "OBSERVATION_MODIFIER", 10, 19], ["changes", "OBSERVATION", 20, 27], ["molecular interactions", "OBSERVATION", 31, 53]]], ["Signal changes on the array upon complex formation may either result from a masking of a binding site for a peptide on the array, or from binding to a protein that indirectly mediates binding to a peptide on the array.", [["Signal changes", "PROBLEM", 0, 14], ["a binding site", "PROBLEM", 87, 101]]], ["Competition with peptides corresponding to interaction motifs provides detailed information on the architecture of signaling complexes; lack of individual signaling proteins reveals the functional interdependence of interactions in the network.", [["interaction motifs", "PROTEIN", 43, 61], ["signaling complexes", "PROTEIN", 115, 134], ["signaling proteins", "PROTEIN", 155, 173], ["signaling complexes", "PROBLEM", 115, 134], ["individual signaling proteins", "PROBLEM", 144, 173]]], ["In summary, for the analysis of signaling networks, peptide microarrays enable the parallel detection of changes in patterns of interactions which allow the identifi cation of functional interdependencies with minimum a priori knowledge.", [["the analysis", "TEST", 16, 28], ["signaling networks", "PROBLEM", 32, 50], ["peptide microarrays", "TEST", 52, 71], ["the parallel detection", "TEST", 79, 101]]], ["Cell.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4]]], ["Prot., 6 (2007 503-513 S14-3 Increased multiple antibiotic resistance in the face of declining antibiotic discovery is one of society's most pressing health issues.", [["Increased multiple antibiotic resistance", "TREATMENT", 29, 69], ["declining antibiotic discovery", "TREATMENT", 85, 115], ["antibiotic resistance", "OBSERVATION", 48, 69]]], ["Antimicrobial peptides represent a promising new class of antibiotics.", [["Antimicrobial peptides", "TREATMENT", 0, 22], ["antibiotics", "TREATMENT", 58, 69]]], ["Here we asked whether it is possible to make small broad spectrum peptides without employing prior assumptions, by capitalizing on already accumulated chemical and biological information.", [["small broad spectrum peptides", "PROBLEM", 45, 74]]], ["Using peptide array technology, two large semi-random 9-amino-acid peptide libraries were iteratively created using the amino acid composition of the most active peptides.", [["9-amino-acid", "CHEMICAL", 54, 66], ["amino acid", "CHEMICAL", 120, 130], ["9-amino-acid", "CHEMICAL", 54, 66], ["amino acid", "CHEMICAL", 120, 130], ["amino acid", "AMINO_ACID", 120, 130], ["peptide array technology", "TREATMENT", 6, 30], ["two large semi-random 9-amino-acid peptide libraries", "TREATMENT", 32, 84], ["the amino acid composition", "TREATMENT", 116, 142]]], ["The resultant data was used together with powerful machine learning techniques to create quantitative in silico models of antibiotic activity.", [["powerful machine learning techniques", "TREATMENT", 42, 78], ["antibiotic activity", "TREATMENT", 122, 141]]], ["Based on random testing these models proved remarkably effective in predicting the activity of 100,000 virtual peptides.", [["random testing", "TEST", 9, 23]]], ["The best peptides, representing the top quartile of predicted activities, were effective against a broad array of multi-resistant \"Superbugs\", more effective than the most advanced clinical candidate peptide, and protective against Staphylococcus aureus infections in animal models.S14-4The use of plasma proteomics to study disease pathogenesis Mechanisms underlying disease pathogenesis are not well understood in the context of common etiological factors such as microbial infection, infl ammation, malignancy or tissue breakdown.", [["plasma", "ANATOMY", 298, 304], ["tissue", "ANATOMY", 516, 522], ["Staphylococcus aureus infections", "DISEASE", 232, 264], ["microbial infection", "DISEASE", 466, 485], ["malignancy", "DISEASE", 502, 512], ["Superbugs", "SIMPLE_CHEMICAL", 131, 140], ["Staphylococcus aureus", "ORGANISM", 232, 253], ["plasma", "ORGANISM_SUBSTANCE", 298, 304], ["tissue", "TISSUE", 516, 522], ["Staphylococcus aureus", "SPECIES", 232, 253], ["Staphylococcus aureus", "SPECIES", 232, 253], ["multi-resistant \"Superbugs\"", "PROBLEM", 114, 141], ["Staphylococcus aureus infections in animal models", "PROBLEM", 232, 281], ["plasma proteomics", "TEST", 298, 315], ["underlying disease pathogenesis", "PROBLEM", 357, 388], ["common etiological factors", "PROBLEM", 431, 457], ["microbial infection", "PROBLEM", 466, 485], ["infl ammation", "PROBLEM", 487, 500], ["malignancy", "PROBLEM", 502, 512], ["tissue breakdown", "PROBLEM", 516, 532], ["multi-resistant", "OBSERVATION_MODIFIER", 114, 129], ["Staphylococcus aureus", "OBSERVATION", 232, 253], ["disease", "OBSERVATION", 368, 375], ["microbial", "OBSERVATION_MODIFIER", 466, 475], ["infection", "OBSERVATION", 476, 485], ["malignancy", "OBSERVATION", 502, 512], ["tissue", "OBSERVATION_MODIFIER", 516, 522], ["breakdown", "OBSERVATION_MODIFIER", 523, 532]]], ["Such processes may be elucidated by identifying disease-related molecular markers, such as acute phase proteins, cytokines, cytoskeletal fragments and autoantigens.S14-4In an attempt to identify such markers, we used two proteomic methods to analyze plasma samples from patients and healthy donors in a series of studies ranging from cancer to autoimmune disease.", [["cytoskeletal fragments", "ANATOMY", 124, 146], ["plasma samples", "ANATOMY", 250, 264], ["cancer", "ANATOMY", 334, 340], ["cancer", "DISEASE", 334, 340], ["autoimmune disease", "DISEASE", 344, 362], ["cytoskeletal", "CELLULAR_COMPONENT", 124, 136], ["S14-4In", "GENE_OR_GENE_PRODUCT", 164, 171], ["plasma samples", "ORGANISM_SUBSTANCE", 250, 264], ["patients", "ORGANISM", 270, 278], ["cancer", "CANCER", 334, 340], ["molecular markers", "PROTEIN", 64, 81], ["acute phase proteins", "PROTEIN", 91, 111], ["cytokines", "PROTEIN", 113, 122], ["cytoskeletal fragments", "PROTEIN", 124, 146], ["autoantigens", "PROTEIN", 151, 163], ["patients", "SPECIES", 270, 278], ["disease-related molecular markers", "PROBLEM", 48, 81], ["acute phase proteins", "PROBLEM", 91, 111], ["cytokines", "PROBLEM", 113, 122], ["cytoskeletal fragments", "PROBLEM", 124, 146], ["autoantigens", "PROBLEM", 151, 163], ["plasma samples", "TEST", 250, 264], ["a series of studies", "TEST", 301, 320], ["autoimmune disease", "PROBLEM", 344, 362], ["disease", "OBSERVATION", 48, 55], ["molecular markers", "OBSERVATION", 64, 81], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["cytoskeletal fragments", "OBSERVATION", 124, 146], ["cancer", "OBSERVATION", 334, 340], ["autoimmune disease", "OBSERVATION", 344, 362]]], ["The fi rst method allowed to evaluate changes in concentration of glycoproteins, and to comprehensively survey the plasma proteome.", [["plasma", "ANATOMY", 115, 121], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["glycoproteins", "PROTEIN", 66, 79], ["The fi rst method", "TEST", 0, 17], ["changes in concentration of glycoproteins", "PROBLEM", 38, 79], ["the plasma proteome", "TEST", 111, 130]]], ["The second method, intact peptidomics, was used to assess changes in endogenous proteolytic activity by analyzing the low molecular weight (LMW) component.", [["changes in endogenous proteolytic activity", "PROBLEM", 58, 100], ["endogenous proteolytic activity", "OBSERVATION", 69, 100], ["low molecular", "OBSERVATION_MODIFIER", 118, 131]]], ["The integrated proteomic and peptidomic analysis of plasma samples identifi ed a number of cytoskeletal and Ca 2+ -binding proteins and their proteolytic fragments in the disease samples.", [["plasma samples", "ANATOMY", 52, 66], ["cytoskeletal", "ANATOMY", 91, 103], ["samples", "ANATOMY", 179, 186], ["Ca", "CHEMICAL", 108, 110], ["Ca 2+", "CHEMICAL", 108, 113], ["plasma samples", "ORGANISM_SUBSTANCE", 52, 66], ["cytoskeletal", "CELLULAR_COMPONENT", 91, 103], ["Ca 2+ -binding proteins", "GENE_OR_GENE_PRODUCT", 108, 131], ["cytoskeletal and Ca 2+ -binding proteins", "PROTEIN", 91, 131], ["proteolytic fragments", "PROTEIN", 142, 163], ["The integrated proteomic", "TEST", 0, 24], ["peptidomic analysis", "TEST", 29, 48], ["plasma samples", "TEST", 52, 66], ["Ca", "TEST", 108, 110], ["binding proteins", "PROBLEM", 115, 131], ["their proteolytic fragments in the disease samples", "PROBLEM", 136, 186], ["proteolytic fragments", "OBSERVATION", 142, 163], ["disease", "OBSERVATION", 171, 178]]], ["The measurements were compared to healthy donors and several of the observed differential quantitations were independently verifi ed by ELISA.", [["donors", "ORGANISM", 42, 48], ["The measurements", "TEST", 0, 16]]], ["The identifi ed changes in plasma proteome and peptidome, and the underlying altered endogenous protease activity may result in the generation of novel autoantigens.", [["plasma proteome", "ANATOMY", 27, 42], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["protease", "PROTEIN", 96, 104], ["novel autoantigens", "PROTEIN", 146, 164], ["plasma proteome", "TEST", 27, 42], ["the underlying altered endogenous protease activity", "PROBLEM", 62, 113], ["novel autoantigens", "PROBLEM", 146, 164], ["altered", "OBSERVATION_MODIFIER", 77, 84], ["endogenous protease activity", "OBSERVATION", 85, 113]]], ["We have confi rmed this hypothesis by the observation of autoantibodies in patients and upon extension of these studies to larger populations of patients; we may gain additional understanding of the role of etiological factors in different disease pathways and genomic penetrance.Phosphorylation-Dependent Protein Design: Design of Protein Kinase-Inducible Domains as Genetically Encodable Sensors of Protein Kinase ActivityZondlo, Neal; Balakrishnan, Shalini; Gao, Feng University of Delaware, UNITED STATES Protein phosphorylation is a ubiquitous signaling mechanism important in cellular regulation.", [["cellular", "ANATOMY", 582, 590], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 145, 153], ["cellular", "CELL", 582, 590], ["autoantibodies", "PROTEIN", 57, 71], ["Protein Kinase-Inducible Domains", "PROTEIN", 332, 364], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 145, 153], ["autoantibodies", "PROBLEM", 57, 71], ["these studies", "TEST", 106, 119], ["different disease pathways", "PROBLEM", 230, 256], ["genomic penetrance", "PROBLEM", 261, 279], ["Phosphorylation", "TEST", 280, 295], ["Protein Kinase", "TEST", 332, 346], ["Inducible Domains", "PROBLEM", 347, 364], ["genomic penetrance", "OBSERVATION", 261, 279]]], ["Misregulation of protein kinases and phosphatases is implicated in diverse human diseases, including cancer, Alzheimer's disease, and diabetes, as well as bacterial and viral pathogenicity.", [["cancer", "ANATOMY", 101, 107], ["human diseases", "DISEASE", 75, 89], ["cancer", "DISEASE", 101, 107], ["Alzheimer's disease", "DISEASE", 109, 128], ["diabetes", "DISEASE", 134, 142], ["protein kinases", "GENE_OR_GENE_PRODUCT", 17, 32], ["human", "ORGANISM", 75, 80], ["cancer", "CANCER", 101, 107], ["protein kinases", "PROTEIN", 17, 32], ["phosphatases", "PROTEIN", 37, 49], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["Misregulation of protein kinases", "PROBLEM", 0, 32], ["phosphatases", "TEST", 37, 49], ["diverse human diseases", "PROBLEM", 67, 89], ["cancer", "PROBLEM", 101, 107], ["Alzheimer's disease", "PROBLEM", 109, 128], ["diabetes", "PROBLEM", 134, 142], ["bacterial and viral pathogenicity", "PROBLEM", 155, 188], ["protein kinases", "OBSERVATION", 17, 32], ["diverse human diseases", "OBSERVATION", 67, 89], ["cancer", "OBSERVATION", 101, 107], ["Alzheimer's disease", "OBSERVATION", 109, 128], ["diabetes", "OBSERVATION", 134, 142], ["bacterial", "OBSERVATION_MODIFIER", 155, 164], ["viral pathogenicity", "OBSERVATION", 169, 188]]], ["We have used protein design to develop novel protein motifs, termed protein kinase-inducible domains (pKIDs), whose structures are dependent on their phosphorylation state.", [["protein kinase-inducible domains", "GENE_OR_GENE_PRODUCT", 68, 100], ["pKIDs", "GENE_OR_GENE_PRODUCT", 102, 107], ["protein motifs", "PROTEIN", 45, 59], ["protein kinase-inducible domains", "PROTEIN", 68, 100], ["pKIDs", "PROTEIN", 102, 107], ["protein design", "TREATMENT", 13, 27], ["novel protein motifs", "TEST", 39, 59], ["protein kinase", "TEST", 68, 82], ["inducible domains (pKIDs)", "PROBLEM", 83, 108], ["dependent", "OBSERVATION_MODIFIER", 131, 140]]], ["The basis of the design is the use of phosphoserine, phosphothreonine, or phosphotyrosine as a mimic of a structurally important Glu residue in a protein.", [["phosphoserine", "CHEMICAL", 38, 51], ["phosphothreonine", "CHEMICAL", 53, 69], ["phosphotyrosine", "CHEMICAL", 74, 89], ["Glu", "CHEMICAL", 129, 132], ["phosphoserine", "CHEMICAL", 38, 51], ["phosphothreonine", "CHEMICAL", 53, 69], ["phosphotyrosine", "CHEMICAL", 74, 89], ["Glu", "CHEMICAL", 129, 132], ["phosphoserine", "AMINO_ACID", 38, 51], ["phosphothreonine", "SIMPLE_CHEMICAL", 53, 69], ["phosphotyrosine", "AMINO_ACID", 74, 89], ["Glu", "AMINO_ACID", 129, 132], ["phosphoserine", "TREATMENT", 38, 51], ["phosphothreonine", "TREATMENT", 53, 69], ["phosphotyrosine", "TREATMENT", 74, 89], ["Glu residue", "OBSERVATION", 129, 140]]], ["Protein kinase-inducible domains are 15-25 amino acid sequences that were designed based on EF-hand domains, replacing the conserved Glu at residue 12, which binds metal in a bidentate manner, with phosphoserine, phosphothreonine, or phosphotyrosine.", [["amino acid", "CHEMICAL", 43, 53], ["Glu", "CHEMICAL", 133, 136], ["phosphoserine", "CHEMICAL", 198, 211], ["phosphothreonine", "CHEMICAL", 213, 229], ["phosphotyrosine", "CHEMICAL", 234, 249], ["amino acid", "CHEMICAL", 43, 53], ["Glu", "CHEMICAL", 133, 136], ["phosphoserine", "CHEMICAL", 198, 211], ["phosphothreonine", "CHEMICAL", 213, 229], ["phosphotyrosine", "CHEMICAL", 234, 249], ["Protein kinase-inducible domains", "GENE_OR_GENE_PRODUCT", 0, 32], ["amino acid", "AMINO_ACID", 43, 53], ["Glu", "AMINO_ACID", 133, 136], ["phosphoserine", "SIMPLE_CHEMICAL", 198, 211], ["phosphothreonine", "SIMPLE_CHEMICAL", 213, 229], ["phosphotyrosine", "GENE_OR_GENE_PRODUCT", 234, 249], ["Protein kinase-inducible domains", "PROTEIN", 0, 32], ["15-25 amino acid sequences", "DNA", 37, 63], ["EF-hand domains", "PROTEIN", 92, 107], ["Protein kinase", "TEST", 0, 14], ["inducible domains", "PROBLEM", 15, 32], ["amino acid sequences", "TEST", 43, 63], ["EF", "TEST", 92, 94], ["the conserved Glu at residue", "PROBLEM", 119, 147], ["phosphoserine", "TREATMENT", 198, 211], ["phosphothreonine", "TREATMENT", 213, 229], ["phosphotyrosine", "TREATMENT", 234, 249]]], ["Non-phosphorylated pKIDs do not bind terbium and exhibit weak or no fl uorescence, whereas phosphorylated pKIDs bind terbium and exhibit strong terbium fl uorescence.", [["terbium", "CHEMICAL", 37, 44], ["terbium", "CHEMICAL", 117, 124], ["terbium", "CHEMICAL", 144, 151], ["terbium", "CHEMICAL", 37, 44], ["terbium", "CHEMICAL", 117, 124], ["terbium", "CHEMICAL", 144, 151], ["pKIDs", "GENE_OR_GENE_PRODUCT", 19, 24], ["terbium", "SIMPLE_CHEMICAL", 37, 44], ["pKIDs", "GENE_OR_GENE_PRODUCT", 106, 111], ["terbium", "SIMPLE_CHEMICAL", 117, 124], ["terbium fl uorescence", "SIMPLE_CHEMICAL", 144, 165], ["pKIDs", "PROTEIN", 19, 24], ["phosphorylated pKIDs", "PROTEIN", 91, 111], ["Non-phosphorylated pKIDs", "PROBLEM", 0, 24], ["fl uorescence", "PROBLEM", 68, 81], ["strong terbium fl uorescence", "PROBLEM", 137, 165], ["strong", "OBSERVATION_MODIFIER", 137, 143], ["terbium fl", "OBSERVATION", 144, 154]]], ["The structure and fl uorescence of pKIDs are dependent on phosphorylation, and may exhibit essentially complete phosphorylation-dependent switching.", [["pKIDs", "GENE_OR_GENE_PRODUCT", 35, 40], ["pKIDs", "PROTEIN", 35, 40], ["pKIDs", "PROBLEM", 35, 40], ["phosphorylation", "TREATMENT", 58, 73], ["fl uorescence", "OBSERVATION", 18, 31], ["dependent", "OBSERVATION_MODIFIER", 45, 54], ["dependent switching", "OBSERVATION", 128, 147]]], ["We demonstrate the generality of this architecture with pKID peptides containing complex protein kinase recognition sequences for multiple protein kinases, including PKA, PKC, Erk, and Abl.", [["PKA", "GENE_OR_GENE_PRODUCT", 166, 169], ["PKC", "GENE_OR_GENE_PRODUCT", 171, 174], ["Erk", "GENE_OR_GENE_PRODUCT", 176, 179], ["Abl", "GENE_OR_GENE_PRODUCT", 185, 188], ["complex protein kinase recognition sequences", "PROTEIN", 81, 125], ["protein kinases", "PROTEIN", 139, 154], ["PKA", "PROTEIN", 166, 169], ["PKC", "PROTEIN", 171, 174], ["Erk", "PROTEIN", 176, 179], ["Abl", "PROTEIN", 185, 188], ["pKID peptides", "TREATMENT", 56, 69], ["complex protein kinase recognition sequences", "PROBLEM", 81, 125], ["multiple protein kinases", "TEST", 130, 154], ["PKA", "TEST", 166, 169], ["PKC", "TEST", 171, 174], ["Erk", "TEST", 176, 179], ["protein kinase", "OBSERVATION", 89, 103], ["protein kinases", "OBSERVATION", 139, 154]]], ["Protein kinaseinducible domains may be used as in vitro fl uorescent sensors of protein kinase activity and protein phosphatase activity.", [["Protein kinaseinducible domains", "PROTEIN", 0, 31], ["protein kinase", "PROTEIN", 80, 94], ["protein phosphatase", "PROTEIN", 108, 127], ["Protein kinaseinducible domains", "TREATMENT", 0, 31], ["protein kinase activity", "TEST", 80, 103], ["protein phosphatase activity", "TEST", 108, 136]]], ["Protein kinase-inducible domains are compatible with complex solution environments, including cell extracts.", [["cell extracts", "ANATOMY", 94, 107], ["cell extracts", "ORGANISM_SUBSTANCE", 94, 107], ["Protein kinase-inducible domains", "PROTEIN", 0, 32], ["Protein kinase", "TEST", 0, 14], ["inducible domains", "PROBLEM", 15, 32], ["complex solution environments", "PROBLEM", 53, 82], ["cell extracts", "TREATMENT", 94, 107], ["inducible domains", "OBSERVATION", 15, 32], ["compatible with", "UNCERTAINTY", 37, 52], ["complex", "OBSERVATION_MODIFIER", 53, 60], ["cell extracts", "OBSERVATION", 94, 107]]], ["Protein kinase-inducible domains may also be used for the fl uorescent detection of protein kinase inhibitors.Title Abs NoPhosphorylation-Dependent Protein Design: Design of Protein Kinase-Inducible Domains as Genetically Encodable Sensors of Protein Kinase Activity Zondlo, Neal S15-1Title Abs NoPhage selection of chemically constrained peptides Heinis, Christian S15-2 PNA zipper: inducing dimerization of the basic region of a bZip protein by a PNA duplex Romanelli, Alessandra S15-3Title Abs NoDeveloping Peptide Antagonists for both UFH and LMWH Liang, Jun F. (James) S15-4 S15-2Heinis, Christian LMB, UNITED KINGDOMThe discovery of synthetic molecules with high affi nity and specifi city for biological targets is a central problem in drug discovery.", [["UFH", "CHEMICAL", 539, 542], ["bZip", "GENE_OR_GENE_PRODUCT", 431, 435], ["Protein kinase-inducible domains", "PROTEIN", 0, 32], ["Title Abs", "PROTEIN", 110, 119], ["Protein Kinase-Inducible Domains", "PROTEIN", 174, 206], ["Protein Kinase Activity Zondlo, Neal S15-1Title Abs", "PROTEIN", 243, 294], ["Christian S15-2 PNA zipper", "PROTEIN", 356, 382], ["basic region", "PROTEIN", 413, 425], ["bZip protein", "PROTEIN", 431, 443], ["Protein kinase", "TEST", 0, 14], ["inducible domains", "PROBLEM", 15, 32], ["the fl uorescent detection", "TEST", 54, 80], ["protein kinase inhibitors", "TREATMENT", 84, 109], ["Protein Kinase", "TEST", 174, 188], ["Inducible Domains", "PROBLEM", 189, 206], ["Protein Kinase", "TEST", 243, 257], ["Activity", "TEST", 258, 266], ["Zondlo", "TEST", 267, 273], ["Neal", "TEST", 275, 279], ["chemically constrained peptides Heinis", "PROBLEM", 316, 354], ["a bZip protein", "TEST", 429, 443], ["a PNA duplex Romanelli", "TEST", 447, 469], ["Alessandra S15", "TREATMENT", 471, 485], ["3Title Abs", "TREATMENT", 486, 496], ["Peptide Antagonists", "TREATMENT", 510, 529], ["both UFH", "TREATMENT", 534, 542], ["LMWH Liang", "TREATMENT", 547, 557], ["LMWH Liang", "OBSERVATION", 547, 557], ["LMB", "ANATOMY", 603, 606], ["synthetic molecules", "OBSERVATION", 639, 658], ["central", "OBSERVATION_MODIFIER", 724, 731]]], ["We have developed an effi cient strategy for the generation of chemically constrained peptides with high affi nity and specifi city for biological targets.", [["an effi cient strategy", "TREATMENT", 18, 40], ["chemically constrained peptides", "PROBLEM", 63, 94]]], ["Molecules with desired specifi cities were isolated by phage display using repertoires of random linear peptides that were, before phage selection, reacted with a chemical scaffold to form molecules with constrained peptide loops.", [["random linear peptides", "TREATMENT", 90, 112], ["phage selection", "TREATMENT", 131, 146], ["a chemical scaffold", "TREATMENT", 161, 180], ["constrained peptide loops", "PROBLEM", 204, 229], ["peptide loops", "OBSERVATION", 216, 229]]], ["We linked peptides (17 amino acids) on phage via three cysteine side chains to a small molecule scaffold to obtain a single product isomer.", [["amino acids", "CHEMICAL", 23, 34], ["cysteine", "CHEMICAL", 55, 63], ["amino acids", "CHEMICAL", 23, 34], ["cysteine", "CHEMICAL", 55, 63], ["amino acids", "AMINO_ACID", 23, 34], ["peptides (17 amino acids", "TREATMENT", 10, 34], ["phage via three cysteine side chains", "TREATMENT", 39, 75], ["a small molecule scaffold", "TREATMENT", 79, 104], ["small molecule scaffold", "OBSERVATION", 81, 104]]], ["Reaction conditions were chosen to selectively modify the peptides but spare the coat proteins of the phage particles.", [["coat proteins", "PROTEIN", 81, 94], ["Reaction conditions", "PROBLEM", 0, 19], ["the peptides", "TREATMENT", 54, 66]]], ["Highly specifi c binders with nanomolar affi nities were obtained against the two serine proteases human plasma kallikrein and cathepsin G. An affi nity matured inhibitor of human plasma kallikrein with an apparent Ki of 1.5 nM effi ciently suppressed contact activation in human plasma.", [["plasma", "ANATOMY", 105, 111], ["plasma", "ANATOMY", 180, 186], ["plasma", "ANATOMY", 280, 286], ["effi", "CHEMICAL", 228, 232], ["serine", "CHEMICAL", 82, 88], ["specifi c binders", "SIMPLE_CHEMICAL", 7, 24], ["nanomolar affi nities", "SIMPLE_CHEMICAL", 30, 51], ["human", "ORGANISM", 99, 104], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["kallikrein", "GENE_OR_GENE_PRODUCT", 112, 122], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 127, 138], ["human", "ORGANISM", 174, 179], ["plasma", "ORGANISM_SUBSTANCE", 180, 186], ["kallikrein", "GENE_OR_GENE_PRODUCT", 187, 197], ["human", "ORGANISM", 274, 279], ["plasma", "ORGANISM_SUBSTANCE", 280, 286], ["serine proteases", "PROTEIN", 82, 98], ["human plasma kallikrein", "PROTEIN", 99, 122], ["cathepsin G", "PROTEIN", 127, 138], ["human plasma kallikrein", "PROTEIN", 174, 197], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 274, 279], ["Highly specifi c binders", "TREATMENT", 0, 24], ["nanomolar affi nities", "TREATMENT", 30, 51], ["the two serine proteases human plasma kallikrein", "TREATMENT", 74, 122], ["cathepsin G", "TREATMENT", 127, 138], ["An affi nity matured inhibitor", "TREATMENT", 140, 170], ["human plasma kallikrein", "TREATMENT", 174, 197], ["an apparent Ki", "TEST", 203, 217]]], ["The sequence specifi c DNA binding of gene-regulatory proteins is often mediated by dimeric proteins, which recognize DNA as homodimers or heterodimers.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["regulatory proteins", "PROTEIN", 43, 62], ["dimeric proteins", "PROTEIN", 84, 100], ["homodimers", "PROTEIN", 125, 135], ["heterodimers", "PROTEIN", 139, 151], ["The sequence specifi", "TEST", 0, 20], ["DNA binding of gene-regulatory proteins", "PROBLEM", 23, 62], ["dimeric proteins", "PROBLEM", 84, 100], ["heterodimers", "TREATMENT", 139, 151]]], ["The basic leucine zipper (bZip) DNA binding proteins are transcriptional regulatory proteins consisting of a coiled coil leucine zipper dimerization domain and a highly charged basic region responsible for the DNA binding.", [["leucine", "CHEMICAL", 10, 17], ["leucine", "CHEMICAL", 121, 128], ["leucine", "CHEMICAL", 10, 17], ["leucine", "CHEMICAL", 121, 128], ["basic leucine zipper (bZip", "GENE_OR_GENE_PRODUCT", 4, 30], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 210, 213], ["basic leucine zipper (bZip) DNA binding proteins", "PROTEIN", 4, 52], ["transcriptional regulatory proteins", "PROTEIN", 57, 92], ["coiled coil leucine zipper dimerization domain", "PROTEIN", 109, 155], ["highly charged basic region", "PROTEIN", 162, 189], ["The basic leucine zipper (bZip) DNA binding proteins", "TREATMENT", 0, 52], ["transcriptional regulatory proteins", "TREATMENT", 57, 92], ["a coiled coil leucine zipper dimerization domain", "TREATMENT", 107, 155], ["the DNA binding", "PROBLEM", 206, 221], ["leucine zipper", "OBSERVATION", 10, 24]]], ["Several efforts have been devoted to the synthesis of minimized bZip analogues, able to bind DNA.", [["bZip", "CHEMICAL", 64, 68], ["bZip analogues", "SIMPLE_CHEMICAL", 64, 78], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["minimized bZip analogues", "TREATMENT", 54, 78]]], ["The dimerization of the basic region (BR) has been achieved in several ways, for example by host-guest complexes of -cyclodextrin and adamantane, by photoresponsive devices as azobenzene, by Fe(II) complexes, by disulfi de bond between extra cysteines.", [["of -cyclodextrin", "CHEMICAL", 113, 129], ["adamantane", "CHEMICAL", 134, 144], ["azobenzene", "CHEMICAL", 176, 186], ["Fe(II", "CHEMICAL", 191, 196], ["disulfi", "CHEMICAL", 212, 219], ["adamantane", "CHEMICAL", 134, 144], ["azobenzene", "CHEMICAL", 176, 186], ["Fe(II)", "CHEMICAL", 191, 197], ["disulfi", "CHEMICAL", 212, 219], ["cysteines", "CHEMICAL", 242, 251], ["of -cyclodextrin", "SIMPLE_CHEMICAL", 113, 129], ["adamantane", "SIMPLE_CHEMICAL", 134, 144], ["azobenzene", "SIMPLE_CHEMICAL", 176, 186], ["Fe(II)", "SIMPLE_CHEMICAL", 191, 197], ["disulfi de bond", "SIMPLE_CHEMICAL", 212, 227], ["extra cysteines", "SIMPLE_CHEMICAL", 236, 251], ["basic region", "PROTEIN", 24, 36], ["BR", "PROTEIN", 38, 40], ["Fe(II) complexes", "PROTEIN", 191, 207], ["cyclodextrin", "TREATMENT", 117, 129], ["adamantane", "TREATMENT", 134, 144], ["photoresponsive devices as azobenzene", "TREATMENT", 149, 186], ["extra cysteines", "TREATMENT", 236, 251], ["dimerization", "OBSERVATION", 4, 16], ["extra cysteines", "OBSERVATION", 236, 251]]], ["In this work we present a new tool for the dimerization of the basic region of bZip proteins based on the use of a short PNA duplex.", [["bZip", "GENE_OR_GENE_PRODUCT", 79, 83], ["basic region", "PROTEIN", 63, 75], ["bZip proteins", "PROTEIN", 79, 92], ["bZip proteins", "TREATMENT", 79, 92], ["a short PNA duplex", "TREATMENT", 113, 131]]], ["We used the PNA duplex as dimerization tool in consideration of its high thermal, chemical and enzymatic stability, which will reveal useful for its future use as a decoy.", [["the PNA duplex", "TREATMENT", 8, 22], ["dimerization tool", "TEST", 26, 43], ["a decoy", "TREATMENT", 163, 170], ["PNA", "OBSERVATION", 12, 15]]], ["The PNA dimerizer was linked to the BR peptide by a native chemical ligation reaction.", [["PNA dimerizer", "CHEMICAL", 4, 17], ["PNA dimerizer", "SIMPLE_CHEMICAL", 4, 17], ["The PNA dimerizer", "PROBLEM", 0, 17], ["a native chemical ligation reaction", "TREATMENT", 50, 85], ["PNA", "OBSERVATION", 4, 7], ["native", "OBSERVATION_MODIFIER", 52, 58], ["chemical ligation", "OBSERVATION", 59, 76]]], ["The peptide, corresponding to the basic region of the GCN4 protein, was obtained by solid phase synthesis with an extra Lys residue at the C-terminus.", [["Lys", "CHEMICAL", 120, 123], ["Lys", "CHEMICAL", 120, 123], ["C", "CHEMICAL", 139, 140], ["GCN4", "GENE_OR_GENE_PRODUCT", 54, 58], ["basic region", "PROTEIN", 34, 46], ["GCN4 protein", "PROTEIN", 54, 66], ["C-terminus", "PROTEIN", 139, 149], ["The peptide", "TEST", 0, 11], ["the GCN4 protein", "TEST", 50, 66], ["solid phase synthesis", "TREATMENT", 84, 105], ["an extra Lys residue at the C-terminus", "PROBLEM", 111, 149], ["GCN4 protein", "OBSERVATION", 54, 66], ["extra Lys residue", "OBSERVATION", 114, 131]]], ["The Lys side chain was selectively deprotected on the resin and reacted with the monobenzylthioester of the succinic acid to give the C-terminus thioester peptide.", [["Lys side", "CHEMICAL", 4, 12], ["monobenzylthioester", "CHEMICAL", 81, 100], ["succinic acid", "CHEMICAL", 108, 121], ["Lys", "CHEMICAL", 4, 7], ["monobenzylthioester", "CHEMICAL", 81, 100], ["succinic acid", "CHEMICAL", 108, 121], ["C", "CHEMICAL", 134, 135], ["thioester", "CHEMICAL", 145, 154], ["monobenzylthioester", "SIMPLE_CHEMICAL", 81, 100], ["succinic acid", "SIMPLE_CHEMICAL", 108, 121], ["C-terminus thioester peptide", "SIMPLE_CHEMICAL", 134, 162], ["C-terminus", "PROTEIN", 134, 144], ["The Lys side chain", "TREATMENT", 0, 18], ["the resin", "TREATMENT", 50, 59], ["the succinic acid", "TREATMENT", 104, 121], ["the C-terminus thioester peptide", "TREATMENT", 130, 162]]], ["The peptide was reacted with complementary PNA strands bearing a cysteine respectively at the C and the N terminus to give the PNA-peptide conjugate.", [["cysteine", "CHEMICAL", 65, 73], ["cysteine", "CHEMICAL", 65, 73], ["N", "CHEMICAL", 104, 105], ["cysteine", "AMINO_ACID", 65, 73], ["PNA", "SIMPLE_CHEMICAL", 127, 130], ["C and the N terminus", "PROTEIN", 94, 114], ["a cysteine", "TREATMENT", 63, 73], ["the N terminus", "TREATMENT", 100, 114], ["the PNA", "PROBLEM", 123, 130], ["peptide conjugate", "PROBLEM", 131, 148], ["PNA", "OBSERVATION", 43, 46], ["PNA", "OBSERVATION", 127, 130]]], ["Formation of the PNA duplex induces dimerization of the BR peptides, to give a molecule able to bind its target DNA.", [["BR peptides", "GENE_OR_GENE_PRODUCT", 56, 67], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["the PNA duplex", "TREATMENT", 13, 27], ["the BR peptides", "TREATMENT", 52, 67], ["PNA", "OBSERVATION", 17, 20]]], ["CD spectra of the PNA-peptide single strand and of the dimeric (PNA-peptide) show the pronounced helical tendency of the ligated molecules.", [["ligated molecules", "PROTEIN", 121, 138], ["CD spectra", "TEST", 0, 10], ["the PNA", "TEST", 14, 21], ["the dimeric (PNA-peptide", "TEST", 51, 75], ["the pronounced helical tendency of the ligated molecules", "PROBLEM", 82, 138], ["PNA", "OBSERVATION", 18, 21], ["PNA", "OBSERVATION", 64, 67], ["pronounced", "OBSERVATION_MODIFIER", 86, 96], ["helical", "OBSERVATION_MODIFIER", 97, 104], ["tendency", "OBSERVATION", 105, 113], ["ligated molecules", "OBSERVATION", 121, 138]]], ["After complexation with the target DNA sequence, the BR helical content increases.", [["DNA", "CELLULAR_COMPONENT", 35, 38], ["target DNA sequence", "DNA", 28, 47], ["the target DNA sequence", "TEST", 24, 47], ["the BR helical content", "TEST", 49, 71]]], ["The ability of binding DNA was further confi rmed by EMSA assays.Developing Peptide Antagonists for both UFH and LMWHVaynshteyn, Yekaterina; Liang, Jun F. (James) Stevens institute of Technology, UNITED STATES Low molecular weight heparin (LMWH), derived from native heparin by chemical or enzymatic method, is a new generation of anticoagulant in an attempt to abate the side-effects of heparin.", [["UFH", "CHEMICAL", 105, 108], ["heparin", "CHEMICAL", 231, 238], ["LMWH", "CHEMICAL", 240, 244], ["heparin", "CHEMICAL", 267, 274], ["heparin", "CHEMICAL", 388, 395], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["Low molecular weight heparin", "SIMPLE_CHEMICAL", 210, 238], ["LMWH", "SIMPLE_CHEMICAL", 240, 244], ["heparin", "SIMPLE_CHEMICAL", 267, 274], ["heparin", "SIMPLE_CHEMICAL", 388, 395], ["binding DNA", "DNA", 15, 26], ["binding DNA", "PROBLEM", 15, 26], ["EMSA assays", "TEST", 53, 64], ["Peptide Antagonists", "TREATMENT", 76, 95], ["both UFH", "TREATMENT", 100, 108], ["LMWHVaynshteyn", "TREATMENT", 113, 127], ["Low molecular weight heparin (LMWH", "TREATMENT", 210, 244], ["native heparin", "TREATMENT", 260, 274], ["enzymatic method", "TREATMENT", 290, 306], ["anticoagulant", "TREATMENT", 331, 344], ["heparin", "TREATMENT", 388, 395], ["UFH", "OBSERVATION", 105, 108]]], ["LMWHs have high bioavailability after subcutaneous injection, long half-life, and fewer adverse effects compared with unfractionated heparin, in particular, a much lower risk of heparin-induced thrombocytopenia and osteoporosis.", [["subcutaneous", "ANATOMY", 38, 50], ["heparin", "CHEMICAL", 133, 140], ["heparin", "CHEMICAL", 178, 185], ["thrombocytopenia", "DISEASE", 194, 210], ["osteoporosis", "DISEASE", 215, 227], ["LMWHs", "SIMPLE_CHEMICAL", 0, 5], ["heparin", "SIMPLE_CHEMICAL", 133, 140], ["heparin", "SIMPLE_CHEMICAL", 178, 185], ["LMWHs", "TREATMENT", 0, 5], ["subcutaneous injection", "TREATMENT", 38, 60], ["fewer adverse effects", "PROBLEM", 82, 103], ["unfractionated heparin", "TREATMENT", 118, 140], ["heparin", "TREATMENT", 178, 185], ["thrombocytopenia", "PROBLEM", 194, 210], ["osteoporosis", "PROBLEM", 215, 227], ["high", "OBSERVATION_MODIFIER", 11, 15], ["bioavailability", "OBSERVATION_MODIFIER", 16, 31], ["heparin", "OBSERVATION", 178, 185], ["thrombocytopenia", "OBSERVATION", 194, 210], ["osteoporosis", "OBSERVATION", 215, 227]]], ["Despite the clinical benefi ts, LMWH suffers from shortcomings of its own.", [["LMWH", "CHEMICAL", 32, 36], ["LMWH", "TREATMENT", 32, 36], ["LMWH", "OBSERVATION", 32, 36]]], ["Unlike unfractionated heparin (UFH) can be reversed by protamine, protamine, a anti-heparin drug, appears to only neutralize approximately 50 % of the anti-Xa activity of LMWH.", [["heparin", "CHEMICAL", 22, 29], ["UFH", "CHEMICAL", 31, 34], ["protamine", "CHEMICAL", 55, 64], ["protamine", "CHEMICAL", 66, 75], ["LMWH", "CHEMICAL", 171, 175], ["protamine", "CHEMICAL", 66, 75], ["unfractionated heparin", "SIMPLE_CHEMICAL", 7, 29], ["UFH", "SIMPLE_CHEMICAL", 31, 34], ["protamine", "SIMPLE_CHEMICAL", 55, 64], ["protamine", "SIMPLE_CHEMICAL", 66, 75], ["anti-heparin", "SIMPLE_CHEMICAL", 79, 91], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 151, 158], ["LMWH", "SIMPLE_CHEMICAL", 171, 175], ["anti-Xa", "PROTEIN", 151, 158], ["unfractionated heparin (UFH", "TREATMENT", 7, 34], ["protamine", "TREATMENT", 55, 64], ["protamine", "TREATMENT", 66, 75], ["a anti-heparin drug", "TREATMENT", 77, 96], ["the anti-Xa activity of LMWH", "TREATMENT", 147, 175], ["LMWH", "OBSERVATION", 171, 175]]], ["Therefore, even though it is approved as effective anticoagulant for the prevention and treatment of various thrombotic disorders, LMWH is restrained from being used in the patients at high risk of bleeding, or in whom rapid reversal of anticoagulation may be required such as in intensive care units, operating theatres, and for patients with renal impairment.", [["renal", "ANATOMY", 344, 349], ["thrombotic disorders", "DISEASE", 109, 129], ["LMWH", "CHEMICAL", 131, 135], ["bleeding", "DISEASE", 198, 206], ["renal impairment", "DISEASE", 344, 360], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 330, 338], ["renal", "ORGAN", 344, 349], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 330, 338], ["effective anticoagulant", "TREATMENT", 41, 64], ["the prevention", "TREATMENT", 69, 83], ["treatment", "TREATMENT", 88, 97], ["various thrombotic disorders", "PROBLEM", 101, 129], ["LMWH", "TREATMENT", 131, 135], ["bleeding", "PROBLEM", 198, 206], ["anticoagulation", "TREATMENT", 237, 252], ["renal impairment", "PROBLEM", 344, 360], ["various", "OBSERVATION_MODIFIER", 101, 108], ["thrombotic", "OBSERVATION", 109, 119], ["bleeding", "OBSERVATION", 198, 206], ["renal", "ANATOMY", 344, 349], ["impairment", "OBSERVATION", 350, 360]]], ["So far, there is no proven method for LMWH neutralization, rendering the limitation and risk of LMWH drug.", [["LMWH", "CHEMICAL", 38, 42], ["LMWH", "CHEMICAL", 96, 100], ["LMWH", "SIMPLE_CHEMICAL", 38, 42], ["LMWH", "SIMPLE_CHEMICAL", 96, 100], ["LMWH neutralization", "TREATMENT", 38, 57], ["LMWH drug", "TREATMENT", 96, 105], ["no proven", "UNCERTAINTY", 17, 26], ["neutralization", "OBSERVATION", 43, 57], ["LMWH", "OBSERVATION", 96, 100]]], ["We have tried to identify the key heparin neutralization sequences in protamine and expected that small peptides with key sequences may neutralize LMWH completely.", [["heparin", "CHEMICAL", 34, 41], ["protamine", "CHEMICAL", 70, 79], ["LMWH", "CHEMICAL", 147, 151], ["heparin", "SIMPLE_CHEMICAL", 34, 41], ["protamine", "SIMPLE_CHEMICAL", 70, 79], ["LMWH", "SIMPLE_CHEMICAL", 147, 151], ["the key heparin neutralization sequences", "TREATMENT", 26, 66], ["protamine", "TREATMENT", 70, 79], ["small peptides with key sequences", "PROBLEM", 98, 131], ["LMWH", "TREATMENT", 147, 151]]], ["Through carefully designed enzyme digestion approaches and peptide isolation technology, new peptides with strong anti-heparin activity to both unfractionated heparin (UFH) and low molecular weight heparin (LMWH) have been found.", [["heparin", "CHEMICAL", 159, 166], ["UFH", "CHEMICAL", 168, 171], ["heparin", "CHEMICAL", 198, 205], ["LMWH", "CHEMICAL", 207, 211], ["heparin", "SIMPLE_CHEMICAL", 159, 166], ["UFH", "SIMPLE_CHEMICAL", 168, 171], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 177, 205], ["LMWH", "SIMPLE_CHEMICAL", 207, 211], ["enzyme digestion approaches", "TREATMENT", 27, 54], ["peptide isolation technology", "TREATMENT", 59, 87], ["new peptides", "TREATMENT", 89, 101], ["strong anti-heparin activity", "TREATMENT", 107, 135], ["both unfractionated heparin", "TREATMENT", 139, 166], ["UFH", "TREATMENT", 168, 171], ["low molecular weight heparin (LMWH", "TREATMENT", 177, 211]]], ["Preclinical studies show that the new antiheparin peptides have strong heparin and LMWH neutralization activity but with much less toxicity compared to the protamine on the market.", [["heparin", "CHEMICAL", 71, 78], ["LMWH", "CHEMICAL", 83, 87], ["toxicity", "DISEASE", 131, 139], ["protamine", "CHEMICAL", 156, 165], ["heparin", "SIMPLE_CHEMICAL", 71, 78], ["LMWH", "SIMPLE_CHEMICAL", 83, 87], ["protamine", "SIMPLE_CHEMICAL", 156, 165], ["Preclinical studies", "TEST", 0, 19], ["the new antiheparin peptides", "TREATMENT", 30, 58], ["strong heparin", "TREATMENT", 64, 78], ["LMWH neutralization activity", "TREATMENT", 83, 111], ["much less toxicity", "PROBLEM", 121, 139], ["the protamine", "TREATMENT", 152, 165], ["LMWH", "OBSERVATION", 83, 87], ["neutralization activity", "OBSERVATION", 88, 111]]], ["Finding of antagonists with complete heparin and LMWH neutralization ability is a very exciting achievement of great signifi cance.", [["heparin", "CHEMICAL", 37, 44], ["LMWH", "CHEMICAL", 49, 53], ["heparin", "SIMPLE_CHEMICAL", 37, 44], ["LMWH", "SIMPLE_CHEMICAL", 49, 53], ["antagonists", "TREATMENT", 11, 22], ["complete heparin", "TREATMENT", 28, 44], ["LMWH neutralization", "TREATMENT", 49, 68], ["LMWH", "OBSERVATION", 49, 53]]], ["Now we are working with local pharmaceutical company to extend the preclinical trails on these peptides.Frontier and Perspectives -Specifi c and Sensitive Identifi cation of Peptides Using Peptidomics and MALDI Imaging Mass SpectrometryAndr\u00e9n, PerUniversity of Uppsala, Dept. of Pharmaceutical Biosciences, Medical Mass Spectrometry, SWEDENImaging MALDI mass spectrometry (IMS) and peptidomics (nanoLC ESI MS) are powerful tools utilized for thorough imaging and profi ling of a large number of neuropeptides, small proteins and drugs.", [["these peptides", "TREATMENT", 89, 103], ["Sensitive Identifi cation of Peptides", "TREATMENT", 145, 182], ["Peptidomics", "TEST", 189, 200], ["MALDI Imaging", "TEST", 205, 218], ["Pharmaceutical Biosciences", "TREATMENT", 279, 305], ["Medical Mass Spectrometry", "TEST", 307, 332], ["MALDI mass spectrometry", "PROBLEM", 348, 371], ["peptidomics (nanoLC ESI MS", "PROBLEM", 382, 408], ["thorough imaging", "TEST", 442, 458], ["small proteins and drugs", "PROBLEM", 510, 534], ["large", "OBSERVATION_MODIFIER", 479, 484]]], ["IMS is a relatively new technology and can be used to locate specifi c molecules from frozen tissue sections of a tissue.", [["tissue sections", "ANATOMY", 93, 108], ["tissue", "ANATOMY", 114, 120], ["specifi c molecules", "GENE_OR_GENE_PRODUCT", 61, 80], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 93, 108], ["tissue", "TISSUE", 114, 120], ["specifi c molecules", "PROTEIN", 61, 80], ["frozen tissue", "OBSERVATION_MODIFIER", 86, 99], ["tissue", "ANATOMY", 114, 120]]], ["Using a raster of mass spectra over a given area of a section, images of samples are produced in specifi c m/z values.", [["samples", "ANATOMY", 73, 80], ["a raster of mass spectra", "TREATMENT", 6, 30], ["images of samples", "TEST", 63, 80], ["mass", "OBSERVATION", 18, 22]]], ["Each spot on the sample irradiated by the laser is approximately 50 microns in diameter and the resulting spectrum contains hundreds of individual signals.", [["sample", "ANATOMY", 17, 23], ["50 microns", "OBSERVATION_MODIFIER", 65, 75], ["hundreds", "OBSERVATION_MODIFIER", 124, 132], ["individual signals", "OBSERVATION", 136, 154]]], ["These m/z values can then be assembled from these mass spectra to produce selected m/z images.", [["These m/z values", "TEST", 0, 16], ["these mass spectra", "PROBLEM", 44, 62], ["selected m/z images", "TEST", 74, 93], ["mass", "OBSERVATION", 50, 54]]], ["However, peptidomics and IMS analysis may be complicated by protein fragments that may be produced post-mortem during conventional sample handling.", [["sample", "ANATOMY", 131, 137], ["peptidomics", "TEST", 9, 20], ["IMS analysis", "TEST", 25, 37], ["protein fragments", "PROBLEM", 60, 77], ["conventional sample handling", "TREATMENT", 118, 146], ["protein fragments", "OBSERVATION", 60, 77]]], ["A novel sample preparation method and peptide identifi cation tools for analysis of brain lysates and tissue sections were used to study changes in peptide expression in experimental Parkinson's disease (PD) and to identify novel, potentially biologically active neuropeptides.", [["sample", "ANATOMY", 8, 14], ["brain lysates", "ANATOMY", 84, 97], ["tissue sections", "ANATOMY", 102, 117], ["Parkinson's disease", "DISEASE", 183, 202], ["PD", "DISEASE", 204, 206], ["brain lysates", "ORGANISM_SUBSTANCE", 84, 97], ["tissue sections", "CANCER", 102, 117], ["A novel sample preparation method", "TREATMENT", 0, 33], ["brain lysates", "TEST", 84, 97], ["tissue sections", "TEST", 102, 117], ["experimental Parkinson's disease", "PROBLEM", 170, 202], ["brain", "ANATOMY", 84, 89]]], ["The brain tissue were either analyzed by nanoLC-ESI MSMS after homogenization of specifi c brain regions or cut by a cryomicrotome and studied by IMS.University of Uppsala, Dept. of Pharmaceutical Biosciences, Medical Mass Spectrometry, SWEDENTo optimize the identifi cation process for endogenous peptides we used our in-house constructed SwePep database (www.swepep.org).", [["brain tissue", "ANATOMY", 4, 16], ["specifi c brain", "ANATOMY", 81, 96], ["brain tissue", "TISSUE", 4, 16], ["brain", "ORGAN", 91, 96], ["cation", "SIMPLE_CHEMICAL", 268, 274], ["specifi c brain regions", "DNA", 81, 104], ["specifi c brain regions", "PROBLEM", 81, 104], ["Pharmaceutical Biosciences", "TREATMENT", 182, 208], ["Medical Mass Spectrometry", "TREATMENT", 210, 235], ["the identifi cation process", "TREATMENT", 255, 282], ["endogenous peptides", "PROBLEM", 287, 306], ["brain tissue", "ANATOMY", 4, 16], ["brain", "ANATOMY", 91, 96]]], ["The analysis demonstrated several differentially expressed peptides and small proteins in the experimental models of PD.", [["PD", "DISEASE", 117, 119], ["The analysis", "TEST", 0, 12], ["several differentially expressed peptides", "PROBLEM", 26, 67], ["small proteins", "PROBLEM", 72, 86], ["PD", "PROBLEM", 117, 119], ["several", "OBSERVATION_MODIFIER", 26, 33], ["differentially", "OBSERVATION_MODIFIER", 34, 48], ["small", "OBSERVATION_MODIFIER", 72, 77], ["proteins", "OBSERVATION", 78, 86], ["experimental models", "OBSERVATION_MODIFIER", 94, 113]]], ["Preclinical methods that could improve thecharacterization of these features as early as possible in the drug development would help identifying potentially successful drug candidates and/or eliminate those that have adverse properties.", [["Preclinical methods", "TREATMENT", 0, 19]]], ["The direct analysis of tissues using IMS allows both endogenous and exogenous compounds present in tissues to be detected with molecular specifi city while maintaining their spatial orientation.", [["tissues", "ANATOMY", 23, 30], ["tissues", "ANATOMY", 99, 106], ["tissues", "TISSUE", 23, 30], ["tissues", "TISSUE", 99, 106], ["The direct analysis", "TEST", 0, 19], ["exogenous compounds", "OBSERVATION", 68, 87]]], ["In the present study we have applied IMS to characterize the distribution of a drug in lung of rats dosed by inhalation.", [["lung", "ANATOMY", 87, 91], ["lung", "ORGAN", 87, 91], ["rats", "ORGANISM", 95, 99], ["rats", "SPECIES", 95, 99], ["the present study", "TEST", 3, 20], ["a drug in lung of rats", "TREATMENT", 77, 99], ["lung", "ANATOMY", 87, 91]]], ["The result showed that although the highest concentration of the drug was observed in the central lung compartment, it was rapidly transported from the central conducting airways to alveolar beds in the upper and lower parenchyma.", [["central lung compartment", "ANATOMY", 90, 114], ["airways", "ANATOMY", 171, 178], ["alveolar beds", "ANATOMY", 182, 195], ["upper", "ANATOMY", 203, 208], ["lower parenchyma", "ANATOMY", 213, 229], ["lung compartment", "MULTI-TISSUE_STRUCTURE", 98, 114], ["airways", "MULTI-TISSUE_STRUCTURE", 171, 178], ["alveolar beds", "MULTI-TISSUE_STRUCTURE", 182, 195], ["upper", "ORGANISM_SUBDIVISION", 203, 208], ["lower parenchyma", "MULTI-TISSUE_STRUCTURE", 213, 229], ["central", "ANATOMY_MODIFIER", 90, 97], ["lung", "ANATOMY", 98, 102], ["compartment", "ANATOMY_MODIFIER", 103, 114], ["central", "ANATOMY_MODIFIER", 152, 159], ["airways", "ANATOMY", 171, 178], ["alveolar beds", "OBSERVATION", 182, 195], ["upper", "ANATOMY_MODIFIER", 203, 208], ["lower", "ANATOMY_MODIFIER", 213, 218], ["parenchyma", "ANATOMY_MODIFIER", 219, 229]]], ["The distribution pattern and the levels of the drug in consecutive lung tissue sections correlated very well when comparing the analysis performed in MS and MS/MS mode.", [["lung tissue sections", "ANATOMY", 67, 87], ["lung tissue sections", "MULTI-TISSUE_STRUCTURE", 67, 87], ["the drug in consecutive lung tissue sections", "PROBLEM", 43, 87], ["the analysis", "TEST", 124, 136], ["MS", "TEST", 150, 152], ["MS", "TEST", 157, 159], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["pattern", "OBSERVATION_MODIFIER", 17, 24], ["drug", "OBSERVATION_MODIFIER", 47, 51], ["lung tissue", "ANATOMY", 67, 78]]], ["It is concluded that IMS proved sensitive, specifi c, and highly useful to the image analysis of traditional small molecule drugs directly in tissue sections.Title Abs NoFrontier The emerging relevance of glycan-encoded information in a plethora of biological events directs increasing attention to interaction structures between bioactive glycan determinants and their endogenous receptors, such as lectins (1).", [["tissue sections", "ANATOMY", 142, 157], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 142, 157], ["lectins (1)", "GENE_OR_GENE_PRODUCT", 400, 411], ["Title Abs", "PROTEIN", 158, 167], ["endogenous receptors", "PROTEIN", 370, 390], ["lectins", "PROTEIN", 400, 407], ["the image analysis", "TEST", 75, 93], ["traditional small molecule drugs", "TREATMENT", 97, 129], ["molecule drugs", "OBSERVATION", 115, 129]]], ["Structures of carbohydrate complexes with lectins and antibodies have been determined in a few cases by Xray crystallography and NMR, however both methods are limited by large amounts and high purity of material required.", [["carbohydrate", "CHEMICAL", 14, 26], ["lectins", "GENE_OR_GENE_PRODUCT", 42, 49], ["carbohydrate complexes", "PROTEIN", 14, 36], ["lectins", "PROTEIN", 42, 49], ["antibodies", "PROTEIN", 54, 64], ["lectins and antibodies", "PROBLEM", 42, 64], ["Xray crystallography", "TEST", 104, 124], ["NMR", "TEST", 129, 132], ["high purity of material", "PROBLEM", 188, 211], ["carbohydrate complexes", "OBSERVATION", 14, 36], ["large", "OBSERVATION_MODIFIER", 170, 175], ["amounts", "OBSERVATION_MODIFIER", 176, 183], ["high purity", "OBSERVATION_MODIFIER", 188, 199]]], ["We report here a new direct method for molecular mapping of peptide motifs in lectin carbohydrate domains (CRD) by the combination of proteolytic excision of protein-carbohydrate complexes and mass spectrometry (CREDEX: Carbohydrate-REcognition-Domain-EXcision).", [["carbohydrate", "CHEMICAL", 85, 97], ["carbohydrate", "CHEMICAL", 166, 178], ["Carbohydrate", "CHEMICAL", 220, 232], ["lectin carbohydrate domains", "PROTEIN", 78, 105], ["CRD", "PROTEIN", 107, 110], ["protein-carbohydrate complexes", "PROTEIN", 158, 188], ["molecular mapping of peptide motifs", "TREATMENT", 39, 74], ["proteolytic excision of protein-carbohydrate complexes", "TREATMENT", 134, 188], ["mass spectrometry", "PROBLEM", 193, 210], ["Carbohydrate", "TEST", 220, 232], ["EXcision", "TREATMENT", 252, 260]]], ["The CREDEX-MS method was applied to the identifi cation of CRDs of human galectin-3 and galectin-1, for which X-ray crystal structures of their lactose complexes have been determined.", [["lactose", "CHEMICAL", 144, 151], ["lactose", "CHEMICAL", 144, 151], ["human", "ORGANISM", 67, 72], ["galectin-3", "GENE_OR_GENE_PRODUCT", 73, 83], ["galectin-1", "GENE_OR_GENE_PRODUCT", 88, 98], ["lactose", "SIMPLE_CHEMICAL", 144, 151], ["CRDs", "PROTEIN", 59, 63], ["human galectin-3", "PROTEIN", 67, 83], ["galectin-1", "PROTEIN", 88, 98], ["lactose complexes", "PROTEIN", 144, 161], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["The CREDEX-MS method", "TREATMENT", 0, 20], ["human galectin", "TEST", 67, 81], ["galectin", "TEST", 88, 96], ["lactose complexes", "OBSERVATION", 144, 161]]], ["Lactose was covalently coupled to epoxy-activated Sepharose, galectins added to the affi nity matrix and the lectin complexes digested using trypsin.", [["Lactose", "CHEMICAL", 0, 7], ["Lactose", "CHEMICAL", 0, 7], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["Sepharose", "SIMPLE_CHEMICAL", 50, 59], ["galectins", "GENE_OR_GENE_PRODUCT", 61, 70], ["matrix", "CELLULAR_COMPONENT", 94, 100], ["lectin", "GENE_OR_GENE_PRODUCT", 109, 115], ["trypsin", "GENE_OR_GENE_PRODUCT", 141, 148], ["galectins", "PROTEIN", 61, 70], ["lectin complexes", "PROTEIN", 109, 125], ["trypsin", "PROTEIN", 141, 148], ["Lactose", "TREATMENT", 0, 7], ["epoxy-activated Sepharose", "TREATMENT", 34, 59], ["galectins", "TREATMENT", 61, 70], ["the affi nity matrix", "TREATMENT", 80, 100], ["trypsin", "TREATMENT", 141, 148]]], ["After removal of unbound fragments, competitive elution of remaining affi nity-bound gal-peptides with lactose followed by MALDI-MS provided the identifi cation of specifi c peptides, gal-3(152-162) and -(177-183), and gal-1(37-48) and (64-73), in complete agreement with CRDs from the crystal structures.", [["fragments", "ANATOMY", 25, 34], ["lactose", "CHEMICAL", 103, 110], ["lactose", "CHEMICAL", 103, 110], ["affi nity", "SIMPLE_CHEMICAL", 69, 78], ["gal-peptides", "GENE_OR_GENE_PRODUCT", 85, 97], ["lactose", "SIMPLE_CHEMICAL", 103, 110], ["cation", "SIMPLE_CHEMICAL", 154, 160], ["specifi c peptides", "GENE_OR_GENE_PRODUCT", 164, 182], ["gal-3(152-162", "SIMPLE_CHEMICAL", 184, 197], ["gal-1(37-48", "SIMPLE_CHEMICAL", 219, 230], ["CRDs", "SIMPLE_CHEMICAL", 272, 276], ["CRDs", "PROTEIN", 272, 276], ["removal", "TREATMENT", 6, 13], ["unbound fragments", "PROBLEM", 17, 34], ["remaining affi nity", "TREATMENT", 59, 78], ["lactose", "TREATMENT", 103, 110], ["gal", "TEST", 184, 187], ["gal", "TEST", 219, 222], ["unbound fragments", "OBSERVATION", 17, 34]]], ["Their specifi city was confi rmed by affi nity-MS (2)Song, Zhao; Etzkorn, Felicia A. Virginia Tech, UNITED STATESRegulation of the cell cycle by Pin1 can only be accomplished if a pSer/Thr-cis/trans-Pro equilibrium is upset by outside action.", [["cell", "ANATOMY", 131, 135], ["pSer", "CHEMICAL", 180, 184], ["Thr-cis/trans-Pro", "CHEMICAL", 185, 202], ["cell", "CELL", 131, 135], ["Pin1", "GENE_OR_GENE_PRODUCT", 145, 149], ["pSer", "GENE_OR_GENE_PRODUCT", 180, 184], ["Thr-", "GENE_OR_GENE_PRODUCT", 185, 189], ["Pin1", "PROTEIN", 145, 149]]], ["We hypothesized that a kinase upstream of Cdc25C is conformation specifi c and causes just such an upset of the equilibrium by phosphorylating one isomer at a pSer-Pro site in Cdc25C.", [["pSer-Pro", "CHEMICAL", 159, 167], ["Cdc25C", "GENE_OR_GENE_PRODUCT", 42, 48], ["specifi c", "GENE_OR_GENE_PRODUCT", 65, 74], ["Cdc25C", "GENE_OR_GENE_PRODUCT", 176, 182], ["Cdc25C", "PROTEIN", 42, 48], ["pSer-Pro site", "PROTEIN", 159, 172], ["Cdc25C", "PROTEIN", 176, 182], ["a kinase upstream", "TEST", 21, 38]]], ["Conformationally constrained alkene isosteres of Ser-cis-Pro and Ser-trans-Pro were incorporated into Cdc25C peptides corresponding to a phosphorylation site for Cdc2 kinase.", [["alkene", "CHEMICAL", 29, 35], ["Ser-cis-Pro", "CHEMICAL", 49, 60], ["Ser-trans-Pro", "CHEMICAL", 65, 78], ["alkene", "CHEMICAL", 29, 35], ["Ser-cis-Pro", "CHEMICAL", 49, 60], ["Ser-trans-Pro", "CHEMICAL", 65, 78], ["alkene isosteres", "SIMPLE_CHEMICAL", 29, 45], ["Ser-cis-Pro", "SIMPLE_CHEMICAL", 49, 60], ["Ser-trans-Pro", "SIMPLE_CHEMICAL", 65, 78], ["Cdc25C", "GENE_OR_GENE_PRODUCT", 102, 108], ["Cdc2 kinase", "GENE_OR_GENE_PRODUCT", 162, 173], ["Cdc25C", "PROTEIN", 102, 108], ["phosphorylation site", "PROTEIN", 137, 157], ["Cdc2 kinase", "PROTEIN", 162, 173], ["Cdc25C peptides", "TREATMENT", 102, 117], ["a phosphorylation site", "TREATMENT", 135, 157], ["Cdc2 kinase", "TEST", 162, 173]]], ["The peptide isosteres were phosphorylated by Cdc2 kinase with ATP.", [["ATP", "CHEMICAL", 62, 65], ["ATP", "CHEMICAL", 62, 65], ["Cdc2", "GENE_OR_GENE_PRODUCT", 45, 49], ["ATP", "SIMPLE_CHEMICAL", 62, 65], ["Cdc2 kinase", "PROTEIN", 45, 56], ["The peptide isosteres", "TREATMENT", 0, 21], ["ATP", "PROBLEM", 62, 65]]], ["Product phosphopeptide isosteres were detected using SIMS in LC-MSMS.", [["Product phosphopeptide isosteres", "TREATMENT", 0, 32]]], ["Control phosphopeptide isosteres were synthesized to optimize MS sensitivity.", [["Control phosphopeptide isosteres", "TREATMENT", 0, 32], ["MS sensitivity", "PROBLEM", 62, 76]]], ["Cdc2 kinase phosphorylated only the Ser-trans-Pro isostere, and only at the specifi c site, not at three other possible sites in the peptide, as shown by MSMS peptide sequencing.S16-4Modifi cations in the chemical structure of Trojan carriers: impact on cargo delivery Cell-penetrating peptides (CPPs) are promising tools for delivering bioactive cargoes.", [["Cell", "ANATOMY", 269, 273], ["Ser-trans-Pro", "CHEMICAL", 36, 49], ["S16-4Modifi cations", "CHEMICAL", 178, 197], ["Ser-trans-Pro", "CHEMICAL", 36, 49], ["S16-4Modifi", "CHEMICAL", 178, 189], ["Cdc2", "GENE_OR_GENE_PRODUCT", 0, 4], ["S16-4Modifi cations", "SIMPLE_CHEMICAL", 178, 197], ["Cdc2 kinase", "PROTEIN", 0, 11], ["Ser-trans-Pro isostere", "DNA", 36, 58], ["specifi c site", "DNA", 76, 90], ["Cdc2 kinase phosphorylated", "TEST", 0, 26], ["S16-4Modifi cations", "TREATMENT", 178, 197], ["cargo delivery", "TREATMENT", 254, 268], ["Cell-penetrating peptides", "TREATMENT", 269, 294], ["bioactive cargoes", "TREATMENT", 337, 354], ["Trojan carriers", "OBSERVATION", 227, 242]]], ["One of the challenges now is to design CPPs with improved effi ciencies of delivery and which can specifi cally target cargoes to the different cellular organelles.", [["cellular organelles", "ANATOMY", 144, 163], ["cellular organelles", "CELLULAR_COMPONENT", 144, 163], ["delivery", "TREATMENT", 75, 83], ["cellular organelles", "OBSERVATION", 144, 163]]], ["Using an original library of pseudo-peptide carriers, we have explored the impact on cargo delivery of changing the functional groups of the carrier (ammonium, guanidinium, myristyl) and the spatial distribution of these groups (Aussedat et al. 2008 ).", [["ammonium, guanidinium", "CHEMICAL", 150, 171], ["myristyl", "CHEMICAL", 173, 181], ["ammonium", "CHEMICAL", 150, 158], ["guanidinium", "CHEMICAL", 160, 171], ["myristyl", "CHEMICAL", 173, 181], ["ammonium", "SIMPLE_CHEMICAL", 150, 158], ["guanidinium", "SIMPLE_CHEMICAL", 160, 171], ["myristyl", "SIMPLE_CHEMICAL", 173, 181], ["pseudo-peptide carriers", "TREATMENT", 29, 52], ["cargo delivery", "TREATMENT", 85, 99], ["the carrier (ammonium, guanidinium", "TREATMENT", 137, 171], ["myristyl", "TREATMENT", 173, 181]]], ["These pseudo-peptide carriers were obtained by modular construction from the alpha, alpha-disubstituted amino acid \"bis-ornithine\".", [["alpha, alpha-disubstituted amino acid", "CHEMICAL", 77, 114], ["bis-ornithine", "CHEMICAL", 116, 129], ["alpha, alpha-disubstituted amino acid", "CHEMICAL", 77, 114], ["bis-ornithine", "CHEMICAL", 116, 129], ["alpha-disubstituted amino acid", "SIMPLE_CHEMICAL", 84, 114], ["bis-ornithine", "SIMPLE_CHEMICAL", 116, 129], ["These pseudo-peptide carriers", "PROBLEM", 0, 29], ["alpha-disubstituted amino acid", "TREATMENT", 84, 114], ["alpha", "ANATOMY", 77, 82]]], ["This amino acid offers great fl exibility in the design of polymers with linear, branched or dendrimeric structures.", [["amino acid", "CHEMICAL", 5, 15], ["amino acid", "CHEMICAL", 5, 15], ["amino acid", "AMINO_ACID", 5, 15], ["This amino acid", "TEST", 0, 15], ["linear, branched or dendrimeric structures", "PROBLEM", 73, 115], ["fl exibility", "OBSERVATION", 29, 41], ["linear", "OBSERVATION_MODIFIER", 73, 79], ["branched", "OBSERVATION_MODIFIER", 81, 89]]], ["The quantifi cation of the internalized cargo and the study of its intracellular degradation were performed by a method based on MALDI-TOF MS. Its intracellular localization was studied by confocal microscopy.", [["intracellular", "ANATOMY", 67, 80], ["intracellular", "ANATOMY", 147, 160], ["cation", "SIMPLE_CHEMICAL", 13, 19], ["cargo", "CELLULAR_COMPONENT", 40, 45], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["the study", "TEST", 50, 59], ["confocal microscopy", "TEST", 189, 208]]], ["Data show that the chemical structure of the carrier has a strong impact on the intracellular localization of the cargo.", [["intracellular", "ANATOMY", 80, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["cargo", "CELLULAR_COMPONENT", 114, 119]]], ["Commun, 2008 , 12, 1398 .S17-1The type of bond between lipid chain and peptide determines the route of uptake of lipopeptides into antigen presenting cells: example of an encephalitogenic epitope.", [["cells", "ANATOMY", 150, 155], ["lipid chain", "SIMPLE_CHEMICAL", 55, 66], ["cells", "CELL", 150, 155], ["antigen presenting cells", "CELL_TYPE", 131, 155], ["encephalitogenic epitope", "PROTEIN", 171, 195], ["lipid chain and peptide", "TREATMENT", 55, 78], ["uptake of lipopeptides", "TREATMENT", 103, 125], ["an encephalitogenic epitope", "PROBLEM", 168, 195], ["encephalitogenic epitope", "OBSERVATION", 171, 195]]], ["Proteolipid protein (PLP) is the most abundant protein of central nervous system myelin, and is posttranslationally acylated at six cysteine residues by covalent attachment of palmitic acid via thioester linkage.", [["central nervous system myelin", "ANATOMY", 58, 87], ["palmitic acid", "CHEMICAL", 176, 189], ["cysteine", "CHEMICAL", 132, 140], ["palmitic acid", "CHEMICAL", 176, 189], ["thioester", "CHEMICAL", 194, 203], ["Proteolipid protein", "GENE_OR_GENE_PRODUCT", 0, 19], ["PLP", "GENE_OR_GENE_PRODUCT", 21, 24], ["central nervous system", "ANATOMICAL_SYSTEM", 58, 80], ["myelin", "ORGANISM_SUBSTANCE", 81, 87], ["palmitic acid", "SIMPLE_CHEMICAL", 176, 189], ["thioester", "SIMPLE_CHEMICAL", 194, 203], ["Proteolipid protein", "PROTEIN", 0, 19], ["PLP", "PROTEIN", 21, 24], ["Proteolipid protein", "TEST", 0, 19], ["PLP", "TEST", 21, 24], ["central nervous system myelin", "PROBLEM", 58, 87], ["six cysteine residues", "TREATMENT", 128, 149], ["palmitic acid via thioester linkage", "TREATMENT", 176, 211], ["most abundant", "OBSERVATION_MODIFIER", 33, 46], ["protein", "OBSERVATION", 47, 54], ["central", "ANATOMY_MODIFIER", 58, 65], ["nervous system myelin", "OBSERVATION", 66, 87], ["acylated", "OBSERVATION_MODIFIER", 116, 124], ["cysteine residues", "OBSERVATION", 132, 149], ["palmitic acid", "OBSERVATION", 176, 189]]], ["PLP is a potent immunogen which induces experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis.", [["PLP", "CHEMICAL", 0, 3], ["autoimmune encephalomyelitis", "DISEASE", 53, 81], ["EAE", "DISEASE", 83, 86], ["multiple sclerosis", "DISEASE", 109, 127], ["PLP", "CHEMICAL", 0, 3], ["PLP", "GENE_OR_GENE_PRODUCT", 0, 3], ["a potent immunogen", "TREATMENT", 7, 25], ["experimental autoimmune encephalomyelitis", "PROBLEM", 40, 81], ["multiple sclerosis", "PROBLEM", 109, 127], ["autoimmune encephalomyelitis", "OBSERVATION", 53, 81], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["sclerosis", "OBSERVATION", 118, 127]]], ["We were interested in the effects of palmitoylation on the encephalitogenic and immunogenic properties of PLP.", [["PLP", "CHEMICAL", 106, 109], ["PLP", "GENE_OR_GENE_PRODUCT", 106, 109], ["PLP", "PROTEIN", 106, 109], ["palmitoylation", "TREATMENT", 37, 51], ["the encephalitogenic", "TREATMENT", 55, 75], ["PLP", "PROBLEM", 106, 109]]], ["We have shown that thiopalmitoylation of PLP encephalitogenic epitopes (S-palm peptide) increased the immune response as well as the development and chronicity of EAE.", [["S-palm peptide", "CHEMICAL", 72, 86], ["EAE", "DISEASE", 163, 166], ["PLP", "CHEMICAL", 41, 44], ["PLP encephalitogenic epitopes", "GENE_OR_GENE_PRODUCT", 41, 70], ["PLP encephalitogenic epitopes", "PROTEIN", 41, 70], ["PLP encephalitogenic epitopes", "TREATMENT", 41, 70], ["EAE", "PROBLEM", 163, 166], ["immune response", "OBSERVATION", 102, 117]]], ["Our work also suggested that the lability of the thioester bond between the peptide and fatty acid was important for CD4+ T cells, as PLP lipopeptides synthesized with the fatty acid attached via an amide linkage at the N-terminus (N-palm peptide) induced a greater proportion of CD8+ T cells and were not encephalitogenic.", [["CD4+", "ANATOMY", 117, 121], ["T cells", "ANATOMY", 122, 129], ["T cells", "ANATOMY", 285, 292], ["fatty acid", "CHEMICAL", 88, 98], ["fatty acid", "CHEMICAL", 172, 182], ["N-palm peptide", "CHEMICAL", 232, 246], ["thioester", "CHEMICAL", 49, 58], ["fatty acid", "CHEMICAL", 88, 98], ["PLP", "CHEMICAL", 134, 137], ["fatty acid", "CHEMICAL", 172, 182], ["amide", "CHEMICAL", 199, 204], ["fatty acid", "SIMPLE_CHEMICAL", 88, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 117, 120], ["T cells", "CELL", 122, 129], ["PLP lipopeptides", "GENE_OR_GENE_PRODUCT", 134, 150], ["fatty acid", "SIMPLE_CHEMICAL", 172, 182], ["CD8", "GENE_OR_GENE_PRODUCT", 280, 283], ["T cells", "CELL", 285, 292], ["CD4", "PROTEIN", 117, 120], ["T cells", "CELL_TYPE", 122, 129], ["N-terminus", "PROTEIN", 220, 230], ["CD8", "PROTEIN", 280, 283], ["T cells", "CELL_TYPE", 285, 292], ["the lability of the thioester bond", "PROBLEM", 29, 63], ["the peptide and fatty acid", "TEST", 72, 98], ["CD4", "PROBLEM", 117, 120], ["PLP lipopeptides", "TREATMENT", 134, 150], ["the fatty acid", "TREATMENT", 168, 182], ["an amide linkage", "TREATMENT", 196, 212], ["the N-terminus", "TREATMENT", 216, 230], ["encephalitogenic", "PROBLEM", 306, 322], ["CD8", "OBSERVATION", 280, 283], ["not", "UNCERTAINTY", 302, 305], ["encephalitogenic", "OBSERVATION", 306, 322]]], ["Recently, we have determined the mechanisms responsible for these observations and have shown that: -the effi ciency of uptake of both the S-palm and N-palm peptides by antigen presenting cells (APC) is much greater than for non palmitoylated peptide. -the type of bond between lipid chain and peptide determines the route of uptake of the lipopeptides by APC: (i) The S-palm peptide is taken up into APC via an endocytic route, the thioester bond is cleaved in the endosome, and the peptide is subsequently presented in the context of MHC class II (ii) The N-palm peptide rapidly enters into the cytoplasm of the APC, the amide bond between peptide and lipid is not cleaved, and the lipopeptide travels via the endoplasmic reticulum to complex with MHC class I These fi ndings have potential application for the development of methods to specifi cally induce MHC class II-restricted responses and also for vaccine development.", [["antigen presenting cells", "ANATOMY", 169, 193], ["endosome", "ANATOMY", 466, 474], ["cytoplasm", "ANATOMY", 597, 606], ["endoplasmic reticulum", "ANATOMY", 712, 733], ["S-palm and N-palm", "CHEMICAL", 139, 156], ["N-palm peptide", "CHEMICAL", 558, 572], ["APC", "CHEMICAL", 356, 359], ["APC", "CHEMICAL", 401, 404], ["thioester", "CHEMICAL", 433, 442], ["APC", "CHEMICAL", 614, 617], ["amide", "CHEMICAL", 623, 628], ["antigen presenting", "GENE_OR_GENE_PRODUCT", 169, 187], ["cells", "CELL", 188, 193], ["APC", "GENE_OR_GENE_PRODUCT", 195, 198], ["lipid chain", "SIMPLE_CHEMICAL", 278, 289], ["APC", "GENE_OR_GENE_PRODUCT", 356, 359], ["APC", "GENE_OR_GENE_PRODUCT", 401, 404], ["endosome", "CELLULAR_COMPONENT", 466, 474], ["cytoplasm", "ORGANISM_SUBSTANCE", 597, 606], ["APC", "GENE_OR_GENE_PRODUCT", 614, 617], ["lipid", "SIMPLE_CHEMICAL", 654, 659], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 712, 733], ["MHC class I", "GENE_OR_GENE_PRODUCT", 750, 761], ["antigen presenting cells", "CELL_TYPE", 169, 193], ["APC", "CELL_TYPE", 195, 198], ["APC", "CELL_TYPE", 356, 359], ["APC", "CELL_TYPE", 401, 404], ["MHC class II", "PROTEIN", 536, 548], ["APC", "CELL_TYPE", 614, 617], ["MHC class I", "PROTEIN", 750, 761], ["MHC class II", "PROTEIN", 860, 872], ["APC", "TEST", 195, 198], ["non palmitoylated peptide", "TREATMENT", 225, 250], ["the type of bond between lipid chain and peptide", "TREATMENT", 253, 301], ["The N-palm peptide", "TREATMENT", 554, 572], ["the APC", "TREATMENT", 610, 617], ["the amide bond between peptide", "TREATMENT", 619, 649], ["vaccine development", "TREATMENT", 907, 926], ["palm", "ANATOMY", 141, 145], ["APC", "OBSERVATION", 614, 617]]], ["References: Greer JM, et al., J. Immunol., 2001 , 166, 6907 Pfender NA, et al., J. Immunol., 2008 , 180, 1398 Medical peptide chemistryTitle Abs NoThe type of bond between lipid chain and peptide determines the route of uptake of lipopeptides into antigen presenting cells: example of an encephalitogenic epitope.", [["cells", "ANATOMY", 267, 272], ["lipid chain", "SIMPLE_CHEMICAL", 172, 183], ["cells", "CELL", 267, 272], ["Title Abs", "PROTEIN", 135, 144], ["antigen presenting cells", "CELL_TYPE", 248, 272], ["encephalitogenic epitope", "PROTEIN", 288, 312], ["Medical peptide chemistry", "TEST", 110, 135], ["lipid chain", "TREATMENT", 172, 183], ["uptake of lipopeptides", "TREATMENT", 220, 242], ["an encephalitogenic epitope", "PROBLEM", 285, 312], ["encephalitogenic epitope", "OBSERVATION", 288, 312]]], ["Trifi lieff, Elisabeth S17-1 The peptides were radioactively labeled and the organ distribution with respect to a specifi c targeting to the transplanted hepatocytes, as well as the peptide stability was investigated.", [["organ", "ANATOMY", 77, 82], ["hepatocytes", "ANATOMY", 154, 165], ["organ", "ORGAN", 77, 82], ["specifi c", "GENE_OR_GENE_PRODUCT", 114, 123], ["hepatocytes", "CELL", 154, 165], ["specifi c", "PROTEIN", 114, 123], ["transplanted hepatocytes", "CELL_TYPE", 141, 165], ["Trifi", "TEST", 0, 5], ["transplanted", "ANATOMY_MODIFIER", 141, 153], ["hepatocytes", "ANATOMY", 154, 165]]], ["We observed that the peptides exclusively target the liver, obviously encompassing a speciesindependent determinant of hepatotropism.", [["liver", "ANATOMY", 53, 58], ["hepatotropism", "DISEASE", 119, 132], ["liver", "ORGAN", 53, 58], ["the peptides", "TEST", 17, 29], ["hepatotropism", "PROBLEM", 119, 132], ["liver", "ANATOMY", 53, 58], ["hepatotropism", "OBSERVATION", 119, 132]]], ["Using the series of peptides carrying deletions, point mutations, D-amino acid exchanges, sequence permutations and lipid variations we found that (i) N-terminal acylation prevents renal secretion of the peptide and leads to systemic retention, (ii) a highly conserved 7 a.a. sequence motif is the pharmacophore required for liver-targeting (iii) peptides containing this sequence are taken up by hepatocytes and accumulate within the cells.", [["renal", "ANATOMY", 181, 186], ["liver", "ANATOMY", 325, 330], ["hepatocytes", "ANATOMY", 397, 408], ["cells", "ANATOMY", 435, 440], ["D-amino acid", "CHEMICAL", 66, 78], ["D-amino acid", "CHEMICAL", 66, 78], ["D-amino acid", "SIMPLE_CHEMICAL", 66, 78], ["renal", "ORGAN", 181, 186], ["liver", "ORGAN", 325, 330], ["hepatocytes", "CELL", 397, 408], ["cells", "CELL", 435, 440], ["hepatocytes", "CELL_TYPE", 397, 408], ["peptides carrying deletions", "TREATMENT", 20, 47], ["point mutations", "PROBLEM", 49, 64], ["D-amino acid exchanges", "TREATMENT", 66, 88], ["sequence permutations", "TREATMENT", 90, 111], ["lipid variations", "TEST", 116, 132], ["N-terminal acylation", "TREATMENT", 151, 171], ["renal secretion of the peptide", "PROBLEM", 181, 211], ["systemic retention", "PROBLEM", 225, 243], ["liver-targeting (iii) peptides", "TREATMENT", 325, 355], ["this sequence", "TEST", 367, 380], ["renal", "ANATOMY", 181, 186], ["secretion", "OBSERVATION", 187, 196], ["systemic retention", "OBSERVATION", 225, 243], ["liver", "ANATOMY", 325, 330], ["hepatocytes", "ANATOMY", 397, 408], ["cells", "ANATOMY", 435, 440]]], ["This process is highly specifi c and differs from constitutive hepatic delivery via the blood, since single amino acid exchanges within the conserved motif resulted in a total loss of specifi city.", [["hepatic", "ANATOMY", 63, 70], ["blood", "ANATOMY", 88, 93], ["amino acid", "CHEMICAL", 108, 118], ["amino acid", "CHEMICAL", 108, 118], ["hepatic", "ORGAN", 63, 70], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["amino acid", "AMINO_ACID", 108, 118], ["constitutive hepatic delivery", "TREATMENT", 50, 79], ["the blood", "TEST", 84, 93], ["single amino acid exchanges", "TREATMENT", 101, 128], ["a total loss of specifi city", "PROBLEM", 168, 196], ["hepatic", "ANATOMY", 63, 70], ["total", "OBSERVATION_MODIFIER", 170, 175], ["loss", "OBSERVATION_MODIFIER", 176, 180]]], ["HBVpreS-mediated drug targeting opens a highly selective approach to deliver drugs to hepatocytes or hepatoma cells.", [["hepatocytes", "ANATOMY", 86, 97], ["hepatoma cells", "ANATOMY", 101, 115], ["HBVpreS", "CHEMICAL", 0, 7], ["HBVpreS", "SIMPLE_CHEMICAL", 0, 7], ["hepatocytes", "CELL", 86, 97], ["hepatoma cells", "CELL", 101, 115], ["hepatocytes", "CELL_TYPE", 86, 97], ["hepatoma cells", "CELL_TYPE", 101, 115], ["HBVpreS", "TREATMENT", 0, 7], ["drugs", "TREATMENT", 77, 82], ["hepatoma cells", "PROBLEM", 101, 115], ["hepatocytes", "ANATOMY", 86, 97], ["hepatoma cells", "OBSERVATION", 101, 115]]], ["Possible applications include the delivery of interferons, inhibitors of HCV or HBV replication, cell cycle inhibitors for HCC treatment, inhibitors of plasmodium falciparum, siRNAs or peptides for MHC-mediated antigen presenta S18-1Austen, Brian; Cheng, Elliott; Mohammed, Yeser St George's University of London, UNITED KINGDOMSeveral peptides that contain a retroinverso form of a amyloid binding domain ffvlk, gadolinium chelated by DOTA, and a potential blood brain penetration moiety, have been synthesised and characterised by HPLC and mass spectrometry.", [["cell", "ANATOMY", 97, 101], ["HCC", "ANATOMY", 123, 126], ["blood brain", "ANATOMY", 458, 469], ["HCC", "DISEASE", 123, 126], ["plasmodium falciparum", "DISEASE", 152, 173], ["gadolinium", "CHEMICAL", 413, 423], ["DOTA", "CHEMICAL", 436, 440], ["gadolinium", "CHEMICAL", 413, 423], ["DOTA", "CHEMICAL", 436, 440], ["interferons", "GENE_OR_GENE_PRODUCT", 46, 57], ["HCV", "ORGANISM", 73, 76], ["HBV", "ORGANISM", 80, 83], ["cell", "CELL", 97, 101], ["HCC", "CANCER", 123, 126], ["plasmodium falciparum", "ORGANISM", 152, 173], ["amyloid binding domain ffvlk", "SIMPLE_CHEMICAL", 383, 411], ["gadolinium chelated", "SIMPLE_CHEMICAL", 413, 432], ["DOTA", "SIMPLE_CHEMICAL", 436, 440], ["blood", "ORGANISM_SUBSTANCE", 458, 463], ["brain", "ORGAN", 464, 469], ["interferons", "PROTEIN", 46, 57], ["MHC", "PROTEIN", 198, 201], ["amyloid binding domain", "PROTEIN", 383, 405], ["plasmodium falciparum", "SPECIES", 152, 173], ["HCV", "SPECIES", 73, 76], ["HBV", "SPECIES", 80, 83], ["plasmodium falciparum", "SPECIES", 152, 173], ["applications", "TREATMENT", 9, 21], ["the delivery of interferons", "TREATMENT", 30, 57], ["inhibitors", "TREATMENT", 59, 69], ["HCV", "PROBLEM", 73, 76], ["HBV replication", "TREATMENT", 80, 95], ["cell cycle inhibitors", "TREATMENT", 97, 118], ["HCC treatment", "TREATMENT", 123, 136], ["inhibitors", "TREATMENT", 138, 148], ["plasmodium falciparum", "PROBLEM", 152, 173], ["siRNAs or peptides", "TREATMENT", 175, 193], ["MHC", "TEST", 198, 201], ["a amyloid binding domain ffvlk", "PROBLEM", 381, 411], ["a potential blood brain penetration moiety", "PROBLEM", 446, 488], ["mass spectrometry", "PROBLEM", 542, 559], ["brain", "ANATOMY", 464, 469]]], ["Peptides containing a cell penetrating peptide with clustered cationic residues show rapid, reversible binding to immobilised aggregated amyloid by SPR in a Biacore; wheras those containing aliphatic amines show much poorer binding.", [["cell", "ANATOMY", 22, 26], ["aliphatic amines", "CHEMICAL", 190, 206], ["aliphatic amines", "CHEMICAL", 190, 206], ["cell", "CELL", 22, 26], ["aliphatic amines", "SIMPLE_CHEMICAL", 190, 206], ["Peptides", "TREATMENT", 0, 8], ["a cell penetrating peptide", "TREATMENT", 20, 46], ["clustered cationic residues", "PROBLEM", 52, 79], ["rapid, reversible binding to immobilised aggregated amyloid", "PROBLEM", 85, 144], ["aliphatic amines", "TEST", 190, 206], ["cationic residues", "OBSERVATION", 62, 79], ["rapid", "OBSERVATION_MODIFIER", 85, 90], ["amyloid", "OBSERVATION", 137, 144]]], ["APP-transfected cells treated with lactalysin to allow accumulation of amyloid, showed high localisation of the poly-cationic peptide, and weaker localisation of the aminated peptide.", [["cells", "ANATOMY", 16, 21], ["lactalysin", "CHEMICAL", 35, 45], ["lactalysin", "CHEMICAL", 35, 45], ["APP", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 16, 21], ["lactalysin", "SIMPLE_CHEMICAL", 35, 45], ["amyloid", "GENE_OR_GENE_PRODUCT", 71, 78], ["poly-cationic peptide", "SIMPLE_CHEMICAL", 112, 133], ["APP-transfected cells", "CELL_LINE", 0, 21], ["lactalysin", "TREATMENT", 35, 45], ["accumulation of amyloid", "PROBLEM", 55, 78], ["the poly-cationic peptide", "TREATMENT", 108, 133], ["weaker localisation of the aminated peptide", "PROBLEM", 139, 182], ["amyloid", "OBSERVATION", 71, 78]]], ["The aminated form, however, showed, better uptake into brain in vivo.", [["brain", "ANATOMY", 55, 60], ["brain", "ORGAN", 55, 60], ["brain", "ANATOMY", 55, 60]]], ["The MRI T2 image obtained 2 hours after iv injection of 0.5mg of the aminated reagent gave hypointense regions in the hippocampal area in an APP/PS double transgenic mouse.Teixid\u00f3, Meritxell; Tarrago, Teresa; Giralt, Ernest Institute for Research in Biomedicine Barcelona, SPAINSeveral severe health disorders require treatment of the brain, including Parkinson's and Alzheimer's, but also schizophrenia (SZ), epilepsy, and bipolar disorder (BD).", [["hippocampal area", "ANATOMY", 118, 134], ["brain", "ANATOMY", 335, 340], ["health disorders", "DISEASE", 293, 309], ["Parkinson's and Alzheimer's, but also schizophrenia", "DISEASE", 352, 403], ["SZ", "DISEASE", 405, 407], ["epilepsy", "DISEASE", 410, 418], ["bipolar disorder", "DISEASE", 424, 440], ["BD", "DISEASE", 442, 444], ["hippocampal area", "MULTI-TISSUE_STRUCTURE", 118, 134], ["APP", "GENE_OR_GENE_PRODUCT", 141, 144], ["PS", "GENE_OR_GENE_PRODUCT", 145, 147], ["mouse", "ORGANISM", 166, 171], ["brain", "ORGAN", 335, 340], ["APP", "PROTEIN", 141, 144], ["mouse", "SPECIES", 166, 171], ["mouse", "SPECIES", 166, 171], ["The MRI T2 image", "TEST", 0, 16], ["iv injection", "TREATMENT", 40, 52], ["the aminated reagent", "TREATMENT", 65, 85], ["hypointense regions in the hippocampal area", "PROBLEM", 91, 134], ["an APP/PS double transgenic mouse", "TREATMENT", 138, 171], ["SPAINSeveral severe health disorders", "PROBLEM", 273, 309], ["the brain", "PROBLEM", 331, 340], ["Parkinson's", "PROBLEM", 352, 363], ["Alzheimer's", "PROBLEM", 368, 379], ["schizophrenia (SZ)", "PROBLEM", 390, 408], ["epilepsy", "PROBLEM", 410, 418], ["bipolar disorder", "PROBLEM", 424, 440], ["hippocampal", "ANATOMY", 118, 129], ["brain", "ANATOMY", 335, 340], ["Parkinson", "OBSERVATION", 352, 361], ["epilepsy", "OBSERVATION", 410, 418], ["bipolar disorder", "OBSERVATION", 424, 440]]], ["In recent years, the POP serine protease has gained importance as a target for the treatment of SZ and BD.", [["SZ", "DISEASE", 96, 98], ["BD", "DISEASE", 103, 105], ["serine", "CHEMICAL", 25, 31], ["POP serine protease", "GENE_OR_GENE_PRODUCT", 21, 40], ["BD", "GENE_OR_GENE_PRODUCT", 103, 105], ["POP serine protease", "PROTEIN", 21, 40], ["the POP serine protease", "TREATMENT", 17, 40], ["SZ", "PROBLEM", 96, 98], ["BD", "PROBLEM", 103, 105], ["SZ", "OBSERVATION", 96, 98]]], ["(1, 2) The search for new drugs for the treatment of CNS diseases involves an additional obstacle, the blood-brain barrier (BBB).", [["CNS", "ANATOMY", 53, 56], ["blood-brain barrier", "ANATOMY", 103, 122], ["BBB", "ANATOMY", 124, 127], ["CNS diseases", "DISEASE", 53, 65], ["CNS", "ANATOMICAL_SYSTEM", 53, 56], ["blood-", "MULTI-TISSUE_STRUCTURE", 103, 109], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 109, 122], ["BBB", "MULTI-TISSUE_STRUCTURE", 124, 127], ["new drugs", "TREATMENT", 22, 31], ["CNS diseases", "PROBLEM", 53, 65], ["the blood", "TEST", 99, 108], ["CNS", "ANATOMY", 53, 56], ["diseases", "OBSERVATION", 57, 65], ["brain", "ANATOMY", 109, 114]]], ["Our research interest focuses on fi nding a peptide that is a selective POP inhibitor and shows effi cient CNS-targeting and BBB transport.", [["BBB", "MULTI-TISSUE_STRUCTURE", 125, 128], ["a selective POP inhibitor", "TREATMENT", 60, 85]]], ["Our design is based on two observations: i) Berberine, an alkaloid found in Rhizoma coptidis, has a pyridinium moiety and is a POP inhibitor (i.c.", [["Berberine", "CHEMICAL", 44, 53], ["Rhizoma coptidis", "CHEMICAL", 76, 92], ["pyridinium", "CHEMICAL", 100, 110], ["Berberine", "CHEMICAL", 44, 53], ["pyridinium", "CHEMICAL", 100, 110], ["Berberine", "SIMPLE_CHEMICAL", 44, 53], ["Rhizoma coptidis", "ORGANISM", 76, 92], ["pyridinium moiety", "SIMPLE_CHEMICAL", 100, 117], ["Rhizoma coptidis", "SPECIES", 76, 92], ["Rhizoma coptidis", "SPECIES", 76, 92], ["Berberine", "TREATMENT", 44, 53], ["an alkaloid", "PROBLEM", 55, 66], ["Rhizoma coptidis", "TREATMENT", 76, 92], ["a pyridinium moiety", "TREATMENT", 98, 117], ["a POP inhibitor", "TREATMENT", 125, 140], ["Rhizoma coptidis", "OBSERVATION", 76, 92]]], ["50 135 M) 2 and ii) some redox chemical delivery systems (3) are based on the transformation between pyridinium and dyhydropiridine moieties.", [["pyridinium", "CHEMICAL", 101, 111], ["dyhydropiridine", "CHEMICAL", 116, 131], ["pyridinium", "CHEMICAL", 101, 111], ["dyhydropiridine", "CHEMICAL", 116, 131], ["pyridinium", "SIMPLE_CHEMICAL", 101, 111], ["dyhydropiridine moieties", "SIMPLE_CHEMICAL", 116, 140], ["some redox chemical delivery systems", "TREATMENT", 20, 56], ["pyridinium and dyhydropiridine moieties", "TREATMENT", 101, 140]]], ["A fi rst cyclic dipeptide (DKP) modifi ed with a dihydropyridine moietyTitle Abs NoSynthesis of smart potential MRI contrast reagents that bind aggregated amyloid for the diagnosis of Alzheimer's disease Austen , Brian S18-1Title Abs NoPeptide antagonists of protein-protein interactions identifi ed by screening protein fragments derived by enzyme degradation Ruvo, Menotti S18-2Title Abs NoA novel family of selective prolyl oligopeptidase (POP) inhibitors based on a cyclic dipeptide scaffold shows effective CNS-targeting and blood-brain barrier (BBB) transport Teixid\u00f3, Meritxell S18-3Title Abs NoChemo-enzymatic synthesis of C-terminal aryl amides of amino acids and peptides Nuijens, Timo P18-4Title Abs NoMimetibodies\u2122, A New Platform Technology for the Development of Biologically Active Peptides that Prolongs the Half-Life Heavner, George P18-5 was prepared and evaluated.", [["CNS", "ANATOMY", 512, 515], ["blood", "ANATOMY", 530, 535], ["cyclic dipeptide", "CHEMICAL", 9, 25], ["DKP", "CHEMICAL", 27, 30], ["dihydropyridine", "CHEMICAL", 49, 64], ["Alzheimer's disease", "DISEASE", 184, 203], ["C-terminal aryl amides", "CHEMICAL", 631, 653], ["amino acids", "CHEMICAL", 657, 668], ["fi rst cyclic dipeptide", "CHEMICAL", 2, 25], ["DKP", "CHEMICAL", 27, 30], ["dihydropyridine", "CHEMICAL", 49, 64], ["prolyl", "CHEMICAL", 420, 426], ["cyclic dipeptide", "CHEMICAL", 470, 486], ["C", "CHEMICAL", 631, 632], ["aryl amides", "CHEMICAL", 642, 653], ["amino acids", "CHEMICAL", 657, 668], ["fi rst cyclic dipeptide", "SIMPLE_CHEMICAL", 2, 25], ["DKP", "SIMPLE_CHEMICAL", 27, 30], ["dihydropyridine", "SIMPLE_CHEMICAL", 49, 64], ["amyloid", "GENE_OR_GENE_PRODUCT", 155, 162], ["Ruvo", "SIMPLE_CHEMICAL", 361, 365], ["prolyl oligopeptidase", "SIMPLE_CHEMICAL", 420, 441], ["POP", "GENE_OR_GENE_PRODUCT", 443, 446], ["CNS", "ANATOMICAL_SYSTEM", 512, 515], ["blood", "ORGANISM_SUBSTANCE", 530, 535], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 536, 549], ["BBB", "MULTI-TISSUE_STRUCTURE", 551, 554], ["C-terminal aryl amides", "SIMPLE_CHEMICAL", 631, 653], ["amino acids", "AMINO_ACID", 657, 668], ["Title Abs", "PROTEIN", 71, 80], ["protein fragments", "PROTEIN", 313, 330], ["enzyme degradation Ruvo, Menotti S18-2Title Abs NoA novel family", "PROTEIN", 342, 406], ["A fi rst cyclic dipeptide (DKP)", "TREATMENT", 0, 31], ["a dihydropyridine moiety", "TREATMENT", 47, 71], ["MRI contrast reagents", "TEST", 112, 133], ["Alzheimer's disease", "PROBLEM", 184, 203], ["protein", "TEST", 259, 266], ["protein interactions", "PROBLEM", 267, 287], ["screening protein fragments", "TEST", 303, 330], ["enzyme degradation", "TEST", 342, 360], ["Ruvo", "TEST", 361, 365], ["Menotti", "TEST", 367, 374], ["selective prolyl oligopeptidase (POP) inhibitors", "TREATMENT", 410, 458], ["a cyclic dipeptide scaffold", "TREATMENT", 468, 495], ["effective CNS", "PROBLEM", 502, 515], ["blood", "TEST", 530, 535], ["transport", "TEST", 556, 565], ["Teixid\u00f3", "TEST", 566, 573], ["Meritxell", "TEST", 575, 584], ["enzymatic synthesis", "TREATMENT", 608, 627], ["C-terminal aryl amides", "TREATMENT", 631, 653], ["amino acids", "TREATMENT", 657, 668], ["peptides", "TEST", 673, 681], ["Nuijens", "TEST", 682, 689], ["Timo P18", "TEST", 691, 699], ["brain", "ANATOMY", 536, 541]]], ["This DKP with the dihydropyridine moiety crossed the BBB by passive diffusion (PAMPA assay, Pe: 0.24 10 -6 cm/s) but did not show inhibitory activity against POP.", [["BBB", "ANATOMY", 53, 56], ["DKP", "CHEMICAL", 5, 8], ["dihydropyridine", "CHEMICAL", 18, 33], ["POP", "DISEASE", 158, 161], ["dihydropyridine", "CHEMICAL", 18, 33], ["DKP", "SIMPLE_CHEMICAL", 5, 8], ["dihydropyridine moiety", "SIMPLE_CHEMICAL", 18, 40], ["BBB", "MULTI-TISSUE_STRUCTURE", 53, 56], ["the dihydropyridine moiety", "TREATMENT", 14, 40], ["passive diffusion", "TEST", 60, 77], ["PAMPA assay", "TEST", 79, 90], ["Pe", "TEST", 92, 94], ["POP", "PROBLEM", 158, 161], ["Pe", "OBSERVATION", 92, 94]]], ["In contrast, the active DKP with a pyridinium moiety acted as a selective POP inhibitor (I.C. 50 : 101.2 M), and will have restricted elimination because of its ionic nature.", [["DKP", "CHEMICAL", 24, 27], ["pyridinium", "CHEMICAL", 35, 45], ["DKP", "CHEMICAL", 24, 27], ["pyridinium", "CHEMICAL", 35, 45], ["DKP", "SIMPLE_CHEMICAL", 24, 27], ["pyridinium moiety", "SIMPLE_CHEMICAL", 35, 52], ["a pyridinium moiety", "TREATMENT", 33, 52], ["a selective POP inhibitor", "TREATMENT", 62, 87], ["active", "OBSERVATION_MODIFIER", 17, 23]]], ["Using this candidate as a starting point, we synthesized and evaluated a family of modifi ed cyclic dipeptides in order to improve both permeability across the BBB and POP inhibition.", [["modifi ed cyclic dipeptides", "CHEMICAL", 83, 110], ["modifi ed cyclic dipeptides", "SIMPLE_CHEMICAL", 83, 110], ["BBB", "MULTI-TISSUE_STRUCTURE", 160, 163], ["modifi ed cyclic dipeptides", "TREATMENT", 83, 110], ["POP inhibition", "TREATMENT", 168, 182]]], ["The modifi cations introduced were based on our results on BBB-transport of mono-and di-N-Me-DKPs.", [["modifi cations", "SIMPLE_CHEMICAL", 4, 18], ["BBB", "SIMPLE_CHEMICAL", 59, 62], ["mono-and di-N-Me-DKPs", "SIMPLE_CHEMICAL", 76, 97], ["mono-and di-N-Me-DKPs", "PROTEIN", 76, 97], ["The modifi cations", "TREATMENT", 0, 18]]], ["(4 Protein tridimensional structure is the complex recapitulation of local and distant intramolecular forces that cooperatively contribute to maintain the global energetic equilibrium.", [["complex", "OBSERVATION_MODIFIER", 43, 50], ["local", "OBSERVATION_MODIFIER", 69, 74], ["distant", "OBSERVATION_MODIFIER", 79, 86], ["intramolecular forces", "OBSERVATION", 87, 108], ["global", "OBSERVATION_MODIFIER", 155, 161], ["energetic equilibrium", "OBSERVATION", 162, 183]]], ["In this scenario, secondary structure motifs and small protein domains can be seen as discrete building blocks that when isolated from the protein context can be studied to gain structural insights on the protein original structure or as structural modules useful to prevent interactions with external partners.", [["secondary structure motifs", "PROTEIN", 18, 44], ["small protein domains", "PROTEIN", 49, 70], ["secondary structure motifs", "PROBLEM", 18, 44], ["small protein domains", "PROBLEM", 49, 70], ["small", "OBSERVATION_MODIFIER", 49, 54], ["protein domains", "OBSERVATION", 55, 70]]], ["In this context, peptides derived by protein digestion with proteases and separated by chromatographic techniques can be usefully utilized in screening assays to search for protein-protein interaction antagonists.", [["protein-protein interaction antagonists", "GENE_OR_GENE_PRODUCT", 173, 212], ["proteases", "PROTEIN", 60, 69], ["proteases", "TREATMENT", 60, 69], ["screening assays", "TEST", 142, 158], ["protein-protein interaction antagonists", "TREATMENT", 173, 212]]], ["This procedure has been successfully applied to several interacting systems, such as Bcl10 oligomers, Gadd45b dimers and to the PED-PLD1 interaction, identifying in some cases peptide inhibitors with nM effi cacy.Title Abs NoIn the past several decades, hundreds of peptides have been identifi ed which have specifi c biological activity and are highly potent in in vitro assays but lack the prerequisite pharmacokinetics to become effi cacious human therapeutics.", [["Bcl10", "GENE_OR_GENE_PRODUCT", 85, 90], ["Gadd45b", "GENE_OR_GENE_PRODUCT", 102, 109], ["PLD1", "GENE_OR_GENE_PRODUCT", 132, 136], ["human", "ORGANISM", 445, 450], ["Gadd45b dimers", "PROTEIN", 102, 116], ["PLD1", "PROTEIN", 132, 136], ["Title Abs NoIn", "PROTEIN", 213, 227], ["human", "SPECIES", 445, 450], ["human", "SPECIES", 445, 450], ["This procedure", "TREATMENT", 0, 14], ["Bcl10 oligomers", "TREATMENT", 85, 100], ["Gadd45b dimers", "TREATMENT", 102, 116], ["some cases peptide inhibitors", "TREATMENT", 165, 194], ["vitro assays", "TEST", 366, 378]]], ["We have developed a novel antibody-based platform technology that provides an improved pharmacokinetic profi le for biologically active peptides, resulting in a long duration of action.", [["a novel antibody", "TEST", 18, 34]]], ["One such Mimetibody\u2122, CNTO 528, is a novel erythropoietin (EPO) receptor agonist.", [["Mimetibody\u2122", "CHEMICAL", 9, 20], ["CNTO 528", "CHEMICAL", 22, 30], ["CNTO 528", "CHEMICAL", 22, 30], ["CNTO 528", "SIMPLE_CHEMICAL", 22, 30], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 43, 57], ["EPO", "GENE_OR_GENE_PRODUCT", 59, 62], ["erythropoietin (EPO) receptor", "PROTEIN", 43, 72], ["a novel erythropoietin (EPO) receptor agonist", "TREATMENT", 35, 80]]], ["Although CNTO 528 bears no sequence homology to erythropoietin, it is a potent erythropoietin receptor agonist, rescuing EPO dependent cells from apoptosis in vitro and stimulating erythropoiesis in vivo.", [["cells", "ANATOMY", 135, 140], ["CNTO 528", "CHEMICAL", 9, 17], ["CNTO 528", "CHEMICAL", 9, 17], ["CNTO 528", "GENE_OR_GENE_PRODUCT", 9, 17], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 48, 62], ["erythropoietin receptor", "GENE_OR_GENE_PRODUCT", 79, 102], ["EPO", "GENE_OR_GENE_PRODUCT", 121, 124], ["cells", "CELL", 135, 140], ["CNTO 528", "PROTEIN", 9, 17], ["erythropoietin", "PROTEIN", 48, 62], ["erythropoietin receptor", "PROTEIN", 79, 102], ["EPO", "PROTEIN", 121, 124], ["erythropoietin", "TREATMENT", 48, 62], ["a potent erythropoietin receptor agonist", "TREATMENT", 70, 110], ["EPO dependent cells", "TREATMENT", 121, 140], ["apoptosis", "PROBLEM", 146, 155], ["vitro and stimulating erythropoiesis", "TREATMENT", 159, 195], ["stimulating erythropoiesis", "OBSERVATION", 169, 195]]], ["Studies were done in normal rats to explore the pharmacodynamics and pharmacokinetics of CNTO 528 in normal rats and to demonstrate its effi cacy in rat models of anemia.", [["CNTO 528", "CHEMICAL", 89, 97], ["anemia", "DISEASE", 163, 169], ["CNTO 528", "CHEMICAL", 89, 97], ["rats", "ORGANISM", 28, 32], ["CNTO 528", "SIMPLE_CHEMICAL", 89, 97], ["rats", "ORGANISM", 108, 112], ["rat", "ORGANISM", 149, 152], ["rats", "SPECIES", 28, 32], ["rats", "SPECIES", 108, 112], ["rat", "SPECIES", 149, 152], ["Studies", "TEST", 0, 7], ["the pharmacodynamics", "TEST", 44, 64], ["pharmacokinetics of CNTO", "TEST", 69, 93], ["anemia", "PROBLEM", 163, 169], ["anemia", "OBSERVATION", 163, 169]]], ["In vitro, CNTO 528 was approximately 10 fold less potent than rhEPO in stimulating the growth of UT-7EPO cells.", [["UT-7EPO cells", "ANATOMY", 97, 110], ["CNTO 528", "CHEMICAL", 10, 18], ["rhEPO", "CHEMICAL", 62, 67], ["CNTO 528", "CHEMICAL", 10, 18], ["CNTO 528", "SIMPLE_CHEMICAL", 10, 18], ["rhEPO", "SIMPLE_CHEMICAL", 62, 67], ["UT-7EPO cells", "CELL", 97, 110], ["rhEPO", "PROTEIN", 62, 67], ["UT-7EPO cells", "CELL_LINE", 97, 110], ["CNTO", "TEST", 10, 14], ["rhEPO", "TREATMENT", 62, 67]]], ["Despite this lower in vitro potency, when compared to rhEPO and darbepoietin in normal rats, a single subcutaneous dose of CNTO 528 resulted in a longer-lived reticulocytosis and longer-lived increase in hemoglobin.", [["subcutaneous", "ANATOMY", 102, 114], ["rhEPO", "CHEMICAL", 54, 59], ["darbepoietin", "CHEMICAL", 64, 76], ["CNTO 528", "CHEMICAL", 123, 131], ["reticulocytosis", "DISEASE", 159, 174], ["darbepoietin", "CHEMICAL", 64, 76], ["CNTO 528", "CHEMICAL", 123, 131], ["rhEPO", "SIMPLE_CHEMICAL", 54, 59], ["darbepoietin", "SIMPLE_CHEMICAL", 64, 76], ["rats", "ORGANISM", 87, 91], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 204, 214], ["rhEPO", "PROTEIN", 54, 59], ["hemoglobin", "PROTEIN", 204, 214], ["rats", "SPECIES", 87, 91], ["rhEPO", "TREATMENT", 54, 59], ["darbepoietin", "TREATMENT", 64, 76], ["a single subcutaneous dose of CNTO", "TREATMENT", 93, 127], ["a longer-lived reticulocytosis", "PROBLEM", 144, 174], ["hemoglobin", "TEST", 204, 214], ["reticulocytosis", "OBSERVATION", 159, 174], ["increase", "OBSERVATION_MODIFIER", 192, 200], ["hemoglobin", "OBSERVATION_MODIFIER", 204, 214]]], ["Also, CNTO 528 caused only minor changes in red cell distribution width (RDW) or mean cell volume (MCV) and led to the release of mature reticulocytes.", [["red cell", "ANATOMY", 44, 52], ["cell", "ANATOMY", 86, 90], ["reticulocytes", "ANATOMY", 137, 150], ["CNTO 528", "CHEMICAL", 6, 14], ["CNTO 528", "CHEMICAL", 6, 14], ["CNTO 528", "SIMPLE_CHEMICAL", 6, 14], ["red cell", "CELL", 44, 52], ["cell", "CELL", 86, 90], ["reticulocytes", "CELL", 137, 150], ["mature reticulocytes", "CELL_TYPE", 130, 150], ["minor changes in red cell distribution width", "PROBLEM", 27, 71], ["RDW", "TEST", 73, 76], ["mean cell volume", "TEST", 81, 97], ["MCV", "TEST", 99, 102], ["mature reticulocytes", "PROBLEM", 130, 150], ["minor", "OBSERVATION_MODIFIER", 27, 32], ["changes", "OBSERVATION", 33, 40], ["red cell", "OBSERVATION", 44, 52], ["distribution", "OBSERVATION_MODIFIER", 53, 65], ["width", "OBSERVATION_MODIFIER", 66, 71], ["mean cell volume", "OBSERVATION", 81, 97], ["mature reticulocytes", "OBSERVATION", 130, 150]]], ["We have also shown that CNTO 528 was effi cacious in rat models of anemia and in a rat model of pure red cell aplasia.", [["red cell", "ANATOMY", 101, 109], ["CNTO 528", "CHEMICAL", 24, 32], ["anemia", "DISEASE", 67, 73], ["red cell aplasia", "DISEASE", 101, 117], ["CNTO 528", "CHEMICAL", 24, 32], ["CNTO 528", "SIMPLE_CHEMICAL", 24, 32], ["rat", "ORGANISM", 53, 56], ["rat", "ORGANISM", 83, 86], ["red cell", "CELL", 101, 109], ["rat", "SPECIES", 53, 56], ["rat", "SPECIES", 83, 86], ["rat", "SPECIES", 53, 56], ["rat", "SPECIES", 83, 86], ["CNTO", "TEST", 24, 28], ["anemia", "PROBLEM", 67, 73], ["pure red cell aplasia", "PROBLEM", 96, 117], ["rat models", "OBSERVATION_MODIFIER", 53, 63], ["anemia", "OBSERVATION", 67, 73], ["pure red cell aplasia", "OBSERVATION", 96, 117]]], ["Taken together, our data show that CNTO 528 is a novel stimulant of erythropoiesis in rats.", [["CNTO 528", "CHEMICAL", 35, 43], ["CNTO 528", "CHEMICAL", 35, 43], ["CNTO 528", "GENE_OR_GENE_PRODUCT", 35, 43], ["rats", "ORGANISM", 86, 90], ["rats", "SPECIES", 86, 90], ["our data", "TEST", 16, 24], ["erythropoiesis in rats", "PROBLEM", 68, 90], ["erythropoiesis", "OBSERVATION", 68, 82]]], ["This platform has been applied to other biologically active peptides as well and has proven to be a robust platform for enhancing the pharmacokinetics of peptides that would otherwise be rapidly cleared.", [["enhancing the pharmacokinetics of peptides", "TREATMENT", 120, 162], ["rapidly", "OBSERVATION_MODIFIER", 187, 194], ["cleared", "OBSERVATION", 195, 202]]]], "f6d1e68561dad02f11de4b9882893826bb6321a4": [["In the mid-1990s, the Taiwanese government began to wage war on drugs and discussed possible revisions to applicable laws and policies to respond to the increase in drug crimes.", [["drugs", "TREATMENT", 64, 69]]], ["The revision and renaming of the Narcotics Hazard Prevention Act in 1998 ushered in a new stage, in which more participants in drug use treatment were allowed and a number of psychiatrists who specialized in addiction intervention and treatment were required.", [["participants", "SPECIES", 111, 123], ["The revision", "TREATMENT", 0, 12], ["renaming", "TREATMENT", 17, 25], ["the Narcotics", "TREATMENT", 29, 42], ["treatment", "TREATMENT", 136, 145], ["addiction intervention", "TREATMENT", 208, 230], ["treatment", "TREATMENT", 235, 244], ["revision", "OBSERVATION", 4, 12]]], ["However, compared with the mainstream psychiatric community, these psychiatrists were few and marginal.", [["psychiatric", "DISEASE", 38, 49], ["marginal", "OBSERVATION_MODIFIER", 94, 102]]], ["Given the long-held belief that addiction is an intractable personal moral defect and the limited resources allocated to illegal drug use and users, psychiatric treatments and interventions were not fully recognized and utilized.", [["addiction", "DISEASE", 32, 41], ["psychiatric", "DISEASE", 149, 160], ["an intractable personal moral defect", "PROBLEM", 45, 81], ["psychiatric treatments", "TREATMENT", 149, 171], ["interventions", "TREATMENT", 176, 189], ["intractable", "OBSERVATION_MODIFIER", 48, 59], ["moral defect", "OBSERVATION", 69, 81]]]], "deeea6d8ce6527172459bee3ea8c409415c02acc": [["IntroductionReversible addition-fragmentation chain transfer (RAFT) polymerization is a well-known reversible-deactivation radical polymerization (RDRP) mechanism that has attracted great attention due to its versatility in controlling the composition and molecular weight (M w ) of the resulting polymers using mild reaction conditions [1, 2] .", [["RDRP", "SIMPLE_CHEMICAL", 147, 151], ["deactivation radical polymerization (RDRP)", "TREATMENT", 110, 152], ["the resulting polymers", "TREATMENT", 283, 305], ["mild reaction conditions", "PROBLEM", 312, 336], ["fragmentation", "OBSERVATION_MODIFIER", 32, 45], ["chain", "OBSERVATION_MODIFIER", 46, 51], ["radical polymerization", "OBSERVATION", 123, 145]]], ["In the past years, this polymerization mechanism has been explored to encapsulate inorganic cores in order to obtain well-defined core-shell nanostructures via RAFT-assisted encapsulating emulsion polymerization (REEP) [3, 4] .", [["RAFT", "CHEMICAL", 160, 164], ["RAFT", "SIMPLE_CHEMICAL", 160, 164], ["this polymerization mechanism", "PROBLEM", 19, 48], ["inorganic cores", "TREATMENT", 82, 97], ["RAFT-assisted encapsulating emulsion polymerization", "TREATMENT", 160, 211], ["shell nanostructures", "OBSERVATION", 135, 155], ["emulsion polymerization", "OBSERVATION", 188, 211]]], ["This strategy involves two main steps: first, the adsorption of a previously prepared amphiphilic polymer containing a chain transfer agent (CTA)-the macroRAFT (MR) agent, onto the inorganic core; and then chain extension via RAFT emulsion polymerization under monomer-starved conditions.", [["CTA", "SIMPLE_CHEMICAL", 141, 144], ["macroRAFT", "SIMPLE_CHEMICAL", 150, 159], ["RAFT emulsion", "SIMPLE_CHEMICAL", 226, 239], ["MR", "PROTEIN", 161, 163], ["a previously prepared amphiphilic polymer", "TREATMENT", 64, 105], ["a chain transfer agent", "TREATMENT", 117, 139], ["CTA", "TEST", 141, 144], ["the macroRAFT (MR) agent", "TREATMENT", 146, 170], ["the inorganic core", "TREATMENT", 177, 195], ["RAFT emulsion polymerization", "TREATMENT", 226, 254]]], ["The MR agent acts as a surfactant, thus allowing emulsion polymerization to be carried out without additional surfactants.Introduction(97%, Sigma-Aldrich), N-(3-dimethylaminopropyl)-N -ethyl-carbodiimide (EDC, Sigma-Aldrich), N,N-dimethylaminopyridine (DMAP, Aldrich, 99%), biotin (\u226599%, TLC lyophilized powder from Sigma-Aldrich), avidin (from chicken egg white, Pierce\u2122, from ThermoFisher Scientific), bovine serum albumin (BSA, Sigma-Aldrich) and copper (II) sulfate pentahydrate (CuSO 4 \u00b75H 2 O, JMGS) were used as received.", [["serum", "ANATOMY", 411, 416], ["N-(3-dimethylaminopropyl)-N -ethyl-carbodiimide", "CHEMICAL", 156, 203], ["EDC", "CHEMICAL", 205, 208], ["N,N-dimethylaminopyridine", "CHEMICAL", 226, 251], ["DMAP", "CHEMICAL", 253, 257], ["biotin", "CHEMICAL", 274, 280], ["copper", "CHEMICAL", 450, 456], ["sulfate pentahydrate", "CHEMICAL", 462, 482], ["CuSO 4 \u00b75H 2 O", "CHEMICAL", 484, 498], ["N-(3-dimethylaminopropyl)-N -ethyl-carbodiimide", "CHEMICAL", 156, 203], ["EDC", "CHEMICAL", 205, 208], ["N,N-dimethylaminopyridine", "CHEMICAL", 226, 251], ["DMAP", "CHEMICAL", 253, 257], ["Aldrich", "CHEMICAL", 259, 266], ["biotin", "CHEMICAL", 274, 280], ["copper (II) sulfate pentahydrate", "CHEMICAL", 450, 482], ["CuSO 4 \u00b75H 2 O", "CHEMICAL", 484, 498], ["JMGS", "CHEMICAL", 500, 504], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 140, 153], ["N-(3-dimethylaminopropyl)-N -ethyl-carbodiimide", "SIMPLE_CHEMICAL", 156, 203], ["EDC", "SIMPLE_CHEMICAL", 205, 208], ["Sigma-Aldrich), N,N-dimethylaminopyridine", "SIMPLE_CHEMICAL", 210, 251], ["DMAP", "SIMPLE_CHEMICAL", 253, 257], ["Aldrich, 99%", "SIMPLE_CHEMICAL", 259, 271], ["biotin", "SIMPLE_CHEMICAL", 274, 280], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 316, 329], ["avidin", "SIMPLE_CHEMICAL", 332, 338], ["chicken", "ORGANISM", 345, 352], ["Pierce\u2122", "SIMPLE_CHEMICAL", 364, 371], ["bovine", "ORGANISM", 404, 410], ["serum", "ORGANISM_SUBSTANCE", 411, 416], ["albumin", "SIMPLE_CHEMICAL", 417, 424], ["BSA", "SIMPLE_CHEMICAL", 426, 429], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 431, 444], ["copper (II) sulfate pentahydrate", "SIMPLE_CHEMICAL", 450, 482], ["CuSO 4 \u00b75H 2 O", "SIMPLE_CHEMICAL", 484, 498], ["JMGS", "SIMPLE_CHEMICAL", 500, 504], ["MR", "PROTEIN", 4, 6], ["chicken", "SPECIES", 345, 352], ["bovine", "SPECIES", 404, 410], ["chicken", "SPECIES", 345, 352], ["bovine", "SPECIES", 404, 410], ["a surfactant", "TREATMENT", 21, 33], ["emulsion polymerization", "TREATMENT", 49, 72], ["additional surfactants", "TREATMENT", 99, 121], ["Sigma-Aldrich)", "TREATMENT", 140, 154], ["dimethylaminopropyl)", "TREATMENT", 161, 181], ["ethyl-carbodiimide (EDC", "TREATMENT", 185, 208], ["Sigma-Aldrich)", "TREATMENT", 210, 224], ["dimethylaminopyridine (DMAP", "TREATMENT", 230, 257], ["Aldrich", "TREATMENT", 259, 266], ["biotin (\u2265", "TREATMENT", 274, 283], ["TLC lyophilized powder", "TREATMENT", 288, 310], ["Sigma-Aldrich)", "TREATMENT", 316, 330], ["avidin", "TREATMENT", 332, 338], ["bovine serum albumin", "TEST", 404, 424], ["BSA", "TEST", 426, 429], ["Sigma-Aldrich)", "TREATMENT", 431, 445], ["copper (II) sulfate pentahydrate (CuSO", "TREATMENT", 450, 488], ["JMGS)", "TREATMENT", 500, 505]]], ["Sodium ascorbate was prepared by the neutralization of a solution of L-ascorbic acid (Panreac) with sodium bicarbonate, precipitated with isopropanol, and dried at 40 \u2022 C under vacuum [21] .", [["Sodium ascorbate", "CHEMICAL", 0, 16], ["L-ascorbic acid", "CHEMICAL", 69, 84], ["Panreac", "CHEMICAL", 86, 93], ["sodium bicarbonate", "CHEMICAL", 100, 118], ["isopropanol", "CHEMICAL", 138, 149], ["Sodium ascorbate", "CHEMICAL", 0, 16], ["L-ascorbic acid", "CHEMICAL", 69, 84], ["Panreac", "CHEMICAL", 86, 93], ["sodium bicarbonate", "CHEMICAL", 100, 118], ["isopropanol", "CHEMICAL", 138, 149], ["Sodium ascorbate", "SIMPLE_CHEMICAL", 0, 16], ["L-ascorbic acid", "SIMPLE_CHEMICAL", 69, 84], ["Panreac", "SIMPLE_CHEMICAL", 86, 93], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 100, 118], ["isopropanol", "SIMPLE_CHEMICAL", 138, 149], ["Sodium ascorbate", "TREATMENT", 0, 16], ["a solution of L-ascorbic acid (Panreac", "TREATMENT", 55, 93], ["sodium bicarbonate", "TREATMENT", 100, 118], ["isopropanol", "TREATMENT", 138, 149]]], ["Prior to use, 3-butyn-1-ol (Aldrich, 93%) was bubbled for 1 h with dry nitrogen and then stored in a flask containing molecular sieves 3 \u00c5, under dry nitrogen.", [["3-butyn-1-ol", "CHEMICAL", 14, 26], ["dry nitrogen", "CHEMICAL", 67, 79], ["dry nitrogen", "CHEMICAL", 146, 158], ["3-butyn-1-ol", "CHEMICAL", 14, 26], ["nitrogen", "CHEMICAL", 71, 79], ["nitrogen", "CHEMICAL", 150, 158], ["3-butyn-1-ol", "SIMPLE_CHEMICAL", 14, 26], ["Aldrich", "SIMPLE_CHEMICAL", 28, 35], ["butyn", "TEST", 16, 21], ["dry nitrogen", "TREATMENT", 67, 79], ["a flask containing molecular sieves", "TREATMENT", 99, 134], ["dry nitrogen", "TREATMENT", 146, 158]]], ["N,N-Dimethylformamide (DMF, VWR AnalaR, 99.5%) was dried with molecular sieves 3 \u00c5 for 24 h before use.", [["N,N-Dimethylformamide", "CHEMICAL", 0, 21], ["DMF", "CHEMICAL", 23, 26], ["N,N-Dimethylformamide", "CHEMICAL", 0, 21], ["DMF", "CHEMICAL", 23, 26], ["N,N-Dimethylformamide", "SIMPLE_CHEMICAL", 0, 21], ["DMF", "SIMPLE_CHEMICAL", 23, 26], ["Dimethylformamide", "TREATMENT", 4, 21], ["VWR AnalaR", "TREATMENT", 28, 38], ["molecular sieves", "TREATMENT", 62, 78]]], ["Ethanol and diethyl ether BDH Prolabo were purchased from VWR.", [["Ethanol", "CHEMICAL", 0, 7], ["diethyl ether", "CHEMICAL", 12, 25], ["Ethanol", "CHEMICAL", 0, 7], ["diethyl ether", "CHEMICAL", 12, 25], ["BDH", "CHEMICAL", 26, 29], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["diethyl ether BDH Prolabo", "SIMPLE_CHEMICAL", 12, 37], ["Ethanol and diethyl ether BDH Prolabo", "TREATMENT", 0, 37]]], ["Dimethyl sulfoxide-d 6 ((CD 3 ) 2 SO, Merck) was used to dissolve the macroRAFT agent for 1 H-NMR subsequent characterization.", [["Dimethyl sulfoxide", "CHEMICAL", 0, 18], ["Dimethyl sulfoxide", "CHEMICAL", 0, 18], ["(CD 3 ) 2 SO", "CHEMICAL", 24, 36], ["H", "CHEMICAL", 92, 93], ["Dimethyl sulfoxide-d 6", "SIMPLE_CHEMICAL", 0, 22], ["(CD 3 ) 2 SO", "SIMPLE_CHEMICAL", 24, 36], ["Merck", "SIMPLE_CHEMICAL", 38, 43], ["Dimethyl sulfoxide-d 6 ((CD 3 ) 2 SO, Merck)", "TREATMENT", 0, 44]]], ["Ultrapure water obtained from a MilliQ water purification system (Millipore, Billerica, MA, USA) was used throughout the work.Synthesis of MacroRAFT AgentsTTC-A was dissolved in ethanol; then, the monomer AA or PEGA was added followed by the initiator ACPA.", [["MacroRAFT", "CHEMICAL", 139, 148], ["AgentsTTC-A", "CHEMICAL", 149, 160], ["ethanol", "CHEMICAL", 178, 185], ["AA", "CHEMICAL", 205, 207], ["PEGA", "CHEMICAL", 211, 215], ["ethanol", "CHEMICAL", 178, 185], ["PEGA", "CHEMICAL", 211, 215], ["MacroRAFT AgentsTTC-A", "SIMPLE_CHEMICAL", 139, 160], ["ethanol", "SIMPLE_CHEMICAL", 178, 185], ["monomer AA", "SIMPLE_CHEMICAL", 197, 207], ["PEGA", "SIMPLE_CHEMICAL", 211, 215], ["ACPA", "GENE_OR_GENE_PRODUCT", 252, 256], ["ACPA", "PROTEIN", 252, 256], ["Ultrapure water", "TREATMENT", 0, 15], ["a MilliQ water purification system", "TREATMENT", 30, 64], ["Synthesis of MacroRAFT AgentsTTC", "TREATMENT", 126, 158], ["the monomer AA", "TREATMENT", 193, 207], ["PEGA", "TREATMENT", 211, 215]]], ["1,3,5-Trioxane was also added as internal standard for the determination of monomer conversion by 1 H NMR using a ratio [trioxane]/[monomer] = 6.", [["1,3,5-Trioxane", "CHEMICAL", 0, 14], ["1 H", "CHEMICAL", 98, 101], ["trioxane", "CHEMICAL", 121, 129], ["1,3,5-Trioxane", "CHEMICAL", 0, 14], ["1 H", "CHEMICAL", 98, 101], ["trioxane", "CHEMICAL", 121, 129], ["1,3,5-Trioxane", "SIMPLE_CHEMICAL", 0, 14], ["trioxane", "SIMPLE_CHEMICAL", 121, 129], ["Trioxane", "TREATMENT", 6, 14], ["a ratio [trioxane]/[monomer]", "TREATMENT", 112, 140]]], ["The mixture was purged with nitrogen for 30 min in an ice bath under stirring.", [["nitrogen", "CHEMICAL", 28, 36], ["nitrogen", "CHEMICAL", 28, 36], ["nitrogen", "SIMPLE_CHEMICAL", 28, 36], ["nitrogen", "TREATMENT", 28, 36], ["an ice bath", "TREATMENT", 51, 62]]], ["The reaction was carried out at 70 \u2022 C during 4 h for the synthesis of P(PEGA 40 )-TTC, while for the synthesis of P(AA 2 -co-PEGA 40 )-TTC, first, AA was polymerized during 3 h, and then PEGA was added and the polymerization proceeded over 4 extra hours.", [["P(PEGA 40 )-TTC", "CHEMICAL", 71, 86], ["AA 2 -co-PEGA 40 )", "CHEMICAL", 117, 135], ["AA", "CHEMICAL", 148, 150], ["PEGA", "CHEMICAL", 188, 192], ["P(PEGA 40 )-TTC", "CHEMICAL", 71, 86], ["P(AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 115, 139], ["PEGA", "CHEMICAL", 188, 192], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 73, 86], ["AA 2 -co-PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 117, 139], ["AA", "SIMPLE_CHEMICAL", 148, 150], ["PEGA", "SIMPLE_CHEMICAL", 188, 192], ["The reaction", "PROBLEM", 0, 12], ["PEGA", "TEST", 73, 77], ["TTC", "TEST", 83, 86], ["P", "TEST", 115, 116], ["AA", "TEST", 117, 119], ["PEGA", "TEST", 126, 130], ["TTC", "TEST", 136, 139], ["PEGA", "TREATMENT", 188, 192], ["the polymerization", "TREATMENT", 207, 225]]], ["Aliquots were withdrawn and analyzed by 1 H NMR for the determination of monomer conversion.", [["Aliquots", "ANATOMY", 0, 8], ["1 H", "CHEMICAL", 40, 43], ["Aliquots", "ORGANISM_SUBSTANCE", 0, 8], ["Aliquots", "TREATMENT", 0, 8], ["monomer conversion", "PROBLEM", 73, 91], ["monomer conversion", "OBSERVATION", 73, 91]]], ["The final product was precipitated using cold diethyl ether.", [["diethyl ether", "CHEMICAL", 46, 59], ["diethyl ether", "CHEMICAL", 46, 59], ["cold diethyl ether", "SIMPLE_CHEMICAL", 41, 59], ["cold diethyl ether", "TREATMENT", 41, 59]]], ["The resulting yellow viscous liquid was further purified by two additional dissolution/precipitations steps using room temperature and cold diethyl ether, respectively, and then dried under reduced pressure at room temperature.Preparation of N3-MacroRAFT AgentIn a 100 mL round bottom flask, the previously prepared P(AA 2 -co-PEGA 40 )-TTC (1.5 g) was dissolved in dichloromethane (15 mL); then, EDC (0.020 g) and DMAP (0.003 g) were added under stirring using an ice bath.", [["diethyl ether", "CHEMICAL", 140, 153], ["N3-MacroRAFT", "CHEMICAL", 242, 254], ["AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 318, 340], ["dichloromethane", "CHEMICAL", 366, 381], ["EDC", "CHEMICAL", 397, 400], ["DMAP", "CHEMICAL", 415, 419], ["diethyl ether", "CHEMICAL", 140, 153], ["P(AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 316, 340], ["dichloromethane", "CHEMICAL", 366, 381], ["EDC", "CHEMICAL", 397, 400], ["DMAP", "CHEMICAL", 415, 419], ["cold diethyl ether", "SIMPLE_CHEMICAL", 135, 153], ["N3-MacroRAFT AgentIn", "SIMPLE_CHEMICAL", 242, 262], ["AA 2 -co-PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 318, 340], ["dichloromethane", "SIMPLE_CHEMICAL", 366, 381], ["EDC", "SIMPLE_CHEMICAL", 397, 400], ["DMAP", "SIMPLE_CHEMICAL", 415, 419], ["The resulting yellow viscous liquid", "PROBLEM", 0, 35], ["cold diethyl ether", "TREATMENT", 135, 153], ["N3", "TREATMENT", 242, 244], ["MacroRAFT AgentIn", "TREATMENT", 245, 262], ["AA 2 -co-PEGA", "TREATMENT", 318, 331], ["TTC", "TREATMENT", 337, 340], ["dichloromethane", "TREATMENT", 366, 381], ["DMAP", "TREATMENT", 415, 419], ["an ice bath", "TREATMENT", 462, 473], ["yellow", "OBSERVATION_MODIFIER", 14, 20], ["viscous liquid", "OBSERVATION", 21, 35], ["pressure", "OBSERVATION_MODIFIER", 198, 206]]], ["The 3-azido-1-propanol (0.0153 mL) was added to the mixture, and the reaction was carried out for 2 h, upon which it was allowed to thaw to room temperature and stirred for 2 days.", [["3-azido-1-propanol", "CHEMICAL", 4, 22], ["3-azido-1-propanol", "CHEMICAL", 4, 22], ["3-azido-1-propanol", "SIMPLE_CHEMICAL", 4, 22], ["azido", "TREATMENT", 6, 11], ["propanol", "TREATMENT", 14, 22], ["the reaction", "PROBLEM", 65, 77]]], ["The azide-functionalized macroRAFT agent (N3-macroRAFT agent) was purified by dialysis (Spectra/Por \u00ae Dialysis Membrane MWCO 6-8 kDa from SpectrumLabs.com).", [["azide", "CHEMICAL", 4, 9], ["N3-macroRAFT", "CHEMICAL", 42, 54], ["azide", "CHEMICAL", 4, 9], ["azide", "SIMPLE_CHEMICAL", 4, 9], ["macroRAFT agent", "SIMPLE_CHEMICAL", 25, 40], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 42, 54], ["The azide-functionalized macroRAFT agent", "TREATMENT", 0, 40], ["N3-macroRAFT agent", "TREATMENT", 42, 60], ["dialysis (Spectra/Por \u00ae Dialysis Membrane MWCO", "TREATMENT", 78, 124]]], ["Dichloromethane was used as solvent during one day and replaced at least twice.Preparation of Au NPs by the Citrate Method (Au-Cit NPs)Following the procedure of Turkevich et al. [22] , 10 mL of sodium citrate solution (38.8 mM) were added to 100 mL of HAuCl 4 \u00b73H 2 O solution (1 mM) previously brought to 90 \u2022 C and under vigorous stirring.", [["Dichloromethane", "CHEMICAL", 0, 15], ["Au NPs", "CHEMICAL", 94, 100], ["Au-Cit NPs", "CHEMICAL", 124, 134], ["sodium citrate", "CHEMICAL", 195, 209], ["HAuCl 4 \u00b73H 2 O", "CHEMICAL", 253, 268], ["Dichloromethane", "CHEMICAL", 0, 15], ["Au", "CHEMICAL", 94, 96], ["Citrate", "CHEMICAL", 108, 115], ["Au", "CHEMICAL", 124, 126], ["sodium citrate", "CHEMICAL", 195, 209], ["HAuCl 4 \u00b73H 2 O", "CHEMICAL", 253, 268], ["Dichloromethane", "SIMPLE_CHEMICAL", 0, 15], ["Au NPs", "SIMPLE_CHEMICAL", 94, 100], ["Citrate", "SIMPLE_CHEMICAL", 108, 115], ["Au-Cit NPs", "SIMPLE_CHEMICAL", 124, 134], ["sodium citrate solution", "SIMPLE_CHEMICAL", 195, 218], ["3H 2 O solution", "SIMPLE_CHEMICAL", 262, 277], ["Dichloromethane", "TREATMENT", 0, 15], ["Au NPs", "TREATMENT", 94, 100], ["the Citrate Method (Au-Cit NPs)", "TREATMENT", 104, 135], ["the procedure of Turkevich et al.", "TREATMENT", 145, 178], ["sodium citrate solution", "TREATMENT", 195, 218], ["HAuCl", "TREATMENT", 253, 258], ["vigorous stirring", "OBSERVATION", 324, 341]]], ["After 1 h, heating was switched off, and stirring was kept overnight.", [["heating", "TREATMENT", 11, 18]]], ["Prior to use, the colloid was centrifuged for 30 min at 15,600\u00d7 g.", [["the colloid", "TREATMENT", 14, 25]]], ["The supernatant was removed and replaced by an equal volume of ultrapure water.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["an equal volume of ultrapure water", "TREATMENT", 44, 78]]], ["Au NPs with a diameter of circa 15 nm were obtained, and the concentration (mol NPs/L) was calculated by UV-Vis spectroscopy as described in the literature [23] .Copolymerization of MacroRAFT Agent via RAFT Emulsion PolymerizationThe diblock copolymers were prepared by RAFT emulsion polymerization.", [["Au", "CHEMICAL", 0, 2], ["Au", "CHEMICAL", 0, 2], ["Au NPs", "SIMPLE_CHEMICAL", 0, 6], ["MacroRAFT Agent", "SIMPLE_CHEMICAL", 182, 197], ["diblock copolymers", "SIMPLE_CHEMICAL", 234, 252], ["RAFT", "SIMPLE_CHEMICAL", 270, 274], ["the concentration (mol NPs/L)", "TREATMENT", 57, 86], ["Copolymerization of MacroRAFT Agent", "TREATMENT", 162, 197], ["RAFT Emulsion Polymerization", "TREATMENT", 202, 230], ["The diblock copolymers", "TREATMENT", 230, 252], ["RAFT emulsion polymerization", "TREATMENT", 270, 298], ["RAFT", "OBSERVATION", 202, 206], ["Emulsion Polymerization", "OBSERVATION", 207, 230], ["diblock copolymers", "OBSERVATION", 234, 252], ["emulsion polymerization", "OBSERVATION", 275, 298]]], ["The macroRAFT agent was dissolved in water, and the pH was adjusted to 7.5 using an aqueous solution of NaOH (0.5 M).", [["NaOH", "CHEMICAL", 104, 108], ["NaOH", "CHEMICAL", 104, 108], ["macroRAFT", "SIMPLE_CHEMICAL", 4, 13], ["water", "SIMPLE_CHEMICAL", 37, 42], ["NaOH", "SIMPLE_CHEMICAL", 104, 108], ["The macroRAFT agent", "TREATMENT", 0, 19], ["the pH", "TEST", 48, 54], ["an aqueous solution of NaOH", "TREATMENT", 81, 108]]], ["Then, the solution of initiator VA-044 (1.4 mL, 3.2 mM) was added to the reaction vessel.", [["vessel", "ANATOMY", 82, 88], ["VA-044", "CHEMICAL", 32, 38], ["VA-044", "CHEMICAL", 32, 38], ["VA-044", "SIMPLE_CHEMICAL", 32, 38], ["vessel", "MULTI-TISSUE_STRUCTURE", 82, 88], ["the solution of initiator VA", "TREATMENT", 6, 34], ["vessel", "ANATOMY", 82, 88]]], ["The reaction vessel was placed in an ice bath, and the mixture was purged with nitrogen for 30 min under stirring.", [["vessel", "ANATOMY", 13, 19], ["nitrogen", "CHEMICAL", 79, 87], ["nitrogen", "CHEMICAL", 79, 87], ["vessel", "MULTI-TISSUE_STRUCTURE", 13, 19], ["nitrogen", "SIMPLE_CHEMICAL", 79, 87], ["The reaction vessel", "TREATMENT", 0, 19], ["an ice bath", "TREATMENT", 34, 45], ["nitrogen", "TREATMENT", 79, 87], ["vessel", "ANATOMY", 13, 19]]], ["The polymerization was started by placing the reaction vessel in an oil bath at 44 \u2022 C. An aliquot (100 \u00b5L) of the mixture of hydrophobic monomers (10 MMA: 1 BA w/w) was added each hour during the first 6 h of reaction, which continued for 18 more hours.", [["vessel", "ANATOMY", 55, 61], ["oil", "ANATOMY", 68, 71], ["MMA", "CHEMICAL", 151, 154], ["vessel", "MULTI-TISSUE_STRUCTURE", 55, 61], ["oil", "ORGANISM_SUBSTANCE", 68, 71], ["The polymerization", "TREATMENT", 0, 18], ["the reaction vessel", "TREATMENT", 42, 61], ["an oil bath", "TREATMENT", 65, 76], ["the mixture of hydrophobic monomers", "TREATMENT", 111, 146], ["BA w/w)", "TREATMENT", 158, 165], ["vessel", "ANATOMY", 55, 61]]], ["After this, the reaction vessel was placed in an ice bath in contact with oxygen to stop the polymerization.", [["vessel", "ANATOMY", 25, 31], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 74, 80], ["vessel", "MULTI-TISSUE_STRUCTURE", 25, 31], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["the reaction vessel", "TREATMENT", 12, 31], ["an ice bath", "TREATMENT", 46, 57], ["oxygen", "TREATMENT", 74, 80], ["the polymerization", "TREATMENT", 89, 107], ["vessel", "ANATOMY", 25, 31]]], ["Samples were periodically withdrawn to monitor the monomer conversion by gravimetric analyses and the evolution of the average particle diameter by dynamic light scattering (DLS) measurements.Preparation of N3-Copolymer@Au NPs via REEPN3-copolymer@Au NPs were prepared using a mixture of the macroRAFT P(PEGA 40 )-TTC with a macroRAFT agent modified with the azide group (N3-macroRAFT agent) using a ratio of [2 macroRAFT: 1 N3-macroRAFT] in two steps: (1) adsorption of the macroRAFT mixture onto Au NPs to afford N3-macroRAFT@Au NPs, which was followed by (2) chain extension via REEP.Preparation of N3-Copolymer@Au NPs via REEPRegarding step (1), a solution of N3-macroRAFT agent (0.05 mM) and a solution of macroRAFT agent (0.05 mM) were prepared, and the pH was increased to 7-8 with the use of NaOH (0.1 M and 0.01 M).", [["N3-Copolymer@Au", "CHEMICAL", 207, 222], ["REEPN3-copolymer@Au", "CHEMICAL", 231, 250], ["RAFT P(PEGA 40 )-TTC", "CHEMICAL", 297, 317], ["azide", "CHEMICAL", 359, 364], ["N3-macroRAFT", "CHEMICAL", 372, 384], ["Au NPs", "CHEMICAL", 498, 504], ["N3-macroRAFT@Au", "CHEMICAL", 515, 530], ["N3-Copolymer@Au NPs", "CHEMICAL", 602, 621], ["N3-macroRAFT", "CHEMICAL", 664, 676], ["NaOH", "CHEMICAL", 800, 804], ["N3-Copolymer@Au", "CHEMICAL", 207, 222], ["PEGA 40 )-TTC", "CHEMICAL", 304, 317], ["azide", "CHEMICAL", 359, 364], ["N3-macroRAFT", "CHEMICAL", 372, 384], ["Au", "CHEMICAL", 498, 500], ["N3-macroRAFT@Au", "CHEMICAL", 515, 530], ["N3-Copolymer@Au", "CHEMICAL", 602, 617], ["N3-macroRAFT", "CHEMICAL", 664, 676], ["NaOH", "CHEMICAL", 800, 804], ["N3-Copolymer@Au NPs", "SIMPLE_CHEMICAL", 207, 226], ["REEPN3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 231, 254], ["azide", "SIMPLE_CHEMICAL", 359, 364], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 372, 384], ["1 N3-macroRAFT", "SIMPLE_CHEMICAL", 423, 437], ["Au NPs", "SIMPLE_CHEMICAL", 498, 504], ["N3-macroRAFT@Au NPs", "SIMPLE_CHEMICAL", 515, 534], ["N3-Copolymer@Au NPs", "SIMPLE_CHEMICAL", 602, 621], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 664, 676], ["macroRAFT", "SIMPLE_CHEMICAL", 711, 720], ["NaOH", "SIMPLE_CHEMICAL", 800, 804], ["REEP", "PROTEIN", 582, 586], ["Samples", "TEST", 0, 7], ["gravimetric analyses", "TEST", 73, 93], ["N3", "TREATMENT", 207, 209], ["Copolymer@Au NPs", "TREATMENT", 210, 226], ["REEPN3-copolymer@Au NPs", "TREATMENT", 231, 254], ["PEGA", "TEST", 304, 308], ["a macroRAFT agent", "TREATMENT", 323, 340], ["the azide group (N3-macroRAFT agent", "TREATMENT", 355, 390], ["a ratio", "TEST", 398, 405], ["the macroRAFT mixture", "TREATMENT", 471, 492], ["Au NPs", "TREATMENT", 498, 504], ["N3-macroRAFT@Au NPs", "TREATMENT", 515, 534], ["N3-Copolymer@Au NPs", "TREATMENT", 602, 621], ["a solution of N3-macroRAFT agent", "TREATMENT", 650, 682], ["a solution of macroRAFT agent", "TREATMENT", 697, 726], ["the pH", "TEST", 756, 762], ["NaOH", "TREATMENT", 800, 804]]], ["N3-macroRAFT agent solution (6.7 mL) was first added dropwise to a dispersion of Au NPs (2 mL, 6.0 \u00d7 10 \u22129 mol NPs/L) and stirred for 2 h.", [["N3-macroRAFT", "CHEMICAL", 0, 12], ["Au NPs", "CHEMICAL", 81, 87], ["Au", "CHEMICAL", 81, 83], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 0, 12], ["Au NPs", "SIMPLE_CHEMICAL", 81, 87], ["N3-macroRAFT agent solution", "TREATMENT", 0, 27], ["a dispersion of Au NPs", "TREATMENT", 65, 87]]], ["Then, 13.3 mL of macroRAFT agent solution was also added dropwise, and the mixture was stirred overnight, at room temperature.", [["macroRAFT", "SIMPLE_CHEMICAL", 17, 26], ["macroRAFT agent solution", "TREATMENT", 17, 41]]], ["The mixture was centrifuged for 30 min at 15,600\u00d7 g, the supernatant was collected, and the precipitate redispersed in 10 mL of ultrapure water.Preparation of N3-Copolymer@Au NPs via REEPIn step (2), the pH of the freshly prepared N3-macroRAFT@Au NPs (9 mL) was adjusted to pH = 8 using NaOH (0.1 or 0.01 M), and then a solution of initiator VA-044 (1 mL, 0.25 mM) and 5 \u00b5L of the mixture of hydrophobic monomers MMA:BA (10:1 w/w) were added.", [["supernatant", "ANATOMY", 57, 68], ["N3-Copolymer@Au", "CHEMICAL", 159, 174], ["RAFT@Au NPs", "CHEMICAL", 239, 250], ["NaOH", "CHEMICAL", 287, 291], ["VA-044", "CHEMICAL", 342, 348], ["MMA", "CHEMICAL", 413, 416], ["BA", "CHEMICAL", 417, 419], ["N3-Copolymer@Au", "CHEMICAL", 159, 174], ["N3", "CHEMICAL", 231, 233], ["RAFT@Au", "CHEMICAL", 239, 246], ["NaOH", "CHEMICAL", 287, 291], ["VA-044", "CHEMICAL", 342, 348], ["MMA", "CHEMICAL", 413, 416], ["N3-Copolymer@Au NPs", "SIMPLE_CHEMICAL", 159, 178], ["REEPIn", "SIMPLE_CHEMICAL", 183, 189], ["N3-macroRAFT@Au NPs", "SIMPLE_CHEMICAL", 231, 250], ["NaOH", "SIMPLE_CHEMICAL", 287, 291], ["VA-044", "SIMPLE_CHEMICAL", 342, 348], ["MMA", "SIMPLE_CHEMICAL", 413, 416], ["BA", "SIMPLE_CHEMICAL", 417, 419], ["ultrapure water", "TREATMENT", 128, 143], ["N3", "TREATMENT", 159, 161], ["Copolymer@Au NPs", "TREATMENT", 162, 178], ["the pH", "TEST", 200, 206], ["macroRAFT@Au NPs", "TREATMENT", 234, 250], ["pH", "TEST", 274, 276], ["a solution of initiator VA", "TREATMENT", 318, 344], ["BA (10:1 w/w)", "TREATMENT", 417, 430]]], ["The mixture was purged with nitrogen for 30 min in an ice bath under stirring, and the polymerization started by placing the reaction vessel in an oil bath at 44 \u2022 C. Then, 20 \u00b5L more of MMA:BA (10:1 w/w) was added in the first 6 h (5 \u00b5L, each hour, using a microsyringe), and the polymerization continued up to a total of 24 h.", [["vessel", "ANATOMY", 134, 140], ["oil", "ANATOMY", 147, 150], ["nitrogen", "CHEMICAL", 28, 36], ["MMA", "CHEMICAL", 187, 190], ["BA", "CHEMICAL", 191, 193], ["nitrogen", "CHEMICAL", 28, 36], ["MMA", "CHEMICAL", 187, 190], ["nitrogen", "SIMPLE_CHEMICAL", 28, 36], ["vessel", "MULTI-TISSUE_STRUCTURE", 134, 140], ["oil", "ORGANISM_SUBSTANCE", 147, 150], ["MMA", "SIMPLE_CHEMICAL", 187, 190], ["BA", "SIMPLE_CHEMICAL", 191, 193], ["nitrogen", "TREATMENT", 28, 36], ["an ice bath", "TREATMENT", 51, 62], ["the polymerization", "TREATMENT", 83, 101], ["the reaction vessel", "TREATMENT", 121, 140], ["an oil bath", "TREATMENT", 144, 155], ["a microsyringe)", "TREATMENT", 256, 271], ["the polymerization", "TREATMENT", 277, 295], ["vessel", "ANATOMY", 134, 140]]], ["The polymerization was quenched by placing the reaction vessel in an ice bath and by opening it to have contact with oxygen from the air.", [["vessel", "ANATOMY", 56, 62], ["oxygen", "CHEMICAL", 117, 123], ["oxygen", "CHEMICAL", 117, 123], ["vessel", "MULTI-TISSUE_STRUCTURE", 56, 62], ["oxygen", "SIMPLE_CHEMICAL", 117, 123], ["The polymerization", "TREATMENT", 0, 18], ["an ice bath", "TREATMENT", 66, 77], ["vessel", "ANATOMY", 56, 62], ["air", "ANATOMY", 133, 136]]], ["The resulting colloid was centrifuged 30 min at 15,600\u00d7 g, the supernatant was collected, and the precipitate was redispersed in the same volume using ultrapure water.Preparation of Copolymer@Au NPs via REEPCopolymer@Au NPs, without azide functional groups, were prepared following the same procedure as described above for the preparation of N3-copolymer@Au NPs, but in this case, during the adsorption step, only P(PEGA 40 )-TTC was used.", [["supernatant", "ANATOMY", 63, 74], ["Copolymer@Au NPs", "CHEMICAL", 182, 198], ["REEPCopolymer@Au NPs", "CHEMICAL", 203, 223], ["azide", "CHEMICAL", 233, 238], ["N3-copolymer@Au", "CHEMICAL", 343, 358], ["REEPCopolymer@Au", "CHEMICAL", 203, 219], ["azide", "CHEMICAL", 233, 238], ["N3", "CHEMICAL", 343, 345], ["P(PEGA 40 )-TTC", "CHEMICAL", 415, 430], ["Copolymer@Au NPs", "SIMPLE_CHEMICAL", 182, 198], ["REEPCopolymer@Au NPs", "SIMPLE_CHEMICAL", 203, 223], ["azide", "SIMPLE_CHEMICAL", 233, 238], ["N3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 343, 362], ["The resulting colloid", "TREATMENT", 0, 21], ["ultrapure water", "TREATMENT", 151, 166], ["Copolymer@Au NPs", "TREATMENT", 182, 198], ["REEPCopolymer@Au NPs", "TREATMENT", 203, 223], ["azide functional groups", "TREATMENT", 233, 256], ["the same procedure", "TREATMENT", 282, 300], ["N3-copolymer@Au NPs", "TREATMENT", 343, 362], ["colloid", "OBSERVATION", 14, 21]]], ["A solution of macroRAFT agent (20 mL, 0.05 mM, pH 7-8) was added dropwise under stirring, to a dispersion of Au NPs (2 mL, 6.0 \u00d7 10 \u22129 mol NPs/L) and stirred overnight at room temperature.Synthesis of Alkynated BiotinBiotin was functionalized with an alkyne group following the work of Matyjaszewski et al. [24] .", [["Au NPs", "CHEMICAL", 109, 115], ["Alkynated BiotinBiotin", "CHEMICAL", 201, 223], ["Au", "CHEMICAL", 109, 111], ["Alkynated BiotinBiotin", "CHEMICAL", 201, 223], ["alkyne", "CHEMICAL", 251, 257], ["macroRAFT", "SIMPLE_CHEMICAL", 14, 23], ["Au NPs", "SIMPLE_CHEMICAL", 109, 115], ["Alkynated BiotinBiotin", "SIMPLE_CHEMICAL", 201, 223], ["A solution of macroRAFT agent", "TREATMENT", 0, 29], ["pH", "TEST", 47, 49], ["Au NPs", "TREATMENT", 109, 115], ["Synthesis of Alkynated BiotinBiotin", "TREATMENT", 188, 223], ["an alkyne group", "TREATMENT", 248, 263]]], ["The DMF used in this synthesis was previously dried using molecular sieves and purged with nitrogen.", [["DMF", "CHEMICAL", 4, 7], ["nitrogen", "CHEMICAL", 91, 99], ["DMF", "CHEMICAL", 4, 7], ["nitrogen", "CHEMICAL", 91, 99], ["DMF", "SIMPLE_CHEMICAL", 4, 7], ["nitrogen", "SIMPLE_CHEMICAL", 91, 99], ["The DMF", "TREATMENT", 0, 7], ["this synthesis", "TREATMENT", 16, 30], ["molecular sieves", "TREATMENT", 58, 74], ["nitrogen", "TREATMENT", 91, 99]]], ["First, 0.7 g of biotin, 1.1 g of EDC, and 0.035 g of DMAP were added to a 100 mL round-bottom flask.", [["biotin", "CHEMICAL", 16, 22], ["EDC", "CHEMICAL", 33, 36], ["DMAP", "CHEMICAL", 53, 57], ["biotin", "CHEMICAL", 16, 22], ["EDC", "CHEMICAL", 33, 36], ["DMAP", "CHEMICAL", 53, 57], ["biotin", "SIMPLE_CHEMICAL", 16, 22], ["EDC", "SIMPLE_CHEMICAL", 33, 36], ["DMAP", "SIMPLE_CHEMICAL", 53, 57], ["biotin", "TREATMENT", 16, 22], ["EDC", "TREATMENT", 33, 36], ["DMAP", "TREATMENT", 53, 57], ["bottom flask", "OBSERVATION", 87, 99]]], ["The contents were vacuum dried, and 49 mL of DMF was added.", [["DMF", "CHEMICAL", 45, 48], ["DMF", "CHEMICAL", 45, 48], ["DMF", "SIMPLE_CHEMICAL", 45, 48], ["vacuum dried", "TREATMENT", 18, 30], ["DMF", "TREATMENT", 45, 48], ["vacuum dried", "OBSERVATION", 18, 30]]], ["The flask was placed in an ice bath.", [["The flask", "TREATMENT", 0, 9], ["an ice bath", "TREATMENT", 24, 35]]], ["Then, 0.4 g of 3-butyn-1-ol was dissolved in 4.7 mL of DMF, in N 2 atmosphere.", [["3-butyn-1-ol", "CHEMICAL", 15, 27], ["DMF", "CHEMICAL", 55, 58], ["3-butyn-1-ol", "CHEMICAL", 15, 27], ["DMF", "CHEMICAL", 55, 58], ["3-butyn-1-ol", "SIMPLE_CHEMICAL", 15, 27], ["DMF", "SIMPLE_CHEMICAL", 55, 58], ["DMF", "TREATMENT", 55, 58]]], ["This solution was added slowly to the reaction vessel using a syringe pump over a period of 2 h.", [["vessel", "ANATOMY", 47, 53], ["vessel", "MULTI-TISSUE_STRUCTURE", 47, 53], ["This solution", "TREATMENT", 0, 13], ["a syringe pump", "TREATMENT", 60, 74], ["vessel", "ANATOMY", 47, 53]]], ["The mixture was allowed to reach room temperature and was stirred under nitrogen for 2 days.", [["nitrogen", "CHEMICAL", 72, 80], ["nitrogen", "CHEMICAL", 72, 80], ["nitrogen", "TREATMENT", 72, 80]]], ["After this period of time, the DMF was removed using a rotary evaporator, and the contents were dissolved into 80 mL of dichloromethane.", [["DMF", "CHEMICAL", 31, 34], ["dichloromethane", "CHEMICAL", 120, 135], ["DMF", "CHEMICAL", 31, 34], ["dichloromethane", "CHEMICAL", 120, 135], ["DMF", "SIMPLE_CHEMICAL", 31, 34], ["dichloromethane", "SIMPLE_CHEMICAL", 120, 135], ["the DMF", "TREATMENT", 27, 34], ["a rotary evaporator", "TREATMENT", 53, 72], ["dichloromethane", "TREATMENT", 120, 135]]], ["This solution was washed once with 50 mL of an aqueous solution of NaOH (1 M) and four times with 50 mL of distilled water.", [["NaOH", "CHEMICAL", 67, 71], ["NaOH", "CHEMICAL", 67, 71], ["NaOH", "SIMPLE_CHEMICAL", 67, 71], ["This solution", "TREATMENT", 0, 13], ["an aqueous solution of NaOH", "TREATMENT", 44, 71]]], ["Dichloromethane was removed using a rotary evaporator.", [["Dichloromethane", "CHEMICAL", 0, 15], ["Dichloromethane", "CHEMICAL", 0, 15], ["Dichloromethane", "SIMPLE_CHEMICAL", 0, 15], ["Dichloromethane", "TREATMENT", 0, 15], ["a rotary evaporator", "TREATMENT", 34, 53]]], ["The resulting white-brownish solid was dissolved in THF and then precipitated twice into an excess ofPreparation of Biotin-Copolymer@Au NPs via Click ReactionFirst, 250 \u00b5L of alkynated biotin (1.67 mM, aqueous DMSO solution 10% to ensure full solubilization of biotin) was added to 10 mL of N3-copolymer@Au nanostructures, under stirring.", [["THF", "CHEMICAL", 52, 55], ["Biotin-Copolymer@Au NPs", "CHEMICAL", 116, 139], ["alkynated biotin", "CHEMICAL", 175, 191], ["DMSO", "CHEMICAL", 210, 214], ["biotin", "CHEMICAL", 261, 267], ["THF", "CHEMICAL", 52, 55], ["Biotin", "CHEMICAL", 116, 122], ["alkynated biotin", "CHEMICAL", 175, 191], ["DMSO", "CHEMICAL", 210, 214], ["biotin", "CHEMICAL", 261, 267], ["N3", "CHEMICAL", 291, 293], ["THF", "SIMPLE_CHEMICAL", 52, 55], ["Biotin-Copolymer@Au NPs", "SIMPLE_CHEMICAL", 116, 139], ["alkynated biotin", "SIMPLE_CHEMICAL", 175, 191], ["biotin", "SIMPLE_CHEMICAL", 261, 267], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 291, 321], ["The resulting white-brownish solid", "PROBLEM", 0, 34], ["Biotin", "TREATMENT", 116, 122], ["Copolymer@Au NPs", "TREATMENT", 123, 139], ["alkynated biotin", "TREATMENT", 175, 191], ["aqueous DMSO solution", "TREATMENT", 202, 223], ["full solubilization of biotin)", "TREATMENT", 238, 268], ["N3-copolymer@Au nanostructures", "TREATMENT", 291, 321], ["white", "OBSERVATION_MODIFIER", 14, 19], ["brownish solid", "OBSERVATION_MODIFIER", 20, 34]]], ["Then, 42 \u00b5L of CuSO 4 \u00b75H 2 O (2.5 mM) and 42 \u00b5L of sodium ascorbate (5 mM) were added, and the mixture was stirred for 24 h.", [["CuSO 4 \u00b75H 2 O", "CHEMICAL", 15, 29], ["sodium ascorbate", "CHEMICAL", 52, 68], ["CuSO 4 \u00b75H 2 O", "CHEMICAL", 15, 29], ["sodium ascorbate", "CHEMICAL", 52, 68], ["5H 2 O", "SIMPLE_CHEMICAL", 23, 29], ["sodium ascorbate", "SIMPLE_CHEMICAL", 52, 68], ["sodium ascorbate (5 mM)", "TREATMENT", 52, 75]]], ["The determination of azide moieties in the nanostructure was not possible; therefore, it was considered to be 8 \u00d7 10 \u22127 moles (i.e., the number of moles of N3-macroRAFT agent used in the adsorption).", [["azide", "CHEMICAL", 21, 26], ["azide", "CHEMICAL", 21, 26], ["N3", "CHEMICAL", 156, 158], ["azide moieties", "SIMPLE_CHEMICAL", 21, 35], ["The determination of azide moieties", "TREATMENT", 0, 35], ["N3", "TREATMENT", 156, 158], ["macroRAFT agent", "TREATMENT", 159, 174], ["azide moieties", "OBSERVATION", 21, 35], ["not possible", "UNCERTAINTY", 61, 73]]], ["Based on this, the ratios used were: 1 [azide]: 0.5 [alkyne]: 0.125 [CuSO 4 ]: 0.25 [sodium ascorbate].", [["azide", "CHEMICAL", 40, 45], ["sodium ascorbate", "CHEMICAL", 85, 101], ["azide", "CHEMICAL", 40, 45], ["alkyne", "CHEMICAL", 53, 59], ["[CuSO 4 ]", "CHEMICAL", 68, 77], ["sodium ascorbate", "CHEMICAL", 85, 101], ["1 [azide]: 0.5 [alkyne", "SIMPLE_CHEMICAL", 37, 59], ["[CuSO 4 ]: 0.25 [sodium ascorbate", "SIMPLE_CHEMICAL", 68, 101], ["the ratios", "TEST", 15, 25], ["azide", "TEST", 40, 45], ["sodium ascorbate", "TEST", 85, 101]]], ["After 24 h, the colloidal mixture was centrifuged for 30 min at 15,600\u00d7 g, the supernatant was collected, and the precipitate was redispersed in 10 mL using ultrapure water.Preparation of Biotin-Copolymer@Au NPs via Click ReactionThe same procedure was also applied to the copolymer@Au nanostructures (without azide moieties), which was used as control of the click reaction (\"click control\").", [["supernatant", "ANATOMY", 79, 90], ["Biotin-Copolymer@Au NPs", "CHEMICAL", 188, 211], ["azide moieties", "CHEMICAL", 310, 324], ["Biotin", "CHEMICAL", 188, 194], ["azide", "CHEMICAL", 310, 315], ["Biotin-Copolymer@Au NPs", "SIMPLE_CHEMICAL", 188, 211], ["azide moieties", "SIMPLE_CHEMICAL", 310, 324], ["the colloidal mixture", "TREATMENT", 12, 33], ["ultrapure water", "TREATMENT", 157, 172], ["Biotin-Copolymer@Au NPs", "TREATMENT", 188, 211], ["The same procedure", "TREATMENT", 230, 248], ["the copolymer@Au nanostructures", "TREATMENT", 269, 300], ["azide moieties", "TREATMENT", 310, 324], ["the click reaction", "PROBLEM", 356, 374]]], ["Furthermore, these nanostructures were extensively rinsed to assess the efficiency of the click reaction.", [["the click reaction", "PROBLEM", 86, 104], ["click reaction", "OBSERVATION", 90, 104]]], ["Thus, three precipitation/redispersion cycles by centrifugation were performed in the colloid, using ultrapure water or an aqueous solution containing DMSO (1 DMSO:10 H 2 O v/v) in order to increase the solubility of biotin in the supernatant.", [["supernatant", "ANATOMY", 231, 242], ["DMSO", "CHEMICAL", 151, 155], ["DMSO", "CHEMICAL", 159, 163], ["biotin", "CHEMICAL", 217, 223], ["DMSO", "CHEMICAL", 151, 155], ["DMSO", "CHEMICAL", 159, 163], ["biotin", "CHEMICAL", 217, 223], ["water", "SIMPLE_CHEMICAL", 111, 116], ["DMSO", "SIMPLE_CHEMICAL", 151, 155], ["biotin", "SIMPLE_CHEMICAL", 217, 223], ["three precipitation/redispersion cycles", "TREATMENT", 6, 45], ["ultrapure water", "TREATMENT", 101, 116], ["an aqueous solution containing DMSO", "TREATMENT", 120, 155], ["the solubility of biotin", "TREATMENT", 199, 223]]], ["The relative portions used were based of the information available in data sheets of biotin.", [["biotin", "CHEMICAL", 85, 91], ["biotin", "CHEMICAL", 85, 91], ["biotin", "SIMPLE_CHEMICAL", 85, 91], ["biotin", "TREATMENT", 85, 91]]], ["However, an interesting study regarding the solubility of biotin in different solvents and temperatures has been reported by Chen et al. [25] .Biosensing TestsA solution of avidin and BSA (0.5 mg/mL) was prepared with phosphate saline buffer (PBS, pH 7.4, 10 mM).", [["biotin", "CHEMICAL", 58, 64], ["BSA", "CHEMICAL", 184, 187], ["phosphate", "CHEMICAL", 218, 227], ["biotin", "CHEMICAL", 58, 64], ["phosphate", "CHEMICAL", 218, 227], ["biotin", "SIMPLE_CHEMICAL", 58, 64], ["avidin", "SIMPLE_CHEMICAL", 173, 179], ["BSA", "SIMPLE_CHEMICAL", 184, 187], ["phosphate saline buffer", "SIMPLE_CHEMICAL", 218, 241], ["an interesting study", "TEST", 9, 29], ["the solubility of biotin in different solvents", "TREATMENT", 40, 86], ["Biosensing TestsA solution of avidin and BSA", "TREATMENT", 143, 187], ["phosphate saline buffer", "TREATMENT", 218, 241], ["pH", "TEST", 248, 250]]], ["First, 10 \u00b5L of BSA or avidin solution were added to 350 \u00b5L of biotin-copolymer@Au NPs, neat copolymer@Au NPs, and copolymer@Au NPs (without azide moiety) submitted to the click chemistry reaction (named \"click control\"); the last two were used as controls.", [["BSA", "CHEMICAL", 16, 19], ["biotin-copolymer@Au", "CHEMICAL", 63, 82], ["copolymer@Au NPs", "CHEMICAL", 115, 131], ["azide moiety", "CHEMICAL", 141, 153], ["biotin", "CHEMICAL", 63, 69], ["azide", "CHEMICAL", 141, 146], ["BSA", "SIMPLE_CHEMICAL", 16, 19], ["avidin solution", "SIMPLE_CHEMICAL", 23, 38], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 63, 86], ["neat copolymer@Au NPs", "SIMPLE_CHEMICAL", 88, 109], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 115, 131], ["azide moiety", "SIMPLE_CHEMICAL", 141, 153], ["BSA or avidin solution", "TREATMENT", 16, 38], ["biotin", "TREATMENT", 63, 69], ["copolymer@Au NPs", "TREATMENT", 70, 86], ["neat copolymer@Au NPs", "TREATMENT", 88, 109], ["copolymer@Au NPs", "TREATMENT", 115, 131], ["azide moiety", "TREATMENT", 141, 153], ["the click chemistry reaction", "TEST", 168, 196]]], ["After 10 min, the visible spectra were recorded.", [["the visible spectra", "PROBLEM", 14, 33]]], ["As a control of the dilution, PBS was also added to the Au nanostructures.Preparation of Langmuir Monolayers to Study Copolymer-Biotin-Avidin InteractionsFirst, 600 \u00b5L of a biotin solution (0.4 mg/mL) was added to 34 \u00b5L of latex and stirred overnight.", [["Au", "CHEMICAL", 56, 58], ["biotin", "CHEMICAL", 173, 179], ["Au", "CHEMICAL", 56, 58], ["Avidin", "CHEMICAL", 135, 141], ["biotin", "CHEMICAL", 173, 179], ["PBS", "SIMPLE_CHEMICAL", 30, 33], ["Copolymer-Biotin-Avidin", "SIMPLE_CHEMICAL", 118, 141], ["biotin", "SIMPLE_CHEMICAL", 173, 179], ["the dilution", "TREATMENT", 16, 28], ["PBS", "TREATMENT", 30, 33], ["Langmuir Monolayers", "TREATMENT", 89, 108], ["Study Copolymer-Biotin-Avidin InteractionsFirst", "TREATMENT", 112, 159], ["a biotin solution", "TREATMENT", 171, 188], ["latex", "TREATMENT", 223, 228]]], ["The mixture was dried under an air flow and then dissolved with an ethanol:chloroform (1:10) solvent mixture.", [["ethanol", "CHEMICAL", 67, 74], ["ethanol", "CHEMICAL", 67, 74], ["chloroform", "CHEMICAL", 75, 85], ["ethanol", "SIMPLE_CHEMICAL", 67, 74], ["chloroform", "SIMPLE_CHEMICAL", 75, 85], ["an air flow", "TREATMENT", 28, 39], ["an ethanol:chloroform", "TREATMENT", 64, 85], ["air flow", "OBSERVATION", 31, 39]]], ["Then, 10 \u00b5L of this solution (2 mg/mL of copolymer containing biotin) was spread on the air/water interface using ultrapure water or an aqueous solution of avidin as the subphase.", [["biotin", "CHEMICAL", 62, 68], ["biotin", "CHEMICAL", 62, 68], ["biotin", "SIMPLE_CHEMICAL", 62, 68], ["water", "SIMPLE_CHEMICAL", 124, 129], ["avidin", "GENE_OR_GENE_PRODUCT", 156, 162], ["this solution", "TREATMENT", 15, 28], ["copolymer containing biotin)", "TREATMENT", 41, 69], ["the air/water interface", "TREATMENT", 84, 107], ["ultrapure water", "TREATMENT", 114, 129], ["an aqueous solution of avidin", "TREATMENT", 133, 162]]], ["The avidin solution used as the subphase was prepared by diluting 500 \u00b5L of an avidin solution (0.5 mg/mL) in 500 mL of ultrapure water.", [["avidin", "GENE_OR_GENE_PRODUCT", 4, 10], ["avidin", "GENE_OR_GENE_PRODUCT", 79, 85], ["The avidin solution", "TREATMENT", 0, 19], ["the subphase", "TREATMENT", 28, 40], ["an avidin solution", "TREATMENT", 76, 94], ["ultrapure water", "TREATMENT", 120, 135]]], ["Before barriers compression started, the copolymer-biotin mixture was allowed to reach equilibrium (solvent evaporation) for 15 min.", [["copolymer-biotin", "CHEMICAL", 41, 57], ["biotin", "CHEMICAL", 51, 57], ["biotin", "SIMPLE_CHEMICAL", 51, 57], ["barriers compression", "TREATMENT", 7, 27], ["the copolymer-biotin mixture", "TREATMENT", 37, 65], ["equilibrium (solvent evaporation", "TREATMENT", 87, 119]]], ["These studies were performed in collaboration with Oliveira's group in Brazil (University of S\u00e3o Paulo in S\u00e3o Carlos) in a class 10,000 clean room and a KSV-Nima Small KN2001.", [["These studies", "TEST", 0, 13], ["a KSV", "TEST", 151, 156]]], ["Then, 10 \u00b5L of copolymer solution containing biotin, as described above, were spread at the air/water interface using an aqueous solution of avidin (0.5 mg/mL) as the subphase.", [["biotin", "CHEMICAL", 45, 51], ["biotin", "CHEMICAL", 45, 51], ["biotin", "SIMPLE_CHEMICAL", 45, 51], ["avidin", "SIMPLE_CHEMICAL", 141, 147], ["copolymer solution containing biotin", "TREATMENT", 15, 51], ["the air/water interface", "TREATMENT", 88, 111], ["an aqueous solution of avidin", "TREATMENT", 118, 147]]], ["Before barriers compression started, the copolymer-biotin mixture was allowed to reach equilibrium (solvent evaporation) for 15 min plus a time contact of 20 min, 1 h, 2 h, or 3 h.", [["copolymer-biotin", "CHEMICAL", 41, 57], ["biotin", "CHEMICAL", 51, 57], ["biotin", "SIMPLE_CHEMICAL", 51, 57], ["barriers compression", "TREATMENT", 7, 27], ["the copolymer-biotin mixture", "TREATMENT", 37, 65], ["equilibrium (solvent evaporation", "TREATMENT", 87, 119]]], ["Langmuir monolayers were prepared by compressing the barriers at 10 mm 2 /min.CharacterizationThe UV/VIS spectra of the colloids were recorded using quartz cells, a Jasco V-560 UV/VIS spectrometer, and using water as the reference.", [["quartz cells", "ANATOMY", 149, 161], ["quartz cells", "CELL", 149, 161], ["quartz cells", "CELL_LINE", 149, 161], ["Langmuir monolayers", "TREATMENT", 0, 19], ["the colloids", "TREATMENT", 116, 128], ["UV/VIS spectrometer", "TREATMENT", 177, 196]]], ["The zeta potential and dynamic light scattering (DLS) measurements were carried out using a ZetaSizer Nano ZS Model Zen 3500 from Malvern.", [["dynamic light scattering (DLS) measurements", "TEST", 23, 66], ["a ZetaSizer Nano ZS Model Zen", "TREATMENT", 90, 119], ["zeta", "OBSERVATION_MODIFIER", 4, 8]]], ["The Au colloids were analyzed as prepared, and the latexes were 10-fold diluted.", [["Au", "CHEMICAL", 4, 6], ["Au", "CHEMICAL", 4, 6], ["Au colloids", "SIMPLE_CHEMICAL", 4, 15], ["The Au colloids", "TREATMENT", 0, 15], ["the latexes", "TEST", 47, 58]]], ["Centrifugation was performed in a Force 1618 Microcentrifuge at room temperature.", [["Centrifugation", "TREATMENT", 0, 14]]], ["Fourier-transform infrared (FTIR) spectra were acquired using a Bruker Optics Tensor 27 spectrometer coupled to a horizontal attenuated total reflectance (ATR) cell, using 1024 scans at a resolution 4 cm \u22121 .", [["ATR) cell", "ANATOMY", 155, 164], ["horizontal attenuated total reflectance (ATR) cell", "CELL_LINE", 114, 164], ["a Bruker Optics Tensor 27 spectrometer", "TREATMENT", 62, 100], ["1024 scans", "TEST", 172, 182]]], ["1 H-NMR spectra were recorded on a Bruker Avance 300 spectrometer.", [["H-NMR spectra", "TEST", 2, 15]]], ["Scanning Electron Microscopy (SEM) in transmission mode (STEM) images were obtained using a Hitachi SU-70 operating at 15 or 30 kV.", [["Scanning Electron Microscopy", "TEST", 0, 28], ["a Hitachi SU", "TEST", 90, 102]]], ["The samples were prepared by placing a drop of diluted colloidal solutions on a copper grid coated with an amorphous carbon film and left to evaporate.CharacterizationGel permeation chromatography -size exclusion chromatography (GPC-SEC) analysis were performed in Department of Chemistry Engineering-DEQUI in the Engineering School of Lorena-EEL-USP, Brazil, in a GPC instrument from Waters adapted with a TDA 302 Triple Detector Array from Viscotek.", [["samples", "ANATOMY", 4, 11], ["copper", "CHEMICAL", 80, 86], ["copper", "CHEMICAL", 80, 86], ["carbon", "CHEMICAL", 117, 123], ["a drop of diluted colloidal solutions", "TREATMENT", 37, 74], ["a copper grid coated", "TREATMENT", 78, 98], ["an amorphous carbon film", "TREATMENT", 104, 128], ["CharacterizationGel permeation chromatography", "TEST", 151, 196], ["size exclusion chromatography", "TEST", 198, 227], ["GPC", "TEST", 229, 232], ["a GPC instrument", "TREATMENT", 363, 379], ["a TDA", "TREATMENT", 405, 410], ["left", "ANATOMY_MODIFIER", 133, 137], ["size", "OBSERVATION_MODIFIER", 198, 202]]], ["To characterize the samples, THF was used as eluent with triethylamine (0.3% v/v), and a flow rate of 1.0 mL\u00b7min \u22121 was used.", [["samples", "ANATOMY", 20, 27], ["THF", "CHEMICAL", 29, 32], ["triethylamine", "CHEMICAL", 57, 70], ["THF", "CHEMICAL", 29, 32], ["triethylamine", "CHEMICAL", 57, 70], ["THF", "SIMPLE_CHEMICAL", 29, 32], ["triethylamine", "SIMPLE_CHEMICAL", 57, 70], ["THF", "TREATMENT", 29, 32], ["triethylamine", "TREATMENT", 57, 70], ["a flow rate", "TEST", 87, 98]]], ["The samples were solubilized overnight, filtered using a polytetrafluoroethylene (PTFE) membrane (pore size of 0.45 \u00b5m), and afterwards, 100 \u00b5L was immediately injected.", [["samples", "ANATOMY", 4, 11], ["pore", "ANATOMY", 98, 102], ["polytetrafluoroethylene", "CHEMICAL", 57, 80], ["PTFE", "CHEMICAL", 82, 86], ["a polytetrafluoroethylene (PTFE) membrane (pore size", "TREATMENT", 55, 107]]], ["The separation occurred in three columns from Phenomenex with size exclusion limits of 10 3 \u00c5, 10 4 \u00c5, and 10 6 \u00c5.", [["The separation", "PROBLEM", 0, 14], ["separation", "OBSERVATION_MODIFIER", 4, 14], ["three columns", "OBSERVATION_MODIFIER", 27, 40], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["The temperature of the columns and detector was maintained at 35 \u2022 C during the analysis.", [["the analysis", "TEST", 76, 88]]], ["The average molar masses (number-average molar mass, M n , and weight-average molar mass, M w ) and the molar mass dispersity (\u00d0 = M w /M n ) were derived from the refractive index (RI) signal using a calibration curve based on polystyrene standard from Sigma-Aldrich and Viscotek.Synthesis of MacroRAFT AgentsTwo types of macroRAFT agents have been synthesized in this work following a similar procedure but in which either P(PEGA 40 )-TTC or P(AA 2 -co-PEGA 40 )-TTC was used.", [["PEGA 40 )-TTC", "CHEMICAL", 427, 440], ["AA 2 -co-PEGA 40", "CHEMICAL", 446, 462], ["polystyrene", "CHEMICAL", 228, 239], ["P(AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 444, 468], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 254, 267], ["Viscotek", "SIMPLE_CHEMICAL", 272, 280], ["macroRAFT agents", "SIMPLE_CHEMICAL", 323, 339], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 427, 440], ["AA 2 -co-PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 446, 468], ["The average molar masses", "PROBLEM", 0, 24], ["average molar mass", "PROBLEM", 33, 51], ["weight-average molar mass", "PROBLEM", 63, 88], ["the molar mass dispersity", "PROBLEM", 100, 125], ["the refractive index", "TEST", 160, 180], ["a calibration curve", "TEST", 199, 218], ["Synthesis of MacroRAFT Agent", "TREATMENT", 281, 309], ["macroRAFT agents", "TREATMENT", 323, 339], ["a similar procedure", "TREATMENT", 385, 404], ["PEGA", "TEST", 427, 431], ["TTC", "TEST", 437, 440], ["AA", "TEST", 446, 448], ["TTC", "TREATMENT", 465, 468], ["average", "OBSERVATION_MODIFIER", 4, 11], ["molar", "OBSERVATION_MODIFIER", 12, 17], ["masses", "OBSERVATION", 18, 24], ["average", "OBSERVATION_MODIFIER", 33, 40], ["molar", "OBSERVATION_MODIFIER", 41, 46], ["mass", "OBSERVATION", 47, 51], ["molar", "OBSERVATION_MODIFIER", 78, 83], ["mass", "OBSERVATION", 84, 88], ["molar", "ANATOMY", 104, 109], ["mass", "OBSERVATION", 110, 114], ["refractive index", "OBSERVATION", 164, 180]]], ["The latter was subsequently modified in order to anchor an azide moiety, yielding an N3-macroRAFT agent (see Scheme 1).", [["azide", "CHEMICAL", 59, 64], ["azide", "CHEMICAL", 59, 64], ["azide", "SIMPLE_CHEMICAL", 59, 64], ["RAFT", "SIMPLE_CHEMICAL", 93, 97], ["an azide moiety", "TREATMENT", 56, 71], ["an N3", "TREATMENT", 82, 87], ["RAFT agent", "TREATMENT", 93, 103]]], ["The monomer PEGA was selected because polymers such as poly(ethylene glycol) are biocompatible.", [["PEGA", "CHEMICAL", 12, 16], ["poly(ethylene glycol", "CHEMICAL", 55, 75], ["PEGA", "CHEMICAL", 12, 16], ["poly(ethylene glycol)", "CHEMICAL", 55, 76], ["PEGA", "SIMPLE_CHEMICAL", 12, 16], ["poly(ethylene glycol", "SIMPLE_CHEMICAL", 55, 75], ["The monomer PEGA", "TREATMENT", 0, 16], ["polymers such as poly(ethylene glycol)", "TREATMENT", 38, 76]]], ["Furthermore, these polymer coatings limit nonspecific interactions with proteins, [26] [27] [28] , which could be very important for the application of surface-coated Au nanostructures as biosensors.Synthesis of MacroRAFT Agentsspectrometer, and using water as the reference.", [["surface", "ANATOMY", 152, 159], ["Au", "CHEMICAL", 167, 169], ["[26] [27] [28]", "SIMPLE_CHEMICAL", 82, 96], ["Au nanostructures", "SIMPLE_CHEMICAL", 167, 184], ["these polymer coatings", "TREATMENT", 13, 35], ["surface-coated Au nanostructures", "TREATMENT", 152, 184], ["Synthesis of MacroRAFT Agentsspectrometer", "TREATMENT", 199, 240]]], ["The zeta potential and dynamic light scattering (DLS) measurements were carried out using a ZetaSizer Nano ZS Model Zen 3500 from Malvern.", [["dynamic light scattering (DLS) measurements", "TEST", 23, 66], ["a ZetaSizer Nano ZS Model Zen", "TREATMENT", 90, 119], ["zeta", "OBSERVATION_MODIFIER", 4, 8]]], ["The Au colloids were analyzed as prepared, and the latexes were 10-fold diluted.", [["Au", "CHEMICAL", 4, 6], ["Au", "CHEMICAL", 4, 6], ["Au colloids", "SIMPLE_CHEMICAL", 4, 15], ["The Au colloids", "TREATMENT", 0, 15], ["the latexes", "TEST", 47, 58]]], ["Centrifugation was performed in a Force 1618 Microcentrifuge at room temperature.", [["Centrifugation", "TREATMENT", 0, 14]]], ["Fourier-transform infrared (FTIR) spectra were acquired using a Bruker Optics Tensor 27 spectrometer coupled to a horizontal attenuated total reflectance (ATR) cell, using 1024 scans at a resolution 4 cm \u22121 .", [["ATR) cell", "ANATOMY", 155, 164], ["horizontal attenuated total reflectance (ATR) cell", "CELL_LINE", 114, 164], ["a Bruker Optics Tensor 27 spectrometer", "TREATMENT", 62, 100], ["1024 scans", "TEST", 172, 182]]], ["1 H-NMR spectra were recorded on a Bruker Avance 300 spectrometer.", [["H-NMR spectra", "TEST", 2, 15]]], ["Scanning Electron Microscopy (SEM) in transmission mode (STEM) images were obtained using a Hitachi SU-70 operating at 15 or 30 kV.", [["Scanning Electron Microscopy", "TEST", 0, 28], ["a Hitachi SU", "TEST", 90, 102]]], ["The samples were prepared by placing a drop of diluted colloidal solutions on a copper grid coated with an amorphous carbon film and left to evaporate.Synthesis of MacroRAFT AgentsGel permeation chromatography -size exclusion chromatography (GPC-SEC) analysis were performed in Department of Chemistry Engineering-DEQUI in the Engineering School of Lorena-EEL-USP, Brazil, in a GPC instrument from Waters adapted with a TDA 302 Triple Detector Array from Viscotek.", [["samples", "ANATOMY", 4, 11], ["copper", "CHEMICAL", 80, 86], ["copper", "CHEMICAL", 80, 86], ["carbon", "CHEMICAL", 117, 123], ["MacroRAFT AgentsGel", "SIMPLE_CHEMICAL", 164, 183], ["a drop of diluted colloidal solutions", "TREATMENT", 37, 74], ["a copper grid coated", "TREATMENT", 78, 98], ["an amorphous carbon film", "TREATMENT", 104, 128], ["Synthesis of MacroRAFT AgentsGel permeation chromatography", "TEST", 151, 209], ["size exclusion chromatography", "TEST", 211, 240], ["GPC", "TEST", 242, 245], ["a GPC instrument", "TREATMENT", 376, 392], ["a TDA", "TREATMENT", 418, 423], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["To characterize the samples, THF was used as eluent with triethylamine (0.3% v/v), and a flow rate of 1.0 mL.min \u22121 was used.", [["samples", "ANATOMY", 20, 27], ["THF", "CHEMICAL", 29, 32], ["triethylamine", "CHEMICAL", 57, 70], ["THF", "CHEMICAL", 29, 32], ["triethylamine", "CHEMICAL", 57, 70], ["THF", "SIMPLE_CHEMICAL", 29, 32], ["triethylamine", "SIMPLE_CHEMICAL", 57, 70], ["THF", "TREATMENT", 29, 32], ["triethylamine", "TREATMENT", 57, 70], ["a flow rate", "TEST", 87, 98]]], ["The samples were solubilized overnight, filtered using a polytetrafluoroethylene (PTFE) membrane (pore size of 0.45 \u00b5m), and afterwards, 100 \u00b5L was immediately injected.", [["samples", "ANATOMY", 4, 11], ["pore", "ANATOMY", 98, 102], ["polytetrafluoroethylene", "CHEMICAL", 57, 80], ["PTFE", "CHEMICAL", 82, 86], ["a polytetrafluoroethylene (PTFE) membrane (pore size", "TREATMENT", 55, 107]]], ["The separation occurred in three columns from Phenomenex with size exclusion limits of 10 3 \u00c5, 10 4 \u00c5, and 10 6 \u00c5.", [["The separation", "PROBLEM", 0, 14], ["separation", "OBSERVATION_MODIFIER", 4, 14], ["three columns", "OBSERVATION_MODIFIER", 27, 40], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["The temperature of the columns and detector was maintained at 35 \u00b0C during the analysis.", [["the analysis", "TEST", 75, 87]]], ["The average molar masses (number-average molar mass, Mn, and weight-average molar mass, Mw) and the molar mass dispersity (\u00d0 = Mw/Mn) were derived from the refractive index (RI) signal using a calibration curve based on polystyrene standard from Sigma-Aldrich and Viscotek.Synthesis of MacroRAFT AgentsTwo types of macroRAFT agents have been synthesized in this work following a similar procedure but in which either P(PEGA40)-TTC or P(AA2-co-PEGA40)-TTC was used.", [["Mn", "CHEMICAL", 53, 55], ["AA2-co-PEGA40", "CHEMICAL", 436, 449], ["Mn", "CHEMICAL", 53, 55], ["Mn", "CHEMICAL", 130, 132], ["polystyrene", "CHEMICAL", 220, 231], ["P(PEGA40)-TTC", "CHEMICAL", 417, 430], ["P(AA2-co-PEGA40)-TTC", "CHEMICAL", 434, 454], ["Mn", "SIMPLE_CHEMICAL", 53, 55], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 246, 259], ["Viscotek", "SIMPLE_CHEMICAL", 264, 272], ["macroRAFT agents", "SIMPLE_CHEMICAL", 315, 331], ["PEGA40)-TTC", "SIMPLE_CHEMICAL", 419, 430], ["AA2-co-PEGA40", "SIMPLE_CHEMICAL", 436, 449], ["The average molar masses", "PROBLEM", 0, 24], ["average molar mass", "PROBLEM", 33, 51], ["Mn", "TEST", 53, 55], ["weight-average molar mass", "PROBLEM", 61, 86], ["the molar mass dispersity", "PROBLEM", 96, 121], ["the refractive index", "TEST", 152, 172], ["a calibration curve", "TEST", 191, 210], ["Synthesis of MacroRAFT Agent", "TREATMENT", 273, 301], ["macroRAFT agents", "TREATMENT", 315, 331], ["a similar procedure", "TREATMENT", 377, 396], ["PEGA40", "TEST", 419, 425], ["TTC", "TEST", 427, 430], ["AA2", "TEST", 436, 439], ["TTC", "TREATMENT", 451, 454], ["average", "OBSERVATION_MODIFIER", 4, 11], ["molar", "OBSERVATION_MODIFIER", 12, 17], ["masses", "OBSERVATION", 18, 24], ["number", "OBSERVATION_MODIFIER", 26, 32], ["average", "OBSERVATION_MODIFIER", 33, 40], ["molar", "OBSERVATION_MODIFIER", 41, 46], ["mass", "OBSERVATION", 47, 51], ["Mn", "OBSERVATION_MODIFIER", 53, 55], ["molar", "OBSERVATION_MODIFIER", 76, 81], ["mass", "OBSERVATION", 82, 86], ["molar", "OBSERVATION_MODIFIER", 100, 105], ["mass", "OBSERVATION", 106, 110], ["dispersity", "OBSERVATION_MODIFIER", 111, 121], ["refractive index", "OBSERVATION", 156, 172]]], ["The latter was subsequently modified in order to anchor an azide moiety, yielding an N3-macroRAFT agent (see Scheme 1).", [["azide", "CHEMICAL", 59, 64], ["azide", "CHEMICAL", 59, 64], ["azide", "SIMPLE_CHEMICAL", 59, 64], ["RAFT", "SIMPLE_CHEMICAL", 93, 97], ["an azide moiety", "TREATMENT", 56, 71], ["an N3", "TREATMENT", 82, 87], ["RAFT agent", "TREATMENT", 93, 103]]], ["The monomer PEGA was selected because polymers such as poly(ethylene glycol) are biocompatible.", [["PEGA", "CHEMICAL", 12, 16], ["poly(ethylene glycol", "CHEMICAL", 55, 75], ["PEGA", "CHEMICAL", 12, 16], ["poly(ethylene glycol)", "CHEMICAL", 55, 76], ["PEGA", "SIMPLE_CHEMICAL", 12, 16], ["poly(ethylene glycol", "SIMPLE_CHEMICAL", 55, 75], ["The monomer PEGA", "TREATMENT", 0, 16], ["polymers such as poly(ethylene glycol)", "TREATMENT", 38, 76]]], ["Furthermore, these polymer coatings limit nonspecific interactions with proteins, [26] [27] [28] , which could be very important for the application of surface-coated Au nanostructures as biosensors.", [["surface", "ANATOMY", 152, 159], ["Au", "CHEMICAL", 167, 169], ["[26] [27] [28]", "SIMPLE_CHEMICAL", 82, 96], ["Au nanostructures", "SIMPLE_CHEMICAL", 167, 184], ["these polymer coatings", "TREATMENT", 13, 35], ["surface-coated Au nanostructures", "TREATMENT", 152, 184]]], ["In order to functionalize the P(AA 2 -co-PEGA 40 )-TTC with the azide moiety, the macroRAFT agent was dispersed in dichloromethane, and EDC was added to activate the carboxylic groups of the AA units in the presence of 4-(dimethylamino)pyridine (DMAP).", [["AA 2 -co-PEGA 40", "CHEMICAL", 32, 48], ["TTC", "CHEMICAL", 51, 54], ["azide", "CHEMICAL", 64, 69], ["dichloromethane", "CHEMICAL", 115, 130], ["EDC", "CHEMICAL", 136, 139], ["AA", "CHEMICAL", 191, 193], ["4-(dimethylamino)pyridine", "CHEMICAL", 219, 244], ["DMAP", "CHEMICAL", 246, 250], ["P(AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 30, 54], ["azide", "CHEMICAL", 64, 69], ["dichloromethane", "CHEMICAL", 115, 130], ["EDC", "CHEMICAL", 136, 139], ["carboxylic", "CHEMICAL", 166, 176], ["4-(dimethylamino)pyridine", "CHEMICAL", 219, 244], ["DMAP", "CHEMICAL", 246, 250], ["AA 2 -co-PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 32, 54], ["azide moiety", "SIMPLE_CHEMICAL", 64, 76], ["macroRAFT", "SIMPLE_CHEMICAL", 82, 91], ["dichloromethane", "SIMPLE_CHEMICAL", 115, 130], ["EDC", "SIMPLE_CHEMICAL", 136, 139], ["AA", "SIMPLE_CHEMICAL", 191, 193], ["4-(dimethylamino)pyridine", "SIMPLE_CHEMICAL", 219, 244], ["DMAP", "SIMPLE_CHEMICAL", 246, 250], ["AA", "TEST", 32, 34], ["the azide moiety", "TREATMENT", 60, 76], ["the macroRAFT agent", "TREATMENT", 78, 97], ["dichloromethane", "TREATMENT", 115, 130], ["the carboxylic groups", "TREATMENT", 162, 183], ["the AA units", "TREATMENT", 187, 199], ["4-(dimethylamino)pyridine (DMAP", "TREATMENT", 219, 250]]], ["The 3-azido-1-propanol was added to the reaction vessel and stirred at room temperature over two days.Synthesis of MacroRAFT AgentsThe N3-macroRAFT agent was characterized by ATR-FTIR and 1 H-NMR spectroscopies.", [["vessel", "ANATOMY", 49, 55], ["3-azido-1-propanol", "CHEMICAL", 4, 22], ["N3-macroRAFT", "CHEMICAL", 135, 147], ["3-azido-1-propanol", "CHEMICAL", 4, 22], ["N3-macroRAFT", "CHEMICAL", 135, 147], ["1 H", "CHEMICAL", 188, 191], ["3-azido-1-propanol", "SIMPLE_CHEMICAL", 4, 22], ["vessel", "MULTI-TISSUE_STRUCTURE", 49, 55], ["MacroRAFT Agents", "SIMPLE_CHEMICAL", 115, 131], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 135, 147], ["azido", "TREATMENT", 6, 11], ["propanol", "TREATMENT", 14, 22], ["Synthesis of MacroRAFT Agents", "TREATMENT", 102, 131], ["The N3-macroRAFT agent", "TREATMENT", 131, 153], ["1 H-NMR spectroscopies", "TREATMENT", 188, 210], ["vessel", "ANATOMY", 49, 55]]], ["The new ester bond was difficult to identify by ATR-FTIR spectroscopy because its vibration frequency Polymers 2020, 12, 1442 7 of 18 (1730 cm \u22121 ) overlaps with the ester bonds of the PEGA repeating unit of the macroRAFT agent.", [["ester", "CHEMICAL", 8, 13], ["ester", "CHEMICAL", 166, 171], ["PEGA", "CHEMICAL", 185, 189], ["ester", "CHEMICAL", 8, 13], ["ester", "CHEMICAL", 166, 171], ["PEGA", "CHEMICAL", 185, 189], ["ester", "SIMPLE_CHEMICAL", 8, 13], ["ATR", "SIMPLE_CHEMICAL", 48, 51], ["ester", "SIMPLE_CHEMICAL", 166, 171], ["PEGA", "SIMPLE_CHEMICAL", 185, 189], ["macroRAFT", "SIMPLE_CHEMICAL", 212, 221], ["ATR-FTIR spectroscopy", "TEST", 48, 69], ["its vibration frequency Polymers", "TEST", 78, 110], ["the macroRAFT agent", "TREATMENT", 208, 227], ["new", "OBSERVATION_MODIFIER", 4, 7], ["ester bond", "OBSERVATION", 8, 18]]], ["Nevertheless, the vibrational mode characteristic of the azide was observed at 2097 cm \u22121 , as illustrated in Figure S1 in the Supporting Information.", [["azide", "CHEMICAL", 57, 62], ["azide", "CHEMICAL", 57, 62], ["azide", "SIMPLE_CHEMICAL", 57, 62]]], ["The presence of the azide was further confirmed by 1 H-NMR spectroscopy (Figure 1 ), which revealed the presence of peaks at 4.57 and at 1.66 ppm corresponding to the protons from two methylene groups of 3-azido-1-propanol [29] .", [["azide", "CHEMICAL", 20, 25], ["methylene", "CHEMICAL", 184, 193], ["3-azido-1-propanol", "CHEMICAL", 204, 222], ["azide", "CHEMICAL", 20, 25], ["H", "CHEMICAL", 53, 54], ["methylene", "CHEMICAL", 184, 193], ["3-azido-1-propanol", "CHEMICAL", 204, 222], ["azide", "SIMPLE_CHEMICAL", 20, 25], ["protons", "SIMPLE_CHEMICAL", 167, 174], ["methylene", "SIMPLE_CHEMICAL", 184, 193], ["3-azido-1-propanol [29]", "SIMPLE_CHEMICAL", 204, 227], ["the azide", "TREATMENT", 16, 25], ["NMR spectroscopy", "TEST", 55, 71], ["two methylene groups", "TREATMENT", 180, 200], ["azido", "TREATMENT", 206, 211], ["propanol", "TREATMENT", 214, 222]]], ["However, the signal of the protons associated with the CH 2 -N moiety is masked by the signals of the PEGA chains.", [["CH 2 -N", "CHEMICAL", 55, 62], ["CH 2 -N", "CHEMICAL", 55, 62], ["PEGA", "CHEMICAL", 102, 106], ["protons", "SIMPLE_CHEMICAL", 27, 34], ["PEGA chains", "PROTEIN", 102, 113], ["PEGA chains", "ANATOMY", 102, 113]]], ["The ratio of the integrated peaks at the chemical shifts 4.57 ppm and 0.84 ppm, corresponding to the methyl of the Z-group, indicates that there is one or two azide moieties per polymer chain (see details in the Supporting Information).Synthesis of MacroRAFT AgentsPolymers 2020, 12, 1442 7 of 18 In order to functionalize the P(AA2-co-PEGA40)-TTC with the azide moiety, the macroRAFT agent was dispersed in dichloromethane, and EDC was added to activate the carboxylic groups of the AA units in the presence of 4-(dimethylamino)pyridine (DMAP).", [["PEGA40", "CHEMICAL", 336, 342], ["TTC", "CHEMICAL", 344, 347], ["azide", "CHEMICAL", 357, 362], ["dichloromethane", "CHEMICAL", 408, 423], ["EDC", "CHEMICAL", 429, 432], ["AA", "CHEMICAL", 484, 486], ["4-(dimethylamino)pyridine", "CHEMICAL", 512, 537], ["DMAP", "CHEMICAL", 539, 543], ["methyl", "CHEMICAL", 101, 107], ["azide", "CHEMICAL", 159, 164], ["P(AA2-co-PEGA40)-TTC", "CHEMICAL", 327, 347], ["azide", "CHEMICAL", 357, 362], ["dichloromethane", "CHEMICAL", 408, 423], ["EDC", "CHEMICAL", 429, 432], ["carboxylic", "CHEMICAL", 459, 469], ["4-(dimethylamino)pyridine", "CHEMICAL", 512, 537], ["DMAP", "CHEMICAL", 539, 543], ["azide moieties", "SIMPLE_CHEMICAL", 159, 173], ["AA2-co-PEGA40)-TTC", "SIMPLE_CHEMICAL", 329, 347], ["azide moiety", "SIMPLE_CHEMICAL", 357, 369], ["macroRAFT", "SIMPLE_CHEMICAL", 375, 384], ["dichloromethane", "SIMPLE_CHEMICAL", 408, 423], ["EDC", "SIMPLE_CHEMICAL", 429, 432], ["AA", "SIMPLE_CHEMICAL", 484, 486], ["4-(dimethylamino)pyridine", "SIMPLE_CHEMICAL", 512, 537], ["DMAP", "SIMPLE_CHEMICAL", 539, 543], ["The ratio", "TEST", 0, 9], ["Synthesis of MacroRAFT AgentsPolymers", "TREATMENT", 236, 273], ["AA2", "TEST", 329, 332], ["TTC", "TREATMENT", 344, 347], ["the azide moiety", "TREATMENT", 353, 369], ["the macroRAFT agent", "TREATMENT", 371, 390], ["dichloromethane", "TREATMENT", 408, 423], ["the carboxylic groups", "TREATMENT", 455, 476], ["the AA units", "TREATMENT", 480, 492], ["4-(dimethylamino)pyridine (DMAP", "TREATMENT", 512, 543], ["peaks", "OBSERVATION_MODIFIER", 28, 33]]], ["The 3-azido-1-propanol was added to the reaction vessel and stirred at room temperature over two days.Synthesis of MacroRAFT AgentsThe N3-macroRAFT agent was characterized by ATR-FTIR and 1 H-NMR spectroscopies.", [["vessel", "ANATOMY", 49, 55], ["3-azido-1-propanol", "CHEMICAL", 4, 22], ["N3-macroRAFT", "CHEMICAL", 135, 147], ["3-azido-1-propanol", "CHEMICAL", 4, 22], ["N3-macroRAFT", "CHEMICAL", 135, 147], ["1 H", "CHEMICAL", 188, 191], ["3-azido-1-propanol", "SIMPLE_CHEMICAL", 4, 22], ["vessel", "MULTI-TISSUE_STRUCTURE", 49, 55], ["MacroRAFT Agents", "SIMPLE_CHEMICAL", 115, 131], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 135, 147], ["azido", "TREATMENT", 6, 11], ["propanol", "TREATMENT", 14, 22], ["Synthesis of MacroRAFT Agents", "TREATMENT", 102, 131], ["The N3-macroRAFT agent", "TREATMENT", 131, 153], ["1 H-NMR spectroscopies", "TREATMENT", 188, 210], ["vessel", "ANATOMY", 49, 55]]], ["The new ester bond was difficult to identify by ATR-FTIR spectroscopy because its vibration frequency (1730 cm \u22121 ) overlaps with the ester bonds of the PEGA repeating unit of the macroRAFT agent.", [["ester", "CHEMICAL", 8, 13], ["ester", "CHEMICAL", 134, 139], ["PEGA", "CHEMICAL", 153, 157], ["ester", "CHEMICAL", 8, 13], ["ester", "CHEMICAL", 134, 139], ["PEGA", "CHEMICAL", 153, 157], ["ester", "SIMPLE_CHEMICAL", 8, 13], ["ATR", "SIMPLE_CHEMICAL", 48, 51], ["ester", "SIMPLE_CHEMICAL", 134, 139], ["PEGA", "SIMPLE_CHEMICAL", 153, 157], ["macroRAFT", "SIMPLE_CHEMICAL", 180, 189], ["ATR-FTIR spectroscopy", "TEST", 48, 69], ["its vibration frequency", "PROBLEM", 78, 101], ["the macroRAFT agent", "TREATMENT", 176, 195], ["new", "OBSERVATION_MODIFIER", 4, 7], ["ester bond", "OBSERVATION", 8, 18]]], ["Nevertheless, the vibrational mode characteristic of the azide was observed at 2097 cm \u22121 , as illustrated in Figure S1 in the Supporting Information.", [["azide", "CHEMICAL", 57, 62], ["azide", "CHEMICAL", 57, 62], ["azide", "SIMPLE_CHEMICAL", 57, 62]]], ["The presence of the azide was further confirmed by 1 H-NMR spectroscopy (Figure 1 ), which revealed the presence of peaks at 4.57 and at 1.66 ppm corresponding to the protons from two methylene groups of 3-azido-1-propanol [29] .", [["azide", "CHEMICAL", 20, 25], ["methylene", "CHEMICAL", 184, 193], ["3-azido-1-propanol", "CHEMICAL", 204, 222], ["azide", "CHEMICAL", 20, 25], ["H", "CHEMICAL", 53, 54], ["methylene", "CHEMICAL", 184, 193], ["3-azido-1-propanol", "CHEMICAL", 204, 222], ["azide", "SIMPLE_CHEMICAL", 20, 25], ["protons", "SIMPLE_CHEMICAL", 167, 174], ["methylene", "SIMPLE_CHEMICAL", 184, 193], ["3-azido-1-propanol [29]", "SIMPLE_CHEMICAL", 204, 227], ["the azide", "TREATMENT", 16, 25], ["NMR spectroscopy", "TEST", 55, 71], ["two methylene groups", "TREATMENT", 180, 200], ["azido", "TREATMENT", 206, 211], ["propanol", "TREATMENT", 214, 222]]], ["However, the signal of the protons associated with the CH2-N moiety is masked by the signals of the PEGA chains.", [["CH2-N", "CHEMICAL", 55, 60], ["CH2-N", "CHEMICAL", 55, 60], ["PEGA", "CHEMICAL", 100, 104], ["protons", "SIMPLE_CHEMICAL", 27, 34], ["CH2-N moiety", "PROTEIN", 55, 67], ["PEGA chains", "PROTEIN", 100, 111], ["the CH2-N moiety", "TREATMENT", 51, 67], ["PEGA chains", "ANATOMY", 100, 111]]], ["The ratio of the integrated peaks at the chemical shifts 4.57 ppm and 0.84 ppm, corresponding to the methyl of the Z-group, indicates that there is one or two azide moieties per polymer chain (see details in the Supporting Information).Preparation of Copolymer@Au NPsCopolymer@Au NPs were prepared via RAFT-assisted encapsulating emulsion polymerization (REEP).", [["Copolymer@Au NPsCopolymer@Au", "CHEMICAL", 251, 279], ["RAFT", "CHEMICAL", 302, 306], ["methyl", "CHEMICAL", 101, 107], ["azide", "CHEMICAL", 159, 164], ["azide moieties", "SIMPLE_CHEMICAL", 159, 173], ["Copolymer@Au NPsCopolymer@Au NPs", "SIMPLE_CHEMICAL", 251, 283], ["RAFT", "SIMPLE_CHEMICAL", 302, 306], ["The ratio", "TEST", 0, 9], ["Copolymer@Au NPsCopolymer@Au NPs", "TREATMENT", 251, 283], ["RAFT-assisted encapsulating emulsion polymerization", "TREATMENT", 302, 353], ["peaks", "OBSERVATION_MODIFIER", 28, 33]]], ["This strategy requires two steps: (1) the adsorption of the macroRAFT agent onto the NPs and (2) chain extension via the emulsion polymerization of hydrophobic monomers.", [["the macroRAFT agent", "TREATMENT", 56, 75], ["the NPs and (2) chain extension", "TREATMENT", 81, 112], ["the emulsion polymerization of hydrophobic monomers", "TREATMENT", 117, 168], ["hydrophobic monomers", "OBSERVATION", 148, 168]]], ["Due to the presence of azide moieties in this study, a radical initiator with a high decomposition rate coefficient (VA-044) was used in order to perform the emulsion polymerization step below 50 \u00b0C [30] .", [["azide", "CHEMICAL", 23, 28], ["VA-044", "CHEMICAL", 117, 123], ["azide", "CHEMICAL", 23, 28], ["azide moieties", "SIMPLE_CHEMICAL", 23, 37], ["azide moieties", "TREATMENT", 23, 37], ["this study", "TEST", 41, 51], ["a radical initiator", "TREATMENT", 53, 72], ["a high decomposition rate coefficient", "TREATMENT", 78, 115], ["the emulsion polymerization step", "TREATMENT", 154, 186], ["azide moieties", "OBSERVATION", 23, 37]]], ["Although Farinha et al. [19] reported the use of higher temperature in the presence of azide moieties for the sake of safety, to prevent secondary side reactions, the use of lower temperature was considered a better option.", [["azide", "CHEMICAL", 87, 92], ["azide", "CHEMICAL", 87, 92], ["azide moieties", "SIMPLE_CHEMICAL", 87, 101], ["higher temperature", "PROBLEM", 49, 67], ["azide moieties", "TREATMENT", 87, 101], ["secondary side reactions", "PROBLEM", 137, 161], ["lower temperature", "PROBLEM", 174, 191]]], ["This was further supported by the fact that azides can undergo cycloaddition reactions with the double bonds of methyl methacrylate monomers [31] .", [["azides", "CHEMICAL", 44, 50], ["methyl methacrylate", "CHEMICAL", 112, 131], ["azides", "CHEMICAL", 44, 50], ["methyl methacrylate", "CHEMICAL", 112, 131], ["azides", "SIMPLE_CHEMICAL", 44, 50], ["methyl methacrylate monomers [31]", "SIMPLE_CHEMICAL", 112, 145], ["azides", "TREATMENT", 44, 50], ["cycloaddition reactions", "TREATMENT", 63, 86], ["the double bonds of methyl methacrylate monomers", "TREATMENT", 92, 140]]], ["As in our previous studies, the encapsulation of Au NPs via REEP was carried out at 70 \u00b0C using ACPA as the initiator [15, 16] , and the effect of temperature on VA-044 on the polymerization of the hydrophobic monomers via RAFT emulsion polymerization was first studied in the absence of Au NPs.Preparation of Copolymer@Au NPsFor comparative purposes, chain extension of the macroRAFT P(PEGA40)-TTC was first carried out via RAFT emulsion polymerization at 70 \u00b0C using VA-044 as the initiator.", [["Au NPs", "CHEMICAL", 49, 55], ["REEP", "CHEMICAL", 60, 64], ["VA-044", "CHEMICAL", 162, 168], ["RAFT emulsion", "CHEMICAL", 223, 236], ["Au", "CHEMICAL", 288, 290], ["Copolymer@Au NPs", "CHEMICAL", 310, 326], ["RAFT P(PEGA40)-TTC", "CHEMICAL", 380, 398], ["VA-044", "CHEMICAL", 469, 475], ["Au", "CHEMICAL", 49, 51], ["VA-044", "CHEMICAL", 162, 168], ["Au", "CHEMICAL", 288, 290], ["Copolymer@Au", "CHEMICAL", 310, 322], ["RAFT P(PEGA40)-TTC", "CHEMICAL", 380, 398], ["VA-044", "CHEMICAL", 469, 475], ["Au NPs", "SIMPLE_CHEMICAL", 49, 55], ["REEP", "SIMPLE_CHEMICAL", 60, 64], ["VA-044", "SIMPLE_CHEMICAL", 162, 168], ["RAFT emulsion", "SIMPLE_CHEMICAL", 223, 236], ["Au NPs", "SIMPLE_CHEMICAL", 288, 294], ["Copolymer@Au NPs", "SIMPLE_CHEMICAL", 310, 326], ["RAFT P", "SIMPLE_CHEMICAL", 380, 386], ["PEGA40", "SIMPLE_CHEMICAL", 387, 393], ["RAFT", "SIMPLE_CHEMICAL", 425, 429], ["VA-044", "SIMPLE_CHEMICAL", 469, 475], ["RAFT P(PEGA40)-TTC", "DNA", 380, 398], ["Au NPs via REEP", "TREATMENT", 49, 64], ["VA", "TEST", 162, 164], ["the hydrophobic monomers", "TREATMENT", 194, 218], ["RAFT emulsion polymerization", "TREATMENT", 223, 251], ["Copolymer@Au NPs", "TREATMENT", 310, 326], ["comparative purposes", "TEST", 330, 350], ["TTC", "TEST", 395, 398], ["RAFT emulsion polymerization", "TREATMENT", 425, 453], ["hydrophobic monomers", "OBSERVATION", 198, 218], ["RAFT", "OBSERVATION", 223, 227], ["emulsion polymerization", "OBSERVATION", 228, 251], ["Au NPs", "OBSERVATION", 288, 294], ["macro", "OBSERVATION", 375, 380]]], ["The polymerization conditions, [macroRAFT]/[initiator] and [monomer]/[macroRAFT] ratios, were kept the same as inPreparation of Copolymer@Au NPsCopolymer@Au NPs were prepared via RAFT-assisted encapsulating emulsion polymerization (REEP).", [["RAFT", "CHEMICAL", 179, 183], ["[monomer]", "SIMPLE_CHEMICAL", 59, 68], ["[macroRAFT]", "SIMPLE_CHEMICAL", 69, 80], ["Copolymer@Au NPsCopolymer@Au NPs", "SIMPLE_CHEMICAL", 128, 160], ["RAFT", "SIMPLE_CHEMICAL", 179, 183], ["The polymerization conditions", "TREATMENT", 0, 29], ["macroRAFT]/[initiator] and [monomer]/[macroRAFT] ratios", "TREATMENT", 32, 87], ["Copolymer@Au NPsCopolymer@Au NPs", "TREATMENT", 128, 160], ["RAFT-assisted encapsulating emulsion polymerization", "TREATMENT", 179, 230]]], ["This strategy requires two steps: (1) the adsorption of the macroRAFT agent onto the NPs and (2) chain extension via the emulsion polymerization of hydrophobic monomers.", [["the macroRAFT agent", "TREATMENT", 56, 75], ["the NPs and (2) chain extension", "TREATMENT", 81, 112], ["the emulsion polymerization of hydrophobic monomers", "TREATMENT", 117, 168], ["hydrophobic monomers", "OBSERVATION", 148, 168]]], ["Due to the presence of azide moieties in this study, a radical initiator with a high decomposition rate coefficient (VA-044) was used in order to perform the emulsion polymerization step below 50 \u2022 C [30] .", [["azide", "CHEMICAL", 23, 28], ["VA-044", "CHEMICAL", 117, 123], ["azide", "CHEMICAL", 23, 28], ["azide moieties", "SIMPLE_CHEMICAL", 23, 37], ["azide moieties", "TREATMENT", 23, 37], ["this study", "TEST", 41, 51], ["a radical initiator", "TREATMENT", 53, 72], ["a high decomposition rate coefficient", "TREATMENT", 78, 115], ["the emulsion polymerization step", "TEST", 154, 186], ["azide moieties", "OBSERVATION", 23, 37]]], ["Although Farinha et al. [19] reported the use of higher temperature in the presence of azide moieties for the sake of safety, to prevent secondary side reactions, the use of lower temperature was considered a better option.", [["azide", "CHEMICAL", 87, 92], ["azide", "CHEMICAL", 87, 92], ["azide moieties", "SIMPLE_CHEMICAL", 87, 101], ["higher temperature", "PROBLEM", 49, 67], ["azide moieties", "TREATMENT", 87, 101], ["secondary side reactions", "PROBLEM", 137, 161], ["lower temperature", "PROBLEM", 174, 191]]], ["This was further supported by the fact that azides can undergo cycloaddition reactions with the double bonds of methyl methacrylate monomers [31] .", [["azides", "CHEMICAL", 44, 50], ["methyl methacrylate", "CHEMICAL", 112, 131], ["azides", "CHEMICAL", 44, 50], ["methyl methacrylate", "CHEMICAL", 112, 131], ["azides", "SIMPLE_CHEMICAL", 44, 50], ["methyl methacrylate monomers [31]", "SIMPLE_CHEMICAL", 112, 145], ["azides", "TREATMENT", 44, 50], ["cycloaddition reactions", "TREATMENT", 63, 86], ["the double bonds of methyl methacrylate monomers", "TREATMENT", 92, 140]]], ["As in our previous studies, the encapsulation of Au NPs via REEP was carried out at 70 \u2022 C using ACPA as the initiator [15, 16] , and the effect of temperature on VA-044 on the polymerization of the hydrophobic monomers via RAFT emulsion polymerization was first studied in the absence of Au NPs.Preparation of Copolymer@Au NPsFor comparative purposes, chain extension of the macroRAFT P(PEGA 40 )-TTC was first carried out via RAFT emulsion polymerization at 70 \u2022 C using VA-044 as the initiator.", [["Au NPs", "CHEMICAL", 49, 55], ["REEP", "CHEMICAL", 60, 64], ["VA-044", "CHEMICAL", 163, 169], ["RAFT emulsion", "CHEMICAL", 224, 237], ["Au", "CHEMICAL", 289, 291], ["Copolymer@Au NPs", "CHEMICAL", 311, 327], ["RAFT P(PEGA 40 )-TTC", "CHEMICAL", 381, 401], ["VA-044", "CHEMICAL", 473, 479], ["Au", "CHEMICAL", 49, 51], ["VA-044", "CHEMICAL", 163, 169], ["Au", "CHEMICAL", 289, 291], ["Copolymer@Au", "CHEMICAL", 311, 323], ["RAFT P(PEGA 40 )-TTC", "CHEMICAL", 381, 401], ["Au NPs", "SIMPLE_CHEMICAL", 49, 55], ["REEP", "SIMPLE_CHEMICAL", 60, 64], ["VA-044", "SIMPLE_CHEMICAL", 163, 169], ["RAFT emulsion", "SIMPLE_CHEMICAL", 224, 237], ["Au NPs", "SIMPLE_CHEMICAL", 289, 295], ["Copolymer@Au NPs", "SIMPLE_CHEMICAL", 311, 327], ["RAFT P", "SIMPLE_CHEMICAL", 381, 387], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 388, 401], ["RAFT", "SIMPLE_CHEMICAL", 428, 432], ["VA-044", "SIMPLE_CHEMICAL", 473, 479], ["Au NPs via REEP", "TREATMENT", 49, 64], ["VA", "TEST", 163, 165], ["the hydrophobic monomers", "TREATMENT", 195, 219], ["RAFT emulsion polymerization", "TREATMENT", 224, 252], ["Copolymer@Au NPs", "TREATMENT", 311, 327], ["comparative purposes", "TEST", 331, 351], ["PEGA", "TEST", 388, 392], ["TTC", "TEST", 398, 401], ["RAFT emulsion polymerization", "TREATMENT", 428, 456], ["hydrophobic monomers", "OBSERVATION", 199, 219], ["RAFT emulsion", "OBSERVATION", 224, 237], ["Au NPs", "OBSERVATION", 289, 295], ["macro", "OBSERVATION", 376, 381]]], ["The polymerization conditions, [macroRAFT]/[initiator] and [monomer]/[macroRAFT] ratios, were kept the same as in our previous work where ACPA was used as the initiator [16] as well as the mixture of hydrophobic monomers methyl methacrylate (MMA) and butyl acrylate (BA) (10:1 w/w) [15] .", [["ACPA", "CHEMICAL", 138, 142], ["methyl methacrylate", "CHEMICAL", 221, 240], ["MMA", "CHEMICAL", 242, 245], ["butyl acrylate", "CHEMICAL", 251, 265], ["BA", "CHEMICAL", 267, 269], ["methyl methacrylate", "CHEMICAL", 221, 240], ["MMA", "CHEMICAL", 242, 245], ["butyl acrylate", "CHEMICAL", 251, 265], ["[monomer]", "SIMPLE_CHEMICAL", 59, 68], ["[macroRAFT]", "SIMPLE_CHEMICAL", 69, 80], ["ACPA", "GENE_OR_GENE_PRODUCT", 138, 142], ["hydrophobic monomers methyl methacrylate", "SIMPLE_CHEMICAL", 200, 240], ["MMA", "SIMPLE_CHEMICAL", 242, 245], ["butyl acrylate", "SIMPLE_CHEMICAL", 251, 265], ["BA", "SIMPLE_CHEMICAL", 267, 269], ["ACPA", "PROTEIN", 138, 142], ["The polymerization conditions", "TREATMENT", 0, 29], ["macroRAFT]/[initiator] and [monomer]/[macroRAFT] ratios", "TREATMENT", 32, 87], ["the mixture of hydrophobic monomers methyl methacrylate (MMA) and butyl acrylate (BA)", "TREATMENT", 185, 270]]], ["As expected, monomer conversion was much higher when VA-044 was used.", [["VA-044", "CHEMICAL", 53, 59], ["VA-044", "CHEMICAL", 53, 59], ["VA-044", "SIMPLE_CHEMICAL", 53, 59], ["monomer conversion", "PROBLEM", 13, 31]]], ["In fact, 81% of monomer conversion was obtained after 1 h of polymerization and after 4 h, 100% of monomer conversion was reached, which corresponds to a DP MMA:BA = 168.", [["MMA", "CHEMICAL", 157, 160], ["BA", "CHEMICAL", 161, 163], ["MMA", "CHEMICAL", 157, 160], ["MMA", "SIMPLE_CHEMICAL", 157, 160], ["polymerization", "TREATMENT", 61, 75], ["a DP MMA", "TEST", 152, 160], ["BA", "TEST", 161, 163]]], ["Then, a similar polymerization was carried out using VA-044 but at 44 \u2022 C. In this case, only 34% conversion was reached after 24 h; see Figure S2B in Supporting Information.", [["VA-044", "CHEMICAL", 53, 59], ["VA-044", "SIMPLE_CHEMICAL", 53, 59], ["a similar polymerization", "TREATMENT", 6, 30], ["VA", "TEST", 53, 55]]], ["When comparing the results obtained using VA-044 at 70 \u2022 C with those obtained using ACPA also at 70 \u2022 C in our previous studies [15, 16] , it is striking to observe that 81% monomer conversion was only obtained after 4 h of reaction, when the latter was used as an initiator.", [["VA-044", "CHEMICAL", 42, 48], ["ACPA", "PROTEIN", 85, 89], ["VA", "TEST", 42, 44], ["ACPA", "TEST", 85, 89], ["reaction", "PROBLEM", 225, 233]]], ["Differences in the rate of polymerization using ACPA and VA-044 at 70 \u2022 C were previously reported by Perrier et al. [32, 33] and are due to the fact that VA-044 has a higher decomposition rate coefficient (k d ) which allows increasing the rate of the polymerization reaction without affecting its livingness.Preparation of Copolymer@Au NPsThe use of REEP to encapsulate the Au NPs requires the controlled addition of the hydrophobic monomers to guarantee the stability of the colloidal system.", [["VA-044", "CHEMICAL", 57, 63], ["VA-044", "CHEMICAL", 155, 161], ["Copolymer@Au NPs", "CHEMICAL", 325, 341], ["REEP", "CHEMICAL", 352, 356], ["Au", "CHEMICAL", 376, 378], ["VA-044", "CHEMICAL", 155, 161], ["Copolymer@Au", "CHEMICAL", 325, 337], ["Au", "CHEMICAL", 376, 378], ["VA-044", "SIMPLE_CHEMICAL", 57, 63], ["VA-044", "SIMPLE_CHEMICAL", 155, 161], ["Copolymer@Au NPs", "SIMPLE_CHEMICAL", 325, 341], ["REEP", "SIMPLE_CHEMICAL", 352, 356], ["Au NPs", "SIMPLE_CHEMICAL", 376, 382], ["ACPA", "PROTEIN", 48, 52], ["ACPA", "TEST", 48, 52], ["VA", "TEST", 57, 59], ["VA", "TEST", 155, 157], ["the polymerization reaction", "PROBLEM", 249, 276], ["Copolymer@Au NPs", "TREATMENT", 325, 341], ["REEP", "TREATMENT", 352, 356], ["the Au NPs", "TREATMENT", 372, 382], ["the hydrophobic monomers", "TREATMENT", 419, 443], ["colloidal system", "OBSERVATION", 478, 494]]], ["Additionally, it also prevents chain extension from the free macroRAFT agent present in solution, which is a competitive process in relation to the polymerization from the macroRAFT@Au NPs [15] .", [["RAFT@Au NPs", "CHEMICAL", 177, 188], ["RAFT@Au", "CHEMICAL", 177, 184], ["RAFT@Au", "SIMPLE_CHEMICAL", 177, 184], ["chain extension", "PROBLEM", 31, 46], ["the free macroRAFT agent", "TREATMENT", 52, 76], ["a competitive process", "PROBLEM", 107, 128], ["the polymerization", "TREATMENT", 144, 162], ["prevents", "UNCERTAINTY", 22, 30], ["chain", "OBSERVATION_MODIFIER", 31, 36], ["macro", "OBSERVATION", 172, 177]]], ["Therefore, besides the experiments carried out under batch conditions discussed above, the polymerizations were also studied under monomer starved conditions.", [["the polymerizations", "TREATMENT", 87, 106]]], ["In this case, at 70 \u2022 C monomer conversion was 35% and it was 24% at 44 \u2022 C. The reactions were also followed by DLS in order to monitor the evolution of particle size distribution over time (Figure 2 ), together with the monomer conversion over time.", [["C monomer conversion", "TEST", 22, 42], ["DLS", "TEST", 113, 116], ["particle", "OBSERVATION_MODIFIER", 154, 162], ["size", "OBSERVATION_MODIFIER", 163, 167], ["distribution", "OBSERVATION_MODIFIER", 168, 180]]], ["Figure 2 shows that when the reaction was carried out at 44 \u2022 C, both PdI and zeta potential do not stabilize when compared to the results obtained at 70 \u2022 C. This suggests that the macroRAFT agent does not seem to be leaving the growing polymer particles to reinitiate the polymerization.", [["PdI", "SIMPLE_CHEMICAL", 70, 73], ["the reaction", "PROBLEM", 25, 37], ["the macroRAFT agent", "PROBLEM", 178, 197], ["the polymerization", "TREATMENT", 270, 288]]], ["Hence, the use of a sacrificial macroRAFT agent might have been required to ensure the living behavior of the polymerization. our previous work where ACPA was used as the initiator [16] as well as the mixture of hydrophobic monomers methyl methacrylate (MMA) and butyl acrylate (BA) (10:1 w/w) [15] .", [["ACPA", "CHEMICAL", 150, 154], ["methyl methacrylate", "CHEMICAL", 233, 252], ["MMA", "CHEMICAL", 254, 257], ["butyl acrylate", "CHEMICAL", 263, 277], ["BA", "CHEMICAL", 279, 281], ["methyl methacrylate", "CHEMICAL", 233, 252], ["MMA", "CHEMICAL", 254, 257], ["butyl acrylate", "CHEMICAL", 263, 277], ["ACPA", "GENE_OR_GENE_PRODUCT", 150, 154], ["hydrophobic monomers methyl methacrylate", "SIMPLE_CHEMICAL", 212, 252], ["MMA", "SIMPLE_CHEMICAL", 254, 257], ["butyl acrylate", "SIMPLE_CHEMICAL", 263, 277], ["BA", "SIMPLE_CHEMICAL", 279, 281], ["ACPA", "PROTEIN", 150, 154], ["a sacrificial macroRAFT agent", "TREATMENT", 18, 47], ["the polymerization", "TREATMENT", 106, 124], ["the mixture of hydrophobic monomers methyl methacrylate (MMA) and butyl acrylate (BA)", "TREATMENT", 197, 282]]], ["As expected, monomer conversion was much higher when VA-044 was used.", [["VA-044", "CHEMICAL", 53, 59], ["VA-044", "CHEMICAL", 53, 59], ["VA-044", "SIMPLE_CHEMICAL", 53, 59], ["monomer conversion", "PROBLEM", 13, 31]]], ["In fact, 81% of monomer conversion was obtained after 1 h of polymerization and after 4 h, 100% of monomer conversion was reached, which corresponds to a DPMMA:BA = 168.", [["DPMMA", "CHEMICAL", 154, 159], ["BA", "CHEMICAL", 160, 162], ["polymerization", "TREATMENT", 61, 75], ["monomer conversion", "TREATMENT", 99, 117]]], ["Then, a similar polymerization was carried out using VA-044 but at 44 \u00b0C. In this case, only 34% conversion was reached after 24 h; see Figure S2B in Supporting Information.", [["VA-044", "CHEMICAL", 53, 59], ["VA-044", "SIMPLE_CHEMICAL", 53, 59], ["a similar polymerization", "TREATMENT", 6, 30], ["VA", "TEST", 53, 55]]], ["When comparing the results obtained using VA-044 at 70 \u00b0C with those obtained using ACPA also at 70 \u00b0C in our previous studies [15, 16] , it is striking to observe that 81% monomer conversion was only obtained after 4 h of reaction, when the latter was used as an initiator.", [["VA-044", "CHEMICAL", 42, 48], ["ACPA", "PROTEIN", 84, 88], ["VA", "TEST", 42, 44], ["ACPA", "TEST", 84, 88], ["our previous studies", "TEST", 106, 126], ["reaction", "PROBLEM", 223, 231]]], ["Differences in the rate of polymerization using ACPA and VA-044 at 70 \u00b0C were previously reported by Perrier et al. [32, 33] and are due to the fact that VA-044 has a higher decomposition rate coefficient (kd) which allows increasing the rate of the polymerization reaction without affecting its livingness.", [["VA-044", "CHEMICAL", 57, 63], ["VA-044", "CHEMICAL", 154, 160], ["VA-044", "CHEMICAL", 154, 160], ["VA-044", "SIMPLE_CHEMICAL", 57, 63], ["VA-044", "SIMPLE_CHEMICAL", 154, 160], ["ACPA", "PROTEIN", 48, 52], ["ACPA", "TEST", 48, 52], ["VA", "TEST", 57, 59], ["VA", "TEST", 154, 156], ["a higher decomposition rate coefficient", "PROBLEM", 165, 204], ["the polymerization reaction", "PROBLEM", 246, 273]]], ["The use of REEP to encapsulate the Au NPs requires the controlled addition of the hydrophobic monomers to guarantee the stability of the colloidal system.", [["REEP", "CHEMICAL", 11, 15], ["Au", "CHEMICAL", 35, 37], ["Au", "CHEMICAL", 35, 37], ["REEP", "SIMPLE_CHEMICAL", 11, 15], ["Au NPs", "SIMPLE_CHEMICAL", 35, 41], ["REEP", "TREATMENT", 11, 15], ["the Au NPs", "TREATMENT", 31, 41], ["the hydrophobic monomers", "TREATMENT", 78, 102], ["colloidal system", "OBSERVATION", 137, 153]]], ["Additionally, it also prevents chain extension from the free macroRAFT agent present in solution, which is a competitive process in relation to the polymerization from the macroRAFT@Au NPs [15] .", [["RAFT@Au NPs", "CHEMICAL", 177, 188], ["RAFT@Au", "CHEMICAL", 177, 184], ["RAFT@Au", "SIMPLE_CHEMICAL", 177, 184], ["chain extension", "PROBLEM", 31, 46], ["the free macroRAFT agent", "TREATMENT", 52, 76], ["a competitive process", "PROBLEM", 107, 128], ["the polymerization", "TREATMENT", 144, 162], ["prevents", "UNCERTAINTY", 22, 30], ["chain", "OBSERVATION_MODIFIER", 31, 36], ["macro", "OBSERVATION", 172, 177]]], ["Therefore, besides the experiments carried out under batch conditions discussed above, the polymerizations were also studied under monomer starved conditions.", [["the polymerizations", "TREATMENT", 87, 106]]], ["In this case, at 70 \u00b0C monomer conversion was 35% and it was 24% at 44 \u00b0C. The reactions were also followed by DLS in order to monitor the evolution of particle size distribution over time (Figure 2 ), together with the monomer conversion over time.", [["particle", "OBSERVATION_MODIFIER", 152, 160], ["size", "OBSERVATION_MODIFIER", 161, 165], ["distribution", "OBSERVATION_MODIFIER", 166, 178]]], ["Figure 2 shows that when the reaction was carried out at 44 \u00b0C, both PdI and zeta potential do not stabilize when compared to the results obtained at 70 \u00b0C. This suggests that the macroRAFT agent does not seem to be leaving the growing polymer particles to reinitiate the polymerization.", [["PdI", "SIMPLE_CHEMICAL", 69, 72], ["the reaction", "PROBLEM", 25, 37], ["the macroRAFT agent", "PROBLEM", 176, 195], ["the polymerization", "TREATMENT", 268, 286]]], ["Hence, the use of a sacrificial macroRAFT agent might have been required to ensure the living behavior of the polymerization.", [["a sacrificial macroRAFT agent", "TREATMENT", 18, 47], ["the polymerization", "TREATMENT", 106, 124]]], ["The average molar mass of these copolymers was characterized by GPC-SEC analysis (Table 1) .", [["The average molar mass of these copolymers", "PROBLEM", 0, 42], ["GPC", "TEST", 64, 67], ["SEC analysis", "TEST", 68, 80], ["average", "OBSERVATION_MODIFIER", 4, 11], ["molar", "OBSERVATION_MODIFIER", 12, 17], ["mass", "OBSERVATION", 18, 22]]], ["Even though only one peak was detected for the sample prepared at 70 \u00b0C, the dispersity (\u0110) was 1.66, which is too high for controlled reversible deactivation radical polymerizations.", [["controlled reversible deactivation radical polymerizations", "TREATMENT", 124, 182], ["reversible", "OBSERVATION_MODIFIER", 135, 145], ["deactivation", "OBSERVATION_MODIFIER", 146, 158], ["radical polymerizations", "OBSERVATION", 159, 182]]], ["The GPC-SEC results also confirm the low monomer conversion obtained namely for the copolymerization carried out at 44 \u00b0C, but in this case, the \u0110 = 1.27 indicates a controlled polymerization.", [["The GPC", "TEST", 0, 7], ["the copolymerization", "TEST", 80, 100], ["a controlled polymerization", "PROBLEM", 164, 191]]], ["As regards the discrepancy between the degree of polymerization (DP) and the average molar masses obtained gravimetrically and by GPC-SEC, this was naturally expected due to the major differences between the two methods.", [["the average molar masses", "PROBLEM", 73, 97], ["GPC", "TEST", 130, 133], ["polymerization", "OBSERVATION_MODIFIER", 49, 63], ["masses", "OBSERVATION", 91, 97]]], ["However, in the present study, the discrepancy may have been exacerbated by the fact that the calibration curve for GPC-SEC analysis was performed using polystyrene standards.", [["polystyrene", "CHEMICAL", 153, 164], ["GPC", "SIMPLE_CHEMICAL", 116, 119], ["the present study", "TEST", 12, 29], ["the calibration curve", "TEST", 90, 111], ["GPC-SEC analysis", "TEST", 116, 132], ["polystyrene standards", "TREATMENT", 153, 174]]], ["The average molar mass of these copolymers was characterized by GPC-SEC analysis (Table 1) .", [["The average molar mass of these copolymers", "PROBLEM", 0, 42], ["GPC", "TEST", 64, 67], ["SEC analysis", "TEST", 68, 80], ["average", "OBSERVATION_MODIFIER", 4, 11], ["molar", "OBSERVATION_MODIFIER", 12, 17], ["mass", "OBSERVATION", 18, 22]]], ["Even though only one peak was detected for the sample prepared at 70 \u2022 C, the dispersity (\u00d0) was 1.66, which is too high for controlled reversible deactivation radical polymerizations.", [["the dispersity", "TEST", 74, 88], ["controlled reversible deactivation radical polymerizations", "TREATMENT", 125, 183], ["reversible", "OBSERVATION_MODIFIER", 136, 146], ["deactivation", "OBSERVATION_MODIFIER", 147, 159], ["radical polymerizations", "OBSERVATION", 160, 183]]], ["The GPC-SEC results also confirm the low monomer conversion obtained namely for the copolymerization carried out at 44 \u2022 C, but in this case, the \u00d0 = 1.27 indicates a controlled polymerization.", [["The GPC", "TEST", 0, 7], ["the copolymerization", "TEST", 80, 100], ["a controlled polymerization", "PROBLEM", 165, 192]]], ["As regards the discrepancy between the degree of polymerization (DP) and the average molar masses obtained gravimetrically and by GPC-SEC, this was naturally expected due to the major differences between the two methods.", [["the average molar masses", "PROBLEM", 73, 97], ["GPC", "TEST", 130, 133], ["polymerization", "OBSERVATION_MODIFIER", 49, 63], ["masses", "OBSERVATION", 91, 97]]], ["However, in the present study, the discrepancy may have been exacerbated by the fact that the calibration curve for GPC-SEC analysis was performed using polystyrene standards.", [["polystyrene", "CHEMICAL", 153, 164], ["GPC", "SIMPLE_CHEMICAL", 116, 119], ["the present study", "TEST", 12, 29], ["the calibration curve", "TEST", 90, 111], ["GPC-SEC analysis", "TEST", 116, 132], ["polystyrene standards", "TREATMENT", 153, 174]]], ["Moreover, it should be stressed that the value for DP in the case of the copolymers corresponds to that associated with the chain length reached upon chain extension (DP MMA:BA ).", [["DP MMA", "CHEMICAL", 167, 173], ["DP", "PROBLEM", 51, 53], ["the copolymers", "TREATMENT", 69, 83], ["the chain length", "PROBLEM", 120, 136]]], ["The results show that carrying out chain extension using emulsion polymerization under monomer starved conditions and at a low temperature compromises the yield of polymerization.Preparation of Copolymer@Au NPs at 44 \u2022 CTwo types of Au nanostructures have been prepared after establishing the polymerization conditions for using the P(PEGA 40 )-TTC macroRAFT agent.", [["Copolymer@Au NPs", "CHEMICAL", 194, 210], ["Au", "CHEMICAL", 233, 235], ["Copolymer@Au", "CHEMICAL", 194, 206], ["Au", "CHEMICAL", 233, 235], ["P(PEGA 40 )-TTC", "CHEMICAL", 333, 348], ["Copolymer@Au NPs", "SIMPLE_CHEMICAL", 194, 210], ["Au nanostructures", "SIMPLE_CHEMICAL", 233, 250], ["TTC macroRAFT", "SIMPLE_CHEMICAL", 345, 358], ["carrying out chain extension", "PROBLEM", 22, 50], ["emulsion polymerization", "TREATMENT", 57, 80], ["a low temperature", "PROBLEM", 121, 138], ["polymerization", "TREATMENT", 164, 178], ["Copolymer@Au NPs", "TREATMENT", 194, 210], ["Au nanostructures", "TREATMENT", 233, 250], ["the polymerization conditions", "TREATMENT", 289, 318], ["the P(PEGA", "TREATMENT", 329, 339], ["TTC macroRAFT agent", "TREATMENT", 345, 364]]], ["One of such Au nanostructures comprises the use of the macroRAFT agent P(PEGA 40 )-TTC to yield the copolymer@Au NPs without azide moiety.", [["Au", "CHEMICAL", 12, 14], ["RAFT agent P(PEGA 40 )-TTC", "CHEMICAL", 60, 86], ["azide", "CHEMICAL", 125, 130], ["Au", "CHEMICAL", 12, 14], ["P(PEGA 40 )-TTC", "CHEMICAL", 71, 86], ["azide", "CHEMICAL", 125, 130], ["RAFT", "SIMPLE_CHEMICAL", 60, 64], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 73, 86], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 100, 116], ["azide moiety", "SIMPLE_CHEMICAL", 125, 137], ["such Au nanostructures", "TREATMENT", 7, 29], ["TTC", "PROBLEM", 83, 86], ["the copolymer@Au NPs", "TREATMENT", 96, 116], ["azide moiety", "TREATMENT", 125, 137], ["macro", "OBSERVATION", 55, 60]]], ["The second one uses a mixture of this macroRAFT agent with the macroRAFT agent modified with the azide group (2 macroRAFT:1 N3-macroRAFT) to yield N3-copolymer@Au NPs.", [["azide", "CHEMICAL", 97, 102], ["N3-copolymer@Au", "CHEMICAL", 147, 162], ["azide", "CHEMICAL", 97, 102], ["1 N3-macroRAFT", "CHEMICAL", 122, 136], ["N3", "CHEMICAL", 147, 149], ["macroRAFT", "SIMPLE_CHEMICAL", 38, 47], ["azide", "SIMPLE_CHEMICAL", 97, 102], ["1 N3-macroRAFT", "SIMPLE_CHEMICAL", 122, 136], ["N3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 147, 166], ["this macroRAFT agent", "TREATMENT", 33, 53], ["the macroRAFT agent", "TREATMENT", 59, 78], ["the azide group", "TREATMENT", 93, 108], ["copolymer@Au NPs", "TREATMENT", 150, 166]]], ["The [2 macroRAFT: 1 N3-macroRAFT] molar ratio was selected in order to add the azide functionality to the nanostructure without significant perturbation of the emulsion copolymerization.", [["azide", "CHEMICAL", 79, 84], ["[2 macroRAFT: 1 N3-macroRAFT", "CHEMICAL", 4, 32], ["azide", "CHEMICAL", 79, 84], ["1 N3-macroRAFT", "SIMPLE_CHEMICAL", 18, 32], ["azide", "SIMPLE_CHEMICAL", 79, 84], ["N3-macroRAFT] molar ratio", "TREATMENT", 20, 45], ["the azide functionality", "TREATMENT", 75, 98], ["the emulsion copolymerization", "TREATMENT", 156, 185], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["perturbation", "OBSERVATION", 140, 152], ["emulsion copolymerization", "OBSERVATION", 160, 185]]], ["Notice should be made that even though the determination of the amount of azide moiety per NP was not possible during the adsorption step, the solution of N3-macroRAFT agent was added dropwise to the colloidal Au NPs and stirred 2 h prior to the addition of the solution of macroRAFT agent (without azide) to ensure that all the N3-macroRAFT was adsorbed.", [["azide", "CHEMICAL", 74, 79], ["N3-macroRAFT", "CHEMICAL", 155, 167], ["Au", "CHEMICAL", 210, 212], ["azide", "CHEMICAL", 299, 304], ["azide", "CHEMICAL", 74, 79], ["N3-macroRAFT", "CHEMICAL", 155, 167], ["Au", "CHEMICAL", 210, 212], ["azide", "CHEMICAL", 299, 304], ["N3-macroRAFT", "CHEMICAL", 329, 341], ["azide moiety", "SIMPLE_CHEMICAL", 74, 86], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 155, 167], ["colloidal Au NPs", "SIMPLE_CHEMICAL", 200, 216], ["macroRAFT agent", "SIMPLE_CHEMICAL", 274, 289], ["azide", "SIMPLE_CHEMICAL", 299, 304], ["N3-macroRAFT", "SIMPLE_CHEMICAL", 329, 341], ["macroRAFT", "PROTEIN", 332, 341], ["azide moiety", "TREATMENT", 74, 86], ["the solution of N3-macroRAFT agent", "TREATMENT", 139, 173], ["the colloidal Au NPs", "TREATMENT", 196, 216], ["the solution of macroRAFT agent", "TREATMENT", 258, 289], ["azide", "TREATMENT", 299, 304]]], ["Specifically, the main objective was to keep some carboxylate anions available to provide colloidal stabilization by electrostatic interactions and also to avoid crowding the surface with azide moieties.", [["surface", "ANATOMY", 175, 182], ["azide", "CHEMICAL", 188, 193], ["carboxylate", "CHEMICAL", 50, 61], ["azide", "CHEMICAL", 188, 193], ["carboxylate anions", "SIMPLE_CHEMICAL", 50, 68], ["surface", "CELLULAR_COMPONENT", 175, 182], ["azide moieties", "SIMPLE_CHEMICAL", 188, 202], ["some carboxylate anions", "TREATMENT", 45, 68], ["colloidal stabilization", "TREATMENT", 90, 113], ["azide moieties", "TREATMENT", 188, 202], ["main", "OBSERVATION_MODIFIER", 18, 22], ["azide moieties", "OBSERVATION", 188, 202]]], ["The former was used as reference, and the characterization of this colloid is presented in the Supporting Information ( Figures S3 and S4, Table S2 ), whilst the characterization of the azide functionalized nanostructures is discussed below.", [["azide", "CHEMICAL", 186, 191], ["azide", "CHEMICAL", 186, 191], ["azide", "SIMPLE_CHEMICAL", 186, 191], ["this colloid", "PROBLEM", 62, 74], ["the azide functionalized nanostructures", "TREATMENT", 182, 221]]], ["Figure 3 shows for the Au NPs, a first shift of \u03bb LSPR from 523 nm to 526 nm, and then to 529 nm, after adsorption of the macroRAFT agents onto Au NPs and after the chain extension from the N3-macroRAFT@Au NPs respectively (see \u03bb LSPR values in Table 2 ).", [["Au", "CHEMICAL", 23, 25], ["Au NPs", "CHEMICAL", 144, 150], ["RAFT@Au NPs", "CHEMICAL", 198, 209], ["Au", "CHEMICAL", 23, 25], ["Au", "CHEMICAL", 144, 146], ["RAFT@Au", "CHEMICAL", 198, 205], ["Au NPs", "SIMPLE_CHEMICAL", 23, 29], ["macroRAFT agents", "SIMPLE_CHEMICAL", 122, 138], ["Au NPs", "SIMPLE_CHEMICAL", 144, 150], ["RAFT@Au NPs", "SIMPLE_CHEMICAL", 198, 209], ["the macroRAFT agents", "TREATMENT", 118, 138], ["Au NPs", "TREATMENT", 144, 150], ["the chain extension", "PROBLEM", 161, 180]]], ["Moreover, the increase of the absorbance band around 200-250 nm is associated with the presence of the hydrophobic block, indicating that chain extension from N3-macroRAFT@Au NPs had occurred, yielding N3-copolymer@Au NPs [15] .", [["RAFT@Au NPs", "CHEMICAL", 167, 178], ["RAFT@Au", "CHEMICAL", 167, 174], ["N3", "CHEMICAL", 202, 204], ["RAFT@Au NPs", "SIMPLE_CHEMICAL", 167, 178], ["N3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 202, 221], ["the absorbance band", "TEST", 26, 45], ["the hydrophobic block", "PROBLEM", 99, 120], ["chain extension", "PROBLEM", 138, 153], ["RAFT@Au NPs", "TREATMENT", 167, 178], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["hydrophobic block", "OBSERVATION", 103, 120]]], ["The DLS results (Table 2) show that after chain extension, there was a slight increase of the hydrodynamic average diameter (z-average), which is in line with our previous studies performed at 70 \u2022 C [16] .", [["chain extension", "TEST", 42, 57], ["our previous studies", "TEST", 159, 179], ["slight", "OBSERVATION_MODIFIER", 71, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["hydrodynamic", "OBSERVATION_MODIFIER", 94, 106], ["average", "OBSERVATION_MODIFIER", 107, 114], ["diameter", "OBSERVATION_MODIFIER", 115, 123]]], ["Furthermore, the small increase is in agreement with the low degree of polymerization registered for the corresponding copolymer. .", [["the small increase", "PROBLEM", 13, 31], ["the corresponding copolymer", "TREATMENT", 101, 128], ["small", "OBSERVATION_MODIFIER", 17, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["low degree", "OBSERVATION_MODIFIER", 57, 67]]], ["UV-Vis spectra of Au nanostructures before and after emulsion copolymerization at 44 \u00b0C, with azide moiety.Au NPsAs regards the surface charge of these nanostructures, Table 2 shows that after the adsorption of macroRAFT agents ([2 macroRAFT: 1 N3-macroRAFT] ratio) onto Au NPs, the zeta potential decreased from about \u221250 to \u221225 mV.", [["surface", "ANATOMY", 128, 135], ["Au", "CHEMICAL", 18, 20], ["azide", "CHEMICAL", 94, 99], ["Au", "CHEMICAL", 107, 109], ["Au NPs", "CHEMICAL", 271, 277], ["Au", "CHEMICAL", 18, 20], ["azide", "CHEMICAL", 94, 99], ["Au", "CHEMICAL", 107, 109], ["Au", "CHEMICAL", 271, 273], ["Au nanostructures", "SIMPLE_CHEMICAL", 18, 35], ["azide moiety", "SIMPLE_CHEMICAL", 94, 106], ["Au NPsAs", "SIMPLE_CHEMICAL", 107, 115], ["RAFT", "SIMPLE_CHEMICAL", 216, 220], ["Au NPs", "SIMPLE_CHEMICAL", 271, 277], ["UV", "TREATMENT", 0, 2], ["Vis spectra of Au nanostructures", "TREATMENT", 3, 35], ["emulsion copolymerization", "TREATMENT", 53, 78], ["azide moiety", "TREATMENT", 94, 106], ["RAFT agents", "TREATMENT", 216, 227], ["macroRAFT", "TREATMENT", 248, 257], ["Au NPs", "TREATMENT", 271, 277], ["the zeta", "TEST", 279, 287], ["decreased", "OBSERVATION_MODIFIER", 298, 307]]], ["This is associated with the replacement of the citrate ions at the Au NPs surface by the macroRAFT agents, which have one or two available carboxylic groups per chain, therefore decreasing the charge density of the NPs.", [["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate ions", "SIMPLE_CHEMICAL", 47, 59], ["macroRAFT agents", "SIMPLE_CHEMICAL", 89, 105], ["NPs", "SIMPLE_CHEMICAL", 215, 218], ["the replacement of the citrate ions", "TREATMENT", 24, 59], ["the Au NPs surface", "TREATMENT", 63, 81], ["the macroRAFT agents", "TREATMENT", 85, 105], ["the NPs", "TREATMENT", 211, 218], ["replacement", "OBSERVATION", 28, 39], ["charge density", "OBSERVATION_MODIFIER", 193, 207]]], ["Nevertheless, the colloid proved to be stable even after the copolymerization occurred because no aggregation was observed by monitoring the system using UV-Vis spectroscopy ( Figure 3) .", [["the copolymerization", "TREATMENT", 57, 77], ["aggregation", "PROBLEM", 98, 109], ["UV", "TREATMENT", 154, 156], ["Vis spectroscopy", "TEST", 157, 173], ["stable", "OBSERVATION_MODIFIER", 39, 45]]], ["Furthermore, electron microscopy images ( Figure 4 ) showed that after chain extension, the polymer shell is well-defined (inset in Figures 4B and S5 in the Supporting Information).", [["electron microscopy images", "TEST", 13, 39], ["chain extension", "PROBLEM", 71, 86], ["the polymer shell", "TREATMENT", 88, 105], ["shell", "OBSERVATION_MODIFIER", 100, 105]]], ["As regards the surface charge of these nanostructures, Table 2 shows that after the adsorption of macroRAFT agents ([2 macroRAFT: 1 N3-macroRAFT] ratio) onto Au NPs, the zeta potential decreased from about \u221250 to \u221225 mV.", [["surface", "ANATOMY", 15, 22], ["Au NPs", "CHEMICAL", 158, 164], ["Au", "CHEMICAL", 158, 160], ["RAFT", "SIMPLE_CHEMICAL", 103, 107], ["Au NPs", "SIMPLE_CHEMICAL", 158, 164], ["RAFT agents", "TREATMENT", 103, 114], ["macroRAFT", "TREATMENT", 135, 144], ["Au NPs", "TREATMENT", 158, 164], ["the zeta", "TEST", 166, 174], ["decreased", "OBSERVATION_MODIFIER", 185, 194]]], ["This is associated with the replacement of the citrate ions at the Au NPs surface by the macroRAFT agents, which have one or two available carboxylic groups per chain, therefore decreasing the charge density of the NPs.", [["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate ions", "SIMPLE_CHEMICAL", 47, 59], ["macroRAFT agents", "SIMPLE_CHEMICAL", 89, 105], ["NPs", "SIMPLE_CHEMICAL", 215, 218], ["the replacement of the citrate ions", "TREATMENT", 24, 59], ["the Au NPs surface", "TREATMENT", 63, 81], ["the macroRAFT agents", "TREATMENT", 85, 105], ["the NPs", "TREATMENT", 211, 218], ["replacement", "OBSERVATION", 28, 39], ["charge density", "OBSERVATION_MODIFIER", 193, 207]]], ["Nevertheless, the colloid proved to be stable even after the copolymerization occurred because no aggregation was observed by monitoring the system using UV-Vis spectroscopy ( Figure 3 ).", [["the copolymerization", "TREATMENT", 57, 77], ["aggregation", "PROBLEM", 98, 109], ["UV", "TREATMENT", 154, 156], ["Vis spectroscopy", "TEST", 157, 173], ["stable", "OBSERVATION_MODIFIER", 39, 45]]], ["Furthermore, electron microscopy images (Figure 4 ) showed that after chain extension, the polymer shell is well-defined (inset in Figure 4B and Figure S5 in the Supporting Information). .", [["electron microscopy images", "TEST", 13, 39], ["chain extension", "PROBLEM", 70, 85], ["the polymer shell", "TREATMENT", 87, 104]]], ["UV-Vis spectra of Au nanostructures before and after emulsion copolymerization at 44 \u00b0C, with azide moiety.Au NPsAs regards the surface charge of these nanostructures, Table 2 shows that after the adsorption of macroRAFT agents ([2 macroRAFT: 1 N3-macroRAFT] ratio) onto Au NPs, the zeta potential decreased from about \u221250 to \u221225 mV.", [["surface", "ANATOMY", 128, 135], ["Au", "CHEMICAL", 18, 20], ["azide", "CHEMICAL", 94, 99], ["Au", "CHEMICAL", 107, 109], ["Au NPs", "CHEMICAL", 271, 277], ["Au", "CHEMICAL", 18, 20], ["azide", "CHEMICAL", 94, 99], ["Au", "CHEMICAL", 107, 109], ["Au", "CHEMICAL", 271, 273], ["Au nanostructures", "SIMPLE_CHEMICAL", 18, 35], ["azide moiety", "SIMPLE_CHEMICAL", 94, 106], ["Au NPsAs", "SIMPLE_CHEMICAL", 107, 115], ["RAFT", "SIMPLE_CHEMICAL", 216, 220], ["Au NPs", "SIMPLE_CHEMICAL", 271, 277], ["UV", "TREATMENT", 0, 2], ["Vis spectra of Au nanostructures", "TREATMENT", 3, 35], ["emulsion copolymerization", "TREATMENT", 53, 78], ["azide moiety", "TREATMENT", 94, 106], ["RAFT agents", "TREATMENT", 216, 227], ["macroRAFT", "TREATMENT", 248, 257], ["Au NPs", "TREATMENT", 271, 277], ["the zeta", "TEST", 279, 287], ["decreased", "OBSERVATION_MODIFIER", 298, 307]]], ["This is associated with the replacement of the citrate ions at the Au NPs surface by the macroRAFT agents, which have one or two available carboxylic groups per chain, therefore decreasing the charge density of the NPs.", [["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate", "CHEMICAL", 47, 54], ["Au", "CHEMICAL", 67, 69], ["carboxylic", "CHEMICAL", 139, 149], ["citrate ions", "SIMPLE_CHEMICAL", 47, 59], ["macroRAFT agents", "SIMPLE_CHEMICAL", 89, 105], ["NPs", "SIMPLE_CHEMICAL", 215, 218], ["the replacement of the citrate ions", "TREATMENT", 24, 59], ["the Au NPs surface", "TREATMENT", 63, 81], ["the macroRAFT agents", "TREATMENT", 85, 105], ["the NPs", "TREATMENT", 211, 218], ["replacement", "OBSERVATION", 28, 39], ["charge density", "OBSERVATION_MODIFIER", 193, 207]]], ["Nevertheless, the colloid proved to be stable even after the copolymerization occurred because no aggregation was observed by monitoring the system using UV-Vis spectroscopy ( Figure 3 ).", [["the copolymerization", "TREATMENT", 57, 77], ["aggregation", "PROBLEM", 98, 109], ["UV", "TREATMENT", 154, 156], ["Vis spectroscopy", "TEST", 157, 173], ["stable", "OBSERVATION_MODIFIER", 39, 45]]], ["Furthermore, electron microscopy images ( Figure 4 ) showed that after chain extension, the polymer shell is well-defined (inset in Figures 4B and S5 in the Supporting Information).Biosensing ResponseIn order to evaluate the use of the above Au nanostructures for biosensing applications, the biotin-avidin (bioreceptor-biotarget) conjugate system was used here.", [["Au", "CHEMICAL", 242, 244], ["biotin-avidin", "CHEMICAL", 293, 306], ["Au", "CHEMICAL", 242, 244], ["biotin", "CHEMICAL", 293, 299], ["biotin-avidin", "SIMPLE_CHEMICAL", 293, 306], ["bioreceptor", "SIMPLE_CHEMICAL", 308, 319], ["avidin", "PROTEIN", 300, 306], ["electron microscopy images", "TEST", 13, 39], ["chain extension", "PROBLEM", 71, 86], ["the polymer shell", "TREATMENT", 88, 105], ["the above Au nanostructures", "TREATMENT", 232, 259], ["biosensing applications", "TREATMENT", 264, 287], ["the biotin-avidin (bioreceptor-biotarget) conjugate system", "TREATMENT", 289, 347], ["shell", "OBSERVATION_MODIFIER", 100, 105]]], ["For that purpose, the N3-copolymer@Au nanostructures were first biotinylated.", [["N3", "CHEMICAL", 22, 24], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 22, 52], ["the N3-copolymer@Au nanostructures", "TREATMENT", 18, 52]]], ["Alkynated biotin (biotin-CCH, see the synthesis and characterization in the Supporting Information) was covalently bound to the N3-copolymer@Au nanostructures in the presence of CuSO 4 and sodium ascorbate, forming a covalent 1,2,3-triazole linkage via click chemistry yielding biotin-copolymer@Au NPs ( Figure 5 ).Biosensing Responsebiotin-avidin (bioreceptor-biotarget) conjugate system was used here.", [["Alkynated biotin", "CHEMICAL", 0, 16], ["biotin-CCH", "CHEMICAL", 18, 28], ["CuSO 4", "CHEMICAL", 178, 184], ["sodium ascorbate", "CHEMICAL", 189, 205], ["1,2,3-triazole", "CHEMICAL", 226, 240], ["biotin-copolymer@Au", "CHEMICAL", 278, 297], ["Responsebiotin-avidin", "CHEMICAL", 326, 347], ["biotin", "CHEMICAL", 10, 16], ["biotin-CCH", "CHEMICAL", 18, 28], ["N3", "CHEMICAL", 128, 130], ["CuSO 4", "CHEMICAL", 178, 184], ["sodium ascorbate", "CHEMICAL", 189, 205], ["1,2,3-triazole", "CHEMICAL", 226, 240], ["biotin", "CHEMICAL", 278, 284], ["Alkynated", "SIMPLE_CHEMICAL", 0, 9], ["biotin", "SIMPLE_CHEMICAL", 10, 16], ["biotin-CCH", "SIMPLE_CHEMICAL", 18, 28], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 128, 158], ["CuSO 4", "SIMPLE_CHEMICAL", 178, 184], ["sodium ascorbate", "SIMPLE_CHEMICAL", 189, 205], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 226, 240], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 278, 301], ["Responsebiotin-avidin", "SIMPLE_CHEMICAL", 326, 347], ["bioreceptor-biotarget", "SIMPLE_CHEMICAL", 349, 370], ["Biosensing Responsebiotin-avidin (bioreceptor-biotarget) conjugate", "PROTEIN", 315, 381], ["Alkynated biotin", "TEST", 0, 16], ["sodium ascorbate", "TEST", 189, 205], ["a covalent 1,2,3-triazole linkage", "TREATMENT", 215, 248], ["click chemistry", "TEST", 253, 268], ["biotin-copolymer@Au NPs", "TREATMENT", 278, 301], ["Biosensing Responsebiotin-avidin (bioreceptor-biotarget) conjugate system", "TREATMENT", 315, 388]]], ["For that purpose, the N3-copolymer@Au nanostructures were first biotinylated.", [["N3", "CHEMICAL", 22, 24], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 22, 52], ["the N3-copolymer@Au nanostructures", "TREATMENT", 18, 52]]], ["Alkynated biotin (biotin-CCH, see the synthesis and characterization in the Supporting Information) was covalently bound to the N3-copolymer@Au nanostructures in the presence of CuSO4 and sodium ascorbate, forming a covalent 1,2,3-triazole linkage via click chemistry yielding biotin-copolymer@Au NPs ( Figure 5 ).Biosensing ResponseAfter biotinylation, the UV-Vis spectrum showed a small shift in the \u03bbLSPR (\u0394\u03bb ~ + 1 nm) and no sign of aggregation (data not shown).", [["Alkynated biotin", "CHEMICAL", 0, 16], ["biotin-CCH", "CHEMICAL", 18, 28], ["CuSO4", "CHEMICAL", 178, 183], ["sodium ascorbate", "CHEMICAL", 188, 204], ["1,2,3-triazole", "CHEMICAL", 225, 239], ["biotin-copolymer@Au", "CHEMICAL", 277, 296], ["biotin", "CHEMICAL", 10, 16], ["biotin-CCH", "CHEMICAL", 18, 28], ["N3", "CHEMICAL", 128, 130], ["CuSO4", "CHEMICAL", 178, 183], ["sodium ascorbate", "CHEMICAL", 188, 204], ["1,2,3-triazole", "CHEMICAL", 225, 239], ["biotin", "CHEMICAL", 277, 283], ["Alkynated", "SIMPLE_CHEMICAL", 0, 9], ["biotin", "SIMPLE_CHEMICAL", 10, 16], ["biotin-CCH", "SIMPLE_CHEMICAL", 18, 28], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 128, 158], ["CuSO4", "SIMPLE_CHEMICAL", 178, 183], ["sodium ascorbate", "SIMPLE_CHEMICAL", 188, 204], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 225, 239], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 277, 300], ["Alkynated biotin", "TEST", 0, 16], ["the N3-copolymer@Au nanostructures", "TREATMENT", 124, 158], ["CuSO4 and sodium ascorbate", "TREATMENT", 178, 204], ["a covalent 1,2,3-triazole linkage", "TREATMENT", 214, 247], ["click chemistry", "TEST", 252, 267], ["biotin-copolymer@Au NPs", "TREATMENT", 277, 300], ["the UV-Vis spectrum", "TEST", 354, 373], ["a small shift", "PROBLEM", 381, 394], ["the \u03bbLSPR", "TEST", 398, 407], ["aggregation", "PROBLEM", 437, 448], ["small", "OBSERVATION_MODIFIER", 383, 388], ["shift", "OBSERVATION", 389, 394], ["no sign of", "UNCERTAINTY", 426, 436], ["aggregation", "OBSERVATION", 437, 448]]], ["The formation of the 1,2,3-triazole linkage, or consumption of azide, could not be detected due to the small amount of azide/triazole group in the Au colloid.", [["1,2,3-triazole", "CHEMICAL", 21, 35], ["azide", "CHEMICAL", 63, 68], ["azide", "CHEMICAL", 119, 124], ["triazole", "CHEMICAL", 125, 133], ["Au", "CHEMICAL", 147, 149], ["1,2,3-triazole", "CHEMICAL", 21, 35], ["azide", "CHEMICAL", 63, 68], ["azide", "CHEMICAL", 119, 124], ["triazole", "CHEMICAL", 125, 133], ["Au", "CHEMICAL", 147, 149], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 21, 35], ["azide", "SIMPLE_CHEMICAL", 63, 68], ["azide", "SIMPLE_CHEMICAL", 119, 124], ["triazole", "SIMPLE_CHEMICAL", 125, 133], ["Au colloid", "SIMPLE_CHEMICAL", 147, 157], ["the 1,2,3-triazole linkage", "TREATMENT", 17, 43], ["azide", "TREATMENT", 63, 68], ["azide/triazole group", "TREATMENT", 119, 139], ["the Au colloid", "TREATMENT", 143, 157], ["small", "OBSERVATION_MODIFIER", 103, 108], ["amount", "OBSERVATION_MODIFIER", 109, 115]]], ["However, as the click chemistry is known to be a very specific and highly efficient reaction [34] , it was assumed that the reaction occurred yielding stable biotin-copolymer@Au NPs, and the optical biosensing response to the presence of the proteins of the ensuing Au nanostructures was studied.", [["biotin", "CHEMICAL", 158, 164], ["Au", "CHEMICAL", 266, 268], ["biotin", "CHEMICAL", 158, 164], ["Au", "CHEMICAL", 266, 268], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 158, 181], ["Au nanostructures", "SIMPLE_CHEMICAL", 266, 283], ["the click chemistry", "TEST", 12, 31], ["the reaction", "PROBLEM", 120, 132], ["copolymer@Au NPs", "TREATMENT", 165, 181], ["the ensuing Au nanostructures", "TREATMENT", 254, 283], ["stable", "OBSERVATION_MODIFIER", 151, 157]]], ["Moreover, notice should be made that the nanostructures were extensively rinsed to assess the efficiency of the click reaction.", [["the nanostructures", "PROBLEM", 37, 55], ["the click reaction", "PROBLEM", 108, 126], ["click", "OBSERVATION", 112, 117]]], ["Additionally, this procedure was repeated in order to obtain enough material for the biosensing tests as well as for other ongoing studies, proving the reproducibility of this procedure.", [["this procedure", "TREATMENT", 14, 28], ["the biosensing tests", "TEST", 81, 101], ["other ongoing studies", "TEST", 117, 138], ["this procedure", "TREATMENT", 171, 185]]], ["The optical response of the biotinylated and non-biotinylated copolymer@Au NPs was assessed by adding to the colloidal nanostructures avidin, which is a protein that has high affinity toward biotin.", [["biotin", "CHEMICAL", 191, 197], ["biotin", "CHEMICAL", 191, 197], ["non-biotinylated copolymer@Au NPs", "SIMPLE_CHEMICAL", 45, 78], ["avidin", "GENE_OR_GENE_PRODUCT", 134, 140], ["biotin", "SIMPLE_CHEMICAL", 191, 197], ["the biotinylated and non-biotinylated copolymer@Au NPs", "TREATMENT", 24, 78], ["the colloidal nanostructures avidin", "TREATMENT", 105, 140], ["a protein", "PROBLEM", 151, 160], ["biotin", "TREATMENT", 191, 197]]], ["BSA was used as a control because it is a protein that does not have affinity to biotin.", [["BSA", "CHEMICAL", 0, 3], ["biotin", "CHEMICAL", 81, 87], ["biotin", "CHEMICAL", 81, 87], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["biotin", "SIMPLE_CHEMICAL", 81, 87], ["BSA", "TEST", 0, 3], ["biotin", "TREATMENT", 81, 87]]], ["Furthermore, since the addition of protein solution slightly dilutes the colloids, the same volume of phosphate buffer saline (PBS, pH 7.4, 10 mM) was added to all the colloids.Biosensing ResponseFor comparison and as a control experiment, three Au colloids were tested: biotin-copolymer@Au NPs, the neat copolymer@Au NPs, and copolymer@Au NPs submitted to the conditions used in the click reaction (\"click control\").", [["phosphate", "CHEMICAL", 102, 111], ["Au", "CHEMICAL", 246, 248], ["biotin", "CHEMICAL", 271, 277], ["copolymer@Au", "CHEMICAL", 327, 339], ["phosphate", "CHEMICAL", 102, 111], ["Au", "CHEMICAL", 246, 248], ["biotin", "CHEMICAL", 271, 277], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 102, 125], ["Au colloids", "SIMPLE_CHEMICAL", 246, 257], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 271, 294], ["neat copolymer@Au NPs", "SIMPLE_CHEMICAL", 300, 321], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 327, 343], ["protein solution", "TREATMENT", 35, 51], ["the colloids", "TREATMENT", 69, 81], ["phosphate buffer saline", "TREATMENT", 102, 125], ["PBS", "TEST", 127, 130], ["pH", "TEST", 132, 134], ["three Au colloids", "TREATMENT", 240, 257], ["biotin-copolymer@Au NPs", "TREATMENT", 271, 294], ["the neat copolymer@Au NPs", "TREATMENT", 296, 321], ["copolymer@Au NPs", "TREATMENT", 327, 343], ["the click reaction", "PROBLEM", 380, 398]]], ["The latter were copolymer@Au NPs (without the azide moiety), which were submitted to the same reaction conditions used to carry out the click reaction (i.e., alkynated biotin, CuSO4 and sodium ascorbate) and extensively rinsed, as described in the Experimental section to assess the efficiency of the click reaction.", [["copolymer@Au NPs", "CHEMICAL", 16, 32], ["azide", "CHEMICAL", 46, 51], ["alkynated biotin", "CHEMICAL", 158, 174], ["CuSO4", "CHEMICAL", 176, 181], ["sodium ascorbate", "CHEMICAL", 186, 202], ["azide", "CHEMICAL", 46, 51], ["biotin", "CHEMICAL", 168, 174], ["CuSO4", "CHEMICAL", 176, 181], ["sodium ascorbate", "CHEMICAL", 186, 202], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 16, 32], ["azide moiety", "SIMPLE_CHEMICAL", 46, 58], ["biotin", "SIMPLE_CHEMICAL", 168, 174], ["CuSO4", "SIMPLE_CHEMICAL", 176, 181], ["sodium ascorbate", "SIMPLE_CHEMICAL", 186, 202], ["copolymer@Au NPs", "TREATMENT", 16, 32], ["the azide moiety", "TREATMENT", 42, 58], ["the click reaction", "PROBLEM", 132, 150], ["CuSO4 and sodium ascorbate", "TREATMENT", 176, 202], ["the click reaction", "PROBLEM", 297, 315]]], ["Solutions of avidin and of BSA (0.5 mg/mL) in PBS were added to the Au nanostructures, and after 10 min, the samples were characterized by UV-Vis spectroscopy.", [["samples", "ANATOMY", 109, 116], ["BSA", "CHEMICAL", 27, 30], ["Au", "CHEMICAL", 68, 70], ["Au", "CHEMICAL", 68, 70], ["avidin", "GENE_OR_GENE_PRODUCT", 13, 19], ["BSA", "SIMPLE_CHEMICAL", 27, 30], ["PBS", "SIMPLE_CHEMICAL", 46, 49], ["Solutions of avidin", "TREATMENT", 0, 19], ["BSA", "TREATMENT", 27, 30], ["PBS", "TREATMENT", 46, 49], ["the samples", "TEST", 105, 116], ["Vis spectroscopy", "TEST", 142, 158]]], ["As a control of the dilution, PBS was also added to the three types of Au nanostructures.Biosensing ResponseIn Figure 6A the UV-Vis spectra are shown, and as it can be observed, a small decrease of the absorbance and a small shift in the \u03bbLSPR (\u0394\u03bb = + 1 nm) occurred, especially in the presence of avidin, which indicates the occurrence of specific interactions.", [["Au", "CHEMICAL", 71, 73], ["Au", "CHEMICAL", 71, 73], ["PBS", "SIMPLE_CHEMICAL", 30, 33], ["Au nanostructures", "SIMPLE_CHEMICAL", 71, 88], ["avidin", "GENE_OR_GENE_PRODUCT", 298, 304], ["avidin", "PROTEIN", 298, 304], ["the dilution", "TREATMENT", 16, 28], ["PBS", "TREATMENT", 30, 33], ["a small decrease of the absorbance", "PROBLEM", 178, 212], ["a small shift", "PROBLEM", 217, 230], ["the \u03bbLSPR", "TEST", 234, 243], ["small", "OBSERVATION_MODIFIER", 180, 185], ["decrease", "OBSERVATION_MODIFIER", 186, 194], ["absorbance", "OBSERVATION_MODIFIER", 202, 212], ["small", "OBSERVATION_MODIFIER", 219, 224], ["shift", "OBSERVATION_MODIFIER", 225, 230]]], ["Nevertheless, nonspecific interactions seem to have occurred as well with the control of BSA, which might be assigned to a variety of interactions (electrostatic, H bonding, van der Waals, etc.) occurring between the nanostructures and the proteins [35, 36] .", [["H", "CHEMICAL", 163, 164], ["BSA", "SIMPLE_CHEMICAL", 89, 92], ["nonspecific interactions", "PROBLEM", 14, 38]]], ["In fact, at this pH (approximately 6, see Table 2 ), BSA presents a negative surface charge After biotinylation, the UV-Vis spectrum showed a small shift in the \u03bb LSPR (\u2206\u03bb~+1 nm) and no sign of aggregation (data not shown).", [["surface", "ANATOMY", 77, 84], ["BSA", "SIMPLE_CHEMICAL", 53, 56], ["biotinylation", "TEST", 98, 111], ["the UV-Vis spectrum", "TEST", 113, 132], ["a small shift", "PROBLEM", 140, 153], ["the \u03bb LSPR", "TEST", 157, 167], ["aggregation", "PROBLEM", 194, 205], ["small", "OBSERVATION_MODIFIER", 142, 147], ["shift", "OBSERVATION", 148, 153], ["no sign of", "UNCERTAINTY", 183, 193], ["aggregation", "OBSERVATION", 194, 205]]], ["The formation of the 1,2,3-triazole linkage, or consumption of azide, could not be detected due to the small amount of azide/triazole group in the Au colloid.", [["1,2,3-triazole", "CHEMICAL", 21, 35], ["azide", "CHEMICAL", 63, 68], ["azide", "CHEMICAL", 119, 124], ["triazole", "CHEMICAL", 125, 133], ["Au", "CHEMICAL", 147, 149], ["1,2,3-triazole", "CHEMICAL", 21, 35], ["azide", "CHEMICAL", 63, 68], ["azide", "CHEMICAL", 119, 124], ["triazole", "CHEMICAL", 125, 133], ["Au", "CHEMICAL", 147, 149], ["1,2,3-triazole", "SIMPLE_CHEMICAL", 21, 35], ["azide", "SIMPLE_CHEMICAL", 63, 68], ["azide", "SIMPLE_CHEMICAL", 119, 124], ["triazole", "SIMPLE_CHEMICAL", 125, 133], ["Au colloid", "SIMPLE_CHEMICAL", 147, 157], ["the 1,2,3-triazole linkage", "TREATMENT", 17, 43], ["azide", "TREATMENT", 63, 68], ["azide/triazole group", "TREATMENT", 119, 139], ["the Au colloid", "TREATMENT", 143, 157], ["small", "OBSERVATION_MODIFIER", 103, 108], ["amount", "OBSERVATION_MODIFIER", 109, 115]]], ["However, as the click chemistry is known to be a very specific and highly efficient reaction [34] , it was assumed that the reaction occurred yielding stable biotin-copolymer@Au NPs, and the optical biosensing response to the presence of the proteins of the ensuing Au nanostructures was studied.", [["biotin", "CHEMICAL", 158, 164], ["Au", "CHEMICAL", 266, 268], ["biotin", "CHEMICAL", 158, 164], ["Au", "CHEMICAL", 266, 268], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 158, 181], ["Au nanostructures", "SIMPLE_CHEMICAL", 266, 283], ["the click chemistry", "TEST", 12, 31], ["the reaction", "PROBLEM", 120, 132], ["copolymer@Au NPs", "TREATMENT", 165, 181], ["the ensuing Au nanostructures", "TREATMENT", 254, 283], ["stable", "OBSERVATION_MODIFIER", 151, 157]]], ["Moreover, notice should be made that the nanostructures were extensively rinsed to assess the efficiency of the click reaction.", [["the nanostructures", "PROBLEM", 37, 55], ["the click reaction", "PROBLEM", 108, 126], ["click", "OBSERVATION", 112, 117]]], ["Additionally, this procedure was repeated in order to obtain enough material for the biosensing tests as well as for other ongoing studies, proving the reproducibility of this procedure.Biosensing ResponseThe optical response of the biotinylated and non-biotinylated copolymer@Au NPs was assessed by adding to the colloidal nanostructures avidin, which is a protein that has high affinity toward biotin.", [["biotin", "CHEMICAL", 396, 402], ["biotin", "CHEMICAL", 396, 402], ["non-biotinylated copolymer@Au NPs", "SIMPLE_CHEMICAL", 250, 283], ["avidin", "GENE_OR_GENE_PRODUCT", 339, 345], ["biotin", "SIMPLE_CHEMICAL", 396, 402], ["this procedure", "TREATMENT", 14, 28], ["the biosensing tests", "TEST", 81, 101], ["other ongoing studies", "TEST", 117, 138], ["this procedure", "TREATMENT", 171, 185], ["the biotinylated and non-biotinylated copolymer@Au NPs", "TREATMENT", 229, 283], ["the colloidal nanostructures avidin", "TREATMENT", 310, 345], ["a protein", "PROBLEM", 356, 365], ["biotin", "TREATMENT", 396, 402]]], ["BSA was used as a control because it is a protein that does not have affinity to biotin.", [["BSA", "CHEMICAL", 0, 3], ["biotin", "CHEMICAL", 81, 87], ["biotin", "CHEMICAL", 81, 87], ["BSA", "SIMPLE_CHEMICAL", 0, 3], ["biotin", "SIMPLE_CHEMICAL", 81, 87], ["BSA", "TEST", 0, 3], ["biotin", "TREATMENT", 81, 87]]], ["Furthermore, since the addition of protein solution slightly dilutes the colloids, the same volume of phosphate buffer saline (PBS, pH 7.4, 10 mM) was added to all the colloids.Biosensing ResponseFor comparison and as a control experiment, three Au colloids were tested: biotin-copolymer@Au NPs, the neat copolymer@Au NPs, and copolymer@Au NPs submitted to the conditions used in the click reaction (\"click control\").", [["phosphate", "CHEMICAL", 102, 111], ["Au", "CHEMICAL", 246, 248], ["biotin", "CHEMICAL", 271, 277], ["copolymer@Au", "CHEMICAL", 327, 339], ["phosphate", "CHEMICAL", 102, 111], ["Au", "CHEMICAL", 246, 248], ["biotin", "CHEMICAL", 271, 277], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 102, 125], ["Au colloids", "SIMPLE_CHEMICAL", 246, 257], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 271, 294], ["neat copolymer@Au NPs", "SIMPLE_CHEMICAL", 300, 321], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 327, 343], ["protein solution", "TREATMENT", 35, 51], ["the colloids", "TREATMENT", 69, 81], ["phosphate buffer saline", "TREATMENT", 102, 125], ["PBS", "TEST", 127, 130], ["pH", "TEST", 132, 134], ["three Au colloids", "TREATMENT", 240, 257], ["biotin-copolymer@Au NPs", "TREATMENT", 271, 294], ["the neat copolymer@Au NPs", "TREATMENT", 296, 321], ["copolymer@Au NPs", "TREATMENT", 327, 343], ["the click reaction", "PROBLEM", 380, 398]]], ["The latter were copolymer@Au NPs (without the azide moiety), which were submitted to the same reaction conditions used to carry out the click reaction (i.e., alkynated biotin, CuSO 4 and sodium ascorbate) and extensively rinsed, as described in the Experimental section to assess the efficiency of the click reaction.", [["copolymer@Au NPs", "CHEMICAL", 16, 32], ["azide", "CHEMICAL", 46, 51], ["alkynated biotin", "CHEMICAL", 158, 174], ["CuSO 4", "CHEMICAL", 176, 182], ["sodium ascorbate", "CHEMICAL", 187, 203], ["azide", "CHEMICAL", 46, 51], ["biotin", "CHEMICAL", 168, 174], ["CuSO 4", "CHEMICAL", 176, 182], ["sodium ascorbate", "CHEMICAL", 187, 203], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 16, 32], ["azide moiety", "SIMPLE_CHEMICAL", 46, 58], ["alkynated biotin", "SIMPLE_CHEMICAL", 158, 174], ["CuSO 4", "SIMPLE_CHEMICAL", 176, 182], ["sodium ascorbate", "SIMPLE_CHEMICAL", 187, 203], ["copolymer@Au NPs", "TREATMENT", 16, 32], ["the azide moiety", "TREATMENT", 42, 58], ["the click reaction", "PROBLEM", 132, 150], ["sodium ascorbate", "TREATMENT", 187, 203], ["the click reaction", "PROBLEM", 298, 316]]], ["Solutions of avidin and of BSA (0.5 mg/mL) in PBS were added to the Au nanostructures, and after 10 min, the samples were characterized by UV-Vis spectroscopy.", [["samples", "ANATOMY", 109, 116], ["BSA", "CHEMICAL", 27, 30], ["Au", "CHEMICAL", 68, 70], ["Au", "CHEMICAL", 68, 70], ["avidin", "GENE_OR_GENE_PRODUCT", 13, 19], ["BSA", "SIMPLE_CHEMICAL", 27, 30], ["PBS", "SIMPLE_CHEMICAL", 46, 49], ["Solutions of avidin", "TREATMENT", 0, 19], ["BSA", "TREATMENT", 27, 30], ["PBS", "TREATMENT", 46, 49], ["the samples", "TEST", 105, 116], ["Vis spectroscopy", "TEST", 142, 158]]], ["As a control of the dilution, PBS was also added to the three types of Au nanostructures.Biosensing ResponseIn Figure 6A the UV-Vis spectra are shown, and as it can be observed, a small decrease of the absorbance and a small shift in the \u03bb LSPR (\u2206\u03bb = + 1 nm) occurred, especially in the presence of avidin, which indicates the occurrence of specific interactions.", [["Au", "CHEMICAL", 71, 73], ["Au", "CHEMICAL", 71, 73], ["PBS", "SIMPLE_CHEMICAL", 30, 33], ["Au nanostructures", "SIMPLE_CHEMICAL", 71, 88], ["avidin", "GENE_OR_GENE_PRODUCT", 299, 305], ["avidin", "PROTEIN", 299, 305], ["the dilution", "TREATMENT", 16, 28], ["PBS", "TREATMENT", 30, 33], ["a small decrease of the absorbance", "PROBLEM", 178, 212], ["a small shift", "PROBLEM", 217, 230], ["the \u03bb LSPR", "TEST", 234, 244], ["small", "OBSERVATION_MODIFIER", 180, 185], ["decrease", "OBSERVATION_MODIFIER", 186, 194], ["absorbance", "OBSERVATION_MODIFIER", 202, 212], ["small", "OBSERVATION_MODIFIER", 219, 224], ["shift", "OBSERVATION_MODIFIER", 225, 230]]], ["Nevertheless, nonspecific interactions seem to have occurred as well with the control of BSA, which might be assigned to a variety of interactions (electrostatic, H bonding, van der Waals, etc.) occurring between the nanostructures and the proteins [35, 36] .", [["H", "CHEMICAL", 163, 164], ["BSA", "SIMPLE_CHEMICAL", 89, 92], ["nonspecific interactions", "PROBLEM", 14, 38]]], ["In fact, at this pH (approximately 6, see Table 2 ), BSA presents a negative surface charge (pI = 4.7), while avidin is positively charged (pI = 10); hence, it will show a stronger response in these conditions.", [["surface", "ANATOMY", 77, 84], ["BSA", "CHEMICAL", 53, 56], ["BSA", "SIMPLE_CHEMICAL", 53, 56], ["avidin", "GENE_OR_GENE_PRODUCT", 110, 116], ["avidin", "PROTEIN", 110, 116], ["BSA", "TEST", 53, 56], ["pI", "TEST", 93, 95], ["pI", "TEST", 140, 142]]], ["Figure 6B shows the visible spectra of the biotinylated nanostructures, which exhibit a strong decrease in the optical absorbance, the broadening, and the shift of the LSPR band (\u2206\u03bb = +7 nm), revealing aggregation of the nanostructures resulting from the strong interaction between avidin and the biotinylated nanostructure.", [["avidin", "GENE_OR_GENE_PRODUCT", 282, 288], ["avidin", "PROTEIN", 282, 288], ["Figure 6B", "TEST", 0, 9], ["the biotinylated nanostructures", "PROBLEM", 39, 70], ["a strong decrease in the optical absorbance", "PROBLEM", 86, 129], ["the LSPR band", "TEST", 164, 177], ["aggregation of the nanostructures", "PROBLEM", 202, 235], ["the strong interaction between avidin and the biotinylated nanostructure", "PROBLEM", 251, 323], ["biotinylated nanostructures", "OBSERVATION", 43, 70], ["strong", "OBSERVATION_MODIFIER", 88, 94], ["decrease", "OBSERVATION_MODIFIER", 95, 103], ["optical absorbance", "OBSERVATION", 111, 129], ["broadening", "OBSERVATION_MODIFIER", 135, 145], ["aggregation", "OBSERVATION", 202, 213], ["strong", "OBSERVATION_MODIFIER", 255, 261], ["interaction", "OBSERVATION", 262, 273], ["biotinylated nanostructure", "OBSERVATION", 297, 323]]], ["Surprisingly, the LSPR band of copolymer@Au NPs submitted to the \"click reaction\" (\"click control\" in Figure 6C ) showed similar behavior in the presence of avidin.", [["copolymer@Au NPs", "CHEMICAL", 31, 47], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 31, 47], ["avidin", "GENE_OR_GENE_PRODUCT", 157, 163], ["avidin", "PROTEIN", 157, 163], ["copolymer@Au NPs", "TREATMENT", 31, 47]]], ["This result was not expected for the nanostructures without azide moieties, because the colloid had been extensively washed to remove unreacted species.", [["azide", "CHEMICAL", 60, 65], ["azide", "CHEMICAL", 60, 65], ["azide moieties", "SIMPLE_CHEMICAL", 60, 74], ["colloid", "SIMPLE_CHEMICAL", 88, 95], ["azide moieties", "TREATMENT", 60, 74], ["the colloid", "PROBLEM", 84, 95], ["unreacted species", "PROBLEM", 134, 151], ["unreacted species", "OBSERVATION", 134, 151]]], ["This evidence indicates that alkynated biotin was not only covalently linked to the nanostructure by the specific click chemistry reaction with the azide but also adsorbed and/or was trapped in the polymer shell, contributing to the aggregation when in the presence of avidin.", [["biotin", "CHEMICAL", 39, 45], ["azide", "CHEMICAL", 148, 153], ["aggregation", "DISEASE", 233, 244], ["alkynated biotin", "CHEMICAL", 29, 45], ["azide", "CHEMICAL", 148, 153], ["alkynated", "SIMPLE_CHEMICAL", 29, 38], ["biotin", "SIMPLE_CHEMICAL", 39, 45], ["azide", "SIMPLE_CHEMICAL", 148, 153], ["avidin", "GENE_OR_GENE_PRODUCT", 269, 275], ["avidin", "PROTEIN", 269, 275], ["alkynated biotin", "PROBLEM", 29, 45], ["the specific click chemistry reaction", "PROBLEM", 101, 138], ["the azide", "TREATMENT", 144, 153], ["the aggregation", "PROBLEM", 229, 244]]], ["Therefore, intensive washing steps (precipitation/redispersion cycles) by centrifugation were performed in this colloid and, despite that, it still specifically aggregates in the presence of avidin (data not shown).Biosensing ResponsePolymers 2020, 12, 1442 12 of 18 (pI = 4.7), while avidin is positively charged (pI = 10); hence, it will show a stronger response in these conditions.", [["avidin", "GENE_OR_GENE_PRODUCT", 191, 197], ["avidin", "GENE_OR_GENE_PRODUCT", 285, 291], ["avidin", "PROTEIN", 191, 197], ["intensive washing steps", "TREATMENT", 11, 34], ["precipitation/redispersion cycles", "TREATMENT", 36, 69], ["Biosensing ResponsePolymers", "TEST", 215, 242], ["pI", "TEST", 268, 270], ["pI", "TEST", 315, 317]]], ["Figure 6B shows the visible spectra of the biotinylated nanostructures, which exhibit a strong decrease in the optical absorbance, the broadening, and the shift of the LSPR band (\u0394\u03bb = + 7 nm), revealing aggregation of the nanostructures resulting from the strong interaction between avidin and the biotinylated nanostructure.", [["avidin", "GENE_OR_GENE_PRODUCT", 283, 289], ["avidin", "PROTEIN", 283, 289], ["Figure 6B", "TEST", 0, 9], ["the biotinylated nanostructures", "PROBLEM", 39, 70], ["a strong decrease in the optical absorbance", "PROBLEM", 86, 129], ["the LSPR band", "TEST", 164, 177], ["aggregation of the nanostructures", "PROBLEM", 203, 236], ["the strong interaction between avidin and the biotinylated nanostructure", "PROBLEM", 252, 324], ["biotinylated nanostructures", "OBSERVATION", 43, 70], ["strong", "OBSERVATION_MODIFIER", 88, 94], ["decrease", "OBSERVATION_MODIFIER", 95, 103], ["optical absorbance", "OBSERVATION", 111, 129], ["broadening", "OBSERVATION_MODIFIER", 135, 145], ["aggregation", "OBSERVATION", 203, 214], ["strong", "OBSERVATION_MODIFIER", 256, 262], ["interaction", "OBSERVATION", 263, 274], ["biotinylated nanostructure", "OBSERVATION", 298, 324]]], ["Surprisingly, the LSPR band of copolymer@Au NPs submitted to the \"click reaction\" (\"click control\" in Figure 6C ) showed similar behavior in the presence of avidin.", [["copolymer@Au NPs", "CHEMICAL", 31, 47], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 31, 47], ["avidin", "GENE_OR_GENE_PRODUCT", 157, 163], ["avidin", "PROTEIN", 157, 163], ["copolymer@Au NPs", "TREATMENT", 31, 47]]], ["This result was not expected for the nanostructures without azide moieties, because the colloid had been extensively washed to remove unreacted species.", [["azide", "CHEMICAL", 60, 65], ["azide", "CHEMICAL", 60, 65], ["azide moieties", "SIMPLE_CHEMICAL", 60, 74], ["colloid", "SIMPLE_CHEMICAL", 88, 95], ["azide moieties", "TREATMENT", 60, 74], ["the colloid", "PROBLEM", 84, 95], ["unreacted species", "PROBLEM", 134, 151], ["unreacted species", "OBSERVATION", 134, 151]]], ["This evidence indicates that alkynated biotin was not only covalently linked to the nanostructure by the specific click chemistry reaction with the azide but also adsorbed and/or was trapped in the polymer shell, contributing to the aggregation when in the presence of avidin.", [["biotin", "CHEMICAL", 39, 45], ["azide", "CHEMICAL", 148, 153], ["aggregation", "DISEASE", 233, 244], ["alkynated biotin", "CHEMICAL", 29, 45], ["azide", "CHEMICAL", 148, 153], ["alkynated", "SIMPLE_CHEMICAL", 29, 38], ["biotin", "SIMPLE_CHEMICAL", 39, 45], ["azide", "SIMPLE_CHEMICAL", 148, 153], ["avidin", "GENE_OR_GENE_PRODUCT", 269, 275], ["avidin", "PROTEIN", 269, 275], ["alkynated biotin", "PROBLEM", 29, 45], ["the specific click chemistry reaction", "PROBLEM", 101, 138], ["the azide", "TREATMENT", 144, 153], ["the aggregation", "PROBLEM", 229, 244]]], ["Therefore, intensive washing steps (precipitation/redispersion cycles) by centrifugation were performed in this colloid and, despite that, it still specifically aggregates in the presence of avidin (data not shown).", [["avidin", "GENE_OR_GENE_PRODUCT", 191, 197], ["avidin", "PROTEIN", 191, 197], ["intensive washing steps", "TREATMENT", 11, 34], ["precipitation/redispersion cycles", "TREATMENT", 36, 69]]], ["In a second experiment, BSA was mixed with the nanostructures for 30 min before adding avidin to evaluate the possibility of minimizing nonspecific interactions, [37] .", [["BSA", "CHEMICAL", 24, 27], ["BSA", "SIMPLE_CHEMICAL", 24, 27], ["avidin", "GENE_OR_GENE_PRODUCT", 87, 93], ["avidin", "TREATMENT", 87, 93], ["minimizing nonspecific interactions", "PROBLEM", 125, 160]]], ["After 10 min in contact with avidin, the optical properties of the Au nanostructures were evaluated by visible spectroscopy (Figure 7) .", [["Au", "CHEMICAL", 67, 69], ["Au", "CHEMICAL", 67, 69], ["avidin", "GENE_OR_GENE_PRODUCT", 29, 35], ["Au nanostructures", "SIMPLE_CHEMICAL", 67, 84], ["avidin", "TREATMENT", 29, 35], ["the Au nanostructures", "TREATMENT", 63, 84], ["visible spectroscopy", "TEST", 103, 123]]], ["The use of a higher amount of BSA (60 \u00b5L) did not change the LSPR band, as compared with the 10 \u00b5L tested in the first experiment.", [["BSA", "CHEMICAL", 30, 33], ["BSA", "SIMPLE_CHEMICAL", 30, 33], ["a higher amount of BSA", "TREATMENT", 11, 33], ["LSPR band", "OBSERVATION", 61, 70]]], ["Interestingly, the visible spectra of these nanostructures in contact with BSA and then with avidin showed that there was no broadening of the LSPR band, unlike the visible spectra in Figure 6 , suggesting a different aggregation profile.", [["BSA", "SIMPLE_CHEMICAL", 75, 78], ["avidin", "GENE_OR_GENE_PRODUCT", 93, 99], ["avidin", "PROTEIN", 93, 99], ["avidin", "TREATMENT", 93, 99], ["broadening of the LSPR band", "PROBLEM", 125, 152], ["a different aggregation profile", "PROBLEM", 206, 237], ["nanostructures", "OBSERVATION_MODIFIER", 44, 58], ["no", "UNCERTAINTY", 122, 124], ["broadening", "OBSERVATION_MODIFIER", 125, 135], ["LSPR band", "OBSERVATION", 143, 152], ["different", "OBSERVATION_MODIFIER", 208, 217], ["aggregation profile", "OBSERVATION", 218, 237]]], ["In other words, BSA interacted with the Au nanostructures via nonspecific interactions without inducing aggregation and stayed at the surface of the nanostructures.", [["surface", "ANATOMY", 134, 141], ["Au", "CHEMICAL", 40, 42], ["Au", "CHEMICAL", 40, 42], ["BSA", "SIMPLE_CHEMICAL", 16, 19], ["surface", "CELLULAR_COMPONENT", 134, 141], ["the Au nanostructures", "TREATMENT", 36, 57], ["nonspecific interactions", "PROBLEM", 62, 86], ["inducing aggregation", "PROBLEM", 95, 115]]], ["Hence, when avidin was added, aggregation was induced due to the specific interaction with biotin.", [["biotin", "CHEMICAL", 91, 97], ["biotin", "CHEMICAL", 91, 97], ["avidin", "GENE_OR_GENE_PRODUCT", 12, 18], ["biotin", "SIMPLE_CHEMICAL", 91, 97], ["avidin", "TREATMENT", 12, 18], ["biotin", "TREATMENT", 91, 97]]], ["However, due to the presence of BSA (dimensions: 4 \u00d7 4 \u00d7 14 nm 3 [38] ) at the surface of the nanostructures, the gold cores in the aggregates were more apart from each other, so the \u03bbLSPR did not shift neither suffered a broadening, as was observed in the colloids without BSA; even so, some aggregation occurred.", [["surface", "ANATOMY", 79, 86], ["aggregation", "DISEASE", 293, 304], ["BSA", "SIMPLE_CHEMICAL", 32, 35], ["surface", "CELLULAR_COMPONENT", 79, 86], ["BSA", "SIMPLE_CHEMICAL", 274, 277], ["some aggregation", "PROBLEM", 288, 304], ["nanostructures", "OBSERVATION_MODIFIER", 94, 108], ["gold", "OBSERVATION_MODIFIER", 114, 118], ["cores", "OBSERVATION_MODIFIER", 119, 124], ["aggregation", "OBSERVATION", 293, 304]]], ["In a second experiment, BSA was mixed with the nanostructures for 30 min before adding avidin to evaluate the possibility of minimizing nonspecific interactions, [37] .", [["BSA", "CHEMICAL", 24, 27], ["BSA", "SIMPLE_CHEMICAL", 24, 27], ["avidin", "GENE_OR_GENE_PRODUCT", 87, 93], ["avidin", "TREATMENT", 87, 93], ["minimizing nonspecific interactions", "PROBLEM", 125, 160]]], ["After 10 min in contact with avidin, the optical properties of the Au nanostructures were evaluated by visible spectroscopy (Figure 7) .", [["Au", "CHEMICAL", 67, 69], ["Au", "CHEMICAL", 67, 69], ["avidin", "GENE_OR_GENE_PRODUCT", 29, 35], ["Au nanostructures", "SIMPLE_CHEMICAL", 67, 84], ["avidin", "TREATMENT", 29, 35], ["the Au nanostructures", "TREATMENT", 63, 84], ["visible spectroscopy", "TEST", 103, 123]]], ["The use of a higher amount of BSA (60 \u00b5L) did not change the LSPR band, as compared with the 10 \u00b5L tested in the first experiment.", [["BSA", "CHEMICAL", 30, 33], ["BSA", "SIMPLE_CHEMICAL", 30, 33], ["a higher amount of BSA", "TREATMENT", 11, 33], ["LSPR band", "OBSERVATION", 61, 70]]], ["Interestingly, the visible spectra of these nanostructures in contact with BSA and then with avidin showed that there was no broadening of the LSPR band, unlike the visible spectra in Figure 6 , suggesting a different aggregation profile.", [["BSA", "SIMPLE_CHEMICAL", 75, 78], ["avidin", "GENE_OR_GENE_PRODUCT", 93, 99], ["avidin", "PROTEIN", 93, 99], ["avidin", "TREATMENT", 93, 99], ["broadening of the LSPR band", "PROBLEM", 125, 152], ["a different aggregation profile", "PROBLEM", 206, 237], ["nanostructures", "OBSERVATION_MODIFIER", 44, 58], ["no", "UNCERTAINTY", 122, 124], ["broadening", "OBSERVATION_MODIFIER", 125, 135], ["LSPR band", "OBSERVATION", 143, 152], ["different", "OBSERVATION_MODIFIER", 208, 217], ["aggregation profile", "OBSERVATION", 218, 237]]], ["In other words, BSA interacted with the Au nanostructures via nonspecific interactions without inducing aggregation and stayed at the surface of the nanostructures.", [["surface", "ANATOMY", 134, 141], ["Au", "CHEMICAL", 40, 42], ["Au", "CHEMICAL", 40, 42], ["BSA", "SIMPLE_CHEMICAL", 16, 19], ["surface", "CELLULAR_COMPONENT", 134, 141], ["the Au nanostructures", "TREATMENT", 36, 57], ["nonspecific interactions", "PROBLEM", 62, 86], ["inducing aggregation", "PROBLEM", 95, 115]]], ["Hence, when avidin was added, aggregation was induced due to the specific interaction with biotin.", [["biotin", "CHEMICAL", 91, 97], ["biotin", "CHEMICAL", 91, 97], ["avidin", "GENE_OR_GENE_PRODUCT", 12, 18], ["biotin", "SIMPLE_CHEMICAL", 91, 97], ["avidin", "TREATMENT", 12, 18], ["biotin", "TREATMENT", 91, 97]]], ["However, due to the presence of BSA (dimensions: 4 \u00d7 4 \u00d7 14 nm 3 [38] ) at the surface of the nanostructures, the gold cores in the aggregates were more apart from each other, so the \u03bb LSPR did not shift neither suffered a broadening, as was observed in the colloids without BSA; even so, some aggregation occurred.Langmuir-Blodgett Studies at the Air/Water InterfaceThe adsorption and/or trapping of biotin by the polymer shell was not expected as discussed before.", [["surface", "ANATOMY", 79, 86], ["aggregation", "DISEASE", 294, 305], ["biotin", "CHEMICAL", 401, 407], ["biotin", "CHEMICAL", 401, 407], ["BSA", "SIMPLE_CHEMICAL", 32, 35], ["surface", "CELLULAR_COMPONENT", 79, 86], ["BSA", "SIMPLE_CHEMICAL", 275, 278], ["biotin", "SIMPLE_CHEMICAL", 401, 407], ["some aggregation", "PROBLEM", 289, 305], ["Langmuir", "TEST", 315, 323], ["The adsorption and/or trapping of biotin by the polymer shell", "TREATMENT", 367, 428], ["nanostructures", "OBSERVATION_MODIFIER", 94, 108], ["gold", "OBSERVATION_MODIFIER", 114, 118], ["cores", "OBSERVATION_MODIFIER", 119, 124], ["aggregation", "OBSERVATION", 294, 305]]], ["Hence, considering that Langmuir monolayers have been very successfully used to unravel interactions of biomolecules as well as nanoparticles with monolayers at air/water interface, including the kinetics of such interactions [39] , this approach was also followed here.", [["monolayers", "CELL", 147, 157], ["Langmuir monolayers", "CELL_LINE", 24, 43], ["Langmuir monolayers", "TREATMENT", 24, 43], ["nanoparticles with monolayers at air/water interface", "TREATMENT", 128, 180]]], ["In particular, these studies were carried out to better understand the copolymer-biotin-avidin interactions, namely in what regards the interaction between biotin adsorption and the trapping of biotin by the polymer shell as well as the kinetics of botin/avidin interaction.", [["biotin", "CHEMICAL", 156, 162], ["biotin", "CHEMICAL", 194, 200], ["botin", "CHEMICAL", 249, 254], ["biotin", "CHEMICAL", 81, 87], ["biotin", "CHEMICAL", 156, 162], ["biotin", "CHEMICAL", 194, 200], ["botin", "CHEMICAL", 249, 254], ["biotin", "SIMPLE_CHEMICAL", 81, 87], ["avidin", "SIMPLE_CHEMICAL", 88, 94], ["biotin", "SIMPLE_CHEMICAL", 156, 162], ["biotin", "SIMPLE_CHEMICAL", 194, 200], ["botin", "SIMPLE_CHEMICAL", 249, 254], ["avidin", "GENE_OR_GENE_PRODUCT", 255, 261], ["avidin", "PROTEIN", 255, 261], ["these studies", "TEST", 15, 28], ["the copolymer-biotin-avidin interactions", "TREATMENT", 67, 107], ["biotin adsorption", "TREATMENT", 156, 173], ["the trapping of biotin by the polymer shell", "TREATMENT", 178, 221]]], ["For this particular study, biotin (without alkyne function) was mixed with the copolymer (without the azide moiety) before spreading it on the water surface.", [["biotin", "CHEMICAL", 27, 33], ["azide", "CHEMICAL", 102, 107], ["biotin", "CHEMICAL", 27, 33], ["alkyne", "CHEMICAL", 43, 49], ["azide", "CHEMICAL", 102, 107], ["biotin", "SIMPLE_CHEMICAL", 27, 33], ["alkyne", "SIMPLE_CHEMICAL", 43, 49], ["azide moiety", "SIMPLE_CHEMICAL", 102, 114], ["this particular study", "TEST", 4, 25], ["biotin", "TREATMENT", 27, 33], ["the copolymer", "TREATMENT", 75, 88], ["the azide moiety", "TREATMENT", 98, 114]]], ["As the monolayer of the copolymer prepared at 44 \u00b0C afforded an unstable monolayer at the air/water interface due to its low molar mass (DPMMA:BA = 56), the copolymer prepared at 70 \u00b0C (DPMMA:BA = 168) was used.Langmuir-Blodgett Studies at the Air/Water InterfaceThe copolymer solution or copolymer solution containing biotin was spread on the water surface and later on the surface of an aqueous solution of avidin (0.5 mg/L).", [["monolayer", "ANATOMY", 7, 16], ["monolayer", "ANATOMY", 73, 82], ["surface", "ANATOMY", 350, 357], ["surface", "ANATOMY", 375, 382], ["DPMMA", "CHEMICAL", 186, 191], ["BA", "CHEMICAL", 192, 194], ["biotin", "CHEMICAL", 319, 325], ["biotin", "CHEMICAL", 319, 325], ["monolayer", "CELL", 7, 16], ["monolayer", "CELL", 73, 82], ["biotin", "SIMPLE_CHEMICAL", 319, 325], ["avidin", "SIMPLE_CHEMICAL", 409, 415], ["the copolymer", "TREATMENT", 20, 33], ["an unstable monolayer", "PROBLEM", 61, 82], ["its low molar mass", "PROBLEM", 117, 135], ["BA", "TEST", 143, 145], ["the copolymer", "TEST", 153, 166], ["Langmuir", "TEST", 211, 219], ["The copolymer solution or copolymer solution containing biotin", "TREATMENT", 263, 325], ["the water surface", "TREATMENT", 340, 357], ["an aqueous solution of avidin", "TREATMENT", 386, 415], ["unstable monolayer", "OBSERVATION", 64, 82], ["low molar", "OBSERVATION_MODIFIER", 121, 130], ["mass", "OBSERVATION", 131, 135]]], ["Upon solvent evaporation, the Langmuir monolayers were prepared by compressing the barriers.", [["Langmuir monolayers", "CELL_LINE", 30, 49], ["solvent evaporation", "TREATMENT", 5, 24], ["the Langmuir monolayers", "TREATMENT", 26, 49]]], ["In a preliminary study, the Langmuir surface pressure-area isotherm ( Figure S8 in Supporting Information) of the copolymer mixed with biotin showed a similar isotherm profile to that obtained for the neat copolymer.", [["surface", "ANATOMY", 37, 44], ["biotin", "CHEMICAL", 135, 141], ["biotin", "CHEMICAL", 135, 141], ["biotin", "SIMPLE_CHEMICAL", 135, 141], ["a preliminary study", "TEST", 3, 22], ["the Langmuir surface pressure", "TEST", 24, 53], ["the copolymer mixed with biotin", "TREATMENT", 110, 141], ["the neat copolymer", "TREATMENT", 197, 215]]], ["However, the liquid-condensed phase was formed at higher mean molecular areas, i.e., 1753 \u00c5 2 , instead of 1670 \u00c5 2 for the neat copolymer.", [["the neat copolymer", "TREATMENT", 120, 138], ["condensed phase", "OBSERVATION_MODIFIER", 20, 35]]], ["This result suggests that biotin was at the air/water interface and not just interacting with the hydrophilic PEGA chains, thus occupying space between the copolymer chains and shifting the liquid-condensed phase formation to a higher mean molecular area.", [["biotin", "CHEMICAL", 26, 32], ["biotin", "CHEMICAL", 26, 32], ["PEGA", "CHEMICAL", 110, 114], ["biotin", "SIMPLE_CHEMICAL", 26, 32], ["hydrophilic PEGA chains", "PROTEIN", 98, 121], ["biotin", "TREATMENT", 26, 32], ["the hydrophilic PEGA chains", "TREATMENT", 94, 121], ["the copolymer chains", "TREATMENT", 152, 172], ["shifting the liquid-condensed phase formation", "TREATMENT", 177, 222], ["biotin", "OBSERVATION", 26, 32], ["water interface", "OBSERVATION", 48, 63], ["hydrophilic", "ANATOMY_MODIFIER", 98, 109], ["PEGA chains", "ANATOMY", 110, 121], ["copolymer chains", "OBSERVATION", 156, 172], ["liquid", "OBSERVATION_MODIFIER", 190, 196], ["condensed phase", "OBSERVATION_MODIFIER", 197, 212], ["higher", "OBSERVATION_MODIFIER", 228, 234]]], ["No significant changes have been observed using an avidin solution instead of ultrapure water as the subphase.", [["avidin", "GENE_OR_GENE_PRODUCT", 51, 57], ["significant changes", "PROBLEM", 3, 22], ["an avidin solution", "TREATMENT", 48, 66], ["ultrapure water", "TREATMENT", 78, 93], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["changes", "OBSERVATION", 15, 22]]], ["This could indicate that the biotin was not available to interact with avidin, i.e., avidin did not migrate to the air/water interface to interact with biotin, nor did biotin migrate to the subphase to interact with avidin.", [["biotin", "CHEMICAL", 29, 35], ["biotin", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 168, 174], ["biotin", "CHEMICAL", 29, 35], ["biotin", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 168, 174], ["biotin", "SIMPLE_CHEMICAL", 29, 35], ["avidin", "GENE_OR_GENE_PRODUCT", 71, 77], ["avidin", "GENE_OR_GENE_PRODUCT", 85, 91], ["biotin", "SIMPLE_CHEMICAL", 152, 158], ["biotin", "SIMPLE_CHEMICAL", 168, 174], ["avidin", "GENE_OR_GENE_PRODUCT", 216, 222], ["avidin", "PROTEIN", 71, 77], ["avidin", "PROTEIN", 85, 91], ["avidin", "PROTEIN", 216, 222], ["the biotin", "PROBLEM", 25, 35], ["avidin", "TREATMENT", 71, 77], ["biotin", "TREATMENT", 152, 158], ["biotin", "TREATMENT", 168, 174], ["avidin", "TREATMENT", 216, 222]]], ["Assuming that time could be a parameter to be taken into consideration, the effect of contact time between the monolayer and the bioanalyte was evaluated.", [["monolayer", "ANATOMY", 111, 120], ["monolayer", "CELL", 111, 120], ["bioanalyte", "SIMPLE_CHEMICAL", 129, 139]]], ["After spreading the Langmuir monolayers and waiting for 15 min to allow solvent evaporation, additional contact times of 20 min, 1 h, 2 h, and 3 h were tested prior to compression of the monolayer.", [["monolayer", "ANATOMY", 187, 196], ["monolayer", "CELL", 187, 196], ["Langmuir monolayers", "CELL_LINE", 20, 39], ["the Langmuir monolayers", "TREATMENT", 16, 39], ["solvent evaporation", "TREATMENT", 72, 91]]], ["The surface pressure versus area obtained for the different contact times considered are shown in Figure 8 .Langmuir-Blodgett Studies at the Air/Water InterfaceThe adsorption and/or trapping of biotin by the polymer shell was not expected as discussed before.", [["surface", "ANATOMY", 4, 11], ["biotin", "CHEMICAL", 194, 200], ["biotin", "CHEMICAL", 194, 200], ["biotin", "SIMPLE_CHEMICAL", 194, 200], ["The surface pressure versus area", "TREATMENT", 0, 32], ["Langmuir", "TEST", 108, 116], ["Blodgett Studies", "TEST", 117, 133], ["the Air/Water Interface", "TREATMENT", 137, 160], ["The adsorption and/or trapping of biotin by the polymer shell", "TREATMENT", 160, 221], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["pressure", "OBSERVATION_MODIFIER", 12, 20]]], ["Hence, considering that Langmuir monolayers have been very successfully used to unravel interactions of biomolecules as well as nanoparticles with monolayers at air/water interface, including the kinetics of such interactions [39] , this approach was also followed here.", [["monolayers", "CELL", 147, 157], ["Langmuir monolayers", "CELL_LINE", 24, 43], ["Langmuir monolayers", "TREATMENT", 24, 43], ["nanoparticles with monolayers at air/water interface", "TREATMENT", 128, 180]]], ["In particular, these studies were carried out to better understand the copolymer-biotin-avidin interactions, namely in what regards the interaction between biotin adsorption and the trapping of biotin by the polymer shell as well as the kinetics of botin/avidin interaction.", [["biotin", "CHEMICAL", 156, 162], ["biotin", "CHEMICAL", 194, 200], ["botin", "CHEMICAL", 249, 254], ["biotin", "CHEMICAL", 81, 87], ["biotin", "CHEMICAL", 156, 162], ["biotin", "CHEMICAL", 194, 200], ["botin", "CHEMICAL", 249, 254], ["biotin", "SIMPLE_CHEMICAL", 81, 87], ["avidin", "SIMPLE_CHEMICAL", 88, 94], ["biotin", "SIMPLE_CHEMICAL", 156, 162], ["biotin", "SIMPLE_CHEMICAL", 194, 200], ["botin", "SIMPLE_CHEMICAL", 249, 254], ["avidin", "GENE_OR_GENE_PRODUCT", 255, 261], ["avidin", "PROTEIN", 255, 261], ["these studies", "TEST", 15, 28], ["the copolymer-biotin-avidin interactions", "TREATMENT", 67, 107], ["biotin adsorption", "TREATMENT", 156, 173], ["the trapping of biotin by the polymer shell", "TREATMENT", 178, 221]]], ["For this particular study, biotin (without alkyne function) was mixed with the copolymer (without the azide moiety) before spreading it on the water surface.", [["biotin", "CHEMICAL", 27, 33], ["azide", "CHEMICAL", 102, 107], ["biotin", "CHEMICAL", 27, 33], ["alkyne", "CHEMICAL", 43, 49], ["azide", "CHEMICAL", 102, 107], ["biotin", "SIMPLE_CHEMICAL", 27, 33], ["alkyne", "SIMPLE_CHEMICAL", 43, 49], ["azide moiety", "SIMPLE_CHEMICAL", 102, 114], ["this particular study", "TEST", 4, 25], ["biotin", "TREATMENT", 27, 33], ["the copolymer", "TREATMENT", 75, 88], ["the azide moiety", "TREATMENT", 98, 114]]], ["As the monolayer of the copolymer prepared at 44 \u2022 C afforded an unstable monolayer at the air/water interface due to its low molar mass (DP MMA:BA = 56), the copolymer prepared at 70 \u2022 C (DP MMA:BA = 168) was used.Langmuir-Blodgett Studies at the Air/Water InterfaceThe copolymer solution or copolymer solution containing biotin was spread on the water surface and later on the surface of an aqueous solution of avidin (0.5 mg/L).", [["monolayer", "ANATOMY", 7, 16], ["monolayer", "ANATOMY", 74, 83], ["surface", "ANATOMY", 354, 361], ["surface", "ANATOMY", 379, 386], ["MMA", "CHEMICAL", 141, 144], ["DP MMA", "CHEMICAL", 189, 195], ["biotin", "CHEMICAL", 323, 329], ["biotin", "CHEMICAL", 323, 329], ["monolayer", "CELL", 7, 16], ["monolayer", "CELL", 74, 83], ["DP MMA", "SIMPLE_CHEMICAL", 189, 195], ["biotin", "SIMPLE_CHEMICAL", 323, 329], ["avidin", "SIMPLE_CHEMICAL", 413, 419], ["the copolymer", "TREATMENT", 20, 33], ["an unstable monolayer at the air/water interface", "TREATMENT", 62, 110], ["its low molar mass", "PROBLEM", 118, 136], ["BA", "TEST", 145, 147], ["the copolymer", "TEST", 155, 168], ["BA", "TEST", 196, 198], ["Langmuir", "TEST", 215, 223], ["The copolymer solution or copolymer solution containing biotin", "TREATMENT", 267, 329], ["the water surface", "TREATMENT", 344, 361], ["an aqueous solution of avidin", "TREATMENT", 390, 419], ["unstable monolayer", "OBSERVATION_MODIFIER", 65, 83], ["low molar", "OBSERVATION_MODIFIER", 122, 131], ["mass", "OBSERVATION", 132, 136]]], ["Upon solvent evaporation, the Langmuir monolayers were prepared by compressing the barriers.", [["Langmuir monolayers", "CELL_LINE", 30, 49], ["solvent evaporation", "TREATMENT", 5, 24], ["the Langmuir monolayers", "TREATMENT", 26, 49]]], ["In a preliminary study, the Langmuir surface pressure-area isotherm ( Figure S8 in Supporting Information) of the copolymer mixed with biotin showed a similar isotherm profile to that obtained for the neat copolymer.", [["surface", "ANATOMY", 37, 44], ["biotin", "CHEMICAL", 135, 141], ["biotin", "CHEMICAL", 135, 141], ["biotin", "SIMPLE_CHEMICAL", 135, 141], ["a preliminary study", "TEST", 3, 22], ["the Langmuir surface pressure", "TEST", 24, 53], ["the copolymer mixed with biotin", "TREATMENT", 110, 141], ["the neat copolymer", "TREATMENT", 197, 215]]], ["However, the liquid-condensed phase was formed at higher mean molecular areas, i.e., 1753 \u00c5 2 , instead of 1670 \u00c5 2 for the neat copolymer.", [["the neat copolymer", "TREATMENT", 120, 138], ["condensed phase", "OBSERVATION_MODIFIER", 20, 35]]], ["This result suggests that biotin was at the air/water interface and not just interacting with the hydrophilic PEGA chains, thus occupying space between the copolymer chains and shifting the liquid-condensed phase formation to a higher mean molecular area.", [["biotin", "CHEMICAL", 26, 32], ["biotin", "CHEMICAL", 26, 32], ["PEGA", "CHEMICAL", 110, 114], ["biotin", "SIMPLE_CHEMICAL", 26, 32], ["hydrophilic PEGA chains", "PROTEIN", 98, 121], ["biotin", "TREATMENT", 26, 32], ["the hydrophilic PEGA chains", "TREATMENT", 94, 121], ["the copolymer chains", "TREATMENT", 152, 172], ["shifting the liquid-condensed phase formation", "TREATMENT", 177, 222], ["biotin", "OBSERVATION", 26, 32], ["water interface", "OBSERVATION", 48, 63], ["hydrophilic", "ANATOMY_MODIFIER", 98, 109], ["PEGA chains", "ANATOMY", 110, 121], ["copolymer chains", "OBSERVATION", 156, 172], ["liquid", "OBSERVATION_MODIFIER", 190, 196], ["condensed phase", "OBSERVATION_MODIFIER", 197, 212], ["higher", "OBSERVATION_MODIFIER", 228, 234]]], ["No significant changes have been observed using an avidin solution instead of ultrapure water as the subphase.", [["avidin", "GENE_OR_GENE_PRODUCT", 51, 57], ["significant changes", "PROBLEM", 3, 22], ["an avidin solution", "TREATMENT", 48, 66], ["ultrapure water", "TREATMENT", 78, 93], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["changes", "OBSERVATION", 15, 22]]], ["This could indicate that the biotin was not available to interact with avidin, i.e., avidin did not migrate to the air/water interface to interact with biotin, nor did biotin migrate to the subphase to interact with avidin.", [["biotin", "CHEMICAL", 29, 35], ["biotin", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 168, 174], ["biotin", "CHEMICAL", 29, 35], ["biotin", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 168, 174], ["biotin", "SIMPLE_CHEMICAL", 29, 35], ["avidin", "GENE_OR_GENE_PRODUCT", 71, 77], ["avidin", "GENE_OR_GENE_PRODUCT", 85, 91], ["biotin", "SIMPLE_CHEMICAL", 152, 158], ["biotin", "SIMPLE_CHEMICAL", 168, 174], ["avidin", "GENE_OR_GENE_PRODUCT", 216, 222], ["avidin", "PROTEIN", 71, 77], ["avidin", "PROTEIN", 85, 91], ["avidin", "PROTEIN", 216, 222], ["the biotin", "PROBLEM", 25, 35], ["avidin", "TREATMENT", 71, 77], ["biotin", "TREATMENT", 152, 158], ["biotin", "TREATMENT", 168, 174], ["avidin", "TREATMENT", 216, 222]]], ["Assuming that time could be a parameter to be taken into consideration, the effect of contact time between the monolayer and the bioanalyte was evaluated.", [["monolayer", "ANATOMY", 111, 120], ["monolayer", "CELL", 111, 120], ["bioanalyte", "SIMPLE_CHEMICAL", 129, 139]]], ["After spreading the Langmuir monolayers and waiting for 15 min to allow solvent evaporation, additional contact times of 20 min, 1 h, 2 h, and 3 h were tested prior to compression of the monolayer.", [["monolayer", "ANATOMY", 187, 196], ["monolayer", "CELL", 187, 196], ["Langmuir monolayers", "CELL_LINE", 20, 39], ["the Langmuir monolayers", "TREATMENT", 16, 39], ["solvent evaporation", "TREATMENT", 72, 91]]], ["The surface pressure versus area obtained for the different contact times considered are shown in Figure 8 .Langmuir-Blodgett Studies at the Air/Water InterfaceAlthough only a small difference can be observed after 20 min of contact between the monolayer and the subphase, upon 1 h, the isotherms showed a distinct profile, indicating that avidin was adsorbed onto the monolayer causing its expansion, especially when the monolayer was compressed to values smaller than 3000 \u00c5 2 where a transition from expanded to condensed liquid took place.", [["surface", "ANATOMY", 4, 11], ["monolayer", "ANATOMY", 369, 378], ["monolayer", "ANATOMY", 422, 431], ["monolayer", "CELL", 245, 254], ["avidin", "GENE_OR_GENE_PRODUCT", 340, 346], ["monolayer", "CELL", 369, 378], ["monolayer", "CELL", 422, 431], ["The surface pressure versus area", "TREATMENT", 0, 32], ["Langmuir", "TEST", 108, 116], ["a small difference", "PROBLEM", 174, 192], ["the isotherms", "TEST", 283, 296], ["avidin", "PROBLEM", 340, 346], ["its expansion", "PROBLEM", 387, 400], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["small", "OBSERVATION_MODIFIER", 176, 181], ["expansion", "OBSERVATION_MODIFIER", 391, 400], ["condensed liquid", "OBSERVATION", 515, 531]]], ["These results indicate that this interaction is in fact time-dependent and is in agreement with what was observed in the colloids where biotin was not covalently bonded to the polymer shell.", [["biotin", "CHEMICAL", 136, 142], ["biotin", "CHEMICAL", 136, 142], ["biotin", "SIMPLE_CHEMICAL", 136, 142], ["biotin", "TREATMENT", 136, 142]]], ["Although only a small difference can be observed after 20 min of contact between the monolayer and the subphase, upon 1 h, the isotherms showed a distinct profile, indicating that avidin was adsorbed onto the monolayer causing its expansion, especially when the monolayer was compressed to values smaller than 3000 \u00c5 2 where a transition from expanded to condensed liquid took place.", [["monolayer", "ANATOMY", 85, 94], ["monolayer", "ANATOMY", 209, 218], ["monolayer", "ANATOMY", 262, 271], ["monolayer", "CELL", 85, 94], ["avidin", "GENE_OR_GENE_PRODUCT", 180, 186], ["monolayer", "CELL", 209, 218], ["monolayer", "CELL", 262, 271], ["a small difference", "PROBLEM", 14, 32], ["the isotherms", "TEST", 123, 136], ["avidin", "PROBLEM", 180, 186], ["its expansion", "PROBLEM", 227, 240], ["small", "OBSERVATION_MODIFIER", 16, 21], ["difference", "OBSERVATION", 22, 32], ["expansion", "OBSERVATION_MODIFIER", 231, 240], ["condensed liquid", "OBSERVATION", 355, 371]]], ["These results indicate that this interaction is in fact time-dependent and is in agreement with what was observed in the colloids where biotin was not covalently bonded to the polymer shell.Langmuir-Blodgett Studies at the Air/Water InterfaceAs a final remark, it should be stressed that even though the biofunctionalization of copolymer@Au nanostructures via click chemistry is interesting for a variety of (bio)receptors in the specific case of biotin-avidin conjugate, the low solubility of biotin in water also revealed drawbacks.", [["biotin", "CHEMICAL", 136, 142], ["biotin-avidin", "CHEMICAL", 447, 460], ["biotin", "CHEMICAL", 494, 500], ["biotin", "CHEMICAL", 136, 142], ["biotin", "CHEMICAL", 447, 453], ["biotin", "CHEMICAL", 494, 500], ["biotin", "SIMPLE_CHEMICAL", 136, 142], ["copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 328, 355], ["biotin-avidin conjugate", "SIMPLE_CHEMICAL", 447, 470], ["biotin", "SIMPLE_CHEMICAL", 494, 500], ["water", "SIMPLE_CHEMICAL", 504, 509], ["(bio)receptors", "PROTEIN", 408, 422], ["biotin", "TREATMENT", 136, 142], ["Langmuir", "TEST", 190, 198], ["copolymer@Au nanostructures", "TREATMENT", 328, 355], ["click chemistry", "TEST", 360, 375], ["a variety of (bio)receptors", "TREATMENT", 395, 422], ["biotin-avidin conjugate", "TREATMENT", 447, 470], ["the low solubility of biotin in water", "TREATMENT", 472, 509], ["low solubility", "OBSERVATION_MODIFIER", 476, 490]]], ["Nevertheless, it can be easily adapted to different bioreceptor-biotarget systems following a postfunctionalization strategy of N3-copolymer@Au NPs.", [["N3-copolymer@Au", "CHEMICAL", 128, 143], ["N3", "CHEMICAL", 128, 130], ["N3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 128, 147], ["a postfunctionalization strategy", "TREATMENT", 92, 124], ["N3-copolymer@Au NPs", "TREATMENT", 128, 147]]], ["Alternatively, the use of biorecognition elements with higher solubility in water should be considered for the functionalization of N3-copolymer@Au nanostructures via click chemistry in order to ensure the complete removal of unbound material.Langmuir-Blodgett Studies at the Air/Water InterfaceIn the case of biotin or similar ligands (e.g., low solubility), the strategies to use click chemistry together with REEP methodology should be further studied in order to control the amount of bioreceptor anchored at the NPs surface.", [["N3-copolymer@Au", "CHEMICAL", 132, 147], ["biotin", "CHEMICAL", 310, 316], ["N3", "CHEMICAL", 132, 134], ["biotin", "CHEMICAL", 310, 316], ["water", "SIMPLE_CHEMICAL", 76, 81], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 132, 162], ["biotin", "SIMPLE_CHEMICAL", 310, 316], ["REEP", "SIMPLE_CHEMICAL", 412, 416], ["biorecognition elements", "DNA", 26, 49], ["biorecognition elements", "TREATMENT", 26, 49], ["higher solubility in water", "TREATMENT", 55, 81], ["the functionalization of N3-copolymer@Au nanostructures", "TREATMENT", 107, 162], ["click chemistry", "TEST", 167, 182], ["the complete removal of unbound material", "TREATMENT", 202, 242], ["Langmuir", "TEST", 243, 251], ["Blodgett Studies", "TEST", 252, 268], ["biotin", "TREATMENT", 310, 316], ["similar ligands", "PROBLEM", 320, 335], ["click chemistry", "TEST", 382, 397], ["REEP methodology", "TREATMENT", 412, 428], ["low solubility", "OBSERVATION_MODIFIER", 343, 357], ["NPs", "OBSERVATION_MODIFIER", 517, 520], ["surface", "OBSERVATION_MODIFIER", 521, 528]]], ["The results obtained using copolymer@Au NPs mixed with alkynated biotin (\"click control\") have revealed potential to be applied to other (bio)molecules with low solubility in water.", [["copolymer@Au NPs", "CHEMICAL", 27, 43], ["alkynated biotin", "CHEMICAL", 55, 71], ["alkynated biotin", "CHEMICAL", 55, 71], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 27, 43], ["alkynated biotin", "SIMPLE_CHEMICAL", 55, 71], ["water", "SIMPLE_CHEMICAL", 175, 180], ["copolymer@Au NPs", "TREATMENT", 27, 43], ["alkynated biotin (\"click control", "TREATMENT", 55, 87], ["low solubility in water", "TREATMENT", 157, 180], ["low solubility", "OBSERVATION_MODIFIER", 157, 171]]], ["According to the work reported by Sasaki et al. [40] , in connection with the preparation of poly[poly(ethylene glycol) methacrylates containing OH on the PEG side chains via ruthenium catalyzed living radical polymerization and subsequent functionalization with biotin for bioapplications, the use of OH-containing groups instead of their methylated counterparts seems a possible alternative.", [["poly[poly(ethylene glycol) methacrylates", "CHEMICAL", 93, 133], ["OH", "CHEMICAL", 145, 147], ["PEG side", "CHEMICAL", 155, 163], ["ruthenium", "CHEMICAL", 175, 184], ["biotin", "CHEMICAL", 263, 269], ["OH", "CHEMICAL", 302, 304], ["poly[poly(ethylene glycol) methacrylates", "CHEMICAL", 93, 133], ["OH", "CHEMICAL", 145, 147], ["PEG", "CHEMICAL", 155, 158], ["ruthenium", "CHEMICAL", 175, 184], ["biotin", "CHEMICAL", 263, 269], ["OH", "CHEMICAL", 302, 304], ["poly[poly(ethylene glycol) methacrylates", "SIMPLE_CHEMICAL", 93, 133], ["OH", "SIMPLE_CHEMICAL", 145, 147], ["PEG side chains", "SIMPLE_CHEMICAL", 155, 170], ["ruthenium", "SIMPLE_CHEMICAL", 175, 184], ["biotin", "SIMPLE_CHEMICAL", 263, 269], ["OH", "SIMPLE_CHEMICAL", 302, 304], ["the preparation of poly[poly(ethylene glycol) methacrylates", "TREATMENT", 74, 133], ["the PEG side chains", "TREATMENT", 151, 170], ["ruthenium catalyzed", "TREATMENT", 175, 194], ["radical polymerization", "TREATMENT", 202, 224], ["subsequent functionalization with biotin", "TREATMENT", 229, 269], ["bioapplications", "TREATMENT", 274, 289], ["OH-containing groups", "TREATMENT", 302, 322], ["radical polymerization", "OBSERVATION", 202, 224]]], ["In any case, regardless of the synthetic route adopted, based on the results obtained in the present work, the covalent bond between biotin and the copolymer would need assessment.Langmuir-Blodgett Studies at the Air/Water InterfaceThese copolymer@Au nanostructures have also shown potential to be explored for drug carrier/delivery systems, since PEG is also known to have thermal responsiveness [41] .", [["biotin", "CHEMICAL", 133, 139], ["PEG", "CHEMICAL", 348, 351], ["biotin", "CHEMICAL", 133, 139], ["PEG", "CHEMICAL", 348, 351], ["biotin", "SIMPLE_CHEMICAL", 133, 139], ["PEG", "SIMPLE_CHEMICAL", 348, 351], ["the covalent bond between biotin", "TREATMENT", 107, 139], ["the copolymer", "TREATMENT", 144, 157], ["assessment", "TEST", 169, 179], ["Langmuir", "TEST", 180, 188], ["Blodgett Studies", "TEST", 189, 205], ["the Air/Water InterfaceThese copolymer@Au nanostructures", "TREATMENT", 209, 265], ["drug carrier/delivery systems", "TREATMENT", 311, 340], ["PEG", "TREATMENT", 348, 351], ["thermal responsiveness", "PROBLEM", 374, 396]]], ["Moreover, the synthetic strategy outlined in this work also allows the incorporation of monomers containing fluorophores in well-defined positions along the polymer shell, which can be tuned to maximize photoluminescence quenching and thus afford more sensitive biosensors [42] .Langmuir-Blodgett Studies at the Air/Water InterfaceIn what regards the limited monomer conversion values achieved due to the low reaction temperature and the use of monomer starved conditions required by the presence of azide moieties and REEP respectively, both can be overcome in the light of the results reported by Farinha et al. [19] , the work of Stenzel [43] , or alternatively the use of a redox initiation system as proposed by Bai et al. [44] .", [["azide", "CHEMICAL", 500, 505], ["REEP", "CHEMICAL", 519, 523], ["azide", "CHEMICAL", 500, 505], ["azide moieties", "SIMPLE_CHEMICAL", 500, 514], ["REEP", "SIMPLE_CHEMICAL", 519, 523], ["Stenzel [43]", "SIMPLE_CHEMICAL", 633, 645], ["the incorporation of monomers containing fluorophores", "TREATMENT", 67, 120], ["the polymer shell", "TREATMENT", 153, 170], ["photoluminescence quenching", "PROBLEM", 203, 230], ["Langmuir", "TEST", 279, 287], ["the Air/Water InterfaceIn", "TREATMENT", 308, 333], ["the low reaction temperature", "PROBLEM", 401, 429], ["monomer starved conditions", "TREATMENT", 445, 471], ["azide moieties", "TREATMENT", 500, 514], ["a redox initiation system", "TREATMENT", 676, 701]]], ["As a final remark, it should be stressed that even though the biofunctionalization of copolymer@Au nanostructures via click chemistry is interesting for a variety of (bio)receptors in the specific case of biotin-avidin conjugate, the low solubility of biotin in water also revealed drawbacks.", [["biotin-avidin", "CHEMICAL", 205, 218], ["biotin", "CHEMICAL", 252, 258], ["biotin", "CHEMICAL", 205, 211], ["biotin", "CHEMICAL", 252, 258], ["copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 86, 113], ["biotin-avidin conjugate", "SIMPLE_CHEMICAL", 205, 228], ["biotin", "SIMPLE_CHEMICAL", 252, 258], ["water", "SIMPLE_CHEMICAL", 262, 267], ["(bio)receptors", "PROTEIN", 166, 180], ["copolymer@Au nanostructures", "TREATMENT", 86, 113], ["click chemistry", "TEST", 118, 133], ["a variety of (bio)receptors", "TREATMENT", 153, 180], ["biotin-avidin conjugate", "TREATMENT", 205, 228], ["the low solubility of biotin in water", "TREATMENT", 230, 267], ["low solubility", "OBSERVATION_MODIFIER", 234, 248]]], ["Nevertheless, it can be easily adapted to different bioreceptor-biotarget systems following a post-functionalization strategy of N3-copolymer@Au NPs.", [["N3-copolymer@Au", "CHEMICAL", 129, 144], ["N3", "CHEMICAL", 129, 131], ["N3-copolymer@Au NPs", "SIMPLE_CHEMICAL", 129, 148], ["a post-functionalization strategy", "TREATMENT", 92, 125], ["N3-copolymer@Au NPs", "TREATMENT", 129, 148]]], ["Alternatively, the use of biorecognition elements with higher solubility in water should be considered for the functionalization of N3-copolymer@Au nanostructures via click chemistry in order to ensure the complete removal of unbound material.Langmuir-Blodgett Studies at the Air/Water InterfaceIn the case of biotin or similar ligands (e.g., low solubility), the strategies to use click chemistry together with REEP methodology should be further studied in order to control the amount of bioreceptor anchored at the NPs surface.", [["N3-copolymer@Au", "CHEMICAL", 132, 147], ["biotin", "CHEMICAL", 310, 316], ["N3", "CHEMICAL", 132, 134], ["biotin", "CHEMICAL", 310, 316], ["water", "SIMPLE_CHEMICAL", 76, 81], ["N3-copolymer@Au nanostructures", "SIMPLE_CHEMICAL", 132, 162], ["biotin", "SIMPLE_CHEMICAL", 310, 316], ["REEP", "SIMPLE_CHEMICAL", 412, 416], ["biorecognition elements", "DNA", 26, 49], ["biorecognition elements", "TREATMENT", 26, 49], ["higher solubility in water", "TREATMENT", 55, 81], ["the functionalization of N3-copolymer@Au nanostructures", "TREATMENT", 107, 162], ["click chemistry", "TEST", 167, 182], ["the complete removal of unbound material", "TREATMENT", 202, 242], ["Langmuir", "TEST", 243, 251], ["Blodgett Studies", "TEST", 252, 268], ["biotin", "TREATMENT", 310, 316], ["similar ligands", "PROBLEM", 320, 335], ["click chemistry", "TEST", 382, 397], ["REEP methodology", "TREATMENT", 412, 428], ["low solubility", "OBSERVATION_MODIFIER", 343, 357], ["NPs", "OBSERVATION_MODIFIER", 517, 520], ["surface", "OBSERVATION_MODIFIER", 521, 528]]], ["The results obtained using copolymer@Au NPs mixed with alkynated biotin (\"click control\") have revealed potential to be applied to other (bio)molecules with low solubility in water.", [["copolymer@Au NPs", "CHEMICAL", 27, 43], ["alkynated biotin", "CHEMICAL", 55, 71], ["alkynated biotin", "CHEMICAL", 55, 71], ["copolymer@Au NPs", "SIMPLE_CHEMICAL", 27, 43], ["alkynated biotin", "SIMPLE_CHEMICAL", 55, 71], ["water", "SIMPLE_CHEMICAL", 175, 180], ["copolymer@Au NPs", "TREATMENT", 27, 43], ["alkynated biotin (\"click control", "TREATMENT", 55, 87], ["low solubility in water", "TREATMENT", 157, 180], ["low solubility", "OBSERVATION_MODIFIER", 157, 171]]], ["According to the work reported by Sasaki et al. [40] , in connection with the preparation of poly[poly(ethylene glycol) methacrylates containing OH on the PEG side chains via ruthenium catalyzed living radical polymerization and subsequent functionalization with biotin for bioapplications, the use of OH-containing groups instead of their methylated counterparts seems a possible alternative.", [["poly[poly(ethylene glycol) methacrylates", "CHEMICAL", 93, 133], ["OH", "CHEMICAL", 145, 147], ["PEG side", "CHEMICAL", 155, 163], ["ruthenium", "CHEMICAL", 175, 184], ["biotin", "CHEMICAL", 263, 269], ["OH", "CHEMICAL", 302, 304], ["poly[poly(ethylene glycol) methacrylates", "CHEMICAL", 93, 133], ["OH", "CHEMICAL", 145, 147], ["PEG", "CHEMICAL", 155, 158], ["ruthenium", "CHEMICAL", 175, 184], ["biotin", "CHEMICAL", 263, 269], ["OH", "CHEMICAL", 302, 304], ["poly[poly(ethylene glycol) methacrylates", "SIMPLE_CHEMICAL", 93, 133], ["OH", "SIMPLE_CHEMICAL", 145, 147], ["PEG side chains", "SIMPLE_CHEMICAL", 155, 170], ["ruthenium", "SIMPLE_CHEMICAL", 175, 184], ["biotin", "SIMPLE_CHEMICAL", 263, 269], ["OH", "SIMPLE_CHEMICAL", 302, 304], ["the preparation of poly[poly(ethylene glycol) methacrylates", "TREATMENT", 74, 133], ["the PEG side chains", "TREATMENT", 151, 170], ["ruthenium catalyzed", "TREATMENT", 175, 194], ["radical polymerization", "TREATMENT", 202, 224], ["subsequent functionalization with biotin", "TREATMENT", 229, 269], ["bioapplications", "TREATMENT", 274, 289], ["OH-containing groups", "TREATMENT", 302, 322], ["radical polymerization", "OBSERVATION", 202, 224]]], ["In any case, regardless of the synthetic route adopted, based on the results obtained in the present work, the covalent bond between biotin and the copolymer would need assessment.Langmuir-Blodgett Studies at the Air/Water InterfaceThese copolymer@Au nanostructures have also shown potential to be explored for drug carrier/delivery systems, since PEG is also known to have thermal responsiveness [41] .", [["biotin", "CHEMICAL", 133, 139], ["PEG", "CHEMICAL", 348, 351], ["biotin", "CHEMICAL", 133, 139], ["PEG", "CHEMICAL", 348, 351], ["biotin", "SIMPLE_CHEMICAL", 133, 139], ["PEG", "SIMPLE_CHEMICAL", 348, 351], ["the covalent bond between biotin", "TREATMENT", 107, 139], ["the copolymer", "TREATMENT", 144, 157], ["assessment", "TEST", 169, 179], ["Langmuir", "TEST", 180, 188], ["Blodgett Studies", "TEST", 189, 205], ["the Air/Water InterfaceThese copolymer@Au nanostructures", "TREATMENT", 209, 265], ["drug carrier/delivery systems", "TREATMENT", 311, 340], ["PEG", "TREATMENT", 348, 351], ["thermal responsiveness", "PROBLEM", 374, 396]]], ["Moreover, the synthetic strategy outlined in this work also allows the incorporation of monomers containing fluorophores in well-defined positions along the polymer shell, which can be tuned to maximize photoluminescence quenching and thus afford more sensitive biosensors [42] .Langmuir-Blodgett Studies at the Air/Water InterfaceIn what regards the limited monomer conversion values achieved due to the low reaction temperature and the use of monomer starved conditions required by the presence of azide moieties and REEP respectively, both can be overcome in the light of the results reported by Farinha et al. [19] , the work of Stenzel [43] , or alternatively the use of a redox initiation system as proposed by Bai et al. [44] .Langmuir-Blodgett Studies at the Air/Water InterfaceFinally, it should be emphasized that functionalizing tailor-made stable gold nanostructures in physiological medium toward biosensing still continues to be a challenge [45] .", [["azide", "CHEMICAL", 500, 505], ["REEP", "CHEMICAL", 519, 523], ["azide", "CHEMICAL", 500, 505], ["azide moieties", "SIMPLE_CHEMICAL", 500, 514], ["REEP", "SIMPLE_CHEMICAL", 519, 523], ["Stenzel [43]", "SIMPLE_CHEMICAL", 633, 645], ["gold nanostructures", "SIMPLE_CHEMICAL", 859, 878], ["the incorporation of monomers containing fluorophores", "TREATMENT", 67, 120], ["the polymer shell", "TREATMENT", 153, 170], ["photoluminescence quenching", "PROBLEM", 203, 230], ["Langmuir", "TEST", 279, 287], ["the Air/Water InterfaceIn", "TREATMENT", 308, 333], ["the low reaction temperature", "PROBLEM", 401, 429], ["monomer starved conditions", "TREATMENT", 445, 471], ["azide moieties", "TREATMENT", 500, 514], ["a redox initiation system", "TREATMENT", 676, 701], ["Langmuir", "TEST", 734, 742]]], ["Indeed, although the desired core-shell nanostructures were obtained, further studies should be performed to get a better understanding about the chain extension from the macroRAFT@Au NPs, for example, in order to control the thickness of the polymer shell, which can be important to the response of the colloid to an external signal (e.g., temperature).ConclusionsFunctional polymer@Au nanostructures, with a core-shell type structure, were prepared combining RAFT-assisted encapsulating emulsion polymerization (REEP) and click chemistry.", [["RAFT", "CHEMICAL", 461, 465], ["macroRAFT@Au", "CHEMICAL", 171, 183], ["macroRAFT@Au NPs", "SIMPLE_CHEMICAL", 171, 187], ["RAFT", "SIMPLE_CHEMICAL", 461, 465], ["further studies", "TEST", 70, 85], ["the macroRAFT@Au NPs", "TREATMENT", 167, 187], ["the thickness of the polymer shell", "TREATMENT", 222, 256], ["Functional polymer@Au nanostructures", "PROBLEM", 365, 401], ["RAFT-assisted encapsulating emulsion polymerization", "TREATMENT", 461, 512], ["click chemistry", "TEST", 524, 539], ["polymer shell", "OBSERVATION", 243, 256], ["polymer@Au nanostructures", "OBSERVATION", 376, 401], ["shell type", "OBSERVATION", 415, 425]]], ["Despite the low monomer conversion (around 30%) due to the need to carry out chain extension at 44 \u2022 C, the colloidal stability of the ensuing Au nanostructure was good.ConclusionsFurthermore, the possibility to post-functionalize robust functional core-shell plasmonic nanostructures with any desired bioreceptor proves to be a very interesting strategy especially if the bioreceptors have good water solubility.", [["Au", "CHEMICAL", 143, 145], ["Au", "CHEMICAL", 143, 145], ["Au nanostructure", "SIMPLE_CHEMICAL", 143, 159], ["water", "SIMPLE_CHEMICAL", 396, 401], ["the low monomer conversion", "TREATMENT", 8, 34], ["chain extension", "PROBLEM", 77, 92], ["the ensuing Au nanostructure", "TREATMENT", 131, 159], ["functional core-shell plasmonic nanostructures", "TREATMENT", 238, 284], ["low monomer", "OBSERVATION_MODIFIER", 12, 23], ["colloidal stability", "OBSERVATION", 108, 127], ["Au nanostructure", "OBSERVATION", 143, 159], ["shell plasmonic", "OBSERVATION", 254, 269]]], ["In fact, considering the COVID-19 pandemic, this type of nanostructures can find potential application in rapid and simple test kits in the point of care [46] .ConclusionsDepending on the functionalities associated with the polymer shell, a variety of biosensors is envisaged, such as pH, temperature, and photoluminescence quenching.", [["the COVID", "TEST", 21, 30], ["simple test kits", "TEST", 116, 132], ["the polymer shell", "TREATMENT", 220, 237], ["pH", "TEST", 285, 287], ["temperature", "TEST", 289, 300]]], ["The biosensing tests proved that biotin-copolymer@Au NPs specifically respond to the presence of avidin, inducing aggregation and subsequently changing the LSPR band.", [["biotin", "CHEMICAL", 33, 39], ["biotin", "CHEMICAL", 33, 39], ["biotin-copolymer@Au NPs", "SIMPLE_CHEMICAL", 33, 56], ["avidin", "GENE_OR_GENE_PRODUCT", 97, 103], ["avidin", "PROTEIN", 97, 103], ["The biosensing tests", "TEST", 0, 20], ["biotin-copolymer@Au NPs", "TREATMENT", 33, 56], ["avidin", "TREATMENT", 97, 103], ["inducing aggregation", "PROBLEM", 105, 125], ["the LSPR band", "TREATMENT", 152, 165]]], ["This interaction was proven to be time dependent.ConclusionsSupplementary Materials: The following are available online at http://www.mdpi.com/2073-4360/12/7/1442/s1, Table S1 : Experimental conditions used in the synthesis of the macroRAFT agents, Figure S1 : ATR-FTIR spectra of P(AA 2 -co-PEGA 40 )-TTC before and after functionalization with the azide moiety, Figure S2 : Monomer conversion (gravimetric analysis) and hydrodynamic diameter (z-average, DLS measurements) of aliquots withdrawn during the batch copolymerization of MMA:BA (10:1 w/w) in the presence of P(PEGA 40 )-TTC using the initiator VA-044 at (A) 70 \u2022 C and at (B) 44 \u2022 C, Figure S3 : UV-Vis spectra of Au nanostructures before and after emulsion copolymerization at 44 \u2022 C, without azide functional groups, Table S2 : \u03bb LSPR , DLS and zeta potential (\u03b6) measurements of Au nanostructures before and after emulsion copolymerization at 44 \u2022 C, without azide functional groups, Figure S4 : STEM images of Au nanostructures prepared only with P(PEGA 40 )-TTC, without azide moiety, Figure S5 : SEM images of Au nanostructures prepared with the mixture 2macroRAFT:1 N3-macroRAFT agents after emulsion copolymerization, Figure S6 : Preparation of alkynated biotin, Figure S7 : 1 H-NMR of alkynated biotin in DMSO-d 6 , Figure S8 : Langmuir surface pressure-area isotherms of the copolymer P(PEGA40)-b-(MMA-co-BA)-TTC (VA-044 at 70 \u2022 C) mixed with biotin before spreading and using ultra-pure water as subphase or an avidin solution (0.5 mg/L in ultra-pure water).", [["AA 2 -co-PEGA 40 )", "CHEMICAL", 283, 301], ["TTC", "CHEMICAL", 302, 305], ["azide", "CHEMICAL", 350, 355], ["MMA", "CHEMICAL", 533, 536], ["BA", "CHEMICAL", 537, 539], ["PEGA 40 )-TTC", "CHEMICAL", 572, 585], ["VA-044", "CHEMICAL", 606, 612], ["Au", "CHEMICAL", 676, 678], ["azide", "CHEMICAL", 756, 761], ["Au", "CHEMICAL", 844, 846], ["azide", "CHEMICAL", 924, 929], ["Au", "CHEMICAL", 976, 978], ["azide", "CHEMICAL", 1038, 1043], ["Au", "CHEMICAL", 1078, 1080], ["alkynated biotin", "CHEMICAL", 1215, 1231], ["alkynated biotin", "CHEMICAL", 1256, 1272], ["DMSO", "CHEMICAL", 1276, 1280], ["PEGA40)-b-(MMA-co-BA", "CHEMICAL", 1359, 1379], ["TTC", "CHEMICAL", 1381, 1384], ["VA-044", "CHEMICAL", 1386, 1392], ["biotin", "CHEMICAL", 1415, 1421], ["P(AA 2 -co-PEGA 40 )-TTC", "CHEMICAL", 281, 305], ["azide", "CHEMICAL", 350, 355], ["MMA", "CHEMICAL", 533, 536], ["P(PEGA 40 )-TTC", "CHEMICAL", 570, 585], ["Au", "CHEMICAL", 676, 678], ["azide", "CHEMICAL", 756, 761], ["Au", "CHEMICAL", 844, 846], ["azide", "CHEMICAL", 924, 929], ["Au", "CHEMICAL", 976, 978], ["P(PEGA 40 )-TTC", "CHEMICAL", 1013, 1028], ["azide", "CHEMICAL", 1038, 1043], ["Au", "CHEMICAL", 1078, 1080], ["alkynated biotin", "CHEMICAL", 1215, 1231], ["H", "CHEMICAL", 1247, 1248], ["alkynated biotin", "CHEMICAL", 1256, 1272], ["DMSO", "CHEMICAL", 1276, 1280], ["P(PEGA40)-b-(MMA-co-BA)-TTC", "CHEMICAL", 1357, 1384], ["VA-044", "CHEMICAL", 1386, 1392], ["biotin", "CHEMICAL", 1415, 1421], ["ATR", "SIMPLE_CHEMICAL", 261, 264], ["AA 2 -co-PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 283, 305], ["azide moiety", "SIMPLE_CHEMICAL", 350, 362], ["Monomer", "SIMPLE_CHEMICAL", 376, 383], ["MMA", "SIMPLE_CHEMICAL", 533, 536], ["BA", "SIMPLE_CHEMICAL", 537, 539], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 572, 585], ["VA-044", "SIMPLE_CHEMICAL", 606, 612], ["(A) 70 \u2022 C", "SIMPLE_CHEMICAL", 616, 626], ["(B) 44 \u2022 C", "SIMPLE_CHEMICAL", 634, 644], ["Au nanostructures", "SIMPLE_CHEMICAL", 676, 693], ["azide", "SIMPLE_CHEMICAL", 756, 761], ["Au nanostructures", "SIMPLE_CHEMICAL", 844, 861], ["azide", "SIMPLE_CHEMICAL", 924, 929], ["Au nanostructures", "SIMPLE_CHEMICAL", 976, 993], ["PEGA 40 )-TTC", "SIMPLE_CHEMICAL", 1015, 1028], ["azide moiety", "SIMPLE_CHEMICAL", 1038, 1050], ["Au nanostructures", "SIMPLE_CHEMICAL", 1078, 1095], ["1 N3-macroRAFT agents", "SIMPLE_CHEMICAL", 1133, 1154], ["alkynated biotin", "SIMPLE_CHEMICAL", 1215, 1231], ["1 H-NMR", "SIMPLE_CHEMICAL", 1245, 1252], ["alkynated biotin", "SIMPLE_CHEMICAL", 1256, 1272], ["DMSO", "SIMPLE_CHEMICAL", 1276, 1280], ["PEGA40)-b-(MMA-co-BA)-TTC", "SIMPLE_CHEMICAL", 1359, 1384], ["VA-044", "SIMPLE_CHEMICAL", 1386, 1392], ["biotin", "SIMPLE_CHEMICAL", 1415, 1421], ["Experimental conditions", "PROBLEM", 178, 201], ["the macroRAFT agents", "TREATMENT", 227, 247], ["ATR", "TEST", 261, 264], ["P", "TEST", 281, 282], ["AA", "TEST", 283, 285], ["PEGA", "TEST", 292, 296], ["TTC", "TEST", 302, 305], ["the azide moiety", "TREATMENT", 346, 362], ["gravimetric analysis", "TEST", 396, 416], ["hydrodynamic diameter", "TEST", 422, 443], ["DLS measurements", "TEST", 456, 472], ["the initiator VA", "TEST", 592, 608], ["C", "TEST", 625, 626], ["UV", "TEST", 658, 660], ["Vis spectra of Au nanostructures", "TREATMENT", 661, 693], ["emulsion copolymerization", "TREATMENT", 711, 736], ["LSPR", "TEST", 794, 798], ["DLS", "TEST", 801, 804], ["Au nanostructures", "TREATMENT", 844, 861], ["emulsion copolymerization", "TREATMENT", 879, 904], ["Au nanostructures", "TREATMENT", 976, 993], ["PEGA", "TEST", 1015, 1019], ["azide moiety", "TREATMENT", 1038, 1050], ["Au nanostructures", "TREATMENT", 1078, 1095], ["the mixture", "TREATMENT", 1110, 1121], ["macroRAFT agents", "TREATMENT", 1138, 1154], ["emulsion copolymerization", "TREATMENT", 1161, 1186], ["alkynated biotin", "TREATMENT", 1215, 1231], ["NMR", "TEST", 1249, 1252], ["alkynated biotin", "PROBLEM", 1256, 1272], ["DMSO", "TEST", 1276, 1280], ["Langmuir surface pressure", "TEST", 1299, 1324], ["the copolymer P", "TEST", 1343, 1358], ["PEGA40", "TEST", 1359, 1365], ["MMA", "TEST", 1370, 1373], ["TTC", "TEST", 1381, 1384], ["biotin", "TREATMENT", 1415, 1421], ["ultra-pure water as subphase", "TREATMENT", 1449, 1477], ["an avidin solution", "TREATMENT", 1481, 1499], ["hydrodynamic diameter", "OBSERVATION_MODIFIER", 422, 443]]]]}